1	S	NN	O	s	_	0	SENT_1	[p1l21t108r44b145],
2	@	SYM	O	@	dep	3	SENT_1	[p1l51t108r134b145],
3	1ŊR	NN	O	1ŋr	rcmod	1	SENT_1	[p1l51t108r134b145],
4	+	CC	O	+	_	0	SENT_1	[p1l51t108r134b145],
5	E	NN	O	e	conj_+	1	SENT_1	[p1l143t108r163b145],
6	A	DT	O	a	det	7	SENT_1	[p1l306t108r334b145],
7	%	NN	O	%	dep	5	SENT_1	[p1l343t108r399b145],
8	R	NN	O	r	dep	1	SENT_1	[p1l343t108r399b145],
9	+	CC	O	+	_	0	SENT_1	[p1l343t108r399b145],
10	nature	NN	O	nature	nn	12	SENT_1	[p1l1797t124r1888b145],
11	publishing	NN	O	publishing	nn	12	SENT_1	[p1l1897t121r2046b152],
12	group	NN	O	group	conj_+	8	SENT_1	[p1l2055t128r2139b152],

1	Treatment	NN	O	treatment	_	0	SENT_2	[p1l19t265r463b337],
2	of	IN	O	of	_	0	SENT_2	[p1l487t260r575b337],
3	BRAF	NN	O	braf	prep_of	1	SENT_2	[p1l596t264r1162b337],
4	.	.	O	.	_	0	SENT_2	[p1l596t264r1162b337],

1	—	NN	O	—	_	0	SENT_3	[p1l596t264r1162b337],
2	.	.	O	.	_	0	SENT_3	[p1l596t264r1162b337],

1	Mutant	JJ	O	mutant	_	0	SENT_4	[p1l596t264r1162b337],
2	Me	PRP	O	I	nsubj	3	SENT_4	[p1l1188t261r1837b337],
3	|	VBD	O	|	rcmod	1	SENT_4	[p1l1188t261r1837b337],
4	anoma	NN	O	anoma	dobj	3	SENT_4	[p1l1188t261r1837b337],
5	:	:	O	:	_	0	SENT_4	[p1l1188t261r1837b337],
6	The	DT	O	the	det	8	SENT_4	[p1l1188t261r1837b337],
7	Role	NN	O	role	nn	8	SENT_4	[p1l1866t261r2045b337],
8	ofvemurafenib	NN	O	ofvemurafenib	dep	4	SENT_4	[p1l23t372r673b449],
9	and	CC	O	and	_	0	SENT_4	[p1l698t373r854b449],
10	OtherTherapies	NNS	O	othertherapy	conj_and	8	SENT_4	[p1l882t373r1560b468],

1	S	NN	O	s	nn	4	SENT_5	[p1l21t523r42b557],
2	]	CD	NUMBER	]	num	4	SENT_5	[p1l54t516r188b569],
3	ang1	NN	O	ang1	nn	4	SENT_5	[p1l54t516r188b569],
4	’	NN	O	’	_	0	SENT_5	[p1l54t516r188b569],
5	2	CD	NUMBER	2	dep	4	SENT_5	[p1l54t516r188b569],
6	and	CC	O	and	_	0	SENT_5	[p1l199t521r275b557],
7	MB	NN	O	mb	nn	8	SENT_5	[p1l285t524r357b557],
8	Atkins3	NN	O	atkins3	conj_and	5	SENT_5	[p1l369t516r549b557],
9	’	CD	NUMBER	’	number	10	SENT_5	[p1l369t516r549b557],
10	4	CD	NUMBER	4	dep	8	SENT_5	[p1l369t516r549b557],

1	The	DT	O	the	det	2	SENT_6	[p1l19t641r84b672],
2	discovery	NN	O	discovery	nsubj	10	SENT_6	[p1l93t641r262b680],
3	of	IN	O	of	_	0	SENT_6	[p1l271t641r307b672],
4	activating	VBG	O	activate	prepc_of	2	SENT_6	[p1l314t642r489b680],
5	BRAF	NN	O	braf	nn	6	SENT_6	[p1l500t643r591b671],
6	mutations	NNS	O	mutation	dobj	4	SENT_6	[p1l602t642r781b672],
7	in	IN	O	in	_	0	SENT_6	[p1l791t642r820b671],
8	melanomas	NNS	O	melanoma	prep_in	4	SENT_6	[p1l832t641r1036b672],
9	has	VBZ	O	have	aux	10	SENT_6	[p1l1047t641r1105b672],
10	led	VBN	O	lead	_	0	SENT_6	[p1l1115t641r1166b672],
11	to	TO	O	to	_	0	SENT_6	[p1l1176t645r1212b672],
12	the	DT	O	the	det	13	SENT_6	[p1l1220t641r1278b672],
13	investigation	NN	O	investigation	prep_to	10	SENT_6	[p1l1288t642r1516b680],
14	of	IN	O	of	_	0	SENT_6	[p1l1527t641r1563b672],
15	small	JJ	O	small	amod	17	SENT_6	[p1l1570t641r1660b672],
16	molecular	JJ	O	molecular	amod	17	SENT_6	[p1l1672t641r1847b672],
17	inhibitors	NNS	O	inhibitor	prep_of	13	SENT_6	[p1l1857t641r2025b672],
18	targeting	VBG	O	target	xcomp	10	SENT_6	[p1l20t695r184b733],
19	BRAF	NN	O	braf	nn	20	SENT_6	[p1l195t695r286b724],
20	mutation	NN	O	mutation	dobj	18	SENT_6	[p1l297t695r457b724],
21	and	CC	O	and	_	0	SENT_6	[p1l468t694r533b724],
22	MEK	NN	O	mek	dobj	18	SENT_6	[p1l544t695r630b729],
23	,	,	O	,	_	0	SENT_6	[p1l544t695r630b729],
24	a	DT	O	a	det	26	SENT_6	[p1l639t703r657b724],
25	downstream	JJ	O	downstream	amod	26	SENT_6	[p1l667t694r888b724],
26	protein	NN	O	protein	appos	20	SENT_6	[p1l900t695r1026b732],
27	within	IN	O	within	_	0	SENT_6	[p1l1036t694r1147b724],
28	the	DT	O	the	det	31	SENT_6	[p1l1156t694r1214b724],
29	mitogen-activated	JJ	O	mitogen-activated	amod	31	SENT_6	[p1l1224t694r1550b733],
30	protein	NN	O	protein	nn	31	SENT_6	[p1l1561t695r1688b732],
31	kinase	NN	O	kinase	prep_within	26	SENT_6	[p1l1699t694r1811b724],
32	(	CD	NUMBER	(	num	35	SENT_6	[p1l1821t695r1949b729],
33	MAPK	NN	O	mapk	nn	35	SENT_6	[p1l1821t695r1949b729],
34	)	NN	O	)	nn	35	SENT_6	[p1l1821t695r1949b729],
35	pathway	NN	O	pathway	dep	26	SENT_6	[p1l1960t694r2119b733],
36	.	.	O	.	_	0	SENT_6	[p1l1960t694r2119b733],

1	This	DT	O	this	det	2	SENT_7	[p1l19t748r91b778],
2	article	NN	O	article	nsubj	12	SENT_7	[p1l99t748r209b778],
3	reviews	VBZ	O	review	_	0	SENT_7	[p1l219t748r351b778],
4	the	DT	O	the	det	5	SENT_7	[p1l360t748r418b778],
5	role	NN	O	role	dobj	3	SENT_7	[p1l428t748r494b778],
6	of	IN	O	of	_	0	SENT_7	[p1l502t747r539b778],
7	mutant	JJ	O	mutant	amod	8	SENT_7	[p1l547t752r675b778],
8	BRAF	NN	ORGANIZATION	braf	prep_of	5	SENT_7	[p1l686t749r776b778],
9	in	IN	O	in	_	0	SENT_7	[p1l787t748r816b778],
10	melanoma	NN	O	melanoma	prep_in	3	SENT_7	[p1l828t748r1014b778],
11	and	CC	O	and	_	0	SENT_7	[p1l1024t748r1089b778],
12	summarizes	VBZ	O	summarize	conj_and	3	SENT_7	[p1l1099t748r1311b778],
13	the	DT	O	the	det	14	SENT_7	[p1l1319t748r1377b778],
14	results	NNS	O	result	dobj	12	SENT_7	[p1l1387t748r1502b778],
15	of	IN	O	of	_	0	SENT_7	[p1l1511t747r1547b778],
16	clinical	JJ	O	clinical	amod	17	SENT_7	[p1l1554t748r1674b778],
17	trials	NNS	O	trial	prep_of	14	SENT_7	[p1l1683t748r1770b778],
18	evaluating	VBG	O	evaluate	xcomp	12	SENT_7	[p1l1779t748r1965b786],
19	inhibitors	NNS	O	inhibitor	dobj	18	SENT_7	[p1l21t801r190b832],
20	of	IN	O	of	_	0	SENT_7	[p1l199t801r236b832],
21	BRAF	NN	O	braf	prep_of	19	SENT_7	[p1l244t802r334b831],
22	and	CC	O	and	_	0	SENT_7	[p1l344t801r409b832],
23	MEK	NN	O	mek	prep_of	19	SENT_7	[p1l420t803r498b831],
24	in	IN	O	in	_	0	SENT_7	[p1l506t802r536b831],
25	BRAF-mutant	JJ	O	braf-mutant	amod	28	SENT_7	[p1l548t802r784b832],
26	me	PRP	O	I	npadvmod	27	SENT_7	[p1l794t801r1052b832],
27	|	JJ	O	|	amod	28	SENT_7	[p1l794t801r1052b832],
28	anoma	NN	O	anoma	prep_in	18	SENT_7	[p1l794t801r1052b832],
29	.	.	O	.	_	0	SENT_7	[p1l794t801r1052b832],

1	We	PRP	O	we	nsubj	15	SENT_8	[p1l794t801r1052b832],
2	further	RB	O	further	advmod	3	SENT_8	[p1l1060t801r1185b832],
3	describe	VBP	O	describe	_	0	SENT_8	[p1l1193t801r1343b832],
4	recent	JJ	O	recent	amod	5	SENT_8	[p1l1353t805r1462b832],
5	findings	NNS	O	finding	dobj	3	SENT_8	[p1l1470t801r1615b840],
6	on	IN	O	on	_	0	SENT_8	[p1l1624t810r1667b832],
7	the	DT	O	the	det	8	SENT_8	[p1l1677t801r1735b832],
8	mechanisms	NNS	O	mechanism	prep_on	3	SENT_8	[p1l1745t801r1964b832],
9	of	IN	O	of	_	0	SENT_8	[p1l1973t801r2010b832],
10	resistance	NN	O	resistance	prep_of	8	SENT_8	[p1l21t855r197b885],
11	to	TO	O	to	_	0	SENT_8	[p1l205t859r241b885],
12	BRAF	NN	O	braf	nn	13	SENT_8	[p1l251t856r342b885],
13	inhibitors	NNS	O	inhibitor	prep_to	10	SENT_8	[p1l353t854r521b885],
14	and	CC	O	and	_	0	SENT_8	[p1l530t854r595b885],
15	discuss	VBP	O	discuss	conj_and	3	SENT_8	[p1l606t854r731b885],
16	ongoing	JJ	O	ongoing	amod	17	SENT_8	[p1l740t855r888b894],
17	efforts	NNS	O	effort	dobj	15	SENT_8	[p1l899t854r1014b885],
18	to	TO	O	to	aux	19	SENT_8	[p1l1022t859r1058b885],
19	combine	VB	O	combine	xcomp	15	SENT_8	[p1l1067t854r1221b885],
20	BRAF	NN	O	braf	nn	21	SENT_8	[p1l1231t856r1322b885],
21	inhibitors	NNS	O	inhibitor	dobj	19	SENT_8	[p1l1332t854r1501b885],
22	with	IN	O	with	_	0	SENT_8	[p1l1509t854r1586b885],
23	other	JJ	O	other	amod	25	SENT_8	[p1l1596t854r1692b885],
24	targeted	VBN	O	target	amod	25	SENT_8	[p1l1699t854r1851b894],
25	agents	NNS	O	agent	prep_with	19	SENT_8	[p1l1861t859r1989b894],
26	.	.	O	.	_	0	SENT_8	[p1l1861t859r1989b894],

1	Finally	RB	O	finally	advmod	4	SENT_9	[p1l1999t854r2120b894],
2	,	,	O	,	_	0	SENT_9	[p1l1999t854r2120b894],
3	we	PRP	O	we	nsubj	4	SENT_9	[p1l20t918r70b939],
4	review	VBP	O	review	_	0	SENT_9	[p1l80t909r196b939],
5	the	DT	O	the	det	6	SENT_9	[p1l204t909r262b939],
6	results	NNS	O	result	dobj	4	SENT_9	[p1l272t909r386b939],
7	of	IN	O	of	_	0	SENT_9	[p1l396t908r432b939],
8	immunotherapy	NN	O	immunotherapy	prep_of	6	SENT_9	[p1l440t909r728b948],
9	in	IN	O	in	_	0	SENT_9	[p1l736t909r766b939],
10	BRAF-mutant	JJ	O	braf-mutant	amod	11	SENT_9	[p1l778t910r1014b939],
11	melanoma	NN	O	melanoma	prep_in	8	SENT_9	[p1l1024t909r1210b939],
12	and	CC	O	and	_	0	SENT_9	[p1l1220t909r1285b939],
13	address	VB	O	address	conj_and	4	SENT_9	[p1l1295t909r1432b939],
14	the	DT	O	the	det	16	SENT_9	[p1l1440t909r1498b939],
15	current	JJ	DATE	current	amod	16	SENT_9	[p1l1507t913r1635b939],
16	status	NN	O	status	dobj	13	SENT_9	[p1l1644t913r1749b939],
17	of	IN	O	of	_	0	SENT_9	[p1l1758t908r1794b939],
18	efforts	NNS	O	effort	prep_of	16	SENT_9	[p1l1801t908r1916b939],
19	to	TO	O	to	prep	13	SENT_9	[p1l1924t913r1960b939],
20	either	CC	O	either	dep	13	SENT_9	[p1l1969t909r2073b939],
21	combine	VBP	O	combine	conj	13	SENT_9	[p1l20t962r174b993],
22	or	CC	O	or	_	0	SENT_9	[p1l183t971r220b993],
23	determine	VBP	O	determine	conj_or	21	SENT_9	[p1l228t962r411b993],
24	the	DT	O	the	det	26	SENT_9	[p1l420t962r477b993],
25	optimal	JJ	O	optimal	amod	26	SENT_9	[p1l486t962r622b1001],
26	sequence	NN	O	sequence	dobj	21	SENT_9	[p1l632t971r800b1000],
27	of	IN	O	of	_	0	SENT_9	[p1l809t962r845b993],
28	these	DT	O	these	det	32	SENT_9	[p1l851t962r948b993],
29	two	CD	NUMBER	two	num	32	SENT_9	[p1l956t966r1023b993],
30	distinct	JJ	O	distinct	amod	32	SENT_9	[p1l1032t962r1163b993],
31	treatment	NN	O	treatment	nn	32	SENT_9	[p1l1171t966r1349b993],
32	approaches	NNS	O	approach	prep_of	26	SENT_9	[p1l1358t962r1573b1001],
33	.	.	O	.	_	0	SENT_9	[p1l1358t962r1573b1001],

1	Although	IN	O	although	mark	10	SENT_10	[p1l1582t962r1748b1001],
2	the	DT	O	the	det	4	SENT_10	[p1l1757t962r1815b993],
3	recent	JJ	O	recent	amod	4	SENT_10	[p1l1825t966r1935b993],
4	advances	NNS	O	advance	nsubj	10	SENT_10	[p1l1943t962r2108b993],
5	in	IN	O	in	_	0	SENT_10	[p1l21t1016r51b1046],
6	melanoma	NN	O	melanoma	nn	7	SENT_10	[p1l62t1015r249b1046],
7	therapy	NN	O	therapy	prep_in	4	SENT_10	[p1l258t1015r397b1055],
8	have	VBP	O	have	aux	10	SENT_10	[p1l406t1015r488b1046],
9	been	VBN	O	be	cop	10	SENT_10	[p1l498t1015r584b1046],
10	dramatic	JJ	O	dramatic	advcl	31	SENT_10	[p1l594t1015r759b1051],
11	,	,	O	,	_	0	SENT_10	[p1l594t1015r759b1051],
12	greater	JJR	O	greater	amod	13	SENT_10	[p1l768t1020r897b1055],
13	understanding	NN	O	understanding	nsubj	31	SENT_10	[p1l906t1015r1167b1055],
14	of	IN	O	of	_	0	SENT_10	[p1l1177t1015r1213b1046],
15	melanoma	NN	O	melanoma	nn	16	SENT_10	[p1l1221t1015r1407b1046],
16	biology	NN	O	biology	prep_of	13	SENT_10	[p1l1418t1015r1552b1055],
17	coupled	VBN	O	couple	partmod	16	SENT_10	[p1l1560t1015r1702b1054],
18	with	IN	O	with	_	0	SENT_10	[p1l1711t1015r1788b1046],
19	the	DT	O	the	det	21	SENT_10	[p1l1797t1015r1855b1046],
20	successful	JJ	O	successful	amod	21	SENT_10	[p1l1864t1015r2040b1046],
21	development	NN	O	development	prep_with	17	SENT_10	[p1l20t1070r258b1108],
22	of	IN	O	of	_	0	SENT_10	[p1l266t1069r303b1100],
23	several	JJ	O	several	amod	25	SENT_10	[p1l309t1070r431b1100],
24	new	JJ	O	new	amod	25	SENT_10	[p1l443t1078r516b1100],
25	treatments	NNS	O	treatment	prep_of	21	SENT_10	[p1l523t1074r718b1100],
26	and	CC	O	and	_	0	SENT_10	[p1l727t1070r793b1100],
27	combination	NN	O	combination	nn	28	SENT_10	[p1l803t1070r1026b1100],
28	regimens	NNS	O	regimen	prep_of	21	SENT_10	[p1l1038t1070r1201b1108],
29	will	MD	O	will	aux	31	SENT_10	[p1l1209t1070r1269b1100],
30	further	RB	O	further	advmod	31	SENT_10	[p1l1278t1069r1404b1100],
31	improve	VB	O	improve	_	0	SENT_10	[p1l1413t1070r1559b1108],
32	patient	NN	O	patient	nn	33	SENT_10	[p1l1569t1070r1694b1108],
33	outcomes	NNS	O	outcome	dobj	31	SENT_10	[p1l1703t1074r1877b1100],
34	in	IN	O	in	_	0	SENT_10	[p1l1887t1070r1916b1100],
35	the	DT	DATE	the	det	36	SENT_10	[p1l1926t1070r1984b1100],
36	future	NN	DATE	future	prep_in	31	SENT_10	[p1l1992t1069r2109b1100],
37	.	.	O	.	_	0	SENT_10	[p1l1992t1069r2109b1100],

1	Melanoma	NN	O	melanoma	nsubjpass	3	SENT_11	[p1l9t1258r369b1319],
2	is	VBZ	O	be	auxpass	3	SENT_11	[p1l391t1264r439b1319],
3	expected	VBN	O	expect	_	0	SENT_11	[p1l463t1258r761b1338],
4	to	TO	O	to	aux	6	SENT_11	[p1l782t1270r846b1319],
5	be	VB	O	be	auxpass	6	SENT_11	[p1l868t1258r946b1319],
6	diagnosed	VBN	O	diagnose	xcomp	3	SENT_11	[p1l969t1258r1314b1339],
7	in	IN	O	in	_	0	SENT_11	[p1l1335t1264r1401b1318],
8	~	NN	O	~	nn	10	SENT_11	[p1l1425t1264r1690b1327],
9	76,690	CD	NUMBER	76,690	num	10	SENT_11	[p1l1425t1264r1690b1327],
10	persons	NNS	O	person	prep_in	6	SENT_11	[p1l1713t1279r1973b1338],
11	in	IN	O	in	_	0	SENT_11	[p1l1997t1264r2062b1318],
12	the	DT	O	the	det	14	SENT_11	[p1l9t1357r114b1418],
13	United	NNP	LOCATION	United	nn	14	SENT_11	[p1l139t1357r373b1418],
14	States	NNPS	LOCATION	States	prep_in	6	SENT_11	[p1l397t1361r608b1426],
15	,	,	O	,	_	0	SENT_11	[p1l397t1361r608b1426],
16	and	CC	O	and	_	0	SENT_11	[p1l634t1357r760b1418],
17	~	NN	O	~	nsubjpass	36	SENT_11	[p1l785t1364r1012b1426],
18	9,48	CD	NUMBER	9,48	num	17	SENT_11	[p1l785t1364r1012b1426],
19	O	NN	O	o	nn	20	SENT_11	[p1l785t1364r1012b1426],
20	patients	NNS	O	patient	nsubj	22	SENT_11	[p1l1037t1363r1306b1437],
21	will	MD	O	will	aux	22	SENT_11	[p1l1329t1357r1454b1418],
22	die	VB	O	die	rcmod	17	SENT_11	[p1l1479t1357r1579b1418],
23	of	IN	O	of	_	0	SENT_11	[p1l1604t1357r1677b1418],
24	the	DT	O	the	det	25	SENT_11	[p1l1691t1357r1797b1418],
25	disease	NN	O	disease	prep_of	22	SENT_11	[p1l1822t1357r2062b1418],
26	in	IN	O	in	_	0	SENT_11	[p1l10t1462r75b1516],
27	2013.1	CD	NUMBER	2013.1	num	28	SENT_11	[p1l98t1448r305b1517],
28	Patients	NNS	O	patient	prep_in	25	SENT_11	[p1l333t1461r598b1517],
29	with	IN	O	with	_	0	SENT_11	[p1l620t1456r771b1517],
30	early	JJ	O	early	amod	33	SENT_11	[p1l794t1456r1157b1537],
31	—	JJ	O	—	amod	33	SENT_11	[p1l794t1456r1157b1537],
32	stage	NN	O	stage	nn	33	SENT_11	[p1l794t1456r1157b1537],
33	melanomas	NNS	O	melanoma	prep_with	28	SENT_11	[p1l1180t1456r1568b1517],
34	can	MD	O	can	aux	36	SENT_11	[p1l1592t1478r1708b1517],
35	be	VB	O	be	auxpass	36	SENT_11	[p1l1728t1456r1807b1517],
36	treated	VBN	O	treat	conj_and	3	SENT_11	[p1l1829t1456r2064b1517],
37	successfully	RB	O	successfully	advmod	36	SENT_11	[p1l10t1555r402b1636],
38	with	IN	O	with	_	0	SENT_11	[p1l419t1555r567b1616],
39	surgery	NN	O	surgery	prep_with	36	SENT_11	[p1l590t1577r857b1636],
40	;	:	O	;	_	0	SENT_11	[p1l590t1577r857b1636],
41	however	RB	O	however	advmod	47	SENT_11	[p1l879t1555r1172b1624],
42	,	,	O	,	_	0	SENT_11	[p1l879t1555r1172b1624],
43	a	DT	O	a	det	45	SENT_11	[p1l1197t1577r1230b1616],
44	substantial	JJ	O	substantial	amod	45	SENT_11	[p1l1252t1555r1608b1616],
45	minority	NN	O	minority	nsubj	47	SENT_11	[p1l1630t1561r1925b1636],
46	will	MD	O	will	aux	47	SENT_11	[p1l1942t1555r2063b1616],
47	develop	VB	O	develop	parataxis	3	SENT_11	[p1l10t1654r276b1734],
48	disseminated	VBN	O	disseminate	dep	47	SENT_11	[p1l305t1654r762b1715],
49	disease	NN	O	disease	nn	50	SENT_11	[p1l789t1654r1032b1715],
50	(	NN	O	(	nsubj	51	SENT_11	[p1l1063t1654r1260b1735],
51	stage	NN	O	stage	ccomp	48	SENT_11	[p1l1063t1654r1260b1735],
52	IV	CD	NUMBER	iv	num	53	SENT_11	[p1l1287t1655r1421b1728],
53	)	NN	O	)	dobj	51	SENT_11	[p1l1287t1655r1421b1728],
54	.	.	O	.	_	0	SENT_11	[p1l1287t1655r1421b1728],

1	The	DT	O	the	det	2	SENT_12	[p1l1451t1654r1575b1715],
2	prognosis	NN	O	prognosis	nsubj	12	SENT_12	[p1l1601t1660r1939b1735],
3	for	IN	O	for	_	0	SENT_12	[p1l1967t1654r2065b1715],
4	patients	NNS	O	patient	prep_for	2	SENT_12	[p1l8t1759r260b1833],
5	with	IN	O	with	_	0	SENT_12	[p1l277t1753r421b1814],
6	stage	NN	O	stage	nn	8	SENT_12	[p1l440t1764r597b1834],
7	IV	CD	NUMBER	iv	num	8	SENT_12	[p1l616t1758r697b1814],
8	melanoma	NN	O	melanoma	prep_with	4	SENT_12	[p1l715t1753r1055b1814],
9	has	VBZ	O	have	aux	12	SENT_12	[p1l1071t1753r1176b1814],
10	historically	RB	O	historically	advmod	12	SENT_12	[p1l1195t1753r1554b1834],
11	been	VBN	O	be	cop	12	SENT_12	[p1l1567t1753r1721b1814],
12	poor	JJ	O	poor	_	0	SENT_12	[p1l1739t1774r1903b1833],
13	,	,	O	,	_	0	SENT_12	[p1l1739t1774r1903b1833],
14	with	IN	O	with	_	0	SENT_12	[p1l1921t1753r2065b1814],
15	median	JJ	O	median	amod	16	SENT_12	[p1l9t1852r263b1913],
16	survival	NN	O	survival	prep_with	12	SENT_12	[p1l286t1852r554b1913],
17	less	JJR	DURATION	less	mwe	18	SENT_12	[p1l575t1852r692b1913],
18	than	IN	DURATION	than	quantmod	19	SENT_12	[p1l714t1852r866b1913],
19	1	CD	DURATION	1	num	20	SENT_12	[p1l895t1859r919b1912],
20	year	NN	NUMBER	year	dep	16	SENT_12	[p1l946t1874r1089b1933],
21	and	CC	O	and	_	0	SENT_12	[p1l1111t1852r1235b1913],
22	a	DT	O	a	det	26	SENT_12	[p1l1258t1874r1292b1913],
23	5-year	JJ	DURATION	5-year	amod	26	SENT_12	[p1l1315t1859r1525b1933],
24	overall	JJ	O	overall	amod	26	SENT_12	[p1l1547t1852r1774b1913],
25	survival	NN	O	survival	nn	26	SENT_12	[p1l1797t1852r2064b1913],
26	rate	NN	O	rate	prep_with	12	SENT_12	[p1l10t1962r131b2012],
27	of	IN	O	of	_	0	SENT_12	[p1l153t1951r224b2012],
28	<	JJR	O	<	prep_of	26	SENT_12	[p1l238t1969r275b2010],
29	10	CD	PERCENT	10	number	30	SENT_12	[p1l288t1956r436b2013],
30	%	NN	PERCENT	%	amod	28	SENT_12	[p1l288t1956r436b2013],
31	.	.	O	.	_	0	SENT_12	[p1l288t1956r436b2013],

1	Two	CD	NUMBER	two	num	2	SENT_13	[p1l80t2053r215b2111],
2	drugs	NNS	O	drug	nsubj	3	SENT_13	[p1l235t2050r414b2131],
3	approved	VBN	O	approve	dep	30	SENT_13	[p1l433t2050r729b2130],
4	by	IN	O	by	_	0	SENT_13	[p1l744t2050r823b2131],
5	the	DT	O	the	det	7	SENT_13	[p1l836t2050r936b2111],
6	US	NNP	ORGANIZATION	US	nn	7	SENT_13	[p1l954t2054r1047b2111],
7	Food	NNP	ORGANIZATION	Food	prep_by	3	SENT_13	[p1l1068t2050r1232b2111],
8	and	CC	ORGANIZATION	and	_	0	SENT_13	[p1l1250t2050r1368b2111],
9	Drug	NNP	ORGANIZATION	Drug	nn	10	SENT_13	[p1l1385t2055r1554b2131],
10	Administration	NNP	ORGANIZATION	Administration	conj_and	7	SENT_13	[p1l1569t2050r2063b2111],
11	(	CD	NUMBER	(	num	12	SENT_13	[p1l13t2149r240b2223],
12	FDA	NNP	ORGANIZATION	FDA	dep	7	SENT_13	[p1l13t2149r240b2223],
13	)	CD	NUMBER	)	num	12	SENT_13	[p1l13t2149r240b2223],
14	,	,	O	,	_	0	SENT_13	[p1l13t2149r240b2223],
15	namely	RB	O	namely	advmod	7	SENT_13	[p1l261t2149r511b2230],
16	,	,	O	,	_	0	SENT_13	[p1l261t2149r511b2230],
17	dacarbazine	NN	O	dacarbazine	prep_by	3	SENT_13	[p1l534t2149r928b2210],
18	and	CC	O	and	_	0	SENT_13	[p1l949t2149r1070b2210],
19	recombinant	JJ	O	recombinant	amod	22	SENT_13	[p1l1090t2149r1510b2210],
20	human	JJ	O	human	amod	22	SENT_13	[p1l1528t2149r1761b2210],
21	interleukin	NN	O	interleukin	nn	22	SENT_13	[p1l1781t2149r2061b2210, p1l8t2248r186b2308],
22	—	NN	O	—	prep_by	3	SENT_13	[p1l1781t2149r2061b2210, p1l8t2248r186b2308],
23	2	CD	NUMBER	2	number	24	SENT_13	[p1l1781t2149r2061b2210, p1l8t2248r186b2308],
24	(	CD	NUMBER	(	num	26	SENT_13	[p1l214t2249r427b2322],
25	IL-2	NN	O	il-2	nn	26	SENT_13	[p1l214t2249r427b2322],
26	)	NN	O	)	dobj	3	SENT_13	[p1l214t2249r427b2322],
27	,	,	O	,	_	0	SENT_13	[p1l214t2249r427b2322],
28	had	VBD	O	have	aux	30	SENT_13	[p1l450t2248r575b2309],
29	been	VBN	O	be	auxpass	30	SENT_13	[p1l595t2248r755b2309],
30	used	VBN	O	use	_	0	SENT_13	[p1l777t2248r932b2309],
31	for	IN	O	for	_	0	SENT_13	[p1l953t2248r1049b2309],
32	the	DT	O	the	det	33	SENT_13	[p1l1069t2248r1173b2309],
33	treatment	NN	O	treatment	prep_for	30	SENT_13	[p1l1195t2259r1524b2309],
34	of	IN	O	of	_	0	SENT_13	[p1l1546t2248r1618b2309],
35	patients	NNS	O	patient	prep_of	33	SENT_13	[p1l1630t2254r1894b2328],
36	with	IN	O	with	_	0	SENT_13	[p1l1915t2248r2064b2309],
37	stage	NN	O	stage	nn	39	SENT_13	[p1l10t2358r170b2428],
38	IV	CD	NUMBER	iv	num	39	SENT_13	[p1l191t2352r273b2408],
39	melanoma	NN	O	melanoma	prep_with	30	SENT_13	[p1l292t2347r639b2408],
40	in	IN	O	in	_	0	SENT_13	[p1l658t2353r721b2407],
41	the	DT	O	the	det	43	SENT_13	[p1l739t2347r842b2408],
42	United	NNP	LOCATION	United	nn	43	SENT_13	[p1l861t2347r1086b2408],
43	States	NNPS	LOCATION	States	prep_in	39	SENT_13	[p1l1106t2351r1289b2408],
44	before	IN	O	before	_	0	SENT_13	[p1l1307t2347r1513b2408],
45	2011	CD	DATE	2011	prep_before	30	SENT_13	[p1l1533t2353r1682b2408],
46	(	CD	NUMBER	(	num	49	SENT_13	[p1l1711t2348r1959b2427],
47	Figure	NN	O	figure	nn	49	SENT_13	[p1l1711t2348r1959b2427],
48	1	CD	NUMBER	1	num	49	SENT_13	[p1l1982t2347r2060b2421],
49	)	NN	O	)	nsubjpass	30	SENT_13	[p1l1982t2347r2060b2421],
50	.	.	O	.	_	0	SENT_13	[p1l1982t2347r2060b2421],

1	Dacarbazine	NN	PERSON	dacarbazine	nsubj	2	SENT_14	[p1l10t2446r425b2507],
2	yielded	VBD	O	yield	_	0	SENT_14	[p1l445t2446r687b2527],
3	tumor	NN	O	tumor	nn	4	SENT_14	[p1l707t2458r915b2507],
4	responses	NNS	O	response	dobj	2	SENT_14	[p1l936t2467r1257b2526],
5	in	IN	O	in	_	0	SENT_14	[p1l1279t2452r1344b2506],
6	~	NN	O	~	prep_in	2	SENT_14	[p1l1368t2451r1676b2508],
7	10	CD	PERCENT	10	num	6	SENT_14	[p1l1368t2451r1676b2508],
8	—	CD	PERCENT	—	number	9	SENT_14	[p1l1368t2451r1676b2508],
9	15	CD	PERCENT	15	dep	10	SENT_14	[p1l1368t2451r1676b2508],
10	%	NN	PERCENT	%	dep	6	SENT_14	[p1l1368t2451r1676b2508],
11	of	IN	O	of	_	0	SENT_14	[p1l1700t2446r1772b2507],
12	patients	NNS	O	patient	prep_of	6	SENT_14	[p1l1783t2452r2062b2526],
13	,	,	O	,	_	0	SENT_14	[p1l1783t2452r2062b2526],
14	but	CC	O	but	_	0	SENT_14	[p1l8t2545r115b2606],
15	this	DT	O	this	nsubj	18	SENT_14	[p1l132t2545r249b2606],
16	did	VBD	O	do	aux	18	SENT_14	[p1l269t2545r374b2606],
17	not	RB	O	not	neg	18	SENT_14	[p1l391t2556r499b2606],
18	translate	VB	O	translate	conj_but	2	SENT_14	[p1l516t2545r791b2606],
19	into	IN	O	into	_	0	SENT_14	[p1l810t2551r936b2606],
20	a	DT	O	a	det	22	SENT_14	[p1l957t2567r990b2606],
21	signiﬁcant	JJ	O	signiﬁcant	amod	22	SENT_14	[p1l1008t2545r1343b2626],
22	prolongation	NN	O	prolongation	prep_into	18	SENT_14	[p1l1360t2545r1779b2626],
23	in	IN	O	in	_	0	SENT_14	[p1l1798t2551r1861b2605],
24	either	CC	O	either	preconj	26	SENT_14	[p1l1880t2545r2066b2606],
25	median	NN	O	median	nn	26	SENT_14	[p1l9t2644r257b2705],
26	progression	NN	O	progression	prep_in	22	SENT_14	[p1l276t2644r818b2725],
27	—	CD	NUMBER	—	npadvmod	28	SENT_14	[p1l276t2644r818b2725],
28	free	JJ	O	free	amod	26	SENT_14	[p1l276t2644r818b2725],
29	or	CC	O	or	_	0	SENT_14	[p1l839t2666r908b2705],
30	overall	JJ	O	overall	amod	31	SENT_14	[p1l927t2644r1148b2705],
31	survival	NN	O	survival	prep_in	22	SENT_14	[p1l1168t2636r1476b2705],
32	?	.	O	?	_	0	SENT_14	[p1l1168t2636r1476b2705],

1	Although	IN	O	although	dep	109	SENT_15	[p1l1496t2644r1810b2725],
2	combinations	NNS	O	combination	dep	109	SENT_15	[p1l1831t2644r2060b2705, p1l9t2749r245b2804],
3	of	IN	O	of	dep	109	SENT_15	[p1l266t2743r335b2804],
4	cytotoxic	JJ	O	cytotoxic	dep	109	SENT_15	[p1l346t2749r639b2824],
5	agents	NNS	O	agent	dep	109	SENT_15	[p1l659t2755r860b2824],
6	have	VBP	O	have	dep	109	SENT_15	[p1l878t2743r1025b2804],
7	often	RB	O	often	dep	109	SENT_15	[p1l1045t2743r1208b2804],
8	produced	VBN	O	produce	dep	109	SENT_15	[p1l1225t2743r1535b2823],
9	higher	JJR	O	higher	dep	109	SENT_15	[p1l1553t2743r1763b2824],
10	response	NN	O	response	dep	109	SENT_15	[p1l1781t2764r2064b2823],
11	rates	NNS	O	rate	dep	109	SENT_15	[p1l10t2854r166b2903],
12	than	IN	O	than	dep	109	SENT_15	[p1l189t2842r342b2903],
13	dacarbazine	NN	O	dacarbazine	dep	109	SENT_15	[p1l365t2842r773b2903],
14	alone	RB	O	alone	dep	109	SENT_15	[p1l796t2842r995b2911],
15	,	,	O	,	_	0	SENT_15	[p1l796t2842r995b2911],
16	they	PRP	O	they	dep	109	SENT_15	[p1l1019t2842r1168b2923],
17	also	RB	O	also	dep	109	SENT_15	[p1l1188t2842r1317b2903],
18	increased	VBD	O	increase	dep	109	SENT_15	[p1l1341t2842r1664b2903],
19	the	DT	O	the	dep	109	SENT_15	[p1l1685t2842r1790b2903],
20	toxicity	NN	O	toxicity	dep	109	SENT_15	[p1l1812t2848r2068b2923],
21	without	IN	O	without	dep	109	SENT_15	[p1l8t2941r261b3002],
22	a	DT	O	a	dep	109	SENT_15	[p1l279t2963r312b3002],
23	signiﬁcant	JJ	O	signiﬁcant	dep	109	SENT_15	[p1l331t2941r666b3022],
24	improvement	NN	O	improvement	dep	109	SENT_15	[p1l684t2947r1122b3021],
25	in	IN	O	in	dep	109	SENT_15	[p1l1140t2947r1203b3001],
26	survival	NN	O	survival	dep	109	SENT_15	[p1l1223t2941r1478b3002],
27	as	IN	O	as	dep	109	SENT_15	[p1l1497t2963r1558b3002],
28	compared	VBN	O	compare	dep	109	SENT_15	[p1l1578t2941r1902b3021],
29	with	IN	O	with	dep	109	SENT_15	[p1l1918t2941r2062b3002],
30	that	DT	O	that	dep	109	SENT_15	[p1l9t3040r142b3101],
31	for	IN	O	for	dep	109	SENT_15	[p1l165t3040r262b3101],
32	using	VBG	O	use	dep	109	SENT_15	[p1l286t3046r471b3121],
33	dacarbazine	NN	O	dacarbazine	dep	109	SENT_15	[p1l494t3040r905b3101],
34	alone	RB	O	alone	dep	109	SENT_15	[p1l931t3032r1211b3101],
35	.3	NN	NUMBER	.3	dep	109	SENT_15	[p1l931t3032r1211b3101],
36	’	CD	NUMBER	’	dep	109	SENT_15	[p1l931t3032r1211b3101],
37	4	CD	NUMBER	4	dep	109	SENT_15	[p1l931t3032r1211b3101],
38	For	IN	O	for	dep	109	SENT_15	[p1l1236t3045r1351b3101],
39	high	JJ	O	high	dep	109	SENT_15	[p1l1373t3040r1716b3121],
40	—	NN	O	—	dep	109	SENT_15	[p1l1373t3040r1716b3121],
41	dose	NN	O	dose	dep	109	SENT_15	[p1l1373t3040r1716b3121],
42	IL-2	NN	O	il-2	dep	109	SENT_15	[p1l1742t3045r1882b3100],
43	(	CD	NUMBER	(	dep	109	SENT_15	[p1l1912t3041r2061b3113],
44	HD	NN	O	hd	dep	109	SENT_15	[p1l1912t3041r2061b3113],
45	IL-2	NN	O	il-2	dep	109	SENT_15	[p1l10t3140r200b3213],
46	)	NN	O	)	dep	109	SENT_15	[p1l10t3140r200b3213],
47	,	,	O	,	_	0	SENT_15	[p1l10t3140r200b3213],
48	a	DT	O	a	dep	109	SENT_15	[p1l225t3161r259b3200],
49	pooled	JJ	O	pooled	dep	109	SENT_15	[p1l279t3139r515b3219],
50	analysis	NN	O	analysis	dep	109	SENT_15	[p1l538t3139r800b3220],
51	of	IN	O	of	dep	109	SENT_15	[p1l824t3139r897b3200],
52	270	CD	NUMBER	270	dep	109	SENT_15	[p1l911t3146r1029b3200],
53	patients	NNS	O	patient	dep	109	SENT_15	[p1l1052t3145r1319b3219],
54	reported	VBD	O	report	dep	109	SENT_15	[p1l1343t3139r1636b3219],
55	an	DT	O	a	dep	109	SENT_15	[p1l1659t3161r1737b3200],
56	objective	JJ	O	objective	dep	109	SENT_15	[p1l1761t3139r2063b3220],
57	response	NN	O	response	dep	109	SENT_15	[p1l10t3259r298b3318],
58	rate	NN	O	rate	dep	109	SENT_15	[p1l318t3250r440b3299],
59	of	IN	O	of	dep	109	SENT_15	[p1l461t3238r532b3299],
60	16	CD	PERCENT	16	dep	109	SENT_15	[p1l549t3243r680b3300],
61	%	NN	PERCENT	%	dep	109	SENT_15	[p1l549t3243r680b3300],
62	(	CD	PERCENT	(	dep	109	SENT_15	[p1l705t3239r828b3311],
63	6	CD	PERCENT	6	dep	109	SENT_15	[p1l705t3239r828b3311],
64	%	NN	PERCENT	%	dep	109	SENT_15	[p1l705t3239r828b3311],
65	complete	JJ	O	complete	dep	109	SENT_15	[p1l850t3238r1148b3318],
66	responses	NNS	O	response	dep	109	SENT_15	[p1l1169t3239r1534b3318],
67	)	RB	O	)	dep	109	SENT_15	[p1l1169t3239r1534b3318],
68	,	,	O	,	_	0	SENT_15	[p1l1169t3239r1534b3318],
69	with	IN	O	with	dep	109	SENT_15	[p1l1554t3238r1701b3299],
70	44	CD	PERCENT	44	dep	109	SENT_15	[p1l1720t3243r1858b3300],
71	%	NN	PERCENT	%	dep	109	SENT_15	[p1l1720t3243r1858b3300],
72	of	IN	O	of	dep	109	SENT_15	[p1l1880t3238r1951b3299],
73	the	DT	O	the	dep	109	SENT_15	[p1l1961t3238r2063b3299],
74	responding	VBG	O	respond	dep	109	SENT_15	[p1l10t3337r383b3418],
75	patients	NNS	O	patient	dep	109	SENT_15	[p1l400t3343r660b3417],
76	surviving	VBG	O	survive	dep	109	SENT_15	[p1l681t3343r991b3418],
77	beyond	IN	O	beyond	dep	109	SENT_15	[p1l1007t3337r1253b3418],
78	5	CD	DURATION	5	dep	109	SENT_15	[p1l1274t3344r1306b3398],
79	years	NNS	NUMBER	year	dep	109	SENT_15	[p1l1326t3330r1542b3418],
80	.5	CD	NUMBER	.5	dep	109	SENT_15	[p1l1326t3330r1542b3418],
81	Clinical	JJ	O	clinical	dep	109	SENT_15	[p1l1564t3337r1820b3398],
82	beneﬁt	NN	O	beneﬁt	dep	109	SENT_15	[p1l1837t3337r2064b3398],
83	was	VBD	O	be	dep	109	SENT_15	[p1l8t3458r128b3497],
84	most	RBS	O	most	dep	109	SENT_15	[p1l148t3448r311b3497],
85	frequent	JJ	O	frequent	dep	109	SENT_15	[p1l329t3436r607b3516],
86	in	IN	O	in	dep	109	SENT_15	[p1l625t3442r689b3496],
87	patients	NNS	O	patient	dep	109	SENT_15	[p1l708t3442r965b3516],
88	with	IN	O	with	dep	109	SENT_15	[p1l984t3436r1130b3497],
89	metastases	NNS	O	metastase	dep	109	SENT_15	[p1l1149t3447r1498b3497],
90	largely	RB	O	largely	dep	109	SENT_15	[p1l1517t3436r1736b3517],
91	restricted	JJ	O	restricted	dep	109	SENT_15	[p1l1752t3436r2063b3497],
92	to	TO	O	to	dep	109	SENT_15	[p1l9t3546r71b3596],
93	lung	NN	O	lung	dep	109	SENT_15	[p1l90t3535r236b3616],
94	and	CC	O	and	dep	109	SENT_15	[p1l254t3535r399b3598],
95	/	:	O	/	dep	109	SENT_15	[p1l254t3535r399b3598],
96	or	CC	O	or	dep	109	SENT_15	[p1l404t3557r473b3596],
97	soft	JJ	O	soft	dep	109	SENT_15	[p1l492t3535r608b3596],
98	tissue	NN	O	tissue	dep	109	SENT_15	[p1l625t3541r824b3604],
99	,	,	O	,	_	0	SENT_15	[p1l625t3541r824b3604],
100	good	JJ	O	good	dep	109	SENT_15	[p1l845t3535r1009b3616],
101	performance	NN	O	performance	dep	109	SENT_15	[p1l1026t3535r1445b3615],
102	status	NN	O	status	dep	109	SENT_15	[p1l1466t3546r1666b3604],
103	,	,	O	,	_	0	SENT_15	[p1l1466t3546r1666b3604],
104	and	CC	O	and	dep	109	SENT_15	[p1l1688t3535r1808b3596],
105	normal	JJ	O	normal	dep	109	SENT_15	[p1l1826t3535r2063b3596],
106	serum	NN	O	serum	dep	109	SENT_15	[p1l10t3656r218b3695],
107	lactate	NN	O	lactate	dep	109	SENT_15	[p1l238t3634r452b3695],
108	dehydrogenase	NN	O	dehydrogenase	dep	109	SENT_15	[p1l475t3634r970b3715],
109	levels	NNS	O	level	_	0	SENT_15	[p1l991t3634r1187b3695],
110	.	.	O	.	_	0	SENT_15	[p1l991t3634r1187b3695],

1	Biochemotherapy	NNP	PERSON	Biochemotherapy	nsubj	13	SENT_16	[p1l1213t3634r1813b3715],
2	,	,	O	,	_	0	SENT_16	[p1l1213t3634r1813b3715],
3	a	DT	O	a	det	4	SENT_16	[p1l1837t3656r1871b3695],
4	combination	NN	O	combination	appos	1	SENT_16	[p1l1892t3656r2060b3695, p1l8t3733r289b3794],
5	of	IN	O	of	_	0	SENT_16	[p1l311t3733r383b3794],
6	IL-2	NN	O	il-2	nn	9	SENT_16	[p1l397t3738r535b3793],
7	and	CC	O	and	_	0	SENT_16	[p1l560t3733r683b3794],
8	cisplatin	NN	O	cisplatin	nn	9	SENT_16	[p1l704t3733r1208b3813],
9	—	NN	O	—	prep_of	4	SENT_16	[p1l704t3733r1208b3813],
10	based	VBN	O	base	partmod	9	SENT_16	[p1l704t3733r1208b3813],
11	chemotherapy	NN	O	chemotherapy	dobj	10	SENT_16	[p1l1230t3733r1719b3814],
12	,	,	O	,	_	0	SENT_16	[p1l1230t3733r1719b3814],
13	produced	VBD	O	produce	_	0	SENT_16	[p1l1742t3733r2063b3813],
14	promising	JJ	O	promising	amod	15	SENT_16	[p2l38t231r398b308],
15	results	NNS	O	result	dobj	13	SENT_16	[p2l421t225r646b288],
16	in	IN	O	in	_	0	SENT_16	[p2l671t231r738b287],
17	phase	NN	O	phase	nn	19	SENT_16	[p2l761t225r960b307],
18	II	CD	NUMBER	ii	num	19	SENT_16	[p2l984t230r1039b287],
19	trials	NNS	O	trial	prep_in	13	SENT_16	[p2l1063t225r1238b288],
20	and	CC	O	and	_	0	SENT_16	[p2l1264t225r1392b288],
21	resulted	VBD	O	result	conj_and	13	SENT_16	[p2l1416t225r1694b288],
22	in	IN	O	in	_	0	SENT_16	[p2l1717t231r1784b287],
23	prolongation	NN	O	prolongation	prep_in	21	SENT_16	[p2l1808t225r2148b308, p2l38t332r175b389],
24	of	IN	O	of	_	0	SENT_16	[p2l198t326r271b389],
25	median	JJ	O	median	amod	27	SENT_16	[p2l284t326r540b389],
26	progression-free	JJ	O	progression-free	amod	27	SENT_16	[p2l562t326r1123b409],
27	survival	NN	O	survival	prep_of	23	SENT_16	[p2l1147t326r1417b389],
28	in	IN	O	in	_	0	SENT_16	[p2l1439t332r1505b388],
29	randomized	VBN	O	randomize	prepc_in	21	SENT_16	[p2l1528t326r1941b389],
30	trials	NNS	O	trial	dobj	29	SENT_16	[p2l1961t326r2150b397],
31	;	:	O	;	_	0	SENT_16	[p2l1961t326r2150b397],
32	however	RB	O	however	advmod	35	SENT_16	[p2l38t427r337b498],
33	,	,	O	,	_	0	SENT_16	[p2l38t427r337b498],
34	there	EX	O	there	expl	35	SENT_16	[p2l358t427r530b490],
35	was	VBD	O	be	parataxis	13	SENT_16	[p2l549t449r673b490],
36	no	DT	O	no	det	37	SENT_16	[p2l694t449r779b490],
37	improvement	NN	O	improvement	iobj	35	SENT_16	[p2l801t433r1258b509],
38	in	IN	O	in	_	0	SENT_16	[p2l1277t433r1343b489],
39	median	JJ	O	median	amod	41	SENT_16	[p2l1363t427r1618b490],
40	overall	JJ	O	overall	amod	41	SENT_16	[p2l1639t427r1866b490],
41	survival	NN	O	survival	prep_in	37	SENT_16	[p2l1886t427r2154b490],
42	relative	JJ	O	relative	advmod	37	SENT_16	[p2l39t527r284b590],
43	to	TO	O	to	_	0	SENT_16	[p2l304t539r369b590],
44	that	DT	O	that	prep_to	42	SENT_16	[p2l391t527r523b590],
45	with	IN	O	with	_	0	SENT_16	[p2l542t527r693b590],
46	chemotherapy	NN	O	chemotherapy	prep_with	44	SENT_16	[p2l714t527r1202b610],
47	alone	RB	O	alone	advmod	37	SENT_16	[p2l1221t519r1451b590],
48	.6	CD	NUMBER	.6	dep	37	SENT_16	[p2l1221t519r1451b590],

1	DISCOVERY	NN	O	discovery	nsubj	6	SENT_17	[p2l43t739r450b794],
2	OF	IN	O	of	_	0	SENT_17	[p2l467t739r560b794],
3	THE	DT	O	the	det	5	SENT_17	[p2l575t740r713b793],
4	BRAF	NN	MISC	braf	nn	5	SENT_17	[p2l734t740r917b793],
5	MUTATION	NN	O	mutation	prep_of	1	SENT_17	[p2l938t739r1315b794],
6	Activating	VBG	O	activate	ccomp	79	SENT_17	[p2l38t837r398b916],
7	mutations	NNS	O	mutation	dobj	6	SENT_17	[p2l419t839r766b896],
8	in	IN	O	in	_	0	SENT_17	[p2l790t839r856b895],
9	the	DT	O	the	det	16	SENT_17	[p2l878t833r985b896],
10	mitogen-activated	JJ	O	mitogen-activated	amod	16	SENT_17	[p2l1008t833r1639b916],
11	protein	NN	O	protein	nn	16	SENT_17	[p2l1660t839r1911b915],
12	kinase	NN	O	kinase	nn	16	SENT_17	[p2l1932t833r2152b896],
13	(	CD	NUMBER	(	num	16	SENT_17	[p2l43t934r338b1010],
14	MAPK	NN	O	mapk	nn	16	SENT_17	[p2l43t934r338b1010],
15	)	NN	O	)	nn	16	SENT_17	[p2l43t934r338b1010],
16	pathway	NN	O	pathway	prep_in	6	SENT_17	[p2l365t934r669b1017],
17	,	,	O	,	_	0	SENT_17	[p2l365t934r669b1017],
18	which	WDT	O	which	nsubj	19	SENT_17	[p2l694t934r907b997],
19	incorporates	VBZ	O	incorporate	rcmod	16	SENT_17	[p2l931t940r1371b1016],
20	the	DT	O	the	det	21	SENT_17	[p2l1395t934r1503b997],
21	enzymes	NNS	O	enzyme	dobj	19	SENT_17	[p2l1529t955r1828b1017],
22	RAS	NN	O	ra	nn	25	SENT_17	[p2l1854t938r2004b997],
23	(	CD	NUMBER	(	num	25	SENT_17	[p2l2033t935r2154b1010],
24	rat	NN	O	rat	nn	25	SENT_17	[p2l2033t935r2154b1010],
25	sarcoma	NN	O	sarcoma	dep	21	SENT_17	[p2l40t1057r355b1106],
26	;	:	O	;	_	0	SENT_17	[p2l40t1057r355b1106],
27	encoded	VBN	O	encode	dep	21	SENT_17	[p2l384t1035r685b1098],
28	by	IN	O	by	_	0	SENT_17	[p2l709t1035r795b1118],
29	HRAS	NNP	ORGANIZATION	HRAS	prep_by	27	SENT_17	[p2l816t1039r1054b1106],
30	,	,	O	,	_	0	SENT_17	[p2l816t1039r1054b1106],
31	NRAS	NNS	ORGANIZATION	nra	conj_and	29	SENT_17	[p2l1080t1039r1314b1106],
32	,	,	O	,	_	0	SENT_17	[p2l1080t1039r1314b1106],
33	and	CC	O	and	_	0	SENT_17	[p2l1344t1035r1474b1098],
34	KRAS	NNP	ORGANIZATION	KRAS	conj_and	29	SENT_17	[p2l1498t1036r1759b1111],
35	)	CD	NUMBER	)	num	34	SENT_17	[p2l1498t1036r1759b1111],
36	,	,	O	,	_	0	SENT_17	[p2l1498t1036r1759b1111],
37	RAF	NN	O	raf	appos	29	SENT_17	[p2l1788t1039r1946b1097],
38	(	CD	NUMBER	(	num	37	SENT_17	[p2l1977t1036r2149b1117, p2l39t1136r171b1219],
39	rapidly	RB	O	rapidly	advmod	40	SENT_17	[p2l1977t1036r2149b1117, p2l39t1136r171b1219],
40	accelerated	VBD	O	accelerate	partmod	37	SENT_17	[p2l192t1136r578b1199],
41	ﬁbrosarcoma	NN	O	ﬁbrosarcoma	dobj	40	SENT_17	[p2l601t1136r1075b1207],
42	;	:	O	;	_	0	SENT_17	[p2l601t1136r1075b1207],
43	encoded	VBN	O	encode	parataxis	27	SENT_17	[p2l1102t1136r1395b1199],
44	by	IN	O	by	_	0	SENT_17	[p2l1417t1136r1501b1219],
45	ARAF	NN	ORGANIZATION	araf	nn	47	SENT_17	[p2l1518t1140r1752b1207],
46	,	,	O	,	_	0	SENT_17	[p2l1518t1140r1752b1207],
47	BRAF	NN	O	braf	prep_by	43	SENT_17	[p2l1775t1140r1999b1207],
48	,	,	O	,	_	0	SENT_17	[p2l1775t1140r1999b1207],
49	and	CC	O	and	_	0	SENT_17	[p2l2026t1136r2153b1199],
50	CRAP	NN	O	crap	nn	51	SENT_17	[p2l42t1238r302b1313],
51	)	NN	O	)	conj_and	47	SENT_17	[p2l42t1238r302b1313],
52	,	,	O	,	_	0	SENT_17	[p2l42t1238r302b1313],
53	MEK	NN	O	mek	dep	43	SENT_17	[p2l329t1242r515b1299],
54	(	CD	NUMBER	(	num	53	SENT_17	[p2l542t1237r1903b1320],
55	MAPK/eXtracellular-signal-regulated	JJ	O	mapk/extracellular-signal-regulated	amod	60	SENT_17	[p2l542t1237r1903b1320],
56	kinase	NN	O	kinase	nn	60	SENT_17	[p2l1926t1237r2151b1300],
57	(	NN	O	(	nn	60	SENT_17	[p2l43t1338r253b1414],
58	ERK	NN	O	erk	nn	60	SENT_17	[p2l43t1338r253b1414],
59	)	NN	O	)	nn	60	SENT_17	[p2l43t1338r253b1414],
60	kinase	NN	O	kinase	dep	53	SENT_17	[p2l280t1338r518b1409],
61	;	:	O	;	_	0	SENT_17	[p2l280t1338r518b1409],
62	encoded	VBN	O	encode	parataxis	27	SENT_17	[p2l544t1338r837b1401],
63	by	IN	O	by	_	0	SENT_17	[p2l857t1338r942b1421],
64	MAP2K1	NN	O	map2k1	nn	67	SENT_17	[p2l959t1342r1272b1400],
65	and	CC	O	and	_	0	SENT_17	[p2l1304t1338r1430b1401],
66	MAP2K2	NN	O	map2k2	conj_and	64	SENT_17	[p2l1450t1338r1819b1414],
67	)	NN	O	)	prep_by	62	SENT_17	[p2l1450t1338r1819b1414],
68	,	,	O	,	_	0	SENT_17	[p2l1450t1338r1819b1414],
69	and	CC	O	and	_	0	SENT_17	[p2l1845t1338r1972b1401],
70	ERK	NN	O	erk	nsubj	72	SENT_17	[p2l1995t1343r2153b1400],
71	(	CD	NUMBER	(	num	70	SENT_17	[p2l43t1439r364b1514],
72	encoded	VBN	O	encode	ccomp	79	SENT_17	[p2l43t1439r364b1514],
73	by	IN	O	by	_	0	SENT_17	[p2l385t1439r469b1522],
74	MAPK1	NN	O	mapk1	nn	77	SENT_17	[p2l487t1443r759b1501],
75	and	CC	O	and	_	0	SENT_17	[p2l790t1439r918b1502],
76	MAPK3	NN	O	mapk3	conj_and	74	SENT_17	[p2l938t1439r1266b1515],
77	)	NN	O	)	prep_by	72	SENT_17	[p2l938t1439r1266b1515],
78	,	,	O	,	_	0	SENT_17	[p2l938t1439r1266b1515],
79	result	VBP	O	result	_	0	SENT_17	[p2l1292t1439r1485b1502],
80	in	IN	O	in	_	0	SENT_17	[p2l1508t1445r1575b1501],
81	constitutive	JJ	O	constitutive	amod	82	SENT_17	[p2l1599t1445r2004b1502],
82	signaling	NN	O	signaling	prep_in	79	SENT_17	[p2l2030t1445r2150b1522, p2l39t1540r264b1623],
83	that	WDT	O	that	nsubj	84	SENT_17	[p2l287t1540r427b1603],
84	leads	VBZ	O	lead	rcmod	82	SENT_17	[p2l450t1540r629b1603],
85	to	TO	O	to	_	0	SENT_17	[p2l655t1552r723b1603],
86	oncogenic	JJ	O	oncogenic	amod	88	SENT_17	[p2l751t1546r1116b1623],
87	cell	NN	O	cell	nn	88	SENT_17	[p2l1142t1540r1261b1603],
88	proliferation	NN	O	proliferation	prep_to	84	SENT_17	[p2l1285t1540r1739b1622],
89	and	CC	O	and	_	0	SENT_17	[p2l1766t1540r1896b1603],
90	escape	NN	O	escape	prep_to	84	SENT_17	[p2l1922t1562r2152b1622],
91	from	IN	O	from	_	0	SENT_17	[p2l39t1640r206b1703],
92	apoptosis7	NN	O	apoptosis7	prep_from	84	SENT_17	[p2l229t1633r584b1722],
93	(	CD	NUMBER	(	num	96	SENT_17	[p2l609t1641r869b1722],
94	Figure	NN	O	figure	nn	96	SENT_17	[p2l609t1641r869b1722],
95	2	CD	NUMBER	2	num	96	SENT_17	[p2l890t1641r976b1716],
96	)	NN	O	)	nsubj	79	SENT_17	[p2l890t1641r976b1716],
97	.	.	O	.	_	0	SENT_17	[p2l890t1641r976b1716],

1	Somatic	JJ	MISC	somatic	dep	132	SENT_18	[p2l1002t1644r1276b1703],
2	mutations	NNS	O	mutation	dep	132	SENT_18	[p2l1298t1646r1644b1703],
3	in	IN	O	in	dep	132	SENT_18	[p2l1666t1646r1732b1702],
4	NRAS	NNS	O	nra	dep	132	SENT_18	[p2l1752t1644r1961b1703],
5	(	CD	NUMBER	(	dep	132	SENT_18	[p2l1986t1641r2149b1722, p2l40t1753r179b1805],
6	present	JJ	DATE	present	dep	132	SENT_18	[p2l1986t1641r2149b1722, p2l40t1753r179b1805],
7	in	IN	O	in	dep	132	SENT_18	[p2l202t1748r268b1804],
8	10-20	CD	PERCENT	10-20	dep	132	SENT_18	[p2l299t1747r564b1806],
9	%	NN	PERCENT	%	dep	132	SENT_18	[p2l299t1747r564b1806],
10	of	IN	O	of	dep	132	SENT_18	[p2l591t1742r664b1805],
11	tumors	NNS	O	tumor	dep	132	SENT_18	[p2l678t1743r951b1818],
12	)	CD	NUMBER	)	dep	132	SENT_18	[p2l678t1743r951b1818],
13	were	VBD	O	be	dep	132	SENT_18	[p2l977t1764r1139b1805],
14	the	DT	O	the	dep	132	SENT_18	[p2l1162t1742r1269b1805],
15	only	JJ	O	only	dep	132	SENT_18	[p2l1294t1742r1446b1825],
16	recurrent	JJ	O	recurrent	dep	132	SENT_18	[p2l1467t1754r1791b1805],
17	activating	NN	O	activating	dep	132	SENT_18	[p2l1814t1748r2153b1825],
18	oncogene	NN	O	oncogene	dep	132	SENT_18	[p2l40t1864r369b1925],
19	mutations	NNS	O	mutation	dep	132	SENT_18	[p2l393t1848r741b1905],
20	identiﬁed	VBN	O	identiﬁed	dep	132	SENT_18	[p2l766t1842r1097b1905],
21	in	IN	O	in	dep	132	SENT_18	[p2l1120t1848r1187b1904],
22	melanoma	NN	O	melanoma	dep	132	SENT_18	[p2l1211t1842r1576b1905],
23	before	IN	O	before	dep	132	SENT_18	[p2l1597t1842r1814b1905],
24	2002.8	CD	NUMBER	2002.8	dep	132	SENT_18	[p2l1839t1834r2151b1905],
25	‘	CD	NUMBER	‘	dep	132	SENT_18	[p2l1839t1834r2151b1905],
26	10	CD	NUMBER	10	dep	132	SENT_18	[p2l1839t1834r2151b1905],
27	Davies	NNP	PERSON	Davies	dep	132	SENT_18	[p2l39t1949r263b2007],
28	et	FW	O	et	dep	132	SENT_18	[p2l285t1955r344b2007],
29	al.	FW	O	al.	dep	132	SENT_18	[p2l362t1944r435b2007],
30	reported	VBN	O	report	dep	132	SENT_18	[p2l460t1944r751b2026],
31	in	IN	O	in	dep	132	SENT_18	[p2l771t1950r836b2006],
32	2002	CD	DATE	2002	dep	132	SENT_18	[p2l857t1951r1014b2007],
33	that	WDT	O	that	dep	132	SENT_18	[p2l1036t1944r1167b2007],
34	~	VBP	O	~	dep	132	SENT_18	[p2l1189t1950r1501b2008],
35	40	CD	PERCENT	40	dep	132	SENT_18	[p2l1189t1950r1501b2008],
36	—	CD	PERCENT	—	dep	132	SENT_18	[p2l1189t1950r1501b2008],
37	50	CD	PERCENT	50	dep	132	SENT_18	[p2l1189t1950r1501b2008],
38	%	NN	PERCENT	%	dep	132	SENT_18	[p2l1189t1950r1501b2008],
39	of	IN	O	of	dep	132	SENT_18	[p2l1525t1944r1597b2007],
40	melanomas	NNS	O	melanoma	dep	132	SENT_18	[p2l1609t1944r1993b2007],
41	harbor	VBP	O	harbor	dep	132	SENT_18	[p2l2014t1944r2149b2007, p2l37t2045r155b2108],
42	a	DT	O	a	dep	132	SENT_18	[p2l176t2067r209b2108],
43	mutation	NN	O	mutation	dep	132	SENT_18	[p2l229t2051r541b2108],
44	in	IN	O	in	dep	132	SENT_18	[p2l562t2051r628b2107],
45	the	DT	O	the	dep	132	SENT_18	[p2l648t2045r753b2108],
46	BRAF	NN	O	braf	dep	132	SENT_18	[p2l773t2049r979b2107],
47	gene	NN	O	gene	dep	132	SENT_18	[p2l996t2067r1168b2128],
48	,	,	O	,	_	0	SENT_18	[p2l996t2067r1168b2128],
49	mostly	RB	O	mostly	dep	132	SENT_18	[p2l1191t2045r1422b2128],
50	conﬁned	VBN	O	conﬁned	dep	132	SENT_18	[p2l1441t2045r1737b2108],
51	to	TO	O	to	dep	132	SENT_18	[p2l1757t2056r1822b2108],
52	a	DT	O	a	dep	132	SENT_18	[p2l1845t2067r1879b2108],
53	speciﬁc	NN	O	speciﬁc	dep	132	SENT_18	[p2l1900t2045r2150b2127],
54	point	NN	O	point	dep	132	SENT_18	[p2l38t2152r223b2228],
55	mutation	NN	O	mutation	dep	132	SENT_18	[p2l245t2152r562b2209],
56	at	IN	O	at	dep	132	SENT_18	[p2l587t2158r647b2209],
57	nucleotide	NN	O	nucleotide	dep	132	SENT_18	[p2l669t2146r1032b2209],
58	1799	CD	DATE	1799	dep	132	SENT_18	[p2l1063t2153r1238b2217],
59	,	,	O	,	_	0	SENT_18	[p2l1063t2153r1238b2217],
60	leading	VBG	O	lead	dep	132	SENT_18	[p2l1263t2146r1518b2229],
61	to	TO	O	to	dep	132	SENT_18	[p2l1540t2158r1606b2209],
62	a	DT	O	a	dep	132	SENT_18	[p2l1631t2168r1666b2209],
63	change	NN	O	change	dep	132	SENT_18	[p2l1689t2146r1929b2229],
64	in	IN	O	in	dep	132	SENT_18	[p2l1953t2152r2020b2208],
65	the	DT	O	the	dep	132	SENT_18	[p2l2043t2146r2150b2209],
66	V600	NN	O	v600	dep	132	SENT_18	[p2l38t2251r220b2309],
67	amino	NN	O	amino	dep	132	SENT_18	[p2l245t2252r463b2309],
68	acid	NN	O	acid	dep	132	SENT_18	[p2l488t2238r679b2309],
69	.9	CD	NUMBER	.9	dep	132	SENT_18	[p2l488t2238r679b2309],
70	V600E	NN	O	v600e	dep	132	SENT_18	[p2l701t2251r933b2309],
71	mutation	NN	O	mutation	dep	132	SENT_18	[p2l957t2252r1273b2309],
72	(	NN	O	(	dep	132	SENT_18	[p2l1300t2246r1740b2322],
73	substitution	NN	O	substitution	dep	132	SENT_18	[p2l1300t2246r1740b2322],
74	of	IN	O	of	dep	132	SENT_18	[p2l1764t2246r1838b2309],
75	glutamic	JJ	O	glutamic	dep	132	SENT_18	[p2l1852t2246r2152b2329],
76	acid	NN	O	acid	dep	132	SENT_18	[p2l40t2348r183b2411],
77	for	IN	O	for	dep	132	SENT_18	[p2l207t2348r306b2411],
78	valine	NN	O	valine	dep	132	SENT_18	[p2l327t2348r539b2411],
79	at	IN	O	at	dep	132	SENT_18	[p2l565t2360r625b2411],
80	position	NN	O	position	dep	132	SENT_18	[p2l648t2354r937b2430],
81	600	CD	NUMBER	600	dep	132	SENT_18	[p2l963t2349r1112b2424],
82	)	NN	O	)	dep	132	SENT_18	[p2l963t2349r1112b2424],
83	makes	VBZ	O	make	dep	132	SENT_18	[p2l1141t2348r1361b2411],
84	up	RP	O	up	dep	132	SENT_18	[p2l1386t2370r1472b2430],
85	>	JJR	O	>	dep	132	SENT_18	[p2l1501t2353r1692b2412],
86	90	CD	PERCENT	90	dep	132	SENT_18	[p2l1501t2353r1692b2412],
87	%	NN	PERCENT	%	dep	132	SENT_18	[p2l1501t2353r1692b2412],
88	of	IN	O	of	dep	132	SENT_18	[p2l1720t2348r1795b2411],
89	the	DT	O	the	dep	132	SENT_18	[p2l1809t2348r1918b2411],
90	mutations	NNS	O	mutation	dep	132	SENT_18	[p2l1942t2360r2150b2411, p2l38t2455r206b2512],
91	in	IN	O	in	dep	132	SENT_18	[p2l228t2455r295b2511],
92	BRAF	NN	O	braf	dep	132	SENT_18	[p2l315t2453r522b2511],
93	within	IN	O	within	dep	132	SENT_18	[p2l537t2449r760b2512],
94	melanoma	NN	O	melanoma	dep	132	SENT_18	[p2l781t2449r1160b2520],
95	,	,	O	,	_	0	SENT_18	[p2l781t2449r1160b2520],
96	with	IN	O	with	dep	132	SENT_18	[p2l1182t2449r1334b2512],
97	the	DT	O	the	dep	132	SENT_18	[p2l1355t2449r1461b2512],
98	remainder	NN	O	remainder	dep	132	SENT_18	[p2l1483t2449r1840b2512],
99	of	IN	O	of	dep	132	SENT_18	[p2l1861t2449r1934b2512],
100	mutations	NNS	O	mutation	dep	132	SENT_18	[p2l1946t2461r2149b2512, p2l38t2557r208b2614],
101	largely	RB	O	largely	dep	132	SENT_18	[p2l232t2551r464b2634],
102	resulting	VBG	O	result	dep	132	SENT_18	[p2l484t2551r790b2634],
103	from	IN	O	from	dep	132	SENT_18	[p2l812t2551r981b2614],
104	other	JJ	O	other	dep	132	SENT_18	[p2l1006t2551r1189b2614],
105	amino	NN	O	amino	dep	132	SENT_18	[p2l1213t2557r1431b2614],
106	acid	NN	O	acid	dep	132	SENT_18	[p2l1457t2551r1598b2614],
107	substitutions	NNS	O	substitution	dep	132	SENT_18	[p2l1622t2551r2067b2614],
108	at	IN	O	at	dep	132	SENT_18	[p2l2092t2563r2151b2614],
109	this	DT	O	this	dep	132	SENT_18	[p2l38t2651r166b2714],
110	position	NN	O	position	dep	132	SENT_18	[p2l190t2657r481b2733],
111	(	CD	NUMBER	(	dep	132	SENT_18	[p2l509t2652r801b2726],
112	V600K	NN	O	v600k	dep	132	SENT_18	[p2l509t2652r801b2726],
113	,	,	O	,	_	0	SENT_18	[p2l509t2652r801b2726],
114	V600D	NN	O	v600d	dep	132	SENT_18	[p2l826t2656r1093b2722],
115	,	,	O	,	_	0	SENT_18	[p2l826t2656r1093b2722],
116	or	CC	O	or	dep	132	SENT_18	[p2l1120t2674r1193b2714],
117	V600R	NN	O	v600r	dep	132	SENT_18	[p2l1215t2643r1570b2727],
118	)	CD	NUMBER	)	dep	132	SENT_18	[p2l1215t2643r1570b2727],
119	.11	CD	NUMBER	.11	dep	132	SENT_18	[p2l1215t2643r1570b2727],
120	BRAF	NN	O	braf	dep	132	SENT_18	[p2l1596t2655r1809b2713],
121	mutation	NN	O	mutation	dep	132	SENT_18	[p2l1829t2657r2152b2714],
122	is	VBZ	O	be	dep	132	SENT_18	[p2l39t2759r89b2816],
123	more	RBR	O	more	dep	132	SENT_18	[p2l114t2775r292b2816],
124	common	JJ	O	common	dep	132	SENT_18	[p2l317t2775r625b2816],
125	in	IN	O	in	dep	132	SENT_18	[p2l650t2759r716b2815],
126	tumors	NNS	O	tumor	dep	132	SENT_18	[p2l740t2765r987b2816],
127	from	IN	O	from	dep	132	SENT_18	[p2l1011t2753r1180b2816],
128	patients	NNS	O	patient	dep	132	SENT_18	[p2l1202t2759r1475b2835],
129	with	IN	O	with	dep	132	SENT_18	[p2l1498t2753r1652b2816],
130	a	DT	O	a	dep	132	SENT_18	[p2l1677t2775r1711b2816],
131	younger	JJR	O	younger	dep	132	SENT_18	[p2l1732t2775r2017b2836],
132	age	NN	O	age	_	0	SENT_18	[p2l2041t2775r2151b2836],

1	‘	NNP	O	‘	nn	3	SENT_19	[p2l22t2921r191b2954],
2	Department	NNP	O	Department	nn	3	SENT_19	[p2l22t2921r191b2954],
3	ofMedicine	NN	O	ofmedicine	_	0	SENT_19	[p2l198t2924r354b2951],
4	,	,	O	,	_	0	SENT_19	[p2l198t2924r354b2951],
5	Georgetown	NNP	ORGANIZATION	Georgetown	nn	8	SENT_19	[p2l361t2925r522b2954],
6	University	NNP	ORGANIZATION	University	nn	8	SENT_19	[p2l531t2925r660b2954],
7	School	NNP	ORGANIZATION	School	nn	8	SENT_19	[p2l666t2924r752b2948],
8	ofMedicine	NNP	O	ofMedicine	appos	3	SENT_19	[p2l760t2924r916b2951],
9	,	,	O	,	_	0	SENT_19	[p2l760t2924r916b2951],
10	Washington	NNP	LOCATION	Washington	appos	3	SENT_19	[p2l922t2924r1084b2954],
11	,	,	O	,	_	0	SENT_19	[p2l922t2924r1084b2954],
12	DC	NNP	ORGANIZATION	DC	appos	3	SENT_19	[p2l1092t2925r1134b2951],
13	,	,	O	,	_	0	SENT_19	[p2l1092t2925r1134b2951],
14	USA	NNP	LOCATION	USA	appos	3	SENT_19	[p2l1143t2925r1201b2951],
15	;	:	O	;	_	0	SENT_19	[p2l1143t2925r1201b2951],
16	2Hemato	NNP	O	2Hemato	nn	18	SENT_19	[p2l1208t2921r1380b2954],
17	|	CD	NUMBER	|	num	18	SENT_19	[p2l1208t2921r1380b2954],
18	ogy	NN	O	ogy	dep	3	SENT_19	[p2l1208t2921r1380b2954],
19	and	CC	O	and	_	0	SENT_19	[p2l1387t2924r1434b2948],
20	Oncology	NN	O	oncology	conj_and	18	SENT_19	[p2l1442t2924r1572b2954],
21	,	,	O	,	_	0	SENT_19	[p2l1442t2924r1572b2954],
22	MedStarWashington	NNP	ORGANIZATION	MedStarWashington	nn	24	SENT_19	[p2l1580t2924r1847b2954],
23	Hospital	NNP	ORGANIZATION	Hospital	nn	24	SENT_19	[p2l1856t2924r1960b2954],
24	Center	NNP	ORGANIZATION	Center	appos	3	SENT_19	[p2l1968t2925r2058b2951],
25	,	,	O	,	_	0	SENT_19	[p2l1968t2925r2058b2951],
26	Washington	NNP	LOCATION	Washington	appos	3	SENT_19	[p2l20t2961r182b2991],
27	,	,	O	,	_	0	SENT_19	[p2l20t2961r182b2991],
28	DC	NNP	ORGANIZATION	DC	appos	3	SENT_19	[p2l191t2962r233b2988],
29	,	,	O	,	_	0	SENT_19	[p2l191t2962r233b2988],
30	USA	NNP	LOCATION	USA	appos	3	SENT_19	[p2l241t2962r300b2988],
31	;	:	O	;	_	0	SENT_19	[p2l241t2962r300b2988],
32	3Division	NN	O	3division	dep	3	SENT_19	[p2l307t2958r420b2985],
33	of	IN	O	of	_	0	SENT_19	[p2l429t2961r455b2985],
34	Hematology	NNP	O	Hematology	prep_of	32	SENT_19	[p2l461t2961r620b2991],
35	and	CC	O	and	_	0	SENT_19	[p2l626t2961r674b2985],
36	Oncology	NNP	O	Oncology	conj_and	34	SENT_19	[p2l682t2961r812b2991],
37	,	,	O	,	_	0	SENT_19	[p2l682t2961r812b2991],
38	Georgetown	NNP	ORGANIZATION	Georgetown	nn	40	SENT_19	[p2l819t2962r980b2991],
39	University	NNP	ORGANIZATION	University	nn	40	SENT_19	[p2l989t2963r1118b2991],
40	School	NNP	ORGANIZATION	School	appos	3	SENT_19	[p2l1124t2961r1210b2985],
41	of	IN	ORGANIZATION	of	_	0	SENT_19	[p2l1218t2961r1245b2985],
42	Medicine	NNP	ORGANIZATION	Medicine	prep_of	40	SENT_19	[p2l1250t2961r1374b2988],
43	,	,	O	,	_	0	SENT_19	[p2l1250t2961r1374b2988],
44	Washington	NNP	LOCATION	Washington	appos	3	SENT_19	[p2l1379t2961r1542b2991],
45	,	,	O	,	_	0	SENT_19	[p2l1379t2961r1542b2991],
46	DC	NNP	ORGANIZATION	DC	appos	3	SENT_19	[p2l1550t2962r1592b2988],
47	,	,	O	,	_	0	SENT_19	[p2l1550t2962r1592b2988],
48	USA	NNP	LOCATION	USA	appos	3	SENT_19	[p2l1601t2962r1659b2988],
49	;	:	O	;	_	0	SENT_19	[p2l1601t2962r1659b2988],
50	4Georgetown-Lombardi	NNP	O	4Georgetown-Lombardi	nn	53	SENT_19	[p2l1665t2958r1974b2991],
51	Comprehensive	NNP	ORGANIZATION	Comprehensive	nn	53	SENT_19	[p2l21t2999r224b3028],
52	Cancer	NNP	ORGANIZATION	Cancer	nn	53	SENT_19	[p2l231t3000r320b3022],
53	Center	NNP	ORGANIZATION	Center	dep	3	SENT_19	[p2l326t3000r416b3025],
54	,	,	O	,	_	0	SENT_19	[p2l326t3000r416b3025],
55	Washington	NNP	LOCATION	Washington	nn	59	SENT_19	[p2l421t2999r583b3028],
56	,	,	O	,	_	0	SENT_19	[p2l421t2999r583b3028],
57	DC	NNP	ORGANIZATION	DC	appos	59	SENT_19	[p2l592t3000r634b3025],
58	,	,	O	,	_	0	SENT_19	[p2l592t3000r634b3025],
59	USA	NNP	LOCATION	USA	appos	53	SENT_19	[p2l642t3000r701b3022],
60	.	.	O	.	_	0	SENT_19	[p2l642t3000r701b3022],

1	Correspondence	NN	O	correspondence	_	0	SENT_20	[p2l708t2999r928b3028],
2	:	:	O	:	_	0	SENT_20	[p2l708t2999r928b3028],
3	MB	NNP	PERSON	MB	nn	4	SENT_20	[p2l936t3000r975b3022],
4	Atkins	NNP	PERSON	Atkins	dep	1	SENT_20	[p2l982t2999r1062b3022],
5	(	CD	NUMBER	(	num	7	SENT_20	[p2l1070t2999r1163b3025],
6	mba41	NN	O	mba41	nn	7	SENT_20	[p2l1070t2999r1163b3025],
7	@georgetown.edu	NN	O	@georgetown.edu	dep	4	SENT_20	[p2l1169t2999r1416b3028],
8	)	CD	NUMBER	)	dep	4	SENT_20	[p2l1169t2999r1416b3028],
9	Received	VBN	O	receive	partmod	4	SENT_20	[p2l22t3039r130b3062],
10	14	CD	DATE	14	num	11	SENT_20	[p2l141t3041r168b3062],
11	August	NNP	DATE	August	nsubj	15	SENT_20	[p2l175t3040r263b3068],
12	201	CD	NUMBER	201	number	13	SENT_20	[p2l270t3041r308b3062],
13	3	CD	NUMBER	3	dep	11	SENT_20	[p2l316t3041r335b3065],
14	;	:	O	;	_	0	SENT_20	[p2l316t3041r335b3065],
15	accepted	VBN	O	accept	dep	9	SENT_20	[p2l342t3039r455b3068],
16	25	CD	DATE	25	num	17	SENT_20	[p2l463t3041r491b3062],
17	September	NNP	DATE	September	tmod	15	SENT_20	[p2l500t3039r637b3068],
18	201	CD	NUMBER	201	num	17	SENT_20	[p2l644t3041r682b3062],
19	3	CD	NUMBER	3	dep	17	SENT_20	[p2l690t3041r708b3065],
20	;	:	O	;	_	0	SENT_20	[p2l690t3041r708b3065],
21	advance	NN	O	advance	nn	23	SENT_20	[p2l716t3039r819b3062],
22	onllne	NN	O	onllne	nn	23	SENT_20	[p2l827t3039r903b3062],
23	publication	NN	O	publication	dep	1	SENT_20	[p2l912t3039r1049b3068],
24	27	CD	NUMBER	27	num	25	SENT_20	[p2l1058t3041r1086b3062],
25	November20l	NN	O	november20l	dep	23	SENT_20	[p2l1095t3039r1271b3062],
26	3	CD	NUMBER	3	dep	25	SENT_20	[p2l1278t3041r1296b3062],
27	.	.	O	.	_	0	SENT_20	[p2l1278t3041r1296b3062],

1	doi	FW	O	doi	_	0	SENT_21	[p2l1304t3039r1358b3062],
2	:	:	O	:	_	0	SENT_21	[p2l1304t3039r1358b3062],
3	l	NN	O	l	nn	5	SENT_21	[p2l1304t3039r1358b3062],
4	0.1	CD	NUMBER	0.1	num	5	SENT_21	[p2l1365t3041r1394b3062],
5	038/c	NN	O	038/c	dep	1	SENT_21	[p2l1401t3039r1549b3068],
6	|	CD	NUMBER	|	num	7	SENT_21	[p2l1401t3039r1549b3068],
7	pt	NN	O	pt	dep	15	SENT_21	[p2l1401t3039r1549b3068],
8	.20	CD	NUMBER	.20	num	9	SENT_21	[p2l1401t3039r1549b3068],
9	l	NN	O	l	dep	7	SENT_21	[p2l1401t3039r1549b3068],
10	3.1	CD	NUMBER	3.1	number	11	SENT_21	[p2l1557t3041r1585b3062],
11	97	CD	NUMBER	97	dep	9	SENT_21	[p2l1592t3041r1621b3062],
12	24	CD	NUMBER	24	num	13	SENT_21	[p2l21t3082r52b3103],
13	VOLUME	NN	O	volume	dep	15	SENT_21	[p2l1368t3082r1476b3103],
14	95	CD	NUMBER	95	num	15	SENT_21	[p2l1484t3082r1511b3103],
15	NUMBER	NN	O	number	dep	18	SENT_21	[p2l1521t3082r1629b3103],
16	1	CD	NUMBER	1	dep	15	SENT_21	[p2l1639t3083r1646b3103],
17	I	PRP	O	I	nsubj	18	SENT_21	[p2l1659t3080r1662b3110],
18	JANUARY	VBP	DATE	january	dep	1	SENT_21	[p2l1671t3082r1789b3103],
19	2014	CD	DATE	2014	num	21	SENT_21	[p2l1796t3082r1855b3103],
20	|	JJ	O	|	amod	21	SENT_21	[p2l1864t3080r1866b3110],
21	www.nature.com/cpt	NN	O	www.nature.com/cpt	dobj	18	SENT_21	[p2l1875t3082r2140b3108],

1	Illustrated	NNP	O	Illustrated	_	0	SENT_22	[p2l1832t3634r1850b3737],
2	by	IN	O	by	dep	1	SENT_22	[p2l1832t3602r1855b3626],
3	Zina	NNP	PERSON	Zina	nn	4	SENT_22	[p2l1832t3548r1850b3594],
4	Deretsky	NNP	PERSON	Deretsky	pobj	2	SENT_22	[p2l1832t3445r1855b3539],

1	Figure	NNP	O	Figure	nsubj	5	SENT_23	[p3l21t39r111b69],
2	1	CD	NUMBER	1	num	1	SENT_23	[p3l120t40r130b62],
3	The	DT	O	the	det	4	SENT_23	[p3l157t38r206b63],
4	treatment	NN	O	treatment	dep	1	SENT_23	[p3l213t42r347b63],
5	approved	VBN	O	approve	_	0	SENT_23	[p3l354t38r481b69],
6	by	IN	O	by	_	0	SENT_23	[p3l490t38r522b69],
7	the	DT	O	the	det	9	SENT_23	[p3l528t38r572b63],
8	US	NNP	ORGANIZATION	US	nn	9	SENT_23	[p3l580t39r614b63],
9	Food	NNP	ORGANIZATION	Food	prep_by	5	SENT_23	[p3l623t38r687b63],
10	and	CC	ORGANIZATION	and	_	0	SENT_23	[p3l696t38r745b63],
11	Drug	NNP	ORGANIZATION	Drug	nn	12	SENT_23	[p3l755t39r819b69],
12	Administration	NNP	ORGANIZATION	Administration	conj_and	9	SENT_23	[p3l827t38r1025b63],
13	for	IN	O	for	_	0	SENT_23	[p3l1033t38r1070b63],
14	advanced	JJ	O	advanced	amod	15	SENT_23	[p3l1077t38r1205b63],
15	melanoma	NN	O	melanoma	prep_for	5	SENT_23	[p3l1215t38r1362b63],
16	.	.	O	.	_	0	SENT_23	[p3l1215t38r1362b63],

1	Vemurafenib	NNP	O	Vemurafenib	nn	2	SENT_24	[p3l490t1270r808b1313],
2	Dabrafenib	NNP	O	Dabrafenib	_	0	SENT_24	[p3l513t1340r788b1383],
3	LGX818	NN	O	lgx818	dep	2	SENT_24	[p3l547t1409r753b1453],

1	Trametinib	NN	O	trametinib	_	0	SENT_25	[p3l517t1655r780b1697],
2	GDC0973	NN	O	gdc0973	nn	3	SENT_25	[p3l523t1724r776b1767],
3	MEK162	NN	O	mek162	dep	1	SENT_25	[p3l542t1795r758b1837],

1	Illustrated	NNP	O	Illustrated	_	0	SENT_26	[p3l1968t2305r2004b2515],
2	by	IN	O	by	dep	1	SENT_26	[p3l1968t2239r2014b2287],
3	Zina	NNP	PERSON	Zina	nn	4	SENT_26	[p3l1968t2129r2004b2224],
4	Deretsky	NNP	PERSON	Deretsky	pobj	2	SENT_26	[p3l1968t1917r2014b2110],

1	Figure	NN	O	figure	_	0	SENT_27	[p3l10t2677r197b2738],
2	2	CD	NUMBER	2	num	3	SENT_27	[p3l213t2679r245b2724],
3	Agents	NNS	O	agent	dep	1	SENT_27	[p3l295t2678r488b2738],
4	targeting	VBG	O	target	partmod	1	SENT_27	[p3l503t2678r757b2738],
5	the	DT	O	the	det	9	SENT_27	[p3l775t2676r864b2725],
6	activated	VBN	O	activate	amod	9	SENT_27	[p3l881t2676r1133b2725],
7	MAPK	NN	ORGANIZATION	mapk	nn	9	SENT_27	[p3l1153t2678r1316b2724],
8	signaling	NN	O	signaling	nn	9	SENT_27	[p3l1331t2676r1578b2738],
9	pathway	NN	O	pathway	dobj	4	SENT_27	[p3l1599t2676r1836b2739],
10	in	IN	O	in	_	0	SENT_27	[p3l1852t2678r1897b2724],
11	BRAFV6OO	NN	O	brafv6oo	nn	13	SENT_27	[p3l11t2763r291b2810],
12	mutant	JJ	O	mutant	amod	13	SENT_27	[p3l310t2769r511b2810],
13	melanoma	NN	O	melanoma	prep_in	4	SENT_27	[p3l529t2761r836b2810],
14	.	.	O	.	_	0	SENT_27	[p3l529t2761r836b2810],

1	MAPK	NN	O	mapk	nn	6	SENT_28	[p3l854t2763r1030b2818],
2	,	,	O	,	_	0	SENT_28	[p3l854t2763r1030b2818],
3	mitogen	NN	O	mitogen	dep	6	SENT_28	[p3l1048t2761r1556b2823],
4	—	NN	O	—	nn	6	SENT_28	[p3l1048t2761r1556b2823],
5	activated	VBN	O	activate	amod	6	SENT_28	[p3l1048t2761r1556b2823],
6	protein	NN	O	protein	_	0	SENT_28	[p3l1577t2764r1773b2823],
7	kinase	NN	O	kinase	dep	6	SENT_28	[p3l1794t2761r1977b2810],
8	.	.	O	.	_	0	SENT_28	[p3l1794t2761r1977b2810],

1	at	IN	O	at	_	0	SENT_29	[p3l9t2991r71b3042],
2	diagnosis	NN	O	diagnosis	prep_at	33	SENT_29	[p3l96t2979r451b3063],
3	,	,	O	,	_	0	SENT_29	[p3l96t2979r451b3063],
4	tumors	NNS	O	tumor	prep_at	33	SENT_29	[p3l478t2991r733b3042],
5	with	IN	O	with	_	0	SENT_29	[p3l758t2979r917b3042],
6	a	DT	O	a	det	8	SENT_29	[p3l943t3002r978b3042],
7	truncal	JJ	O	truncal	amod	8	SENT_29	[p3l1001t2979r1261b3042],
8	location	NN	O	location	prep_with	4	SENT_29	[p3l1284t2979r1595b3051],
9	,	,	O	,	_	0	SENT_29	[p3l1284t2979r1595b3051],
10	and	CC	O	and	_	0	SENT_29	[p3l1623t2979r1754b3042],
11	superﬁcial	JJ	O	superﬁcial	amod	15	SENT_29	[p3l1779t2979r2151b3062],
12	spreading	NN	O	spreading	amod	15	SENT_29	[p3l10t3083r355b3167],
13	and	CC	O	and	_	0	SENT_29	[p3l379t3083r508b3146],
14	nodular	JJ	O	nodular	amod	15	SENT_29	[p3l532t3083r811b3146],
15	subtypes	NNS	O	subtype	conj_and	2	SENT_29	[p3l836t3083r1161b3167],
16	,	,	O	,	_	0	SENT_29	[p3l836t3083r1161b3167],
17	whereas	IN	O	whereas	mark	20	SENT_29	[p3l1185t3083r1471b3146],
18	it	PRP	O	it	nsubj	20	SENT_29	[p3l1496t3089r1544b3146],
19	is	VBZ	O	be	cop	20	SENT_29	[p3l1567t3089r1619b3146],
20	uncommon	JJ	O	uncommon	dep	2	SENT_29	[p3l1644t3106r2055b3146],
21	in	IN	O	in	_	0	SENT_29	[p3l2080t3089r2148b3145],
22	melanomas	NNS	O	melanoma	prep_in	20	SENT_29	[p3l8t3186r408b3249],
23	arising	VBG	O	arise	partmod	22	SENT_29	[p3l432t3192r670b3270],
24	from	IN	O	from	_	0	SENT_29	[p3l691t3186r862b3249],
25	mucosal	JJ	O	mucosal	amod	28	SENT_29	[p3l885t3186r1176b3249],
26	or	CC	O	or	_	0	SENT_29	[p3l1199t3209r1272b3249],
27	acral	JJ	O	acral	conj_or	25	SENT_29	[p3l1295t3186r1462b3249],
28	surfaces	NNS	O	surface	prep_from	23	SENT_29	[p3l1485t3186r1765b3249],
29	or	CC	O	or	_	0	SENT_29	[p3l1789t3209r1862b3249],
30	chronic	JJ	O	chronic	amod	32	SENT_29	[p3l1884t3186r2149b3249],
31	sun	NN	O	sun	nn	32	SENT_29	[p3l9t3289r485b3373],
32	—	NN	O	—	conj_or	28	SENT_29	[p3l9t3289r485b3373],
33	damaged	VBD	O	damage	_	0	SENT_29	[p3l9t3289r485b3373],
34	skin	NN	O	skin	dobj	33	SENT_29	[p3l509t3289r652b3352],
35	such	JJ	O	such	_	0	SENT_29	[p3l678t3289r835b3352],
36	as	IN	O	as	_	0	SENT_29	[p3l860t3312r926b3352],
37	that	DT	O	that	prep_such_as	34	SENT_29	[p3l949t3289r1086b3352],
38	typically	RB	O	typically	advmod	39	SENT_29	[p3l1108t3289r1409b3373],
39	seen	VBN	O	see	partmod	37	SENT_29	[p3l1431t3312r1582b3352],
40	in	IN	O	in	_	0	SENT_29	[p3l1607t3295r1675b3351],
41	the	DT	O	the	det	42	SENT_29	[p3l1698t3289r1807b3352],
42	head	NN	O	head	prep_in	39	SENT_29	[p3l1830t3289r1998b3352],
43	and	CC	O	and	_	0	SENT_29	[p3l2022t3289r2150b3352],
44	the	DT	O	the	det	45	SENT_29	[p3l8t3391r115b3455],
45	neck	NN	O	neck	prep_in	39	SENT_29	[p3l138t3383r430b3455],
46	.9	CD	NUMBER	.9	nsubj	33	SENT_29	[p3l138t3383r430b3455],
47	’12	CD	NUMBER	’12	num	49	SENT_29	[p3l138t3383r430b3455],
48	BRAF	NN	O	braf	nn	49	SENT_29	[p3l451t3395r663b3454],
49	mutation	NN	O	mutation	nsubj	50	SENT_29	[p3l680t3398r1000b3455],
50	is	VBZ	O	be	rcmod	46	SENT_29	[p3l1022t3398r1072b3455],
51	of	IN	O	of	_	0	SENT_29	[p3l1096t3391r1171b3455],
52	prognostic	JJ	O	prognostic	amod	53	SENT_29	[p3l1182t3398r1556b3476],
53	Value	NN	O	value	prep_of	50	SENT_29	[p3l1575t3391r1759b3455],
54	and	CC	O	and	_	0	SENT_29	[p3l1782t3391r1927b3464],
55	,	,	O	,	_	0	SENT_29	[p3l1782t3391r1927b3464],
56	in	IN	O	in	mark	62	SENT_29	[p3l1951t3398r2019b3454],
57	the	DT	O	the	det	58	SENT_29	[p3l2040t3391r2148b3455],
58	absence	NN	O	absence	nsubj	62	SENT_29	[p3l9t3495r281b3558],
59	of	IN	O	of	_	0	SENT_29	[p3l306t3495r381b3558],
60	BRAF	NN	O	braf	nn	61	SENT_29	[p3l395t3495r926b3558],
61	—	NN	O	—	prep_of	58	SENT_29	[p3l395t3495r926b3558],
62	directed	VBD	O	direct	parataxis	50	SENT_29	[p3l395t3495r926b3558],
63	therapy	NN	O	therapy	dobj	62	SENT_29	[p3l947t3495r1224b3579],
64	,	,	O	,	_	0	SENT_29	[p3l947t3495r1224b3579],
65	is	VBZ	O	be	auxpass	66	SENT_29	[p3l1250t3501r1301b3558],
66	associated	VBN	O	associate	conj_and	50	SENT_29	[p3l1327t3495r1683b3558],
67	with	IN	O	with	_	0	SENT_29	[p3l1704t3495r1860b3558],
68	inferior	JJ	O	inferior	amod	69	SENT_29	[p3l1884t3495r2150b3558],
69	survival	NN	O	survival	prep_with	66	SENT_29	[p3l9t3598r285b3661],
70	in	IN	O	in	_	0	SENT_29	[p3l307t3604r374b3660],
71	the	DT	O	the	det	73	SENT_29	[p3l395t3598r502b3661],
72	metastatic	JJ	O	metastatic	amod	73	SENT_29	[p3l525t3604r880b3661],
73	setting	NN	O	setting	prep_in	69	SENT_29	[p3l903t3604r1136b3682],
74	and	CC	O	and	_	0	SENT_29	[p3l1157t3598r1285b3661],
75	in	IN	O	in	_	0	SENT_29	[p3l1306t3604r1373b3660],
76	patients	NNS	O	patient	conj_and	73	SENT_29	[p3l1394t3604r1667b3681],
77	with	IN	O	with	_	0	SENT_29	[p3l1689t3598r1843b3661],
78	resected	JJ	O	resected	amod	81	SENT_29	[p3l1866t3598r2150b3661],
79	stage	NN	O	stage	nn	81	SENT_29	[p3l10t3713r186b3785],
80	III	CD	NUMBER	iii	num	81	SENT_29	[p3l214t3705r302b3763],
81	melanoma	NN	O	melanoma	prep_with	76	SENT_29	[p3l329t3692r898b3764],
82	.12	CD	NUMBER	.12	number	83	SENT_29	[p3l329t3692r898b3764],
83	‘	CD	NUMBER	‘	num	84	SENT_29	[p3l329t3692r898b3764],
84	14	CD	NUMBER	14	dep	69	SENT_29	[p3l329t3692r898b3764],
85	Although	IN	O	although	mark	86	SENT_29	[p3l923t3700r1268b3785],
86	much	JJ	O	much	dep	66	SENT_29	[p3l1294t3700r1497b3764],
87	of	IN	O	of	_	0	SENT_29	[p3l1524t3700r1601b3764],
88	the	DT	O	the	prep_of	46	SENT_29	[p3l1617t3700r1728b3764],
89	transforming	VBG	O	transform	amod	88	SENT_29	[p3l1754t3700r2146b3764, p4l9t22r121b100],

1	activity	NN	O	activity	nsubjpass	6	SENT_30	[p4l145t22r410b100],
2	of	IN	O	of	_	0	SENT_30	[p4l432t16r509b79],
3	mutant	JJ	O	mutant	amod	4	SENT_30	[p4l524t28r782b79],
4	BRAF	NN	ORGANIZATION	braf	prep_of	1	SENT_30	[p4l807t20r1018b79],
5	is	VBZ	O	be	auxpass	6	SENT_30	[p4l1045t22r1096b79],
6	mediated	VBN	O	mediate	_	0	SENT_30	[p4l1123t16r1455b79],
7	through	IN	O	through	_	0	SENT_30	[p4l1479t16r1768b100],
8	activation	NN	O	activation	prep_through	6	SENT_30	[p4l1794t22r2147b79],
9	of	IN	O	of	_	0	SENT_30	[p4l9t119r85b182],
10	the	DT	O	the	det	12	SENT_30	[p4l100t119r210b182],
11	MAPK	NN	ORGANIZATION	mapk	nn	12	SENT_30	[p4l236t123r485b181],
12	pathway	NN	O	pathway	prep_of	8	SENT_30	[p4l507t119r818b203],
13	,	,	O	,	_	0	SENT_30	[p4l507t119r818b203],
14	BRAF	NN	O	braf	nn	15	SENT_30	[p4l843t123r1059b182],
15	mutations	NNS	O	mutation	nsubj	17	SENT_30	[p4l1080t125r1440b182],
16	also	RB	O	also	advmod	17	SENT_30	[p4l1466t119r1603b182],
17	appear	VBP	O	appear	conj_and	6	SENT_30	[p4l1630t141r1870b202],
18	to	TO	O	to	aux	19	SENT_30	[p4l1893t131r1961b182],
19	have	VB	O	have	xcomp	17	SENT_30	[p4l1986t119r2148b182],
20	an	DT	O	a	det	21	SENT_30	[p4l9t245r93b285],
21	impact	NN	O	impact	dobj	19	SENT_30	[p4l122t228r373b305],
22	on	IN	O	on	_	0	SENT_30	[p4l402t245r492b285],
23	the	DT	O	the	det	25	SENT_30	[p4l520t222r632b285],
24	tumor	NN	O	tumor	nn	25	SENT_30	[p4l660t234r888b285],
25	microenvironment	NN	O	microenvironment	prep_on	21	SENT_30	[p4l915t228r1629b294],
26	,	,	O	,	_	0	SENT_30	[p4l915t228r1629b294],
27	including	VBG	O	include	_	0	SENT_30	[p4l1660t222r2009b306],
28	the	DT	O	the	det	29	SENT_30	[p4l2035t222r2147b285],
29	production	NN	O	production	prep_including	21	SENT_30	[p4l7t325r401b408],
30	of	IN	O	of	_	0	SENT_30	[p4l425t325r500b388],
31	immunosuppressive	JJ	O	immunosuppressive	amod	32	SENT_30	[p4l513t331r1219b408],
32	factors	NNS	O	factor	prep_of	29	SENT_30	[p4l1243t325r1477b388],
33	by	IN	O	by	_	0	SENT_30	[p4l1498t325r1583b409],
34	tumor	NN	O	tumor	nn	35	SENT_30	[p4l1602t337r1821b388],
35	cells	NNS	O	cell	prep_by	17	SENT_30	[p4l1844t325r1991b388],
36	that	WDT	O	that	nsubj	37	SENT_30	[p4l2013t325r2150b388],
37	contribute	VBP	O	contribute	rcmod	35	SENT_30	[p4l9t428r378b491],
38	to	TO	O	to	_	0	SENT_30	[p4l402t440r470b491],
39	immune	JJ	O	immune	amod	40	SENT_30	[p4l497t434r796b491],
40	evasion	NN	O	evasion	prep_to	37	SENT_30	[p4l821t434r1088b491],
41	and	CC	O	and	_	0	SENT_30	[p4l1114t428r1244b491],
42	the	DT	O	the	det	43	SENT_30	[p4l1268t428r1377b491],
43	production	NN	O	production	nsubj	65	SENT_30	[p4l1402t428r1803b511],
44	of	IN	O	of	_	0	SENT_30	[p4l1829t428r1905b491],
45	vascular	JJ	O	vascular	amod	51	SENT_30	[p4l1918t451r2146b491, p4l7t531r100b594],
46	endothelial	JJ	O	endothelial	amod	51	SENT_30	[p4l124t531r522b594],
47	growth	NN	O	growth	nn	51	SENT_30	[p4l547t531r798b615],
48	factor	NN	O	factor	nn	51	SENT_30	[p4l822t531r1029b594],
49	(	CD	NUMBER	(	num	51	SENT_30	[p4l1056t532r1330b607],
50	VEGF	NN	O	vegf	nn	51	SENT_30	[p4l1056t532r1330b607],
51	)	NN	O	)	prep_of	43	SENT_30	[p4l1056t532r1330b607],
52	that	WDT	O	that	nsubj	53	SENT_30	[p4l1358t531r1496b594],
53	leads	VBZ	O	lead	rcmod	51	SENT_30	[p4l1518t531r1696b594],
54	to	TO	O	to	_	0	SENT_30	[p4l1720t543r1787b594],
55	increased	VBN	O	increase	amod	56	SENT_30	[p4l1814t531r2150b594],
56	vascularity	NN	O	vascularity	prep_to	53	SENT_30	[p4l6t625r546b718],
57	.15	CD	NUMBER	.15	number	58	SENT_30	[p4l6t625r546b718],
58	’16	CD	NUMBER	’16	num	60	SENT_30	[p4l6t625r546b718],
59	These	DT	O	these	det	60	SENT_30	[p4l570t633r767b697],
60	changes	NNS	O	change	dobj	53	SENT_30	[p4l792t633r1067b718],
61	in	IN	O	in	_	0	SENT_30	[p4l1093t640r1160b696],
62	the	DT	O	the	det	63	SENT_30	[p4l1183t633r1292b697],
63	microenvironment	NN	O	microenvironment	prep_in	60	SENT_30	[p4l1316t640r1981b697],
64	may	MD	O	may	aux	65	SENT_30	[p4l2004t656r2153b718],
65	inﬂuence	VB	O	inﬂuence	conj_and	6	SENT_30	[p4l9t737r326b800],
66	response	NN	O	response	dobj	65	SENT_30	[p4l348t759r651b820],
67	and	CC	O	and	_	0	SENT_30	[p4l674t737r800b800],
68	resistance	NN	O	resistance	dobj	65	SENT_30	[p4l821t743r1159b800],
69	to	TO	O	to	_	0	SENT_30	[p4l1180t749r1246b800],
70	therapy	NN	O	therapy	prep_to	65	SENT_30	[p4l1268t737r1533b821],
71	and	CC	O	and	_	0	SENT_30	[p4l1552t737r1679b800],
72	be	VB	O	be	cop	73	SENT_30	[p4l1697t737r1777b800],
73	important	JJ	O	important	conj_and	65	SENT_30	[p4l1799t743r2150b820],
74	in	IN	O	in	_	0	SENT_30	[p4l9t846r75b902],
75	identifying	VBG	O	identify	prepc_in	73	SENT_30	[p4l97t840r476b924],
76	opportunities	NNS	O	opportunity	dobj	75	SENT_30	[p4l497t846r963b923],
77	and	CC	O	and	_	0	SENT_30	[p4l987t840r1113b903],
78	timing	NN	O	timing	conj_and	76	SENT_30	[p4l1132t846r1363b924],
79	for	IN	O	for	_	0	SENT_30	[p4l1383t840r1481b903],
80	combination	NN	O	combination	nn	82	SENT_30	[p4l1502t840r1939b903],
81	treatment	NN	O	treatment	nn	82	SENT_30	[p4l1960t852r2146b903, p4l8t955r188b1006],
82	approaches	NNS	O	approach	prep_for	75	SENT_30	[p4l211t943r621b1026],
83	.	.	O	.	_	0	SENT_30	[p4l211t943r621b1026],

1	TARGETED	VBN	O	target	_	0	SENT_31	[p4l8t1054r386b1108],
2	THERAPY	NN	O	therapy	dobj	1	SENT_31	[p4l401t1054r738b1108],
3	FOR	IN	O	for	_	0	SENT_31	[p4l758t1053r899b1109],
4	PATIENTS	NNS	O	patient	prep_for	2	SENT_31	[p4l920t1054r1256b1108],
5	WITH	IN	O	with	_	0	SENT_31	[p4l1271t1054r1459b1108],
6	BRAF-MUTANT	NN	O	braf-mutant	prep_with	1	SENT_31	[p4l1483t1054r2013b1109],

1	MELANOMA	NN	O	melanoma	_	0	SENT_32	[p4l11t1156r445b1212],

1	Early	RB	O	early	advmod	11	SENT_33	[p4l11t1258r181b1331],
2	efforts	NNS	O	effort	pobj	1	SENT_33	[p4l197t1257r426b1315],
3	with	IN	O	with	_	0	SENT_33	[p4l442t1258r593b1315],
4	BRAF	NN	ORGANIZATION	braf	nn	7	SENT_33	[p4l615t1260r795b1315],
5	and	CC	O	and	_	0	SENT_33	[p4l813t1258r941b1315],
6	MEK	NN	O	mek	nn	7	SENT_33	[p4l962t1260r1115b1314],
7	inhibition	NN	O	inhibition	prep_with	1	SENT_33	[p4l1132t1258r1469b1315],
8	The	DT	O	the	det	11	SENT_33	[p4l8t1354r137b1418],
9	ﬁrst	JJ	O	ﬁrst	amod	11	SENT_33	[p4l165t1354r305b1418],
10	Raf	NN	ORGANIZATION	raf	nn	11	SENT_33	[p4l333t1354r461b1418],
11	inhibitor	NN	O	inhibitor	nsubj	16	SENT_33	[p4l480t1354r799b1418],
12	tested	VBN	O	test	partmod	11	SENT_33	[p4l826t1354r1037b1418],
13	in	IN	O	in	_	0	SENT_33	[p4l1065t1360r1134b1417],
14	melanoma	NN	O	melanoma	prep_in	12	SENT_33	[p4l1162t1354r1541b1418],
15	was	VBD	O	be	cop	16	SENT_33	[p4l1566t1377r1697b1418],
16	sorafenib	NN	O	sorafenib	_	0	SENT_33	[p4l1728t1354r2078b1426],
17	,	,	O	,	_	0	SENT_33	[p4l1728t1354r2078b1426],
18	a	DT	O	a	det	22	SENT_33	[p4l2108t1377r2143b1418],
19	small	JJ	O	small	amod	22	SENT_33	[p4l9t1458r541b1521],
20	—	NN	O	—	nn	22	SENT_33	[p4l9t1458r541b1521],
21	molecule	NN	O	molecule	nn	22	SENT_33	[p4l9t1458r541b1521],
22	inhibitor	NN	O	inhibitor	conj_and	16	SENT_33	[p4l565t1458r871b1521],
23	of	IN	O	of	_	0	SENT_33	[p4l894t1458r968b1521],
24	VEGF	NN	O	vegf	nn	25	SENT_33	[p4l980t1462r1196b1521],
25	receptors	NNS	O	receptor	prep_of	22	SENT_33	[p4l1220t1470r1537b1541],
26	and	CC	O	and	_	0	SENT_33	[p4l1562t1458r1689b1521],
27	RAF	NN	ORGANIZATION	raf	nn	29	SENT_33	[p4l1712t1462r1867b1521],
28	kinases	NNS	O	kinase	nn	29	SENT_33	[p4l1890t1458r2141b1521],
29	(	NN	O	(	conj_and	16	SENT_33	[p4l12t1561r372b1645],
30	including	VBG	O	include	_	0	SENT_33	[p4l12t1561r372b1645],
31	both	DT	O	both	preconj	35	SENT_33	[p4l392t1561r554b1624],
32	BRAF	NN	O	braf	nn	35	SENT_33	[p4l578t1565r786b1624],
33	and	CC	O	and	_	0	SENT_33	[p4l812t1561r940b1624],
34	CRAF	NN	ORGANIZATION	craf	conj_and	32	SENT_33	[p4l964t1562r1227b1638],
35	)	NN	O	)	prep_including	29	SENT_33	[p4l964t1562r1227b1638],
36	.	.	O	.	_	0	SENT_33	[p4l964t1562r1227b1638],

1	In	IN	O	in	_	0	SENT_34	[p4l1255t1566r1327b1623],
2	early	JJ	O	early	amod	4	SENT_34	[p4l1351t1561r1521b1645],
3	clinical	JJ	O	clinical	amod	4	SENT_34	[p4l1541t1561r1791b1624],
4	trials	NNS	O	trial	prep_in	10	SENT_34	[p4l1813t1561r2007b1633],
5	,	,	O	,	_	0	SENT_34	[p4l1813t1561r2007b1633],
6	the	DT	O	the	det	9	SENT_34	[p4l2031t1561r2140b1624],
7	single	JJ	O	single	amod	9	SENT_34	[p4l9t1664r213b1748],
8	agent	NN	O	agent	nn	9	SENT_34	[p4l240t1676r429b1748],
9	sorafenib	NN	O	sorafenib	nsubj	10	SENT_34	[p4l454t1664r781b1727],
10	showed	VBD	O	show	_	0	SENT_34	[p4l808t1664r1075b1727],
11	little	JJ	O	little	amod	12	SENT_34	[p4l1098t1664r1257b1727],
12	eﬂicacy	NN	O	eﬂicacy	dobj	10	SENT_34	[p4l1283t1664r1558b1748],
13	,	,	O	,	_	0	SENT_34	[p4l1283t1664r1558b1748],
14	with	IN	O	with	prep	10	SENT_34	[p4l1584t1664r1742b1727],
15	1	CD	NUMBER	1	num	16	SENT_34	[p4l1774t1671r1799b1726],
16	response	NN	O	response	npadvmod	17	SENT_34	[p4l1831t1686r2142b1747],
17	out	IN	O	out	pcomp	14	SENT_34	[p4l9t1779r121b1830],
18	of	IN	O	of	_	0	SENT_34	[p4l144t1767r219b1830],
19	39	CD	NUMBER	39	num	20	SENT_34	[p4l234t1774r310b1830],
20	patients	NNS	O	patient	prep_of	10	SENT_34	[p4l334t1773r606b1850],
21	and	CC	O	and	_	0	SENT_34	[p4l631t1767r759b1830],
22	a	DT	O	a	det	27	SENT_34	[p4l782t1790r817b1830],
23	median	JJ	O	median	amod	27	SENT_34	[p4l838t1767r1099b1830],
24	progression	NN	O	progression	nn	27	SENT_34	[p4l1121t1767r1693b1851],
25	—	CD	NUMBER	—	num	27	SENT_34	[p4l1121t1767r1693b1851],
26	free	JJ	O	free	amod	27	SENT_34	[p4l1121t1767r1693b1851],
27	survival	NN	O	survival	conj_and	20	SENT_34	[p4l1717t1767r1991b1830],
28	of	IN	O	of	_	0	SENT_34	[p4l2015t1767r2089b1830],
29	3	CD	DURATION	3	num	30	SENT_34	[p4l2104t1774r2138b1830],
30	months	NNS	NUMBER	month	prep_of	27	SENT_34	[p4l8t1861r348b1932],
31	.	.	O	.	_	0	SENT_34	[p4l8t1861r348b1932],

1	”	NN	O	”	nsubj	38	SENT_35	[p4l8t1861r348b1932],
2	Moreover	RB	O	moreover	advmod	1	SENT_35	[p4l368t1874r712b1941],
3	,	,	O	,	_	0	SENT_35	[p4l368t1874r712b1941],
4	randomized	VBN	O	randomize	partmod	38	SENT_35	[p4l734t1869r1147b1932],
5	phase	NN	O	phase	dobj	4	SENT_35	[p4l1165t1869r1358b1952],
6	III	CD	NUMBER	iii	num	7	SENT_35	[p4l1379t1874r1462b1931],
7	trials	NNS	O	trial	nsubj	8	SENT_35	[p4l1482t1869r1652b1932],
8	failed	VBD	O	fail	rcmod	5	SENT_35	[p4l1673t1869r1860b1932],
9	to	TO	O	to	aux	10	SENT_35	[p4l1879t1881r1944b1932],
10	show	VB	O	show	xcomp	8	SENT_35	[p4l1967t1869r2143b1932],
11	any	DT	O	any	det	12	SENT_35	[p4l9t1995r133b2056],
12	beneﬁt	NN	O	beneﬁt	dobj	10	SENT_35	[p4l150t1972r391b2035],
13	from	IN	O	from	_	0	SENT_35	[p4l413t1972r585b2035],
14	combining	VBG	O	combine	prepc_from	10	SENT_35	[p4l608t1972r987b2056],
15	sorafenib	NN	O	sorafenib	dobj	14	SENT_35	[p4l1010t1972r1331b2035],
16	with	IN	O	with	_	0	SENT_35	[p4l1354t1972r1510b2035],
17	cytotoxic	JJ	O	cytotoxic	amod	18	SENT_35	[p4l1534t1978r1852b2056],
18	chemotherapy	NN	O	chemotherapy	prep_with	14	SENT_35	[p4l1876t1972r2138b2035, p4l7t2066r332b2158],
19	.18	CD	NUMBER	.18	num	21	SENT_35	[p4l1876t1972r2138b2035, p4l7t2066r332b2158],
20	Mechanistic	JJ	MISC	mechanistic	amod	21	SENT_35	[p4l352t2074r757b2137],
21	investigations	NNS	O	investigation	nsubj	22	SENT_35	[p4l776t2080r1233b2158],
22	suggest	VBP	O	suggest	rcmod	18	SENT_35	[p4l1254t2086r1496b2158],
23	that	IN	O	that	complm	28	SENT_35	[p4l1514t2074r1644b2137],
24	sorafenib	NN	O	sorafenib	nsubj	28	SENT_35	[p4l1663t2074r1969b2137],
25	does	VBZ	O	do	aux	28	SENT_35	[p4l1991t2074r2141b2137],
26	not	RB	O	not	neg	28	SENT_35	[p4l8t2189r123b2240],
27	effectively	RB	O	effectively	advmod	28	SENT_35	[p4l146t2177r495b2261],
28	inhibit	VB	O	inhibit	ccomp	22	SENT_35	[p4l515t2177r746b2240],
29	BRAF	NN	O	braf	dobj	28	SENT_35	[p4l769t2181r986b2249],
30	,	,	O	,	_	0	SENT_35	[p4l769t2181r986b2249],
31	in	IN	O	in	_	0	SENT_35	[p4l1011t2183r1078b2239],
32	particular	JJ	O	particular	prep_in	4	SENT_35	[p4l1100t2177r1456b2260],
33	,	,	O	,	_	0	SENT_35	[p4l1100t2177r1456b2260],
34	BRAFV6OOE	NN	O	brafv6ooe	nsubj	38	SENT_35	[p4l1481t2181r1927b2240],
35	at	IN	O	at	_	0	SENT_35	[p4l1951t2189r2011b2240],
36	the	DT	O	the	det	37	SENT_35	[p4l2032t2177r2140b2240],
37	maximum	NN	O	maximum	prep_at	34	SENT_35	[p4l8t2286r358b2343],
38	tolerated	VBD	O	tolerate	_	0	SENT_35	[p4l377t2280r675b2343],
39	dose	NN	O	dose	dobj	38	SENT_35	[p4l695t2280r847b2343],
40	as	IN	O	as	mark	41	SENT_35	[p4l867t2303r931b2343],
41	determined	VBN	O	determine	advcl	38	SENT_35	[p4l952t2280r1344b2343],
42	by	IN	O	by	_	0	SENT_35	[p4l1361t2280r1444b2364],
43	phospho	NN	O	phospho	prep_by	41	SENT_35	[p4l1459t2280r1943b2363],
44	.	.	O	.	_	0	SENT_35	[p4l1459t2280r1943b2363],

1	—	NN	O	—	_	0	SENT_36	[p4l1459t2280r1943b2363],
2	.	.	O	.	_	0	SENT_36	[p4l1459t2280r1943b2363],

1	ERK	NN	O	erk	nn	2	SENT_37	[p4l1459t2280r1943b2363],
2	levels	NNS	O	level	conj_and	2	SENT_37	[p4l1960t2280r2142b2343],
3	in	IN	O	in	_	0	SENT_37	[p4l9t2388r75b2444],
4	biopsy	NN	O	biopsy	nn	5	SENT_37	[p4l94t2383r321b2466],
5	specimens	NNS	O	specimen	prep_in	2	SENT_37	[p4l341t2388r695b2465],
6	before	IN	O	before	_	0	SENT_37	[p4l715t2382r930b2445],
7	and	CC	O	and	_	0	SENT_37	[p4l952t2382r1078b2445],
8	during	IN	O	during	_	0	SENT_37	[p4l1099t2382r1330b2466],
9	treatment	NN	O	treatment	prep_before	2	SENT_37	[p4l1348t2374r1764b2445],
10	.	.	O	.	_	0	SENT_37	[p4l1348t2374r1764b2445],

1	”	NN	O	”	_	0	SENT_38	[p4l1348t2374r1764b2445],

1	MF265	NN	O	mf265	nsubj	9	SENT_39	[p4l82t2489r353b2548],
2	and	CC	O	and	_	0	SENT_39	[p4l376t2485r499b2548],
3	XL281	NN	O	xl281	nsubj	9	SENT_39	[p4l516t2490r730b2548],
4	are	VBP	O	be	cop	9	SENT_39	[p4l756t2508r854b2548],
5	broad	JJ	O	broad	amod	9	SENT_39	[p4l872t2485r1417b2568],
6	—	NN	O	—	nn	9	SENT_39	[p4l872t2485r1417b2568],
7	spectrum	NN	O	spectrum	nn	9	SENT_39	[p4l872t2485r1417b2568],
8	kinase	NN	O	kinase	nn	9	SENT_39	[p4l1435t2485r1648b2548],
9	inhibitors	NNS	O	inhibitor	_	0	SENT_39	[p4l1668t2485r1991b2548],
10	that	WDT	O	that	nsubj	11	SENT_39	[p4l2011t2485r2141b2548],
11	have	VBP	O	have	rcmod	9	SENT_39	[p4l7t2588r166b2651],
12	a	DT	O	a	det	14	SENT_39	[p4l191t2611r226b2651],
13	greater	JJR	O	greater	amod	14	SENT_39	[p4l248t2600r491b2672],
14	potency	NN	O	potency	dobj	11	SENT_39	[p4l513t2600r796b2672],
15	and	CC	O	and	_	0	SENT_39	[p4l817t2588r946b2651],
16	modestly	RB	O	modestly	advmod	14	SENT_39	[p4l968t2588r1293b2672],
17	improved	VBN	O	improve	amod	18	SENT_39	[p4l1313t2588r1649b2671],
18	selectivity	NN	O	selectivity	dobj	11	SENT_39	[p4l1674t2588r2024b2672],
19	for	IN	O	for	_	0	SENT_39	[p4l2044t2588r2144b2651],
20	BRAF	NN	O	braf	prep_for	18	SENT_39	[p4l9t2695r213b2754],
21	as	IN	O	as	mark	22	SENT_39	[p4l236t2714r300b2754],
22	compared	VBN	O	compare	advcl	11	SENT_39	[p4l322t2691r663b2774],
23	with	IN	O	with	_	0	SENT_39	[p4l682t2691r834b2754],
24	sorafenib	NN	O	sorafenib	prep_with	22	SENT_39	[p4l856t2691r1185b2754],
25	.	.	O	.	_	0	SENT_39	[p4l856t2691r1185b2754],

1	In	IN	O	in	_	0	SENT_40	[p4l1209t2696r1280b2753],
2	a	DT	O	a	det	3	SENT_40	[p4l1302t2714r1336b2754],
3	phase	NN	O	phase	prep_in	38	SENT_40	[p4l1355t2691r1549b2774],
4	I	PRP	O	I	dep	3	SENT_40	[p4l1570t2696r1594b2753],
5	dose	NN	O	dose	nn	6	SENT_40	[p4l1617t2691r2143b2775],
6	—	NN	O	—	nsubj	7	SENT_40	[p4l1617t2691r2143b2775],
7	escalating	VBG	O	escalate	parataxis	38	SENT_40	[p4l1617t2691r2143b2775],
8	trial	NN	O	trial	dobj	7	SENT_40	[p4l7t2794r148b2857],
9	of	IN	O	of	_	0	SENT_40	[p4l170t2794r244b2857],
10	RAF265	NN	O	raf265	prep_of	8	SENT_40	[p4l257t2798r554b2866],
11	,	,	O	,	_	0	SENT_40	[p4l257t2798r554b2866],
12	clinical	JJ	O	clinical	amod	13	SENT_40	[p4l578t2794r822b2857],
13	activity	NN	O	activity	nsubjpass	15	SENT_40	[p4l844t2800r1096b2878],
14	was	VBD	O	be	auxpass	15	SENT_40	[p4l1112t2817r1238b2857],
15	observed	VBN	O	observe	dep	7	SENT_40	[p4l1261t2794r1571b2857],
16	in	IN	O	in	_	0	SENT_40	[p4l1592t2800r1658b2856],
17	multiple	JJ	O	multiple	amod	19	SENT_40	[p4l1680t2794r1964b2877],
18	dose	NN	O	dose	nn	19	SENT_40	[p4l1987t2794r2141b2857],
19	cohorts	NNS	O	cohort	prep_in	15	SENT_40	[p4l9t2896r265b2959],
20	of	IN	O	of	_	0	SENT_40	[p4l289t2896r363b2959],
21	patients	NNS	O	patient	prep_of	19	SENT_40	[p4l375t2902r645b2979],
22	with	IN	O	with	_	0	SENT_40	[p4l666t2896r820b2959],
23	BRAF	NN	O	braf	nn	26	SENT_40	[p4l843t2900r1331b2959],
24	—	NN	O	—	nn	26	SENT_40	[p4l843t2900r1331b2959],
25	mutant	JJ	O	mutant	amod	26	SENT_40	[p4l843t2900r1331b2959],
26	melanoma	NN	O	melanoma	prep_with	21	SENT_40	[p4l1352t2888r1796b2959],
27	.2	NN	NUMBER	.2	tmod	15	SENT_40	[p4l1352t2888r1796b2959],
28	°	CD	NUMBER	°	num	27	SENT_40	[p4l1352t2888r1796b2959],
29	However	RB	O	however	advmod	27	SENT_40	[p4l1820t2901r2140b2968],
30	,	,	O	,	_	0	SENT_40	[p4l1820t2901r2140b2968],
31	a	DT	O	a	det	34	SENT_40	[p4l9t3022r44b3062],
32	continuous	JJ	O	continuous	amod	34	SENT_40	[p4l69t3005r467b3062],
33	daily	JJ	SET	daily	amod	34	SENT_40	[p4l494t2999r668b3083],
34	dose	NN	O	dose	nsubjpass	38	SENT_40	[p4l691t2999r850b3062],
35	of	IN	O	of	_	0	SENT_40	[p4l877t2999r953b3062],
36	RAF265	NN	O	raf265	prep_of	34	SENT_40	[p4l970t3003r1256b3062],
37	was	VBD	O	be	auxpass	38	SENT_40	[p4l1283t3022r1413b3062],
38	found	VBN	O	find	_	0	SENT_40	[p4l1440t2999r1651b3062],
39	to	TO	O	to	aux	40	SENT_40	[p4l1675t3011r1743b3062],
40	have	VB	O	have	xcomp	38	SENT_40	[p4l1769t2999r1930b3062],
41	acute	JJ	O	acute	amod	43	SENT_40	[p4l1957t3011r2141b3062],
42	dose	NN	O	dose	nn	43	SENT_40	[p4l9t3102r467b3186],
43	—	NN	O	—	dobj	40	SENT_40	[p4l9t3102r467b3186],
44	limiting	VBG	O	limit	partmod	43	SENT_40	[p4l9t3102r467b3186],
45	toxicities	NNS	O	toxicity	dobj	44	SENT_40	[p4l485t3108r807b3174],
46	,	,	O	,	_	0	SENT_40	[p4l485t3108r807b3174],
47	including	VBG	O	include	_	0	SENT_40	[p4l829t3102r1154b3186],
48	pulmonary	JJ	O	pulmonary	amod	49	SENT_40	[p4l1171t3102r1554b3186],
49	embolism	NN	O	embolism	prep_including	45	SENT_40	[p4l1571t3102r1924b3174],
50	,	,	O	,	_	0	SENT_40	[p4l1571t3102r1924b3174],
51	visual	JJ	O	visual	amod	52	SENT_40	[p4l1943t3102r2142b3165],
52	disturbance	NN	O	disturbance	prep_including	45	SENT_40	[p4l9t3205r432b3277],
53	,	,	O	,	_	0	SENT_40	[p4l9t3205r432b3277],
54	hyperlipasemia	NN	O	hyperlipasemia	prep_including	45	SENT_40	[p4l456t3205r1005b3289],
55	,	,	O	,	_	0	SENT_40	[p4l456t3205r1005b3289],
56	diarrhea	NN	O	diarrhea	prep_including	45	SENT_40	[p4l1031t3205r1339b3277],
57	,	,	O	,	_	0	SENT_40	[p4l1031t3205r1339b3277],
58	and	CC	O	and	_	0	SENT_40	[p4l1365t3205r1493b3268],
59	ataxia	NN	O	ataxia	prep_including	45	SENT_40	[p4l1515t3211r1735b3277],
60	,	,	O	,	_	0	SENT_40	[p4l1515t3211r1735b3277],
61	in	IN	O	in	_	0	SENT_40	[p4l1760t3211r1827b3267],
62	addition	NN	O	addition	_	0	SENT_40	[p4l1851t3205r2142b3268],
63	to	TO	O	to	_	0	SENT_40	[p4l7t3320r73b3371],
64	delayed	VBN	O	delay	amod	66	SENT_40	[p4l95t3308r352b3392],
65	dose	NN	O	dose	nn	66	SENT_40	[p4l373t3308r831b3392],
66	—	NN	O	—	conj_in	43	SENT_40	[p4l373t3308r831b3392],
67	limiting	VBG	O	limit	partmod	66	SENT_40	[p4l373t3308r831b3392],
68	hematologic	JJ	O	hematologic	amod	69	SENT_40	[p4l849t3308r1270b3392],
69	toxicity	NN	O	toxicity	dobj	67	SENT_40	[p4l1289t3314r1552b3392],
70	.	.	O	.	_	0	SENT_40	[p4l1289t3314r1552b3392],

1	Activity	NN	O	activity	nsubjpass	4	SENT_41	[p4l1574t3312r1846b3392],
2	was	VBD	O	be	auxpass	4	SENT_41	[p4l1861t3331r1986b3371],
3	also	RB	O	also	advmod	4	SENT_41	[p4l2009t3308r2138b3371],
4	noted	VBN	O	note	ccomp	33	SENT_41	[p4l8t3411r205b3474],
5	in	IN	O	in	_	0	SENT_41	[p4l227t3417r293b3473],
6	BRAF	NNP	O	BRAF	nn	10	SENT_41	[p4l314t3415r524b3474],
7	wild	JJ	O	wild	amod	10	SENT_41	[p4l540t3411r870b3495],
8	—	NN	O	—	nn	10	SENT_41	[p4l540t3411r870b3495],
9	type	NN	O	type	nn	10	SENT_41	[p4l540t3411r870b3495],
10	tumors	NNS	O	tumor	prep_in	4	SENT_41	[p4l891t3423r1156b3483],
11	,	,	O	,	_	0	SENT_41	[p4l891t3423r1156b3483],
12	suggesting	VBG	O	suggest	partmod	10	SENT_41	[p4l1181t3417r1542b3495],
13	that	IN	O	that	complm	28	SENT_41	[p4l1563t3411r1697b3474],
14	nonselective	JJ	O	nonselective	amod	15	SENT_41	[p4l1718t3411r2143b3474],
15	inhibition	NN	O	inhibition	nsubj	28	SENT_41	[p4l9t3514r352b3577],
16	of	IN	O	of	_	0	SENT_41	[p4l376t3514r450b3577],
17	tumors	NNS	O	tumor	prep_of	15	SENT_41	[p4l462t3526r708b3577],
18	with	IN	O	with	_	0	SENT_41	[p4l730t3514r884b3577],
19	activated	VBN	O	activate	amod	21	SENT_41	[p4l908t3514r1216b3577],
20	MAPK	NN	O	mapk	nn	21	SENT_41	[p4l1237t3518r1480b3576],
21	pathway	NN	O	pathway	prep_with	17	SENT_41	[p4l1500t3514r1791b3598],
22	or	CC	O	or	_	0	SENT_41	[p4l1812t3537r1884b3577],
23	inhibition	NN	O	inhibition	conj_or	21	SENT_41	[p4l1906t3514r2137b3577, p4l7t3623r148b3680],
24	of	IN	O	of	_	0	SENT_41	[p4l173t3617r248b3680],
25	other	JJ	O	other	amod	27	SENT_41	[p4l263t3617r450b3680],
26	drug	NN	O	drug	nn	27	SENT_41	[p4l473t3617r639b3701],
27	targets	NNS	O	target	prep_of	23	SENT_41	[p4l660t3629r894b3701],
28	(	VBP	O	(	ccomp	12	SENT_41	[p4l922t3618r1083b3701],
29	e.g.	FW	O	e.g.	dobj	28	SENT_41	[p4l922t3618r1083b3701],
30	,	,	O	,	_	0	SENT_41	[p4l922t3618r1083b3701],
31	VEGF	NN	O	vegf	nn	32	SENT_41	[p4l1108t3621r1327b3680],
32	receptors	NNS	O	receptor	nsubj	33	SENT_41	[p4l1352t3618r1702b3700],
33	)	VBP	O	)	_	0	SENT_41	[p4l1352t3618r1702b3700],
34	contributed	VBN	O	contribute	dep	33	SENT_41	[p4l1731t3617r2143b3680],
35	to	TO	O	to	_	0	SENT_41	[p4l7t3732r74b3783],
36	its	PRP$	O	its	poss	37	SENT_41	[p4l98t3726r174b3783],
37	efﬁcacy	NN	O	efﬁcacy	prep_to	34	SENT_41	[p4l199t3720r466b3804],
38	.	.	O	.	_	0	SENT_41	[p4l199t3720r466b3804],

1	Given	VBN	O	give	_	0	SENT_42	[p4l493t3724r698b3783],
2	the	DT	O	the	det	5	SENT_42	[p4l720t3720r827b3783],
3	limited	JJ	O	limited	amod	5	SENT_42	[p4l849t3720r1097b3783],
4	therapeutic	JJ	O	therapeutic	amod	5	SENT_42	[p4l1118t3720r1512b3803],
5	index	NN	O	index	dep	1	SENT_42	[p4l1535t3720r1729b3783],
6	of	IN	O	of	_	0	SENT_42	[p4l1751t3720r1825b3783],
7	RAF265	NN	O	raf265	prep_of	5	SENT_42	[p4l1839t3724r2140b3792],
8	,	,	O	,	_	0	SENT_42	[p4l1839t3724r2140b3792],

1	further	RB	O	further	advmod	7	SENT_43	[p5l8t16r252b79],
2	clinical	JJ	O	clinical	amod	3	SENT_43	[p5l273t16r517b79],
3	development	NN	O	development	nsubjpass	7	SENT_43	[p5l539t16r983b99],
4	has	VBZ	O	have	aux	7	SENT_43	[p5l1002t16r1113b79],
5	not	RB	O	not	neg	7	SENT_43	[p5l1136t28r1249b79],
6	been	VBN	O	be	auxpass	7	SENT_43	[p5l1267t16r1432b79],
7	pursued	VBN	O	pursue	_	0	SENT_43	[p5l1452t16r1747b99],
8	.	.	O	.	_	0	SENT_43	[p5l1452t16r1747b99],

1	The	DT	O	the	det	2	SENT_44	[p5l81t119r206b182],
2	observation	NN	O	observation	_	0	SENT_44	[p5l230t119r633b182],
3	that	IN	O	that	complm	7	SENT_44	[p5l655t119r788b182],
4	nearly	RB	O	nearly	advmod	6	SENT_44	[p5l809t119r1023b203],
5	all	DT	O	all	det	6	SENT_44	[p5l1043t119r1121b182],
6	melanomas	NNS	O	melanoma	nsubj	7	SENT_44	[p5l1143t119r1534b182],
7	showed	VBD	O	show	dep	2	SENT_44	[p5l1558t119r1815b182],
8	constitutive	JJ	O	constitutive	amod	11	SENT_44	[p5l1838t125r2138b182, p5l7t228r132b285],
9	MAPK	NN	O	mapk	nn	11	SENT_44	[p5l155t226r401b284],
10	pathway	NN	O	pathway	nn	11	SENT_44	[p5l421t222r716b306],
11	activity	NN	O	activity	nsubj	12	SENT_44	[p5l737t228r995b306],
12	led	VBD	O	lead	ccomp	7	SENT_44	[p5l1013t222r1119b285],
13	to	TO	O	to	_	0	SENT_44	[p5l1140t234r1207b285],
14	the	DT	O	the	det	16	SENT_44	[p5l1231t222r1339b285],
15	clinical	JJ	O	clinical	amod	16	SENT_44	[p5l1363t222r1613b285],
16	trials	NNS	O	trial	prep_to	12	SENT_44	[p5l1635t222r1810b285],
17	of	IN	O	of	_	0	SENT_44	[p5l1835t222r1910b285],
18	smallmolecule	JJ	O	smallmolecule	amod	20	SENT_44	[p5l1925t222r2137b285, p5l8t324r335b388],
19	MEK	NN	O	mek	nn	20	SENT_44	[p5l363t329r552b387],
20	inhibitors	NNS	O	inhibitor	prep_of	16	SENT_44	[p5l579t324r931b388],
21	such	JJ	O	such	_	0	SENT_44	[p5l961t324r1123b388],
22	as	IN	O	as	_	0	SENT_44	[p5l1152t347r1218b388],
23	PD0325901	NN	O	pd0325901	prep_such_as	20	SENT_44	[p5l1249t329r1685b396],
24	,	,	O	,	_	0	SENT_44	[p5l1249t329r1685b396],
25	selumetinib	NN	O	selumetinib	nn	28	SENT_44	[p5l1716t324r2139b388],
26	(	CD	NUMBER	(	num	28	SENT_44	[p5l12t429r420b505],
27	AZD6244	NN	O	azd6244	nn	28	SENT_44	[p5l12t429r420b505],
28	)	NN	O	)	prep_such_as	20	SENT_44	[p5l12t429r420b505],
29	,	,	O	,	_	0	SENT_44	[p5l12t429r420b505],
30	and	CC	O	and	_	0	SENT_44	[p5l443t428r568b491],
31	CI	NN	O	ci	prep_such_as	20	SENT_44	[p5l588t432r697b491],
32	-	:	O	-	_	0	SENT_44	[p5l588t432r697b491],
33	1040	CD	DATE	1040	dep	2	SENT_44	[p5l711t435r864b491],
34	in	IN	O	in	_	0	SENT_44	[p5l886t434r952b490],
35	melanoma	NN	O	melanoma	prep_in	33	SENT_44	[p5l971t428r1346b491],
36	.	.	O	.	_	0	SENT_44	[p5l971t428r1346b491],

1	In	IN	O	in	_	0	SENT_45	[p5l1370t433r1440b490],
2	the	DT	O	the	det	3	SENT_45	[p5l1460t428r1565b491],
3	phase	NN	O	phase	prep_in	12	SENT_45	[p5l1585t428r1778b511],
4	I	PRP	O	I	dep	5	SENT_45	[p5l1799t433r1822b490],
5	trial	NN	O	trial	dep	3	SENT_45	[p5l1843t428r1999b500],
6	,	,	O	,	_	0	SENT_45	[p5l1843t428r1999b500],
7	one	CD	NUMBER	one	num	10	SENT_45	[p5l2021t451r2143b491],
8	BRAF-mutant	JJ	O	braf-mutant	amod	10	SENT_45	[p5l9t535r494b594],
9	melanoma	NN	O	melanoma	nn	10	SENT_45	[p5l514t531r876b594],
10	patient	NN	O	patient	nsubjpass	12	SENT_45	[p5l894t537r1133b614],
11	was	VBD	O	be	auxpass	12	SENT_45	[p5l1151t554r1277b594],
12	noted	VBN	O	note	_	0	SENT_45	[p5l1298t531r1494b594],
13	to	TO	O	to	aux	14	SENT_45	[p5l1513t543r1579b594],
14	have	VB	O	have	xcomp	12	SENT_45	[p5l1600t531r1755b594],
15	a	DT	O	a	det	17	SENT_45	[p5l1777t554r1811b594],
16	complete	JJ	O	complete	amod	17	SENT_45	[p5l1831t531r2141b614],
17	response	NN	O	response	dobj	14	SENT_45	[p5l9t655r320b716],
18	to	TO	O	to	_	0	SENT_45	[p5l346t645r414b696],
19	selumetinib	NN	O	selumetinib	prep_to	17	SENT_45	[p5l443t633r860b696],
20	that	WDT	O	that	nsubj	21	SENT_45	[p5l888t633r1026b696],
21	lasted	VBD	O	last	rcmod	17	SENT_45	[p5l1051t633r1257b696],
22	more	JJR	DURATION	more	mwe	23	SENT_45	[p5l1283t656r1466b696],
23	than	IN	DURATION	than	quantmod	24	SENT_45	[p5l1492t633r1652b696],
24	15	CD	DURATION	15	num	25	SENT_45	[p5l1685t640r1757b696],
25	months	NNS	NUMBER	month	tmod	21	SENT_45	[p5l1786t625r2137b696],
26	.	.	O	.	_	0	SENT_45	[p5l1786t625r2137b696],

1	”	NN	O	”	ccomp	13	SENT_46	[p5l1786t625r2137b696],
2	However	RB	O	however	advmod	1	SENT_46	[p5l9t741r334b808],
3	,	,	O	,	_	0	SENT_46	[p5l9t741r334b808],
4	a	DT	O	a	det	7	SENT_46	[p5l359t759r394b799],
5	subsequent	JJ	O	subsequent	amod	7	SENT_46	[p5l418t736r810b819],
6	clinical	JJ	O	clinical	amod	7	SENT_46	[p5l832t736r1082b799],
7	trial	NN	O	trial	nsubj	13	SENT_46	[p5l1104t736r1247b799],
8	of	IN	O	of	_	0	SENT_46	[p5l1271t736r1346b799],
9	selumetinib	NN	O	selumetinib	prep_of	7	SENT_46	[p5l1361t736r1769b799],
10	compared	VBN	O	compare	_	0	SENT_46	[p5l1794t736r2142b819],
11	with	IN	O	with	prepc_compared_with	9	SENT_46	[p5l7t839r156b902],
12	temozolomide	NN	O	temozolomide	pobj	9	SENT_46	[p5l175t839r660b902],
13	showed	VBD	O	show	_	0	SENT_46	[p5l681t839r933b902],
14	no	DT	O	no	det	16	SENT_46	[p5l952t862r1037b902],
15	signiﬁcant	NN	O	signiﬁcant	nn	16	SENT_46	[p5l1059t839r1407b923],
16	difference	NN	O	difference	dobj	13	SENT_46	[p5l1426t839r1755b902],
17	in	IN	O	in	_	0	SENT_46	[p5l1776t845r1841b901],
18	progression	NN	O	progression	nn	21	SENT_46	[p5l1859t861r2139b923, p5l9t942r309b1005],
19	—	CD	NUMBER	—	num	21	SENT_46	[p5l1859t861r2139b923, p5l9t942r309b1005],
20	free	JJ	O	free	amod	21	SENT_46	[p5l1859t861r2139b923, p5l9t942r309b1005],
21	survival	NN	O	survival	prep_in	13	SENT_46	[p5l330t942r599b1005],
22	or	CC	O	or	_	0	SENT_46	[p5l619t965r690b1005],
23	response	NN	O	response	nn	24	SENT_46	[p5l710t964r1007b1025],
24	rate	NN	O	rate	prep_in	13	SENT_46	[p5l1028t954r1153b1005],
25	in	IN	O	in	_	0	SENT_46	[p5l1174t948r1240b1004],
26	patients	NNS	O	patient	prep_in	13	SENT_46	[p5l1259t948r1526b1025],
27	with	IN	O	with	prep	26	SENT_46	[p5l1545t942r1696b1005],
28	unresectable	JJ	O	unresectable	amod	29	SENT_46	[p5l1716t942r2143b1005],
29	stage	NN	O	stage	dep	27	SENT_46	[p5l9t1056r173b1128],
30	III	CD	NUMBER	iii	dep	29	SENT_46	[p5l193t1048r302b1110],
31	/	:	O	/	punct	29	SENT_46	[p5l193t1048r302b1110],
32	IV	CD	NUMBER	iv	num	33	SENT_46	[p5l307t1049r392b1107],
33	melanoma	NN	O	melanoma	dep	29	SENT_46	[p5l411t1044r766b1107],
34	unselected	JJ	O	unselected	amod	33	SENT_46	[p5l785t1044r1140b1107],
35	for	IN	O	for	_	0	SENT_46	[p5l1159t1044r1254b1107],
36	BRAF/NRAS	NN	O	braf/nras	nn	37	SENT_46	[p5l1271t1048r1705b1110],
37	mutations	NNS	O	mutation	prep_for	33	SENT_46	[p5l1724t1036r2141b1107],
38	.	.	O	.	_	0	SENT_46	[p5l1724t1036r2141b1107],

1	”	NN	O	”	ccomp	12	SENT_47	[p5l1724t1036r2141b1107],
2	Moreover	RB	O	moreover	advmod	1	SENT_47	[p5l8t1151r367b1218],
3	,	,	O	,	_	0	SENT_47	[p5l8t1151r367b1218],
4	the	DT	O	the	det	5	SENT_47	[p5l394t1146r504b1210],
5	use	NN	O	use	nsubjpass	12	SENT_47	[p5l530t1169r645b1210],
6	of	IN	O	of	_	0	SENT_47	[p5l672t1146r748b1210],
7	these	DT	O	these	det	9	SENT_47	[p5l764t1146r946b1210],
8	MEK	NN	O	mek	nn	9	SENT_47	[p5l972t1151r1159b1209],
9	inhibitors	NNS	O	inhibitor	prep_of	5	SENT_47	[p5l1185t1146r1531b1210],
10	was	VBD	O	be	auxpass	12	SENT_47	[p5l1556t1169r1686b1210],
11	further	RBR	O	further	advmod	12	SENT_47	[p5l1713t1146r1967b1210],
12	limited	VBN	O	limit	_	0	SENT_47	[p5l1990t1146r2138b1209, p5l9t1250r140b1313],
13	by	IN	O	by	_	0	SENT_47	[p5l161t1250r247b1334],
14	retinal	JJ	O	retinal	amod	16	SENT_47	[p5l267t1250r496b1313],
15	vein	NN	O	vein	nn	16	SENT_47	[p5l516t1256r665b1313],
16	thrombosis	NN	O	thrombosis	agent	12	SENT_47	[p5l688t1250r1088b1313],
17	reported	VBN	O	report	partmod	16	SENT_47	[p5l1113t1250r1417b1333],
18	in	IN	O	in	_	0	SENT_47	[p5l1440t1256r1508b1312],
19	small	JJ	O	small	amod	20	SENT_47	[p5l1533t1250r1719b1313],
20	numbers	NNS	O	number	prep_in	17	SENT_47	[p5l1742t1250r2052b1313],
21	of	IN	O	of	_	0	SENT_47	[p5l2077t1250r2153b1313],
22	patients	NNS	O	patient	prep_of	20	SENT_47	[p5l7t1359r293b1436],
23	.	.	O	.	_	0	SENT_47	[p5l7t1359r293b1436],

1	FDA-approved	JJ	O	fda-approved	amod	2	SENT_48	[p5l11t1566r511b1638],
2	agents	NNS	O	agent	ccomp	16	SENT_48	[p5l530t1573r763b1639],
3	Meanwhile	RB	O	meanwhile	advmod	2	SENT_48	[p5l8t1663r408b1735],
4	,	,	O	,	_	0	SENT_48	[p5l8t1663r408b1735],
5	several	JJ	O	several	amod	9	SENT_48	[p5l434t1663r670b1726],
6	more	RBR	O	more	dep	8	SENT_48	[p5l692t1686r871b1726],
7	highly	RB	O	highly	advmod	8	SENT_48	[p5l893t1663r1113b1747],
8	selective	JJ	O	selective	amod	9	SENT_48	[p5l1134t1663r1422b1726],
9	inhibitors	NNS	O	inhibitor	nsubjpass	16	SENT_48	[p5l1446t1663r1781b1726],
10	of	IN	O	of	_	0	SENT_48	[p5l1805t1663r1880b1726],
11	mutant	JJ	O	mutant	amod	12	SENT_48	[p5l1893t1675r2142b1726],
12	BRAF	NN	ORGANIZATION	braf	prep_of	9	SENT_48	[p5l9t1770r214b1829],
13	have	VBP	O	have	aux	16	SENT_48	[p5l237t1766r394b1829],
14	been	VBN	O	be	auxpass	16	SENT_48	[p5l415t1766r579b1829],
15	rapidly	RB	O	rapidly	advmod	16	SENT_48	[p5l603t1766r847b1850],
16	developed	VBN	O	develop	_	0	SENT_48	[p5l867t1766r1234b1849],
17	.	.	O	.	_	0	SENT_48	[p5l867t1766r1234b1849],

1	Vemurafenib	NNP	PERSON	Vemurafenib	nsubj	4	SENT_49	[p5l1258t1766r1706b1829],
2	was	VBD	O	be	cop	4	SENT_49	[p5l1729t1789r1856b1829],
3	the	DT	O	the	det	4	SENT_49	[p5l1878t1766r1985b1829],
4	ﬁrst	NN	O	ﬁrst	_	0	SENT_49	[p5l2008t1766r2142b1829],

1	CLINICAL	JJ	O	clinical	amod	2	SENT_50	[p5l21t1915r140b1936],
2	PHARMACOLOGY	NNP	O	PHARMACOLOGY	dep	12	SENT_50	[p5l149t1915r373b1936],
3	&	CC	O	&	_	0	SENT_50	[p5l381t1915r601b1936],
4	THERAPEUT	NNP	O	THERAPEUT	nn	6	SENT_50	[p5l381t1915r601b1936],
5	|	CD	NUMBER	|	num	6	SENT_50	[p5l381t1915r601b1936],
6	CS	NNP	O	CS	conj_and	2	SENT_50	[p5l381t1915r601b1936],
7	|	NNP	O	|	nn	8	SENT_50	[p5l611t1913r729b1943],
8	VOLUME	NNP	O	VOLUME	dep	2	SENT_50	[p5l611t1913r729b1943],
9	95	CD	NUMBER	95	num	10	SENT_50	[p5l737t1915r764b1936],
10	NUMBER	NN	O	number	dep	12	SENT_50	[p5l774t1915r882b1936],
11	1	CD	NUMBER	1	num	12	SENT_50	[p5l892t1916r899b1936],
12	|	CD	NUMBER	|	dep	15	SENT_50	[p5l912t1913r915b1943],
13	JANUARY	NNP	DATE	JANUARY	dep	12	SENT_50	[p5l924t1915r1042b1936],
14	2014	CD	DATE	2014	num	15	SENT_50	[p5l1049t1915r1108b1936],
15	25	CD	DATE	25	_	0	SENT_50	[p5l2109t1915r2139b1936],

1	oral	JJ	O	oral	amod	3	SENT_51	[p5l9t2291r140b2354],
2	BRAF	NN	O	braf	nn	3	SENT_51	[p5l160t2295r364b2354],
3	inhibitor	NN	O	inhibitor	nsubj	26	SENT_51	[p5l386t2291r687b2354],
4	approved	VBN	O	approve	partmod	3	SENT_51	[p5l708t2291r1024b2374],
5	in	IN	O	in	_	0	SENT_51	[p5l1043t2297r1109b2353],
6	2011	CD	DATE	2011	prep_in	4	SENT_51	[p5l1130t2298r1285b2354],
7	by	IN	O	by	_	0	SENT_51	[p5l1310t2291r1393b2375],
8	the	DT	O	the	det	9	SENT_51	[p5l1409t2291r1515b2354],
9	FDA	NNP	ORGANIZATION	FDA	agent	4	SENT_51	[p5l1536t2295r1697b2353],
10	for	IN	O	for	_	0	SENT_51	[p5l1717t2291r1814b2354],
11	the	DT	O	the	det	12	SENT_51	[p5l1832t2291r1938b2354],
12	treatment	NN	O	treatment	prep_for	9	SENT_51	[p5l1958t2303r2140b2354, p5l8t2406r182b2457],
13	of	IN	O	of	_	0	SENT_51	[p5l201t2394r273b2457],
14	patients	NNS	O	patient	prep_of	12	SENT_51	[p5l282t2400r545b2477],
15	with	IN	O	with	_	0	SENT_51	[p5l564t2394r713b2457],
16	unresectable	JJ	O	unresectable	amod	19	SENT_51	[p5l733t2394r1153b2457],
17	or	CC	O	or	_	0	SENT_51	[p5l1174t2417r1244b2457],
18	metastatic	JJ	O	metastatic	conj_or	16	SENT_51	[p5l1262t2400r1604b2457],
19	melanoma	NN	O	melanoma	prep_with	14	SENT_51	[p5l1623t2394r1979b2457],
20	with	IN	O	with	_	0	SENT_51	[p5l1995t2394r2145b2457],
21	BRAFV600E	NN	O	brafv600e	nn	22	SENT_51	[p5l9t2501r452b2560],
22	mutation	NN	O	mutation	prep_with	4	SENT_51	[p5l475t2503r791b2560],
23	(	CD	NUMBER	(	num	22	SENT_51	[p5l818t2498r1038b2573],
24	Table	NNP	O	Table	dep	26	SENT_51	[p5l818t2498r1038b2573],
25	1	CD	NUMBER	1	num	26	SENT_51	[p5l1065t2498r1147b2573],
26	)	CD	NUMBER	)	_	0	SENT_51	[p5l1065t2498r1147b2573],
27	.	.	O	.	_	0	SENT_51	[p5l1065t2498r1147b2573],

1	Vemurafenib	NNP	PERSON	Vemurafenib	nsubjpass	3	SENT_52	[p5l1172t2497r1620b2560],
2	was	VBD	O	be	auxpass	3	SENT_52	[p5l1642t2520r1769b2560],
3	developed	VBN	O	develop	_	0	SENT_52	[p5l1794t2497r2146b2580],
4	through	IN	O	through	_	0	SENT_52	[p5l8t2601r280b2685],
5	a	DT	O	a	det	7	SENT_52	[p5l301t2624r334b2664],
6	crystallographic	JJ	O	crystallographic	amod	7	SENT_52	[p5l354t2601r895b2685],
7	approach	NN	O	approach	prep_through	3	SENT_52	[p5l915t2601r1243b2684],
8	,	,	O	,	_	0	SENT_52	[p5l915t2601r1243b2684],
9	and	CC	O	and	_	0	SENT_52	[p5l1265t2601r1389b2664],
10	it	PRP	O	it	nsubj	11	SENT_52	[p5l1408t2607r1453b2664],
11	demonstrated	VBD	O	demonstrate	conj_and	3	SENT_52	[p5l1473t2601r1938b2664],
12	selective	JJ	O	selective	amod	14	SENT_52	[p5l1958t2601r2142b2664, p5l8t2710r130b2767],
13	potent	JJ	O	potent	amod	14	SENT_52	[p5l150t2716r373b2787],
14	inhibition	NN	O	inhibition	dobj	11	SENT_52	[p5l393t2704r735b2767],
15	for	IN	O	for	_	0	SENT_52	[p5l756t2704r853b2767],
16	BRAFV60O	NN	O	brafv60o	prep_for	11	SENT_52	[p5l874t2708r1264b2767],
17	(	CD	NUMBER	(	num	20	SENT_52	[p5l1290t2704r1780b2780],
18	half-maximal	JJ	O	half-maximal	amod	20	SENT_52	[p5l1290t2704r1780b2780],
19	inhibitory	JJ	O	inhibitory	amod	20	SENT_52	[p5l1801t2704r2149b2788],
20	concentration	NN	O	concentration	nn	24	SENT_52	[p5l9t2812r506b2869],
21	=	JJ	O	=	amod	24	SENT_52	[p5l534t2836r577b2856],
22	31	CD	NUMBER	31	tmod	21	SENT_52	[p5l607t2813r681b2869],
23	nmol/l	NN	O	nmol/l	nn	24	SENT_52	[p5l713t2806r979b2883],
24	)	NN	O	)	dep	11	SENT_52	[p5l713t2806r979b2883],
25	in	IN	O	in	_	0	SENT_52	[p5l1010t2812r1078b2868],
26	kinase	NN	O	kinase	nn	27	SENT_52	[p5l1103t2806r1329b2869],
27	assays	NNS	O	assay	prep_in	11	SENT_52	[p5l1357t2798r1654b2890],
28	.23	CD	NUMBER	.23	num	29	SENT_52	[p5l1357t2798r1654b2890],
29	Vemurafenib	NN	O	vemurafenib	nsubj	30	SENT_52	[p5l1680t2806r2144b2869],
30	inhibits	VBZ	O	inhibit	rcmod	27	SENT_52	[p5l9t2909r280b2972],
31	RAF-driven	JJ	MISC	raf-driven	amod	33	SENT_52	[p5l308t2909r734b2972],
32	downstream	JJ	O	downstream	amod	33	SENT_52	[p5l762t2909r1204b2972],
33	activation	NN	O	activation	dobj	30	SENT_52	[p5l1232t2915r1585b2972],
34	of	IN	O	of	_	0	SENT_52	[p5l1612t2909r1688b2972],
35	ERK	NN	O	erk	prep_of	33	SENT_52	[p5l1705t2914r1870b2972],
36	only	RB	O	only	advmod	35	SENT_52	[p5l1895t2909r2053b2993],
37	in	IN	O	in	_	0	SENT_52	[p5l2076t2915r2145b2971],
38	tumors	NNS	O	tumor	prep_in	35	SENT_52	[p5l8t3024r261b3075],
39	expressing	VBG	O	express	partmod	38	SENT_52	[p5l288t3018r662b3096],
40	mutant	JJ	O	mutant	amod	41	SENT_52	[p5l686t3024r943b3075],
41	BRAFV600E	NN	O	brafv600e	dobj	39	SENT_52	[p5l967t3016r1441b3075],
42	.	.	O	.	_	0	SENT_52	[p5l967t3016r1441b3075],

1	In	IN	O	in	_	0	SENT_53	[p5l1470t3017r1543b3074],
2	BRAF	NN	O	braf	nn	4	SENT_53	[p5l1569t3016r1780b3075],
3	wild	JJ	O	wild	amod	4	SENT_53	[p5l1805t3012r2146b3096],
4	—	NN	O	—	prep_in	13	SENT_53	[p5l1805t3012r2146b3096],
5	type	NN	O	type	nn	6	SENT_53	[p5l1805t3012r2146b3096],
6	tumors	NNS	O	tumor	dep	4	SENT_53	[p5l8t3127r260b3178],
7	and	CC	O	and	_	0	SENT_53	[p5l287t3115r416b3178],
8	in	IN	O	in	dep	4	SENT_53	[p5l441t3121r509b3177],
9	normal	JJ	O	normal	amod	10	SENT_53	[p5l533t3115r792b3178],
10	cells	NNS	O	cell	pobj	8	SENT_53	[p5l817t3115r985b3187],
11	,	,	O	,	_	0	SENT_53	[p5l817t3115r985b3187],
12	it	PRP	O	it	nsubj	13	SENT_53	[p5l1012t3121r1059b3178],
13	appears	VBZ	O	appear	_	0	SENT_53	[p5l1084t3137r1352b3198],
14	to	TO	O	to	aux	15	SENT_53	[p5l1376t3127r1444b3178],
15	activate	VB	O	activate	xcomp	13	SENT_53	[p5l1471t3121r1739b3178],
16	the	DT	O	the	det	18	SENT_53	[p5l1763t3115r1873b3178],
17	MAPK	NN	O	mapk	nn	18	SENT_53	[p5l1898t3119r2146b3177],
18	pathway	NN	O	pathway	dobj	15	SENT_53	[p5l7t3209r370b3301],
19	.	.	O	.	_	0	SENT_53	[p5l7t3209r370b3301],

1	”	NN	O	”	_	0	SENT_54	[p5l7t3209r370b3301],

1	After	IN	O	after	_	0	SENT_55	[p5l81t3320r260b3383],
2	reformulation	NN	O	reformulation	prep_after	8	SENT_55	[p5l282t3320r766b3383],
3	to	TO	O	to	aux	4	SENT_55	[p5l789t3332r855b3383],
4	increase	VB	O	increase	infmod	2	SENT_55	[p5l879t3326r1161b3383],
5	bioavailability	NN	O	bioavailability	dobj	4	SENT_55	[p5l1182t3320r1683b3404],
6	,	,	O	,	_	0	SENT_55	[p5l1182t3320r1683b3404],
7	Vemurafenib	NNP	PERSON	Vemurafenib	nsubj	8	SENT_55	[p5l1705t3320r2144b3383],
8	demonstrated	VBD	O	demonstrate	_	0	SENT_55	[p5l9t3423r505b3486],
9	impressive	JJ	O	impressive	amod	10	SENT_55	[p5l531t3429r909b3506],
10	single-agent	JJ	O	single-agent	amod	12	SENT_55	[p5l938t3423r1372b3507],
11	clinical	JJ	O	clinical	amod	12	SENT_55	[p5l1399t3423r1656b3486],
12	activity	NN	O	activity	dobj	8	SENT_55	[p5l1683t3429r1957b3507],
13	,	,	O	,	_	0	SENT_55	[p5l1683t3429r1957b3507],
14	with	IN	O	with	_	0	SENT_55	[p5l1984t3423r2143b3486],
15	tumor	NN	O	tumor	nn	16	SENT_55	[p5l8t3538r221b3589],
16	shrinkage	NN	O	shrinkage	prep_with	8	SENT_55	[p5l241t3526r570b3610],
17	observed	VBN	O	observe	partmod	16	SENT_55	[p5l591t3526r898b3589],
18	in	IN	O	in	_	0	SENT_55	[p5l917t3532r983b3588],
19	81	CD	PERCENT	81	num	20	SENT_55	[p5l1005t3532r1145b3591],
20	%	NN	PERCENT	%	prep_in	17	SENT_55	[p5l1005t3532r1145b3591],
21	of	IN	O	of	_	0	SENT_55	[p5l1167t3526r1240b3589],
22	patients	NNS	O	patient	prep_of	20	SENT_55	[p5l1250t3532r1516b3609],
23	with	IN	O	with	_	0	SENT_55	[p5l1535t3526r1686b3589],
24	BRAFV600E	NN	O	brafv600e	nn	26	SENT_55	[p5l1707t3530r2143b3589],
25	mutant	JJ	O	mutant	amod	26	SENT_55	[p5l8t3640r256b3691],
26	melanoma	NN	O	melanoma	prep_with	17	SENT_55	[p5l277t3628r639b3691],
27	in	IN	O	in	_	0	SENT_55	[p5l661t3634r727b3690],
28	the	DT	O	the	det	29	SENT_55	[p5l749t3628r855b3691],
29	phase	NN	O	phase	prep_in	26	SENT_55	[p5l877t3628r1071b3711],
30	I	PRP	O	I	nsubj	31	SENT_55	[p5l1095t3633r1118b3690],
31	study	VBP	O	study	rcmod	29	SENT_55	[p5l1143t3620r1400b3712],
32	.25	CD	NUMBER	.25	num	34	SENT_55	[p5l1143t3620r1400b3712],
33	Dose	NN	O	dose	nn	34	SENT_55	[p5l1424t3628r1905b3712],
34	—	NN	O	—	nsubj	35	SENT_55	[p5l1424t3628r1905b3712],
35	limiting	VBG	O	limit	dep	31	SENT_55	[p5l1424t3628r1905b3712],
36	toxicities	NNS	O	toxicity	dobj	35	SENT_55	[p5l1925t3634r2142b3691, p5l8t3737r145b3803],
37	,	,	O	,	_	0	SENT_55	[p5l1925t3634r2142b3691, p5l8t3737r145b3803],
38	including	VBG	O	include	_	0	SENT_55	[p5l170t3731r505b3815],
39	fatigue	NN	O	fatigue	nn	41	SENT_55	[p5l527t3731r783b3815],
40	,	,	O	,	_	0	SENT_55	[p5l527t3731r783b3815],
41	arthralgias	NN	O	arthralgia	prep_including	29	SENT_55	[p5l809t3731r1202b3815],
42	,	,	O	,	_	0	SENT_55	[p5l809t3731r1202b3815],
43	and	CC	O	and	_	0	SENT_55	[p5l1228t3731r1357b3794],
44	rash	NN	O	rash	prep_including	29	SENT_55	[p5l1379t3731r1545b3803],
45	,	,	O	,	_	0	SENT_55	[p5l1379t3731r1545b3803],
46	occurred	VBD	O	occur	partmod	41	SENT_55	[p5l1571t3731r1886b3794],
47	in	IN	O	in	_	0	SENT_55	[p5l1909t3737r1977b3793],
48	four	CD	TIME	four	prep_in	46	SENT_55	[p5l2000t3731r2147b3794],
49	of	IN	TIME	of	_	0	SENT_55	[p6l9t16r85b79],
50	six	CD	TIME	six	num	51	SENT_55	[p6l101t22r196b79],
51	patients	NNS	O	patient	prep_of	29	SENT_55	[p6l218t22r496b99],
52	treated	VBN	O	treat	partmod	51	SENT_55	[p6l520t16r766b79],
53	at	IN	O	at	_	0	SENT_55	[p6l791t28r851b79],
54	the	DT	O	the	det	57	SENT_55	[p6l874t16r983b79],
55	1,120	CD	NUMBER	1,120	number	56	SENT_55	[p6l1015t23r1343b100],
56	—	CD	NUMBER	—	num	57	SENT_55	[p6l1015t23r1343b100],
57	mg	NN	O	mg	prep_at	52	SENT_55	[p6l1015t23r1343b100],
58	twice-daily	JJ	O	twice-daily	amod	60	SENT_55	[p6l1365t16r1760b100],
59	dose	NN	O	dose	nn	60	SENT_55	[p6l1781t16r1940b79],
60	level	NN	O	level	dep	57	SENT_55	[p6l1964t16r2142b88],
61	;	:	O	;	_	0	SENT_55	[p6l1964t16r2142b88],
62	therefore	RB	O	therefore	advmod	69	SENT_55	[p6l8t119r342b191],
63	,	,	O	,	_	0	SENT_55	[p6l8t119r342b191],
64	960	CD	NUMBER	960	num	65	SENT_55	[p6l368t125r489b182],
65	mg	NN	O	mg	nsubjpass	69	SENT_55	[p6l506t142r617b203],
66	twice	RB	O	twice	advmod	69	SENT_55	[p6l638t125r821b182],
67	daily	RB	SET	daily	advmod	69	SENT_55	[p6l846t119r1016b203],
68	was	VBD	O	be	auxpass	69	SENT_55	[p6l1034t142r1162b182],
69	determined	VBN	O	determine	parataxis	8	SENT_55	[p6l1187t119r1593b182],
70	to	TO	O	to	aux	73	SENT_55	[p6l1615t131r1682b182],
71	be	VB	O	be	cop	73	SENT_55	[p6l1704t119r1786b182],
72	the	DT	O	the	det	73	SENT_55	[p6l1808t119r1917b182],
73	maximum	NN	O	maximum	xcomp	69	SENT_55	[p6l1940t125r2141b182, p6l8t245r190b285],
74	tolerated	VBD	O	tolerate	rcmod	73	SENT_55	[p6l209t222r510b285],
75	dose	NN	O	dose	dobj	74	SENT_55	[p6l530t222r700b285],
76	.	.	O	.	_	0	SENT_55	[p6l530t222r700b285],

1	In	IN	O	in	_	0	SENT_56	[p6l723t227r794b284],
2	a	DT	O	a	det	5	SENT_56	[p6l815t245r849b285],
3	phase	NN	O	phase	nn	5	SENT_56	[p6l867t222r1061b305],
4	II	CD	NUMBER	ii	num	5	SENT_56	[p6l1082t227r1135b284],
5	trial	NN	O	trial	prep_in	18	SENT_56	[p6l1155t222r1295b285],
6	of	IN	O	of	_	0	SENT_56	[p6l1316t222r1389b285],
7	132	CD	NUMBER	132	prep_of	5	SENT_56	[p6l1406t229r1518b285],
8	previously	RB	DATE	previously	advmod	9	SENT_56	[p6l1539t222r1895b306],
9	treated	VBN	O	treat	partmod	7	SENT_56	[p6l1910t222r2147b285],
10	patients	NNS	O	patient	dobj	9	SENT_56	[p6l7t331r275b408],
11	with	IN	O	with	_	0	SENT_56	[p6l294t325r446b388],
12	the	DT	O	the	det	15	SENT_56	[p6l465t325r571b388],
13	BRAFV6OOE	NN	O	brafv6ooe	nn	15	SENT_56	[p6l592t329r1030b388],
14	mutant	JJ	O	mutant	amod	15	SENT_56	[p6l1050t337r1297b388],
15	melanoma	NN	O	melanoma	prep_with	9	SENT_56	[p6l1315t325r1693b397],
16	,	,	O	,	_	0	SENT_56	[p6l1315t325r1693b397],
17	vemurafenib	NN	O	vemurafenib	appos	15	SENT_56	[p6l1712t325r2143b388],
18	produced	VBD	O	produce	_	0	SENT_56	[p6l7t428r349b511],
19	a	DT	O	a	det	25	SENT_56	[p6l374t451r410b491],
20	53	CD	PERCENT	53	num	21	SENT_56	[p6l436t434r581b493],
21	%	NN	PERCENT	%	npadvmod	22	SENT_56	[p6l436t434r581b493],
22	conﬁrmed	JJ	O	conﬁrmed	amod	25	SENT_56	[p6l610t428r979b491],
23	overall	JJ	O	overall	amod	25	SENT_56	[p6l1005t428r1244b491],
24	response	NN	O	response	nn	25	SENT_56	[p6l1269t450r1581b511],
25	rate	NN	O	rate	dobj	18	SENT_56	[p6l1608t440r1740b491],
26	(	CD	PERCENT	(	number	27	SENT_56	[p6l1769t429r1901b504],
27	6	CD	PERCENT	6	dep	28	SENT_56	[p6l1769t429r1901b504],
28	%	NN	PERCENT	%	dep	25	SENT_56	[p6l1769t429r1901b504],
29	with	IN	O	with	_	0	SENT_56	[p6l1927t428r2086b491],
30	a	DT	O	a	det	33	SENT_56	[p6l2112t451r2147b491],
31	complete	JJ	O	complete	amod	33	SENT_56	[p6l9t532r322b615],
32	response	NN	O	response	nn	33	SENT_56	[p6l345t532r674b615],
33	)	NN	O	)	prep_with	18	SENT_56	[p6l345t532r674b615],
34	and	CC	O	and	_	0	SENT_56	[p6l702t532r829b595],
35	a	DT	O	a	det	37	SENT_56	[p6l851t555r886b595],
36	median	JJ	O	median	amod	37	SENT_56	[p6l908t532r1167b595],
37	progression	NN	O	progression	prep_with	18	SENT_56	[p6l1189t532r1758b616],
38	—	CD	NUMBER	—	num	40	SENT_56	[p6l1189t532r1758b616],
39	free	JJ	O	free	amod	40	SENT_56	[p6l1189t532r1758b616],
40	survival	NN	O	survival	nsubj	18	SENT_56	[p6l1782t532r2056b595],
41	of	IN	O	of	_	0	SENT_56	[p6l2078t532r2153b595],
42	6.8	CD	DURATION	6.8	num	43	SENT_56	[p6l9t640r104b698],
43	months	NNS	NUMBER	month	prep_of	40	SENT_56	[p6l125t626r460b698],
44	.26	CD	NUMBER	.26	dep	40	SENT_56	[p6l125t626r460b698],
45	The	DT	O	the	det	48	SENT_56	[p6l480t634r603b698],
46	median	NN	O	median	nn	48	SENT_56	[p6l624t634r876b698],
47	overall	JJ	O	overall	amod	48	SENT_56	[p6l897t634r1122b698],
48	survival	NN	O	survival	nsubj	51	SENT_56	[p6l1142t634r1408b698],
49	was	VBD	O	be	cop	51	SENT_56	[p6l1425t657r1549b698],
50	15.9	CD	DURATION	15.9	num	51	SENT_56	[p6l1577t641r1706b698],
51	months	NNS	NUMBER	month	rcmod	44	SENT_56	[p6l1727t634r2000b706],
52	,	,	O	,	_	0	SENT_56	[p6l1727t634r2000b706],
53	and	CC	O	and	_	0	SENT_56	[p6l2022t634r2146b698],
54	the	DT	O	the	det	57	SENT_56	[p6l8t737r114b801],
55	overall	JJ	O	overall	amod	57	SENT_56	[p6l137t737r367b801],
56	survival	NN	O	survival	nn	57	SENT_56	[p6l390t737r660b801],
57	rate	NN	O	rate	conj_and	44	SENT_56	[p6l683t749r810b801],
58	at	IN	O	at	_	0	SENT_56	[p6l833t749r892b801],
59	6	CD	NUMBER	6	prep_at	57	SENT_56	[p6l914t743r969b809],
60	,	,	O	,	_	0	SENT_56	[p6l914t743r969b809],
61	12	CD	NUMBER	12	num	59	SENT_56	[p6l1000t744r1090b809],
62	,	,	O	,	_	0	SENT_56	[p6l1000t744r1090b809],
63	and	CC	DURATION	and	_	0	SENT_56	[p6l1116t737r1242b801],
64	18	CD	DURATION	18	conj_and	59	SENT_56	[p6l1270t744r1340b801],
65	months	NNS	NUMBER	month	nsubj	68	SENT_56	[p6l1365t737r1624b801],
66	was	VBD	O	be	cop	68	SENT_56	[p6l1645t760r1771b801],
67	77	CD	PERCENT	77	num	68	SENT_56	[p6l1796t743r1957b809],
68	%	NN	PERCENT	%	rcmod	59	SENT_56	[p6l1796t743r1957b809],
69	,	,	O	,	_	0	SENT_56	[p6l1796t743r1957b809],
70	58	CD	PERCENT	58	number	71	SENT_56	[p6l1983t743r2144b809],
71	%	NN	PERCENT	%	amod	59	SENT_56	[p6l1983t743r2144b809],
72	,	,	O	,	_	0	SENT_56	[p6l1983t743r2144b809],

1	and	CC	O	and	dep	3	SENT_57	[p6l9t841r136b904],
2	43	CD	PERCENT	43	num	3	SENT_57	[p6l155t846r319b913],
3	%	NN	PERCENT	%	_	0	SENT_57	[p6l155t846r319b913],
4	,	,	O	,	_	0	SENT_57	[p6l155t846r319b913],
5	respectively	RB	O	respectively	amod	3	SENT_57	[p6l342t841r754b925],
6	.	.	O	.	_	0	SENT_57	[p6l342t841r754b925],

1	A	DT	O	a	dep	99	SENT_58	[p6l778t845r835b903],
2	phase	NN	O	phase	dep	99	SENT_58	[p6l855t841r1050b924],
3	III	CD	NUMBER	iii	dep	99	SENT_58	[p6l1072t846r1155b903],
4	randomized	JJ	O	randomized	dep	99	SENT_58	[p6l1178t841r1593b904],
5	trial	NN	O	trial	dep	99	SENT_58	[p6l1613t841r1753b904],
6	comparing	VBG	O	compare	dep	99	SENT_58	[p6l1775t847r2147b925],
7	vemurafenib	NN	O	vemurafenib	dep	99	SENT_58	[p6l6t944r444b1007],
8	with	IN	O	with	dep	99	SENT_58	[p6l467t944r621b1007],
9	dacarbazine	NN	O	dacarbazine	dep	99	SENT_58	[p6l644t944r1060b1007],
10	in	IN	O	in	dep	99	SENT_58	[p6l1083t950r1150b1006],
11	675	CD	NUMBER	675	dep	99	SENT_58	[p6l1174t950r1293b1007],
12	patients	NNS	O	patient	dep	99	SENT_58	[p6l1317t950r1589b1027],
13	with	IN	O	with	dep	99	SENT_58	[p6l1611t944r1766b1007],
14	previously	RB	DATE	previously	dep	99	SENT_58	[p6l1787t944r2149b1028],
15	untreated	JJ	O	untreated	dep	99	SENT_58	[p6l8t1046r345b1118],
16	,	,	O	,	_	0	SENT_58	[p6l8t1046r345b1118],
17	metastatic	JJ	O	metastatic	dep	99	SENT_58	[p6l366t1052r707b1110],
18	melanoma	NN	O	melanoma	dep	99	SENT_58	[p6l726t1046r1080b1110],
19	with	IN	O	with	dep	99	SENT_58	[p6l1097t1046r1246b1110],
20	the	DT	O	the	dep	99	SENT_58	[p6l1264t1046r1368b1110],
21	BRAFV6OOE	NN	O	brafv6ooe	dep	99	SENT_58	[p6l1389t1050r1819b1110],
22	mutation	NN	O	mutation	dep	99	SENT_58	[p6l1838t1052r2145b1110],
23	demonstrated	VBD	O	demonstrate	dep	99	SENT_58	[p6l9t1150r494b1213],
24	signiﬁcantly	RB	O	signiﬁcantly	dep	99	SENT_58	[p6l517t1150r945b1234],
25	increased	VBN	O	increase	dep	99	SENT_58	[p6l965t1150r1297b1213],
26	overall	JJ	O	overall	dep	99	SENT_58	[p6l1320t1150r1555b1213],
27	survival	NN	O	survival	dep	99	SENT_58	[p6l1579t1150r1855b1213],
28	(	NN	O	(	dep	99	SENT_58	[p6l1882t1150r2145b1226],
29	hazard	NN	O	hazard	dep	99	SENT_58	[p6l1882t1150r2145b1226],
30	ratio	NN	O	ratio	dep	99	SENT_58	[p6l9t1259r187b1325],
31	,	,	O	,	_	0	SENT_58	[p6l9t1259r187b1325],
32	HR	NN	DURATION	hr	dep	99	SENT_58	[p6l213t1258r333b1316],
33	=	JJ	O	=	dep	99	SENT_58	[p6l356t1282r399b1303],
34	0.37	CD	NUMBER	0.37	dep	99	SENT_58	[p6l425t1260r586b1325],
35	,	,	O	,	_	0	SENT_58	[p6l425t1260r586b1325],
36	95	CD	PERCENT	95	dep	99	SENT_58	[p6l612t1258r757b1318],
37	%	NN	PERCENT	%	dep	99	SENT_58	[p6l612t1258r757b1318],
38	conﬁdence	NN	O	conﬁdence	dep	99	SENT_58	[p6l783t1253r1162b1316],
39	interval	NN	O	interval	dep	99	SENT_58	[p6l1186t1253r1455b1316],
40	(	CD	NUMBER	(	dep	99	SENT_58	[p6l1481t1253r1620b1330],
41	CI	NN	O	ci	dep	99	SENT_58	[p6l1481t1253r1620b1330],
42	)	NN	O	)	dep	99	SENT_58	[p6l1481t1253r1620b1330],
43	=	JJ	O	=	dep	99	SENT_58	[p6l1649t1282r1692b1303],
44	0.26-0	CD	NUMBER	0.26-0	dep	99	SENT_58	[p6l1718t1259r2073b1325],
45	.55	CD	NUMBER	.55	dep	99	SENT_58	[p6l1718t1259r2073b1325],
46	;	:	O	;	_	0	SENT_58	[p6l1718t1259r2073b1325],
47	P	NN	O	p	dep	99	SENT_58	[p6l2097t1258r2147b1316],
48	<	JJR	O	<	dep	99	SENT_58	[p6l11t1374r50b1418],
49	0.001	CD	NUMBER	0.001	dep	99	SENT_58	[p6l78t1357r292b1433],
50	)	NN	O	)	dep	99	SENT_58	[p6l78t1357r292b1433],
51	and	CC	O	and	dep	99	SENT_58	[p6l320t1356r450b1419],
52	progression	NN	O	progression	dep	99	SENT_58	[p6l472t1356r1054b1440],
53	—	CD	NUMBER	—	dep	99	SENT_58	[p6l472t1356r1054b1440],
54	free	JJ	O	free	dep	99	SENT_58	[p6l472t1356r1054b1440],
55	survival	NN	O	survival	dep	99	SENT_58	[p6l1079t1356r1358b1419],
56	(	CD	NUMBER	(	dep	99	SENT_58	[p6l1385t1357r1534b1432],
57	HR	NN	DURATION	hr	dep	99	SENT_58	[p6l1385t1357r1534b1432],
58	=	JJ	O	=	dep	99	SENT_58	[p6l1557t1385r1600b1406],
59	0.26	CD	NUMBER	0.26	dep	99	SENT_58	[p6l1627t1362r1790b1428],
60	,	,	O	,	_	0	SENT_58	[p6l1627t1362r1790b1428],
61	95	CD	PERCENT	95	dep	99	SENT_58	[p6l1816t1362r1962b1421],
62	%	NN	PERCENT	%	dep	99	SENT_58	[p6l1816t1362r1962b1421],
63	CI	NN	O	ci	dep	99	SENT_58	[p6l1990t1360r2072b1419],
64	=	JJ	O	=	dep	99	SENT_58	[p6l2099t1385r2142b1406],
65	0.20-0	CD	NUMBER	0.20-0	dep	99	SENT_58	[p6l9t1466r358b1531],
66	.33	CD	NUMBER	.33	dep	99	SENT_58	[p6l9t1466r358b1531],
67	;	:	O	;	_	0	SENT_58	[p6l9t1466r358b1531],
68	P	NN	O	p	dep	99	SENT_58	[p6l381t1464r431b1521],
69	<	JJR	O	<	dep	99	SENT_58	[p6l452t1477r491b1521],
70	0.001	CD	NUMBER	0.001	dep	99	SENT_58	[p6l517t1459r726b1536],
71	)	NN	O	)	dep	99	SENT_58	[p6l517t1459r726b1536],
72	at	IN	O	at	dep	99	SENT_58	[p6l754t1471r813b1522],
73	the	DT	O	the	dep	99	SENT_58	[p6l834t1459r941b1522],
74	ﬁrst	NN	O	ﬁrst	dep	99	SENT_58	[p6l963t1459r1097b1522],
75	planned	VBD	O	plan	dep	99	SENT_58	[p6l1118t1459r1399b1542],
76	interim	JJ	O	interim	dep	99	SENT_58	[p6l1421t1465r1677b1522],
77	analysis	NN	O	analysis	dep	99	SENT_58	[p6l1700t1459r1967b1543],
78	conducted	VBN	O	conduct	dep	99	SENT_58	[p6l1991t1482r2142b1522, p6l9t1561r239b1624],
79	after	IN	O	after	dep	99	SENT_58	[p6l259t1561r409b1624],
80	a	DT	O	a	dep	99	SENT_58	[p6l429t1584r463b1624],
81	median	JJ	O	median	dep	99	SENT_58	[p6l481t1561r736b1624],
82	follow-up	NN	O	follow-up	dep	99	SENT_58	[p6l756t1561r1082b1644],
83	of	IN	O	of	dep	99	SENT_58	[p6l1104t1561r1176b1624],
84	only	RB	O	only	dep	99	SENT_58	[p6l1187t1561r1337b1645],
85	3.7	CD	DURATION	3.7	dep	99	SENT_58	[p6l1355t1568r1450b1624],
86	months	NNS	NUMBER	month	dep	99	SENT_58	[p6l1471t1553r1807b1624],
87	.27	CD	NUMBER	.27	dep	99	SENT_58	[p6l1471t1553r1807b1624],
88	Response	NN	O	response	dep	99	SENT_58	[p6l1827t1566r2145b1644],
89	rates	NNS	O	rate	dep	99	SENT_58	[p6l9t1675r171b1726],
90	were	VBD	O	be	dep	99	SENT_58	[p6l194t1686r358b1726],
91	48	CD	PERCENT	48	dep	99	SENT_58	[p6l381t1669r528b1727],
92	%	NN	PERCENT	%	dep	99	SENT_58	[p6l381t1669r528b1727],
93	for	IN	O	for	dep	99	SENT_58	[p6l553t1663r653b1726],
94	vemurafenib	NN	O	vemurafenib	dep	99	SENT_58	[p6l673t1663r1118b1726],
95	and	CC	O	and	dep	99	SENT_58	[p6l1144t1663r1273b1726],
96	5	CD	PERCENT	5	dep	99	SENT_58	[p6l1297t1668r1399b1727],
97	%	NN	PERCENT	%	dep	99	SENT_58	[p6l1297t1668r1399b1727],
98	for	IN	O	for	dep	99	SENT_58	[p6l1424t1663r1524b1726],
99	dacarbazine	NN	O	dacarbazine	_	0	SENT_58	[p6l1548t1663r1986b1726],
100	.	.	O	.	_	0	SENT_58	[p6l1548t1663r1986b1726],

1	In	IN	O	in	_	0	SENT_59	[p6l2014t1668r2086b1725],
2	a	DT	O	a	det	4	SENT_59	[p6l2111t1686r2146b1726],
3	subgroup	NN	O	subgroup	nn	4	SENT_59	[p6l10t1766r346b1850],
4	analysis	NN	O	analysis	prep_in	13	SENT_59	[p6l376t1766r677b1850],
5	,	,	O	,	_	0	SENT_59	[p6l376t1766r677b1850],
6	the	DT	O	the	det	7	SENT_59	[p6l706t1766r817b1829],
7	beneﬁt	NN	O	beneﬁt	nsubj	13	SENT_59	[p6l844t1766r1092b1829],
8	in	IN	O	in	_	0	SENT_59	[p6l1119t1772r1188b1828],
9	overall	JJ	O	overall	amod	10	SENT_59	[p6l1217t1766r1460b1829],
10	survival	NN	O	survival	prep_in	7	SENT_59	[p6l1488t1766r1774b1829],
11	was	VBD	O	be	cop	13	SENT_59	[p6l1801t1789r1932b1829],
12	more	RBR	O	more	advmod	13	SENT_59	[p6l1961t1789r2146b1829],
13	dramatic	JJ	O	dramatic	_	0	SENT_59	[p6l9t1869r323b1932],
14	in	IN	O	in	_	0	SENT_59	[p6l346t1875r415b1931],
15	patients	NNS	O	patient	prep_in	13	SENT_59	[p6l438t1875r715b1952],
16	with	IN	O	with	_	0	SENT_59	[p6l739t1869r896b1932],
17	stage	NN	O	stage	nn	19	SENT_59	[p6l921t1881r1093b1953],
18	Mlc	NN	O	mlc	nn	19	SENT_59	[p6l1117t1874r1273b1932],
19	disease	NN	O	disease	prep_with	15	SENT_59	[p6l1297t1869r1564b1941],
20	,	,	O	,	_	0	SENT_59	[p6l1297t1869r1564b1941],
21	with	IN	O	with	_	0	SENT_59	[p6l1588t1869r1745b1932],
22	the	DT	DATE	the	det	23	SENT_59	[p6l1768t1869r1877b1932],
23	HR	NN	DATE	hr	nsubj	35	SENT_59	[p6l1902t1874r2023b1932],
24	for	IN	O	for	_	0	SENT_59	[p6l2045t1869r2145b1932],
25	death	NN	O	death	prep_for	23	SENT_59	[p6l9t1972r196b2035],
26	in	IN	O	in	_	0	SENT_59	[p6l217t1978r282b2034],
27	the	DT	O	the	det	29	SENT_59	[p6l302t1972r408b2035],
28	vemurafenib	NN	O	vemurafenib	nn	29	SENT_59	[p6l426t1972r857b2035],
29	arm	NN	O	arm	prep_in	25	SENT_59	[p6l880t1995r1015b2035],
30	being	VBG	O	be	cop	35	SENT_59	[p6l1034t1972r1224b2056],
31	0.32	CD	PERCENT	0.32	num	35	SENT_59	[p6l1243t1979r1381b2035],
32	(	CD	PERCENT	(	number	33	SENT_59	[p6l1406t1973r1575b2048],
33	95	CD	PERCENT	95	dep	34	SENT_59	[p6l1406t1973r1575b2048],
34	%	NN	PERCENT	%	dep	35	SENT_59	[p6l1406t1973r1575b2048],
35	CI	NN	O	ci	prepc_with	13	SENT_59	[p6l1598t1976r1679b2035],
36	=	JJ	O	=	dep	35	SENT_59	[p6l1702t2001r1744b2022],
37	0.21-0	CD	NUMBER	0.21-0	num	39	SENT_59	[p6l1767t1972r2141b2049],
38	.50	CD	NUMBER	.50	num	39	SENT_59	[p6l1767t1972r2141b2049],
39	)	NN	O	)	dobj	36	SENT_59	[p6l1767t1972r2141b2049],
40	.	.	O	.	_	0	SENT_59	[p6l1767t1972r2141b2049],

1	In	IN	O	in	_	0	SENT_60	[p6l9t2080r81b2137],
2	patients	NNS	O	patient	prep_in	19	SENT_60	[p6l103t2081r375b2158],
3	with	IN	O	with	_	0	SENT_60	[p6l397t2075r552b2138],
4	stage	NN	O	stage	nn	5	SENT_60	[p6l576t2087r745b2159],
5	IIIC	NNP	O	IIIC	prep_with	2	SENT_60	[p6l769t2079r929b2147],
6	,	,	O	,	_	0	SENT_60	[p6l769t2079r929b2147],
7	Mla	NNP	LOCATION	Mla	conj_or	5	SENT_60	[p6l954t2080r1126b2147],
8	,	,	O	,	_	0	SENT_60	[p6l954t2080r1126b2147],
9	or	CC	O	or	_	0	SENT_60	[p6l1152t2098r1225b2138],
10	Mlb	NNP	O	Mlb	nn	11	SENT_60	[p6l1246t2075r1405b2138],
11	melanoma	NN	O	melanoma	conj_or	5	SENT_60	[p6l1429t2075r1813b2147],
12	,	,	O	,	_	0	SENT_60	[p6l1429t2075r1813b2147],
13	the	DT	O	the	det	16	SENT_60	[p6l1837t2075r1944b2138],
14	overall	JJ	O	overall	amod	16	SENT_60	[p6l1968t2098r2142b2138, p6l9t2178r91b2241],
15	survival	NN	O	survival	nn	16	SENT_60	[p6l117t2178r399b2241],
16	beneﬁt	NN	O	beneﬁt	nsubj	19	SENT_60	[p6l422t2178r667b2241],
17	was	VBD	O	be	cop	19	SENT_60	[p6l689t2201r819b2241],
18	less	RBR	O	less	advmod	19	SENT_60	[p6l844t2178r967b2241],
19	pronounced	JJ	O	pronounced	_	0	SENT_60	[p6l992t2178r1445b2261],
20	,	,	O	,	_	0	SENT_60	[p6l992t2178r1445b2261],
21	with	IN	O	with	mark	30	SENT_60	[p6l1470t2178r1628b2241],
22	an	DT	DURATION	a	det	23	SENT_60	[p6l1655t2201r1737b2241],
23	HR	NN	DURATION	hr	nsubj	30	SENT_60	[p6l1763t2183r1884b2241],
24	of	IN	O	of	_	0	SENT_60	[p6l1908t2178r1984b2241],
25	0.64	CD	PERCENT	0.64	number	26	SENT_60	[p6l2000t2184r2145b2241],
26	(	CD	PERCENT	(	amod	29	SENT_60	[p6l12t2282r187b2357],
27	95	CD	PERCENT	95	num	28	SENT_60	[p6l12t2282r187b2357],
28	%	NN	PERCENT	%	dep	26	SENT_60	[p6l12t2282r187b2357],
29	CI	NN	O	ci	prep_of	23	SENT_60	[p6l215t2285r298b2344],
30	=	JJ	O	=	advcl	19	SENT_60	[p6l327t2310r370b2331],
31	0.29-1	CD	NUMBER	0.29-1	num	32	SENT_60	[p6l397t2282r788b2357],
32	.38	CD	NUMBER	.38	iobj	30	SENT_60	[p6l397t2282r788b2357],
33	)	NN	O	)	dobj	30	SENT_60	[p6l397t2282r788b2357],
34	.	.	O	.	_	0	SENT_60	[p6l397t2282r788b2357],

1	After	IN	O	after	_	0	SENT_61	[p6l816t2281r998b2344],
2	initial	JJ	O	initial	amod	4	SENT_61	[p6l1022t2281r1230b2344],
3	interim	JJ	O	interim	amod	4	SENT_61	[p6l1255t2287r1518b2344],
4	analysis	NN	O	analysis	prep_after	10	SENT_61	[p6l1544t2281r1839b2365],
5	,	,	O	,	_	0	SENT_61	[p6l1544t2281r1839b2365],
6	patients	NNS	O	patient	nsubjpass	10	SENT_61	[p6l1864t2287r2144b2364],
7	on	IN	O	on	_	0	SENT_61	[p6l9t2407r97b2447],
8	dacarbazine	NN	O	dacarbazine	prep_on	6	SENT_61	[p6l122t2384r545b2447],
9	were	VBD	O	be	auxpass	10	SENT_61	[p6l568t2407r733b2447],
10	offered	VBN	O	offer	_	0	SENT_61	[p6l758t2384r1003b2447],
11	the	DT	O	the	det	12	SENT_61	[p6l1025t2384r1135b2447],
12	opportunity	NN	O	opportunity	dobj	10	SENT_61	[p6l1159t2390r1588b2468],
13	to	TO	O	to	aux	14	SENT_61	[p6l1608t2396r1675b2447],
14	cross	VB	O	cross	infmod	12	SENT_61	[p6l1701t2407r1876b2447],
15	over	IN	O	over	prep	14	SENT_61	[p6l1901t2407r2053b2447],
16	to	TO	O	to	pcomp	15	SENT_61	[p6l2075t2396r2143b2447],
17	vemurafenib	NN	O	vemurafenib	pobj	16	SENT_61	[p6l6t2487r455b2550],
18	.	.	O	.	_	0	SENT_61	[p6l6t2487r455b2550],

1	The	DT	O	the	det	3	SENT_62	[p6l479t2487r604b2550],
2	updated	VBN	O	update	amod	3	SENT_62	[p6l626t2487r905b2570],
3	analysis	NN	O	analysis	nsubj	7	SENT_62	[p6l927t2487r1192b2571],
4	of	IN	O	of	_	0	SENT_62	[p6l1214t2487r1288b2550],
5	this	DT	O	this	det	6	SENT_62	[p6l1299t2487r1423b2550],
6	trial	NN	O	trial	prep_of	3	SENT_62	[p6l1445t2487r1586b2550],
7	showed	VBD	O	show	_	0	SENT_62	[p6l1608t2487r1866b2550],
8	that	IN	O	that	complm	15	SENT_62	[p6l1885t2487r2019b2550],
9	the	DT	O	the	det	12	SENT_62	[p6l2038t2487r2145b2550],
10	median	JJ	O	median	amod	12	SENT_62	[p6l8t2589r274b2652],
11	overall	JJ	O	overall	amod	12	SENT_62	[p6l299t2589r537b2652],
12	survival	NN	O	survival	nsubj	15	SENT_62	[p6l562t2589r843b2652],
13	for	IN	O	for	_	0	SENT_62	[p6l867t2589r967b2652],
14	vemurafenib	NN	O	vemurafenib	prep_for	12	SENT_62	[p6l988t2589r1437b2652],
15	was	VBD	O	be	ccomp	7	SENT_62	[p6l1461t2612r1591b2652],
16	13.2	CD	DURATION	13.2	num	17	SENT_62	[p6l1623t2596r1760b2652],
17	months	NNS	NUMBER	month	npadvmod	18	SENT_62	[p6l1786t2589r2053b2652],
18	as	IN	O	as	advmod	15	SENT_62	[p6l2079t2612r2145b2652],
19	compared	VBN	O	compare	_	0	SENT_62	[p6l9t2692r363b2775],
20	with	IN	O	with	prepc_compared_with	15	SENT_62	[p6l385t2692r543b2755],
21	9.6	CD	DURATION	9.6	num	22	SENT_62	[p6l569t2698r669b2755],
22	months	NNS	NUMBER	month	pobj	15	SENT_62	[p6l695t2692r963b2755],
23	in	IN	O	in	_	0	SENT_62	[p6l989t2698r1057b2754],
24	the	DT	O	the	det	26	SENT_62	[p6l1081t2692r1191b2755],
25	dacarbazine	NN	O	dacarbazine	nn	26	SENT_62	[p6l1217t2692r1643b2755],
26	arm	NN	O	arm	prep_in	22	SENT_62	[p6l1670t2715r1829b2764],
27	,	,	O	,	_	0	SENT_62	[p6l1670t2715r1829b2764],
28	with	IN	O	with	_	0	SENT_62	[p6l1854t2692r2012b2755],
29	the	DT	DATE	the	det	30	SENT_62	[p6l2036t2692r2146b2755],
30	HR	NN	DATE	hr	nsubj	39	SENT_62	[p6l9t2799r130b2857],
31	for	IN	O	for	_	0	SENT_62	[p6l150t2794r250b2857],
32	overall	JJ	O	overall	amod	33	SENT_62	[p6l273t2794r508b2857],
33	survival	NN	O	survival	prep_for	30	SENT_62	[p6l532t2794r810b2857],
34	being	VBG	O	be	cop	39	SENT_62	[p6l831t2794r1027b2878],
35	0.76	CD	PERCENT	0.76	num	39	SENT_62	[p6l1049t2800r1191b2857],
36	(	CD	PERCENT	(	number	37	SENT_62	[p6l1219t2795r1392b2870],
37	95	CD	PERCENT	95	dep	38	SENT_62	[p6l1219t2795r1392b2870],
38	%	NN	PERCENT	%	dep	39	SENT_62	[p6l1219t2795r1392b2870],
39	CI	NN	O	ci	prepc_with	15	SENT_62	[p6l1419t2798r1501b2857],
40	=	JJ	O	=	dep	43	SENT_62	[p6l1528t2824r1571b2844],
41	0.63-0	CD	NUMBER	0.63-0	num	42	SENT_62	[p6l1597t2786r2047b2871],
42	.93	CD	NUMBER	.93	dep	40	SENT_62	[p6l1597t2786r2047b2871],
43	)	NN	O	)	dep	56	SENT_62	[p6l1597t2786r2047b2871],
44	.28	CD	NUMBER	.28	num	43	SENT_62	[p6l1597t2786r2047b2871],
45	In	IN	O	in	_	0	SENT_62	[p6l2072t2799r2145b2856],
46	the	DT	O	the	det	48	SENT_62	[p6l7t2897r114b2960],
47	subgroup	NN	O	subgroup	nn	48	SENT_62	[p6l138t2897r460b2981],
48	analysis	NN	O	analysis	prep_in	56	SENT_62	[p6l485t2897r770b2981],
49	,	,	O	,	_	0	SENT_62	[p6l485t2897r770b2981],
50	the	DT	O	the	det	51	SENT_62	[p6l793t2897r900b2960],
51	beneﬁt	NN	O	beneﬁt	nsubj	56	SENT_62	[p6l921t2897r1159b2960],
52	in	IN	O	in	_	0	SENT_62	[p6l1180t2903r1247b2959],
53	overall	JJ	O	overall	amod	54	SENT_62	[p6l1270t2897r1501b2960],
54	survival	NN	O	survival	prep_in	51	SENT_62	[p6l1525t2897r1797b2960],
55	remained	VBD	O	remain	cop	56	SENT_62	[p6l1819t2897r2147b2960],
56	signiﬁcant	JJ	O	signiﬁcant	rcmod	39	SENT_62	[p6l9t3000r357b3084],
57	in	IN	O	in	_	0	SENT_62	[p6l376t3006r441b3062],
58	patients	NNS	O	patient	prep_in	56	SENT_62	[p6l460t3006r724b3083],
59	with	IN	O	with	_	0	SENT_62	[p6l742t3000r892b3063],
60	stage	NN	O	stage	nn	62	SENT_62	[p6l913t3012r1077b3084],
61	Mlc	NN	O	mlc	nn	62	SENT_62	[p6l1097t3005r1246b3063],
62	melanoma	NN	O	melanoma	prep_with	56	SENT_62	[p6l1265t3000r1637b3072],
63	;	:	O	;	_	0	SENT_62	[p6l1265t3000r1637b3072],
64	however	RB	O	however	advmod	67	SENT_62	[p6l1658t3000r1954b3072],
65	,	,	O	,	_	0	SENT_62	[p6l1658t3000r1954b3072],
66	there	EX	O	there	expl	67	SENT_62	[p6l1975t3000r2146b3063],
67	was	VBD	O	be	parataxis	56	SENT_62	[p6l7t3126r134b3166],
68	no	DT	O	no	det	71	SENT_62	[p6l158t3126r245b3166],
69	overall	JJ	O	overall	amod	71	SENT_62	[p6l271t3103r504b3166],
70	survival	NN	O	survival	nn	71	SENT_62	[p6l528t3103r803b3166],
71	difference	NN	O	difference	nsubj	67	SENT_62	[p6l827t3103r1169b3166],
72	for	IN	O	for	_	0	SENT_62	[p6l1192t3103r1291b3166],
73	patients	NNS	O	patient	prep_for	71	SENT_62	[p6l1312t3109r1586b3186],
74	with	IN	O	with	_	0	SENT_62	[p6l1608t3103r1764b3166],
75	stage	NN	O	stage	nn	76	SENT_62	[p6l1787t3115r1957b3187],
76	IIIC	NNP	O	IIIC	prep_with	73	SENT_62	[p6l1982t3107r2143b3175],
77	,	,	O	,	_	0	SENT_62	[p6l1982t3107r2143b3175],
78	Mla	NNP	LOCATION	Mla	prep_with	73	SENT_62	[p6l8t3210r179b3277],
79	,	,	O	,	_	0	SENT_62	[p6l8t3210r179b3277],
80	or	CC	O	or	_	0	SENT_62	[p6l203t3228r274b3269],
81	Mlb	NNP	O	Mlb	nn	82	SENT_62	[p6l295t3205r452b3269],
82	melanoma	NN	O	melanoma	prep_with	73	SENT_62	[p6l475t3205r853b3269],
83	.	.	O	.	_	0	SENT_62	[p6l475t3205r853b3269],

1	Common	JJ	O	common	amod	3	SENT_63	[p7l83t27r419b86],
2	side	JJ	O	side	amod	3	SENT_63	[p7l444t23r579b86],
3	effects	NNS	O	effect	nsubj	7	SENT_63	[p7l604t23r821b86],
4	of	IN	O	of	_	0	SENT_63	[p7l847t23r922b86],
5	Vemurafenib	NNP	O	Vemurafenib	prep_of	3	SENT_63	[p7l933t23r1378b86],
6	were	VBD	O	be	cop	7	SENT_63	[p7l1401t46r1566b86],
7	arthralgia	NN	O	arthralgium	_	0	SENT_63	[p7l1590t23r1952b107],
8	,	,	O	,	_	0	SENT_63	[p7l1590t23r1952b107],
9	rash	NN	O	rash	appos	7	SENT_63	[p7l1977t23r2143b95],
10	,	,	O	,	_	0	SENT_63	[p7l1977t23r2143b95],
11	fatigue	NN	O	fatigue	appos	7	SENT_63	[p7l8t126r254b210],
12	,	,	O	,	_	0	SENT_63	[p7l8t126r254b210],
13	alopecia	NN	O	alopecia	appos	7	SENT_63	[p7l276t126r571b209],
14	,	,	O	,	_	0	SENT_63	[p7l276t126r571b209],
15	photosensitivity	NN	O	photosensitivity	appos	7	SENT_63	[p7l591t126r1145b210],
16	,	,	O	,	_	0	SENT_63	[p7l591t126r1145b210],
17	nausea	NN	O	nausea	appos	7	SENT_63	[p7l1166t149r1414b198],
18	,	,	O	,	_	0	SENT_63	[p7l1166t149r1414b198],
19	and	CC	O	and	_	0	SENT_63	[p7l1437t126r1562b189],
20	diarrhea	NN	O	diarrhea	appos	7	SENT_63	[p7l1582t126r1881b189],
21	.	.	O	.	_	0	SENT_63	[p7l1582t126r1881b189],

1	Thirtyeight	JJ	PERCENT	thirtyeight	amod	2	SENT_64	[p7l1905t126r2141b210, p7l9t229r176b313],
2	percent	NN	PERCENT	percent	nsubj	5	SENT_64	[p7l194t241r450b312],
3	of	IN	O	of	_	0	SENT_64	[p7l470t229r543b292],
4	patients	NNS	O	patient	prep_of	2	SENT_64	[p7l553t235r820b312],
5	required	VBN	O	require	_	0	SENT_64	[p7l841t229r1131b312],
6	dose	NN	O	dose	nn	7	SENT_64	[p7l1151t229r1304b292],
7	modiﬁcation	NN	O	modiﬁcation	nsubj	8	SENT_64	[p7l1324t229r1761b292],
8	due	JJ	O	due	xcomp	5	SENT_64	[p7l1782t229r1904b292],
9	to	TO	O	to	_	0	SENT_64	[p7l1923t241r1989b292],
10	toxicity	NN	O	toxicity	prep_to	8	SENT_64	[p7l2010t241r2143b292, p7l9t338r165b416],
11	.	.	O	.	_	0	SENT_64	[p7l2010t241r2143b292, p7l9t338r165b416],

1	Cutaneous	JJ	MISC	cutaneous	amod	4	SENT_65	[p7l192t336r560b395],
2	squamous	JJ	O	squamous	amod	4	SENT_65	[p7l585t355r933b415],
3	cell	NN	O	cell	nn	4	SENT_65	[p7l958t332r1072b395],
4	carcinomas	NNS	O	carcinoma	nsubj	5	SENT_65	[p7l1096t338r1490b395],
5	(	VBP	O	(	_	0	SENT_65	[p7l1517t332r2147b408],
6	keratoacanthoma	NN	O	keratoacanthoma	nn	7	SENT_65	[p7l1517t332r2147b408],
7	type	NN	O	type	nsubjpass	13	SENT_65	[p7l7t447r156b519],
8	constituting	VBG	O	constitute	partmod	7	SENT_65	[p7l181t441r601b519],
9	the	DT	O	the	det	11	SENT_65	[p7l621t435r730b498],
10	majority	NN	O	majority	nn	11	SENT_65	[p7l753t436r1076b519],
11	)	NN	O	)	dobj	8	SENT_65	[p7l753t436r1076b519],
12	were	VBD	O	be	auxpass	13	SENT_65	[p7l1102t458r1266b498],
13	reported	VBN	O	report	ccomp	5	SENT_65	[p7l1290t435r1591b518],
14	in	IN	O	in	advmod	13	SENT_65	[p7l1614t441r1682b497],
15	up	RB	O	up	advmod	14	SENT_65	[p7l1705t457r1792b518],
16	to	TO	O	to	_	0	SENT_65	[p7l1815t447r1882b498],
17	26	CD	PERCENT	26	num	18	SENT_65	[p7l1907t440r2052b499],
18	%	NN	PERCENT	%	prep_to	13	SENT_65	[p7l1907t440r2052b499],
19	of	IN	O	of	_	0	SENT_65	[p7l2078t435r2153b498],
20	patients	NNS	O	patient	prep_of	18	SENT_65	[p7l7t544r287b621],
21	,	,	O	,	_	0	SENT_65	[p7l7t544r287b621],
22	with	IN	O	with	_	0	SENT_65	[p7l307t538r456b601],
23	a	DT	O	a	det	25	SENT_65	[p7l476t561r510b601],
24	signiﬁcant	JJ	O	signiﬁcant	amod	25	SENT_65	[p7l529t538r875b622],
25	proportion	NN	O	proportion	prep_with	13	SENT_65	[p7l892t544r1261b621],
26	of	IN	O	of	_	0	SENT_65	[p7l1281t538r1354b601],
27	these	DT	O	these	det	28	SENT_65	[p7l1363t538r1533b601],
28	tumors	NNS	O	tumor	prep_of	25	SENT_65	[p7l1553t550r1791b601],
29	harboring	VBG	O	harbor	partmod	28	SENT_65	[p7l1810t538r2147b622],
30	a	DT	O	a	det	31	SENT_65	[p7l9t663r44b703],
31	mutation	NN	O	mutation	dobj	29	SENT_65	[p7l65t646r381b703],
32	in	IN	O	in	_	0	SENT_65	[p7l404t646r471b702],
33	HRAS	NNP	ORGANIZATION	HRAS	prep_in	29	SENT_65	[p7l495t632r794b703],
34	.29	CD	NUMBER	.29	num	33	SENT_65	[p7l495t632r794b703],
35	The	DT	O	the	det	37	SENT_65	[p7l818t640r944b703],
36	paradoxical	JJ	O	paradoxical	amod	37	SENT_65	[p7l965t640r1369b723],
37	activation	NN	O	activation	nsubj	50	SENT_65	[p7l1392t646r1731b703],
38	of	IN	O	of	_	0	SENT_65	[p7l1754t640r1829b703],
39	RAF	NN	ORGANIZATION	raf	nn	40	SENT_65	[p7l1843t644r1997b703],
40	signaling	NN	O	signaling	prep_of	37	SENT_65	[p7l2022t646r2142b724, p7l8t743r221b827],
41	via	IN	O	via	_	0	SENT_65	[p7l236t749r337b806],
42	transactivation	NN	O	transactivation	prep_via	40	SENT_65	[p7l355t749r861b806],
43	of	IN	O	of	_	0	SENT_65	[p7l881t743r954b806],
44	CRAF	NN	ORGANIZATION	craf	prep_of	42	SENT_65	[p7l966t747r1174b806],
45	by	IN	O	by	_	0	SENT_65	[p7l1193t743r1276b827],
46	the	DT	O	the	det	48	SENT_65	[p7l1292t743r1396b806],
47	BRAF	NN	O	braf	nn	48	SENT_65	[p7l1418t747r1620b806],
48	inhibitor	NN	O	inhibitor	prep_by	44	SENT_65	[p7l1641t743r1940b806],
49	probably	RB	O	probably	advmod	50	SENT_65	[p7l1958t743r2143b826, p7l9t845r154b929],
50	accounts	VBZ	O	account	dep	29	SENT_65	[p7l175t857r484b908],
51	for	IN	O	for	_	0	SENT_65	[p7l508t845r609b908],
52	this	DT	O	this	det	55	SENT_65	[p7l631t845r760b908],
53	unique	JJ	O	unique	amod	55	SENT_65	[p7l784t851r1030b928],
54	side	NN	O	side	nn	55	SENT_65	[p7l1055t845r1192b908],
55	effect	NN	O	effect	prep_for	50	SENT_65	[p7l1217t837r1488b908],
56	.	.	O	.	_	0	SENT_65	[p7l1217t837r1488b908],

1	”	NN	O	”	nsubj	13	SENT_66	[p7l1217t837r1488b908],
2	These	DT	O	these	det	4	SENT_66	[p7l1512t845r1712b908],
3	skin	NN	O	skin	nn	4	SENT_66	[p7l1737t845r1882b908],
4	lesions	NNS	O	lesion	dep	1	SENT_66	[p7l1905t845r2144b908],
5	were	VBD	O	be	auxpass	6	SENT_66	[p7l7t971r167b1011],
6	treated	VBN	O	treat	_	0	SENT_66	[p7l188t948r426b1011],
7	with	IN	O	with	_	0	SENT_66	[p7l445t948r598b1011],
8	local	JJ	O	local	amod	9	SENT_66	[p7l617t948r780b1011],
9	excision	NN	O	excision	prep_with	6	SENT_66	[p7l801t954r1078b1011],
10	and	CC	O	and	_	0	SENT_66	[p7l1101t948r1227b1011],
11	did	VBD	O	do	aux	13	SENT_66	[p7l1248t948r1359b1011],
12	not	RB	O	not	neg	13	SENT_66	[p7l1379t960r1493b1011],
13	require	VB	O	require	conj_and	6	SENT_66	[p7l1514t954r1758b1031],
14	dose	NN	O	dose	nn	15	SENT_66	[p7l1780t948r1934b1011],
15	interruption	NN	O	interruption	dobj	13	SENT_66	[p7l1956t954r2142b1011, p7l9t1057r267b1134],
16	or	CC	O	or	_	0	SENT_66	[p7l289t1074r361b1114],
17	reduction	NN	O	reduction	conj_or	15	SENT_66	[p7l382t1051r714b1114],
18	of	IN	O	of	_	0	SENT_66	[p7l736t1051r810b1114],
19	Vemurafenib	NNP	O	Vemurafenib	prep_of	15	SENT_66	[p7l819t1051r1268b1114],
20	.	.	O	.	_	0	SENT_66	[p7l819t1051r1268b1114],

1	Dabrafenib	NNP	PERSON	Dabrafenib	nsubj	7	SENT_67	[p7l82t1154r466b1217],
2	is	VBZ	O	be	cop	7	SENT_67	[p7l489t1160r539b1217],
3	a	DT	O	a	det	7	SENT_67	[p7l561t1177r596b1217],
4	reversible	JJ	O	reversible	amod	7	SENT_67	[p7l617t1154r963b1226],
5	,	,	O	,	_	0	SENT_67	[p7l617t1154r963b1226],
6	adenosine	NN	LOCATION	adenosine	dep	7	SENT_67	[p7l987t1154r1332b1217],
7	triphosphate	NN	O	triphosphate	_	0	SENT_67	[p7l1353t1154r2142b1237, p7l7t1263r132b1320],
8	—	CD	NUMBER	—	num	10	SENT_67	[p7l1353t1154r2142b1237, p7l7t1263r132b1320],
9	competitive	JJ	O	competitive	amod	10	SENT_67	[p7l1353t1154r2142b1237, p7l7t1263r132b1320],
10	inhibitor	NN	O	inhibitor	nsubj	18	SENT_67	[p7l155t1257r464b1320],
11	of	IN	O	of	_	0	SENT_67	[p7l487t1257r562b1320],
12	mutant	JJ	O	mutant	amod	13	SENT_67	[p7l575t1269r827b1320],
13	BRAFV600	NN	O	brafv600	prep_of	10	SENT_67	[p7l850t1261r1246b1320],
14	(	CD	NUMBER	(	num	17	SENT_67	[p7l1275t1257r1773b1333],
15	half-maximal	JJ	O	half-maximal	amod	17	SENT_67	[p7l1275t1257r1773b1333],
16	inhibitory	JJ	O	inhibitory	amod	17	SENT_67	[p7l1796t1257r2150b1341],
17	concentration	NN	O	concentration	dep	13	SENT_67	[p7l9t1366r495b1423],
18	=	JJ	O	=	rcmod	7	SENT_67	[p7l521t1389r563b1410],
19	0.5	CD	NUMBER	0.5	num	21	SENT_67	[p7l589t1367r687b1423],
20	nmol/l	NN	O	nmol/l	nn	21	SENT_67	[p7l713t1360r973b1437],
21	)	NN	O	)	dobj	18	SENT_67	[p7l713t1360r973b1437],
22	that	WDT	O	that	nsubjpass	24	SENT_67	[p7l1000t1360r1136b1423],
23	was	VBD	O	be	auxpass	24	SENT_67	[p7l1156t1383r1284b1423],
24	approved	VBN	O	approve	rcmod	21	SENT_67	[p7l1309t1360r1633b1443],
25	by	IN	O	by	_	0	SENT_67	[p7l1653t1360r1738b1444],
26	the	DT	O	the	det	27	SENT_67	[p7l1757t1360r1865b1423],
27	FDA	NNP	ORGANIZATION	FDA	agent	24	SENT_67	[p7l1890t1364r2054b1422],
28	in	IN	O	in	_	0	SENT_67	[p7l2077t1366r2145b1422],
29	2013	CD	DATE	2013	prep_in	18	SENT_67	[p7l9t1470r188b1527],
30	.	.	O	.	_	0	SENT_67	[p7l9t1470r188b1527],

1	Dabrafenib	NNP	PERSON	Dabrafenib	nsubj	2	SENT_68	[p7l215t1463r601b1527],
2	has	VBZ	O	have	_	0	SENT_68	[p7l625t1463r737b1526],
3	a	DT	O	a	det	5	SENT_68	[p7l762t1486r796b1526],
4	shorter	JJR	O	shorter	amod	5	SENT_68	[p7l819t1463r1065b1526],
5	half-life	NN	O	half-life	dobj	2	SENT_68	[p7l1086t1463r1355b1527],
6	than	IN	O	than	mark	13	SENT_68	[p7l1377t1463r1532b1527],
7	Vemurafenib	JJ	O	vemurafenib	amod	8	SENT_68	[p7l1552t1463r1989b1526],
8	(	NN	O	(	nsubj	13	SENT_68	[p7l2017t1464r2142b1539],
9	5.2	CD	NUMBER	5.2	num	8	SENT_68	[p7l2017t1464r2142b1539],
10	vs.	CC	O	vs.	prep	8	SENT_68	[p7l6t1589r96b1629],
11	50	CD	DURATION	50	num	12	SENT_68	[p7l126t1573r204b1629],
12	hours	NNS	NUMBER	hour	dep	10	SENT_68	[p7l230t1566r459b1643],
13	)	VBP	O	)	advcl	2	SENT_68	[p7l230t1566r459b1643],
14	but	CC	O	but	_	0	SENT_68	[p7l486t1566r603b1629],
15	is	VBZ	O	be	cop	17	SENT_68	[p7l628t1572r679b1629],
16	otherwise	RB	O	otherwise	advmod	17	SENT_68	[p7l706t1566r1052b1629],
17	similar	JJ	O	similar	conj_but	2	SENT_68	[p7l1079t1566r1325b1629],
18	to	TO	O	to	_	0	SENT_68	[p7l1348t1578r1416b1629],
19	it	PRP	O	it	prep_to	17	SENT_68	[p7l1443t1572r1490b1629],
20	in	IN	O	in	_	0	SENT_68	[p7l1514t1572r1582b1629],
21	mode	NN	O	mode	prep_in	17	SENT_68	[p7l1607t1566r1807b1629],
22	of	IN	O	of	_	0	SENT_68	[p7l1833t1566r1909b1629],
23	action	NN	O	action	nn	26	SENT_68	[p7l1926t1572r2144b1629],
24	and	CC	O	and	_	0	SENT_68	[p7l9t1668r135b1731],
25	pharmacodynamic	JJ	O	pharmacodynamic	nn	26	SENT_68	[p7l155t1668r803b1752],
26	effects	NNS	O	effect	prep_of	21	SENT_68	[p7l826t1660r1116b1731],
27	.	.	O	.	_	0	SENT_68	[p7l826t1660r1116b1731],

1	”	NN	O	”	nn	3	SENT_69	[p7l826t1660r1116b1731],
2	A	NN	O	a	nn	3	SENT_69	[p7l1142t1672r1199b1730],
3	phase	NN	O	phase	nsubj	19	SENT_69	[p7l1220t1668r1414b1751],
4	I	PRP	O	I	dep	3	SENT_69	[p7l1438t1673r1461b1730],
5	study	NN	O	study	dep	3	SENT_69	[p7l1485t1668r1672b1752],
6	of	IN	O	of	_	0	SENT_69	[p7l1691t1668r1765b1731],
7	dabrafenib	NN	O	dabrafenib	prep_of	5	SENT_69	[p7l1778t1668r2144b1731],
8	established	VBD	O	establish	_	0	SENT_69	[p7l9t1771r391b1834],
9	a	DT	O	a	det	12	SENT_69	[p7l413t1794r448b1834],
10	phase	NN	O	phase	nn	12	SENT_69	[p7l469t1771r666b1854],
11	II	CD	NUMBER	ii	num	12	SENT_69	[p7l690t1776r743b1833],
12	dose	NN	O	dose	dobj	8	SENT_69	[p7l768t1771r924b1834],
13	of	IN	O	of	_	0	SENT_69	[p7l948t1771r1023b1834],
14	150	CD	NUMBER	150	num	15	SENT_69	[p7l1043t1778r1157b1834],
15	mg	NN	O	mg	prep_of	12	SENT_69	[p7l1173t1794r1282b1855],
16	twice	RB	O	twice	advmod	17	SENT_69	[p7l1303t1777r1484b1834],
17	daily	RB	SET	daily	tmod	8	SENT_69	[p7l1508t1771r1677b1855],
18	and	CC	O	and	_	0	SENT_69	[p7l1697t1771r1825b1834],
19	reported	VBD	O	report	conj_and	8	SENT_69	[p7l1847t1771r2146b1854],
20	a	DT	O	a	det	23	SENT_69	[p7l9t1897r44b1937],
21	conﬁrmed	JJ	O	conﬁrmed	amod	23	SENT_69	[p7l69t1874r438b1937],
22	response	NN	O	response	nn	23	SENT_69	[p7l464t1896r775b1957],
23	rate	NN	O	rate	dobj	19	SENT_69	[p7l801t1886r933b1937],
24	of	IN	O	of	_	0	SENT_69	[p7l960t1874r1036b1937],
25	50	CD	PERCENT	50	num	26	SENT_69	[p7l1054t1879r1199b1939],
26	%	NN	PERCENT	%	prep_of	23	SENT_69	[p7l1054t1879r1199b1939],
27	in	IN	O	in	_	0	SENT_69	[p7l1227t1880r1296b1936],
28	patients	NNS	O	patient	prep_in	26	SENT_69	[p7l1321t1880r1601b1957],
29	with	IN	O	with	_	0	SENT_69	[p7l1626t1874r1784b1937],
30	advanced	JJ	O	advanced	amod	31	SENT_69	[p7l1811t1874r2146b1937],
31	melanoma	NN	O	melanoma	prep_with	19	SENT_69	[p7l8t1977r370b2040],
32	treated	VBN	O	treat	partmod	31	SENT_69	[p7l389t1977r627b2040],
33	at	IN	O	at	_	0	SENT_69	[p7l648t1989r708b2040],
34	this	DT	O	this	det	35	SENT_69	[p7l726t1977r850b2040],
35	dose	NN	O	dose	prep_at	32	SENT_69	[p7l873t1977r1043b2040],
36	.	.	O	.	_	0	SENT_69	[p7l873t1977r1043b2040],

1	A	DT	O	a	det	4	SENT_70	[p7l1067t1981r1124b2039],
2	phase	NN	O	phase	nn	4	SENT_70	[p7l1144t1977r1338b2060],
3	II	CD	NUMBER	ii	num	4	SENT_70	[p7l1360t1982r1413b2039],
4	study	NN	O	study	nsubj	8	SENT_70	[p7l1436t1977r1623b2061],
5	using	VBG	O	use	partmod	4	SENT_70	[p7l1640t1983r1826b2061],
6	this	DT	O	this	det	7	SENT_70	[p7l1844t1977r1968b2040],
7	dose	NN	O	dose	dobj	5	SENT_70	[p7l1991t1977r2145b2040],
8	reported	VBD	O	report	_	0	SENT_70	[p7l9t2080r312b2163],
9	an	DT	O	a	det	13	SENT_70	[p7l336t2103r418b2143],
10	investigator-assessed	JJ	O	investigator-assessed	amod	13	SENT_70	[p7l442t2080r1177b2164],
11	conﬁrmed	JJ	O	conﬁrmed	amod	13	SENT_70	[p7l1201t2080r1567b2143],
12	response	NN	O	response	nn	13	SENT_70	[p7l1589t2102r1898b2163],
13	rate	NN	O	rate	dobj	8	SENT_70	[p7l1922t2092r2052b2143],
14	of	IN	O	of	_	0	SENT_70	[p7l2077t2080r2152b2143],
15	59	CD	PERCENT	59	num	16	SENT_70	[p7l10t2187r154b2247],
16	%	NN	PERCENT	%	prep_of	13	SENT_70	[p7l10t2187r154b2247],
17	and	CC	O	and	_	0	SENT_70	[p7l180t2182r309b2245],
18	a	DT	O	a	det	23	SENT_70	[p7l333t2205r368b2245],
19	median	JJ	O	median	amod	23	SENT_70	[p7l390t2182r654b2245],
20	progression	NN	O	progression	nn	23	SENT_70	[p7l676t2182r1255b2266],
21	—	CD	NUMBER	—	num	23	SENT_70	[p7l676t2182r1255b2266],
22	free	JJ	O	free	amod	23	SENT_70	[p7l676t2182r1255b2266],
23	survival	NN	O	survival	prep_of	13	SENT_70	[p7l1280t2182r1558b2245],
24	of	IN	O	of	_	0	SENT_70	[p7l1582t2182r1657b2245],
25	6.3	CD	DURATION	6.3	num	26	SENT_70	[p7l1671t2188r1769b2245],
26	months	NNS	NUMBER	month	prep_of	23	SENT_70	[p7l1795t2174r2144b2245],
27	.32	CD	NUMBER	.32	num	29	SENT_70	[p7l1795t2174r2144b2245],
28	Clinical	JJ	O	clinical	amod	29	SENT_70	[p7l10t2285r295b2348],
29	activity	NN	O	activity	nsubj	46	SENT_70	[p7l326t2291r597b2369],
30	of	IN	O	of	_	0	SENT_70	[p7l624t2285r702b2348],
31	dabrafenib	NN	O	dabrafenib	prep_of	29	SENT_70	[p7l723t2285r1113b2348],
32	in	IN	O	in	_	0	SENT_70	[p7l1145t2291r1215b2347],
33	a	DT	O	a	det	34	SENT_70	[p7l1246t2308r1282b2348],
34	subset	NN	O	subset	prep_in	31	SENT_70	[p7l1312t2285r1539b2348],
35	of	IN	O	of	_	0	SENT_70	[p7l1569t2285r1646b2348],
36	patients	NNS	O	patient	prep_of	34	SENT_70	[p7l1666t2291r1954b2368],
37	with	IN	O	with	_	0	SENT_70	[p7l1984t2285r2146b2348],
38	BRAFV600K	NN	O	brafv600k	nn	40	SENT_70	[p7l9t2391r478b2450],
39	mutant	JJ	O	mutant	amod	40	SENT_70	[p7l504t2399r763b2450],
40	melanoma	NN	O	melanoma	prep_with	36	SENT_70	[p7l790t2387r1168b2450],
41	in	IN	O	in	_	0	SENT_70	[p7l1194t2393r1263b2449],
42	this	DT	O	this	det	43	SENT_70	[p7l1290t2387r1420b2450],
43	trial	NN	O	trial	prep_in	40	SENT_70	[p7l1448t2387r1597b2450],
44	was	VBD	O	be	cop	46	SENT_70	[p7l1621t2410r1752b2450],
45	somewhat	RB	O	somewhat	advmod	46	SENT_70	[p7l1782t2387r2146b2450],
46	lower	JJR	O	lower	rcmod	26	SENT_70	[p7l7t2490r209b2562],
47	,	,	O	,	_	0	SENT_70	[p7l7t2490r209b2562],
48	with	IN	O	with	_	0	SENT_70	[p7l231t2490r384b2553],
49	a	DT	O	a	det	53	SENT_70	[p7l406t2513r440b2553],
50	13	CD	PERCENT	13	number	51	SENT_70	[p7l468t2496r604b2554],
51	%	NN	PERCENT	%	amod	53	SENT_70	[p7l468t2496r604b2554],
52	response	NN	O	response	nn	53	SENT_70	[p7l628t2512r927b2573],
53	rate	NN	O	rate	prep_with	46	SENT_70	[p7l950t2502r1076b2553],
54	and	CC	O	and	_	0	SENT_70	[p7l1099t2490r1225b2553],
55	a	DT	O	a	det	60	SENT_70	[p7l1247t2513r1281b2553],
56	median	JJ	O	median	amod	60	SENT_70	[p7l1302t2490r1559b2553],
57	progression	NN	O	progression	nn	60	SENT_70	[p7l1580t2490r2144b2574],
58	—	CD	NUMBER	—	num	60	SENT_70	[p7l1580t2490r2144b2574],
59	free	JJ	O	free	amod	60	SENT_70	[p7l1580t2490r2144b2574],
60	survival	NN	O	survival	prep_with	46	SENT_70	[p7l9t2593r279b2656],
61	of	IN	O	of	_	0	SENT_70	[p7l300t2593r374b2656],
62	4-5	CD	NUMBER	4-5	num	63	SENT_70	[p7l384t2600r506b2656],
63	months	NNS	NUMBER	month	prep_of	60	SENT_70	[p7l528t2593r804b2656],
64	.	.	O	.	_	0	SENT_70	[p7l528t2593r804b2656],

1	In	IN	O	in	_	0	SENT_71	[p7l828t2598r899b2655],
2	a	DT	O	a	det	6	SENT_71	[p7l921t2616r955b2656],
3	phase	NN	O	phase	nn	6	SENT_71	[p7l973t2593r1167b2676],
4	III	CD	NUMBER	iii	num	6	SENT_71	[p7l1189t2598r1271b2655],
5	clinical	JJ	O	clinical	amod	6	SENT_71	[p7l1293t2593r1538b2656],
6	trial	NN	O	trial	prep_in	24	SENT_71	[p7l1557t2593r1714b2665],
7	,	,	O	,	_	0	SENT_71	[p7l1557t2593r1714b2665],
8	250	CD	NUMBER	250	num	9	SENT_71	[p7l1736t2600r1855b2656],
9	patients	NNS	O	patient	appos	6	SENT_71	[p7l1876t2599r2145b2676],
10	with	IN	O	with	_	0	SENT_71	[p7l7t2696r165b2759],
11	previously	RB	DATE	previously	advmod	12	SENT_71	[p7l189t2696r562b2780],
12	untreated	JJ	O	untreated	amod	20	SENT_71	[p7l583t2696r943b2768],
13	,	,	O	,	_	0	SENT_71	[p7l583t2696r943b2768],
14	stage	NN	O	stage	conj_or	12	SENT_71	[p7l971t2708r1145b2780],
15	IV	CD	NUMBER	iv	dobj	14	SENT_71	[p7l1171t2701r1260b2759],
16	or	CC	O	or	_	0	SENT_71	[p7l1286t2719r1360b2759],
17	unresectable	JJ	O	unresectable	conj_or	12	SENT_71	[p7l1384t2696r1831b2759],
18	stage	NN	O	stage	dep	12	SENT_71	[p7l1858t2708r2032b2780],
19	III	CD	NUMBER	iii	num	18	SENT_71	[p7l2058t2701r2144b2758],
20	BRAFV600E	NN	O	brafv600e	prep_with	9	SENT_71	[p7l9t2802r463b2861],
21	mutant	JJ	O	mutant	amod	22	SENT_71	[p7l487t2810r743b2861],
22	melanoma	NN	O	melanoma	nsubjpass	24	SENT_71	[p7l767t2798r1141b2861],
23	were	VBD	O	be	auxpass	24	SENT_71	[p7l1162t2821r1328b2861],
24	randomized	VBN	O	randomize	_	0	SENT_71	[p7l1353t2798r1782b2861],
25	to	TO	O	to	aux	26	SENT_71	[p7l1805t2810r1873b2861],
26	receive	VB	O	receive	xcomp	24	SENT_71	[p7l1899t2804r2144b2861],
27	either	CC	O	either	preconj	31	SENT_71	[p7l9t2900r206b2963],
28	dabrafenib	JJ	O	dabrafenib	amod	31	SENT_71	[p7l227t2900r592b2963],
29	(	NN	O	(	nn	31	SENT_71	[p7l618t2901r765b2976],
30	187	CD	NUMBER	187	num	31	SENT_71	[p7l618t2901r765b2976],
31	patients	NNS	O	patient	dobj	26	SENT_71	[p7l786t2901r1082b2983],
32	)	CD	NUMBER	)	dep	31	SENT_71	[p7l786t2901r1082b2983],
33	or	CC	O	or	_	0	SENT_71	[p7l1108t2923r1180b2963],
34	dacarbazine	NN	O	dacarbazine	conj_or	31	SENT_71	[p7l1201t2900r1612b2963],
35	(	CD	NUMBER	(	number	36	SENT_71	[p7l1637t2901r1740b2977],
36	63	CD	NUMBER	63	num	37	SENT_71	[p7l1637t2901r1740b2977],
37	patients	NNS	O	patient	dep	34	SENT_71	[p7l1763t2892r2143b2983],
38	)	IN	O	)	_	0	SENT_71	[p7l1763t2892r2143b2983],
39	.33	CD	NUMBER	.33	prep_)	26	SENT_71	[p7l1763t2892r2143b2983],

1	Table	NNP	O	Table	_	0	SENT_72	[p7l19t3058r106b3086],
2	1	CD	NUMBER	1	num	1	SENT_72	[p7l115t3060r127b3085],
3	Summary	NNP	O	Summary	nsubj	7	SENT_72	[p7l158t3059r313b3093],
4	of	IN	O	of	_	0	SENT_72	[p7l319t3058r353b3086],
5	phase	NN	O	phase	prep_of	3	SENT_72	[p7l359t3058r454b3092],
6	III	CD	NUMBER	iii	num	5	SENT_72	[p7l462t3060r489b3085],
7	randomized	VBN	O	randomize	rcmod	1	SENT_72	[p7l499t3058r690b3086],
8	trials	NNS	O	trial	dobj	7	SENT_72	[p7l698t3058r779b3086],
9	of	IN	O	of	_	0	SENT_72	[p7l786t3058r819b3086],
10	Vemurafenib	NNP	O	Vemurafenib	prep_of	8	SENT_72	[p7l825t3058r1038b3090],
11	,	,	O	,	_	0	SENT_72	[p7l825t3058r1038b3090],
12	dabrafenib	NN	O	dabrafenib	prep_of	8	SENT_72	[p7l1046t3058r1232b3090],
13	,	,	O	,	_	0	SENT_72	[p7l1046t3058r1232b3090],
14	and	CC	O	and	_	0	SENT_72	[p7l1239t3058r1299b3086],
15	trametinib	NN	O	trametinib	prep_of	8	SENT_72	[p7l1306t3058r1478b3086],

1	Number	NN	O	number	nn	4	SENT_73	[p7l262t3118r378b3143],
2	Patient	NN	O	patient	nn	4	SENT_73	[p7l468t3119r568b3143],
3	Response	NN	O	response	nn	4	SENT_73	[p7l697t3119r832b3149],
4	rate	NN	O	rate	dep	21	SENT_73	[p7l840t3121r895b3143],
5	Median	JJ	MISC	median	amod	7	SENT_73	[p7l950t3118r1055b3143],
6	Median	JJ	MISC	median	amod	7	SENT_73	[p7l1153t3118r1258b3143],
7	6-month	NN	DURATION	6-month	dep	4	SENT_73	[p7l1356t3118r1478b3143],
8	12-month	JJ	DURATION	12-month	amod	16	SENT_73	[p7l1541t3118r1679b3143],
9	Subsequent	JJ	O	subsequent	amod	16	SENT_73	[p7l1742t3118r1913b3149],
10	of	IN	O	of	_	0	SENT_73	[p7l244t3157r273b3182],
11	patients	NNS	O	patient	prep_of	9	SENT_73	[p7l280t3158r395b3188],
12	population	NN	O	population	nn	16	SENT_73	[p7l447t3157r603b3188],
13	(	CD	PERCENT	(	num	16	SENT_73	[p7l738t3158r809b3186],
14	95	CD	PERCENT	95	number	15	SENT_73	[p7l738t3158r809b3186],
15	%	NN	PERCENT	%	amod	16	SENT_73	[p7l738t3158r809b3186],
16	Cl	NN	O	cl	dep	7	SENT_73	[p7l816t3158r852b3186],
17	)	CD	NUMBER	)	num	18	SENT_73	[p7l816t3158r852b3186],
18	PFS	NN	O	pf	dep	21	SENT_73	[p7l984t3158r1033b3182],
19	05	CD	NUMBER	05	num	21	SENT_73	[p7l1186t3158r1224b3182],
20	05	CD	NUMBER	05	num	21	SENT_73	[p7l1367t3158r1406b3182],
21	rate	NN	O	rate	dep	25	SENT_73	[p7l1414t3160r1468b3182],
22	05	CD	NUMBER	05	num	24	SENT_73	[p7l1559t3158r1597b3182],
23	rate	NN	O	rate	nn	24	SENT_73	[p7l1606t3161r1660b3182],
24	treatments	NNS	O	treatment	dep	21	SENT_73	[p7l1753t3160r1911b3182],
25	Reference	NNP	O	Reference	_	0	SENT_73	[p7l1992t3157r2132b3182],

1	Vemurafenib	NN	O	vemurafenib	dep	12	SENT_74	[p7l19t3235r196b3260],
2	337	CD	NUMBER	337	num	1	SENT_74	[p7l295t3237r344b3260],
3	Previously	RB	DATE	previously	advmod	5	SENT_74	[p7l439t3235r578b3267],
4	48	CD	PERCENT	48	num	5	SENT_74	[p7l710t3236r878b3264],
5	%	NN	PERCENT	%	dep	1	SENT_74	[p7l710t3236r878b3264],
6	(	CD	NUMBER	(	number	7	SENT_74	[p7l710t3236r878b3264],
7	42	CD	NUMBER	42	num	5	SENT_74	[p7l710t3236r878b3264],
8	—	NN	O	—	dep	12	SENT_74	[p7l710t3236r878b3264],
9	55	CD	NUMBER	55	num	8	SENT_74	[p7l710t3236r878b3264],
10	)	CD	NUMBER	)	number	11	SENT_74	[p7l710t3236r878b3264],
11	5.3	CD	DURATION	5.3	num	12	SENT_74	[p7l925t3237r962b3260],
12	months	NNS	NUMBER	month	dep	16	SENT_74	[p7l972t3235r1076b3260],
13	13.2	CD	DURATION	13.2	num	14	SENT_74	[p7l1130t3235r1296b3260],
14	months	NNS	NUMBER	month	dep	12	SENT_74	[p7l1130t3235r1296b3260],
15	84	CD	PERCENT	84	num	16	SENT_74	[p7l1388t3237r1447b3260],
16	%	NN	PERCENT	%	dep	20	SENT_74	[p7l1388t3237r1447b3260],
17	56	CD	PERCENT	56	num	18	SENT_74	[p7l1580t3237r1639b3260],
18	%	NN	PERCENT	%	dep	16	SENT_74	[p7l1580t3237r1639b3260],
19	18	CD	PERCENT	18	num	20	SENT_74	[p7l1716t3235r1937b3267],
20	%	NN	PERCENT	%	dep	26	SENT_74	[p7l1716t3235r1937b3267],
21	|	CD	NUMBER	|	num	24	SENT_74	[p7l1716t3235r1937b3267],
22	pi	NN	O	pi	nn	24	SENT_74	[p7l1716t3235r1937b3267],
23	|	NN	O	|	nn	24	SENT_74	[p7l1716t3235r1937b3267],
24	imumab	NN	O	imumab	dep	20	SENT_74	[p7l1716t3235r1937b3267],
25	29,30	CD	NUMBER	29,30	num	26	SENT_74	[p7l2025t3237r2098b3264],
26	Dacarbazine	NN	O	dacarbazine	dep	29	SENT_74	[p7l21t3294r191b3319],
27	333	CD	NUMBER	333	number	28	SENT_74	[p7l295t3296r344b3319],
28	““	CD	NUMBER	““	num	29	SENT_74	[p7l439t3275r572b3300],
29	”	NN	O	”	_	0	SENT_74	[p7l439t3275r572b3300],
30	eated	VBN	O	eat	partmod	29	SENT_74	[p7l439t3275r572b3300],
31	5	CD	PERCENT	5	num	32	SENT_74	[p7l737t3294r853b3322],
32	%	NN	PERCENT	%	nsubj	35	SENT_74	[p7l737t3294r853b3322],
33	(	CD	NUMBER	(	num	35	SENT_74	[p7l737t3294r853b3322],
34	3-9	CD	NUMBER	3-9	num	35	SENT_74	[p7l737t3294r853b3322],
35	)	NN	O	)	xcomp	30	SENT_74	[p7l737t3294r853b3322],
36	1.6	CD	DURATION	1.6	num	37	SENT_74	[p7l927t3294r1076b3319],
37	months	NNS	NUMBER	month	dep	39	SENT_74	[p7l927t3294r1076b3319],
38	9.6	CD	DURATION	9.6	num	39	SENT_74	[p7l1127t3294r1279b3319],
39	months	NNS	NUMBER	month	advmod	45	SENT_74	[p7l1127t3294r1279b3319],
40	66	CD	PERCENT	66	num	41	SENT_74	[p7l1388t3295r1447b3319],
41	%	NN	PERCENT	%	dep	39	SENT_74	[p7l1388t3295r1447b3319],
42	44	CD	PERCENT	44	num	43	SENT_74	[p7l1579t3295r1639b3319],
43	%	NN	PERCENT	%	dep	39	SENT_74	[p7l1579t3295r1639b3319],
44	22	CD	PERCENT	22	num	45	SENT_74	[p7l1713t3294r1942b3325],
45	%	NN	PERCENT	%	rcmod	35	SENT_74	[p7l1713t3294r1942b3325],
46	|	CD	NUMBER	|	num	49	SENT_74	[p7l1713t3294r1942b3325],
47	pi	NN	O	pi	nn	49	SENT_74	[p7l1713t3294r1942b3325],
48	|	NN	O	|	nn	49	SENT_74	[p7l1713t3294r1942b3325],
49	imumab	NN	O	imumab	dep	45	SENT_74	[p7l1713t3294r1942b3325],
50	,	,	O	,	_	0	SENT_74	[p7l1713t3294r1942b3325],

1	26.5	CD	PERCENT	26.5	num	2	SENT_75	[p7l1713t3337r1795b3360],
2	%	NN	PERCENT	%	_	0	SENT_75	[p7l1713t3337r1795b3360],
3	BRAF	NN	O	braf	nn	4	SENT_75	[p7l1804t3337r1873b3360],
4	inhibitor	NN	O	inhibitor	dep	2	SENT_75	[p7l1713t3375r1830b3399],

1	Dabrafenib	NN	O	dabrafenib	_	0	SENT_76	[p7l21t3433r173b3458],
2	187	CD	NUMBER	187	num	1	SENT_76	[p7l297t3435r344b3458],
3	Previously	RB	DATE	previously	advmod	5	SENT_76	[p7l439t3433r578b3465],
4	50	CD	PERCENT	50	num	5	SENT_76	[p7l711t3435r770b3458],
5	%	NN	PERCENT	%	dep	1	SENT_76	[p7l711t3435r770b3458],
6	(	CD	NUMBER	(	num	10	SENT_76	[p7l778t3434r878b3462],
7	42-57	CD	NUMBER	42-57	num	10	SENT_76	[p7l778t3434r878b3462],
8	)	NN	O	)	nn	10	SENT_76	[p7l778t3434r878b3462],
9	5.1	CD	DURATION	5.1	num	10	SENT_76	[p7l925t3435r958b3458],
10	months	NNS	NUMBER	month	npadvmod	5	SENT_76	[p7l972t3433r1076b3458],
11	18.2	CD	DURATION	18.2	num	12	SENT_76	[p7l1129t3435r1183b3458],
12	months	NNS	NUMBER	month	tmod	5	SENT_76	[p7l1192t3433r1296b3458],
13	NR	NNP	O	NR	nn	15	SENT_76	[p7l1400t3434r1437b3458],
14	NR	NNP	O	NR	nn	15	SENT_76	[p7l1592t3434r1628b3458],
15	NR	NNP	O	NR	dep	1	SENT_76	[p7l1714t3434r1750b3458],
16	35,36	CD	NUMBER	35,36	num	15	SENT_76	[p7l2025t3435r2098b3462],

1	untreated	JJ	O	untreated	_	0	SENT_77	[p7l439t3473r572b3497],

1	Dacarbazine	NNP	O	Dacarbazine	dep	11	SENT_78	[p7l21t3492r191b3516],
2	63	CD	NUMBER	63	number	3	SENT_78	[p7l311t3493r343b3516],
3	(	CD	NUMBER	(	dep	1	SENT_78	[p7l439t3513r539b3543],
4	except	IN	O	except	_	0	SENT_78	[p7l439t3513r539b3543],
5	HD	NN	O	hd	nn	7	SENT_78	[p7l547t3514r588b3537],
6	”	CD	NUMBER	”	num	7	SENT_78	[p7l597t3513r652b3541],
7	__	NN	O	__	prep_except	3	SENT_78	[p7l597t3513r652b3541],
8	2	CD	NUMBER	2	num	9	SENT_78	[p7l597t3513r652b3541],
9	)	NN	O	)	dep	11	SENT_78	[p7l597t3513r652b3541],
10	7	CD	PERCENT	7	num	11	SENT_78	[p7l729t3493r770b3516],
11	%	NN	PERCENT	%	dep	20	SENT_78	[p7l729t3493r770b3516],
12	(	CD	NUMBER	(	num	16	SENT_78	[p7l778t3492r861b3520],
13	2-16	CD	NUMBER	2-16	num	16	SENT_78	[p7l778t3492r861b3520],
14	)	NN	O	)	nn	16	SENT_78	[p7l778t3492r861b3520],
15	2.7	CD	DURATION	2.7	num	16	SENT_78	[p7l924t3493r963b3516],
16	months	NNS	NUMBER	month	npadvmod	11	SENT_78	[p7l972t3492r1076b3516],
17	15.6	CD	DURATION	15.6	num	18	SENT_78	[p7l1130t3493r1183b3516],
18	months	NNS	NUMBER	month	tmod	16	SENT_78	[p7l1192t3492r1296b3516],
19	NR	NNP	O	NR	nn	20	SENT_78	[p7l1400t3493r1437b3516],
20	NR	NNP	O	NR	dep	24	SENT_78	[p7l1592t3493r1629b3516],
21	57	CD	PERCENT	57	num	22	SENT_78	[p7l1713t3493r1771b3516],
22	%	NN	PERCENT	%	dep	20	SENT_78	[p7l1713t3493r1771b3516],
23	Crossoverto	NN	O	crossoverto	nn	24	SENT_78	[p7l1779t3492r1947b3516],
24	dabrafenib	NN	O	dabrafenib	_	0	SENT_78	[p7l1712t3531r1862b3556],

1	Trametinib	NN	O	trametinib	dep	13	SENT_79	[p8l19t18r168b43],
2	214	CD	NUMBER	214	num	1	SENT_79	[p8l295t20r344b43],
3	Oneprevious	JJ	O	oneprevious	dep	1	SENT_79	[p8l438t19r619b49],
4	22	CD	PERCENT	22	num	5	SENT_79	[p8l711t19r878b46],
5	%	NN	PERCENT	%	dep	3	SENT_79	[p8l711t19r878b46],
6	(	CD	NUMBER	(	number	7	SENT_79	[p8l711t19r878b46],
7	17	CD	NUMBER	17	num	5	SENT_79	[p8l711t19r878b46],
8	—	NN	O	—	dep	13	SENT_79	[p8l711t19r878b46],
9	22	CD	NUMBER	22	num	8	SENT_79	[p8l711t19r878b46],
10	)	CD	NUMBER	)	number	11	SENT_79	[p8l711t19r878b46],
11	4.8	CD	DURATION	4.8	num	13	SENT_79	[p8l923t18r1076b43],
12	months	NNS	NUMBER	month	nn	13	SENT_79	[p8l923t18r1076b43],
13	NR	NN	O	nr	dep	16	SENT_79	[p8l1128t19r1165b42],
14	81	CD	PERCENT	81	num	15	SENT_79	[p8l1388t20r1447b43],
15	%	NN	PERCENT	%	dep	13	SENT_79	[p8l1388t20r1447b43],
16	NR	NN	O	nr	_	0	SENT_79	[p8l1592t19r1629b42],
17	8	CD	PERCENT	8	number	18	SENT_79	[p8l1712t18r1943b46],
18	%	NN	PERCENT	%	amod	19	SENT_79	[p8l1712t18r1943b46],
19	Vemurafenib	NNP	O	Vemurafenib	dep	16	SENT_79	[p8l1712t18r1943b46],
20	,	,	O	,	_	0	SENT_79	[p8l1712t18r1943b46],
21	24	CD	NUMBER	24	appos	19	SENT_79	[p8l2045t20r2078b42],

1	treatment	NN	O	treatment	_	0	SENT_80	[p8l437t61r575b82],
2	5	CD	PERCENT	5	number	3	SENT_80	[p8l1713t57r1919b88],
3	%	NN	PERCENT	%	amod	4	SENT_80	[p8l1713t57r1919b88],
4	ipi	NN	O	ipus	dobj	6	SENT_80	[p8l1713t57r1919b88],
5	|	CD	NUMBER	|	number	6	SENT_80	[p8l1713t57r1919b88],
6	imumab	NN	O	imumab	dep	1	SENT_80	[p8l1713t57r1919b88],
7	a	DT	O	a	det	9	SENT_80	[p8l438t97r651b128],
8	"	``	O	"	punct	9	SENT_80	[p8l438t97r651b128],
9	°	NN	O	°	nsubj	10	SENT_80	[p8l438t97r651b128],
10	Wed	VBD	DATE	wed	ccomp	6	SENT_80	[p8l438t97r651b128],
11	'	''	O	'	_	0	SENT_80	[p8l438t97r651b128],
12	e	SYM	O	e	dep	15	SENT_80	[p8l438t97r651b128],
13	"	``	O	"	punct	15	SENT_80	[p8l438t97r651b128],
14	‘	CD	NUMBER	‘	num	15	SENT_80	[p8l438t97r651b128],
15	ept	NN	O	ept	dep	25	SENT_80	[p8l438t97r651b128],
16	s	NNS	PERCENT	s	num	17	SENT_80	[p8l728t116r861b144],
17	%	NN	PERCENT	%	dep	15	SENT_80	[p8l728t116r861b144],
18	(	CD	NUMBER	(	number	19	SENT_80	[p8l728t116r861b144],
19	4	CD	NUMBER	4	dep	20	SENT_80	[p8l728t116r861b144],
20	—	NN	O	—	amod	17	SENT_80	[p8l728t116r861b144],
21	15	CD	NUMBER	15	number	22	SENT_80	[p8l728t116r861b144],
22	)	CD	NUMBER	)	prep	20	SENT_80	[p8l728t116r861b144],
23	1.5	CD	DURATION	1.5	num	24	SENT_80	[p8l927t116r1076b140],
24	months	NNS	NUMBER	month	dep	22	SENT_80	[p8l927t116r1076b140],
25	NR	NN	O	nr	dep	28	SENT_80	[p8l1129t117r1165b140],
26	67	CD	PERCENT	67	num	27	SENT_80	[p8l1388t117r1447b140],
27	%	NN	PERCENT	%	dep	25	SENT_80	[p8l1388t117r1447b140],
28	NR	NN	O	nr	dep	1	SENT_80	[p8l1592t117r1629b140],
29	6	CD	PERCENT	6	number	30	SENT_80	[p8l1712t115r1943b144],
30	%	NN	PERCENT	%	amod	31	SENT_80	[p8l1712t115r1943b144],
31	Vemurafenib	NNP	O	Vemurafenib	dep	28	SENT_80	[p8l1712t115r1943b144],
32	,	,	O	,	_	0	SENT_80	[p8l1712t115r1943b144],
33	o	NN	PERCENT	o	nn	37	SENT_80	[p8l1712t156r1919b187],
34	%	NN	PERCENT	%	nn	37	SENT_80	[p8l1712t156r1919b187],
35	ipi	NN	O	ipus	nn	37	SENT_80	[p8l1712t156r1919b187],
36	|	NN	O	|	nn	37	SENT_80	[p8l1712t156r1919b187],
37	imumab	NN	O	imumab	appos	31	SENT_80	[p8l1712t156r1919b187],

1	Dacarbazine	NN	O	dacarbazine	_	0	SENT_81	[p8l21t116r191b140],
2	or	CC	O	or	_	0	SENT_81	[p8l198t123r226b140],
3	108	CD	NUMBER	108	num	4	SENT_81	[p8l297t117r344b140],
4	pacntaxel	NN	O	pacntaxel	conj_or	1	SENT_81	[p8l21t156r149b187],
5	BRAF	NN	O	braf	nn	8	SENT_81	[p8l439t138r508b161],
6	or	CC	O	or	_	0	SENT_81	[p8l516t144r544b161],
7	MEK	NN	O	mek	nn	8	SENT_81	[p8l552t138r612b161],
8	inhibitors	NNS	O	inhibitor	dep	1	SENT_81	[p8l439t176r568b201],
9	or	CC	O	or	_	0	SENT_81	[p8l576t184r604b201],
10	ipilimumab	NN	O	ipilimumab	conj_or	8	SENT_81	[p8l439t216r595b247],

1	CI	NN	O	ci	_	0	SENT_82	[p8l20t275r48b299],
2	,	,	O	,	_	0	SENT_82	[p8l20t275r48b299],
3	conﬁdence	NN	O	conﬁdence	nn	4	SENT_82	[p8l55t274r188b296],
4	interval	NN	O	interval	appos	1	SENT_82	[p8l196t274r292b299],
5	;	:	O	;	_	0	SENT_82	[p8l196t274r292b299],
6	HD	NN	O	hd	dep	1	SENT_82	[p8l299t275r340b299],
7	,	,	O	,	_	0	SENT_82	[p8l299t275r340b299],
8	high	JJ	O	high	amod	9	SENT_82	[p8l348t274r399b301],
9	dose	NN	O	dose	appos	6	SENT_82	[p8l407t274r470b299],
10	;	:	O	;	_	0	SENT_82	[p8l407t274r470b299],
11	NR	NNP	MISC	NR	dep	1	SENT_82	[p8l478t275r516b299],
12	,	,	O	,	_	0	SENT_82	[p8l478t275r516b299],
13	not	RB	O	not	neg	14	SENT_82	[p8l523t277r563b296],
14	reported	VBN	O	report	partmod	11	SENT_82	[p8l570t274r681b301],
15	;	:	O	;	_	0	SENT_82	[p8l570t274r681b301],
16	OS	NNP	O	OS	dep	11	SENT_82	[p8l687t275r726b299],
17	,	,	O	,	_	0	SENT_82	[p8l687t275r726b299],
18	overall	JJ	O	overall	amod	19	SENT_82	[p8l733t274r812b296],
19	survival	NN	O	survival	appos	16	SENT_82	[p8l820t274r917b299],
20	;	:	O	;	_	0	SENT_82	[p8l820t274r917b299],
21	PFS	NNP	O	PFS	dep	11	SENT_82	[p8l925t275r972b299],
22	,	,	O	,	_	0	SENT_82	[p8l925t275r972b299],
23	progression	NN	O	progression	appos	21	SENT_82	[p8l980t274r1177b301],
24	—	CD	NUMBER	—	num	26	SENT_82	[p8l980t274r1177b301],
25	free	JJ	O	free	amod	26	SENT_82	[p8l980t274r1177b301],
26	survival	NN	O	survival	dep	23	SENT_82	[p8l1184t274r1281b296],
27	.	.	O	.	_	0	SENT_82	[p8l1184t274r1281b296],

1	26	CD	NUMBER	26	num	2	SENT_83	[p8l20t378r51b399],
2	VOLUME	NN	O	volume	_	0	SENT_83	[p8l1367t378r1475b399],
3	95	CD	NUMBER	95	num	4	SENT_83	[p8l1483t378r1510b399],
4	NUMBER	NN	O	number	dep	2	SENT_83	[p8l1520t378r1628b399],
5	1	CD	NUMBER	1	number	6	SENT_83	[p8l1638t379r1645b399],
6	|	CD	NUMBER	|	dep	4	SENT_83	[p8l1659t376r1661b406],
7	JANUARY	NNP	DATE	JANUARY	dep	6	SENT_83	[p8l1670t378r1788b399],
8	2014	CD	DATE	2014	num	7	SENT_83	[p8l1796t378r1854b399],
9	|	CD	NUMBER	|	num	10	SENT_83	[p8l1863t376r1865b406],
10	www.nature.com/cpt	NN	O	www.nature.com/cpt	dep	2	SENT_83	[p8l1874t378r2139b404],

1	Patients	NNS	O	patient	nsubjpass	8	SENT_84	[p8l9t759r289b817],
2	assigned	VBN	O	assign	partmod	1	SENT_84	[p8l318t754r621b838],
3	to	TO	O	to	_	0	SENT_84	[p8l646t766r714b817],
4	the	DT	O	the	det	6	SENT_84	[p8l741t754r851b817],
5	dacarbazine	NN	O	dacarbazine	nn	6	SENT_84	[p8l879t754r1307b817],
6	arm	NN	O	arm	prep_to	2	SENT_84	[p8l1335t777r1475b817],
7	were	VBD	O	be	auxpass	8	SENT_84	[p8l1500t777r1666b817],
8	permitted	VBN	O	permit	_	0	SENT_84	[p8l1692t754r2047b837],
9	to	TO	O	to	aux	10	SENT_84	[p8l2072t766r2140b817],
10	cross	VB	O	cross	xcomp	8	SENT_84	[p8l9t880r178b920],
11	over	IN	O	over	prep	10	SENT_84	[p8l201t880r348b920],
12	to	TO	O	to	pcomp	11	SENT_84	[p8l368t869r433b920],
13	dabrafenib	NN	O	dabrafenib	pobj	12	SENT_84	[p8l457t857r822b920],
14	at	IN	O	at	_	0	SENT_84	[p8l846t869r905b920],
15	the	DT	O	the	det	16	SENT_84	[p8l924t857r1030b920],
16	time	NN	O	time	prep_at	10	SENT_84	[p8l1051t863r1205b920],
17	of	IN	O	of	_	0	SENT_84	[p8l1227t857r1301b920],
18	disease	NN	O	disease	nn	19	SENT_84	[p8l1314t857r1554b920],
19	progression	NN	O	progression	prep_of	16	SENT_84	[p8l1574t863r1992b941],
20	.	.	O	.	_	0	SENT_84	[p8l1574t863r1992b941],

1	The	DT	O	the	det	4	SENT_85	[p8l2017t857r2142b920],
2	primary	JJ	O	primary	amod	4	SENT_85	[p8l7t966r298b1044],
3	end	NN	O	end	nn	4	SENT_85	[p8l319t960r448b1023],
4	point	NN	O	point	nsubj	10	SENT_85	[p8l469t966r657b1043],
5	of	IN	O	of	_	0	SENT_85	[p8l680t960r755b1023],
6	this	DT	O	this	det	7	SENT_85	[p8l768t960r896b1023],
7	trial	NN	O	trial	prep_of	4	SENT_85	[p8l919t960r1064b1023],
8	was	VBD	O	be	cop	10	SENT_85	[p8l1085t983r1214b1023],
9	progression-free	JJ	O	progression-free	amod	10	SENT_85	[p8l1237t960r1817b1044],
10	survival	NN	O	survival	_	0	SENT_85	[p8l1842t960r2137b1023],
11	.	.	O	.	_	0	SENT_85	[p8l1842t960r2137b1023],

1	Dabrafenib	NN	PERSON	dabrafenib	nsubj	2	SENT_86	[p8l9t1063r402b1126],
2	showed	VBD	O	show	_	0	SENT_86	[p8l429t1063r692b1126],
3	a	DT	O	a	det	6	SENT_86	[p8l716t1086r751b1126],
4	statistically	RB	O	statistically	advmod	5	SENT_86	[p8l774t1063r1168b1147],
5	signiﬁcant	JJ	O	signiﬁcant	amod	6	SENT_86	[p8l1189t1063r1553b1147],
6	improvement	NN	O	improvement	dobj	2	SENT_86	[p8l1576t1069r2051b1146],
7	in	IN	O	in	_	0	SENT_86	[p8l2073t1069r2141b1125],
8	median	JJ	O	median	amod	10	SENT_86	[p8l8t1166r272b1229],
9	progression-free	JJ	O	progression-free	amod	10	SENT_86	[p8l294t1166r873b1250],
10	survival	NN	O	survival	prep_in	2	SENT_86	[p8l897t1166r1175b1229],
11	of	IN	O	of	_	0	SENT_86	[p8l1199t1166r1274b1229],
12	5.1	CD	DURATION	5.1	num	13	SENT_86	[p8l1289t1173r1383b1229],
13	months	NNS	NUMBER	month	prep_of	10	SENT_86	[p8l1413t1166r1677b1229],
14	as	IN	O	as	prep	2	SENT_86	[p8l1703t1189r1768b1229],
15	compared	VBN	O	compare	_	0	SENT_86	[p8l1793t1166r2143b1249],
16	with	IN	O	with	prepc_compared_with	2	SENT_86	[p8l7t1269r167b1332],
17	2.7	CD	DURATION	2.7	num	18	SENT_86	[p8l196t1276r299b1332],
18	months	NNS	NUMBER	month	pobj	2	SENT_86	[p8l328t1269r600b1332],
19	for	IN	O	for	_	0	SENT_86	[p8l630t1269r732b1332],
20	dacarbazine	NN	O	dacarbazine	prep_for	18	SENT_86	[p8l761t1269r1214b1332],
21	.	.	O	.	_	0	SENT_86	[p8l761t1269r1214b1332],

1	The	DT	O	the	det	5	SENT_87	[p8l1246t1269r1383b1332],
2	confirmed	VBN	O	confirm	amod	5	SENT_87	[p8l1413t1269r1791b1332],
3	objective	JJ	O	objective	amod	5	SENT_87	[p8l1820t1269r2143b1353],
4	response	NN	O	response	nn	5	SENT_87	[p8l9t1394r318b1455],
5	rate	NN	O	rate	nsubj	13	SENT_87	[p8l344t1384r475b1435],
6	by	IN	O	by	_	0	SENT_87	[p8l497t1372r584b1456],
7	an	DT	O	a	det	10	SENT_87	[p8l605t1395r687b1435],
8	independent	JJ	O	independent	amod	10	SENT_87	[p8l712t1372r1160b1455],
9	review	NN	O	review	nn	10	SENT_87	[p8l1184t1378r1419b1435],
10	committee	NN	O	committee	prep_by	5	SENT_87	[p8l1441t1378r1817b1435],
11	was	VBD	O	be	cop	13	SENT_87	[p8l1840t1395r1970b1435],
12	50	CD	PERCENT	50	num	13	SENT_87	[p8l1997t1378r2142b1437],
13	%	NN	PERCENT	%	_	0	SENT_87	[p8l1997t1378r2142b1437],
14	for	IN	O	for	_	0	SENT_87	[p8l8t1475r106b1538],
15	dabrafenib	NN	O	dabrafenib	prep_for	13	SENT_87	[p8l127t1475r508b1547],
16	,	,	O	,	_	0	SENT_87	[p8l127t1475r508b1547],
17	with	IN	O	with	_	0	SENT_87	[p8l530t1475r683b1538],
18	a	DT	O	a	det	23	SENT_87	[p8l705t1498r739b1538],
19	3	CD	PERCENT	3	number	20	SENT_87	[p8l761t1480r861b1540],
20	%	NN	PERCENT	%	amod	23	SENT_87	[p8l761t1480r861b1540],
21	complete	JJ	O	complete	amod	23	SENT_87	[p8l885t1475r1195b1558],
22	response	NN	O	response	nn	23	SENT_87	[p8l1217t1497r1516b1558],
23	rate	NN	O	rate	prep_with	13	SENT_87	[p8l1538t1487r1681b1538],
24	.	.	O	.	_	0	SENT_87	[p8l1538t1487r1681b1538],

1	These	DT	O	these	det	2	SENT_88	[p8l1706t1475r1900b1538],
2	results	NNS	O	result	nsubj	4	SENT_88	[p8l1922t1475r2141b1538],
3	are	VBP	O	be	cop	4	SENT_88	[p8l9t1601r110b1641],
4	similar	JJ	O	similar	_	0	SENT_88	[p8l134t1578r374b1641],
5	to	TO	O	to	_	0	SENT_88	[p8l395t1590r461b1641],
6	what	WP	O	what	nsubjpass	8	SENT_88	[p8l484t1578r653b1641],
7	was	VBD	O	be	auxpass	8	SENT_88	[p8l673t1601r800b1641],
8	observed	VBN	O	observe	prepc_to	4	SENT_88	[p8l824t1578r1137b1641],
9	in	IN	O	in	_	0	SENT_88	[p8l1160t1584r1227b1640],
10	the	DT	O	the	det	14	SENT_88	[p8l1249t1578r1356b1641],
11	Vemurafenib	NNP	O	Vemurafenib	nn	14	SENT_88	[p8l1376t1578r1815b1641],
12	phase	NN	O	phase	nn	14	SENT_88	[p8l1838t1578r2034b1661],
13	III	CD	NUMBER	iii	num	14	SENT_88	[p8l2058t1583r2142b1640],
14	trial	NN	O	trial	prep_in	8	SENT_88	[p8l8t1681r166b1753],
15	,	,	O	,	_	0	SENT_88	[p8l8t1681r166b1753],
16	indicating	VBG	O	indicate	partmod	14	SENT_88	[p8l191t1681r540b1765],
17	a	DT	O	a	det	21	SENT_88	[p8l562t1704r596b1744],
18	likely	JJ	O	likely	amod	19	SENT_88	[p8l617t1681r804b1765],
19	equivalent	JJ	O	equivalent	amod	21	SENT_88	[p8l824t1681r1181b1764],
20	antitumor	NN	O	antitumor	nn	21	SENT_88	[p8l1203t1687r1551b1744],
21	activity	NN	O	activity	dobj	16	SENT_88	[p8l1573t1687r1827b1765],
22	for	IN	O	for	_	0	SENT_88	[p8l1846t1681r1944b1744],
23	these	DT	O	these	det	25	SENT_88	[p8l1965t1681r2141b1744],
24	two	CD	NUMBER	two	num	25	SENT_88	[p8l8t1796r135b1847],
25	agents	NNS	O	agent	prep_for	21	SENT_88	[p8l160t1796r395b1868],
26	.	.	O	.	_	0	SENT_88	[p8l160t1796r395b1868],

1	In	IN	O	in	_	0	SENT_89	[p8l422t1789r494b1846],
2	an	DT	O	a	det	4	SENT_89	[p8l518t1807r599b1847],
3	updated	VBN	O	update	amod	4	SENT_89	[p8l623t1784r907b1867],
4	report	NN	O	report	prep_in	16	SENT_89	[p8l930t1796r1165b1867],
5	,	,	O	,	_	0	SENT_89	[p8l930t1796r1165b1867],
6	the	DT	O	the	det	9	SENT_89	[p8l1189t1784r1297b1847],
7	median	JJ	O	median	amod	9	SENT_89	[p8l1321t1784r1583b1847],
8	overall	JJ	O	overall	amod	9	SENT_89	[p8l1607t1784r1841b1847],
9	survival	NN	O	survival	nsubj	16	SENT_89	[p8l1865t1784r2142b1847],
10	for	IN	O	for	_	0	SENT_89	[p8l8t1887r106b1950],
11	the	DT	O	the	det	13	SENT_89	[p8l124t1887r230b1950],
12	dabrafenib	NN	O	dabrafenib	nn	13	SENT_89	[p8l252t1887r889b1950],
13	—	NN	O	—	prep_for	9	SENT_89	[p8l252t1887r889b1950],
14	treated	VBN	O	treat	partmod	13	SENT_89	[p8l252t1887r889b1950],
15	group	NN	O	group	dobj	14	SENT_89	[p8l909t1909r1108b1971],
16	was	VBD	O	be	_	0	SENT_89	[p8l1128t1910r1254b1950],
17	18.2	CD	DURATION	18.2	num	18	SENT_89	[p8l1282t1894r1414b1950],
18	months	NNS	NUMBER	month	npadvmod	19	SENT_89	[p8l1435t1887r1694b1950],
19	as	IN	O	as	advmod	16	SENT_89	[p8l1716t1910r1780b1950],
20	compared	VBN	O	compare	_	0	SENT_89	[p8l1802t1887r2144b1970],
21	with	IN	O	with	prepc_compared_with	16	SENT_89	[p8l7t1990r160b2053],
22	15.6	CD	DURATION	15.6	num	23	SENT_89	[p8l189t1996r321b2053],
23	months	NNS	NUMBER	month	pobj	16	SENT_89	[p8l345t1990r604b2053],
24	in	IN	O	in	_	0	SENT_89	[p8l627t1996r694b2052],
25	the	DT	O	the	det	27	SENT_89	[p8l715t1990r822b2053],
26	dacarbazine	NN	O	dacarbazine	nn	27	SENT_89	[p8l845t1990r1256b2053],
27	group	NN	O	group	prep_in	23	SENT_89	[p8l1279t2012r1496b2074],
28	,	,	O	,	_	0	SENT_89	[p8l1279t2012r1496b2074],
29	which	WDT	O	which	nsubj	31	SENT_89	[p8l1518t1990r1728b2053],
30	was	VBD	O	be	cop	31	SENT_89	[p8l1749t2013r1874b2053],
31	further	JJ	O	further	rcmod	27	SENT_89	[p8l1898t1990r2142b2053],
32	confounded	VBN	O	confound	partmod	31	SENT_89	[p8l9t2093r437b2156],
33	by	IN	O	by	_	0	SENT_89	[p8l460t2093r546b2177],
34	the	DT	O	the	det	35	SENT_89	[p8l567t2093r677b2156],
35	crossover	NN	O	crossover	agent	32	SENT_89	[p8l703t2116r1039b2156],
36	of	IN	O	of	_	0	SENT_89	[p8l1064t2093r1140b2156],
37	the	DT	O	the	det	38	SENT_89	[p8l1154t2093r1265b2156],
38	majority	NN	O	majority	prep_of	35	SENT_89	[p8l1290t2099r1595b2177],
39	of	IN	O	of	_	0	SENT_89	[p8l1618t2093r1693b2156],
40	patients	NNS	O	patient	prep_of	38	SENT_89	[p8l1708t2099r1988b2176],
41	initially	RB	O	initially	advmod	42	SENT_89	[p8l2015t2099r2139b2155, p8l8t2196r186b2280],
42	assigned	VBN	O	assign	partmod	40	SENT_89	[p8l207t2196r506b2280],
43	to	TO	O	to	_	0	SENT_89	[p8l528t2208r596b2259],
44	dacarbazine	NN	O	dacarbazine	prep_to	42	SENT_89	[p8l622t2196r1044b2259],
45	to	TO	O	to	_	0	SENT_89	[p8l1067t2208r1135b2259],
46	dabrafenib	NN	O	dabrafenib	nn	48	SENT_89	[p8l1161t2196r1537b2259],
47	(	CD	NUMBER	(	num	48	SENT_89	[p8l1565t2196r1714b2273],
48	HR	NN	DURATION	hr	prep_to	42	SENT_89	[p8l1565t2196r1714b2273],
49	=	JJ	O	=	amod	48	SENT_89	[p8l1737t2225r1780b2246],
50	0.76	CD	NUMBER	0.76	tmod	49	SENT_89	[p8l1807t2202r1970b2268],
51	,	,	O	,	_	0	SENT_89	[p8l1807t2202r1970b2268],
52	95	CD	PERCENT	95	number	53	SENT_89	[p8l1996t2201r2141b2260],
53	%	NN	PERCENT	%	amod	54	SENT_89	[p8l1996t2201r2141b2260],
54	CI	NN	O	ci	dobj	42	SENT_89	[p8l10t2303r93b2363],
55	=	JJ	O	=	amod	54	SENT_89	[p8l126t2329r169b2349],
56	O.	NNP	O	O.	dep	55	SENT_89	[p8l201t2291r669b2376],
57	48	CD	NUMBER	48	num	56	SENT_89	[p8l201t2291r669b2376],
58	—	CD	NUMBER	—	number	59	SENT_89	[p8l201t2291r669b2376],
59	1.21	CD	NUMBER	1.21	num	60	SENT_89	[p8l201t2291r669b2376],
60	)	NN	O	)	dep	31	SENT_89	[p8l201t2291r669b2376],
61	.34	CD	NUMBER	.34	dep	31	SENT_89	[p8l201t2291r669b2376],
62	The	DT	O	the	det	66	SENT_89	[p8l697t2299r835b2363],
63	most	RBS	O	most	advmod	64	SENT_89	[p8l864t2311r1042b2363],
64	common	JJ	O	common	amod	66	SENT_89	[p8l1071t2322r1391b2363],
65	adverse	JJ	O	adverse	amod	66	SENT_89	[p8l1421t2299r1691b2363],
66	events	NNS	O	event	nsubj	70	SENT_89	[p8l1721t2311r1945b2363],
67	were	VBD	O	be	cop	70	SENT_89	[p8l1973t2322r2141b2363],
68	cutaneous	JJ	O	cutaneous	amod	70	SENT_89	[p8l9t2415r369b2466],
69	(	NN	O	(	nn	70	SENT_89	[p8l400t2403r967b2487],
70	hyperkeratosis	NN	O	hyperkeratosis	rcmod	61	SENT_89	[p8l400t2403r967b2487],
71	,	,	O	,	_	0	SENT_89	[p8l400t2403r967b2487],
72	papillomas	NN	O	papilloma	conj_and	70	SENT_89	[p8l994t2403r1404b2486],
73	,	,	O	,	_	0	SENT_89	[p8l994t2403r1404b2486],
74	and	CC	O	and	_	0	SENT_89	[p8l1433t2403r1563b2466],
75	palmar	JJ	O	palmar	amod	78	SENT_89	[p8l1587t2403r2143b2486],
76	—	JJ	O	—	amod	78	SENT_89	[p8l1587t2403r2143b2486],
77	plantar	JJ	O	plantar	amod	78	SENT_89	[p8l1587t2403r2143b2486],
78	erythrodysesthesia	NN	O	erythrodysesthesium	conj_and	70	SENT_89	[p8l9t2506r717b2590],
79	)	NN	O	)	dep	78	SENT_89	[p8l9t2506r717b2590],
80	,	,	O	,	_	0	SENT_89	[p8l9t2506r717b2590],
81	fatigue	NN	O	fatigue	conj_and	79	SENT_89	[p8l743t2506r998b2590],
82	,	,	O	,	_	0	SENT_89	[p8l743t2506r998b2590],
83	headache	NN	O	headache	conj_and	79	SENT_89	[p8l1022t2506r1368b2578],
84	,	,	O	,	_	0	SENT_89	[p8l1022t2506r1368b2578],
85	and	CC	O	and	_	0	SENT_89	[p8l1394t2506r1523b2569],
86	arthralgia	NN	O	arthralgium	dep	78	SENT_89	[p8l1546t2506r1906b2590],
87	,	,	O	,	_	0	SENT_89	[p8l1546t2506r1906b2590],
88	which	WDT	O	which	nsubj	90	SENT_89	[p8l1930t2506r2144b2569],
89	together	RB	O	together	advmod	90	SENT_89	[p8l8t2609r292b2693],
90	required	VBD	O	require	rcmod	31	SENT_89	[p8l312t2609r601b2692],
91	dose	NN	O	dose	nn	92	SENT_89	[p8l621t2609r774b2672],
92	reduction	NN	O	reduction	dobj	90	SENT_89	[p8l795t2609r1125b2672],
93	in	IN	O	in	_	0	SENT_89	[p8l1145t2615r1211b2671],
94	28	CD	PERCENT	28	num	95	SENT_89	[p8l1232t2614r1373b2674],
95	%	NN	PERCENT	%	prep_in	90	SENT_89	[p8l1232t2614r1373b2674],
96	of	IN	O	of	_	0	SENT_89	[p8l1396t2609r1469b2672],
97	patients	NNS	O	patient	prep_of	95	SENT_89	[p8l1479t2615r1763b2692],
98	.	.	O	.	_	0	SENT_89	[p8l1479t2615r1763b2692],

1	Squamous	JJ	O	squamous	amod	3	SENT_90	[p8l1788t2613r2140b2692],
2	cell	NN	O	cell	nn	3	SENT_90	[p8l9t2711r126b2774],
3	carcinoma	NN	O	carcinoma	nsubjpass	7	SENT_90	[p8l151t2717r523b2774],
4	or	CC	O	or	_	0	SENT_90	[p8l547t2734r621b2774],
5	keratoacanthomas	NNS	O	keratoacanthoma	conj_or	3	SENT_90	[p8l643t2711r1292b2774],
6	were	VBD	O	be	auxpass	7	SENT_90	[p8l1316t2734r1481b2774],
7	observed	VBN	O	observe	_	0	SENT_90	[p8l1507t2711r1827b2774],
8	in	IN	O	in	_	0	SENT_90	[p8l1851t2717r1919b2773],
9	6	CD	PERCENT	6	num	10	SENT_90	[p8l1945t2716r2048b2775],
10	%	NN	PERCENT	%	prep_in	7	SENT_90	[p8l1945t2716r2048b2775],
11	of	IN	O	of	_	0	SENT_90	[p8l2075t2711r2151b2774],
12	patients	NNS	O	patient	prep_of	10	SENT_90	[p8l7t2820r296b2897],
13	.	.	O	.	_	0	SENT_90	[p8l7t2820r296b2897],

1	Photosensitivity	NN	O	photosensitivity	nn	2	SENT_91	[p8l323t2814r881b2898],
2	reactions	NNS	O	reaction	nsubjpass	5	SENT_91	[p8l900t2820r1212b2877],
3	were	VBD	O	be	auxpass	5	SENT_91	[p8l1234t2837r1396b2877],
4	rarely	RB	O	rarely	advmod	5	SENT_91	[p8l1419t2814r1618b2898],
5	seen	VBN	O	see	_	0	SENT_91	[p8l1638t2837r1788b2877],
6	with	IN	O	with	_	0	SENT_91	[p8l1809t2814r1962b2877],
7	dabrafenib	NN	O	dabrafenib	prep_with	5	SENT_91	[p8l1986t2814r2137b2877, p8l9t2917r276b2989],
8	;	:	O	;	_	0	SENT_91	[p8l1986t2814r2137b2877, p8l9t2917r276b2989],
9	however	RB	O	however	advmod	17	SENT_91	[p8l301t2917r613b2989],
10	,	,	O	,	_	0	SENT_91	[p8l301t2917r613b2989],
11	grade	NN	O	grade	nsubjpass	17	SENT_91	[p8l639t2917r834b3001],
12	2	CD	NUMBER	2	num	11	SENT_91	[p8l859t2924r895b2979],
13	or	CC	O	or	_	0	SENT_91	[p8l922t2940r995b2980],
14	3	CD	NUMBER	3	num	15	SENT_91	[p8l1020t2924r1053b2980],
15	pyrexia	NN	O	pyrexia	conj_or	11	SENT_91	[p8l1080t2923r1340b3001],
16	was	VBD	O	be	auxpass	17	SENT_91	[p8l1361t2940r1491b2980],
17	observed	VBN	O	observe	parataxis	5	SENT_91	[p8l1516t2917r1836b2980],
18	in	IN	O	in	_	0	SENT_91	[p8l1859t2923r1927b2979],
19	8	CD	NUMBER	8	num	22	SENT_91	[p8l1953t2924r1988b2980],
20	and	CC	O	and	_	0	SENT_91	[p8l2015t2917r2144b2980],
21	3	CD	PERCENT	3	num	22	SENT_91	[p8l10t3025r129b3092],
22	%	NN	PERCENT	%	prep_in	17	SENT_91	[p8l10t3025r129b3092],
23	,	,	O	,	_	0	SENT_91	[p8l10t3025r129b3092],
24	respectively	RB	O	respectively	advmod	17	SENT_91	[p8l153t3020r564b3104],
25	.	.	O	.	_	0	SENT_91	[p8l153t3020r564b3104],

1	Trametinib	NNP	O	Trametinib	nsubj	10	SENT_92	[p8l82t3123r476b3186],
2	is	VBZ	O	be	cop	10	SENT_92	[p8l501t3129r553b3186],
3	an	DT	O	a	det	10	SENT_92	[p8l579t3146r660b3186],
4	orally	RB	O	orally	advmod	9	SENT_92	[p8l685t3123r887b3207],
5	available	JJ	O	available	amod	9	SENT_92	[p8l909t3123r1231b3195],
6	,	,	O	,	_	0	SENT_92	[p8l909t3123r1231b3195],
7	small-molecule	JJ	O	small-molecule	amod	9	SENT_92	[p8l1258t3123r1819b3195],
8	,	,	O	,	_	0	SENT_92	[p8l1258t3123r1819b3195],
9	selective	JJ	O	selective	amod	10	SENT_92	[p8l1847t3123r2142b3186],
10	inhibitor	NN	O	inhibitor	ccomp	49	SENT_92	[p8l9t3226r304b3289],
11	of	IN	O	of	_	0	SENT_92	[p8l322t3226r395b3289],
12	MEK1	NN	O	mek1	prep_of	10	SENT_92	[p8l404t3231r615b3288],
13	and	CC	O	and	_	0	SENT_92	[p8l642t3226r765b3289],
14	MEK2	NN	O	mek2	prep_of	10	SENT_92	[p8l783t3231r998b3288],
15	that	WDT	O	that	nsubj	16	SENT_92	[p8l1019t3226r1149b3289],
16	demonstrated	VBD	O	demonstrate	rcmod	10	SENT_92	[p8l1168t3226r1630b3289],
17	activity	NN	O	activity	dobj	16	SENT_92	[p8l1649t3232r1895b3310],
18	in	IN	O	in	_	0	SENT_92	[p8l1910t3232r1975b3288],
19	Xenograft	NNP	O	Xenograft	nn	20	SENT_92	[p8l1993t3249r2139b3289, p8l9t3328r208b3412],
20	model	NN	O	model	prep_in	16	SENT_92	[p8l227t3328r442b3391],
21	at	IN	O	at	_	0	SENT_92	[p8l462t3340r520b3391],
22	doses	NNS	O	dose	prep_at	16	SENT_92	[p8l541t3328r724b3391],
23	that	WDT	O	that	nsubj	24	SENT_92	[p8l744t3328r876b3391],
24	appeared	VBD	O	appear	rcmod	22	SENT_92	[p8l896t3328r1204b3411],
25	to	TO	O	to	aux	27	SENT_92	[p8l1223t3340r1288b3391],
26	be	VB	O	be	cop	27	SENT_92	[p8l1307t3328r1386b3391],
27	nontoXic	JJ	O	nontoxic	xcomp	24	SENT_92	[p8l1406t3320r1784b3391],
28	.35	CD	NUMBER	.35	tmod	27	SENT_92	[p8l1406t3320r1784b3391],
29	In	IN	O	in	_	0	SENT_92	[p8l1806t3333r1876b3390],
30	a	DT	O	a	det	36	SENT_92	[p8l1897t3351r1931b3391],
31	phase	NN	O	phase	npadvmod	33	SENT_92	[p8l1949t3328r2142b3411],
32	III	CD	NUMBER	iii	num	31	SENT_92	[p8l9t3436r90b3493],
33	open	JJ	O	open	amod	36	SENT_92	[p8l112t3431r469b3514],
34	—	NN	O	—	nn	36	SENT_92	[p8l112t3431r469b3514],
35	label	NN	O	label	nn	36	SENT_92	[p8l112t3431r469b3514],
36	trial	NN	O	trial	prep_in	27	SENT_92	[p8l488t3431r643b3503],
37	,	,	O	,	_	0	SENT_92	[p8l488t3431r643b3503],
38	322	CD	NUMBER	322	num	39	SENT_92	[p8l666t3438r782b3494],
39	patients	NNS	O	patient	nsubjpass	49	SENT_92	[p8l802t3437r1067b3514],
40	with	IN	O	with	_	0	SENT_92	[p8l1086t3431r1236b3494],
41	metastatic	JJ	O	metastatic	amod	42	SENT_92	[p8l1256t3437r1600b3494],
42	melanoma	NN	O	melanoma	prep_with	39	SENT_92	[p8l1619t3431r1976b3494],
43	with	IN	O	with	_	0	SENT_92	[p8l1993t3431r2144b3494],
44	BRAFV600E	NN	O	brafv600e	nn	47	SENT_92	[p8l9t3537r456b3596],
45	or	CC	O	or	_	0	SENT_92	[p8l480t3556r552b3596],
46	V600K	NN	O	v600k	nn	47	SENT_92	[p8l574t3538r820b3596],
47	mutation	NN	O	mutation	prep_with	42	SENT_92	[p8l841t3539r1160b3596],
48	were	VBD	O	be	auxpass	49	SENT_92	[p8l1182t3556r1345b3596],
49	randomized	VBN	O	randomize	_	0	SENT_92	[p8l1368t3533r1790b3596],
50	to	TO	O	to	aux	51	SENT_92	[p8l1812t3545r1878b3596],
51	receive	VB	O	receive	xcomp	49	SENT_92	[p8l1903t3539r2143b3596],
52	either	CC	O	either	preconj	56	SENT_92	[p9l9t27r203b90],
53	trametinib	NN	O	trametinib	dep	56	SENT_92	[p9l221t27r579b90],
54	or	CC	O	or	_	0	SENT_92	[p9l601t50r672b90],
55	chemotherapy	NN	O	chemotherapy	conj_or	56	SENT_92	[p9l692t27r1178b111],
56	(	CD	NUMBER	(	dobj	51	SENT_92	[p9l1197t27r1418b103],
57	either	CC	O	either	prep	56	SENT_92	[p9l1197t27r1418b103],
58	dacarbazine	NN	O	dacarbazine	nn	61	SENT_92	[p9l1438t27r1843b90],
59	or	CC	O	or	_	0	SENT_92	[p9l1864t50r1935b90],
60	paclitaxel	NN	O	paclitaxel	conj_or	58	SENT_92	[p9l1953t27r2140b110, p9l8t129r196b206],
61	)	NN	O	)	dep	57	SENT_92	[p9l1953t27r2140b110, p9l8t129r196b206],
62	in	IN	O	in	mark	71	SENT_92	[p9l223t135r290b191],
63	a	DT	O	a	det	69	SENT_92	[p9l314t152r349b192],
64	2:1	CD	NUMBER	2:1	num	69	SENT_92	[p9l371t136r464b192],
65	ratio	NN	O	ratio	nn	69	SENT_92	[p9l494t121r735b192],
66	.36	CD	NUMBER	.36	num	69	SENT_92	[p9l494t121r735b192],
67	One	CD	NUMBER	one	num	69	SENT_92	[p9l759t133r904b193],
68	previous	JJ	O	previous	amod	69	SENT_92	[p9l925t135r1222b212],
69	treatment	NN	O	treatment	nsubjpass	71	SENT_92	[p9l1245t141r1585b192],
70	was	VBD	O	be	auxpass	71	SENT_92	[p9l1605t152r1732b192],
71	allowed	VBN	O	allow	advcl	51	SENT_92	[p9l1757t129r2023b192],
72	for	IN	O	for	_	0	SENT_92	[p9l2044t129r2143b192],
73	treatment	NN	O	treatment	prep_for	71	SENT_92	[p9l8t244r343b295],
74	of	IN	O	of	_	0	SENT_92	[p9l364t232r438b295],
75	advanced	JJ	O	advanced	amod	76	SENT_92	[p9l451t232r774b295],
76	melanoma	NN	O	melanoma	prep_of	73	SENT_92	[p9l795t232r1173b304],
77	,	,	O	,	_	0	SENT_92	[p9l795t232r1173b304],
78	with	IN	O	with	_	0	SENT_92	[p9l1195t232r1348b295],
79	the	DT	O	the	det	80	SENT_92	[p9l1368t232r1474b295],
80	exception	NN	O	exception	prep_with	71	SENT_92	[p9l1498t238r1828b315],
81	of	IN	O	of	_	0	SENT_92	[p9l1850t232r1924b295],
82	BRAF	NN	ORGANIZATION	braf	nn	85	SENT_92	[p9l1937t236r2141b295],
83	and	CC	O	and	_	0	SENT_92	[p9l9t335r136b398],
84	MEK	NN	O	mek	conj_and	82	SENT_92	[p9l155t340r338b397],
85	inhibitors	NNS	O	inhibitor	prep_of	80	SENT_92	[p9l358t335r690b398],
86	and	CC	O	and	_	0	SENT_92	[p9l713t335r839b398],
87	ipilimumab	NN	O	ipilimumab	conj_and	85	SENT_92	[p9l860t335r1272b418],
88	.	.	O	.	_	0	SENT_92	[p9l860t335r1272b418],

1	Median	JJ	O	median	amod	3	SENT_93	[p9l1296t335r1558b398],
2	progression-free	JJ	O	progression-free	amod	3	SENT_93	[p9l1579t335r2142b419],
3	survival	NN	O	survival	nsubjpass	5	SENT_93	[p9l9t438r284b501],
4	was	VBD	O	be	auxpass	5	SENT_93	[p9l304t461r432b501],
5	improved	VBN	O	improve	_	0	SENT_93	[p9l456t438r789b521],
6	to	TO	O	to	_	0	SENT_93	[p9l810t450r876b501],
7	4.8	CD	DURATION	4.8	num	8	SENT_93	[p9l900t445r999b501],
8	months	NNS	NUMBER	month	prep_to	5	SENT_93	[p9l1024t438r1285b501],
9	in	IN	O	in	_	0	SENT_93	[p9l1309t444r1377b500],
10	the	DT	O	the	det	12	SENT_93	[p9l1399t438r1506b501],
11	trametinib	NN	O	trametinib	nn	12	SENT_93	[p9l1529t438r1896b501],
12	group	NN	O	group	prep_in	8	SENT_93	[p9l1921t460r2140b522],
13	,	,	O	,	_	0	SENT_93	[p9l1921t460r2140b522],
14	as	IN	O	as	_	0	SENT_93	[p9l9t564r76b604],
15	compared	VBN	O	compare	prepc_as	5	SENT_93	[p9l107t541r468b624],
16	with	IN	O	with	pcomp	15	SENT_93	[p9l495t541r656b604],
17	1.5	CD	DURATION	1.5	num	18	SENT_93	[p9l693t548r788b604],
18	months	NNS	NUMBER	month	pobj	16	SENT_93	[p9l820t541r1092b604],
19	in	IN	O	in	_	0	SENT_93	[p9l1123t547r1192b603],
20	the	DT	O	the	det	22	SENT_93	[p9l1221t541r1333b604],
21	chemotherapy	NN	O	chemotherapy	nn	22	SENT_93	[p9l1364t541r1886b625],
22	group	NN	O	group	prep_in	18	SENT_93	[p9l1911t563r2140b625],
23	.	.	O	.	_	0	SENT_93	[p9l1911t563r2140b625],

1	Overall	JJ	O	overall	amod	3	SENT_94	[p9l10t643r272b706],
2	survival	NN	O	survival	nn	3	SENT_94	[p9l297t643r579b706],
3	rate	NN	O	rate	nsubj	9	SENT_94	[p9l604t655r736b706],
4	at	IN	O	at	_	0	SENT_94	[p9l762t655r823b706],
5	6	CD	DURATION	6	num	6	SENT_94	[p9l848t649r885b706],
6	months	NNS	NUMBER	month	prep_at	3	SENT_94	[p9l911t643r1179b706],
7	was	VBD	O	be	cop	9	SENT_94	[p9l1204t666r1333b706],
8	81	CD	PERCENT	81	num	9	SENT_94	[p9l1361t648r1506b707],
9	%	NN	PERCENT	%	_	0	SENT_94	[p9l1361t648r1506b707],
10	in	IN	O	in	_	0	SENT_94	[p9l1534t649r1603b705],
11	the	DT	O	the	det	13	SENT_94	[p9l1627t643r1737b706],
12	trametinib	NN	O	trametinib	nn	13	SENT_94	[p9l1762t643r2139b706],
13	group	NN	O	group	prep_in	9	SENT_94	[p9l8t768r209b830],
14	and	CC	O	and	_	0	SENT_94	[p9l234t746r361b809],
15	67	CD	PERCENT	67	num	16	SENT_94	[p9l383t751r525b810],
16	%	NN	PERCENT	%	conj_and	9	SENT_94	[p9l383t751r525b810],
17	in	IN	O	in	_	0	SENT_94	[p9l550t752r617b808],
18	the	DT	O	the	det	20	SENT_94	[p9l639t746r746b809],
19	chemotherapy	NN	O	chemotherapy	nn	20	SENT_94	[p9l769t746r1265b830],
20	group	NN	O	group	prep_in	16	SENT_94	[p9l1284t768r1501b830],
21	,	,	O	,	_	0	SENT_94	[p9l1284t768r1501b830],
22	even	RB	O	even	advmod	36	SENT_94	[p9l1527t769r1683b809],
23	though	IN	O	though	dep	36	SENT_94	[p9l1705t746r1952b830],
24	51	CD	NUMBER	51	nsubj	36	SENT_94	[p9l1977t753r2048b809],
25	of	IN	O	of	_	0	SENT_94	[p9l2078t746r2152b809],
26	108	CD	NUMBER	108	num	27	SENT_94	[p9l15t856r127b912],
27	patients	NNS	O	patient	prep_of	24	SENT_94	[p9l151t855r421b932],
28	(	IN	O	(	_	0	SENT_94	[p9l447t849r645b926],
29	47	CD	PERCENT	47	number	30	SENT_94	[p9l447t849r645b926],
30	%	NN	PERCENT	%	amod	31	SENT_94	[p9l447t849r645b926],
31	)	CD	NUMBER	)	prep_(	27	SENT_94	[p9l447t849r645b926],
32	in	IN	O	in	_	0	SENT_94	[p9l672t855r738b911],
33	the	DT	O	the	det	35	SENT_94	[p9l760t849r867b912],
34	chemotherapy	NN	O	chemotherapy	nn	35	SENT_94	[p9l890t849r1384b933],
35	group	NN	O	group	prep_in	31	SENT_94	[p9l1403t871r1604b933],
36	crossed	VBD	O	cross	dep	9	SENT_94	[p9l1628t849r1884b912],
37	over	IN	O	over	_	0	SENT_94	[p9l1906t872r2054b912],
38	to	TO	O	to	aux	39	SENT_94	[p9l2074t861r2141b912],
39	receive	VB	O	receive	dep	50	SENT_94	[p9l9t958r238b1015],
40	trametinib	NN	O	trametinib	nn	42	SENT_94	[p9l257t952r610b1015],
41	(	CD	NUMBER	(	num	42	SENT_94	[p9l634t952r776b1029],
42	HR	NN	DURATION	hr	dobj	39	SENT_94	[p9l634t952r776b1029],
43	for	IN	O	for	_	0	SENT_94	[p9l793t952r888b1015],
44	death	NN	O	death	prep_for	39	SENT_94	[p9l907t952r1090b1015],
45	=	JJ	O	=	amod	44	SENT_94	[p9l1111t981r1152b1002],
46	0.54	CD	NUMBER	0.54	tmod	45	SENT_94	[p9l1174t959r1328b1024],
47	;	:	O	;	_	0	SENT_94	[p9l1174t959r1328b1024],
48	95	CD	PERCENT	95	number	49	SENT_94	[p9l1350t957r1488b1017],
49	%	NN	PERCENT	%	amod	50	SENT_94	[p9l1350t957r1488b1017],
50	CI	NN	O	ci	prep_over	36	SENT_94	[p9l1511t956r1590b1016],
51	=	JJ	O	=	amod	50	SENT_94	[p9l1613t981r1654b1002],
52	0.32-0	CD	NUMBER	0.32-0	number	53	SENT_94	[p9l1676t959r2013b1024],
53	.92	CD	NUMBER	.92	dep	51	SENT_94	[p9l1676t959r2013b1024],
54	;	:	O	;	_	0	SENT_94	[p9l1676t959r2013b1024],
55	P	NN	O	p	dep	50	SENT_94	[p9l2033t957r2081b1014],
56	=	JJ	O	=	amod	58	SENT_94	[p9l2098t981r2140b1002],
57	0.01	CD	NUMBER	0.01	tmod	56	SENT_94	[p9l9t1056r193b1132],
58	)	NN	O	)	dep	55	SENT_94	[p9l9t1056r193b1132],
59	.	.	O	.	_	0	SENT_94	[p9l9t1056r193b1132],

1	The	DT	O	the	det	3	SENT_95	[p9l216t1055r340b1118],
2	response	NN	O	response	nn	3	SENT_95	[p9l360t1077r655b1138],
3	rate	NN	O	rate	nsubj	6	SENT_95	[p9l676t1067r801b1118],
4	was	VBD	O	be	cop	6	SENT_95	[p9l820t1078r944b1118],
5	also	RB	O	also	advmod	6	SENT_95	[p9l966t1055r1094b1118],
6	higher	JJR	O	higher	_	0	SENT_95	[p9l1115t1055r1335b1139],
7	in	IN	O	in	_	0	SENT_95	[p9l1354t1061r1420b1117],
8	the	DT	O	the	det	10	SENT_95	[p9l1439t1055r1544b1118],
9	trametinib	NN	O	trametinib	nn	10	SENT_95	[p9l1563t1055r1921b1118],
10	group	NN	O	group	prep_in	6	SENT_95	[p9l1943t1077r2140b1139],
11	(	CD	PERCENT	(	number	12	SENT_95	[p9l12t1159r214b1234],
12	22	CD	PERCENT	22	dep	13	SENT_95	[p9l12t1159r214b1234],
13	%	NN	PERCENT	%	dep	10	SENT_95	[p9l12t1159r214b1234],
14	)	CD	NUMBER	)	npadvmod	15	SENT_95	[p9l12t1159r214b1234],
15	than	IN	O	than	advmod	6	SENT_95	[p9l240t1158r398b1221],
16	in	IN	O	in	_	0	SENT_95	[p9l422t1164r490b1220],
17	the	DT	O	the	det	19	SENT_95	[p9l513t1158r621b1221],
18	chemotherapy	NN	O	chemotherapy	nn	19	SENT_95	[p9l646t1158r1151b1242],
19	group	NN	O	group	prep_in	6	SENT_95	[p9l1171t1180r1376b1242],
20	(	CD	PERCENT	(	number	21	SENT_95	[p9l1404t1159r1585b1234],
21	8	CD	PERCENT	8	num	22	SENT_95	[p9l1404t1159r1585b1234],
22	%	NN	PERCENT	%	dep	19	SENT_95	[p9l1404t1159r1585b1234],
23	)	CD	NUMBER	)	dep	22	SENT_95	[p9l1404t1159r1585b1234],
24	.	.	O	.	_	0	SENT_95	[p9l1404t1159r1585b1234],

1	Rash	NNP	O	Rash	nsubj	13	SENT_96	[p9l1612t1158r1801b1230],
2	,	,	O	,	_	0	SENT_96	[p9l1612t1158r1801b1230],
3	diarrhea	NN	O	diarrhea	conj_and	1	SENT_96	[p9l1826t1158r2140b1230],
4	,	,	O	,	_	0	SENT_96	[p9l1826t1158r2140b1230],
5	and	CC	O	and	_	0	SENT_96	[p9l9t1261r134b1324],
6	peripheral	JJ	O	peripheral	amod	7	SENT_96	[p9l152t1261r501b1344],
7	edema	NN	O	edema	conj_and	1	SENT_96	[p9l521t1261r743b1324],
8	were	VBD	O	be	cop	13	SENT_96	[p9l760t1284r918b1324],
9	the	DT	O	the	det	13	SENT_96	[p9l938t1261r1043b1324],
10	most	RBS	O	most	advmod	13	SENT_96	[p9l1062t1273r1230b1324],
11	common	JJ	O	common	amod	13	SENT_96	[p9l1249t1284r1552b1324],
12	side	NN	O	side	nn	13	SENT_96	[p9l1573t1261r1703b1324],
13	effects	NNS	O	effect	_	0	SENT_96	[p9l1724t1261r1933b1324],
14	in	IN	O	in	_	0	SENT_96	[p9l1954t1267r2019b1323],
15	the	DT	O	the	det	17	SENT_96	[p9l2038t1261r2143b1324],
16	trametinib	NN	O	trametinib	nn	17	SENT_96	[p9l8t1364r363b1427],
17	group	NN	O	group	prep_in	13	SENT_96	[p9l383t1386r594b1448],
18	.	.	O	.	_	0	SENT_96	[p9l383t1386r594b1448],

1	Notably	RB	O	notably	advmod	9	SENT_97	[p9l616t1364r892b1448],
2	,	,	O	,	_	0	SENT_97	[p9l616t1364r892b1448],
3	no	DT	O	no	det	7	SENT_97	[p9l914t1387r998b1427],
4	cutaneous	JJ	O	cutaneous	amod	7	SENT_97	[p9l1020t1376r1358b1427],
5	squamous	JJ	O	squamous	amod	7	SENT_97	[p9l1379t1387r1716b1447],
6	cell	NN	O	cell	nn	7	SENT_97	[p9l1737t1364r1848b1427],
7	carcinomas	NNS	O	carcinoma	nsubjpass	9	SENT_97	[p9l1868t1370r2141b1427, p9l8t1490r142b1530],
8	were	VBD	O	be	auxpass	9	SENT_97	[p9l160t1490r318b1530],
9	observed	VBN	O	observe	_	0	SENT_97	[p9l339t1467r643b1530],
10	with	IN	O	with	_	0	SENT_97	[p9l660t1467r810b1530],
11	trametinib	NN	O	trametinib	prep_with	9	SENT_97	[p9l829t1467r1200b1530],
12	.	.	O	.	_	0	SENT_97	[p9l829t1467r1200b1530],

1	Decreased	VBN	MISC	decrease	_	0	SENT_98	[p9l1223t1467r1573b1530],
2	ejection	NN	O	ejection	nn	3	SENT_98	[p9l1592t1473r1856b1551],
3	fraction	NN	O	fraction	dobj	1	SENT_98	[p9l1876t1467r2141b1530],
4	or	CC	O	or	_	0	SENT_98	[p9l9t1593r81b1633],
5	ventricular	JJ	O	ventricular	amod	6	SENT_98	[p9l97t1570r476b1633],
6	dysfunction	NN	O	dysfunction	conj_or	3	SENT_98	[p9l496t1570r903b1654],
7	occurred	VBD	O	occur	dep	1	SENT_98	[p9l924t1570r1231b1633],
8	in	IN	O	in	_	0	SENT_98	[p9l1250t1576r1317b1632],
9	7	CD	PERCENT	7	num	10	SENT_98	[p9l1339t1575r1438b1635],
10	%	NN	PERCENT	%	prep_in	7	SENT_98	[p9l1339t1575r1438b1635],
11	of	IN	O	of	_	0	SENT_98	[p9l1461t1570r1534b1633],
12	patients	NNS	O	patient	prep_of	10	SENT_98	[p9l1544t1576r1813b1653],
13	receiving	VBG	O	receive	partmod	12	SENT_98	[p9l1834t1576r2145b1654],
14	trametinib	NN	O	trametinib	nsubj	1	SENT_98	[p9l8t1673r390b1745],
15	,	,	O	,	_	0	SENT_98	[p9l8t1673r390b1745],
16	which	WDT	O	which	nsubj	17	SENT_98	[p9l412t1673r623b1736],
17	required	VBD	O	require	rcmod	14	SENT_98	[p9l645t1673r938b1756],
18	permanent	JJ	O	permanent	amod	19	SENT_98	[p9l959t1685r1338b1756],
19	discontinuation	NN	O	discontinuation	dobj	17	SENT_98	[p9l1361t1673r1903b1736],
20	in	IN	O	in	_	0	SENT_98	[p9l1927t1679r1993b1735],
21	two	CD	NUMBER	two	num	22	SENT_98	[p9l2015t1685r2141b1736],
22	patients	NNS	O	patient	prep_in	17	SENT_98	[p9l7t1782r282b1859],
23	(	IN	O	(	_	0	SENT_98	[p9l310t1777r489b1853],
24	1	CD	PERCENT	1	num	25	SENT_98	[p9l310t1777r489b1853],
25	%	NN	PERCENT	%	prep_(	17	SENT_98	[p9l310t1777r489b1853],
26	)	CD	NUMBER	)	dep	25	SENT_98	[p9l310t1777r489b1853],
27	.	.	O	.	_	0	SENT_98	[p9l310t1777r489b1853],

1	Ocular	JJ	O	ocular	amod	2	SENT_99	[p9l518t1776r758b1839],
2	events	NNS	O	event	nsubj	3	SENT_99	[p9l781t1788r998b1839],
3	occurred	VBD	O	occur	_	0	SENT_99	[p9l1023t1776r1337b1839],
4	in	IN	O	in	_	0	SENT_99	[p9l1360t1782r1427b1838],
5	9	CD	PERCENT	9	num	6	SENT_99	[p9l1451t1782r1553b1841],
6	%	NN	PERCENT	%	prep_in	3	SENT_99	[p9l1451t1782r1553b1841],
7	of	IN	O	of	_	0	SENT_99	[p9l1580t1776r1655b1839],
8	patients	NNS	O	patient	prep_of	6	SENT_99	[p9l1667t1782r1961b1859],
9	,	,	O	,	_	0	SENT_99	[p9l1667t1782r1961b1859],
10	with	IN	O	with	_	0	SENT_99	[p9l1985t1776r2141b1839],
11	blurred	VBN	O	blur	amod	12	SENT_99	[p9l7t1879r255b1942],
12	vision	NN	O	vision	nsubj	17	SENT_99	[p9l271t1885r473b1942],
13	being	VBG	O	be	cop	17	SENT_99	[p9l491t1879r677b1963],
14	the	DT	O	the	det	17	SENT_99	[p9l694t1879r798b1942],
15	most	RBS	O	most	advmod	17	SENT_99	[p9l818t1891r983b1942],
16	frequent	JJ	O	frequent	amod	17	SENT_99	[p9l1001t1879r1283b1962],
17	event	NN	O	event	prepc_with	3	SENT_99	[p9l1303t1891r1496b1951],
18	;	:	O	;	_	0	SENT_99	[p9l1303t1891r1496b1951],
19	however	RB	O	however	advmod	22	SENT_99	[p9l1516t1879r1811b1951],
20	,	,	O	,	_	0	SENT_99	[p9l1516t1879r1811b1951],
21	there	EX	O	there	expl	22	SENT_99	[p9l1831t1879r2001b1942],
22	was	VBD	O	be	parataxis	3	SENT_99	[p9l2019t1902r2142b1942],
23	no	DT	O	no	det	24	SENT_99	[p9l8t2004r95b2045],
24	case	NN	O	case	nsubj	22	SENT_99	[p9l120t2004r261b2045],
25	of	IN	O	of	_	0	SENT_99	[p9l285t1981r359b2045],
26	retinal	JJ	O	retinal	amod	28	SENT_99	[p9l373t1981r597b2045],
27	vein	NN	O	vein	nn	28	SENT_99	[p9l616t1987r764b2045],
28	occlusion	NN	O	occlusion	prep_of	24	SENT_99	[p9l787t1981r1133b2045],
29	.	.	O	.	_	0	SENT_99	[p9l787t1981r1133b2045],

1	On	IN	O	on	_	0	SENT_100	[p9l1160t1985r1268b2045],
2	the	DT	O	the	det	3	SENT_100	[p9l1290t1981r1397b2045],
3	basis	NN	O	basis	prep_on	10	SENT_100	[p9l1419t1981r1586b2045],
4	of	IN	O	of	_	0	SENT_100	[p9l1611t1981r1685b2045],
5	these	DT	O	these	det	6	SENT_100	[p9l1698t1981r1875b2045],
6	results	NNS	O	result	prep_of	3	SENT_100	[p9l1899t1981r2140b2053],
7	,	,	O	,	_	0	SENT_100	[p9l1899t1981r2140b2053],
8	trametinib	NN	O	trametinib	nsubjpass	10	SENT_100	[p9l8t2085r370b2148],
9	was	VBD	O	be	auxpass	10	SENT_100	[p9l392t2108r517b2148],
10	approved	VBN	O	approve	_	0	SENT_100	[p9l541t2085r858b2168],
11	by	IN	O	by	_	0	SENT_100	[p9l877t2085r961b2169],
12	the	DT	O	the	det	13	SENT_100	[p9l978t2085r1084b2148],
13	FDA	NNP	ORGANIZATION	FDA	agent	10	SENT_100	[p9l1108t2089r1269b2147],
14	in	IN	O	in	_	0	SENT_100	[p9l1291t2091r1357b2147],
15	2013	CD	DATE	2013	prep_in	13	SENT_100	[p9l1379t2092r1538b2148],
16	for	IN	O	for	_	0	SENT_100	[p9l1563t2085r1661b2148],
17	the	DT	O	the	det	18	SENT_100	[p9l1680t2085r1786b2148],
18	treatment	NN	O	treatment	prep_for	10	SENT_100	[p9l1808t2097r2143b2148],
19	of	IN	O	of	_	0	SENT_100	[p9l9t2188r86b2251],
20	patients	NNS	O	patient	prep_of	18	SENT_100	[p9l103t2194r386b2271],
21	with	IN	O	with	_	0	SENT_100	[p9l413t2188r572b2251],
22	unresectable	JJ	O	unresectable	amod	25	SENT_100	[p9l600t2188r1053b2251],
23	or	CC	O	or	_	0	SENT_100	[p9l1082t2211r1156b2251],
24	metastatic	JJ	O	metastatic	amod	25	SENT_100	[p9l1183t2194r1551b2251],
25	melanoma	NN	O	melanoma	prep_with	20	SENT_100	[p9l1578t2188r1956b2251],
26	with	IN	O	with	_	0	SENT_100	[p9l1982t2188r2141b2251],
27	BRAF	NN	O	braf	nn	28	SENT_100	[p9l9t2295r213b2353],
28	V600E	NN	O	v600e	prep_with	10	SENT_100	[p9l235t2296r466b2354],
29	or	CC	O	or	_	0	SENT_100	[p9l489t2313r560b2354],
30	V600K	NN	O	v600k	nn	31	SENT_100	[p9l579t2296r821b2354],
31	mutations	NNS	O	mutation	prep_with	10	SENT_100	[p9l841t2297r1202b2354],
32	.	.	O	.	_	0	SENT_100	[p9l841t2297r1202b2354],

1	BRAF	NN	ORGANIZATION	braf	nn	4	SENT_101	[p9l11t2506r191b2561],
2	and	CC	O	and	_	0	SENT_101	[p9l209t2504r337b2561],
3	MEK	NN	O	mek	conj_and	1	SENT_101	[p9l357t2506r511b2560],
4	inhibitors	NNS	O	inhibitor	nsubj	15	SENT_101	[p9l528t2503r863b2561],
5	in	IN	O	in	_	0	SENT_101	[p9l882t2504r941b2560],
6	development	NN	O	development	nn	7	SENT_101	[p9l961t2504r1424b2576],
7	LGX818	NN	O	lgx818	prep_in	4	SENT_101	[p9l9t2605r301b2664],
8	is	VBZ	O	be	cop	15	SENT_101	[p9l329t2607r381b2664],
9	a	DT	O	a	det	15	SENT_101	[p9l409t2624r444b2664],
10	potent	JJ	O	potent	amod	15	SENT_101	[p9l468t2613r699b2684],
11	and	CC	O	and	_	0	SENT_101	[p9l725t2601r855b2664],
12	selective	JJ	O	selective	conj_and	10	SENT_101	[p9l881t2601r1179b2664],
13	RAF	NN	ORGANIZATION	raf	nn	15	SENT_101	[p9l1206t2605r1364b2664],
14	kinase	NN	O	kinase	nn	15	SENT_101	[p9l1391t2601r1617b2664],
15	inhibitor	NN	O	inhibitor	_	0	SENT_101	[p9l1643t2601r1959b2664],
16	with	IN	O	with	_	0	SENT_101	[p9l1982t2601r2141b2664],
17	a	DT	O	a	det	19	SENT_101	[p9l9t2727r44b2767],
18	long	JJ	O	long	amod	19	SENT_101	[p9l65t2704r219b2788],
19	half-life	NN	O	half-life	prep_with	15	SENT_101	[p9l240t2704r511b2767],
20	of	IN	O	of	_	0	SENT_101	[p9l536t2704r610b2767],
21	dissociation	NN	O	dissociation	prep_of	15	SENT_101	[p9l625t2704r1042b2767],
22	from	IN	O	from	_	0	SENT_101	[p9l1065t2704r1236b2767],
23	the	DT	O	the	det	27	SENT_101	[p9l1258t2704r1366b2767],
24	target	NN	O	target	nn	27	SENT_101	[p9l1389t2716r1589b2788],
25	(	CD	NUMBER	(	num	27	SENT_101	[p9l1616t2704r2140b2781],
26	BRAFV600E	NN	O	brafv600e	nn	27	SENT_101	[p9l1616t2704r2140b2781],
27	)	NN	O	)	prep_from	15	SENT_101	[p9l1616t2704r2140b2781],
28	,	,	O	,	_	0	SENT_101	[p9l1616t2704r2140b2781],
29	which	WDT	O	which	nsubj	30	SENT_101	[p9l7t2806r210b2869],
30	translated	VBN	O	translate	rcmod	27	SENT_101	[p9l228t2806r557b2869],
31	into	IN	O	into	_	0	SENT_101	[p9l575t2812r704b2869],
32	longer	JJR	O	longer	amod	34	SENT_101	[p9l723t2806r935b2890],
33	sustained	JJ	O	sustained	amod	34	SENT_101	[p9l954t2806r1266b2869],
34	target	NN	O	target	prep_into	30	SENT_101	[p9l1283t2818r1474b2890],
35	inhibition	NN	O	inhibition	dobj	30	SENT_101	[p9l1492t2798r1901b2869],
36	.37	CD	NUMBER	.37	num	35	SENT_101	[p9l1492t2798r1901b2869],
37	A	DT	O	a	det	38	SENT_101	[p9l1920t2810r1976b2868],
38	total	NN	O	total	nsubjpass	43	SENT_101	[p9l1993t2806r2143b2869],
39	of	IN	O	of	_	0	SENT_101	[p9l10t2909r84b2972],
40	54	CD	NUMBER	54	num	41	SENT_101	[p9l96t2916r174b2972],
41	patients	NNS	O	patient	prep_of	38	SENT_101	[p9l193t2915r462b2992],
42	were	VBD	O	be	auxpass	43	SENT_101	[p9l482t2932r643b2972],
43	enrolled	VBN	O	enrol	rcmod	35	SENT_101	[p9l664t2909r946b2972],
44	in	IN	O	in	_	0	SENT_101	[p9l966t2915r1032b2971],
45	a	DT	O	a	det	46	SENT_101	[p9l1054t2932r1088b2972],
46	phase	NN	O	phase	prep_in	43	SENT_101	[p9l1107t2909r1301b2992],
47	I	PRP	O	I	dep	46	SENT_101	[p9l1323t2914r1347b2971],
48	dose-escalation	JJ	O	dose-escalation	amod	49	SENT_101	[p9l1369t2909r1897b2972],
49	trial	NN	O	trial	dobj	43	SENT_101	[p9l1917t2909r2058b2972],
50	of	IN	O	of	_	0	SENT_101	[p9l2078t2909r2152b2972],
51	LGX818	NN	O	lgx818	prep_of	49	SENT_101	[p9l10t3016r305b3084],
52	,	,	O	,	_	0	SENT_101	[p9l10t3016r305b3084],
53	including	VBG	O	include	_	0	SENT_101	[p9l326t3012r645b3096],
54	26	CD	NUMBER	26	num	55	SENT_101	[p9l663t3018r739b3075],
55	patients	NNS	O	patient	prep_including	15	SENT_101	[p9l759t3018r1021b3095],
56	who	WP	O	who	nsubjpass	59	SENT_101	[p9l1039t3012r1183b3075],
57	were	VBD	O	be	auxpass	59	SENT_101	[p9l1202t3035r1359b3075],
58	previously	RB	DATE	previously	advmod	59	SENT_101	[p9l1378t3012r1727b3096],
59	treated	VBN	O	treat	rcmod	55	SENT_101	[p9l1742t3012r1975b3075],
60	with	IN	O	with	_	0	SENT_101	[p9l1991t3012r2141b3075],
61	BRAF	NN	O	braf	nn	62	SENT_101	[p9l10t3118r213b3177],
62	inhibitors	NNS	O	inhibitor	prep_with	59	SENT_101	[p9l235t3106r647b3177],
63	.38	CD	NUMBER	.38	number	64	SENT_101	[p9l235t3106r647b3177],
64	Sixteen	CD	TIME	sixteen	tmod	59	SENT_101	[p9l669t3118r914b3178],
65	of	IN	TIME	of	_	0	SENT_101	[p9l935t3114r1009b3177],
66	24	CD	TIME	24	num	67	SENT_101	[p9l1020t3121r1098b3176],
67	BRAF	NN	O	braf	prep_of	64	SENT_101	[p9l1119t3118r1322b3177],
68	inhibitor-naive	JJ	O	inhibitor-naive	amod	69	SENT_101	[p9l1344t3114r1854b3177],
69	patients	NNS	O	patient	nsubj	70	SENT_101	[p9l1873t3120r2141b3197],
70	achieved	VBD	O	achieve	rcmod	67	SENT_101	[p9l10t3217r316b3280],
71	partial	JJ	O	partial	amod	72	SENT_101	[p9l338t3217r568b3300],
72	responses	NNS	O	response	nsubj	73	SENT_101	[p9l591t3239r929b3300],
73	(	VBP	O	(	ccomp	70	SENT_101	[p9l957t3217r1181b3294],
74	67	CD	PERCENT	67	num	75	SENT_101	[p9l957t3217r1181b3294],
75	%	NN	PERCENT	%	dobj	73	SENT_101	[p9l957t3217r1181b3294],
76	)	CD	NUMBER	)	dep	64	SENT_101	[p9l957t3217r1181b3294],
77	,	,	O	,	_	0	SENT_101	[p9l957t3217r1181b3294],
78	and	CC	O	and	_	0	SENT_101	[p9l1207t3217r1336b3280],
79	responses	NNS	O	response	nsubjpass	81	SENT_101	[p9l1359t3239r1697b3300],
80	were	VBD	O	be	auxpass	81	SENT_101	[p9l1720t3240r1884b3280],
81	seen	VBN	O	see	conj_and	15	SENT_101	[p9l1908t3240r2061b3280],
82	at	IN	O	at	_	0	SENT_101	[p9l2085t3229r2146b3280],
83	all	DT	O	all	det	85	SENT_101	[p9l10t3320r90b3383],
84	dose	NN	O	dose	nn	85	SENT_101	[p9l114t3320r270b3383],
85	levels	NNS	O	level	prep_at	81	SENT_101	[p9l292t3320r499b3383],
86	.	.	O	.	_	0	SENT_101	[p9l292t3320r499b3383],

1	Responses	NNS	O	response	nsubj	4	SENT_102	[p9l526t3325r886b3403],
2	were	VBD	O	be	cop	4	SENT_102	[p9l909t3343r1072b3383],
3	uncommon	JJ	O	uncommon	amod	4	SENT_102	[p9l1095t3343r1502b3383],
4	(	NN	O	(	_	0	SENT_102	[p9l1530t3321r1750b3397],
5	8.3	CD	PERCENT	8.3	num	6	SENT_102	[p9l1530t3321r1750b3397],
6	%	NN	PERCENT	%	dep	4	SENT_102	[p9l1530t3321r1750b3397],
7	)	CD	NUMBER	)	dep	6	SENT_102	[p9l1530t3321r1750b3397],
8	in	IN	O	in	_	0	SENT_102	[p9l1778t3326r1845b3382],
9	patients	NNS	O	patient	prep_in	7	SENT_102	[p9l1867t3326r2142b3403],
10	who	WP	O	who	nsubjpass	13	SENT_102	[p9l8t3423r156b3486],
11	were	VBD	O	be	auxpass	13	SENT_102	[p9l179t3446r342b3486],
12	previously	RB	DATE	previously	advmod	13	SENT_102	[p9l364t3423r728b3507],
13	treated	VBN	O	treat	rcmod	4	SENT_102	[p9l747t3423r989b3486],
14	with	IN	O	with	_	0	SENT_102	[p9l1009t3423r1164b3486],
15	a	DT	O	a	det	17	SENT_102	[p9l1188t3446r1223b3486],
16	BRAF	NN	O	braf	nn	17	SENT_102	[p9l1246t3427r1453b3486],
17	inhibitor	NN	O	inhibitor	prep_with	13	SENT_102	[p9l1478t3423r1796b3486],
18	.	.	O	.	_	0	SENT_102	[p9l1478t3423r1796b3486],

1	The	DT	O	the	det	5	SENT_103	[p9l1823t3423r1949b3486],
2	most	RBS	O	most	advmod	3	SENT_103	[p9l1972t3435r2145b3486],
3	common	JJ	O	common	amod	5	SENT_103	[p9l10t3549r314b3589],
4	side	NN	O	side	nn	5	SENT_103	[p9l336t3526r467b3589],
5	effects	NNS	O	effect	nsubj	9	SENT_103	[p9l488t3526r698b3589],
6	were	VBD	O	be	cop	9	SENT_103	[p9l717t3549r877b3589],
7	cutaneous	JJ	O	cutaneous	amod	9	SENT_103	[p9l898t3538r1241b3589],
8	(	NN	O	(	nn	9	SENT_103	[p9l1266t3526r1452b3602],
9	rash	NN	O	rash	_	0	SENT_103	[p9l1266t3526r1452b3602],
10	,	,	O	,	_	0	SENT_103	[p9l1266t3526r1452b3602],
11	dry	JJ	O	dry	amod	12	SENT_103	[p9l1475t3526r1593b3610],
12	skin	NN	O	skin	conj_and	9	SENT_103	[p9l1611t3526r1768b3598],
13	,	,	O	,	_	0	SENT_103	[p9l1611t3526r1768b3598],
14	hand	NN	O	hand	advmod	18	SENT_103	[p9l1789t3526r2144b3589],
15	—	CD	NUMBER	—	num	18	SENT_103	[p9l1789t3526r2144b3589],
16	foot	NN	O	foot	nn	18	SENT_103	[p9l1789t3526r2144b3589],
17	skin	NN	O	skin	nn	18	SENT_103	[p9l10t3630r151b3693],
18	reaction	NN	O	reaction	conj_and	9	SENT_103	[p9l175t3636r474b3702],
19	,	,	O	,	_	0	SENT_103	[p9l175t3636r474b3702],
20	pruritus	NN	O	pruritus	conj_and	18	SENT_103	[p9l497t3636r795b3713],
21	,	,	O	,	_	0	SENT_103	[p9l497t3636r795b3713],
22	keratosis	NN	O	keratosis	nn	23	SENT_103	[p9l818t3630r1120b3693],
23	pilaris	NN	O	pilari	conj_and	18	SENT_103	[p9l1142t3630r1374b3713],
24	,	,	O	,	_	0	SENT_103	[p9l1142t3630r1374b3713],
25	and	CC	O	and	_	0	SENT_103	[p9l1399t3630r1526b3693],
26	alopecia	NN	O	alopecia	nn	27	SENT_103	[p9l1548t3630r1878b3713],
27	)	NN	O	)	conj_and	18	SENT_103	[p9l1548t3630r1878b3713],
28	,	,	O	,	_	0	SENT_103	[p9l1548t3630r1878b3713],
29	pain	NN	O	pain	appos	18	SENT_103	[p9l1902t3636r2053b3713],
30	in	IN	O	in	_	0	SENT_103	[p9l2076t3636r2143b3692],
31	extremity	NN	O	extremity	prep_in	29	SENT_103	[p9l10t3739r343b3817],
32	,	,	O	,	_	0	SENT_103	[p9l10t3739r343b3817],
33	arthralgia	NN	O	arthralgium	conj_and	9	SENT_103	[p9l366t3733r711b3817],
34	,	,	O	,	_	0	SENT_103	[p9l366t3733r711b3817],
35	and	CC	O	and	_	0	SENT_103	[p9l734t3733r858b3796],
36	fatigue	NN	O	fatigue	conj_and	9	SENT_103	[p9l877t3733r1121b3817],
37	.	.	O	.	_	0	SENT_103	[p9l877t3733r1121b3817],

1	Squamous	JJ	O	squamous	amod	3	SENT_104	[p9l1145t3737r1494b3816],
2	cell	NN	O	cell	nn	3	SENT_104	[p9l1515t3733r1627b3796],
3	carcinoma	NN	O	carcinoma	nsubjpass	5	SENT_104	[p9l1647t3739r2002b3796],
4	was	VBD	O	be	auxpass	5	SENT_104	[p9l2019t3756r2143b3796],
5	observed	VBN	O	observe	_	0	SENT_104	[p10l10t17r329b80],
6	in	IN	O	in	_	0	SENT_104	[p10l351t23r420b79],
7	two	CD	NUMBER	two	num	8	SENT_104	[p10l442t29r570b80],
8	patients	NNS	O	patient	prep_in	5	SENT_104	[p10l594t23r889b100],
9	.	.	O	.	_	0	SENT_104	[p10l594t23r889b100],

1	The	DT	O	the	det	5	SENT_105	[p10l916t17r1044b80],
2	ongoing	JJ	O	ongoing	amod	5	SENT_105	[p10l1068t23r1356b101],
3	dose	NN	O	dose	nn	5	SENT_105	[p10l1379t17r1537b80],
4	expansion	NN	O	expansion	nn	5	SENT_105	[p10l1562t23r1919b100],
5	phase	NN	O	phase	nsubj	7	SENT_105	[p10l1941t17r2142b100],
6	is	VBZ	O	be	aux	7	SENT_105	[p10l9t126r59b183],
7	studying	VBG	O	study	_	0	SENT_105	[p10l84t120r380b204],
8	the	DT	O	the	det	13	SENT_105	[p10l401t120r507b183],
9	300	CD	NUMBER	300	num	13	SENT_105	[p10l531t127r650b183],
10	mg	NN	O	mg	nn	13	SENT_105	[p10l666t143r775b204],
11	daily	JJ	SET	daily	amod	13	SENT_105	[p10l797t120r964b204],
12	dose	NN	O	dose	nn	13	SENT_105	[p10l984t120r1139b183],
13	level	NN	O	level	dobj	7	SENT_105	[p10l1161t120r1332b183],
14	.	.	O	.	_	0	SENT_105	[p10l1161t120r1332b183],

1	Furthermore	RB	O	furthermore	advmod	4	SENT_106	[p10l1359t120r1820b192],
2	,	,	O	,	_	0	SENT_106	[p10l1359t120r1820b192],
3	there	EX	O	there	expl	4	SENT_106	[p10l1844t120r2018b183],
4	are	VBP	O	be	_	0	SENT_106	[p10l2042t143r2143b183],
5	ongoing	JJ	O	ongoing	amod	7	SENT_106	[p10l10t229r298b307],
6	clinical	JJ	O	clinical	amod	7	SENT_106	[p10l321t223r573b286],
7	trials	NNS	O	trial	nsubj	4	SENT_106	[p10l596t223r772b286],
8	of	IN	O	of	_	0	SENT_106	[p10l798t223r873b286],
9	second	JJ	ORDINAL	second	amod	13	SENT_106	[p10l888t223r1544b307],
10	—	NN	O	—	nn	13	SENT_106	[p10l888t223r1544b307],
11	generation	NN	O	generation	nn	13	SENT_106	[p10l888t223r1544b307],
12	MEK	NN	O	mek	nn	13	SENT_106	[p10l1568t228r1755b285],
13	inhibitors	NNS	O	inhibitor	prep_of	7	SENT_106	[p10l1778t223r2140b295],
14	,	,	O	,	_	0	SENT_106	[p10l1778t223r2140b295],
15	including	VBG	O	include	_	0	SENT_106	[p10l9t326r336b410],
16	GDC	NNP	ORGANIZATION	GDC	prep_including	13	SENT_106	[p10l356t330r730b389],
17	—	CD	NUMBER	—	number	18	SENT_106	[p10l356t330r730b389],
18	0973	CD	DATE	0973	dep	16	SENT_106	[p10l356t330r730b389],
19	and	CC	O	and	_	0	SENT_106	[p10l755t326r881b389],
20	MEK162	NN	O	mek162	prep_including	13	SENT_106	[p10l901t331r1222b389],
21	.	.	O	.	_	0	SENT_106	[p10l901t331r1222b389],

1	Treatment	NN	O	treatment	nsubjpass	11	SENT_107	[p10l8t541r368b596],
2	of	IN	O	of	_	0	SENT_107	[p10l385t538r456b596],
3	patients	NNS	O	patient	prep_of	1	SENT_107	[p10l472t539r754b611],
4	with	IN	O	with	_	0	SENT_107	[p10l769t539r920b596],
5	brain	NN	O	brain	nn	8	SENT_107	[p10l942t539r1118b596],
6	metastasis	NN	O	metastasis	nn	8	SENT_107	[p10l1139t539r1507b596],
7	Brain	NN	O	brain	nn	8	SENT_107	[p10l10t641r199b699],
8	metastases	NNS	O	metastase	prep_with	3	SENT_107	[p10l222t648r594b699],
9	have	VBP	O	have	aux	11	SENT_107	[p10l617t636r775b699],
10	been	VBN	O	be	auxpass	11	SENT_107	[p10l797t636r963b699],
11	noted	VBN	O	note	_	0	SENT_107	[p10l987t636r1187b699],
12	in	IN	O	in	_	0	SENT_107	[p10l1209t642r1277b698],
13	10-40	CD	PERCENT	10-40	num	14	SENT_107	[p10l1307t641r1576b701],
14	%	NN	PERCENT	%	prep_in	11	SENT_107	[p10l1307t641r1576b701],
15	of	IN	O	of	_	0	SENT_107	[p10l1602t636r1677b699],
16	patients	NNS	O	patient	prep_of	14	SENT_107	[p10l1689t642r1964b719],
17	with	IN	O	with	_	0	SENT_107	[p10l1986t636r2142b699],
18	advanced	JJ	O	advanced	amod	19	SENT_107	[p10l10t739r343b802],
19	melanoma	NN	O	melanoma	prep_with	16	SENT_107	[p10l366t739r739b802],
20	and	CC	O	and	_	0	SENT_107	[p10l763t739r893b802],
21	are	VBP	O	be	auxpass	23	SENT_107	[p10l917t762r1020b802],
22	typically	RB	O	typically	advmod	23	SENT_107	[p10l1044t739r1347b823],
23	associated	VBN	O	associate	conj_and	11	SENT_107	[p10l1368t739r1727b802],
24	with	IN	O	with	_	0	SENT_107	[p10l1749t739r1906b802],
25	a	DT	O	a	det	28	SENT_107	[p10l1931t762r1966b802],
26	very	RB	O	very	advmod	27	SENT_107	[p10l1987t762r2144b823],
27	poor	JJ	O	poor	amod	28	SENT_107	[p10l8t863r169b924],
28	prognosis	NN	O	prognosis	prep_with	23	SENT_107	[p10l187t833r593b925],
29	.	.	O	.	_	0	SENT_107	[p10l187t833r593b925],

1	”	RB	O	”	dep	33	SENT_108	[p10l187t833r593b925],
2	Chemotherapy	NNP	O	Chemotherapy	nsubj	4	SENT_108	[p10l615t841r1118b925],
3	has	VBZ	O	have	aux	4	SENT_108	[p10l1134t841r1243b904],
4	limited	VBN	O	limit	ccomp	1	SENT_108	[p10l1262t841r1502b904],
5	eﬂicacy	NN	O	eﬂicacy	dobj	4	SENT_108	[p10l1521t841r1773b925],
6	in	IN	O	in	_	0	SENT_108	[p10l1789t847r1855b903],
7	controlling	VBG	O	control	amod	10	SENT_108	[p10l1875t841r2141b904, p10l8t944r140b1028],
8	melanoma	NN	O	melanoma	nn	10	SENT_108	[p10l160t944r524b1007],
9	brain	NN	O	brain	nn	10	SENT_108	[p10l544t944r725b1007],
10	metastases	NNS	O	metastase	prep_in	4	SENT_108	[p10l747t956r1132b1016],
11	,	,	O	,	_	0	SENT_108	[p10l747t956r1132b1016],
12	with	IN	O	with	mark	16	SENT_108	[p10l1155t944r1308b1007],
13	a	DT	O	a	det	15	SENT_108	[p10l1332t967r1366b1007],
14	tumor	NN	O	tumor	nn	15	SENT_108	[p10l1387t956r1603b1007],
15	response	NN	O	response	nsubj	16	SENT_108	[p10l1624t966r1925b1027],
16	noted	VBD	O	note	dep	10	SENT_108	[p10l1948t944r2145b1007],
17	in	IN	O	in	_	0	SENT_108	[p10l9t1052r76b1108],
18	<	JJR	PERCENT	<	prep_in	16	SENT_108	[p10l99t1064r138b1108],
19	10	CD	PERCENT	10	number	20	SENT_108	[p10l151t1052r287b1111],
20	%	NN	PERCENT	%	amod	18	SENT_108	[p10l151t1052r287b1111],
21	of	IN	O	of	_	0	SENT_108	[p10l311t1046r384b1109],
22	patients	NNS	O	patient	prep_of	16	SENT_108	[p10l395t1052r663b1129],
23	and	CC	O	and	_	0	SENT_108	[p10l686t1046r812b1109],
24	median	JJ	O	median	amod	25	SENT_108	[p10l832t1046r1089b1109],
25	survival	NN	O	survival	prep_of	16	SENT_108	[p10l1111t1046r1382b1109],
26	of	IN	O	of	_	0	SENT_108	[p10l1403t1046r1476b1109],
27	only	RB	O	only	advmod	29	SENT_108	[p10l1489t1046r1639b1130],
28	3-5	CD	NUMBER	3-5	num	29	SENT_108	[p10l1658t1053r1779b1109],
29	months	NNS	NUMBER	month	prep_of	25	SENT_108	[p10l1802t1038r2142b1109],
30	.4	CD	NUMBER	.4	number	31	SENT_108	[p10l1802t1038r2142b1109],
31	°	CD	NUMBER	°	num	32	SENT_108	[p10l1802t1038r2142b1109],
32	Dabrafenib	NN	O	dabrafenib	dep	16	SENT_108	[p10l10t1149r385b1212],
33	showed	VBD	O	show	_	0	SENT_108	[p10l407t1149r659b1212],
34	activity	NN	O	activity	dobj	33	SENT_108	[p10l679t1155r926b1233],
35	in	IN	O	in	_	0	SENT_108	[p10l942t1155r1008b1211],
36	patients	NNS	O	patient	prep_in	33	SENT_108	[p10l1026t1155r1290b1232],
37	with	IN	O	with	_	0	SENT_108	[p10l1308t1149r1458b1212],
38	asymptomatic	JJ	O	asymptomatic	amod	40	SENT_108	[p10l1478t1155r1949b1233],
39	brain	NN	O	brain	nn	40	SENT_108	[p10l1966t1149r2144b1212],
40	metastases	NNS	O	metastase	prep_with	33	SENT_108	[p10l9t1264r368b1315],
41	enrolled	VBN	O	enrol	partmod	40	SENT_108	[p10l389t1252r667b1315],
42	in	IN	O	in	_	0	SENT_108	[p10l686t1258r751b1314],
43	the	DT	O	the	det	45	SENT_108	[p10l770t1252r875b1315],
44	expansion	NN	O	expansion	nn	45	SENT_108	[p10l895t1258r1238b1335],
45	cohort	NN	O	cohort	prep_in	41	SENT_108	[p10l1259t1252r1480b1315],
46	of	IN	O	of	_	0	SENT_108	[p10l1500t1252r1573b1315],
47	the	DT	O	the	det	48	SENT_108	[p10l1582t1252r1687b1315],
48	phase	NN	O	phase	prep_of	45	SENT_108	[p10l1706t1252r1898b1335],
49	I	PRP	O	I	dep	50	SENT_108	[p10l1918t1257r1942b1314],
50	study	NN	O	study	nsubj	33	SENT_108	[p10l1964t1252r2147b1336],
51	of	IN	O	of	_	0	SENT_108	[p10l10t1355r84b1418],
52	dabrafenib	NN	O	dabrafenib	prep_of	50	SENT_108	[p10l98t1355r485b1427],
53	,	,	O	,	_	0	SENT_108	[p10l98t1355r485b1427],
54	which	WDT	O	which	nsubj	55	SENT_108	[p10l508t1355r720b1418],
55	led	VBD	O	lead	rcmod	50	SENT_108	[p10l742t1355r846b1418],
56	to	TO	O	to	_	0	SENT_108	[p10l867t1367r933b1418],
57	a	DT	O	a	det	61	SENT_108	[p10l959t1378r993b1418],
58	formal	JJ	O	formal	amod	61	SENT_108	[p10l1015t1355r1246b1418],
59	phase	NN	O	phase	nn	61	SENT_108	[p10l1267t1355r1464b1438],
60	II	CD	NUMBER	ii	num	61	SENT_108	[p10l1488t1360r1542b1417],
61	study	NN	O	study	prep_to	55	SENT_108	[p10l1567t1355r1763b1439],
62	.	.	O	.	_	0	SENT_108	[p10l1567t1355r1763b1439],

1	This	DT	O	this	det	2	SENT_109	[p10l1789t1355r1933b1418],
2	study	NN	O	study	nsubj	3	SENT_109	[p10l1958t1355r2146b1439],
3	enrolled	VBD	O	enrol	_	0	SENT_109	[p10l10t1458r286b1521],
4	172	CD	NUMBER	172	num	5	SENT_109	[p10l312t1465r422b1521],
5	patients	NNS	O	patient	dobj	3	SENT_109	[p10l442t1464r706b1541],
6	with	IN	O	with	_	0	SENT_109	[p10l724t1458r874b1521],
7	BRAFV600E	NN	O	brafv600e	nn	11	SENT_109	[p10l894t1462r1326b1521],
8	or	CC	O	or	_	0	SENT_109	[p10l1347t1481r1417b1521],
9	V600K	NN	O	v600k	conj_or	7	SENT_109	[p10l1435t1463r1673b1521],
10	mutant	JJ	O	mutant	amod	11	SENT_109	[p10l1691t1470r1934b1521],
11	melanoma	NN	O	melanoma	prep_with	3	SENT_109	[p10l1952t1458r2140b1521, p10l9t1583r200b1623],
12	with	IN	O	with	_	0	SENT_109	[p10l217t1560r366b1623],
13	documented	VBN	O	document	amod	15	SENT_109	[p10l386t1560r807b1623],
14	brain	NN	O	brain	nn	15	SENT_109	[p10l823t1560r999b1623],
15	metastasis	NN	O	metastasis	prep_with	3	SENT_109	[p10l1018t1566r1359b1623],
16	into	IN	O	into	_	0	SENT_109	[p10l1379t1566r1509b1623],
17	one	CD	TIME	one	prep_into	15	SENT_109	[p10l1530t1583r1649b1623],
18	of	IN	TIME	of	_	0	SENT_109	[p10l1670t1560r1742b1623],
19	two	CD	TIME	two	num	20	SENT_109	[p10l1751t1572r1873b1623],
20	cohorts	NNS	O	cohort	prep_of	15	SENT_109	[p10l1895t1560r2143b1623],
21	distinguished	VBN	O	distinguish	partmod	20	SENT_109	[p10l10t1663r492b1747],
22	by	IN	O	by	prep	21	SENT_109	[p10l515t1663r601b1747],
23	whether	IN	O	whether	complm	28	SENT_109	[p10l622t1663r915b1726],
24	or	CC	O	or	_	0	SENT_109	[p10l941t1686r1015b1726],
25	not	RB	O	not	conj_or	28	SENT_109	[p10l1040t1675r1158b1726],
26	they	PRP	O	they	nsubj	28	SENT_109	[p10l1182t1663r1338b1747],
27	had	VBD	O	have	aux	28	SENT_109	[p10l1360t1663r1491b1726],
28	received	VBN	O	receive	ccomp	21	SENT_109	[p10l1516t1663r1811b1726],
29	previous	JJ	O	previous	amod	31	SENT_109	[p10l1835t1669r2140b1746],
30	radiation	NN	O	radiation	nn	31	SENT_109	[p10l10t1765r321b1828],
31	therapy	NN	O	therapy	dobj	28	SENT_109	[p10l341t1765r602b1849],
32	to	TO	O	to	_	0	SENT_109	[p10l619t1777r684b1828],
33	the	DT	O	the	det	34	SENT_109	[p10l706t1765r812b1828],
34	brain	NN	O	brain	prep_to	28	SENT_109	[p10l831t1757r1089b1828],
35	.	.	O	.	_	0	SENT_109	[p10l831t1757r1089b1828],

1	“	NN	O	“	nn	2	SENT_110	[p10l831t1757r1089b1828],
2	Dabrafenib	NN	O	dabrafenib	nsubj	3	SENT_110	[p10l1114t1765r1498b1828],
3	showed	VBD	O	show	conj_and	3	SENT_110	[p10l1521t1765r1778b1828],
4	antitumor	JJ	O	antitumor	amod	5	SENT_110	[p10l1799t1771r2144b1828],
5	activity	NN	O	activity	dobj	3	SENT_110	[p10l10t1874r276b1952],
6	,	,	O	,	_	0	SENT_110	[p10l10t1874r276b1952],
7	with	IN	O	with	_	0	SENT_110	[p10l299t1868r455b1931],
8	an	DT	O	a	det	12	SENT_110	[p10l479t1891r560b1931],
9	overall	JJ	O	overall	amod	12	SENT_110	[p10l584t1868r818b1931],
10	intracranial	JJ	O	intracranial	amod	12	SENT_110	[p10l841t1868r1249b1931],
11	response	NN	O	response	nn	12	SENT_110	[p10l1272t1890r1577b1951],
12	rate	NN	O	rate	prep_with	3	SENT_110	[p10l1601t1880r1730b1931],
13	of	IN	O	of	_	0	SENT_110	[p10l1755t1868r1830b1931],
14	39	CD	PERCENT	39	num	15	SENT_110	[p10l1845t1874r1988b1932],
15	%	NN	PERCENT	%	prep_of	12	SENT_110	[p10l1845t1874r1988b1932],
16	and	CC	O	and	_	0	SENT_110	[p10l2015t1868r2143b1931],
17	31	CD	PERCENT	31	num	18	SENT_110	[p10l11t1977r152b2035],
18	%	NN	PERCENT	%	conj_and	12	SENT_110	[p10l11t1977r152b2035],
19	for	IN	O	for	_	0	SENT_110	[p10l176t1971r274b2034],
20	patients	NNS	O	patient	prep_for	18	SENT_110	[p10l294t1977r563b2054],
21	with	IN	O	with	_	0	SENT_110	[p10l585t1971r738b2034],
22	BMFV6OOE	NN	O	bmfv6ooe	nn	24	SENT_110	[p10l761t1975r1201b2034],
23	mutant	JJ	O	mutant	amod	24	SENT_110	[p10l1223t1983r1471b2034],
24	melanoma	NN	O	melanoma	prep_with	20	SENT_110	[p10l1492t1971r1855b2034],
25	without	IN	O	without	_	0	SENT_110	[p10l1874t1971r2143b2034],
26	and	CC	O	and	_	0	SENT_110	[p10l10t2074r137b2137],
27	with	IN	O	with	_	0	SENT_110	[p10l157t2074r311b2137],
28	previous	JJ	O	previous	amod	30	SENT_110	[p10l332t2080r627b2157],
29	brain	NN	O	brain	nn	30	SENT_110	[p10l649t2074r831b2137],
30	irradiation	NN	O	irradiation	prep_without	3	SENT_110	[p10l854t2074r1242b2146],
31	,	,	O	,	_	0	SENT_110	[p10l854t2074r1242b2146],
32	respectively	RB	O	respectively	advmod	3	SENT_110	[p10l1267t2074r1682b2158],
33	.	.	O	.	_	0	SENT_110	[p10l1267t2074r1682b2158],

1	Median	JJ	O	median	amod	3	SENT_111	[p10l1707t2074r1971b2137],
2	progression-free	JJ	O	progression-free	amod	3	SENT_111	[p10l1993t2096r2138b2157, p10l9t2177r463b2261],
3	survival	NN	O	survival	nsubj	6	SENT_111	[p10l488t2177r765b2240],
4	was	VBD	O	be	cop	6	SENT_111	[p10l786t2200r915b2240],
5	4	CD	DURATION	4	num	6	SENT_111	[p10l938t2184r977b2239],
6	months	NNS	NUMBER	month	_	0	SENT_111	[p10l1001t2177r1284b2249],
7	,	,	O	,	_	0	SENT_111	[p10l1001t2177r1284b2249],
8	and	CC	O	and	_	0	SENT_111	[p10l1311t2177r1439b2240],
9	median	JJ	O	median	amod	11	SENT_111	[p10l1461t2177r1725b2240],
10	overall	JJ	O	overall	amod	11	SENT_111	[p10l1749t2177r1984b2240],
11	survival	NN	O	survival	nsubj	15	SENT_111	[p10l2008t2200r2140b2240, p10l7t2280r169b2343],
12	was	VBD	O	be	cop	15	SENT_111	[p10l187t2303r313b2343],
13	~	CD	NUMBER	~	number	14	SENT_111	[p10l337t2287r420b2343],
14	8	CD	DURATION	8	num	15	SENT_111	[p10l337t2287r420b2343],
15	months	NNS	NUMBER	month	conj_and	6	SENT_111	[p10l443t2280r702b2343],
16	in	IN	O	in	_	0	SENT_111	[p10l723t2286r790b2342],
17	both	DT	O	both	det	18	SENT_111	[p10l808t2280r967b2343],
18	cohorts	NNS	O	cohort	prep_in	15	SENT_111	[p10l989t2280r1261b2343],
19	.	.	O	.	_	0	SENT_111	[p10l989t2280r1261b2343],

1	Objective	NN	O	objective	nn	2	SENT_112	[p10l1286t2280r1610b2364],
2	responses	NNS	O	response	nsubjpass	5	SENT_112	[p10l1632t2302r1962b2363],
3	were	VBD	O	be	auxpass	5	SENT_112	[p10l1982t2303r2143b2343],
4	also	RB	O	also	advmod	5	SENT_112	[p10l10t2383r144b2446],
5	seen	VBN	O	see	_	0	SENT_112	[p10l170t2406r322b2446],
6	in	IN	O	in	_	0	SENT_112	[p10l347t2389r414b2445],
7	5	CD	NUMBER	5	prep_in	5	SENT_112	[p10l440t2391r474b2446],
8	of	IN	O	of	_	0	SENT_112	[p10l500t2383r576b2446],
9	33	CD	NUMBER	33	num	10	SENT_112	[p10l591t2390r668b2446],
10	patients	NNS	O	patient	prep_of	7	SENT_112	[p10l693t2389r970b2466],
11	(	CD	PERCENT	(	number	12	SENT_112	[p10l998t2384r1199b2459],
12	15	CD	PERCENT	15	num	13	SENT_112	[p10l998t2384r1199b2459],
13	%	NN	PERCENT	%	dep	10	SENT_112	[p10l998t2384r1199b2459],
14	)	CD	NUMBER	)	dep	13	SENT_112	[p10l998t2384r1199b2459],
15	with	IN	O	with	_	0	SENT_112	[p10l1225t2383r1382b2446],
16	BRAFV600K	NN	O	brafv600k	nn	18	SENT_112	[p10l1406t2387r1867b2446],
17	mutant	JJ	O	mutant	amod	18	SENT_112	[p10l1890t2395r2143b2446],
18	melanoma	NN	O	melanoma	prep_with	5	SENT_112	[p10l9t2486r396b2549],
19	.	.	O	.	_	0	SENT_112	[p10l9t2486r396b2549],

1	In	IN	O	in	_	0	SENT_113	[p10l424t2491r496b2548],
2	the	DT	O	the	det	4	SENT_113	[p10l519t2486r628b2549],
3	safety	NN	O	safety	nn	4	SENT_113	[p10l653t2486r854b2570],
4	analysis	NN	O	analysis	prep_in	9	SENT_113	[p10l875t2486r1166b2570],
5	,	,	O	,	_	0	SENT_113	[p10l875t2486r1166b2570],
6	only	RB	O	only	advmod	8	SENT_113	[p10l1193t2486r1347b2570],
7	one	CD	NUMBER	one	num	8	SENT_113	[p10l1368t2509r1493b2549],
8	patient	NN	O	patient	nsubj	9	SENT_113	[p10l1515t2492r1761b2569],
9	developed	VBD	O	develop	_	0	SENT_113	[p10l1785t2486r2143b2569],
10	treatment-related	JJ	O	treatment-related	amod	12	SENT_113	[p10l8t2589r600b2652],
11	cerebral	JJ	O	cerebral	amod	12	SENT_113	[p10l620t2589r888b2652],
12	hemorrhage	NN	O	hemorrhage	dobj	9	SENT_113	[p10l906t2589r1333b2673],
13	.	.	O	.	_	0	SENT_113	[p10l906t2589r1333b2673],

1	Vemurafenib	NNP	O	Vemurafenib	nsubj	3	SENT_114	[p10l1356t2589r1794b2652],
2	also	RB	O	also	advmod	3	SENT_114	[p10l1816t2589r1945b2652],
3	demonstrated	VBD	O	demonstrate	_	0	SENT_114	[p10l1967t2589r2141b2652, p10l10t2692r340b2755],
4	intracranial	JJ	O	intracranial	amod	5	SENT_114	[p10l363t2692r773b2755],
5	activity	NN	O	activity	dobj	3	SENT_114	[p10l797t2698r1056b2776],
6	in	IN	O	in	_	0	SENT_114	[p10l1076t2698r1144b2754],
7	case	NN	O	case	nn	8	SENT_114	[p10l1168t2715r1311b2755],
8	reports	NNS	O	report	prep_in	3	SENT_114	[p10l1335t2704r1604b2775],
9	,	,	O	,	_	0	SENT_114	[p10l1335t2704r1604b2775],
10	and	CC	O	and	_	0	SENT_114	[p10l1630t2692r1759b2755],
11	there	EX	O	there	expl	12	SENT_114	[p10l1781t2692r1960b2755],
12	is	VBZ	O	be	conj_and	3	SENT_114	[p10l1984t2698r2035b2755],
13	an	DT	O	a	det	21	SENT_114	[p10l2060t2715r2142b2755],
14	ongoing	JJ	O	ongoing	amod	15	SENT_114	[p10l10t2801r290b2879],
15	single-arm	NN	O	single-arm	dep	21	SENT_114	[p10l312t2795r698b2879],
16	,	,	O	,	_	0	SENT_114	[p10l312t2795r698b2879],
17	phase	NN	O	phase	dep	15	SENT_114	[p10l721t2795r915b2878],
18	II	CD	NUMBER	ii	num	17	SENT_114	[p10l939t2800r1012b2867],
19	,	,	O	,	_	0	SENT_114	[p10l939t2800r1012b2867],
20	multicenter	JJ	O	multicenter	amod	21	SENT_114	[p10l1035t2795r1433b2858],
21	study	NN	O	study	nsubj	12	SENT_114	[p10l1455t2795r1642b2879],
22	evaluating	VBG	O	evaluate	partmod	21	SENT_114	[p10l1661t2795r2015b2879],
23	the	DT	O	the	det	24	SENT_114	[p10l2035t2795r2141b2858],
24	efﬁcacy	NN	O	efﬁcacy	dobj	22	SENT_114	[p10l10t2898r271b2982],
25	and	CC	O	and	_	0	SENT_114	[p10l292t2898r420b2961],
26	safety	NN	O	safety	dobj	22	SENT_114	[p10l443t2898r642b2982],
27	of	IN	O	of	_	0	SENT_114	[p10l663t2898r737b2961],
28	vemurafenib	NN	O	vemurafenib	prep_of	24	SENT_114	[p10l748t2898r1189b2961],
29	in	IN	O	in	_	0	SENT_114	[p10l1214t2904r1281b2960],
30	patients	NNS	O	patient	prep_in	22	SENT_114	[p10l1304t2904r1577b2981],
31	with	IN	O	with	_	0	SENT_114	[p10l1599t2898r1754b2961],
32	melanoma	NN	O	melanoma	nn	34	SENT_114	[p10l1777t2898r2145b2961],
33	brain	NN	O	brain	nn	34	SENT_114	[p10l7t3000r189b3063],
34	metastases	NNS	O	metastase	prep_with	30	SENT_114	[p10l212t2992r662b3063],
35	.	.	O	.	_	0	SENT_114	[p10l212t2992r662b3063],

1	“	NN	O	“	nsubj	2	SENT_115	[p10l212t2992r662b3063],
2	Taken	VBN	O	take	partmod	7	SENT_115	[p10l686t3000r894b3063],
3	together	RB	O	together	advmod	2	SENT_115	[p10l915t3000r1215b3084],
4	,	,	O	,	_	0	SENT_115	[p10l915t3000r1215b3084],
5	these	DT	O	these	det	6	SENT_115	[p10l1239t3000r1416b3063],
6	data	NNS	O	datum	nsubj	7	SENT_115	[p10l1440t3000r1584b3063],
7	suggest	VBP	O	suggest	_	0	SENT_115	[p10l1607t3012r1858b3084],
8	that	IN	O	that	complm	16	SENT_115	[p10l1878t3000r2013b3063],
9	the	DT	O	the	det	10	SENT_115	[p10l2034t3000r2141b3063],
10	presence	NN	O	presence	nsubj	16	SENT_115	[p10l8t3125r311b3186],
11	of	IN	O	of	_	0	SENT_115	[p10l335t3103r409b3166],
12	brain	NN	O	brain	nn	13	SENT_115	[p10l420t3103r604b3166],
13	metastases	NNS	O	metastase	prep_of	10	SENT_115	[p10l627t3115r996b3166],
14	should	MD	O	should	aux	16	SENT_115	[p10l1021t3103r1254b3166],
15	not	RB	O	not	neg	16	SENT_115	[p10l1276t3115r1391b3166],
16	discourage	VB	O	discourage	ccomp	7	SENT_115	[p10l1414t3103r1787b3187],
17	the	DT	O	the	det	18	SENT_115	[p10l1809t3103r1917b3166],
18	use	NN	O	use	dobj	16	SENT_115	[p10l1940t3126r2053b3166],
19	of	IN	O	of	_	0	SENT_115	[p10l2076t3103r2151b3166],
20	BRAF	NN	O	braf	nn	22	SENT_115	[p10l10t3210r214b3269],
21	inhibitor	NN	O	inhibitor	nn	22	SENT_115	[p10l237t3206r540b3269],
22	therapy	NN	O	therapy	prep_of	18	SENT_115	[p10l559t3206r822b3290],
23	in	IN	O	in	_	0	SENT_115	[p10l840t3212r906b3268],
24	patients	NNS	O	patient	prep_in	22	SENT_115	[p10l927t3212r1196b3289],
25	with	IN	O	with	_	0	SENT_115	[p10l1217t3206r1369b3269],
26	either	CC	O	either	preconj	27	SENT_115	[p10l1392t3206r1589b3269],
27	BRAFV600E	NN	O	brafv600e	prep_with	16	SENT_115	[p10l1610t3210r2049b3269],
28	or	CC	O	or	_	0	SENT_115	[p10l2072t3229r2144b3269],
29	V600K	NN	O	v600k	nn	30	SENT_115	[p10l8t3313r250b3371],
30	melanoma	NN	O	melanoma	prep_with	16	SENT_115	[p10l270t3308r647b3371],
31	.	.	O	.	_	0	SENT_115	[p10l270t3308r647b3371],

1	IMMUNOTHERAPY	NN	O	immunotherapy	_	0	SENT_116	[p10l13t3522r673b3578],
2	FOR	IN	O	for	_	0	SENT_116	[p10l693t3522r834b3578],
3	BRAF-MUTANT	JJ	O	braf-mutant	amod	4	SENT_116	[p10l855t3523r1384b3578],
4	MELANOMA	NN	O	melanoma	prep_for	1	SENT_116	[p10l1403t3522r1838b3578],

1	Advances	NNS	O	advance	nsubjpass	13	SENT_117	[p10l9t3618r354b3681],
2	in	IN	O	in	_	0	SENT_117	[p10l383t3624r452b3680],
3	targeted	VBN	O	target	amod	10	SENT_117	[p10l479t3618r774b3702],
4	therapy	NN	O	therapy	dep	3	SENT_117	[p10l801t3618r1077b3702],
5	for	IN	O	for	_	0	SENT_117	[p10l1102t3618r1204b3681],
6	patients	NNS	O	patient	prep_for	4	SENT_117	[p10l1230t3624r1515b3701],
7	with	IN	O	with	_	0	SENT_117	[p10l1542t3618r1702b3681],
8	BRAFV600	NN	O	brafv600	prep_with	6	SENT_117	[p10l1731t3622r2139b3681],
9	mutant	JJ	O	mutant	amod	10	SENT_117	[p10l9t3732r267b3783],
10	melanoma	NN	O	melanoma	prep_in	1	SENT_117	[p10l291t3720r667b3783],
11	should	MD	O	should	aux	13	SENT_117	[p10l693t3720r933b3783],
12	be	VB	O	be	auxpass	13	SENT_117	[p10l955t3720r1038b3783],
13	viewed	VBN	O	view	_	0	SENT_117	[p10l1061t3720r1313b3783],
14	in	IN	O	in	_	0	SENT_117	[p10l1338t3726r1406b3782],
15	the	DT	O	the	det	16	SENT_117	[p10l1431t3720r1541b3783],
16	context	NN	O	context	prep_in	13	SENT_117	[p10l1568t3732r1831b3783],
17	of	IN	O	of	_	0	SENT_117	[p10l1856t3720r1932b3783],
18	existing	VBG	O	exist	prep_of	16	SENT_117	[p10l1949t3726r2139b3783, p11l9t33r118b111],

1	or	CC	O	or	cc	18	SENT_118	[p11l139t50r211b90],
2	new	JJ	O	new	amod	4	SENT_118	[p11l232t50r375b90],
3	immunotherapy	NN	O	immunotherapy	nn	4	SENT_118	[p11l394t27r959b111],
4	options	NNS	O	option	nsubj	18	SENT_118	[p11l977t33r1234b110],
5	in	IN	O	in	_	0	SENT_118	[p11l1256t33r1323b89],
6	melanoma	NN	O	melanoma	prep_in	4	SENT_118	[p11l1344t27r1727b99],
7	,	,	O	,	_	0	SENT_118	[p11l1344t27r1727b99],
8	such	JJ	O	such	_	0	SENT_118	[p11l1751t27r1907b90],
9	as	IN	O	as	_	0	SENT_118	[p11l1930t50r1994b90],
10	HD	NN	O	hd	nn	11	SENT_118	[p11l2017t32r2141b89],
11	IL-2	NN	O	il-2	prep_such_as	17	SENT_118	[p11l10t135r175b202],
12	,	,	O	,	_	0	SENT_118	[p11l10t135r175b202],
13	ipilimumab	NN	O	ipilimumab	conj_and	11	SENT_118	[p11l202t130r626b213],
14	,	,	O	,	_	0	SENT_118	[p11l202t130r626b213],
15	and	CC	O	and	_	0	SENT_118	[p11l653t130r782b193],
16	antibodies	NNS	O	antibody	conj_and	11	SENT_118	[p11l806t130r1170b193],
17	against	IN	O	against	rcmod	6	SENT_118	[p11l1196t136r1442b214],
18	programmed	VBN	O	program	_	0	SENT_118	[p11l1464t130r1927b214],
19	death	NN	O	death	nsubj	21	SENT_118	[p11l1951t130r2144b193],
20	1	CD	NUMBER	1	number	21	SENT_118	[p11l16t240r41b295],
21	(	CD	NUMBER	(	xcomp	18	SENT_118	[p11l75t233r314b310],
22	PD-1	NN	O	pd-1	dep	21	SENT_118	[p11l75t233r314b310],
23	)	CD	NUMBER	)	num	22	SENT_118	[p11l75t233r314b310],
24	or	CC	O	or	_	0	SENT_118	[p11l344t256r417b296],
25	its	PRP$	O	its	poss	27	SENT_118	[p11l440t239r518b296],
26	ligand	NN	O	ligand	nn	27	SENT_118	[p11l542t233r762b317],
27	PD	NN	O	pd	conj_or	21	SENT_118	[p11l786t238r1036b296],
28	.	.	O	.	_	0	SENT_118	[p11l786t238r1036b296],

1	—	NN	O	—	_	0	SENT_119	[p11l786t238r1036b296],
2	.	.	O	.	_	0	SENT_119	[p11l786t238r1036b296],

1	L1	NN	O	l1	_	0	SENT_120	[p11l786t238r1036b296],
2	.	.	O	.	_	0	SENT_120	[p11l786t238r1036b296],

1	Although	IN	O	although	mark	6	SENT_121	[p11l1062t233r1399b317],
2	tumor	NN	O	tumor	nn	4	SENT_121	[p11l1422t245r1643b296],
3	mutation	NN	O	mutation	nn	4	SENT_121	[p11l1666t239r1990b296],
4	status	NN	O	status	nsubj	6	SENT_121	[p11l2015t245r2138b296, p11l8t348r110b399],
5	is	VBZ	O	be	cop	6	SENT_121	[p11l135t342r187b399],
6	critical	JJ	O	critical	advcl	21	SENT_121	[p11l212t336r455b399],
7	to	TO	O	to	_	0	SENT_121	[p11l477t348r545b399],
8	outcomes	NNS	O	outcome	prep_to	6	SENT_121	[p11l571t348r908b399],
9	of	IN	O	of	_	0	SENT_121	[p11l933t336r1009b399],
10	patients	NNS	O	patient	prep_of	8	SENT_121	[p11l1022t342r1300b419],
11	with	IN	O	with	_	0	SENT_121	[p11l1323t336r1480b399],
12	melanoma	NN	O	melanoma	prep_with	6	SENT_121	[p11l1504t336r1875b399],
13	treated	VBN	O	treat	partmod	12	SENT_121	[p11l1898t336r2143b399],
14	with	IN	O	with	_	0	SENT_121	[p11l8t439r161b502],
15	selective	JJ	O	selective	amod	17	SENT_121	[p11l184t439r473b502],
16	BRAF	NN	O	braf	nn	17	SENT_121	[p11l495t443r701b502],
17	inhibitors	NNS	O	inhibitor	prep_with	13	SENT_121	[p11l723t439r1078b511],
18	,	,	O	,	_	0	SENT_121	[p11l723t439r1078b511],
19	limited	JJ	O	limited	amod	20	SENT_121	[p11l1101t439r1348b502],
20	data	NNS	O	datum	nsubj	21	SENT_121	[p11l1369t439r1514b502],
21	exist	VBP	O	exist	_	0	SENT_121	[p11l1536t445r1692b502],
22	regarding	VBG	O	regard	xcomp	21	SENT_121	[p11l1713t439r2046b523],
23	its	PRP$	O	its	poss	25	SENT_121	[p11l2066t445r2142b502],
24	predictive	JJ	O	predictive	amod	25	SENT_121	[p11l8t542r363b625],
25	signiﬁcance	NN	O	signiﬁcance	dobj	22	SENT_121	[p11l389t542r806b626],
26	for	IN	O	for	_	0	SENT_121	[p11l831t542r932b605],
27	other	JJ	O	other	amod	28	SENT_121	[p11l956t542r1144b605],
28	therapies	NNS	O	therapy	prep_for	25	SENT_121	[p11l1167t542r1509b625],
29	,	,	O	,	_	0	SENT_121	[p11l1167t542r1509b625],
30	including	VBG	O	include	_	0	SENT_121	[p11l1536t542r1875b626],
31	immunotherapy	NN	O	immunotherapy	prep_including	25	SENT_121	[p11l1898t548r2139b605, p11l9t645r369b729],
32	.	.	O	.	_	0	SENT_121	[p11l1898t548r2139b605, p11l9t645r369b729],

1	In	IN	O	in	_	0	SENT_122	[p11l394t650r464b707],
2	a	DT	O	a	det	4	SENT_122	[p11l487t668r521b708],
3	retrospective	JJ	O	retrospective	amod	4	SENT_122	[p11l541t651r986b728],
4	analysis	NN	O	analysis	prep_in	29	SENT_122	[p11l1008t645r1274b729],
5	of	IN	O	of	_	0	SENT_122	[p11l1297t645r1370b708],
6	103	CD	NUMBER	103	num	7	SENT_122	[p11l1389t652r1500b708],
7	patients	NNS	O	patient	prep_of	4	SENT_122	[p11l1523t651r1793b728],
8	who	WP	O	who	nsubjpass	10	SENT_122	[p11l1813t645r1959b708],
9	were	VBD	O	be	auxpass	10	SENT_122	[p11l1980t668r2141b708],
10	treated	VBN	O	treat	rcmod	7	SENT_122	[p11l8t748r249b811],
11	with	IN	O	with	_	0	SENT_122	[p11l268t748r423b811],
12	HD	NN	O	hd	nn	13	SENT_122	[p11l445t753r569b810],
13	IL-2	NN	O	il-2	prep_with	10	SENT_122	[p11l595t753r737b810],
14	at	IN	O	at	_	0	SENT_122	[p11l762t760r822b811],
15	two	CD	NUMBER	two	num	16	SENT_122	[p11l842t760r968b811],
16	institutions	NNS	O	institution	prep_at	10	SENT_122	[p11l992t754r1403b820],
17	,	,	O	,	_	0	SENT_122	[p11l992t754r1403b820],
18	patients	NNS	O	patient	appos	16	SENT_122	[p11l1426t754r1698b831],
19	with	IN	O	with	_	0	SENT_122	[p11l1719t748r1873b811],
20	NRAS	NNS	O	nra	prep_with	18	SENT_122	[p11l1895t752r2140b811],
21	—	CD	NUMBER	—	num	23	SENT_122	[p11l1895t752r2140b811],
22	mutant	JJ	O	mutant	amod	23	SENT_122	[p11l9t863r267b914],
23	tumors	NNS	O	tumor	nsubj	24	SENT_122	[p11l291t863r546b914],
24	had	VBD	O	have	rcmod	20	SENT_122	[p11l572t851r704b914],
25	an	DT	O	a	det	28	SENT_122	[p11l730t874r813b914],
26	objective	JJ	O	objective	amod	28	SENT_122	[p11l840t851r1159b935],
27	response	NN	O	response	nn	28	SENT_122	[p11l1186t873r1499b934],
28	rate	NN	O	rate	dobj	24	SENT_122	[p11l1526t863r1658b914],
29	(	VBD	O	(	_	0	SENT_122	[p11l1688t851r2041b934],
30	complete	JJ	O	complete	amod	34	SENT_122	[p11l1688t851r2041b934],
31	or	CC	O	or	_	0	SENT_122	[p11l2068t874r2142b914],
32	partial	JJ	O	partial	conj_or	30	SENT_122	[p11l8t954r243b1037],
33	response	NN	O	response	nn	34	SENT_122	[p11l268t955r608b1037],
34	)	NN	O	)	nsubj	29	SENT_122	[p11l268t955r608b1037],
35	of	IN	O	of	_	0	SENT_122	[p11l638t954r714b1017],
36	47	CD	PERCENT	47	num	37	SENT_122	[p11l729t960r877b1019],
37	%	NN	PERCENT	%	prep_of	34	SENT_122	[p11l729t960r877b1019],
38	as	IN	O	as	_	0	SENT_122	[p11l906t977r972b1017],
39	compared	VBN	O	compare	prepc_as	37	SENT_122	[p11l999t954r1355b1037],
40	with	IN	O	with	pcomp	39	SENT_122	[p11l1378t954r1537b1017],
41	23	CD	PERCENT	23	num	42	SENT_122	[p11l1562t959r1709b1019],
42	%	NN	PERCENT	%	pobj	40	SENT_122	[p11l1562t959r1709b1019],
43	for	IN	O	for	_	0	SENT_122	[p11l1737t954r1838b1017],
44	patients	NNS	O	patient	prep_for	42	SENT_122	[p11l1861t960r2143b1037],

1	CLINICAL	JJ	O	clinical	amod	2	SENT_123	[p11l20t1102r139b1123],
2	PHARMACOLOGY	NNP	O	PHARMACOLOGY	dep	12	SENT_123	[p11l148t1102r373b1123],
3	&	CC	O	&	_	0	SENT_123	[p11l380t1102r600b1123],
4	THERAPEUT	NNP	O	THERAPEUT	nn	6	SENT_123	[p11l380t1102r600b1123],
5	|	CD	NUMBER	|	num	6	SENT_123	[p11l380t1102r600b1123],
6	CS	NNP	O	CS	conj_and	2	SENT_123	[p11l380t1102r600b1123],
7	|	NNP	O	|	nn	8	SENT_123	[p11l610t1100r612b1130],
8	VOLUME	NNP	O	VOLUME	dep	2	SENT_123	[p11l620t1102r728b1123],
9	95	CD	NUMBER	95	num	10	SENT_123	[p11l736t1102r763b1123],
10	NUMBER	NN	O	number	dep	12	SENT_123	[p11l773t1102r881b1123],
11	1	CD	NUMBER	1	num	12	SENT_123	[p11l891t1103r898b1123],
12	|	CD	NUMBER	|	dep	15	SENT_123	[p11l912t1100r914b1130],
13	JANUARY	NNP	DATE	JANUARY	dep	12	SENT_123	[p11l923t1102r1041b1123],
14	2014	CD	DATE	2014	num	15	SENT_123	[p11l1049t1102r1107b1123],
15	27	CD	DATE	27	_	0	SENT_123	[p11l2109t1102r2139b1123],

1	with	IN	O	with	_	0	SENT_124	[p11l7t1478r161b1541],
2	BRAF	NN	O	braf	nn	3	SENT_124	[p11l184t1482r675b1541],
3	—	NN	O	—	prep_with	21	SENT_124	[p11l184t1482r675b1541],
4	mutant	JJ	O	mutant	amod	5	SENT_124	[p11l184t1482r675b1541],
5	melanoma	NN	O	melanoma	dep	3	SENT_124	[p11l696t1478r1061b1541],
6	and	CC	O	and	_	0	SENT_124	[p11l1085t1478r1211b1541],
7	only	RB	O	only	quantmod	8	SENT_124	[p11l1234t1478r1386b1562],
8	12	CD	PERCENT	12	num	9	SENT_124	[p11l1413t1483r1549b1543],
9	%	NN	PERCENT	%	conj_and	3	SENT_124	[p11l1413t1483r1549b1543],
10	for	IN	O	for	_	0	SENT_124	[p11l1575t1478r1673b1541],
11	patients	NNS	O	patient	prep_for	9	SENT_124	[p11l1694t1484r1966b1561],
12	with	IN	O	with	_	0	SENT_124	[p11l1988t1478r2142b1541],
13	tumors	NNS	O	tumor	prep_with	11	SENT_124	[p11l8t1592r249b1643],
14	that	WDT	O	that	nsubj	17	SENT_124	[p11l269t1580r402b1643],
15	were	VBD	O	be	cop	17	SENT_124	[p11l419t1603r578b1643],
16	wild	JJ	O	wild	amod	17	SENT_124	[p11l597t1580r744b1643],
17	type	NN	O	type	rcmod	13	SENT_124	[p11l763t1592r907b1664],
18	for	IN	O	for	_	0	SENT_124	[p11l928t1580r1024b1643],
19	both	DT	O	both	det	20	SENT_124	[p11l1042t1580r1199b1643],
20	mutations	NNS	O	mutation	prep_for	17	SENT_124	[p11l1219t1572r1668b1656],
21	)	VBP	O	)	_	0	SENT_124	[p11l1219t1572r1668b1656],
22	.43	CD	NUMBER	.43	dobj	21	SENT_124	[p11l1219t1572r1668b1656],
23	The	DT	O	the	det	24	SENT_124	[p11l1690t1580r1813b1643],
24	Cytokine	NN	O	cytokine	nsubj	21	SENT_124	[p11l1835t1580r2142b1664],
25	Working	NNP	O	Working	nn	26	SENT_124	[p11l7t1683r309b1767],
26	Group	NNP	O	Group	nsubj	28	SENT_124	[p11l330t1687r548b1766],
27	is	VBZ	O	be	aux	28	SENT_124	[p11l570t1689r620b1746],
28	attempting	VBG	O	attempt	rcmod	24	SENT_124	[p11l642t1689r1014b1767],
29	to	TO	O	to	aux	30	SENT_124	[p11l1032t1695r1098b1746],
30	validate	VB	O	validate	xcomp	28	SENT_124	[p11l1117t1683r1384b1746],
31	this	DT	O	this	det	33	SENT_124	[p11l1404t1683r1528b1746],
32	preliminary	JJ	O	preliminary	amod	33	SENT_124	[p11l1548t1683r1957b1767],
33	ﬁnding	NN	O	ﬁnding	dobj	30	SENT_124	[p11l1975t1683r2137b1746, p11l9t1792r120b1870],
34	in	IN	O	in	_	0	SENT_124	[p11l145t1792r213b1848],
35	a	DT	O	a	det	37	SENT_124	[p11l239t1809r274b1849],
36	prospective	JJ	O	prospective	amod	37	SENT_124	[p11l297t1792r708b1869],
37	phase	NN	O	phase	prep_in	30	SENT_124	[p11l733t1786r935b1869],
38	II	CD	NUMBER	ii	num	41	SENT_124	[p11l961t1791r1016b1848],
39	trial	NN	O	trial	nn	41	SENT_124	[p11l1042t1786r1189b1849],
40	(	CD	NUMBER	(	num	41	SENT_124	[p11l1218t1786r1745b1862],
41	ClinicalTrials	NNS	O	clinicaltrial	dep	37	SENT_124	[p11l1218t1786r1745b1862],
42	.	.	O	.	_	0	SENT_124	[p11l1218t1786r1745b1862],

1	gov	NN	O	gov	nn	2	SENT_125	[p11l1754t1809r1880b1870],
2	identiﬁer	NN	O	identiﬁer	_	0	SENT_125	[p11l1902t1786r2137b1849, p11l8t1889r145b1952],
3	:	:	O	:	_	0	SENT_125	[p11l1902t1786r2137b1849, p11l8t1889r145b1952],
4	NCT01288963	NN	O	nct01288963	nn	5	SENT_125	[p11l174t1889r750b1966],
5	)	NN	O	)	dep	2	SENT_125	[p11l174t1889r750b1966],
6	.	.	O	.	_	0	SENT_125	[p11l174t1889r750b1966],

1	Ipilimumab	NNP	O	Ipilimumab	dep	107	SENT_126	[p11l780t1889r1200b1972],
2	is	VBZ	O	be	dep	107	SENT_126	[p11l1228t1895r1280b1952],
3	a	DT	O	a	dep	107	SENT_126	[p11l1309t1912r1344b1952],
4	monoclonal	JJ	O	monoclonal	dep	107	SENT_126	[p11l1369t1889r1799b1952],
5	antibody	NN	O	antibody	dep	107	SENT_126	[p11l1826t1889r2147b1973],
6	that	WDT	O	that	dep	107	SENT_126	[p11l8t1992r142b2055],
7	blocks	VBZ	O	block	dep	107	SENT_126	[p11l162t1992r382b2055],
8	the	DT	O	the	dep	107	SENT_126	[p11l405t1992r512b2055],
9	immune	JJ	O	immune	dep	107	SENT_126	[p11l535t1998r826b2055],
10	checkpoint	NN	O	checkpoint	dep	107	SENT_126	[p11l850t1992r1248b2075],
11	,	,	O	,	_	0	SENT_126	[p11l850t1992r1248b2075],
12	cytotoxic	JJ	O	cytotoxic	dep	107	SENT_126	[p11l1274t1998r1588b2076],
13	Tlymphocyteassociated	JJ	MISC	tlymphocyteassociated	dep	107	SENT_126	[p11l1611t1992r2139b2076, p11l9t2095r374b2158],
14	antigen	NN	O	antigen	dep	107	SENT_126	[p11l400t2101r663b2179],
15	4	CD	NUMBER	4	dep	107	SENT_126	[p11l688t2102r728b2157],
16	(	CD	NUMBER	(	dep	107	SENT_126	[p11l757t2096r1130b2171],
17	CTLA	NN	O	ctlum	dep	107	SENT_126	[p11l757t2096r1130b2171],
18	—	CD	NUMBER	—	dep	107	SENT_126	[p11l757t2096r1130b2171],
19	4	CD	NUMBER	4	dep	107	SENT_126	[p11l757t2096r1130b2171],
20	)	NN	O	)	dep	107	SENT_126	[p11l757t2096r1130b2171],
21	,	,	O	,	_	0	SENT_126	[p11l757t2096r1130b2171],
22	and	CC	O	and	dep	107	SENT_126	[p11l1158t2095r1289b2158],
23	that	IN	O	that	dep	107	SENT_126	[p11l1313t2095r1453b2158],
24	showed	VBD	O	show	dep	107	SENT_126	[p11l1478t2095r1747b2158],
25	signiﬁcant	JJ	O	signiﬁcant	dep	107	SENT_126	[p11l1772t2095r2144b2179],
26	improvement	NN	O	improvement	dep	107	SENT_126	[p11l9t2204r495b2281],
27	in	IN	O	in	dep	107	SENT_126	[p11l522t2204r591b2260],
28	overall	JJ	O	overall	dep	107	SENT_126	[p11l619t2198r862b2261],
29	survival	NN	O	survival	dep	107	SENT_126	[p11l890t2198r1176b2261],
30	in	IN	O	in	dep	107	SENT_126	[p11l1203t2204r1272b2260],
31	both	CC	O	both	dep	107	SENT_126	[p11l1298t2198r1465b2261],
32	previously	RB	DATE	previously	dep	107	SENT_126	[p11l1491t2198r1869b2282],
33	treated	VBN	O	treat	dep	107	SENT_126	[p11l1892t2198r2144b2261],
34	and	CC	O	and	dep	107	SENT_126	[p11l9t2301r138b2364],
35	treatment-naive	JJ	O	treatment-naive	dep	107	SENT_126	[p11l160t2307r721b2364],
36	patients	NNS	O	patient	dep	107	SENT_126	[p11l744t2307r1020b2384],
37	with	IN	O	with	dep	107	SENT_126	[p11l1043t2301r1199b2364],
38	unresectable	JJ	O	unresectable	dep	107	SENT_126	[p11l1223t2301r1663b2364],
39	or	CC	O	or	dep	107	SENT_126	[p11l1688t2324r1760b2364],
40	metastatic	JJ	O	metastatic	dep	107	SENT_126	[p11l1783t2307r2142b2364],
41	melanoma	NN	O	melanoma	dep	107	SENT_126	[p11l8t2395r521b2466],
42	.44	CD	NUMBER	.44	dep	107	SENT_126	[p11l8t2395r521b2466],
43	’45	CD	NUMBER	’45	dep	107	SENT_126	[p11l8t2395r521b2466],
44	The	DT	O	the	dep	107	SENT_126	[p11l543t2403r666b2466],
45	rates	NNS	O	rate	dep	107	SENT_126	[p11l687t2415r844b2466],
46	of	IN	O	of	dep	107	SENT_126	[p11l865t2403r938b2466],
47	objective	JJ	O	objective	dep	107	SENT_126	[p11l950t2403r1251b2487],
48	responses	NNS	O	response	dep	107	SENT_126	[p11l1272t2425r1600b2486],
49	in	IN	O	in	dep	107	SENT_126	[p11l1621t2409r1687b2465],
50	patients	NNS	O	patient	dep	107	SENT_126	[p11l1706t2409r1972b2486],
51	with	IN	O	with	dep	107	SENT_126	[p11l1992t2403r2143b2466],
52	BRAFV600E	NN	O	brafv600e	dep	107	SENT_126	[p11l9t2510r444b2569],
53	mutation	NN	O	mutation	dep	107	SENT_126	[p11l464t2512r1086b2589],
54	—	CD	NUMBER	—	dep	107	SENT_126	[p11l464t2512r1086b2589],
55	positive	JJ	O	positive	dep	107	SENT_126	[p11l464t2512r1086b2589],
56	melanoma	NN	O	melanoma	dep	107	SENT_126	[p11l1107t2506r1466b2569],
57	(	NN	O	(	dep	107	SENT_126	[p11l1488t2506r1683b2583],
58	10	CD	PERCENT	10	dep	107	SENT_126	[p11l1488t2506r1683b2583],
59	%	NN	PERCENT	%	dep	107	SENT_126	[p11l1488t2506r1683b2583],
60	)	CD	NUMBER	)	dep	107	SENT_126	[p11l1488t2506r1683b2583],
61	were	VBD	O	be	dep	107	SENT_126	[p11l1706t2529r1865b2569],
62	comparable	JJ	O	comparable	dep	107	SENT_126	[p11l1886t2528r2139b2589, p11l9t2609r177b2672],
63	to	TO	O	to	dep	107	SENT_126	[p11l200t2621r266b2672],
64	those	DT	O	those	dep	107	SENT_126	[p11l290t2609r475b2672],
65	in	IN	O	in	dep	107	SENT_126	[p11l499t2615r566b2671],
66	patients	NNS	O	patient	dep	107	SENT_126	[p11l588t2615r861b2692],
67	with	IN	O	with	dep	107	SENT_126	[p11l883t2609r1037b2672],
68	the	DT	O	the	dep	107	SENT_126	[p11l1059t2609r1167b2672],
69	BRAF	NN	O	braf	dep	107	SENT_126	[p11l1191t2613r1397b2672],
70	wild-type	JJ	O	wild-type	dep	107	SENT_126	[p11l1420t2609r1752b2693],
71	melanoma	NN	O	melanoma	dep	107	SENT_126	[p11l1775t2609r2141b2672],
72	(	CD	PERCENT	(	dep	107	SENT_126	[p11l12t2713r206b2789],
73	13	CD	PERCENT	13	dep	107	SENT_126	[p11l12t2713r206b2789],
74	%	NN	PERCENT	%	dep	107	SENT_126	[p11l12t2713r206b2789],
75	)	CD	NUMBER	)	dep	107	SENT_126	[p11l12t2713r206b2789],
76	in	IN	O	in	dep	107	SENT_126	[p11l231t2718r296b2774],
77	a	DT	O	a	dep	107	SENT_126	[p11l318t2735r352b2775],
78	retrospective	JJ	O	retrospective	dep	107	SENT_126	[p11l371t2718r809b2795],
79	data	NN	O	datum	dep	107	SENT_126	[p11l830t2712r972b2775],
80	analysis	NN	O	analysis	dep	107	SENT_126	[p11l993t2712r1254b2796],
81	from	IN	O	from	dep	107	SENT_126	[p11l1276t2712r1441b2775],
82	a	DT	O	a	dep	107	SENT_126	[p11l1462t2735r1496b2775],
83	collection	NN	O	collection	dep	107	SENT_126	[p11l1516t2712r1847b2775],
84	of	IN	O	of	dep	107	SENT_126	[p11l1868t2712r1941b2775],
85	phase	NN	O	phase	dep	107	SENT_126	[p11l1951t2712r2143b2795],
86	II	CD	NUMBER	ii	dep	107	SENT_126	[p11l9t2819r63b2876],
87	trials	NNS	O	trial	dep	107	SENT_126	[p11l87t2814r261b2877],
88	of	IN	O	of	dep	107	SENT_126	[p11l286t2814r360b2877],
89	ipilimumab	JJ	O	ipilimumab	dep	107	SENT_126	[p11l374t2806r858b2897],
90	.46	CD	NUMBER	.46	dep	107	SENT_126	[p11l374t2806r858b2897],
91	Another	DT	O	another	dep	107	SENT_126	[p11l881t2814r1175b2877],
92	immune	JJ	O	immune	dep	107	SENT_126	[p11l1197t2820r1489b2877],
93	checkpoint	NN	O	checkpoint	dep	107	SENT_126	[p11l1513t2814r1915b2897],
94	,	,	O	,	_	0	SENT_126	[p11l1513t2814r1915b2897],
95	PD-1	NN	O	pd-1	dep	107	SENT_126	[p11l1940t2819r2141b2886],
96	,	,	O	,	_	0	SENT_126	[p11l1940t2819r2141b2886],
97	acts	VBZ	O	act	dep	107	SENT_126	[p11l9t2929r144b2980],
98	as	IN	O	as	dep	107	SENT_126	[p11l173t2940r240b2980],
99	an	DT	O	a	dep	107	SENT_126	[p11l269t2940r352b2980],
100	inhibitory	JJ	O	inhibitory	dep	107	SENT_126	[p11l379t2917r747b3001],
101	receptor	NN	O	receptor	dep	107	SENT_126	[p11l771t2929r1071b3000],
102	of	IN	O	of	dep	107	SENT_126	[p11l1098t2917r1175b2980],
103	T	NN	O	t	dep	107	SENT_126	[p11l1192t2920r1243b2979],
104	cells	NNS	O	cell	dep	107	SENT_126	[p11l1271t2917r1423b2980],
105	similar	JJ	O	similar	dep	107	SENT_126	[p11l1452t2917r1703b2980],
106	to	TO	O	to	dep	107	SENT_126	[p11l1728t2929r1797b2980],
107	CTLA-4	NN	O	ctla-4	_	0	SENT_126	[p11l1827t2920r2139b2980],
108	.	.	O	.	_	0	SENT_126	[p11l1827t2920r2139b2980],

1	Early	RB	O	early	advmod	3	SENT_127	[p11l8t3020r194b3104],
2	clinical	JJ	O	clinical	amod	3	SENT_127	[p11l215t3020r468b3083],
3	trials	NNS	O	trial	_	0	SENT_127	[p11l490t3020r667b3083],
4	investigating	VBG	O	investigate	partmod	3	SENT_127	[p11l692t3026r1143b3104],
5	anti-PD	JJ	O	anti-pd	amod	6	SENT_127	[p11l1167t3025r1513b3083],
6	—	NN	O	—	dobj	4	SENT_127	[p11l1167t3025r1513b3083],
7	1	CD	NUMBER	1	num	8	SENT_127	[p11l1167t3025r1513b3083],
8	antibody	NN	O	antibody	tmod	4	SENT_127	[p11l1545t3020r1859b3104],
9	or	CC	O	or	_	0	SENT_127	[p11l1880t3043r1954b3083],
10	antiPD	NN	O	antipd	tmod	4	SENT_127	[p11l1978t3026r2138b3083, p11l9t3127r237b3184],
11	.	.	O	.	_	0	SENT_127	[p11l1978t3026r2138b3083, p11l9t3127r237b3184],

1	—	NN	O	—	_	0	SENT_128	[p11l1978t3026r2138b3083, p11l9t3127r237b3184],
2	.	.	O	.	_	0	SENT_128	[p11l1978t3026r2138b3083, p11l9t3127r237b3184],

1	L1	NN	O	l1	nsubj	3	SENT_129	[p11l1978t3026r2138b3083, p11l9t3127r237b3184],
2	have	VBP	O	have	aux	3	SENT_129	[p11l268t3122r429b3185],
3	shown	VBN	O	show	_	0	SENT_129	[p11l456t3122r685b3185],
4	response	NN	O	response	nn	5	SENT_129	[p11l711t3144r1023b3205],
5	rates	NNS	O	rate	nsubj	10	SENT_129	[p11l1049t3134r1214b3185],
6	of	IN	O	of	_	0	SENT_129	[p11l1240t3122r1316b3185],
7	25	CD	PERCENT	25	num	8	SENT_129	[p11l1332t3114r1801b3187],
8	—	CD	PERCENT	—	prep_of	5	SENT_129	[p11l1332t3114r1801b3187],
9	40	CD	PERCENT	40	num	10	SENT_129	[p11l1332t3114r1801b3187],
10	%	NN	PERCENT	%	xcomp	3	SENT_129	[p11l1332t3114r1801b3187],
11	.47	CD	NUMBER	.47	number	12	SENT_129	[p11l1332t3114r1801b3187],
12	‘	CD	NUMBER	‘	num	10	SENT_129	[p11l1332t3114r1801b3187],
13	49	CD	NUMBER	49	dep	21	SENT_129	[p11l1332t3114r1801b3187],
14	Whether	IN	O	whether	dep	21	SENT_129	[p11l1826t3122r2143b3185],
15	these	DT	O	these	det	19	SENT_129	[p11l8t3225r187b3288],
16	new	JJ	O	new	amod	19	SENT_129	[p11l212t3248r357b3288],
17	immune	JJ	O	immune	amod	19	SENT_129	[p11l379t3231r674b3288],
18	checkpoint	NN	O	checkpoint	nn	19	SENT_129	[p11l698t3225r1086b3308],
19	blockers	NNS	O	blocker	nsubj	21	SENT_129	[p11l1107t3225r1400b3288],
20	will	MD	O	will	aux	21	SENT_129	[p11l1423t3225r1552b3288],
21	have	VB	O	have	csubj	33	SENT_129	[p11l1575t3225r1734b3288],
22	differential	JJ	O	differential	amod	24	SENT_129	[p11l1759t3225r2143b3288],
23	antitumor	NN	O	antitumor	nn	24	SENT_129	[p11l9t3333r367b3390],
24	activities	NNS	O	activity	dobj	21	SENT_129	[p11l391t3333r704b3390],
25	based	VBN	O	base	_	0	SENT_129	[p11l727t3327r930b3390],
26	on	IN	O	on	prepc_based_on	21	SENT_129	[p11l954t3350r1042b3390],
27	BRAF	NN	O	braf	nn	29	SENT_129	[p11l1067t3331r1278b3389],
28	mutational	JJ	O	mutational	amod	29	SENT_129	[p11l1304t3327r1692b3390],
29	status	NN	O	status	pobj	21	SENT_129	[p11l1717t3339r1916b3390],
30	of	IN	O	of	_	0	SENT_129	[p11l1942t3327r2018b3390],
31	the	DT	O	the	det	32	SENT_129	[p11l2031t3327r2141b3390],
32	tumor	NN	O	tumor	prep_of	29	SENT_129	[p11l8t3441r224b3492],
33	remains	VBZ	O	remain	rcmod	10	SENT_129	[p11l246t3435r520b3492],
34	to	TO	O	to	aux	36	SENT_129	[p11l543t3441r608b3492],
35	be	VB	O	be	auxpass	36	SENT_129	[p11l630t3429r710b3492],
36	determined	VBN	O	determine	xcomp	33	SENT_129	[p11l733t3429r1150b3492],
37	.	.	O	.	_	0	SENT_129	[p11l733t3429r1150b3492],

1	Given	VBN	O	give	prep	58	SENT_130	[p12l83t31r298b90],
2	the	DT	O	the	det	15	SENT_130	[p12l329t27r442b90],
3	multiple	JJ	O	multiple	amod	5	SENT_130	[p12l473t27r779b110],
4	treatment	NN	O	treatment	nn	5	SENT_130	[p12l810t39r1170b90],
5	options	NNS	O	option	npadvmod	7	SENT_130	[p12l1201t33r1473b110],
6	now	RB	DATE	now	advmod	5	SENT_130	[p12l1505t50r1661b90],
7	available	JJ	O	available	amod	15	SENT_130	[p12l1690t27r2007b90],
8	for	IN	O	for	_	0	SENT_130	[p12l2039t27r2143b90],
9	patients	NNS	O	patient	prep_for	7	SENT_130	[p12l7t136r296b213],
10	with	IN	O	with	_	0	SENT_130	[p12l327t130r489b193],
11	advanced	JJ	O	advanced	amod	13	SENT_130	[p12l521t130r865b193],
12	BRAF	NN	O	braf	nn	13	SENT_130	[p12l895t134r1412b193],
13	—	NN	O	—	prep_with	9	SENT_130	[p12l895t134r1412b193],
14	mutant	JJ	O	mutant	amod	15	SENT_130	[p12l895t134r1412b193],
15	melanoma	NN	O	melanoma	dep	1	SENT_130	[p12l1442t130r1845b202],
16	,	,	O	,	_	0	SENT_130	[p12l1442t130r1845b202],
17	including	VBG	O	include	_	0	SENT_130	[p12l1879t130r2138b193, p12l9t239r122b317],
18	BRAF	NN	O	braf	nn	19	SENT_130	[p12l151t233r699b317],
19	—	NN	O	—	prep_including	15	SENT_130	[p12l151t233r699b317],
20	targeted	VBN	O	target	partmod	19	SENT_130	[p12l151t233r699b317],
21	therapy	NN	O	therapy	nn	23	SENT_130	[p12l726t233r1004b317],
22	(	NN	O	(	nn	23	SENT_130	[p12l1034t233r1538b310],
23	vemurafenib	NN	O	vemurafenib	dobj	20	SENT_130	[p12l1034t233r1538b310],
24	,	,	O	,	_	0	SENT_130	[p12l1034t233r1538b310],
25	dabrafenib	NN	O	dabrafenib	conj_and	23	SENT_130	[p12l1570t233r1977b305],
26	,	,	O	,	_	0	SENT_130	[p12l1570t233r1977b305],
27	and	CC	O	and	_	0	SENT_130	[p12l2010t233r2142b296],
28	trametinib	NN	O	trametinib	nn	29	SENT_130	[p12l8t336r416b412],
29	)	NN	O	)	conj_and	23	SENT_130	[p12l8t336r416b412],
30	and	CC	O	and	_	0	SENT_130	[p12l447t336r578b399],
31	immunotherapy	NN	O	immunotherapy	nn	33	SENT_130	[p12l604t336r1188b420],
32	(	NN	O	(	nn	33	SENT_130	[p12l1214t336r1656b419],
33	ipilimumab	NN	O	ipilimumab	conj_and	23	SENT_130	[p12l1214t336r1656b419],
34	and	CC	O	and	_	0	SENT_130	[p12l1685t336r1833b408],
35	,	,	O	,	_	0	SENT_130	[p12l1685t336r1833b408],
36	in	IN	O	in	dep	23	SENT_130	[p12l1862t342r1930b398],
37	some	DT	O	some	det	38	SENT_130	[p12l1958t359r2143b399],
38	centers	NNS	O	center	pobj	36	SENT_130	[p12l9t451r269b511],
39	,	,	O	,	_	0	SENT_130	[p12l9t451r269b511],
40	HD	NNP	O	HD	nn	42	SENT_130	[p12l295t444r419b501],
41	IL-2	NN	O	il-2	nn	42	SENT_130	[p12l444t440r637b515],
42	)	NN	O	)	dobj	20	SENT_130	[p12l444t440r637b515],
43	,	,	O	,	_	0	SENT_130	[p12l444t440r637b515],
44	the	DT	O	the	det	45	SENT_130	[p12l660t439r768b502],
45	question	NN	O	question	nsubjpass	58	SENT_130	[p12l791t445r1087b522],
46	of	IN	O	of	_	0	SENT_130	[p12l1110t439r1185b502],
47	which	WDT	O	which	rel	50	SENT_130	[p12l1196t439r1407b502],
48	agent	NN	O	agent	nsubj	50	SENT_130	[p12l1430t451r1614b523],
49	to	TO	O	to	aux	50	SENT_130	[p12l1635t451r1701b502],
50	use	VB	O	use	infmod	45	SENT_130	[p12l1726t462r1837b502],
51	ﬁrst	NN	O	ﬁrst	dobj	50	SENT_130	[p12l1860t439r1994b502],
52	in	IN	O	in	_	0	SENT_130	[p12l2016t445r2083b501],
53	a	DT	O	a	det	55	SENT_130	[p12l2106t462r2141b502],
54	particular	JJ	O	particular	amod	55	SENT_130	[p12l7t542r347b625],
55	patient	NN	O	patient	prep_in	50	SENT_130	[p12l368t548r608b625],
56	is	VBZ	O	be	auxpass	58	SENT_130	[p12l629t548r679b605],
57	frequently	RB	O	frequently	advmod	58	SENT_130	[p12l703t542r1057b626],
58	asked	VBN	O	ask	_	0	SENT_130	[p12l1077t542r1283b605],
59	.	.	O	.	_	0	SENT_130	[p12l1077t542r1283b605],

1	Currently	RB	DATE	currently	advmod	4	SENT_131	[p12l1310t542r1654b626],
2	,	,	O	,	_	0	SENT_131	[p12l1310t542r1654b626],
3	there	EX	O	there	expl	4	SENT_131	[p12l1677t542r1852b605],
4	are	VBP	O	be	_	0	SENT_131	[p12l1875t565r1976b605],
5	limited	JJ	O	limited	amod	6	SENT_131	[p12l1997t542r2139b604, p12l9t645r134b708],
6	data	NNS	O	datum	nsubj	4	SENT_131	[p12l153t645r294b708],
7	to	TO	O	to	aux	8	SENT_131	[p12l312t657r376b708],
8	guide	VB	O	guide	infmod	6	SENT_131	[p12l397t645r582b729],
9	either	CC	O	either	prep	8	SENT_131	[p12l602t645r795b708],
10	the	DT	O	the	det	12	SENT_131	[p12l813t645r917b708],
11	initial	JJ	O	initial	amod	12	SENT_131	[p12l937t645r1133b708],
12	choice	NN	O	choice	dep	9	SENT_131	[p12l1152t645r1365b708],
13	or	CC	O	or	_	0	SENT_131	[p12l1386t668r1456b708],
14	optimal	JJ	O	optimal	amod	15	SENT_131	[p12l1475t645r1734b728],
15	sequence	NN	O	sequence	conj_or	12	SENT_131	[p12l1755t668r2059b728],
16	of	IN	O	of	_	0	SENT_131	[p12l2079t645r2152b708],
17	these	DT	O	these	det	19	SENT_131	[p12l8t749r182b812],
18	treatment	NN	O	treatment	nn	19	SENT_131	[p12l202t761r537b812],
19	approaches	NNS	O	approach	prep_of	12	SENT_131	[p12l557t749r957b832],
20	.	.	O	.	_	0	SENT_131	[p12l557t749r957b832],

1	In	IN	O	in	_	0	SENT_132	[p12l981t754r1052b811],
2	retrospective	JJ	O	retrospective	amod	3	SENT_132	[p12l1073t755r1514b832],
3	studies	NNS	O	study	prep_in	56	SENT_132	[p12l1535t749r1769b812],
4	of	IN	O	of	_	0	SENT_132	[p12l1791t749r1865b812],
5	patients	NNS	O	patient	prep_of	3	SENT_132	[p12l1874t755r2143b832],
6	who	WP	O	who	nsubj	7	SENT_132	[p12l7t852r155b915],
7	received	VBD	O	receive	rcmod	5	SENT_132	[p12l180t852r468b915],
8	both	DT	O	both	preconj	12	SENT_132	[p12l489t852r650b915],
9	ipilimumab	NN	O	ipilimumab	nn	12	SENT_132	[p12l674t852r1077b935],
10	and	CC	O	and	_	0	SENT_132	[p12l1103t852r1231b915],
11	BRAF	NN	O	braf	nn	12	SENT_132	[p12l1254t856r1461b915],
12	inhibitors	NNS	O	inhibitor	dobj	7	SENT_132	[p12l1486t852r1844b924],
13	,	,	O	,	_	0	SENT_132	[p12l1486t852r1844b924],
14	patients	NNS	O	patient	appos	12	SENT_132	[p12l1868t858r2142b935],
15	who	WP	O	who	nsubj	37	SENT_132	[p12l7t955r155b1018],
16	received	VBD	O	receive	rcmod	14	SENT_132	[p12l180t955r469b1018],
17	a	DT	O	a	det	19	SENT_132	[p12l492t978r527b1018],
18	BRAF	NN	O	braf	nn	19	SENT_132	[p12l549t959r757b1018],
19	inhibitor	NN	O	inhibitor	dobj	16	SENT_132	[p12l781t955r1091b1018],
20	followed	VBN	O	follow	partmod	19	SENT_132	[p12l1113t955r1412b1018],
21	by	IN	O	by	_	0	SENT_132	[p12l1432t955r1518b1039],
22	ipilimumab	NN	O	ipilimumab	agent	20	SENT_132	[p12l1537t955r1941b1038],
23	often	RB	O	often	advmod	24	SENT_132	[p12l1966t955r2142b1018],
24	experienced	JJ	O	experienced	amod	22	SENT_132	[p12l9t1059r422b1142],
25	rapid	JJ	O	rapid	amod	27	SENT_132	[p12l441t1059r618b1142],
26	disease	NN	O	disease	nn	27	SENT_132	[p12l638t1059r876b1122],
27	progression	NN	O	progression	dobj	20	SENT_132	[p12l896t1065r1294b1143],
28	following	VBG	O	follow	_	0	SENT_132	[p12l1314t1059r1635b1143],
29	onset	NN	O	onset	prep_following	27	SENT_132	[p12l1654t1071r1834b1122],
30	of	IN	O	of	_	0	SENT_132	[p12l1854t1059r1927b1122],
31	resistance	NN	O	resistance	prep_of	29	SENT_132	[p12l1938t1065r2140b1122, p12l9t1185r157b1225],
32	to	TO	O	to	_	0	SENT_132	[p12l176t1174r240b1225],
33	BRAF	NN	O	braf	nn	34	SENT_132	[p12l261t1166r460b1225],
34	inhibitor	NN	O	inhibitor	prep_to	16	SENT_132	[p12l481t1162r774b1225],
35	and	CC	O	and	_	0	SENT_132	[p12l793t1162r916b1225],
36	were	VBD	O	be	cop	37	SENT_132	[p12l933t1185r1088b1225],
37	unable	JJ	O	unable	rcmod	14	SENT_132	[p12l1108t1162r1329b1225],
38	to	TO	O	to	aux	39	SENT_132	[p12l1348t1174r1412b1225],
39	complete	VB	O	complete	xcomp	37	SENT_132	[p12l1433t1162r1734b1245],
40	ipilimumab	JJ	O	ipilimumab	amod	41	SENT_132	[p12l1754t1162r2139b1245],
41	treatment	NN	O	treatment	nsubj	43	SENT_132	[p12l8t1256r504b1327],
42	.50	CD	NUMBER	.50	npadvmod	43	SENT_132	[p12l8t1256r504b1327],
43	>	JJR	O	>	xcomp	39	SENT_132	[p12l8t1256r504b1327],
44	51	CD	NUMBER	51	dep	43	SENT_132	[p12l8t1256r504b1327],
45	By	IN	O	by	dep	43	SENT_132	[p12l532t1269r623b1348],
46	contrast	NN	O	contrast	pobj	45	SENT_132	[p12l643t1276r940b1336],
47	,	,	O	,	_	0	SENT_132	[p12l643t1276r940b1336],
48	patients	NNS	O	patient	nsubj	56	SENT_132	[p12l964t1270r1237b1347],
49	who	WP	O	who	nsubj	50	SENT_132	[p12l1259t1264r1407b1327],
50	had	VBD	O	have	rcmod	48	SENT_132	[p12l1430t1264r1560b1327],
51	disease	NN	O	disease	nn	52	SENT_132	[p12l1583t1264r1826b1327],
52	progression	NN	O	progression	dobj	50	SENT_132	[p12l1848t1286r2137b1348, p12l9t1373r148b1430],
53	after	IN	O	after	_	0	SENT_132	[p12l169t1367r319b1430],
54	ipilimumab	NN	O	ipilimumab	prep_after	52	SENT_132	[p12l339t1367r730b1450],
55	were	VBD	O	be	cop	56	SENT_132	[p12l750t1390r909b1430],
56	able	JJ	O	able	_	0	SENT_132	[p12l930t1367r1063b1430],
57	to	TO	O	to	aux	58	SENT_132	[p12l1082t1379r1147b1430],
58	receive	VB	O	receive	xcomp	56	SENT_132	[p12l1168t1373r1401b1430],
59	BRAF	NN	O	braf	nn	60	SENT_132	[p12l1422t1371r1624b1430],
60	inhibitors	NNS	O	inhibitor	dobj	58	SENT_132	[p12l1646t1367r1974b1430],
61	subsequently	RB	O	subsequently	advmod	58	SENT_132	[p12l1995t1367r2137b1430, p12l10t1470r355b1554],
62	,	,	O	,	_	0	SENT_132	[p12l1995t1367r2137b1430, p12l10t1470r355b1554],
63	resulting	VBG	O	result	xcomp	58	SENT_132	[p12l380t1470r690b1554],
64	in	IN	O	in	_	0	SENT_132	[p12l712t1476r780b1532],
65	disease	NN	O	disease	nn	66	SENT_132	[p12l804t1470r1051b1533],
66	control	NN	O	control	prep_in	63	SENT_132	[p12l1076t1470r1327b1533],
67	at	IN	O	at	_	0	SENT_132	[p12l1351t1482r1412b1533],
68	a	DT	O	a	det	69	SENT_132	[p12l1435t1493r1470b1533],
69	rate	NN	O	rate	prep_at	63	SENT_132	[p12l1493t1482r1623b1533],
70	similar	JJ	O	similar	amod	69	SENT_132	[p12l1648t1470r1891b1533],
71	to	TO	O	to	_	0	SENT_132	[p12l1913t1482r1980b1533],
72	that	DT	O	that	prep_to	70	SENT_132	[p12l2004t1470r2142b1533],
73	seen	VBN	O	see	partmod	72	SENT_132	[p12l10t1596r164b1636],
74	with	IN	O	with	_	0	SENT_132	[p12l188t1573r346b1636],
75	BRAF	NN	O	braf	nn	76	SENT_132	[p12l373t1577r583b1636],
76	inhibitors	NNS	O	inhibitor	prep_with	73	SENT_132	[p12l611t1573r957b1636],
77	in	IN	O	in	_	0	SENT_132	[p12l984t1579r1053b1635],
78	ipilimumab	JJ	O	ipilimumab	amod	81	SENT_132	[p12l1079t1573r1715b1656],
79	—	NN	O	—	npadvmod	80	SENT_132	[p12l1079t1573r1715b1656],
80	naive	JJ	O	naive	amod	81	SENT_132	[p12l1079t1573r1715b1656],
81	patients	NNS	O	patient	prep_in	76	SENT_132	[p12l1740t1579r2039b1656],
82	.	.	O	.	_	0	SENT_132	[p12l1740t1579r2039b1656],

1	In	IN	O	in	_	0	SENT_133	[p12l2069t1578r2142b1635],
2	the	DT	O	the	det	3	SENT_133	[p12l8t1676r116b1739],
3	absence	NN	O	absence	prep_in	20	SENT_133	[p12l140t1676r411b1739],
4	of	IN	O	of	_	0	SENT_133	[p12l436t1676r511b1739],
5	prospective	JJ	O	prospective	amod	7	SENT_133	[p12l523t1682r925b1759],
6	clinical	JJ	O	clinical	amod	7	SENT_133	[p12l949t1676r1200b1739],
7	data	NNS	O	datum	prep_of	3	SENT_133	[p12l1223t1676r1370b1739],
8	to	TO	O	to	aux	9	SENT_133	[p12l1391t1688r1458b1739],
9	guide	VB	O	guide	infmod	3	SENT_133	[p12l1482t1676r1674b1760],
10	the	DT	O	the	det	11	SENT_133	[p12l1697t1676r1805b1739],
11	choice	NN	O	choice	dobj	9	SENT_133	[p12l1829t1676r2051b1739],
12	of	IN	O	of	_	0	SENT_133	[p12l2075t1676r2150b1739],
13	treatment	NN	O	treatment	nn	14	SENT_133	[p12l8t1791r345b1842],
14	sequence	NN	O	sequence	prep_of	11	SENT_133	[p12l368t1802r699b1862],
15	,	,	O	,	_	0	SENT_133	[p12l368t1802r699b1862],
16	treatment	NN	O	treatment	nn	17	SENT_133	[p12l722t1791r1060b1842],
17	decisions	NNS	O	decision	nsubjpass	20	SENT_133	[p12l1083t1779r1398b1842],
18	should	MD	O	should	aux	20	SENT_133	[p12l1422t1779r1655b1842],
19	be	VB	O	be	auxpass	20	SENT_133	[p12l1674t1779r1754b1842],
20	made	VBN	O	make	_	0	SENT_133	[p12l1777t1779r1965b1842],
21	after	IN	O	after	_	0	SENT_133	[p12l1989t1779r2142b1842],
22	consideration	NN	O	consideration	prep_after	20	SENT_133	[p12l9t1882r480b1945],
23	of	IN	O	of	_	0	SENT_133	[p12l504t1882r578b1945],
24	tumor	NN	O	tumor	nn	25	SENT_133	[p12l590t1894r807b1945],
25	burden	NN	O	burden	prep_of	22	SENT_133	[p12l827t1882r1095b1954],
26	,	,	O	,	_	0	SENT_133	[p12l827t1882r1095b1954],
27	presence	NN	O	presence	prep_after	20	SENT_133	[p12l1118t1904r1419b1965],
28	of	IN	O	of	_	0	SENT_133	[p12l1443t1882r1517b1945],
29	symptoms	NNS	O	symptom	prep_of	27	SENT_133	[p12l1531t1894r1884b1966],
30	related	VBN	O	relate	partmod	29	SENT_133	[p12l1908t1882r2141b1945],
31	to	TO	O	to	_	0	SENT_133	[p12l8t1996r73b2047],
32	melanoma	NN	O	melanoma	prep_to	30	SENT_133	[p12l95t1984r473b2056],
33	,	,	O	,	_	0	SENT_133	[p12l95t1984r473b2056],
34	rate	NN	O	rate	conj_and	22	SENT_133	[p12l495t1996r622b2047],
35	of	IN	O	of	_	0	SENT_133	[p12l643t1984r717b2047],
36	tumor	NN	O	tumor	nn	37	SENT_133	[p12l727t1996r942b2047],
37	growth	NN	O	growth	prep_of	34	SENT_133	[p12l961t1984r1221b2068],
38	,	,	O	,	_	0	SENT_133	[p12l961t1984r1221b2068],
39	and	CC	O	and	_	0	SENT_133	[p12l1245t1984r1370b2047],
40	patient	NN	O	patient	nn	41	SENT_133	[p12l1389t1990r1628b2067],
41	comorbidity	NN	O	comorbidity	conj_and	22	SENT_133	[p12l1648t1976r2141b2068],
42	.52	CD	NUMBER	.52	nsubjpass	62	SENT_133	[p12l1648t1976r2141b2068],
43	In	IN	O	in	_	0	SENT_133	[p12l9t2092r79b2149],
44	patients	NNS	O	patient	prep_in	42	SENT_133	[p12l98t2093r364b2170],
45	with	IN	O	with	_	0	SENT_133	[p12l382t2087r533b2150],
46	asymptomatic	JJ	O	asymptomatic	amod	52	SENT_133	[p12l554t2093r1046b2171],
47	,	,	O	,	_	0	SENT_133	[p12l554t2093r1046b2171],
48	nonbulky	JJ	O	nonbulky	dep	52	SENT_133	[p12l1068t2087r1401b2171],
49	,	,	O	,	_	0	SENT_133	[p12l1068t2087r1401b2171],
50	slowly	RB	O	slowly	advmod	51	SENT_133	[p12l1424t2087r1637b2171],
51	growing	VBG	O	grow	amod	52	SENT_133	[p12l1653t2093r1932b2171],
52	melanoma	NN	O	melanoma	prep_with	44	SENT_133	[p12l1950t2087r2138b2150, p12l8t2213r220b2262],
53	,	,	O	,	_	0	SENT_133	[p12l1950t2087r2138b2150, p12l8t2213r220b2262],
54	treatment	NN	O	treatment	appos	52	SENT_133	[p12l241t2202r575b2253],
55	with	IN	O	with	_	0	SENT_133	[p12l592t2190r744b2253],
56	ipilimumab	NN	O	ipilimumab	nn	59	SENT_133	[p12l765t2190r1159b2273],
57	or	CC	O	or	_	0	SENT_133	[p12l1181t2213r1253b2253],
58	HD	NN	O	hd	nn	59	SENT_133	[p12l1273t2195r1395b2252],
59	IL-2	NN	MISC	il-2	prep_with	54	SENT_133	[p12l1419t2195r1559b2252],
60	could	MD	O	could	aux	62	SENT_133	[p12l1582t2190r1771b2253],
61	be	VB	O	be	auxpass	62	SENT_133	[p12l1788t2190r1867b2253],
62	considered	VBN	O	consider	rcmod	41	SENT_133	[p12l1888t2190r2137b2253, p12l9t2293r156b2356],
63	ﬁrst	JJ	O	ﬁrst	acomp	62	SENT_133	[p12l175t2293r308b2356],
64	unless	IN	O	unless	mark	66	SENT_133	[p12l327t2293r538b2356],
65	patients	NNS	O	patient	nsubj	66	SENT_133	[p12l558t2299r826b2376],
66	have	VBP	O	have	advcl	62	SENT_133	[p12l847t2293r1002b2356],
67	contraindications	NNS	O	contraindication	dobj	66	SENT_133	[p12l1023t2293r1639b2356],
68	.	.	O	.	_	0	SENT_133	[p12l1023t2293r1639b2356],

1	This	DT	O	this	det	2	SENT_134	[p12l1663t2293r1806b2356],
2	approach	NN	O	approach	nsubj	4	SENT_134	[p12l1827t2293r2143b2376],
3	could	MD	O	could	aux	4	SENT_134	[p12l9t2396r205b2459],
4	maximize	VB	O	maximize	_	0	SENT_134	[p12l228t2402r574b2459],
5	the	DT	O	the	det	6	SENT_134	[p12l598t2396r708b2459],
6	chance	NN	O	chance	dobj	4	SENT_134	[p12l733t2396r975b2459],
7	that	IN	O	that	complm	11	SENT_134	[p12l999t2396r1136b2459],
8	such	JJ	O	such	amod	9	SENT_134	[p12l1161t2396r1320b2459],
9	patients	NNS	O	patient	nsubj	11	SENT_134	[p12l1343t2402r1621b2479],
10	might	MD	O	might	aux	11	SENT_134	[p12l1646t2396r1856b2480],
11	achieve	VB	O	achieve	ccomp	4	SENT_134	[p12l1880t2396r2140b2459],
12	a	DT	O	a	det	14	SENT_134	[p12l9t2523r44b2563],
13	durable	JJ	O	durable	amod	14	SENT_134	[p12l67t2500r329b2563],
14	response	NN	O	response	dobj	11	SENT_134	[p12l353t2522r658b2583],
15	from	IN	O	from	_	0	SENT_134	[p12l682t2500r853b2563],
16	immune	JJ	O	immune	amod	17	SENT_134	[p12l876t2506r1170b2563],
17	therapy	NN	O	therapy	prep_from	11	SENT_134	[p12l1193t2500r1460b2584],
18	without	IN	O	without	_	0	SENT_134	[p12l1478t2500r1751b2563],
19	apparently	RB	O	apparently	advmod	20	SENT_134	[p12l1774t2500r2145b2584],
20	compromising	VBG	O	compromise	prepc_without	11	SENT_134	[p12l9t2609r509b2687],
21	their	PRP$	O	they	poss	22	SENT_134	[p12l527t2603r690b2666],
22	ability	NN	O	ability	dobj	20	SENT_134	[p12l712t2603r924b2687],
23	to	TO	O	to	aux	24	SENT_134	[p12l941t2615r1007b2666],
24	respond	VB	O	respond	infmod	22	SENT_134	[p12l1030t2603r1307b2686],
25	to	TO	O	to	_	0	SENT_134	[p12l1327t2615r1392b2666],
26	BRAF	NN	O	braf	nn	27	SENT_134	[p12l1416t2607r1620b2666],
27	inhibitors	NNS	O	inhibitor	prep_to	24	SENT_134	[p12l1643t2603r1992b2666],
28	.	.	O	.	_	0	SENT_134	[p12l1643t2603r1992b2666],

1	COMBINATION	NN	O	combination	nn	2	SENT_135	[p12l9t2817r531b2873],
2	TREATMENTS	NNS	O	treatment	_	0	SENT_135	[p12l547t2818r1025b2873],

1	Combinations	NNS	O	combination	_	0	SENT_136	[p12l9t2919r493b2976],
2	of	IN	O	of	_	0	SENT_136	[p12l511t2918r582b2976],
3	BRAF	NN	O	braf	nn	4	SENT_136	[p12l599t2921r778b2975],
4	inhibitor	NN	O	inhibitor	prep_of	1	SENT_136	[p12l798t2919r1101b2976],
5	and	CC	O	and	_	0	SENT_136	[p12l1116t2919r1245b2976],
6	MEK	NN	O	mek	nn	7	SENT_136	[p12l1265t2921r1419b2975],
7	inhibitor	NN	O	inhibitor	prep_of	1	SENT_136	[p12l1435t2919r1737b2976],

1	Although	IN	O	although	mark	5	SENT_137	[p12l8t3016r342b3100],
2	BRAF	NN	O	braf	nn	4	SENT_137	[p12l366t3020r575b3079],
3	inhibitor	NN	O	inhibitor	nn	4	SENT_137	[p12l600t3016r910b3079],
4	therapy	NN	O	therapy	nsubj	14	SENT_137	[p12l931t3016r1200b3100],
5	produces	VBZ	O	produce	advcl	24	SENT_137	[p12l1219t3016r1538b3099],
6	tumor	NN	O	tumor	nn	7	SENT_137	[p12l1561t3028r1781b3079],
7	responses	NNS	O	response	dobj	5	SENT_137	[p12l1804t3038r2143b3099],
8	in	IN	O	in	_	0	SENT_137	[p12l9t3125r76b3181],
9	the	DT	O	the	det	10	SENT_137	[p12l98t3119r205b3182],
10	majority	NN	O	majority	prep_in	5	SENT_137	[p12l229t3125r526b3203],
11	of	IN	O	of	_	0	SENT_137	[p12l546t3119r620b3182],
12	patients	NNS	O	patient	prep_of	10	SENT_137	[p12l633t3125r905b3202],
13	and	CC	O	and	_	0	SENT_137	[p12l930t3119r1057b3182],
14	prolongs	VBZ	O	prolong	advcl	24	SENT_137	[p12l1078t3119r1381b3203],
15	median	JJ	O	median	amod	16	SENT_137	[p12l1404t3119r1665b3182],
16	survival	NN	O	survival	dobj	14	SENT_137	[p12l1689t3119r1963b3182],
17	relative	JJ	O	relative	advmod	14	SENT_137	[p12l1986t3119r2139b3182, p12l8t3228r133b3285],
18	to	TO	O	to	_	0	SENT_137	[p12l156t3234r223b3285],
19	chemotherapy	NN	O	chemotherapy	prep_to	17	SENT_137	[p12l249t3222r763b3306],
20	,	,	O	,	_	0	SENT_137	[p12l249t3222r763b3306],
21	responses	NNS	O	response	nsubj	24	SENT_137	[p12l789t3244r1128b3305],
22	are	VBP	O	be	cop	24	SENT_137	[p12l1153t3245r1256b3285],
23	largely	RB	O	largely	advmod	24	SENT_137	[p12l1278t3222r1514b3306],
24	partial	JJ	O	partial	_	0	SENT_137	[p12l1532t3222r1780b3305],
25	,	,	O	,	_	0	SENT_137	[p12l1532t3222r1780b3305],
26	and	CC	O	and	_	0	SENT_137	[p12l1807t3222r1935b3285],
27	clinical	JJ	O	clinical	amod	28	SENT_137	[p12l1959t3222r2138b3285, p12l9t3325r102b3388],
28	evidence	NN	O	evidence	nsubj	33	SENT_137	[p12l124t3325r422b3388],
29	of	IN	O	of	_	0	SENT_137	[p12l445t3325r518b3388],
30	tumor	NN	O	tumor	nn	31	SENT_137	[p12l529t3337r744b3388],
31	resistance	NN	O	resistance	prep_of	28	SENT_137	[p12l765t3331r1099b3388],
32	typically	RB	O	typically	advmod	33	SENT_137	[p12l1119t3325r1412b3409],
33	develops	VBZ	O	develop	conj_and	24	SENT_137	[p12l1431t3325r1726b3408],
34	at	IN	O	at	_	0	SENT_137	[p12l1750t3337r1809b3388],
35	a	DT	O	a	det	36	SENT_137	[p12l1830t3348r1864b3388],
36	median	NN	O	median	prep_at	33	SENT_137	[p12l1884t3325r2142b3388],
37	of	IN	O	of	_	0	SENT_137	[p12l9t3427r85b3490],
38	5-7	CD	NUMBER	5-7	num	39	SENT_137	[p12l100t3435r225b3490],
39	months	NNS	NUMBER	month	prep_of	36	SENT_137	[p12l249t3427r532b3490],
40	.	.	O	.	_	0	SENT_137	[p12l249t3427r532b3490],

1	Several	JJ	O	several	amod	4	SENT_138	[p12l560t3427r811b3490],
2	different	JJ	O	different	amod	4	SENT_138	[p12l834t3427r1132b3490],
3	resistance	NN	O	resistance	nn	4	SENT_138	[p12l1154t3433r1497b3490],
4	mechanisms	NNS	O	mechanism	nsubjpass	7	SENT_138	[p12l1521t3427r1958b3490],
5	have	VBP	O	have	aux	7	SENT_138	[p12l1982t3427r2141b3490],
6	been	VBN	O	be	auxpass	7	SENT_138	[p12l7t3530r173b3593],
7	described	VBN	O	describe	_	0	SENT_138	[p12l197t3530r549b3602],
8	,	,	O	,	_	0	SENT_138	[p12l197t3530r549b3602],
9	which	WDT	O	which	nsubjpass	12	SENT_138	[p12l572t3530r784b3593],
10	can	MD	O	can	aux	12	SENT_138	[p12l808t3553r926b3593],
11	be	VB	O	be	auxpass	12	SENT_138	[p12l947t3530r1028b3593],
12	divided	VBN	O	divide	ccomp	7	SENT_138	[p12l1052t3530r1312b3593],
13	into	IN	O	into	_	0	SENT_138	[p12l1335t3536r1470b3593],
14	MAPK	NN	O	mapk	nn	15	SENT_138	[p12l1494t3530r2141b3613],
15	—	NN	O	—	prep_into	12	SENT_138	[p12l1494t3530r2141b3613],
16	dependent	JJ	O	dependent	amod	21	SENT_138	[p12l1494t3530r2141b3613],
17	or	CC	O	or	_	0	SENT_138	[p12l9t3656r81b3696],
18	MAPK	NN	O	mapk	conj_or	16	SENT_138	[p12l101t3633r809b3716],
19	—	CD	NUMBER	—	num	18	SENT_138	[p12l101t3633r809b3716],
20	independent	JJ	O	independent	amod	21	SENT_138	[p12l101t3633r809b3716],
21	pathways	NNS	O	pathway	dep	12	SENT_138	[p12l828t3633r1162b3717],
22	.	.	O	.	_	0	SENT_138	[p12l828t3633r1162b3717],

1	Among	IN	O	among	dep	169	SENT_139	[p13l82t168r344b248],
2	MAPK-dependent	JJ	O	mapk-dependent	dep	169	SENT_139	[p13l365t164r1012b247],
3	resistance	NN	O	resistance	dep	169	SENT_139	[p13l1034t170r1372b227],
4	mechanisms	NNS	O	mechanism	dep	169	SENT_139	[p13l1395t164r1845b236],
5	,	,	O	,	_	0	SENT_139	[p13l1395t164r1845b236],
6	changes	NNS	O	change	dep	169	SENT_139	[p13l1871t164r2143b248],
7	in	IN	O	in	dep	169	SENT_139	[p13l10t273r76b329],
8	BRAF	NN	O	braf	dep	169	SENT_139	[p13l99t271r314b339],
9	,	,	O	,	_	0	SENT_139	[p13l99t271r314b339],
10	such	JJ	O	such	dep	169	SENT_139	[p13l340t267r495b330],
11	as	IN	O	as	dep	169	SENT_139	[p13l518t290r583b330],
12	ampliﬁcation	NN	O	ampliﬁcation	dep	169	SENT_139	[p13l607t267r1060b350],
13	of	IN	O	of	dep	169	SENT_139	[p13l1083t267r1158b330],
14	the	DT	O	the	dep	169	SENT_139	[p13l1169t267r1276b330],
15	mutant	JJ	O	mutant	dep	169	SENT_139	[p13l1298t279r1548b330],
16	BRAFV6OO	NN	O	brafv6oo	dep	169	SENT_139	[p13l1569t271r1961b330],
17	gene	NN	O	gene	dep	169	SENT_139	[p13l1985t290r2142b351],
18	or	CC	O	or	dep	169	SENT_139	[p13l10t393r81b433],
19	truncations	NNS	O	truncation	dep	169	SENT_139	[p13l100t376r488b433],
20	in	IN	O	in	dep	169	SENT_139	[p13l510t376r576b432],
21	the	DT	O	the	dep	169	SENT_139	[p13l596t370r701b433],
22	BRAF	NN	O	braf	dep	169	SENT_139	[p13l722t374r925b433],
23	protein	NN	O	protein	dep	169	SENT_139	[p13l946t376r1192b453],
24	through	IN	O	through	dep	169	SENT_139	[p13l1212t370r1486b454],
25	alternative	JJ	O	alternative	dep	169	SENT_139	[p13l1508t370r1861b433],
26	splicing	NN	O	splicing	dep	169	SENT_139	[p13l1883t370r2145b454],
27	leading	VBG	O	lead	dep	169	SENT_139	[p13l8t473r261b557],
28	to	TO	O	to	dep	169	SENT_139	[p13l280t485r346b536],
29	increased	VBN	O	increase	dep	169	SENT_139	[p13l370t473r696b536],
30	dimerization	NN	O	dimerization	dep	169	SENT_139	[p13l718t473r1159b536],
31	and	CC	O	and	dep	169	SENT_139	[p13l1183t473r1309b536],
32	resultant	JJ	O	resultant	dep	169	SENT_139	[p13l1331t473r1631b536],
33	kinase	NN	O	kinase	dep	169	SENT_139	[p13l1650t473r1869b536],
34	activity	NN	O	activity	dep	169	SENT_139	[p13l1892t479r2145b557],
35	have	VBP	O	have	dep	169	SENT_139	[p13l8t575r160b638],
36	been	VBN	O	be	dep	169	SENT_139	[p13l177t575r337b638],
37	identiﬁed	VBN	O	identiﬁed	dep	169	SENT_139	[p13l356t575r675b638],
38	in	IN	O	in	dep	169	SENT_139	[p13l693t581r758b637],
39	as	RB	O	as	dep	169	SENT_139	[p13l778t598r841b638],
40	many	JJ	O	many	dep	169	SENT_139	[p13l860t598r1049b659],
41	as	IN	O	as	dep	169	SENT_139	[p13l1065t598r1128b638],
42	30	CD	PERCENT	30	dep	169	SENT_139	[p13l1149t581r1287b640],
43	%	NN	PERCENT	%	dep	169	SENT_139	[p13l1149t581r1287b640],
44	of	IN	O	of	dep	169	SENT_139	[p13l1308t575r1381b638],
45	patients	NNS	O	patient	dep	169	SENT_139	[p13l1389t567r1806b658],
46	.53	CD	NUMBER	.53	dep	169	SENT_139	[p13l1389t567r1806b658],
47	=	JJ	O	=	dep	169	SENT_139	[p13l1389t567r1806b658],
48	54	CD	NUMBER	54	dep	169	SENT_139	[p13l1389t567r1806b658],
49	Although	IN	O	although	dep	169	SENT_139	[p13l1824t575r2143b659],
50	secondary	JJ	O	secondary	dep	169	SENT_139	[p13l10t678r349b762],
51	mutations	NNS	O	mutation	dep	169	SENT_139	[p13l364t684r696b741],
52	in	IN	O	in	dep	169	SENT_139	[p13l715t684r779b740],
53	tyrosine	NN	O	tyrosine	dep	169	SENT_139	[p13l797t684r1063b762],
54	kinases	NNS	O	kinase	dep	169	SENT_139	[p13l1081t678r1320b741],
55	are	VBP	O	be	dep	169	SENT_139	[p13l1340t701r1437b741],
56	a	DT	O	a	dep	169	SENT_139	[p13l1456t701r1490b741],
57	common	JJ	O	common	dep	169	SENT_139	[p13l1508t701r1805b741],
58	resistance	NN	O	resistance	dep	169	SENT_139	[p13l1824t684r2144b741],
59	mechanism	NN	O	mechanism	dep	169	SENT_139	[p13l9t781r401b844],
60	in	IN	O	in	dep	169	SENT_139	[p13l423t787r488b843],
61	other	JJ	O	other	dep	169	SENT_139	[p13l511t781r690b844],
62	malignancies	NNS	O	malignancy	dep	169	SENT_139	[p13l710t781r1154b865],
63	treated	VBN	O	treat	dep	169	SENT_139	[p13l1175t781r1411b844],
64	with	IN	O	with	dep	169	SENT_139	[p13l1429t781r1581b844],
65	molecularly	RB	O	molecularly	dep	169	SENT_139	[p13l1601t781r2005b865],
66	targeted	VBN	O	target	dep	169	SENT_139	[p13l2022t793r2139b844, p13l9t884r185b968],
67	therapy	NN	O	therapy	dep	169	SENT_139	[p13l202t884r461b968],
68	,	,	O	,	_	0	SENT_139	[p13l202t884r461b968],
69	this	DT	O	this	dep	169	SENT_139	[p13l481t884r600b947],
70	has	VBZ	O	have	dep	169	SENT_139	[p13l618t884r727b947],
71	not	RB	O	not	dep	169	SENT_139	[p13l746t896r856b947],
72	been	VBN	O	be	dep	169	SENT_139	[p13l871t884r1030b947],
73	reported	VBN	O	report	dep	169	SENT_139	[p13l1049t884r1333b967],
74	to	TO	O	to	dep	169	SENT_139	[p13l1349t896r1413b947],
75	occur	VB	O	occur	dep	169	SENT_139	[p13l1434t907r1620b947],
76	in	IN	O	in	dep	169	SENT_139	[p13l1638t890r1702b946],
77	patients	NNS	O	patient	dep	169	SENT_139	[p13l1720t890r1978b967],
78	with	IN	O	with	dep	169	SENT_139	[p13l1996t884r2143b947],
79	BRAFV600	NN	O	brafv600	dep	169	SENT_139	[p13l10t990r407b1049],
80	mutant	JJ	O	mutant	dep	169	SENT_139	[p13l431t998r683b1049],
81	melanoma	NN	O	melanoma	dep	169	SENT_139	[p13l705t978r1235b1049],
82	.55	NN	NUMBER	.55	dep	169	SENT_139	[p13l705t978r1235b1049],
83	=	JJ	O	=	dep	169	SENT_139	[p13l705t978r1235b1049],
84	56	CD	NUMBER	56	dep	169	SENT_139	[p13l705t978r1235b1049],
85	Instead	RB	O	instead	dep	169	SENT_139	[p13l1258t986r1529b1058],
86	,	,	O	,	_	0	SENT_139	[p13l1258t986r1529b1058],
87	secondary	JJ	O	secondary	dep	169	SENT_139	[p13l1555t986r1914b1070],
88	mutations	NNS	O	mutation	dep	169	SENT_139	[p13l1933t998r2140b1049, p13l8t1095r175b1152],
89	in	IN	O	in	dep	169	SENT_139	[p13l198t1095r264b1151],
90	NRAS	NNS	ORGANIZATION	nra	dep	169	SENT_139	[p13l286t1093r500b1152],
91	and	CC	O	and	dep	169	SENT_139	[p13l524t1089r650b1152],
92	MEK	NN	O	mek	dep	169	SENT_139	[p13l671t1094r853b1151],
93	(	CD	NUMBER	(	dep	169	SENT_139	[p13l878t1090r1223b1172],
94	upstream	JJ	O	upstream	dep	169	SENT_139	[p13l878t1090r1223b1172],
95	and	CC	O	and	dep	169	SENT_139	[p13l1246t1089r1372b1152],
96	downstream	JJ	O	downstream	dep	169	SENT_139	[p13l1394t1089r1817b1152],
97	of	IN	O	of	dep	169	SENT_139	[p13l1840t1089r1913b1152],
98	BRAF	NN	O	braf	dep	169	SENT_139	[p13l1926t1093r2140b1161],
99	,	,	O	,	_	0	SENT_139	[p13l1926t1093r2140b1161],
100	respectively	RB	O	respectively	dep	169	SENT_139	[p13l9t1192r420b1276],
101	)	CD	NUMBER	)	dep	169	SENT_139	[p13l9t1192r420b1276],
102	have	VBP	O	have	dep	169	SENT_139	[p13l442t1192r592b1255],
103	been	VBN	O	be	dep	169	SENT_139	[p13l609t1192r768b1255],
104	detected	VBN	O	detect	dep	169	SENT_139	[p13l788t1192r1065b1255],
105	in	IN	O	in	dep	169	SENT_139	[p13l1083t1198r1148b1254],
106	tumor	NN	O	tumor	dep	169	SENT_139	[p13l1166t1204r1374b1255],
107	samples	NNS	O	sample	dep	169	SENT_139	[p13l1393t1192r1651b1275],
108	obtained	VBN	O	obtain	dep	169	SENT_139	[p13l1672t1192r1961b1255],
109	from	IN	O	from	dep	169	SENT_139	[p13l1979t1192r2141b1255],
110	patients	NNS	O	patient	dep	169	SENT_139	[p13l8t1301r279b1378],
111	whose	WP$	O	whose	dep	169	SENT_139	[p13l301t1295r519b1358],
112	disease	NN	O	disease	dep	169	SENT_139	[p13l543t1295r785b1358],
113	had	VBD	O	have	dep	169	SENT_139	[p13l806t1295r935b1358],
114	progressed	VBN	O	progress	dep	169	SENT_139	[p13l956t1295r1332b1379],
115	during	IN	O	during	dep	169	SENT_139	[p13l1354t1295r1587b1379],
116	BRAF	NN	MISC	braf	dep	169	SENT_139	[p13l1608t1299r1814b1358],
117	inhibitor	NN	O	inhibitor	dep	169	SENT_139	[p13l1838t1295r2143b1358],
118	therapy	NN	O	therapy	dep	169	SENT_139	[p13l8t1389r422b1481],
119	.57	NN	NUMBER	.57	dep	169	SENT_139	[p13l8t1389r422b1481],
120	=	JJ	O	=	dep	169	SENT_139	[p13l8t1389r422b1481],
121	58	CD	NUMBER	58	dep	169	SENT_139	[p13l8t1389r422b1481],
122	In	IN	O	in	dep	169	SENT_139	[p13l446t1402r518b1459],
123	addition	NN	O	addition	dep	169	SENT_139	[p13l541t1397r848b1469],
124	,	,	O	,	_	0	SENT_139	[p13l541t1397r848b1469],
125	overexpression	NN	O	overexpression	dep	169	SENT_139	[p13l873t1403r1389b1480],
126	of	IN	O	of	dep	169	SENT_139	[p13l1412t1397r1487b1460],
127	the	DT	O	the	dep	169	SENT_139	[p13l1498t1397r1606b1460],
128	MAPK	NN	O	mapk	dep	169	SENT_139	[p13l1628t1401r1871b1459],
129	protein	NN	O	protein	dep	169	SENT_139	[p13l1892t1403r2142b1480],
130	cancer	NN	O	cancer	dep	169	SENT_139	[p13l10t1523r240b1563],
131	Osaka	NNP	LOCATION	Osaka	dep	169	SENT_139	[p13l265t1500r483b1563],
132	thyroid	NN	O	thyroid	dep	169	SENT_139	[p13l506t1500r766b1584],
133	kinase	NN	O	kinase	dep	169	SENT_139	[p13l789t1500r1032b1572],
134	,	,	O	,	_	0	SENT_139	[p13l789t1500r1032b1572],
135	which	WDT	O	which	dep	169	SENT_139	[p13l1057t1500r1273b1563],
136	activates	VBZ	O	activate	dep	169	SENT_139	[p13l1299t1506r1599b1563],
137	ERK	NN	ORGANIZATION	erk	dep	169	SENT_139	[p13l1625t1505r1787b1563],
138	primarily	RB	O	primarily	dep	169	SENT_139	[p13l1810t1500r2146b1584],
139	through	IN	O	through	dep	169	SENT_139	[p13l8t1603r283b1687],
140	MEK-dependent	JJ	O	mek-dependent	dep	169	SENT_139	[p13l303t1603r876b1686],
141	mechanisms	NNS	O	mechanism	dep	169	SENT_139	[p13l895t1603r1317b1666],
142	that	WDT	O	that	dep	169	SENT_139	[p13l1337t1603r1470b1666],
143	do	VBP	O	do	dep	169	SENT_139	[p13l1489t1603r1573b1666],
144	not	RB	O	not	dep	169	SENT_139	[p13l1594t1615r1707b1666],
145	require	VB	O	require	dep	169	SENT_139	[p13l1726t1609r1967b1686],
146	RAF	NN	ORGANIZATION	raf	dep	169	SENT_139	[p13l1988t1607r2141b1666],
147	signaling	NN	O	signaling	dep	169	SENT_139	[p13l10t1705r341b1789],
148	,	,	O	,	_	0	SENT_139	[p13l10t1705r341b1789],
149	has	VBZ	O	have	dep	169	SENT_139	[p13l364t1705r477b1768],
150	also	RB	O	also	dep	169	SENT_139	[p13l501t1705r633b1768],
151	been	VBN	O	be	dep	169	SENT_139	[p13l656t1705r822b1768],
152	reported	VBN	O	report	dep	169	SENT_139	[p13l845t1697r1224b1788],
153	.59	CD	NUMBER	.59	dep	169	SENT_139	[p13l845t1697r1224b1788],
154	Several	JJ	O	several	dep	169	SENT_139	[p13l1248t1705r1495b1768],
155	of	IN	O	of	dep	169	SENT_139	[p13l1517t1705r1592b1768],
156	these	DT	O	these	dep	169	SENT_139	[p13l1604t1705r1782b1768],
157	resistance	NN	O	resistance	dep	169	SENT_139	[p13l1805t1711r2142b1768],
158	mechanisms	NNS	O	mechanism	dep	169	SENT_139	[p13l9t1808r431b1871],
159	can	MD	O	can	dep	169	SENT_139	[p13l453t1831r569b1871],
160	be	VB	O	be	dep	169	SENT_139	[p13l588t1808r667b1871],
161	overcome	VBN	O	overcome	dep	169	SENT_139	[p13l689t1831r1017b1871],
162	by	IN	O	by	dep	169	SENT_139	[p13l1036t1808r1120b1892],
163	addition	NN	O	addition	dep	169	SENT_139	[p13l1138t1808r1421b1871],
164	of	IN	O	of	dep	169	SENT_139	[p13l1443t1808r1517b1871],
165	inhibitors	NNS	O	inhibitor	dep	169	SENT_139	[p13l1528t1808r1856b1871],
166	of	IN	O	of	dep	169	SENT_139	[p13l1878t1808r1951b1871],
167	MEK	NN	O	mek	dep	169	SENT_139	[p13l1962t1813r2144b1870],
168	or	CC	O	or	dep	169	SENT_139	[p13l10t1933r84b1973],
169	ERK	NN	O	erk	_	0	SENT_139	[p13l108t1915r287b1973],
170	.	.	O	.	_	0	SENT_139	[p13l108t1915r287b1973],

1	The	DT	O	the	dep	141	SENT_140	[p13l316t1910r444b1973],
2	combination	NN	O	combination	dep	141	SENT_140	[p13l470t1910r919b1973],
3	trial	NN	O	trial	dep	141	SENT_140	[p13l944t1910r1090b1973],
4	of	IN	O	of	dep	141	SENT_140	[p13l1115t1910r1191b1973],
5	dabrafenib	NN	O	dabrafenib	dep	141	SENT_140	[p13l1208t1910r1585b1973],
6	and	CC	O	and	dep	141	SENT_140	[p13l1613t1910r1743b1973],
7	trametinib	NN	O	trametinib	dep	141	SENT_140	[p13l1767t1910r2142b1973],
8	showed	VBD	O	show	dep	141	SENT_140	[p13l10t2013r267b2076],
9	evidence	NN	O	evidence	dep	141	SENT_140	[p13l289t2013r586b2076],
10	of	IN	O	of	dep	141	SENT_140	[p13l608t2013r682b2076],
11	tumor	NN	O	tumor	dep	141	SENT_140	[p13l693t2025r908b2076],
12	response	NN	O	response	dep	141	SENT_140	[p13l929t2035r1227b2096],
13	in	IN	O	in	dep	141	SENT_140	[p13l1250t2019r1316b2075],
14	15	CD	PERCENT	15	dep	141	SENT_140	[p13l1344t2019r1480b2077],
15	%	NN	PERCENT	%	dep	141	SENT_140	[p13l1344t2019r1480b2077],
16	of	IN	O	of	dep	141	SENT_140	[p13l1505t2013r1578b2076],
17	patients	NNS	O	patient	dep	141	SENT_140	[p13l1589t2019r1857b2096],
18	exhibiting	VBG	O	exhibit	dep	141	SENT_140	[p13l1880t2013r2140b2076, p13l9t2121r116b2199],
19	resistance	NN	O	resistance	dep	141	SENT_140	[p13l134t2121r463b2178],
20	to	TO	O	to	dep	141	SENT_140	[p13l482t2127r547b2178],
21	vemurafenib	NN	O	vemurafenib	dep	141	SENT_140	[p13l566t2107r1072b2178],
22	.6	CD	NUMBER	.6	dep	141	SENT_140	[p13l566t2107r1072b2178],
23	°	CD	NUMBER	°	dep	141	SENT_140	[p13l566t2107r1072b2178],
24	In	IN	O	in	dep	141	SENT_140	[p13l1093t2120r1163b2177],
25	addition	NN	O	addition	dep	141	SENT_140	[p13l1183t2115r1484b2187],
26	,	,	O	,	_	0	SENT_140	[p13l1183t2115r1484b2187],
27	the	DT	O	the	dep	141	SENT_140	[p13l1505t2115r1610b2178],
28	combination	NN	O	combination	dep	141	SENT_140	[p13l1630t2115r2060b2178],
29	of	IN	O	of	dep	141	SENT_140	[p13l2080t2115r2153b2178],
30	dabrafenib	NN	O	dabrafenib	dep	141	SENT_140	[p13l10t2218r364b2281],
31	(	NN	O	(	dep	141	SENT_140	[p13l387t2218r529b2295],
32	150	CD	NUMBER	150	dep	141	SENT_140	[p13l387t2218r529b2295],
33	mg	NN	O	mg	dep	141	SENT_140	[p13l543t2241r650b2302],
34	twice	RB	O	twice	dep	141	SENT_140	[p13l666t2224r840b2281],
35	daily	JJ	SET	daily	dep	141	SENT_140	[p13l860t2218r1043b2302],
36	)	NN	O	)	dep	141	SENT_140	[p13l860t2218r1043b2302],
37	and	CC	O	and	dep	141	SENT_140	[p13l1067t2218r1190b2281],
38	trametinib	NN	O	trametinib	dep	141	SENT_140	[p13l1206t2218r1558b2281],
39	(	NN	O	(	dep	141	SENT_140	[p13l1582t2219r1643b2294],
40	2	CD	NUMBER	2	dep	141	SENT_140	[p13l1582t2219r1643b2294],
41	mg	NN	O	mg	dep	141	SENT_140	[p13l1657t2241r1764b2302],
42	once	RB	DATE	once	dep	141	SENT_140	[p13l1782t2241r1936b2281],
43	daily	JJ	SET	daily	dep	141	SENT_140	[p13l1956t2218r2139b2302],
44	)	NN	O	)	dep	141	SENT_140	[p13l1956t2218r2139b2302],
45	in	IN	O	in	dep	141	SENT_140	[p13l9t2327r75b2383],
46	BRAF	NN	O	braf	dep	141	SENT_140	[p13l95t2325r296b2384],
47	inhibitor	NN	O	inhibitor	dep	141	SENT_140	[p13l317t2321r833b2384],
48	—	NN	O	—	dep	141	SENT_140	[p13l317t2321r833b2384],
49	naive	JJ	O	naive	dep	141	SENT_140	[p13l317t2321r833b2384],
50	patients	NNS	O	patient	dep	141	SENT_140	[p13l852t2327r1116b2404],
51	showed	VBD	O	show	dep	141	SENT_140	[p13l1137t2321r1390b2384],
52	an	DT	O	a	dep	141	SENT_140	[p13l1409t2344r1488b2384],
53	improved	JJ	O	improved	dep	141	SENT_140	[p13l1507t2321r1831b2404],
54	response	NN	O	response	dep	141	SENT_140	[p13l1850t2343r2144b2404],
55	rate	NN	O	rate	dep	141	SENT_140	[p13l10t2436r132b2487],
56	of	IN	O	of	dep	141	SENT_140	[p13l152t2424r224b2487],
57	76	CD	PERCENT	76	dep	141	SENT_140	[p13l235t2430r373b2488],
58	%	NN	PERCENT	%	dep	141	SENT_140	[p13l235t2430r373b2488],
59	as	IN	O	as	dep	141	SENT_140	[p13l395t2447r457b2487],
60	compared	VBN	O	compare	dep	141	SENT_140	[p13l477t2424r810b2507],
61	with	IN	O	with	dep	141	SENT_140	[p13l826t2424r974b2487],
62	54	CD	PERCENT	54	dep	141	SENT_140	[p13l995t2429r1133b2489],
63	%	NN	PERCENT	%	dep	141	SENT_140	[p13l995t2429r1133b2489],
64	with	IN	O	with	dep	141	SENT_140	[p13l1152t2424r1301b2487],
65	dabrafenib	NN	O	dabrafenib	dep	141	SENT_140	[p13l1320t2424r1674b2487],
66	monotherapy	NN	O	monotherapy	dep	141	SENT_140	[p13l1694t2424r2146b2508],
67	and	CC	O	and	dep	141	SENT_140	[p13l10t2528r138b2591],
68	prolonged	JJ	O	prolonged	dep	141	SENT_140	[p13l157t2528r511b2612],
69	median	NN	O	median	dep	141	SENT_140	[p13l532t2528r792b2591],
70	progression	NN	O	progression	dep	141	SENT_140	[p13l813t2534r1218b2612],
71	survival	NN	O	survival	dep	141	SENT_140	[p13l1242t2528r1514b2591],
72	as	IN	O	as	dep	141	SENT_140	[p13l1537t2551r1601b2591],
73	compared	VBN	O	compare	dep	141	SENT_140	[p13l1625t2528r1970b2611],
74	with	IN	O	with	dep	141	SENT_140	[p13l1989t2528r2144b2591],
75	dabrafenib	NN	O	dabrafenib	dep	141	SENT_140	[p13l10t2631r375b2694],
76	alone	RB	O	alone	dep	141	SENT_140	[p13l400t2631r582b2694],
77	(	RB	O	(	dep	141	SENT_140	[p13l608t2632r734b2707],
78	9.4	CD	DURATION	9.4	dep	141	SENT_140	[p13l608t2632r734b2707],
79	months	NNS	NUMBER	month	dep	141	SENT_140	[p13l756t2631r1016b2694],
80	vs.	CC	O	vs.	dep	141	SENT_140	[p13l1035t2654r1123b2694],
81	5.8	CD	DURATION	5.8	dep	141	SENT_140	[p13l1150t2638r1245b2694],
82	months	NNS	NUMBER	month	dep	141	SENT_140	[p13l1269t2631r1555b2708],
83	)	RB	O	)	dep	141	SENT_140	[p13l1269t2631r1555b2708],
84	in	IN	O	in	dep	141	SENT_140	[p13l1582t2637r1649b2694],
85	a	DT	O	a	dep	141	SENT_140	[p13l1672t2654r1706b2694],
86	randomized	JJ	O	randomized	dep	141	SENT_140	[p13l1728t2631r2144b2694],
87	phase	NN	O	phase	dep	141	SENT_140	[p13l8t2733r200b2816],
88	II	CD	NUMBER	ii	dep	141	SENT_140	[p13l220t2738r273b2795],
89	trial	NN	O	trial	dep	141	SENT_140	[p13l292t2725r506b2796],
90	.61	CD	NUMBER	.61	dep	141	SENT_140	[p13l292t2725r506b2796],
91	Moreover	RB	O	moreover	dep	141	SENT_140	[p13l529t2738r869b2805],
92	,	,	O	,	_	0	SENT_140	[p13l529t2738r869b2805],
93	the	DT	O	the	dep	141	SENT_140	[p13l889t2733r994b2796],
94	incidence	NN	O	incidence	dep	141	SENT_140	[p13l1014t2733r1337b2796],
95	of	IN	O	of	dep	141	SENT_140	[p13l1357t2733r1430b2796],
96	cutaneous	JJ	O	cutaneous	dep	141	SENT_140	[p13l1441t2745r1780b2796],
97	squamous	JJ	O	squamous	dep	141	SENT_140	[p13l1802t2756r2141b2816],
98	cell	NN	O	cell	dep	141	SENT_140	[p13l10t2836r123b2899],
99	carcinoma	NN	O	carcinoma	dep	141	SENT_140	[p13l145t2842r505b2899],
100	was	VBD	O	be	dep	141	SENT_140	[p13l524t2859r651b2899],
101	7	CD	PERCENT	7	dep	141	SENT_140	[p13l675t2841r775b2900],
102	%	NN	PERCENT	%	dep	141	SENT_140	[p13l675t2841r775b2900],
103	in	IN	O	in	dep	141	SENT_140	[p13l799t2842r866b2898],
104	the	DT	O	the	dep	141	SENT_140	[p13l887t2836r993b2899],
105	combination	NN	O	combination	dep	141	SENT_140	[p13l1017t2836r1451b2899],
106	group	NN	O	group	dep	141	SENT_140	[p13l1473t2858r1690b2920],
107	,	,	O	,	_	0	SENT_140	[p13l1473t2858r1690b2920],
108	as	IN	O	as	dep	141	SENT_140	[p13l1715t2859r1779b2899],
109	compared	VBN	O	compare	dep	141	SENT_140	[p13l1803t2836r2145b2919],
110	with	IN	O	with	dep	141	SENT_140	[p13l8t2939r158b3002],
111	19	CD	PERCENT	19	dep	141	SENT_140	[p13l184t2944r318b3004],
112	%	NN	PERCENT	%	dep	141	SENT_140	[p13l184t2944r318b3004],
113	for	IN	O	for	dep	141	SENT_140	[p13l340t2939r435b3002],
114	dabrafenib	NN	O	dabrafenib	dep	141	SENT_140	[p13l454t2939r813b3002],
115	monotherapy	NN	O	monotherapy	dep	141	SENT_140	[p13l833t2939r1299b3023],
116	,	,	O	,	_	0	SENT_140	[p13l833t2939r1299b3023],
117	suggesting	VBG	O	suggest	dep	141	SENT_140	[p13l1321t2945r1675b3023],
118	that	IN	O	that	dep	141	SENT_140	[p13l1692t2939r1823b3002],
119	the	DT	O	the	dep	141	SENT_140	[p13l1841t2939r1946b3002],
120	addition	NN	O	addition	dep	141	SENT_140	[p13l1966t2939r2139b3002, p13l8t3048r143b3105],
121	of	IN	O	of	dep	141	SENT_140	[p13l162t3042r235b3105],
122	a	DT	O	a	dep	141	SENT_140	[p13l245t3065r280b3105],
123	MEK	NN	O	mek	dep	141	SENT_140	[p13l297t3047r477b3104],
124	inhibitor	NN	O	inhibitor	dep	141	SENT_140	[p13l495t3042r791b3105],
125	was	VBD	O	be	dep	141	SENT_140	[p13l807t3065r931b3105],
126	able	JJ	O	able	dep	141	SENT_140	[p13l951t3042r1082b3105],
127	to	TO	O	to	dep	141	SENT_140	[p13l1101t3054r1165b3105],
128	block	VB	O	block	dep	141	SENT_140	[p13l1184t3042r1370b3105],
129	the	DT	O	the	dep	141	SENT_140	[p13l1386t3042r1490b3105],
130	paradoxical	JJ	O	paradoxical	dep	141	SENT_140	[p13l1508t3042r1899b3125],
131	activation	NN	O	activation	dep	141	SENT_140	[p13l1918t3048r2138b3105, p13l8t3151r142b3208],
132	of	IN	O	of	dep	141	SENT_140	[p13l161t3145r233b3208],
133	the	DT	O	the	dep	141	SENT_140	[p13l242t3145r346b3208],
134	MAPK	NN	ORGANIZATION	mapk	dep	141	SENT_140	[p13l365t3149r601b3207],
135	pathway	NN	O	pathway	dep	141	SENT_140	[p13l617t3145r899b3229],
136	that	WDT	O	that	dep	141	SENT_140	[p13l914t3145r1044b3208],
137	contributed	VBD	O	contribute	dep	141	SENT_140	[p13l1062t3145r1451b3208],
138	to	TO	O	to	dep	141	SENT_140	[p13l1468t3157r1532b3208],
139	these	DT	O	these	dep	141	SENT_140	[p13l1551t3145r1722b3208],
140	skin	NN	O	skin	dep	141	SENT_140	[p13l1742t3145r1878b3208],
141	lesions	NNS	O	lesion	_	0	SENT_140	[p13l1897t3145r2138b3208],
142	.	.	O	.	_	0	SENT_140	[p13l1897t3145r2138b3208],

1	This	DT	O	this	det	2	SENT_141	[p13l9t3248r150b3311],
2	combination	NN	O	combination	nsubjpass	6	SENT_141	[p13l171t3248r597b3311],
3	is	VBZ	O	be	aux	6	SENT_141	[p13l617t3254r666b3311],
4	currently	RB	DATE	currently	advmod	6	SENT_141	[p13l686t3248r996b3332],
5	being	VBG	O	be	auxpass	6	SENT_141	[p13l1010t3248r1198b3332],
6	tested	VBN	O	test	_	0	SENT_141	[p13l1215t3248r1412b3311],
7	in	IN	O	in	_	0	SENT_141	[p13l1430t3254r1496b3310],
8	two	CD	NUMBER	two	num	9	SENT_141	[p13l1514t3260r1637b3311],
9	phase	NN	O	phase	prep_in	6	SENT_141	[p13l1656t3248r1847b3331],
10	III	CD	NUMBER	iii	num	12	SENT_141	[p13l1868t3253r1949b3310],
11	clinical	JJ	O	clinical	amod	12	SENT_141	[p13l1970t3248r2141b3311, p13l10t3351r105b3414],
12	trials	NNS	O	trial	tmod	6	SENT_141	[p13l125t3351r299b3414],
13	comparing	VBG	O	compare	partmod	12	SENT_141	[p13l323t3357r700b3435],
14	it	PRP	O	it	dobj	13	SENT_141	[p13l721t3357r767b3414],
15	with	IN	O	with	_	0	SENT_141	[p13l787t3351r942b3414],
16	either	CC	O	either	preconj	18	SENT_141	[p13l965t3351r1164b3414],
17	dabrafenib	NN	O	dabrafenib	nn	18	SENT_141	[p13l1187t3351r1557b3414],
18	monotherapy	NN	O	monotherapy	prep_with	13	SENT_141	[p13l1581t3351r2052b3435],
19	or	CC	O	or	_	0	SENT_141	[p13l2072t3374r2145b3414],
20	vemurafenib	NN	O	vemurafenib	conj_or	18	SENT_141	[p13l7t3454r438b3517],
21	(	CD	NUMBER	(	num	22	SENT_141	[p13l465t3454r965b3531],
22	ClinicalTrials	NNS	O	clinicaltrial	dep	12	SENT_141	[p13l465t3454r965b3531],
23	.	.	O	.	_	0	SENT_141	[p13l465t3454r965b3531],

1	gov	NN	O	gov	nn	2	SENT_142	[p13l971t3477r1093b3538],
2	identiﬁers	NNS	O	identiﬁers	_	0	SENT_142	[p13l1112t3454r1470b3517],
3	:	:	O	:	_	0	SENT_142	[p13l1112t3454r1470b3517],
4	NCTO	NN	O	ncto	dep	2	SENT_142	[p13l1494t3457r1705b3517],
5	1	CD	NUMBER	1	number	6	SENT_142	[p13l1717t3461r1741b3516],
6	584648	CD	NUMBER	584648	dep	4	SENT_142	[p13l1753t3460r1993b3517],
7	and	CC	O	and	_	0	SENT_142	[p13l2018t3454r2144b3517],
8	NCTO1597908	CD	NUMBER	ncto1597908	num	9	SENT_142	[p13l8t3558r545b3634],
9	)	NN	O	)	dep	2	SENT_142	[p13l8t3558r545b3634],
10	.	.	O	.	_	0	SENT_142	[p13l8t3558r545b3634],

1	Moreover	RB	O	moreover	advmod	48	SENT_143	[p13l568t3562r905b3629],
2	,	,	O	,	_	0	SENT_143	[p13l568t3562r905b3629],
3	a	DT	O	a	det	4	SENT_143	[p13l927t3580r961b3620],
4	phase	NN	O	phase	nsubj	48	SENT_143	[p13l978t3557r1168b3640],
5	I	PRP	O	I	dep	6	SENT_143	[p13l1188t3562r1211b3619],
6	study	NN	O	study	rcmod	4	SENT_143	[p13l1233t3557r1415b3641],
7	of	IN	O	of	_	0	SENT_143	[p13l1431t3557r1503b3620],
8	the	DT	O	the	det	9	SENT_143	[p13l1512t3557r1616b3620],
9	combination	NN	O	combination	prep_of	6	SENT_143	[p13l1636t3557r2061b3620],
10	of	IN	O	of	_	0	SENT_143	[p13l2080t3557r2153b3620],
11	vemurafenib	NN	O	vemurafenib	prep_of	9	SENT_143	[p13l7t3659r436b3722],
12	and	CC	O	and	_	0	SENT_143	[p13l460t3659r586b3722],
13	the	DT	O	the	det	16	SENT_143	[p13l605t3659r711b3722],
14	MEK	NN	O	mek	nn	16	SENT_143	[p13l733t3664r914b3721],
15	inhibitor	NN	O	inhibitor	nn	16	SENT_143	[p13l935t3659r1235b3722],
16	GDC-0973	NN	MISC	gdc-0973	nsubj	17	SENT_143	[p13l1256t3663r1627b3722],
17	showed	VBD	O	show	conj_and	6	SENT_143	[p13l1653t3659r1908b3722],
18	tumor	NN	O	tumor	nn	19	SENT_143	[p13l1928t3671r2142b3722],
19	reduction	NN	O	reduction	nsubjpass	34	SENT_143	[p14l10t30r329b93],
20	in	IN	O	in	_	0	SENT_143	[p14l348t36r412b92],
21	all	DT	O	all	det	25	SENT_143	[p14l432t30r507b93],
22	25	CD	NUMBER	25	num	25	SENT_143	[p14l525t37r600b93],
23	evaluable	JJ	O	evaluable	amod	25	SENT_143	[p14l621t30r927b93],
24	vemurafenib-naive	JJ	O	vemurafenib-naive	amod	25	SENT_143	[p14l943t30r1566b93],
25	patients	NNS	O	patient	prep_in	19	SENT_143	[p14l1585t22r1921b113],
26	.62	CD	NUMBER	.62	num	27	SENT_143	[p14l1585t22r1921b113],
27	Grade	NNP	O	Grade	dep	25	SENT_143	[p14l1941t30r2143b94],
28	3	CD	NUMBER	3	num	27	SENT_143	[p14l11t140r44b196],
29	or	CC	O	or	_	0	SENT_143	[p14l69t156r140b196],
30	4	CD	NUMBER	4	num	32	SENT_143	[p14l159t140r198b195],
31	skin	NN	O	skin	nn	32	SENT_143	[p14l220t133r359b196],
32	rashes	NNS	O	rash	conj_or	27	SENT_143	[p14l380t133r589b196],
33	were	VBD	O	be	auxpass	34	SENT_143	[p14l609t156r768b196],
34	reported	VBN	O	report	ccomp	17	SENT_143	[p14l790t133r1082b216],
35	in	IN	O	in	_	0	SENT_143	[p14l1103t139r1168b195],
36	7	CD	PERCENT	7	num	37	SENT_143	[p14l1192t138r1290b197],
37	%	NN	PERCENT	%	prep_in	34	SENT_143	[p14l1192t138r1290b197],
38	of	IN	O	of	_	0	SENT_143	[p14l1314t133r1388b196],
39	patients	NNS	O	patient	prep_of	37	SENT_143	[p14l1398t139r1682b216],
40	,	,	O	,	_	0	SENT_143	[p14l1398t139r1682b216],
41	and	CC	O	and	_	0	SENT_143	[p14l1706t133r1831b196],
42	only	RB	O	only	quantmod	43	SENT_143	[p14l1852t133r2002b217],
43	1	CD	NUMBER	1	conj_and	37	SENT_143	[p14l2026t140r2051b195],
44	of	IN	O	of	_	0	SENT_143	[p14l2079t133r2152b196],
45	the	DT	O	the	det	47	SENT_143	[p14l8t236r112b299],
46	70	CD	NUMBER	70	num	47	SENT_143	[p14l132t243r207b299],
47	patients	NNS	O	patient	prep_of	4	SENT_143	[p14l226t242r486b319],
48	developed	VBD	O	develop	_	0	SENT_143	[p14l507t236r845b319],
49	cutaneous	JJ	O	cutaneous	amod	50	SENT_143	[p14l864t248r1199b299],
50	squamous	JJ	O	squamous	amod	52	SENT_143	[p14l1220t259r1554b319],
51	cell	NN	O	cell	nn	52	SENT_143	[p14l1574t236r1684b299],
52	carcinoma	NN	O	carcinoma	dobj	48	SENT_143	[p14l1703t242r2067b299],
53	.	.	O	.	_	0	SENT_143	[p14l1703t242r2067b299],

1	A	DT	O	a	det	2	SENT_144	[p14l2088t240r2144b298],
2	phase	NN	O	phase	_	0	SENT_144	[p14l8t339r198b422],
3	III	CD	NUMBER	iii	num	4	SENT_144	[p14l218t344r299b401],
4	trial	NN	O	trial	dep	2	SENT_144	[p14l318t339r455b402],
5	of	IN	O	of	_	0	SENT_144	[p14l474t339r546b402],
6	vemurafenib	NN	O	vemurafenib	prep_of	4	SENT_144	[p14l553t339r976b402],
7	alone	RB	O	alone	advmod	6	SENT_144	[p14l998t339r1175b402],
8	vs.	FW	O	vs.	nn	9	SENT_144	[p14l1192t362r1277b402],
9	vemurafenib	FW	O	vemurafenib	dep	2	SENT_144	[p14l1297t339r1720b402],
10	in	IN	O	in	_	0	SENT_144	[p14l1740t345r1805b401],
11	combination	NN	O	combination	prep_in	9	SENT_144	[p14l1825t339r2141b402, p14l8t448r141b505],
12	with	IN	O	with	_	0	SENT_144	[p14l157t442r305b505],
13	GD	NN	MISC	gd	nn	14	SENT_144	[p14l325t446r440b505],
14	C	NN	O	c	prep_with	11	SENT_144	[p14l448t446r685b505],
15	.	.	O	.	_	0	SENT_144	[p14l448t446r685b505],

1	—	NN	O	—	_	0	SENT_145	[p14l448t446r685b505],
2	.	.	O	.	_	0	SENT_145	[p14l448t446r685b505],

1	O973	NN	O	o973	nsubj	2	SENT_146	[p14l448t446r685b505],
2	is	VBZ	O	be	_	0	SENT_146	[p14l707t448r756b505],
3	currently	RB	DATE	currently	advmod	2	SENT_146	[p14l775t442r1079b526],
4	on	IN	O	on	_	0	SENT_146	[p14l1095t465r1179b505],
5	(	CD	NUMBER	(	num	6	SENT_146	[p14l1200t442r1683b518],
6	ClinicalTrials	NNS	O	clinicaltrial	prep_on	2	SENT_146	[p14l1200t442r1683b518],
7	.	.	O	.	_	0	SENT_146	[p14l1200t442r1683b518],

1	gov	NN	O	gov	nn	2	SENT_147	[p14l1689t465r1807b526],
2	identiﬁer	NN	O	identiﬁer	_	0	SENT_147	[p14l1823t442r2141b505],
3	:	:	O	:	_	0	SENT_147	[p14l1823t442r2141b505],
4	NCTO1689519	NN	O	ncto1689519	nn	5	SENT_147	[p14l8t546r563b621],
5	)	NN	O	)	dep	2	SENT_147	[p14l8t546r563b621],
6	.	.	O	.	_	0	SENT_147	[p14l8t546r563b621],

1	Finally	RB	O	finally	advmod	22	SENT_148	[p14l589t545r835b629],
2	,	,	O	,	_	0	SENT_148	[p14l589t545r835b629],
3	a	DT	O	a	det	7	SENT_148	[p14l860t568r895b608],
4	dose	NN	O	dose	nn	7	SENT_148	[p14l917t545r1449b608],
5	—	NN	O	—	nn	7	SENT_148	[p14l917t545r1449b608],
6	escalation	NN	O	escalation	nn	7	SENT_148	[p14l917t545r1449b608],
7	study	NN	O	study	nsubj	22	SENT_148	[p14l1472t545r1660b629],
8	of	IN	O	of	_	0	SENT_148	[p14l1679t545r1754b608],
9	LGX818	NN	O	lgx818	prep_of	7	SENT_148	[p14l1767t549r2052b608],
10	in	IN	O	in	_	0	SENT_148	[p14l2076t551r2144b607],
11	combination	NN	O	combination	prep_in	9	SENT_148	[p14l10t647r443b711],
12	with	IN	O	with	_	0	SENT_148	[p14l463t647r615b711],
13	an	DT	O	a	det	15	SENT_148	[p14l637t670r717b711],
14	oral	JJ	O	oral	amod	15	SENT_148	[p14l740t647r870b711],
15	MEK1	NN	O	mek1	prep_with	11	SENT_148	[p14l891t651r1140b713],
16	/	:	O	/	punct	18	SENT_148	[p14l891t651r1140b713],
17	2	CD	NUMBER	2	num	18	SENT_148	[p14l1145t654r1181b710],
18	inhibitor	NN	O	inhibitor	dep	15	SENT_148	[p14l1205t647r1517b719],
19	,	,	O	,	_	0	SENT_148	[p14l1205t647r1517b719],
20	MEK162	NN	O	mek162	appos	18	SENT_148	[p14l1540t652r1863b719],
21	,	,	O	,	_	0	SENT_148	[p14l1540t652r1863b719],
22	showed	VBD	O	show	_	0	SENT_148	[p14l1887t647r2144b711],
23	an	DT	O	a	det	26	SENT_148	[p14l10t774r87b814],
24	overall	JJ	O	overall	amod	26	SENT_148	[p14l106t751r326b814],
25	response	NN	O	response	nn	26	SENT_148	[p14l345t773r632b834],
26	rate	NN	O	rate	dobj	22	SENT_148	[p14l651t763r772b814],
27	of	IN	O	of	_	0	SENT_148	[p14l792t751r863b814],
28	71	CD	PERCENT	71	num	29	SENT_148	[p14l874t756r1010b816],
29	%	NN	PERCENT	%	prep_of	26	SENT_148	[p14l874t756r1010b816],
30	for	IN	O	for	_	0	SENT_148	[p14l1030t751r1124b814],
31	BRAF	NN	O	braf	nn	35	SENT_148	[p14l1142t755r1340b814],
32	inhibitor	NN	O	inhibitor	nn	35	SENT_148	[p14l1360t751r1865b814],
33	—	NN	O	—	nn	35	SENT_148	[p14l1360t751r1865b814],
34	naive	JJ	O	naive	amod	35	SENT_148	[p14l1360t751r1865b814],
35	patients	NNS	O	patient	prep_for	29	SENT_148	[p14l1882t757r2140b834],
36	and	CC	O	and	_	0	SENT_148	[p14l10t854r132b917],
37	22	CD	PERCENT	22	num	38	SENT_148	[p14l150t860r288b918],
38	%	NN	PERCENT	%	conj_and	29	SENT_148	[p14l150t860r288b918],
39	for	IN	O	for	_	0	SENT_148	[p14l308t854r402b917],
40	BRAF	NN	O	braf	nn	44	SENT_148	[p14l420t858r618b917],
41	inhibitor	NN	O	inhibitor	nn	44	SENT_148	[p14l638t854r1307b937],
42	—	NN	O	—	nn	44	SENT_148	[p14l638t854r1307b937],
43	pretreated	JJ	O	pretreated	amod	44	SENT_148	[p14l638t854r1307b937],
44	patients	NNS	O	patient	prep_for	38	SENT_148	[p14l1324t860r1582b937],
45	with	IN	O	with	_	0	SENT_148	[p14l1600t854r1747b917],
46	BRAFV600	NN	O	brafv600	nn	48	SENT_148	[p14l1766t858r2143b917],
47	mutant	JJ	O	mutant	amod	48	SENT_148	[p14l9t968r255b1019],
48	melanoma	NN	O	melanoma	prep_with	22	SENT_148	[p14l275t948r713b1019],
49	.	.	O	.	_	0	SENT_148	[p14l275t948r713b1019],

1	“	RB	O	“	advmod	8	SENT_149	[p14l275t948r713b1019],
2	No	DT	O	no	det	4	SENT_149	[p14l736t961r837b1019],
3	febrile	JJ	O	febrile	amod	4	SENT_149	[p14l860t956r1073b1019],
4	events	NNS	O	event	nsubjpass	8	SENT_149	[p14l1095t968r1305b1019],
5	or	CC	O	or	_	0	SENT_149	[p14l1329t979r1400b1019],
6	photosensitivity	NN	O	photosensitivity	conj_or	4	SENT_149	[p14l1419t956r1965b1040],
7	were	VBD	O	be	auxpass	8	SENT_149	[p14l1982t979r2141b1019],
8	reported	VBN	O	report	_	0	SENT_149	[p14l10t1059r318b1142],
9	,	,	O	,	_	0	SENT_149	[p14l10t1059r318b1142],
10	suggesting	VBG	O	suggest	xcomp	8	SENT_149	[p14l342t1065r699b1143],
11	that	IN	O	that	complm	19	SENT_149	[p14l717t1059r850b1122],
12	the	DT	O	the	det	14	SENT_149	[p14l869t1059r975b1122],
13	safety	NN	O	safety	nn	14	SENT_149	[p14l998t1059r1192b1143],
14	proﬁle	NN	O	proﬁle	nsubj	19	SENT_149	[p14l1209t1059r1427b1142],
15	for	IN	O	for	_	0	SENT_149	[p14l1449t1059r1546b1122],
16	this	DT	O	this	det	17	SENT_149	[p14l1565t1059r1688b1122],
17	combination	NN	O	combination	prep_for	14	SENT_149	[p14l1711t1059r2142b1122],
18	is	VBZ	O	be	cop	19	SENT_149	[p14l9t1167r58b1224],
19	different	JJ	O	different	ccomp	10	SENT_149	[p14l79t1161r361b1224],
20	from	IN	O	from	_	0	SENT_149	[p14l379t1161r543b1224],
21	those	DT	O	those	prep_from	19	SENT_149	[p14l561t1161r740b1224],
22	of	IN	O	of	_	0	SENT_149	[p14l760t1161r832b1224],
23	other	JJ	O	other	amod	24	SENT_149	[p14l842t1161r1019b1224],
24	combinations	NNS	O	combination	prep_of	21	SENT_149	[p14l1038t1161r1508b1224],
25	.	.	O	.	_	0	SENT_149	[p14l1038t1161r1508b1224],

1	On	IN	O	on	_	0	SENT_150	[p14l1532t1165r1637b1224],
2	the	DT	O	the	det	3	SENT_150	[p14l1655t1161r1759b1224],
3	basis	NN	O	basis	prep_on	25	SENT_150	[p14l1776t1161r1938b1224],
4	of	IN	O	of	_	0	SENT_150	[p14l1959t1161r2031b1224],
5	the	DT	O	the	det	7	SENT_150	[p14l2040t1161r2144b1224],
6	clinical	JJ	O	clinical	amod	7	SENT_150	[p14l10t1264r253b1327],
7	activity	NN	O	activity	prep_of	3	SENT_150	[p14l276t1270r527b1348],
8	and	CC	O	and	_	0	SENT_150	[p14l546t1264r672b1327],
9	safety	NN	O	safety	nn	10	SENT_150	[p14l694t1264r889b1348],
10	data	NNS	O	datum	conj_and	3	SENT_150	[p14l908t1264r1051b1327],
11	from	IN	O	from	_	0	SENT_150	[p14l1072t1264r1240b1327],
12	this	DT	O	this	det	13	SENT_150	[p14l1260t1264r1384b1327],
13	study	NN	O	study	prep_from	10	SENT_150	[p14l1408t1264r1601b1348],
14	,	,	O	,	_	0	SENT_150	[p14l1408t1264r1601b1348],
15	a	DT	O	a	det	18	SENT_150	[p14l1626t1287r1661b1327],
16	phase	NN	O	phase	nn	18	SENT_150	[p14l1680t1264r1874b1347],
17	III	CD	NUMBER	iii	num	18	SENT_150	[p14l1897t1269r1979b1326],
18	trial	NN	O	trial	nsubjpass	25	SENT_150	[p14l2002t1264r2142b1327],
19	combining	VBG	O	combine	partmod	18	SENT_150	[p14l10t1367r376b1451],
20	LGX818	NN	O	lgx818	dobj	19	SENT_150	[p14l396t1371r676b1430],
21	and	CC	O	and	_	0	SENT_150	[p14l699t1367r824b1430],
22	MEK162	NN	O	mek162	conj_and	20	SENT_150	[p14l844t1372r1145b1430],
23	is	VBZ	O	be	aux	25	SENT_150	[p14l1167t1373r1217b1430],
24	being	VBG	O	be	auxpass	25	SENT_150	[p14l1236t1367r1426b1451],
25	planned	VBN	O	plan	_	0	SENT_150	[p14l1444t1367r1735b1450],
26	.	.	O	.	_	0	SENT_150	[p14l1444t1367r1735b1450],

1	Combinations	NNS	O	combination	nsubj	41	SENT_151	[p14l9t1580r494b1637],
2	with	IN	O	with	_	0	SENT_151	[p14l510t1580r661b1637],
3	immunotherapy	NN	O	immunotherapy	prep_with	1	SENT_151	[p14l683t1580r1246b1653],
4	Another	DT	O	another	det	5	SENT_151	[p14l8t1677r303b1740],
5	approach	NN	O	approach	nsubj	24	SENT_151	[p14l326t1677r649b1760],
6	to	TO	O	to	aux	7	SENT_151	[p14l671t1689r738b1740],
7	extend	VB	O	extend	infmod	5	SENT_151	[p14l764t1677r997b1740],
8	or	CC	O	or	_	0	SENT_151	[p14l1020t1700r1093b1740],
9	enhance	VB	O	enhance	conj_or	7	SENT_151	[p14l1116t1677r1405b1740],
10	the	DT	O	the	det	11	SENT_151	[p14l1427t1677r1536b1740],
11	efficacy	NN	O	efficacy	dobj	7	SENT_151	[p14l1560t1677r1822b1761],
12	of	IN	O	of	_	0	SENT_151	[p14l1843t1677r1918b1740],
13	BRAF	NN	O	braf	nn	15	SENT_151	[p14l1932t1681r2140b1740],
14	inhibitor	NN	O	inhibitor	nn	15	SENT_151	[p14l10t1780r327b1843],
15	therapy	NN	O	therapy	prep_of	11	SENT_151	[p14l351t1780r625b1864],
16	for	IN	O	for	_	0	SENT_151	[p14l648t1780r749b1843],
17	treatment	NN	O	treatment	prep_for	15	SENT_151	[p14l774t1792r1124b1843],
18	of	IN	O	of	_	0	SENT_151	[p14l1150t1780r1227b1843],
19	patients	NNS	O	patient	prep_of	17	SENT_151	[p14l1243t1786r1524b1863],
20	with	IN	O	with	_	0	SENT_151	[p14l1550t1780r1709b1843],
21	BRAFV600	NN	O	brafv600	nn	23	SENT_151	[p14l1736t1784r2140b1843],
22	mutant	JJ	O	mutant	amod	23	SENT_151	[p14l9t1895r259b1946],
23	melanoma	NN	O	melanoma	prep_with	7	SENT_151	[p14l281t1883r647b1946],
24	is	VBZ	O	be	rcmod	3	SENT_151	[p14l669t1889r719b1946],
25	to	TO	O	to	aux	26	SENT_151	[p14l742t1895r809b1946],
26	combine	VB	O	combine	xcomp	24	SENT_151	[p14l833t1883r1131b1946],
27	immunotherapy	NN	O	immunotherapy	dobj	26	SENT_151	[p14l1155t1883r1721b1967],
28	such	JJ	O	such	_	0	SENT_151	[p14l1741t1883r1898b1946],
29	as	IN	O	as	_	0	SENT_151	[p14l1922t1906r1986b1946],
30	that	DT	O	that	prep_such_as	27	SENT_151	[p14l2009t1883r2144b1946],
31	with	IN	O	with	_	0	SENT_151	[p14l8t1986r159b2049],
32	HD	NN	O	hd	nn	33	SENT_151	[p14l180t1991r303b2048],
33	IL-2	NN	O	il-2	prep_with	30	SENT_151	[p14l325t1991r465b2048],
34	or	CC	O	or	_	0	SENT_151	[p14l489t2009r560b2049],
35	ipilimumab	NN	O	ipilimumab	conj_or	33	SENT_151	[p14l579t1986r973b2069],
36	with	IN	O	with	_	0	SENT_151	[p14l993t1986r1144b2049],
37	treatment	NN	O	treatment	prep_with	26	SENT_151	[p14l1164t1998r1497b2049],
38	with	IN	O	with	_	0	SENT_151	[p14l1514t1986r1666b2049],
39	BRAF	NN	O	braf	nn	40	SENT_151	[p14l1686t1990r1890b2049],
40	inhibitors	NNS	O	inhibitor	prep_with	26	SENT_151	[p14l1911t1986r2139b2049, p14l8t2101r142b2152],
41	(	VBP	O	(	conj_or	41	SENT_151	[p14l172t2089r357b2165],
42	with	IN	O	with	_	0	SENT_151	[p14l172t2089r357b2165],
43	or	CC	O	or	_	0	SENT_151	[p14l383t2112r457b2152],
44	without	IN	O	without	_	0	SENT_151	[p14l480t2089r758b2152],
45	MEK	NN	O	mek	nn	46	SENT_151	[p14l783t2094r970b2151],
46	inhibition	NN	O	inhibition	prep_without	41	SENT_151	[p14l995t2089r1378b2166],
47	)	CD	NUMBER	)	num	46	SENT_151	[p14l995t2089r1378b2166],
48	to	TO	O	to	aux	49	SENT_151	[p14l1407t2101r1475b2152],
49	maintain	VB	O	maintain	xcomp	41	SENT_151	[p14l1502t2095r1821b2152],
50	the	DT	O	the	det	51	SENT_151	[p14l1846t2089r1956b2152],
51	high	JJ	O	high	dobj	49	SENT_151	[p14l1982t2089r2141b2173],

1	VOLUME	NN	O	volume	dep	169	SENT_152	[p14l542t2307r765b2349],
2	95	CD	NUMBER	95	dep	169	SENT_152	[p14l783t2308r839b2349],
3	NUMBER	NN	O	number	dep	169	SENT_152	[p14l860t2307r1083b2349],
4	1	CD	NUMBER	1	dep	169	SENT_152	[p14l1104t2309r1118b2349],
5	|	CD	NUMBER	|	dep	169	SENT_152	[p14l1147t2303r1152b2364],
6	JANUARY	NNP	DATE	JANUARY	dep	169	SENT_152	[p14l1170t2307r1415b2349],
7	2014	CD	DATE	2014	dep	169	SENT_152	[p14l1431t2308r1552b2349],
8	|	CD	NUMBER	|	dep	169	SENT_152	[p14l1570t2303r1575b2364],
9	www.nature.com/cpt	JJ	O	www.nature.com/cpt	dep	169	SENT_152	[p14l1593t2307r2143b2360],
10	frequency	NN	O	frequency	dep	169	SENT_152	[p14l8t2712r359b2796],
11	of	IN	O	of	dep	169	SENT_152	[p14l379t2712r454b2775],
12	tumor	NN	O	tumor	dep	169	SENT_152	[p14l467t2724r685b2775],
13	responses	NNS	O	response	dep	169	SENT_152	[p14l708t2734r1044b2795],
14	achieved	VBN	O	achieve	dep	169	SENT_152	[p14l1069t2712r1373b2775],
15	with	IN	O	with	dep	169	SENT_152	[p14l1394t2712r1549b2775],
16	BRAF	NN	ORGANIZATION	braf	dep	169	SENT_152	[p14l1572t2716r1780b2775],
17	inhibitors	NNS	O	inhibitor	dep	169	SENT_152	[p14l1804t2712r2143b2775],
18	and	CC	O	and	dep	169	SENT_152	[p14l9t2815r136b2878],
19	enable	VB	O	enable	dep	169	SENT_152	[p14l158t2815r377b2878],
20	some	DT	O	some	dep	169	SENT_152	[p14l401t2838r579b2878],
21	of	IN	O	of	dep	169	SENT_152	[p14l602t2815r676b2878],
22	these	DT	O	these	dep	169	SENT_152	[p14l688t2815r864b2878],
23	responses	NNS	O	response	dep	169	SENT_152	[p14l887t2837r1219b2898],
24	to	TO	O	to	dep	169	SENT_152	[p14l1242t2827r1307b2878],
25	be	VB	O	be	dep	169	SENT_152	[p14l1330t2815r1409b2878],
26	sustained	VBN	O	sustain	dep	169	SENT_152	[p14l1433t2815r1755b2878],
27	off	IN	O	off	dep	169	SENT_152	[p14l1778t2815r1874b2878],
28	of	IN	O	of	dep	169	SENT_152	[p14l1888t2815r1962b2878],
29	therapy	NN	O	therapy	dep	169	SENT_152	[p14l1974t2815r2139b2878, p14l9t2909r203b3001],
30	.64	CD	NUMBER	.64	dep	169	SENT_152	[p14l1974t2815r2139b2878, p14l9t2909r203b3001],
31	Preclinical	JJ	O	preclinical	dep	169	SENT_152	[p14l227t2917r593b2980],
32	studies	NNS	O	study	dep	169	SENT_152	[p14l616t2917r853b2980],
33	have	VBP	O	have	dep	169	SENT_152	[p14l876t2917r1034b2980],
34	suggested	VBN	O	suggest	dep	169	SENT_152	[p14l1058t2917r1393b3001],
35	that	IN	O	that	dep	169	SENT_152	[p14l1414t2917r1550b2980],
36	BRAF	NN	O	braf	dep	169	SENT_152	[p14l1572t2921r1779b2980],
37	inhibitors	NNS	O	inhibitor	dep	169	SENT_152	[p14l1803t2917r2140b2980],
38	may	MD	O	may	dep	169	SENT_152	[p14l8t3043r151b3104],
39	enhance	VB	O	enhance	dep	169	SENT_152	[p14l168t3020r444b3083],
40	immune	JJ	O	immune	dep	169	SENT_152	[p14l463t3026r744b3083],
41	cell	NN	O	cell	dep	169	SENT_152	[p14l765t3020r875b3083],
42	function	NN	O	function	dep	169	SENT_152	[p14l894t3020r1179b3083],
43	and	CC	O	and	dep	169	SENT_152	[p14l1199t3020r1322b3083],
44	melanoma	NN	O	melanoma	dep	169	SENT_152	[p14l1340t3020r1693b3083],
45	antigen	NN	O	antigen	dep	169	SENT_152	[p14l1712t3026r1957b3104],
46	presentation	NN	O	presentation	dep	169	SENT_152	[p14l1976t3042r2140b3103, p14l9t3114r441b3185],
47	.65	CD	NUMBER	.65	dep	169	SENT_152	[p14l1976t3042r2140b3103, p14l9t3114r441b3185],
48	’66	CD	NUMBER	’66	dep	169	SENT_152	[p14l1976t3042r2140b3103, p14l9t3114r441b3185],
49	Moreover	RB	O	moreover	dep	169	SENT_152	[p14l460t3127r800b3194],
50	,	,	O	,	_	0	SENT_152	[p14l460t3127r800b3194],
51	subsequent	JJ	O	subsequent	dep	169	SENT_152	[p14l822t3122r1199b3205],
52	correlative	JJ	O	correlative	dep	169	SENT_152	[p14l1219t3122r1570b3185],
53	research	NN	O	research	dep	169	SENT_152	[p14l1591t3122r1869b3185],
54	showed	VBD	O	show	dep	169	SENT_152	[p14l1889t3122r2142b3185],
55	an	DT	O	a	dep	169	SENT_152	[p14l9t3248r88b3288],
56	increase	NN	O	increase	dep	169	SENT_152	[p14l109t3231r384b3288],
57	in	IN	O	in	dep	169	SENT_152	[p14l405t3231r471b3287],
58	melanoma	NN	O	melanoma	dep	169	SENT_152	[p14l491t3225r850b3288],
59	antigen	NN	O	antigen	dep	169	SENT_152	[p14l870t3231r1120b3309],
60	expression	NN	O	expression	dep	169	SENT_152	[p14l1141t3231r1499b3308],
61	and	CC	O	and	dep	169	SENT_152	[p14l1520t3225r1645b3288],
62	the	DT	O	the	dep	169	SENT_152	[p14l1664t3225r1769b3288],
63	number	NN	O	number	dep	169	SENT_152	[p14l1790t3225r2060b3288],
64	of	IN	O	of	dep	169	SENT_152	[p14l2079t3225r2153b3288],
65	tumor	NN	O	tumor	dep	169	SENT_152	[p14l8t3328r634b3412],
66	—	NN	O	—	dep	169	SENT_152	[p14l8t3328r634b3412],
67	inﬁltrating	VBG	O	inﬁltrating	dep	169	SENT_152	[p14l8t3328r634b3412],
68	lymphocytes	NNS	O	lymphocyte	dep	169	SENT_152	[p14l654t3328r1097b3412],
69	in	IN	O	in	dep	169	SENT_152	[p14l1121t3334r1188b3390],
70	tumor	NN	O	tumor	dep	169	SENT_152	[p14l1211t3340r1430b3391],
71	biopsies	NNS	O	biopsy	dep	169	SENT_152	[p14l1450t3328r1730b3411],
72	after	IN	O	after	dep	169	SENT_152	[p14l1755t3328r1910b3391],
73	BRAF	NN	O	braf	dep	169	SENT_152	[p14l1933t3332r2141b3391],
74	inhibitor	NN	O	inhibitor	dep	169	SENT_152	[p14l9t3431r327b3494],
75	therapy	NN	O	therapy	dep	169	SENT_152	[p14l352t3431r635b3515],
76	,	,	O	,	_	0	SENT_152	[p14l352t3431r635b3515],
77	which	WDT	O	which	dep	169	SENT_152	[p14l662t3431r880b3494],
78	was	VBD	O	be	dep	169	SENT_152	[p14l905t3454r1036b3494],
79	correlated	VBN	O	correlate	dep	169	SENT_152	[p14l1064t3431r1424b3494],
80	with	IN	O	with	dep	169	SENT_152	[p14l1449t3431r1608b3494],
81	a	DT	O	a	dep	169	SENT_152	[p14l1636t3454r1671b3494],
82	reduction	NN	O	reduction	dep	169	SENT_152	[p14l1697t3431r2044b3494],
83	in	IN	O	in	dep	169	SENT_152	[p14l2072t3437r2141b3493],
84	tumor	NN	O	tumor	dep	169	SENT_152	[p14l8t3545r223b3596],
85	size	NN	O	size	dep	169	SENT_152	[p14l244t3539r367b3596],
86	and	CC	O	and	dep	169	SENT_152	[p14l390t3533r516b3596],
87	an	DT	O	a	dep	169	SENT_152	[p14l538t3556r617b3596],
88	increase	NN	O	increase	dep	169	SENT_152	[p14l639t3539r916b3596],
89	in	IN	O	in	dep	169	SENT_152	[p14l939t3539r1005b3595],
90	necrosis	NN	O	necrosis	dep	169	SENT_152	[p14l1027t3525r1463b3596],
91	.67	CD	NUMBER	.67	dep	169	SENT_152	[p14l1027t3525r1463b3596],
92	’68	CD	NUMBER	’68	dep	169	SENT_152	[p14l1027t3525r1463b3596],
93	Given	VBN	O	give	dep	169	SENT_152	[p14l1487t3537r1689b3597],
94	the	DT	O	the	dep	169	SENT_152	[p14l1710t3533r1816b3596],
95	potential	JJ	O	potential	dep	169	SENT_152	[p14l1837t3533r2143b3616],
96	synergy	NN	O	synergy	dep	169	SENT_152	[p14l9t3659r285b3720],
97	,	,	O	,	_	0	SENT_152	[p14l9t3659r285b3720],
98	a	DT	O	a	dep	169	SENT_152	[p14l310t3659r344b3699],
99	phase	NN	O	phase	dep	169	SENT_152	[p14l364t3636r559b3719],
100	I	PRP	O	I	dep	169	SENT_152	[p14l582t3641r605b3698],
101	clinical	JJ	O	clinical	dep	169	SENT_152	[p14l630t3636r874b3699],
102	trial	NN	O	trial	dep	169	SENT_152	[p14l895t3636r1036b3699],
103	of	IN	O	of	dep	169	SENT_152	[p14l1058t3636r1132b3699],
104	concurrent	JJ	O	concurrent	dep	169	SENT_152	[p14l1145t3648r1523b3699],
105	administration	NN	O	administration	dep	169	SENT_152	[p14l1545t3636r2055b3699],
106	of	IN	O	of	dep	169	SENT_152	[p14l2077t3636r2151b3699],
107	vemurafenib	NN	O	vemurafenib	dep	169	SENT_152	[p14l6t3738r443b3801],
108	and	CC	O	and	dep	169	SENT_152	[p14l468t3738r595b3801],
109	ipilimumab	NN	O	ipilimumab	dep	169	SENT_152	[p14l617t3738r1017b3821],
110	was	VBD	O	be	dep	169	SENT_152	[p14l1040t3761r1166b3801],
111	conducted	VBN	O	conduct	dep	169	SENT_152	[p14l1191t3730r1635b3801],
112	.69	CD	NUMBER	.69	dep	169	SENT_152	[p14l1191t3730r1635b3801],
113	Dose-limiting	JJ	O	dose-limiting	dep	169	SENT_152	[p14l1658t3738r2144b3822],
114	toxicity	NN	O	toxicity	dep	169	SENT_152	[p15l8t26r270b104],
115	of	IN	O	of	dep	169	SENT_152	[p15l290t20r365b83],
116	grade	NN	O	grade	dep	169	SENT_152	[p15l378t20r570b104],
117	3	CD	NUMBER	3	dep	169	SENT_152	[p15l595t27r629b83],
118	elevations	NNS	O	elevation	dep	169	SENT_152	[p15l656t20r999b83],
119	in	IN	O	in	dep	169	SENT_152	[p15l1023t26r1091b82],
120	aminotransferase	NN	O	aminotransferase	dep	169	SENT_152	[p15l1115t20r1715b83],
121	occurred	VBD	O	occur	dep	169	SENT_152	[p15l1739t20r2051b83],
122	in	IN	O	in	dep	169	SENT_152	[p15l2074t26r2141b82],
123	four	CD	TIME	four	dep	169	SENT_152	[p15l8t123r151b186],
124	of	IN	TIME	of	dep	169	SENT_152	[p15l173t123r247b186],
125	six	CD	TIME	six	dep	169	SENT_152	[p15l260t129r353b186],
126	patients	NNS	O	patient	dep	169	SENT_152	[p15l372t129r640b206],
127	in	IN	O	in	dep	169	SENT_152	[p15l663t129r729b185],
128	the	DT	O	the	dep	169	SENT_152	[p15l750t123r856b186],
129	ﬁrst	NN	O	ﬁrst	dep	169	SENT_152	[p15l878t123r1011b186],
130	cohort	NN	O	cohort	dep	169	SENT_152	[p15l1032t123r1257b186],
131	who	WP	O	who	dep	169	SENT_152	[p15l1276t123r1422b186],
132	received	VBD	O	receive	dep	169	SENT_152	[p15l1446t123r1728b186],
133	both	DT	O	both	dep	169	SENT_152	[p15l1747t123r1906b186],
134	agents	NNS	O	agent	dep	169	SENT_152	[p15l1929t135r2141b207],
135	at	IN	O	at	dep	169	SENT_152	[p15l9t238r69b289],
136	the	DT	O	the	dep	169	SENT_152	[p15l90t226r196b289],
137	full	JJ	O	full	dep	169	SENT_152	[p15l219t226r333b289],
138	approved	JJ	O	approved	dep	169	SENT_152	[p15l356t226r675b309],
139	doses	NNS	O	dose	dep	169	SENT_152	[p15l697t226r883b289],
140	and	CC	O	and	dep	169	SENT_152	[p15l908t226r1034b289],
141	in	IN	O	in	dep	169	SENT_152	[p15l1056t232r1123b288],
142	two	CD	TIME	two	dep	169	SENT_152	[p15l1144t238r1270b289],
143	of	IN	TIME	of	dep	169	SENT_152	[p15l1295t226r1369b289],
144	six	CD	TIME	six	dep	169	SENT_152	[p15l1383t232r1476b289],
145	patients	NNS	O	patient	dep	169	SENT_152	[p15l1496t232r1766b309],
146	in	IN	O	in	dep	169	SENT_152	[p15l1790t232r1857b288],
147	the	DT	O	the	dep	169	SENT_152	[p15l1878t226r1985b289],
148	second	JJ	ORDINAL	second	dep	169	SENT_152	[p15l2009t249r2139b289, p15l9t329r141b392],
149	cohort	NN	O	cohort	dep	169	SENT_152	[p15l163t329r388b392],
150	who	WP	O	who	dep	169	SENT_152	[p15l408t329r554b392],
151	received	VBD	O	receive	dep	169	SENT_152	[p15l578t329r861b392],
152	a	DT	O	a	dep	169	SENT_152	[p15l884t352r918b392],
153	lower	JJR	O	lower	dep	169	SENT_152	[p15l938t329r1129b392],
154	dose	NN	O	dose	dep	169	SENT_152	[p15l1151t329r1305b392],
155	of	IN	O	of	dep	169	SENT_152	[p15l1328t329r1402b392],
156	vemurafenib	NN	O	vemurafenib	dep	169	SENT_152	[p15l1412t329r1846b392],
157	(	NN	O	(	dep	169	SENT_152	[p15l1873t330r2019b405],
158	720	CD	NUMBER	720	dep	169	SENT_152	[p15l1873t330r2019b405],
159	mg	NN	O	mg	dep	169	SENT_152	[p15l2035t352r2144b413],
160	twice	RB	O	twice	dep	169	SENT_152	[p15l8t438r182b495],
161	daily	RB	SET	daily	dep	169	SENT_152	[p15l203t432r387b516],
162	)	VBN	O	)	dep	169	SENT_152	[p15l203t432r387b516],
163	together	RB	O	together	dep	169	SENT_152	[p15l409t432r688b516],
164	with	IN	O	with	dep	169	SENT_152	[p15l705t432r854b495],
165	the	DT	O	the	dep	169	SENT_152	[p15l872t432r976b495],
166	full	JJ	O	full	dep	169	SENT_152	[p15l996t432r1106b495],
167	dose	NN	O	dose	dep	169	SENT_152	[p15l1126t432r1276b495],
168	of	IN	O	of	dep	169	SENT_152	[p15l1297t432r1369b495],
169	ipilimumab	NN	O	ipilimumab	_	0	SENT_152	[p15l1379t432r1780b515],
170	.	.	O	.	_	0	SENT_152	[p15l1379t432r1780b515],

1	Given	VBN	O	give	prep	11	SENT_153	[p15l1804t436r2001b495],
2	this	DT	O	this	det	3	SENT_153	[p15l2020t432r2141b495],
3	degree	NN	O	degree	dep	1	SENT_153	[p15l9t535r232b619],
4	of	IN	O	of	_	0	SENT_153	[p15l253t535r326b598],
5	liver	NN	O	liver	nn	6	SENT_153	[p15l336t535r486b598],
6	toxicities	NNS	O	toxicity	prep_of	3	SENT_153	[p15l505t541r828b607],
7	,	,	O	,	_	0	SENT_153	[p15l505t541r828b607],
8	the	DT	O	the	det	9	SENT_153	[p15l850t535r955b598],
9	study	NN	O	study	nsubjpass	11	SENT_153	[p15l977t535r1162b619],
10	was	VBD	O	be	auxpass	11	SENT_153	[p15l1177t558r1303b598],
11	closed	VBN	O	close	_	0	SENT_153	[p15l1324t535r1537b598],
12	to	TO	O	to	_	0	SENT_153	[p15l1556t547r1621b598],
13	further	JJ	O	further	amod	15	SENT_153	[p15l1643t535r1886b598],
14	patient	NN	O	patient	nn	15	SENT_153	[p15l1904t541r2142b618],
15	accrual	NN	O	accrual	prep_to	11	SENT_153	[p15l9t638r285b701],
16	.	.	O	.	_	0	SENT_153	[p15l9t638r285b701],

1	To	TO	O	to	aux	2	SENT_154	[p15l317t641r403b701],
2	inform	VB	O	inform	purpcl	21	SENT_154	[p15l433t638r682b701],
3	the	DT	O	the	det	4	SENT_154	[p15l708t638r819b701],
4	design	NN	O	design	dobj	2	SENT_154	[p15l848t638r1080b722],
5	and	CC	O	and	_	0	SENT_154	[p15l1109t638r1240b701],
6	schedule	NN	O	schedule	dobj	2	SENT_154	[p15l1267t638r1578b701],
7	used	VBN	O	use	partmod	4	SENT_154	[p15l1606t638r1772b701],
8	for	IN	O	for	_	0	SENT_154	[p15l1798t638r1900b701],
9	future	JJ	DATE	future	amod	12	SENT_154	[p15l1927t638r2143b701],
10	combined	JJ	O	combined	amod	12	SENT_154	[p15l9t741r359b804],
11	BRAF	NN	ORGANIZATION	braf	nn	12	SENT_154	[p15l382t745r591b804],
12	inhibitor	NN	O	inhibitor	prep_for	7	SENT_154	[p15l616t741r927b804],
13	and	CC	O	and	_	0	SENT_154	[p15l950t741r1079b804],
14	immunotherapy	NN	O	immunotherapy	nn	15	SENT_154	[p15l1102t741r1675b825],
15	regimens	NNS	O	regimen	conj_and	12	SENT_154	[p15l1695t747r2035b825],
16	,	,	O	,	_	0	SENT_154	[p15l1695t747r2035b825],
17	an	DT	O	a	det	19	SENT_154	[p15l2061t764r2143b804],
18	ongoing	JJ	O	ongoing	amod	19	SENT_154	[p15l9t851r287b929],
19	study	NN	O	study	nsubj	46	SENT_154	[p15l307t845r492b929],
20	is	VBZ	O	be	aux	21	SENT_154	[p15l509t851r559b908],
21	examining	VBG	O	examine	_	0	SENT_154	[p15l580t851r942b929],
22	serial	JJ	O	serial	amod	24	SENT_154	[p15l961t845r1141b908],
23	tumor	NN	O	tumor	nn	24	SENT_154	[p15l1160t857r1374b908],
24	biopsies	NNS	O	biopsy	dobj	21	SENT_154	[p15l1392t845r1665b928],
25	from	IN	O	from	_	0	SENT_154	[p15l1686t845r1853b908],
26	patients	NNS	O	patient	prep_from	21	SENT_154	[p15l1872t851r2140b928],
27	receiving	VBG	O	receive	partmod	26	SENT_154	[p15l9t954r326b1032],
28	vemurafenib	NN	O	vemurafenib	dobj	27	SENT_154	[p15l345t948r787b1011],
29	in	IN	O	in	mark	32	SENT_154	[p15l811t954r879b1010],
30	order	NN	O	order	dep	32	SENT_154	[p15l903t948r1091b1011],
31	to	TO	O	to	aux	32	SENT_154	[p15l1112t960r1179b1011],
32	assess	VB	O	assess	purpcl	27	SENT_154	[p15l1204t971r1403b1011],
33	the	DT	O	the	det	34	SENT_154	[p15l1426t948r1534b1011],
34	mechanisms	NNS	O	mechanism	dobj	32	SENT_154	[p15l1558t948r1991b1011],
35	and	CC	O	and	_	0	SENT_154	[p15l2016t948r2144b1011],
36	kinetics	NNS	O	kinetics	dobj	32	SENT_154	[p15l7t1050r265b1113],
37	of	IN	O	of	_	0	SENT_154	[p15l286t1050r358b1113],
38	T	NN	O	t	nn	41	SENT_154	[p15l368t1050r556b1113],
39	—	NN	O	—	nn	41	SENT_154	[p15l368t1050r556b1113],
40	cell	NN	O	cell	nn	41	SENT_154	[p15l368t1050r556b1113],
41	accumulation	NN	O	accumulation	prep_of	34	SENT_154	[p15l575t1050r1030b1113],
42	within	IN	O	within	_	0	SENT_154	[p15l1048t1050r1265b1113],
43	the	DT	O	the	det	44	SENT_154	[p15l1283t1050r1387b1113],
44	tumors	NNS	O	tumor	prep_within	32	SENT_154	[p15l1405t1062r1644b1113],
45	and	CC	O	and	_	0	SENT_154	[p15l1665t1050r1788b1113],
46	characterize	VBP	O	characterize	conj_and	21	SENT_154	[p15l1807t1050r2139b1113, p15l9t1159r101b1216],

1	the	DT	O	the	det	2	SENT_155	[p15l123t1153r229b1216],
2	speciﬁcity	NN	O	speciﬁcity	nsubj	10	SENT_155	[p15l253t1153r597b1237],
3	and	CC	O	and	_	0	SENT_155	[p15l617t1153r743b1216],
4	function	NN	O	function	nsubj	10	SENT_155	[p15l765t1153r1057b1216],
5	of	IN	O	of	_	0	SENT_155	[p15l1081t1153r1154b1216],
6	the	DT	O	the	det	9	SENT_155	[p15l1166t1153r1272b1216],
7	immune	JJ	O	immune	amod	9	SENT_155	[p15l1296t1159r1584b1216],
8	inﬁltrating	NN	O	inﬁltrating	nn	9	SENT_155	[p15l1607t1153r1975b1237],
9	cells	NNS	O	cell	prep_of	2	SENT_155	[p15l1997t1153r2140b1216],
10	(	VBP	O	(	_	0	SENT_155	[p15l12t1256r515b1333],
11	ClinicalTrials	NNS	O	clinicaltrial	dobj	10	SENT_155	[p15l12t1256r515b1333],
12	.	.	O	.	_	0	SENT_155	[p15l12t1256r515b1333],

1	gov	NN	O	gov	nn	2	SENT_156	[p15l522t1279r644b1340],
2	identiﬁer	NN	O	identiﬁer	_	0	SENT_156	[p15l662t1256r993b1319],
3	:	:	O	:	_	0	SENT_156	[p15l662t1256r993b1319],
4	NCTO1813214	NN	O	ncto1813214	nn	5	SENT_156	[p15l1017t1257r1566b1333],
5	)	NN	O	)	dep	2	SENT_156	[p15l1017t1257r1566b1333],
6	.	.	O	.	_	0	SENT_156	[p15l1017t1257r1566b1333],

1	Combinations	NNS	O	combination	nsubj	12	SENT_157	[p15l9t1469r493b1526],
2	with	IN	O	with	_	0	SENT_157	[p15l510t1469r660b1526],
3	other	JJ	O	other	prep_with	1	SENT_157	[p15l680t1469r868b1526],
4	targeted	VBN	O	target	partmod	3	SENT_157	[p15l883t1469r1182b1542],
5	agents	NNS	O	agent	nn	6	SENT_157	[p15l1200t1475r1434b1542],
6	Resistance	NN	O	resistance	dobj	4	SENT_157	[p15l9t1571r372b1629],
7	to	TO	O	to	_	0	SENT_157	[p15l395t1578r461b1629],
8	BRAF	NN	O	braf	nn	9	SENT_157	[p15l487t1570r694b1629],
9	inhibitors	NNS	O	inhibitor	prep_to	4	SENT_157	[p15l719t1566r1058b1629],
10	can	MD	O	can	aux	12	SENT_157	[p15l1083t1589r1201b1629],
11	also	RB	O	also	advmod	12	SENT_157	[p15l1226t1566r1359b1629],
12	occur	VB	O	occur	_	0	SENT_157	[p15l1384t1589r1581b1629],
13	through	IN	O	through	_	0	SENT_157	[p15l1602t1566r1885b1650],
14	activation	NN	O	activation	prep_through	12	SENT_157	[p15l1908t1572r2138b1629, p15l8t1675r145b1732],
15	of	IN	O	of	_	0	SENT_157	[p15l169t1669r243b1732],
16	non-MAPK	JJ	O	non-mapk	amod	18	SENT_157	[p15l256t1673r666b1732],
17	survival	NN	O	survival	nn	18	SENT_157	[p15l688t1669r960b1732],
18	pathways	NNS	O	pathway	prep_of	14	SENT_157	[p15l981t1669r1317b1753],
19	.	.	O	.	_	0	SENT_157	[p15l981t1669r1317b1753],

1	For	IN	O	for	_	0	SENT_158	[p15l1343t1674r1460b1732],
2	example	NN	O	example	prep_for	7	SENT_158	[p15l1482t1669r1783b1752],
3	,	,	O	,	_	0	SENT_158	[p15l1482t1669r1783b1752],
4	resistance	NN	O	resistance	nsubjpass	7	SENT_158	[p15l1808t1675r2143b1732],
5	has	VBZ	O	have	aux	7	SENT_158	[p15l8t1772r120b1835],
6	been	VBN	O	be	auxpass	7	SENT_158	[p15l141t1772r306b1835],
7	shown	VBN	O	show	_	0	SENT_158	[p15l329t1772r552b1835],
8	to	TO	O	to	aux	10	SENT_158	[p15l574t1784r640b1835],
9	be	VB	O	be	auxpass	10	SENT_158	[p15l662t1772r741b1835],
10	mediated	VBN	O	mediate	xcomp	7	SENT_158	[p15l764t1772r1084b1835],
11	by	IN	O	by	_	0	SENT_158	[p15l1104t1772r1188b1856],
12	the	DT	O	the	det	13	SENT_158	[p15l1206t1772r1313b1835],
13	overexpression	NN	O	overexpression	agent	10	SENT_158	[p15l1337t1778r1850b1855],
14	or	CC	O	or	_	0	SENT_158	[p15l1873t1795r1945b1835],
15	overactivation	NN	O	overactivation	agent	10	SENT_158	[p15l1967t1795r2139b1835, p15l9t1881r357b1938],
16	of	IN	O	of	_	0	SENT_158	[p15l382t1875r458b1938],
17	platelet-derived	JJ	O	platelet-derived	amod	21	SENT_158	[p15l471t1875r1028b1958],
18	growth	NN	O	growth	nn	21	SENT_158	[p15l1052t1875r1302b1959],
19	factor	NN	O	factor	nn	21	SENT_158	[p15l1326t1875r1532b1938],
20	receptor	NN	O	receptor	nn	21	SENT_158	[p15l1555t1887r1848b1958],
21	[	NN	O	[	prep_of	13	SENT_158	[p15l1875t1875r1911b1959],
22	3	CD	NUMBER	3	dep	21	SENT_158	[p15l1875t1875r1911b1959],
23	or	CC	O	or	_	0	SENT_158	[p15l1937t1898r2011b1938],
24	the	DT	O	the	det	27	SENT_158	[p15l2033t1875r2143b1938],
25	insulin-like	JJ	O	insulin-like	amod	27	SENT_158	[p15l9t1978r399b2041],
26	growth	NN	O	growth	nn	27	SENT_158	[p15l420t1978r663b2062],
27	factor	NN	O	factor	conj_or	21	SENT_158	[p15l684t1978r883b2041],
28	1	CD	NUMBER	1	num	29	SENT_158	[p15l910t1985r935b2040],
29	receptor	NN	O	receptor	dep	27	SENT_158	[p15l963t1990r1257b2061],
30	,	,	O	,	_	0	SENT_158	[p15l963t1990r1257b2061],
31	which	WDT	O	which	nsubj	32	SENT_158	[p15l1279t1978r1488b2041],
32	induces	VBZ	O	induce	rcmod	13	SENT_158	[p15l1509t1978r1770b2041],
33	oncogenic	JJ	O	oncogenic	amod	34	SENT_158	[p15l1792t1984r2142b2062],
34	signaling	NN	O	signaling	dobj	32	SENT_158	[p15l9t2080r320b2164],
35	through	IN	O	through	_	0	SENT_158	[p15l341t2080r619b2164],
36	the	DT	O	the	det	40	SENT_158	[p15l640t2080r747b2143],
37	PI3K-Akt	NN	O	pi3k-akt	nn	40	SENT_158	[p15l771t2080r1371b2143],
38	—	CD	NUMBER	—	num	40	SENT_158	[p15l771t2080r1371b2143],
39	mTOR	NN	O	mtor	nn	40	SENT_158	[p15l771t2080r1371b2143],
40	pathway	NN	O	pathway	prep_through	32	SENT_158	[p15l1390t2072r1826b2164],
41	.7	CD	NUMBER	.7	number	42	SENT_158	[p15l1390t2072r1826b2164],
42	°	CD	NUMBER	°	nsubjpass	49	SENT_158	[p15l1390t2072r1826b2164],
43	*	NN	O	*	dep	42	SENT_158	[p15l1390t2072r1826b2164],
44	71	CD	NUMBER	71	num	43	SENT_158	[p15l1390t2072r1826b2164],
45	This	DT	O	this	det	46	SENT_158	[p15l1853t2080r1996b2143],
46	signaling	NN	O	signaling	dep	42	SENT_158	[p15l2020t2086r2139b2164, p15l8t2183r221b2267],
47	can	MD	O	can	aux	49	SENT_158	[p15l240t2206r356b2246],
48	be	VB	O	be	auxpass	49	SENT_158	[p15l374t2183r452b2246],
49	inhibited	VBN	O	inhibit	rcmod	40	SENT_158	[p15l472t2183r779b2246],
50	by	IN	O	by	_	0	SENT_158	[p15l797t2183r879b2267],
51	drugs	NNS	O	drug	agent	49	SENT_158	[p15l896t2183r1086b2267],
52	targeting	VBG	O	target	partmod	51	SENT_158	[p15l1106t2189r1410b2267],
53	PI3K	NN	O	pi3k	dobj	52	SENT_158	[p15l1429t2188r1617b2255],
54	,	,	O	,	_	0	SENT_158	[p15l1429t2188r1617b2255],
55	Akt	NN	O	akt	conj_or	53	SENT_158	[p15l1638t2183r1780b2255],
56	,	,	O	,	_	0	SENT_158	[p15l1638t2183r1780b2255],
57	or	CC	O	or	_	0	SENT_158	[p15l1802t2206r1873b2246],
58	mTOR	NN	O	mtor	conj_or	53	SENT_158	[p15l1892t2186r2138b2246],
59	.	.	O	.	_	0	SENT_158	[p15l1892t2186r2138b2246],

1	Clinical	JJ	O	clinical	amod	2	SENT_159	[p15l10t2286r277b2349],
2	trials	NNS	O	trial	nsubj	15	SENT_159	[p15l298t2286r470b2349],
3	of	IN	O	of	_	0	SENT_159	[p15l494t2286r568b2349],
4	combinations	NNS	O	combination	prep_of	2	SENT_159	[p15l582t2286r1049b2349],
5	of	IN	O	of	_	0	SENT_159	[p15l1073t2286r1147b2349],
6	agents	NNS	O	agent	prep_of	4	SENT_159	[p15l1161t2298r1375b2370],
7	that	WDT	O	that	nsubj	8	SENT_159	[p15l1397t2286r1531b2349],
8	block	VBP	O	block	rcmod	6	SENT_159	[p15l1551t2286r1742b2349],
9	these	DT	O	these	det	10	SENT_159	[p15l1761t2286r1937b2349],
10	pathways	NNS	O	pathway	dobj	8	SENT_159	[p15l1959t2286r2140b2369, p15l7t2412r172b2473],
11	with	IN	O	with	_	0	SENT_159	[p15l194t2389r347b2452],
12	a	DT	O	a	det	14	SENT_159	[p15l371t2412r405b2452],
13	BRAF	NN	O	braf	nn	14	SENT_159	[p15l428t2393r633b2452],
14	inhibitor	NN	O	inhibitor	prep_with	8	SENT_159	[p15l657t2389r962b2452],
15	are	VBP	O	be	_	0	SENT_159	[p15l985t2412r1085b2452],
16	under	IN	O	under	_	0	SENT_159	[p15l1108t2389r1314b2452],
17	way	NN	O	way	prep_under	15	SENT_159	[p15l1334t2412r1478b2473],
18	.	.	O	.	_	0	SENT_159	[p15l1334t2412r1478b2473],

1	(	NN	O	(	nn	2	SENT_160	[p15l1508t2389r2145b2473],
2	ClinicalTrials	NNS	O	clinicaltrial	_	0	SENT_160	[p15l1508t2389r2145b2473],
3	.	.	O	.	_	0	SENT_160	[p15l1508t2389r2145b2473],

1	gov	NN	O	gov	nn	2	SENT_161	[p15l1508t2389r2145b2473],
2	identiﬁers	NNS	O	identiﬁers	_	0	SENT_161	[p15l9t2491r368b2555],
3	:	:	O	:	_	0	SENT_161	[p15l9t2491r368b2555],
4	NCT01616199	NN	O	nct01616199	dep	2	SENT_161	[p15l391t2494r911b2563],
5	,	,	O	,	_	0	SENT_161	[p15l391t2494r911b2563],
6	NCTO1820364	NN	O	ncto1820364	dep	2	SENT_161	[p15l933t2494r1453b2563],
7	,	,	O	,	_	0	SENT_161	[p15l933t2494r1453b2563],
8	NCT01155453	NN	O	nct01155453	dep	2	SENT_161	[p15l1475t2494r1995b2563],
9	,	,	O	,	_	0	SENT_161	[p15l1475t2494r1995b2563],
10	and	CC	O	and	_	0	SENT_161	[p15l2018t2491r2144b2555],
11	NCT01512251	NN	O	nct01512251	conj_and	4	SENT_161	[p15l8t2596r557b2672],
12	)	NN	O	)	dep	4	SENT_161	[p15l8t2596r557b2672],
13	.	.	O	.	_	0	SENT_161	[p15l8t2596r557b2672],

1	Melanomas	NNS	O	melanoma	nsubj	5	SENT_162	[p15l81t2698r479b2761],
2	are	VBP	O	be	cop	5	SENT_162	[p15l504t2721r604b2761],
3	highly	RB	O	highly	advmod	4	SENT_162	[p15l626t2698r845b2782],
4	vascular	JJ	O	vascular	amod	5	SENT_162	[p15l862t2698r1148b2761],
5	tumors	NNS	O	tumor	_	0	SENT_162	[p15l1169t2710r1414b2761],
6	that	WDT	O	that	nsubj	8	SENT_162	[p15l1437t2698r1571b2761],
7	frequently	RB	O	frequently	advmod	8	SENT_162	[p15l1592t2698r1948b2782],
8	overexpress	VBP	O	overexpress	rcmod	5	SENT_162	[p15l1967t2721r2139b2761, p15l9t2823r265b2884],
9	angiogenic	JJ	O	angiogenic	amod	10	SENT_162	[p15l292t2807r677b2885],
10	factors	NNS	O	factor	dobj	8	SENT_162	[p15l701t2801r957b2864],
11	.	.	O	.	_	0	SENT_162	[p15l701t2801r957b2864],

1	Moreover	RB	O	moreover	advmod	5	SENT_163	[p15l985t2806r1343b2873],
2	,	,	O	,	_	0	SENT_163	[p15l985t2806r1343b2873],
3	data	NNS	O	datum	nsubj	5	SENT_163	[p15l1371t2801r1519b2864],
4	collected	VBN	O	collect	partmod	3	SENT_163	[p15l1544t2801r1859b2864],
5	suggest	VBP	O	suggest	_	0	SENT_163	[p15l1884t2813r2142b2885],
6	that	IN	O	that	complm	13	SENT_163	[p15l8t2904r148b2967],
7	that	DT	O	that	det	8	SENT_163	[p15l176t2904r317b2967],
8	restoration	NN	O	restoration	nsubjpass	13	SENT_163	[p15l345t2910r740b2967],
9	of	IN	O	of	_	0	SENT_163	[p15l771t2904r847b2967],
10	MAPK	NN	O	mapk	nn	11	SENT_163	[p15l866t2908r1117b2966],
11	signaling	NN	O	signaling	prep_of	8	SENT_163	[p15l1145t2904r1474b2988],
12	is	VBZ	O	be	auxpass	13	SENT_163	[p15l1502t2910r1555b2967],
13	associated	VBN	O	associate	ccomp	5	SENT_163	[p15l1585t2904r1954b2967],
14	with	IN	O	with	_	0	SENT_163	[p15l1980t2904r2141b2967],
15	increased	VBN	O	increase	amod	16	SENT_163	[p15l9t3006r339b3069],
16	VEGF	NN	O	vegf	prep_with	13	SENT_163	[p15l360t3010r577b3069],
17	production	NN	O	production	nsubj	23	SENT_163	[p15l601t2998r1075b3089],
18	.72	CD	NUMBER	.72	num	17	SENT_163	[p15l601t2998r1075b3089],
19	Consequently	RB	O	consequently	advmod	23	SENT_163	[p15l1101t3006r1593b3090],
20	,	,	O	,	_	0	SENT_163	[p15l1101t3006r1593b3090],
21	it	PRP	O	it	nsubj	23	SENT_163	[p15l1619t3012r1665b3069],
22	is	VBZ	O	be	cop	23	SENT_163	[p15l1687t3012r1738b3069],
23	worth	JJ	O	worth	rcmod	16	SENT_163	[p15l1760t3006r1969b3069],
24	testing	NN	O	testing	dep	41	SENT_163	[p15l1991t3018r2139b3069, p15l9t3115r116b3193],
25	if	IN	O	if	dep	41	SENT_163	[p15l136t3109r190b3171],
26	the	DT	O	the	det	27	SENT_163	[p15l201t3109r307b3172],
27	addition	NN	O	addition	nsubj	41	SENT_163	[p15l329t3109r616b3172],
28	of	IN	O	of	_	0	SENT_163	[p15l637t3109r711b3172],
29	anti-VEGF	JJ	O	anti-vegf	amod	30	SENT_163	[p15l723t3113r1098b3172],
30	therapy	NN	O	therapy	prep_of	27	SENT_163	[p15l1119t3109r1389b3193],
31	,	,	O	,	_	0	SENT_163	[p15l1119t3109r1389b3193],
32	such	JJ	O	such	_	0	SENT_163	[p15l1413t3109r1567b3172],
33	as	IN	O	as	_	0	SENT_163	[p15l1589t3132r1653b3172],
34	bevacizumab	NN	O	bevacizumab	prep_such_as	30	SENT_163	[p15l1673t3109r2140b3181],
35	,	,	O	,	_	0	SENT_163	[p15l1673t3109r2140b3181],
36	to	TO	O	to	_	0	SENT_163	[p15l8t3224r73b3275],
37	a	DT	O	a	det	39	SENT_163	[p15l98t3235r132b3275],
38	BRAF	NN	O	braf	nn	39	SENT_163	[p15l153t3216r358b3275],
39	inhibitor	NN	O	inhibitor	prep_to	30	SENT_163	[p15l381t3212r684b3275],
40	might	MD	O	might	aux	41	SENT_163	[p15l705t3212r908b3296],
41	delay	VB	O	delay	ccomp	23	SENT_163	[p15l930t3212r1109b3296],
42	the	DT	O	the	det	43	SENT_163	[p15l1127t3212r1233b3275],
43	onset	NN	O	onset	dobj	41	SENT_163	[p15l1256t3224r1438b3275],
44	of	IN	O	of	_	0	SENT_163	[p15l1459t3212r1533b3275],
45	resistance	NN	O	resistance	prep_of	43	SENT_163	[p15l1546t3218r1895b3275],
46	.	.	O	.	_	0	SENT_163	[p15l1546t3218r1895b3275],

1	A	DT	O	a	det	3	SENT_164	[p15l1920t3216r1977b3274],
2	randomized	JJ	O	randomized	amod	3	SENT_164	[p15l1999t3235r2139b3275, p15l9t3315r316b3378],
3	phase	NN	O	phase	nsubj	16	SENT_164	[p15l339t3315r539b3398],
4	II	CD	NUMBER	ii	num	5	SENT_164	[p15l564t3320r619b3377],
5	trial	NN	O	trial	dep	3	SENT_164	[p15l643t3315r789b3378],
6	comparing	VBG	O	compare	partmod	3	SENT_164	[p15l814t3321r1197b3399],
7	the	DT	O	the	det	8	SENT_164	[p15l1219t3315r1328b3378],
8	combination	NN	O	combination	dobj	6	SENT_164	[p15l1353t3315r1802b3378],
9	of	IN	O	of	_	0	SENT_164	[p15l1827t3315r1902b3378],
10	vemurafenib	NN	O	vemurafenib	prep_of	8	SENT_164	[p15l1914t3338r2138b3378, p15l9t3418r248b3481],
11	and	CC	O	and	_	0	SENT_164	[p15l271t3418r397b3481],
12	bevacizumab	NN	O	bevacizumab	conj_and	10	SENT_164	[p15l415t3418r865b3481],
13	with	IN	O	with	_	0	SENT_164	[p15l885t3418r1038b3481],
14	vemurafenib	NN	O	vemurafenib	prep_with	6	SENT_164	[p15l1056t3418r1489b3481],
15	alone	RB	O	alone	advmod	16	SENT_164	[p15l1512t3418r1694b3481],
16	is	VBZ	O	be	_	0	SENT_164	[p15l1715t3424r1765b3481],
17	under	IN	O	under	_	0	SENT_164	[p15l1787t3418r1991b3481],
18	way	NN	O	way	nn	20	SENT_164	[p15l2009t3441r2146b3502],
19	(	CD	NUMBER	(	num	20	SENT_164	[p15l12t3521r515b3598],
20	ClinicalTrials	NNS	O	clinicaltrial	prep_under	16	SENT_164	[p15l12t3521r515b3598],
21	.	.	O	.	_	0	SENT_164	[p15l12t3521r515b3598],

1	gov	NN	O	gov	nn	2	SENT_165	[p15l522t3544r644b3605],
2	identiﬁer	NN	O	identiﬁer	_	0	SENT_165	[p15l662t3521r993b3584],
3	:	:	O	:	_	0	SENT_165	[p15l662t3521r993b3584],
4	01495988	CD	NUMBER	01495988	num	5	SENT_165	[p15l1018t3522r1392b3597],
5	)	NN	O	)	dep	2	SENT_165	[p15l1018t3522r1392b3597],
6	.	.	O	.	_	0	SENT_165	[p15l1018t3522r1392b3597],

1	Finally	RB	O	finally	advmod	24	SENT_166	[p15l83t3624r327b3708],
2	,	,	O	,	_	0	SENT_166	[p15l83t3624r327b3708],
3	deregulation	NN	O	deregulation	nsubjpass	24	SENT_166	[p15l350t3624r781b3708],
4	of	IN	O	of	_	0	SENT_166	[p15l802t3624r875b3687],
5	cell	NN	O	cell	nn	7	SENT_166	[p15l887t3624r1000b3687],
6	cycle	NN	O	cycle	nn	7	SENT_166	[p15l1021t3624r1187b3708],
7	checkpoints	NNS	O	checkpoint	prep_of	3	SENT_166	[p15l1209t3624r1635b3707],
8	,	,	O	,	_	0	SENT_166	[p15l1209t3624r1635b3707],
9	such	JJ	O	such	_	0	SENT_166	[p15l1658t3624r1812b3687],
10	as	IN	O	as	_	0	SENT_166	[p15l1834t3647r1897b3687],
11	upregulation	NN	O	upregulation	prep_such_as	3	SENT_166	[p15l1919t3646r2140b3708, p15l8t3727r261b3790],
12	of	IN	O	of	_	0	SENT_166	[p15l289t3727r366b3790],
13	cyclin	NN	O	cyclin	nn	14	SENT_166	[p15l384t3727r1012b3811],
14	—	NN	O	—	prep_of	11	SENT_166	[p15l384t3727r1012b3811],
15	dependent	JJ	O	dependent	amod	16	SENT_166	[p15l384t3727r1012b3811],
16	kinase	NN	O	kinase	dep	14	SENT_166	[p15l1036t3727r1264b3790],
17	4	CD	NUMBER	4	number	18	SENT_166	[p15l1290t3734r1329b3789],
18	(	CD	NUMBER	(	num	20	SENT_166	[p15l1360t3727r1663b3804],
19	CDK4	NN	O	cdk4	nn	20	SENT_166	[p15l1360t3727r1663b3804],
20	)	NN	O	)	dep	16	SENT_166	[p15l1360t3727r1663b3804],
21	,	,	O	,	_	0	SENT_166	[p15l1360t3727r1663b3804],
22	is	VBZ	O	be	auxpass	24	SENT_166	[p15l1692t3733r1744b3790],
23	frequently	RB	O	frequently	advmod	24	SENT_166	[p15l1772t3727r2143b3811],
24	found	VBN	O	find	_	0	SENT_166	[p16l8t16r219b79],
25	in	IN	O	in	_	0	SENT_166	[p16l243t22r312b78],
26	both	CC	O	both	preconj	27	SENT_166	[p16l335t16r499b79],
27	familial	JJ	O	familial	amod	30	SENT_166	[p16l524t16r794b79],
28	and	CC	O	and	_	0	SENT_166	[p16l819t16r949b79],
29	sporadic	JJ	O	sporadic	conj_and	27	SENT_166	[p16l974t16r1276b99],
30	melanoma	NN	O	melanoma	prep_in	24	SENT_166	[p16l1301t16r1675b79],
31	as	IN	O	as	_	0	SENT_166	[p16l1700t39r1766b79],
32	a	DT	O	a	det	33	SENT_166	[p16l1793t39r1828b79],
33	result	NN	O	result	prep_as	30	SENT_166	[p16l1852t16r2049b79],
34	of	IN	O	of	_	0	SENT_166	[p16l2074t16r2150b79],
35	CDKNZAP16	NN	O	cdknzap16	nn	36	SENT_166	[p16l10t110r439b181],
36	deletions	NNS	O	deletion	prep_of	33	SENT_166	[p16l460t118r783b190],
37	,	,	O	,	_	0	SENT_166	[p16l460t118r783b190],
38	mutations	NNS	O	mutation	conj_or	36	SENT_166	[p16l805t124r1165b190],
39	,	,	O	,	_	0	SENT_166	[p16l805t124r1165b190],
40	or	CC	O	or	_	0	SENT_166	[p16l1188t141r1260b181],
41	silencing	NN	O	silencing	conj_or	36	SENT_166	[p16l1280t110r1661b202],
42	.73	CD	NUMBER	.73	num	41	SENT_166	[p16l1280t110r1661b202],
43	Furthermore	RB	O	furthermore	advmod	24	SENT_166	[p16l1684t118r2140b190],
44	,	,	O	,	_	0	SENT_166	[p16l1684t118r2140b190],
45	several	JJ	O	several	amod	46	SENT_166	[p16l10t221r252b284],
46	pathways	NNS	O	pathway	dobj	24	SENT_166	[p16l275t221r602b305],
47	that	WDT	O	that	nsubj	48	SENT_166	[p16l627t221r765b284],
48	confer	VBP	O	confer	rcmod	46	SENT_166	[p16l789t221r1013b284],
49	BRAF	NN	ORGANIZATION	braf	nn	51	SENT_166	[p16l1038t225r1248b284],
50	inhibitor	NN	O	inhibitor	nn	51	SENT_166	[p16l1274t221r1588b284],
51	resistance	NN	O	resistance	nsubj	52	SENT_166	[p16l1612t227r1957b284],
52	converge	VBP	O	converge	ccomp	48	SENT_166	[p16l1983t244r2138b284, p16l6t347r189b408],
53	on	IN	O	on	_	0	SENT_166	[p16l212t347r298b387],
54	activation	NN	O	activation	prep_on	52	SENT_166	[p16l322t330r659b387],
55	of	IN	O	of	_	0	SENT_166	[p16l683t324r757b387],
56	the	DT	O	the	det	61	SENT_166	[p16l769t324r875b387],
57	CDK4	NN	O	cdk4	nn	61	SENT_166	[p16l899t324r1365b408],
58	—	NN	O	—	nn	61	SENT_166	[p16l899t324r1365b408],
59	cyclin	NN	O	cyclin	nn	61	SENT_166	[p16l899t324r1365b408],
60	D	NN	O	d	nn	61	SENT_166	[p16l1389t329r1446b386],
61	complex	NN	O	complex	prep_of	54	SENT_166	[p16l1472t324r1779b407],
62	,	,	O	,	_	0	SENT_166	[p16l1472t324r1779b407],
63	leading	VBG	O	lead	xcomp	52	SENT_166	[p16l1802t324r2055b408],
64	to	TO	O	to	_	0	SENT_166	[p16l2075t336r2140b387],
65	malignant	JJ	O	malignant	amod	66	SENT_166	[p16l8t427r361b511],
66	proliferation	NN	O	proliferation	prep_to	63	SENT_166	[p16l381t427r835b510],
67	.	.	O	.	_	0	SENT_166	[p16l381t427r835b510],

1	Pharmacological	JJ	O	pharmacological	amod	2	SENT_167	[p16l862t427r1445b511],
2	inhibition	NN	O	inhibition	nsubjpass	7	SENT_167	[p16l1467t427r1812b490],
3	of	IN	O	of	_	0	SENT_167	[p16l1836t427r1911b490],
4	CDK4	NN	O	cdk4	prep_of	2	SENT_167	[p16l1925t431r2142b490],
5	is	VBZ	O	be	aux	7	SENT_167	[p16l9t536r60b593],
6	being	VBG	O	be	auxpass	7	SENT_167	[p16l83t530r280b614],
7	explored	VBN	O	explore	_	0	SENT_167	[p16l302t530r609b613],
8	as	IN	O	as	_	0	SENT_167	[p16l633t553r699b593],
9	a	DT	O	a	det	12	SENT_167	[p16l724t553r759b593],
10	potential	JJ	O	potential	amod	12	SENT_167	[p16l781t530r1096b613],
11	therapeutic	JJ	O	therapeutic	amod	12	SENT_167	[p16l1118t530r1520b613],
12	strategy	NN	O	strategy	prep_as	7	SENT_167	[p16l1545t542r1823b614],
13	in	IN	O	in	_	0	SENT_167	[p16l1843t536r1912b592],
14	metastatic	JJ	O	metastatic	amod	15	SENT_167	[p16l1935t542r2137b593, p16l9t639r186b696],
15	melanoma	NN	O	melanoma	prep_in	12	SENT_167	[p16l206t633r584b696],
16	.	.	O	.	_	0	SENT_167	[p16l206t633r584b696],

1	In	IN	O	in	_	0	SENT_168	[p16l608t638r679b695],
2	the	DT	O	the	det	3	SENT_168	[p16l699t633r805b696],
3	phase	NN	O	phase	prep_in	26	SENT_168	[p16l826t633r1020b716],
4	I	PRP	O	I	dep	5	SENT_168	[p16l1042t638r1065b695],
5	study	NN	O	study	dep	3	SENT_168	[p16l1089t633r1275b717],
6	of	IN	O	of	_	0	SENT_168	[p16l1293t633r1366b696],
7	LY2835219	NN	O	ly2835219	prep_of	5	SENT_168	[p16l1378t638r1778b705],
8	,	,	O	,	_	0	SENT_168	[p16l1378t638r1778b705],
9	a	DT	O	a	det	11	SENT_168	[p16l1801t656r1836b696],
10	selective	JJ	O	selective	amod	11	SENT_168	[p16l1856t633r2142b696],
11	inhibitor	NN	O	inhibitor	nsubj	26	SENT_168	[p16l9t736r309b799],
12	of	IN	O	of	_	0	SENT_168	[p16l329t736r402b799],
13	CDK4	NN	O	cdk4	prep_of	11	SENT_168	[p16l414t740r655b802],
14	/	:	O	/	punct	15	SENT_168	[p16l414t740r655b802],
15	6	CD	NUMBER	6	dep	11	SENT_168	[p16l661t742r715b808],
16	,	,	O	,	_	0	SENT_168	[p16l661t742r715b808],
17	one	CD	NUMBER	one	num	18	SENT_168	[p16l738t759r859b799],
18	patient	NN	O	patient	appos	15	SENT_168	[p16l878t742r1116b819],
19	with	IN	O	with	_	0	SENT_168	[p16l1133t736r1284b799],
20	melanoma	NN	O	melanoma	prep_with	11	SENT_168	[p16l1305t736r1664b799],
21	receiving	VBG	O	receive	partmod	20	SENT_168	[p16l1683t742r1993b820],
22	oral	JJ	O	oral	amod	23	SENT_168	[p16l2012t736r2143b799],
23	monotherapy	NN	O	monotherapy	dobj	21	SENT_168	[p16l9t839r462b923],
24	with	IN	O	with	_	0	SENT_168	[p16l476t839r625b902],
25	LY2835219	NN	O	ly2835219	prep_with	21	SENT_168	[p16l645t844r1015b902],
26	had	VBD	O	have	_	0	SENT_168	[p16l1035t839r1160b902],
27	a	DT	O	a	det	30	SENT_168	[p16l1179t862r1213b902],
28	conﬁrmed	JJ	O	conﬁrmed	amod	30	SENT_168	[p16l1232t839r1579b902],
29	partial	JJ	O	partial	amod	30	SENT_168	[p16l1596t839r1814b922],
30	response	NN	O	response	dobj	26	SENT_168	[p16l1833t861r2142b922],
31	,	,	O	,	_	0	SENT_168	[p16l1833t861r2142b922],
32	suggesting	VBG	O	suggest	partmod	30	SENT_168	[p16l10t947r373b1025],
33	single	JJ	O	single	amod	36	SENT_168	[p16l395t941r812b1025],
34	—	JJ	O	—	amod	36	SENT_168	[p16l395t941r812b1025],
35	agent	NN	O	agent	nn	36	SENT_168	[p16l395t941r812b1025],
36	activity	NN	O	activity	dobj	32	SENT_168	[p16l835t933r1162b1025],
37	.74	CD	NUMBER	.74	tmod	26	SENT_168	[p16l835t933r1162b1025],
38	In	IN	O	in	_	0	SENT_168	[p16l1186t946r1257b1003],
39	addition	NN	O	addition	prep_in	59	SENT_168	[p16l1281t941r1588b1013],
40	,	,	O	,	_	0	SENT_168	[p16l1281t941r1588b1013],
41	clinical	JJ	O	clinical	amod	42	SENT_168	[p16l1613t941r1860b1004],
42	trials	NNS	O	trial	nsubj	59	SENT_168	[p16l1881t941r2053b1004],
43	of	IN	O	of	_	0	SENT_168	[p16l2077t941r2152b1004],
44	combinations	NNS	O	combination	prep_of	42	SENT_168	[p16l10t1044r483b1107],
45	of	IN	O	of	_	0	SENT_168	[p16l508t1044r583b1107],
46	CDK4	NN	O	cdk4	nn	50	SENT_168	[p16l597t1048r815b1108],
47	inhibitor	NN	O	inhibitor	nn	50	SENT_168	[p16l839t1044r1147b1107],
48	(	NN	O	(	nn	50	SENT_168	[p16l1173t1044r1496b1121],
49	LEE011	NN	O	lee011	nn	50	SENT_168	[p16l1173t1044r1496b1121],
50	)	NN	O	)	prep_of	44	SENT_168	[p16l1173t1044r1496b1121],
51	and	CC	O	and	_	0	SENT_168	[p16l1524t1044r1652b1107],
52	BRAF	NN	O	braf	nn	56	SENT_168	[p16l1675t1048r1882b1107],
53	inhibitor	NN	O	inhibitor	nn	56	SENT_168	[p16l1907t1044r2141b1107, p16l8t1159r111b1210],
54	(	NN	O	(	nn	56	SENT_168	[p16l139t1148r489b1223],
55	LGX818	NN	O	lgx818	nn	56	SENT_168	[p16l139t1148r489b1223],
56	)	NN	O	)	conj_and	50	SENT_168	[p16l139t1148r489b1223],
57	are	VBP	O	be	cop	59	SENT_168	[p16l520t1170r624b1210],
58	currently	RB	DATE	currently	advmod	59	SENT_168	[p16l651t1147r980b1231],
59	ongoing	JJ	O	ongoing	dep	26	SENT_168	[p16l1002t1153r1293b1231],
60	in	IN	O	in	_	0	SENT_168	[p16l1317t1153r1386b1209],
61	patients	NNS	O	patient	prep_in	59	SENT_168	[p16l1411t1153r1691b1230],
62	with	IN	O	with	_	0	SENT_168	[p16l1716t1147r1874b1210],
63	BRAFmutant	NN	O	brafmutant	nn	65	SENT_168	[p16l1900t1151r2140b1210, p16l9t1261r263b1312],
64	metastatic	JJ	O	metastatic	amod	65	SENT_168	[p16l286t1255r645b1312],
65	melanoma	NN	O	melanoma	prep_with	61	SENT_168	[p16l668t1249r1040b1312],
66	who	WP	O	who	nsubj	70	SENT_168	[p16l1061t1249r1211b1312],
67	are	VBP	O	be	cop	70	SENT_168	[p16l1237t1272r1339b1312],
68	BRAF	NN	O	braf	nn	70	SENT_168	[p16l1364t1253r1574b1311],
69	inhibitor	NN	O	inhibitor	nn	70	SENT_168	[p16l1599t1249r2142b1312],
70	—	NN	O	—	rcmod	65	SENT_168	[p16l1599t1249r2142b1312],
71	naive	JJ	O	naive	amod	70	SENT_168	[p16l1599t1249r2142b1312],
72	or	CC	O	or	_	0	SENT_168	[p16l10t1375r82b1415],
73	who	WP	O	who	nsubj	74	SENT_168	[p16l99t1352r245b1415],
74	progressed	VBD	O	progress	conj_or	59	SENT_168	[p16l266t1352r638b1436],
75	after	IN	O	after	_	0	SENT_168	[p16l658t1352r810b1415],
76	single-agent	JJ	O	single-agent	amod	79	SENT_168	[p16l830t1352r1244b1436],
77	BRAF	NN	O	braf	nn	79	SENT_168	[p16l1264t1356r1468b1415],
78	inhibitor	NN	O	inhibitor	nn	79	SENT_168	[p16l1489t1352r1792b1415],
79	treatment	NN	O	treatment	prep_after	74	SENT_168	[p16l1811t1364r2145b1415],
80	(	CD	NUMBER	(	num	81	SENT_168	[p16l13t1455r516b1532],
81	ClinicalTrials	NNS	O	clinicaltrial	dep	79	SENT_168	[p16l13t1455r516b1532],
82	.	.	O	.	_	0	SENT_168	[p16l13t1455r516b1532],

1	gov	NN	O	gov	nn	2	SENT_169	[p16l523t1478r645b1539],
2	identiﬁers	NNS	O	identiﬁers	_	0	SENT_169	[p16l663t1455r1023b1518],
3	:	:	O	:	_	0	SENT_169	[p16l663t1455r1023b1518],
4	0177776	CD	NUMBER	0177776	num	7	SENT_169	[p16l1048t1461r1333b1518],
5	and	CC	O	and	_	0	SENT_169	[p16l1356t1455r1482b1518],
6	01820364	CD	NUMBER	01820364	num	7	SENT_169	[p16l1503t1456r1877b1531],
7	)	NN	O	)	dep	2	SENT_169	[p16l1503t1456r1877b1531],
8	.	.	O	.	_	0	SENT_169	[p16l1503t1456r1877b1531],

1	ADJUVANT	JJ	O	adjuvant	amod	4	SENT_170	[p16l9t1670r405b1725],
2	THERAPY	NN	O	therapy	nn	4	SENT_170	[p16l418t1670r755b1724],
3	Melanoma	NN	O	melanoma	nn	4	SENT_170	[p16l9t1765r366b1828],
4	patients	NNS	O	patient	nsubj	17	SENT_170	[p16l382t1771r643b1848],
5	with	IN	O	with	_	0	SENT_170	[p16l660t1765r809b1828],
6	regional	JJ	O	regional	amod	9	SENT_170	[p16l828t1765r1098b1849],
7	lymph	NN	O	lymph	nn	9	SENT_170	[p16l1114t1765r1327b1849],
8	node	NN	O	node	nn	9	SENT_170	[p16l1345t1765r1511b1828],
9	involvement	NN	O	involvement	prep_with	4	SENT_170	[p16l1531t1765r1943b1828],
10	or	CC	O	or	_	0	SENT_170	[p16l1961t1788r2031b1828],
11	intransit	JJ	O	intransit	amod	12	SENT_170	[p16l2049t1771r2140b1827, p16l8t1874r227b1931],
12	metastases	NNS	O	metastase	nsubj	17	SENT_170	[p16l246t1880r607b1931],
13	(	JJ	O	(	amod	14	SENT_170	[p16l633t1868r825b1952],
14	stage	NN	O	stage	dep	12	SENT_170	[p16l633t1868r825b1952],
15	III	CD	NUMBER	iii	number	16	SENT_170	[p16l847t1869r956b1945],
16	)	CD	NUMBER	)	dep	14	SENT_170	[p16l847t1869r956b1945],
17	have	VBP	O	have	_	0	SENT_170	[p16l980t1868r1134b1931],
18	a	DT	O	a	det	21	SENT_170	[p16l1157t1891r1191b1931],
19	5-year	JJ	DURATION	5-year	amod	21	SENT_170	[p16l1213t1876r1424b1952],
20	relapse	NN	O	relapse	nn	21	SENT_170	[p16l1445t1868r1678b1951],
21	rate	NN	O	rate	dobj	17	SENT_170	[p16l1700t1880r1826b1931],
22	of	IN	O	of	_	0	SENT_170	[p16l1848t1868r1921b1931],
23	>	JJR	O	>	prep_of	21	SENT_170	[p16l1935t1874r2140b1932],
24	30	CD	PERCENT	30	number	25	SENT_170	[p16l1935t1874r2140b1932],
25	%	NN	PERCENT	%	amod	23	SENT_170	[p16l1935t1874r2140b1932],
26	.	.	O	.	_	0	SENT_170	[p16l1935t1874r2140b1932],

1	Currently	RB	DATE	currently	advmod	2	SENT_171	[p16l11t1971r345b2055],
2	approved	VBN	O	approve	_	0	SENT_171	[p16l364t1971r681b2054],
3	adjuvant	JJ	O	adjuvant	amod	4	SENT_171	[p16l702t1971r997b2055],
4	treatments	NNS	O	treatment	nsubj	5	SENT_171	[p16l1017t1983r1382b2034],
5	(	VBP	O	(	ccomp	2	SENT_171	[p16l1408t1971r1776b2055],
6	high-dose	JJ	O	high-dose	amod	7	SENT_171	[p16l1408t1971r1776b2055],
7	interferon	NN	O	interferon	dobj	5	SENT_171	[p16l1798t1971r2141b2034],
8	and	CC	O	and	_	0	SENT_171	[p16l10t2074r134b2137],
9	pegylated	VBN	O	pegylate	conj_and	2	SENT_171	[p16l150t2074r471b2158],
10	interferon	NN	O	interferon	nn	11	SENT_171	[p16l489t2074r846b2151],
11	)	NN	O	)	dobj	9	SENT_171	[p16l489t2074r846b2151],
12	provide	VBP	O	provide	dep	2	SENT_171	[p16l867t2074r1121b2157],
13	some	DT	O	some	det	23	SENT_171	[p16l1141t2097r1314b2137],
14	improvement	NN	O	improvement	nn	22	SENT_171	[p16l1333t2080r1784b2157],
15	in	IN	O	in	_	0	SENT_171	[p16l1801t2080r1866b2136],
16	relapsefree	NN	O	relapsefree	nn	17	SENT_171	[p16l1885t2074r2141b2157, p16l9t2176r133b2239],
17	survival	NN	O	survival	prep_in	14	SENT_171	[p16l153t2176r417b2239],
18	but	CC	O	but	_	0	SENT_171	[p16l432t2176r544b2239],
19	less	JJR	O	less	nn	22	SENT_171	[p16l560t2176r675b2239],
20	clear	JJ	O	clear	amod	22	SENT_171	[p16l695t2176r985b2239],
21	—	NN	O	—	nn	22	SENT_171	[p16l695t2176r985b2239],
22	cut	NN	O	cut	nn	23	SENT_171	[p16l695t2176r985b2239],
23	improvement	NN	O	improvement	dobj	12	SENT_171	[p16l1003t2182r1455b2259],
24	in	IN	O	in	_	0	SENT_171	[p16l1472t2182r1537b2238],
25	overall	JJ	O	overall	amod	26	SENT_171	[p16l1557t2176r1780b2239],
26	survival	NN	O	survival	prep_in	23	SENT_171	[p16l1799t2169r2142b2239],
27	.75	CD	NUMBER	.75	nsubj	9	SENT_171	[p16l1799t2169r2142b2239],
28	Given	VBN	O	give	prep	41	SENT_171	[p16l11t2283r209b2342],
29	the	DT	O	the	det	30	SENT_171	[p16l228t2279r332b2342],
30	activity	NN	O	activity	dep	28	SENT_171	[p16l353t2285r599b2363],
31	of	IN	O	of	_	0	SENT_171	[p16l615t2279r688b2342],
32	BRAF	NN	O	braf	nn	33	SENT_171	[p16l699t2283r900b2342],
33	inhibitors	NNS	O	inhibitor	prep_of	30	SENT_171	[p16l921t2279r1246b2342],
34	in	IN	O	in	_	0	SENT_171	[p16l1266t2285r1332b2341],
35	patients	NNS	O	patient	prep_in	33	SENT_171	[p16l1350t2285r1613b2362],
36	with	IN	O	with	_	0	SENT_171	[p16l1632t2279r1782b2342],
37	metastatic	JJ	O	metastatic	amod	38	SENT_171	[p16l1801t2285r2143b2342],
38	melanoma	NN	O	melanoma	prep_with	35	SENT_171	[p16l9t2382r390b2454],
39	,	,	O	,	_	0	SENT_171	[p16l9t2382r390b2454],
40	there	EX	O	there	expl	41	SENT_171	[p16l412t2382r587b2445],
41	are	VBP	O	be	rcmod	27	SENT_171	[p16l609t2405r710b2445],
42	ongoing	JJ	O	ongoing	amod	45	SENT_171	[p16l733t2388r1014b2466],
43	adjuvant	JJ	O	adjuvant	amod	45	SENT_171	[p16l1034t2382r1639b2466],
44	—	NN	O	—	nn	45	SENT_171	[p16l1034t2382r1639b2466],
45	placebo	NN	O	placebo	nsubj	41	SENT_171	[p16l1034t2382r1639b2466],
46	controlled	VBN	O	control	partmod	45	SENT_171	[p16l1663t2382r2013b2445],
47	trials	NNS	O	trial	dobj	46	SENT_171	[p16l2033t2388r2141b2445, p16l10t2485r95b2548],
48	of	IN	O	of	_	0	SENT_171	[p16l117t2485r190b2548],
49	1-year	JJ	DURATION	1-year	amod	50	SENT_171	[p16l208t2492r412b2569],
50	vemurafenib	NN	O	vemurafenib	prep_of	47	SENT_171	[p16l429t2485r853b2548],
51	and	CC	O	and	_	0	SENT_171	[p16l877t2485r1001b2548],
52	1-year	JJ	DURATION	1-year	amod	53	SENT_171	[p16l1027t2492r1231b2569],
53	combination	NN	O	combination	conj_and	47	SENT_171	[p16l1252t2485r1677b2548],
54	of	IN	O	of	_	0	SENT_171	[p16l1699t2485r1772b2548],
55	dabrafenib	NN	O	dabrafenib	prep_of	53	SENT_171	[p16l1784t2485r2141b2548],
56	and	CC	O	and	_	0	SENT_171	[p16l10t2588r139b2651],
57	trametinib	NN	O	trametinib	conj_and	55	SENT_171	[p16l161t2588r531b2651],
58	in	IN	O	in	_	0	SENT_171	[p16l557t2594r625b2650],
59	patients	NNS	O	patient	prep_in	27	SENT_171	[p16l648t2594r923b2671],
60	with	IN	O	with	_	0	SENT_171	[p16l946t2588r1102b2651],
61	resected	JJ	O	resected	amod	62	SENT_171	[p16l1126t2588r1411b2651],
62	stage	NN	O	stage	prep_with	59	SENT_171	[p16l1436t2600r1606b2672],
63	III	CD	NUMBER	iii	num	64	SENT_171	[p16l1632t2593r1716b2650],
64	melanomas	NNS	O	melanoma	nsubj	68	SENT_171	[p16l1741t2588r2141b2651],
65	harboring	VBG	O	harbor	partmod	64	SENT_171	[p16l8t2691r349b2775],
66	BRAFV600	NN	O	brafv600	nn	67	SENT_171	[p16l369t2695r755b2754],
67	mutations	NNS	O	mutation	dobj	65	SENT_171	[p16l777t2697r1117b2754],
68	(	VBP	O	(	rcmod	62	SENT_171	[p16l1143t2691r1765b2775],
69	ClinicalTrials	NNS	O	clinicaltrial	dobj	68	SENT_171	[p16l1143t2691r1765b2775],
70	.	.	O	.	_	0	SENT_171	[p16l1143t2691r1765b2775],

1	gov	NN	O	gov	nn	2	SENT_172	[p16l1143t2691r1765b2775],
2	identiﬁers	NNS	O	identiﬁers	_	0	SENT_172	[p16l1783t2691r2137b2754],
3	:	:	O	:	_	0	SENT_172	[p16l1783t2691r2137b2754],
4	01667419	CD	NUMBER	01667419	num	7	SENT_172	[p16l10t2800r331b2857],
5	and	CC	O	and	_	0	SENT_172	[p16l354t2794r479b2857],
6	01682083	CD	NUMBER	01682083	num	7	SENT_172	[p16l500t2795r868b2871],
7	)	NN	O	)	dep	2	SENT_172	[p16l500t2795r868b2871],
8	.	.	O	.	_	0	SENT_172	[p16l500t2795r868b2871],

1	Use	NN	O	use	nsubjpass	12	SENT_173	[p16l892t2799r1015b2857],
2	of	IN	O	of	_	0	SENT_173	[p16l1036t2794r1109b2857],
3	adjuvant	JJ	O	adjuvant	amod	5	SENT_173	[p16l1121t2794r1412b2878],
4	BRAF	NN	O	braf	nn	5	SENT_173	[p16l1432t2798r1635b2857],
5	inhibitors	NNS	O	inhibitor	prep_of	1	SENT_173	[p16l1657t2794r1983b2857],
6	outside	IN	O	outside	_	0	SENT_173	[p16l2005t2806r2141b2857, p16l10t2897r144b2960],
7	of	IN	O	of	_	0	SENT_173	[p16l167t2897r242b2960],
8	clinical	JJ	O	clinical	amod	9	SENT_173	[p16l256t2897r503b2960],
9	trials	NNS	O	trial	prep_outside_of	5	SENT_173	[p16l523t2897r696b2960],
10	should	MD	O	should	aux	12	SENT_173	[p16l720t2897r953b2960],
11	be	VB	O	be	auxpass	12	SENT_173	[p16l973t2897r1053b2960],
12	discouraged	VBN	O	discourage	_	0	SENT_173	[p16l1077t2897r1496b2981],
13	until	IN	O	until	mark	16	SENT_173	[p16l1518t2897r1680b2960],
14	clinical	JJ	O	clinical	amod	15	SENT_173	[p16l1703t2897r1950b2960],
15	trials	NNS	O	trial	nsubj	16	SENT_173	[p16l1971t2897r2143b2960],
16	demonstrate	VBP	O	demonstrate	advcl	12	SENT_173	[p16l10t3000r419b3063],
17	the	DT	O	the	det	19	SENT_173	[p16l436t3000r539b3063],
18	clinical	JJ	O	clinical	amod	19	SENT_173	[p16l558t3000r791b3063],
19	beneﬁt	NN	O	beneﬁt	dobj	16	SENT_173	[p16l806t3000r1033b3063],
20	of	IN	O	of	_	0	SENT_173	[p16l1051t3000r1122b3063],
21	BRAF	NN	O	braf	nn	22	SENT_173	[p16l1131t3004r1329b3063],
22	inhibitors	NNS	O	inhibitor	prep_of	19	SENT_173	[p16l1348t3000r1666b3063],
23	as	IN	O	as	_	0	SENT_173	[p16l1685t3023r1747b3063],
24	an	DT	O	a	det	26	SENT_173	[p16l1766t3023r1844b3063],
25	adjuvant	JJ	O	adjuvant	amod	26	SENT_173	[p16l1863t3000r2145b3084],
26	therapy	NN	O	therapy	prep_as	22	SENT_173	[p16l8t3103r265b3187],
27	for	IN	O	for	_	0	SENT_173	[p16l281t3103r376b3166],
28	high	JJ	O	high	amod	31	SENT_173	[p16l394t3103r705b3187],
29	—	NN	O	—	nn	31	SENT_173	[p16l394t3103r705b3187],
30	risk	NN	O	risk	nn	31	SENT_173	[p16l394t3103r705b3187],
31	patients	NNS	O	patient	prep_for	26	SENT_173	[p16l720t3109r983b3186],
32	with	IN	O	with	_	0	SENT_173	[p16l1001t3103r1152b3166],
33	BRAF-mutant	JJ	O	braf-mutant	amod	34	SENT_173	[p16l1172t3107r1648b3166],
34	melanoma	NN	O	melanoma	prep_with	16	SENT_173	[p16l1667t3103r2037b3166],
35	.	.	O	.	_	0	SENT_173	[p16l1667t3103r2037b3166],

1	CONCLUSION	NN	O	conclusion	dep	8	SENT_174	[p16l10t3317r486b3373],
2	Although	IN	O	although	dep	8	SENT_174	[p16l8t3413r340b3497],
3	advanced	JJ	O	advanced	amod	4	SENT_174	[p16l364t3413r691b3476],
4	melanoma	NN	O	melanoma	nsubj	8	SENT_174	[p16l713t3413r1080b3476],
5	remains	VBZ	O	remain	cop	8	SENT_174	[p16l1102t3419r1378b3476],
6	a	DT	O	a	det	8	SENT_174	[p16l1402t3436r1437b3476],
7	devastating	JJ	O	devastating	amod	8	SENT_174	[p16l1460t3413r1855b3497],
8	disease	NN	O	disease	advcl	26	SENT_174	[p16l1877t3413r2139b3485],
9	,	,	O	,	_	0	SENT_174	[p16l1877t3413r2139b3485],
10	the	DT	O	the	det	11	SENT_174	[p16l8t3516r119b3579],
11	discovery	NN	O	discovery	nsubj	26	SENT_174	[p16l147t3516r492b3600],
12	of	IN	O	of	_	0	SENT_174	[p16l517t3516r593b3579],
13	the	DT	O	the	det	15	SENT_174	[p16l609t3516r720b3579],
14	BRAFV600	NN	O	brafv600	nn	15	SENT_174	[p16l748t3520r1153b3579],
15	mutation	NN	O	mutation	prep_of	11	SENT_174	[p16l1181t3522r1509b3579],
16	and	CC	O	and	_	0	SENT_174	[p16l1537t3516r1668b3579],
17	the	DT	O	the	det	18	SENT_174	[p16l1693t3516r1804b3579],
18	development	NN	O	development	prep_of	11	SENT_174	[p16l1832t3516r2138b3599, p16l9t3631r188b3682],
19	of	IN	O	of	_	0	SENT_174	[p16l210t3619r284b3682],
20	targeted	VBN	O	target	amod	21	SENT_174	[p16l297t3619r579b3703],
21	therapies	NNS	O	therapy	prep_of	18	SENT_174	[p16l600t3619r914b3702],
22	directed	VBN	O	direct	partmod	21	SENT_174	[p16l938t3619r1220b3682],
23	against	IN	O	against	_	0	SENT_174	[p16l1244t3625r1485b3703],
24	it	PRP	O	it	prep_against	22	SENT_174	[p16l1507t3625r1553b3682],
25	have	VBP	O	have	aux	26	SENT_174	[p16l1574t3619r1731b3682],
26	revolutionized	VBN	O	revolutionize	_	0	SENT_174	[p16l1755t3619r2140b3682, p16l10t3722r151b3785],
27	the	DT	O	the	det	28	SENT_174	[p16l173t3722r282b3785],
28	treatment	NN	O	treatment	dobj	26	SENT_174	[p16l304t3734r647b3785],
29	of	IN	O	of	_	0	SENT_174	[p16l670t3722r745b3785],
30	patients	NNS	O	patient	prep_of	28	SENT_174	[p16l757t3728r1032b3805],
31	with	IN	O	with	_	0	SENT_174	[p16l1055t3722r1211b3785],
32	BRAF-mutant	JJ	O	braf-mutant	amod	33	SENT_174	[p16l1234t3726r1730b3785],
33	melanoma	NN	O	melanoma	prep_with	26	SENT_174	[p16l1752t3722r2138b3785],
34	.	.	O	.	_	0	SENT_174	[p16l1752t3722r2138b3785],

1	These	DT	O	these	det	2	SENT_175	[p17l9t17r209b80],
2	agents	NNS	O	agent	nsubj	3	SENT_175	[p17l235t29r455b101],
3	produce	VBP	O	produce	_	0	SENT_175	[p17l480t17r770b100],
4	signiﬁcant	JJ	O	signiﬁcant	amod	6	SENT_175	[p17l797t17r1165b101],
5	antitumor	NN	O	antitumor	nn	6	SENT_175	[p17l1190t23r1547b80],
6	responses	NNS	O	response	dobj	3	SENT_175	[p17l1571t39r1914b100],
7	in	IN	O	in	_	0	SENT_175	[p17l1940t23r2009b79],
8	the	DT	O	the	det	9	SENT_175	[p17l2033t17r2143b80],
9	majority	NN	O	majority	prep_in	6	SENT_175	[p17l9t126r304b204],
10	of	IN	O	of	_	0	SENT_175	[p17l324t120r398b183],
11	patients	NNS	O	patient	prep_of	9	SENT_175	[p17l410t126r700b203],
12	,	,	O	,	_	0	SENT_175	[p17l410t126r700b203],
13	including	VBG	O	include	dep	9	SENT_175	[p17l724t120r1053b204],
14	those	DT	O	those	pobj	13	SENT_175	[p17l1073t120r1257b183],
15	with	IN	O	with	_	0	SENT_175	[p17l1278t120r1432b183],
16	central	JJ	O	central	amod	19	SENT_175	[p17l1455t120r1691b183],
17	nervous	JJ	O	nervous	amod	19	SENT_175	[p17l1713t143r1988b183],
18	system	NN	O	system	nn	19	SENT_175	[p17l2013t143r2140b204, p17l8t235r144b286],
19	metastases	NNS	O	metastase	prep_with	14	SENT_175	[p17l171t235r572b295],
20	,	,	O	,	_	0	SENT_175	[p17l171t235r572b295],
21	and	CC	O	and	_	0	SENT_175	[p17l602t223r733b286],
22	prolong	VB	O	prolong	dep	9	SENT_175	[p17l758t223r1040b307],
23	median	JJ	O	median	amod	25	SENT_175	[p17l1064t223r1333b286],
24	overall	JJ	O	overall	amod	25	SENT_175	[p17l1361t223r1602b286],
25	survival	NN	O	survival	dobj	22	SENT_175	[p17l1629t223r1932b295],
26	;	:	O	;	_	0	SENT_175	[p17l1629t223r1932b295],
27	however	RB	O	however	advmod	31	SENT_175	[p17l1960t223r2139b286, p17l10t349r163b398],
28	,	,	O	,	_	0	SENT_175	[p17l1960t223r2139b286, p17l10t349r163b398],
29	these	DT	O	these	det	30	SENT_175	[p17l187t326r362b389],
30	responses	NNS	O	response	nsubj	31	SENT_175	[p17l385t348r716b409],
31	are	VBP	O	be	dep	25	SENT_175	[p17l740t349r840b389],
32	usually	RB	O	usually	advmod	31	SENT_175	[p17l862t326r1107b410],
33	neither	CC	O	neither	preconj	34	SENT_175	[p17l1126t326r1370b389],
34	complete	JJ	O	complete	amod	6	SENT_175	[p17l1392t326r1702b409],
35	nor	CC	O	nor	_	0	SENT_175	[p17l1725t349r1844b389],
36	durable	JJ	O	durable	conj_nor	34	SENT_175	[p17l1867t326r2140b389],
37	.	.	O	.	_	0	SENT_175	[p17l1867t326r2140b389],

1	Several	JJ	O	several	amod	3	SENT_176	[p17l10t428r250b492],
2	resistance	NN	O	resistance	nn	3	SENT_176	[p17l269t434r596b492],
3	mechanisms	NNS	O	mechanism	nsubjpass	10	SENT_176	[p17l616t428r1035b492],
4	have	VBP	O	have	aux	6	SENT_176	[p17l1055t428r1207b492],
5	been	VBN	O	be	auxpass	6	SENT_176	[p17l1225t428r1387b492],
6	identiﬁed	VBN	O	identiﬁed	_	0	SENT_176	[p17l1407t428r1744b500],
7	,	,	O	,	_	0	SENT_176	[p17l1407t428r1744b500],
8	and	CC	O	and	_	0	SENT_176	[p17l1766t428r1890b492],
9	rationally	RB	O	rationally	advmod	10	SENT_176	[p17l1909t434r2140b492, p17l10t532r136b616],
10	developed	VBD	O	develop	conj_and	6	SENT_176	[p17l159t532r523b615],
11	combinations	NNS	O	combination	dobj	10	SENT_176	[p17l549t532r1034b595],
12	of	IN	O	of	_	0	SENT_176	[p17l1062t532r1138b595],
13	molecularly	RB	O	molecularly	advmod	14	SENT_176	[p17l1154t532r1580b616],
14	targeted	VBN	O	target	amod	15	SENT_176	[p17l1602t532r1893b616],
15	agents	NNS	O	agent	prep_of	11	SENT_176	[p17l1919t544r2140b616],
16	that	WDT	O	that	nsubj	17	SENT_176	[p17l8t635r149b698],
17	target	VBP	O	target	rcmod	15	SENT_176	[p17l175t647r382b719],
18	both	DT	O	both	preconj	19	SENT_176	[p17l408t635r574b698],
19	BRAFV600	NN	O	brafv600	nsubj	25	SENT_176	[p17l603t639r1010b698],
20	and	CC	O	and	_	0	SENT_176	[p17l1040t635r1171b698],
21	speciﬁc	NN	O	speciﬁc	nn	23	SENT_176	[p17l1200t635r1466b718],
22	resistance	NN	O	resistance	nn	23	SENT_176	[p17l1494t641r1847b698],
23	mechanisms	NNS	O	mechanism	conj_and	19	SENT_176	[p17l1875t635r2139b698, p17l9t744r208b801],
24	may	MD	O	may	aux	25	SENT_176	[p17l229t761r375b822],
25	prolong	VB	O	prolong	ccomp	17	SENT_176	[p17l390t738r659b822],
26	the	DT	O	the	det	27	SENT_176	[p17l677t738r783b801],
27	beneﬁt	NN	O	beneﬁt	dobj	25	SENT_176	[p17l802t738r1037b801],
28	from	IN	O	from	_	0	SENT_176	[p17l1056t738r1223b801],
29	BRAF	NN	O	braf	nn	31	SENT_176	[p17l1244t742r1448b801],
30	inhibitor	NN	O	inhibitor	nn	31	SENT_176	[p17l1470t738r1772b801],
31	treatment	NN	O	treatment	prep_from	25	SENT_176	[p17l1790t750r2140b801],
32	.	.	O	.	_	0	SENT_176	[p17l1790t750r2140b801],

1	Immunotherapies	NNS	O	immunotherapy	nsubj	19	SENT_177	[p17l10t841r672b924],
2	,	,	O	,	_	0	SENT_177	[p17l10t841r672b924],
3	such	JJ	O	such	_	0	SENT_177	[p17l702t841r863b904],
4	as	IN	O	as	_	0	SENT_177	[p17l892t864r958b904],
5	treatment	NN	O	treatment	prep_such_as	1	SENT_177	[p17l985t853r1337b904],
6	with	IN	O	with	_	0	SENT_177	[p17l1362t841r1522b904],
7	ipilimumab	NN	O	ipilimumab	prep_with	5	SENT_177	[p17l1549t841r1983b924],
8	,	,	O	,	_	0	SENT_177	[p17l1549t841r1983b924],
9	HD	NN	O	hd	nn	10	SENT_177	[p17l2013t846r2140b903],
10	IL-2	NN	O	il-2	prep_with	5	SENT_177	[p17l10t949r176b1016],
11	,	,	O	,	_	0	SENT_177	[p17l10t949r176b1016],
12	and	CC	O	and	_	0	SENT_177	[p17l204t944r334b1007],
13	PD-1	NN	O	pd-1	nn	16	SENT_177	[p17l358t949r536b1006],
14	or	CC	O	or	_	0	SENT_177	[p17l568t967r642b1007],
15	PD-L1	NN	O	pd-l1	nn	16	SENT_177	[p17l666t949r892b1006],
16	antibody	NN	O	antibody	prep_with	5	SENT_177	[p17l924t944r1249b1028],
17	,	,	O	,	_	0	SENT_177	[p17l924t944r1249b1028],
18	can	MD	O	can	aux	19	SENT_177	[p17l1276t967r1396b1007],
19	beneﬁt	VB	O	beneﬁt	_	0	SENT_177	[p17l1419t944r1663b1007],
20	patients	NNS	O	patient	dobj	19	SENT_177	[p17l1685t950r1963b1027],
21	with	IN	O	with	_	0	SENT_177	[p17l1987t944r2145b1007],
22	BRAFV600	NN	O	brafv600	nn	24	SENT_177	[p17l10t1051r389b1110],
23	mutant	JJ	O	mutant	amod	24	SENT_177	[p17l409t1059r650b1110],
24	melanoma	NN	O	melanoma	prep_with	19	SENT_177	[p17l668t1047r1036b1119],
25	,	,	O	,	_	0	SENT_177	[p17l668t1047r1036b1119],
26	with	IN	O	with	_	0	SENT_177	[p17l1055t1047r1203b1110],
27	more	JJR	O	more	amod	29	SENT_177	[p17l1223t1070r1395b1110],
28	durable	JJ	O	durable	amod	29	SENT_177	[p17l1415t1047r1665b1110],
29	response	NN	O	response	prep_with	19	SENT_177	[p17l1684t1069r1975b1130],
30	with	IN	O	with	_	0	SENT_177	[p17l1993t1047r2142b1110],
31	complete	JJ	O	complete	amod	32	SENT_177	[p17l10t1150r319b1233],
32	response	NN	O	response	prep_with	29	SENT_177	[p17l342t1172r641b1233],
33	in	IN	O	in	_	0	SENT_177	[p17l663t1156r729b1212],
34	a	DT	O	a	det	35	SENT_177	[p17l751t1173r786b1213],
35	subset	NN	O	subset	prep_in	32	SENT_177	[p17l807t1150r1020b1213],
36	of	IN	O	of	_	0	SENT_177	[p17l1041t1150r1114b1213],
37	patients	NNS	O	patient	prep_of	35	SENT_177	[p17l1125t1156r1411b1233],
38	.	.	O	.	_	0	SENT_177	[p17l1125t1156r1411b1233],

1	With	IN	O	with	_	0	SENT_178	[p17l81t1253r255b1316],
2	no	DT	O	no	det	4	SENT_178	[p17l275t1276r361b1316],
3	prospective	JJ	O	prospective	amod	4	SENT_178	[p17l381t1259r775b1336],
4	data	NNS	O	datum	prep_with	26	SENT_178	[p17l796t1253r940b1316],
5	on	IN	O	on	_	0	SENT_178	[p17l960t1276r1046b1316],
6	the	DT	O	the	det	9	SENT_178	[p17l1065t1253r1171b1316],
7	optimal	JJ	O	optimal	amod	9	SENT_178	[p17l1193t1253r1457b1336],
8	treatment	NN	O	treatment	nn	9	SENT_178	[p17l1476t1265r1811b1316],
9	sequence	NN	O	sequence	prep_on	4	SENT_178	[p17l1832t1276r2142b1336],
10	of	IN	O	of	_	0	SENT_178	[p17l10t1356r82b1419],
11	approved	VBN	O	approve	amod	12	SENT_178	[p17l93t1356r404b1439],
12	therapies	NNS	O	therapy	prep_of	9	SENT_178	[p17l422t1356r727b1439],
13	in	IN	O	in	_	0	SENT_178	[p17l747t1362r812b1418],
14	BRAF	NN	O	braf	nn	17	SENT_178	[p17l833t1360r1310b1419],
15	—	NN	O	—	nn	17	SENT_178	[p17l833t1360r1310b1419],
16	mutant	JJ	O	mutant	amod	17	SENT_178	[p17l833t1360r1310b1419],
17	melanoma	NN	O	melanoma	prep_in	12	SENT_178	[p17l1328t1356r1700b1428],
18	,	,	O	,	_	0	SENT_178	[p17l1328t1356r1700b1428],
19	the	DT	O	the	det	20	SENT_178	[p17l1721t1356r1825b1419],
20	choice	NN	O	choice	nsubj	26	SENT_178	[p17l1846t1356r2058b1419],
21	of	IN	O	of	_	0	SENT_178	[p17l2079t1356r2151b1419],
22	initial	JJ	O	initial	amod	23	SENT_178	[p17l9t1459r204b1522],
23	therapy	NN	O	therapy	prep_of	20	SENT_178	[p17l222t1459r479b1543],
24	is	VBZ	O	be	cop	26	SENT_178	[p17l495t1465r544b1522],
25	largely	RB	O	largely	advmod	26	SENT_178	[p17l563t1459r787b1543],
26	empiric	JJ	O	empiric	_	0	SENT_178	[p17l804t1465r1059b1542],
27	and	CC	O	and	_	0	SENT_178	[p17l1080t1459r1203b1522],
28	is	VBZ	O	be	auxpass	29	SENT_178	[p17l1222t1465r1271b1522],
29	based	VBN	O	base	conj_and	26	SENT_178	[p17l1289t1459r1482b1522],
30	on	IN	O	on	_	0	SENT_178	[p17l1501t1482r1585b1522],
31	clinical	JJ	O	clinical	amod	32	SENT_178	[p17l1606t1459r1845b1522],
32	parameters	NNS	O	parameter	prep_on	29	SENT_178	[p17l1863t1481r2141b1542, p17l8t1574r127b1625],
33	such	JJ	O	such	_	0	SENT_178	[p17l149t1562r300b1625],
34	as	IN	O	as	_	0	SENT_178	[p17l320t1585r382b1625],
35	the	DT	O	the	det	36	SENT_178	[p17l402t1562r505b1625],
36	pace	NN	O	pace	prep_such_as	32	SENT_178	[p17l524t1584r674b1645],
37	and	CC	O	and	_	0	SENT_178	[p17l695t1562r818b1625],
38	bulk	NN	O	bulk	conj_and	36	SENT_178	[p17l835t1562r987b1625],
39	of	IN	O	of	_	0	SENT_178	[p17l1004t1562r1076b1625],
40	disease	NN	O	disease	prep_of	36	SENT_178	[p17l1087t1562r1321b1625],
41	and	CC	O	and	_	0	SENT_178	[p17l1341t1562r1465b1625],
42	presence	NN	O	presence	prep_of	36	SENT_178	[p17l1482t1584r1773b1645],
43	or	CC	O	or	_	0	SENT_178	[p17l1793t1585r1864b1625],
44	absence	NN	O	absence	prep_such_as	32	SENT_178	[p17l1883t1562r2142b1625],
45	of	IN	O	of	_	0	SENT_178	[p17l10t1665r84b1728],
46	disease	NN	O	disease	nn	49	SENT_178	[p17l96t1665r602b1728],
47	—	NN	O	—	nn	49	SENT_178	[p17l96t1665r602b1728],
48	related	JJ	O	related	amod	49	SENT_178	[p17l96t1665r602b1728],
49	symptoms	NNS	O	symptom	prep_of	44	SENT_178	[p17l623t1677r990b1749],
50	.	.	O	.	_	0	SENT_178	[p17l623t1677r990b1749],

1	It	PRP	O	it	nsubjpass	3	SENT_179	[p17l1015t1670r1064b1728],
2	is	VBZ	O	be	auxpass	3	SENT_179	[p17l1084t1671r1134b1728],
3	anticipated	VBN	O	anticipate	_	0	SENT_179	[p17l1156t1665r1534b1748],
4	that	IN	O	that	complm	9	SENT_179	[p17l1553t1665r1687b1728],
5	clinical	JJ	O	clinical	amod	6	SENT_179	[p17l1707t1665r1952b1728],
6	trials	NNS	O	trial	nsubj	9	SENT_179	[p17l1971t1665r2142b1728],
7	will	MD	O	will	aux	9	SENT_179	[p17l8t1768r133b1831],
8	formally	RB	O	formally	advmod	9	SENT_179	[p17l155t1768r447b1852],
9	address	VB	O	address	ccomp	3	SENT_179	[p17l467t1768r721b1831],
10	the	DT	O	the	det	13	SENT_179	[p17l744t1768r850b1831],
11	optimal	JJ	O	optimal	amod	13	SENT_179	[p17l873t1768r1137b1851],
12	treatment	NN	O	treatment	nn	13	SENT_179	[p17l1159t1780r1494b1831],
13	sequence	NN	O	sequence	dobj	9	SENT_179	[p17l1516t1791r1827b1851],
14	of	IN	O	of	_	0	SENT_179	[p17l1850t1768r1924b1831],
15	BRAF	NN	O	braf	nn	16	SENT_179	[p17l1937t1772r2142b1831],
16	inhibitor	NN	O	inhibitor	prep_of	13	SENT_179	[p17l10t1871r325b1934],
17	and	CC	O	and	_	0	SENT_179	[p17l351t1871r481b1934],
18	immunotherapy	NN	O	immunotherapy	prep_of	13	SENT_179	[p17l506t1871r1088b1955],
19	in	IN	O	in	_	0	SENT_179	[p17l1110t1877r1179b1933],
20	the	DT	DATE	the	det	22	SENT_179	[p17l1203t1871r1313b1934],
21	near	JJ	DATE	near	amod	22	SENT_179	[p17l1340t1894r1496b1934],
22	future	NN	DATE	future	prep_in	9	SENT_179	[p17l1521t1871r1753b1934],
23	.	.	O	.	_	0	SENT_179	[p17l1521t1871r1753b1934],

1	Moreover	RB	O	moreover	advmod	6	SENT_180	[p17l1781t1876r2141b1943],
2	,	,	O	,	_	0	SENT_180	[p17l1781t1876r2141b1943],
3	this	DT	O	this	det	5	SENT_180	[p17l8t1974r133b2037],
4	patient	NN	O	patient	nn	5	SENT_180	[p17l154t1980r394b2057],
5	population	NN	O	population	nsubj	6	SENT_180	[p17l414t1974r790b2057],
6	represents	VBZ	O	represent	_	0	SENT_180	[p17l813t1986r1160b2057],
7	an	DT	O	a	det	9	SENT_180	[p17l1185t1997r1265b2037],
8	ideal	JJ	O	ideal	amod	9	SENT_180	[p17l1287t1974r1450b2037],
9	group	NN	O	group	dobj	6	SENT_180	[p17l1472t1996r1672b2058],
10	for	IN	O	for	_	0	SENT_180	[p17l1696t1974r1793b2037],
11	combination	NN	O	combination	nn	13	SENT_180	[p17l1815t1974r2139b2037, p17l8t2083r145b2140],
12	treatment	NN	O	treatment	nn	13	SENT_180	[p17l164t2089r497b2140],
13	approaches	NNS	O	approach	prep_for	9	SENT_180	[p17l517t2077r914b2160],
14	.	.	O	.	_	0	SENT_180	[p17l517t2077r914b2160],

1	Studies	NNS	O	study	nsubj	27	SENT_181	[p17l939t2077r1180b2140],
2	combining	VBG	O	combine	partmod	1	SENT_181	[p17l1201t2077r1569b2161],
3	BRAF	NN	O	braf	nn	4	SENT_181	[p17l1588t2081r1791b2140],
4	inhibitors	NNS	O	inhibitor	dobj	2	SENT_181	[p17l1813t2077r2143b2140],
5	with	IN	O	with	_	0	SENT_181	[p17l8t2180r158b2243],
6	immunotherapy	NN	O	immunotherapy	nn	8	SENT_181	[p17l178t2180r732b2264],
7	(	NN	O	(	nn	8	SENT_181	[p17l752t2180r1186b2263],
8	ipilimumab	NN	O	ipilimumab	prep_with	4	SENT_181	[p17l752t2180r1186b2263],
9	,	,	O	,	_	0	SENT_181	[p17l752t2180r1186b2263],
10	HD	NN	O	hd	nn	11	SENT_181	[p17l1208t2185r1330b2242],
11	IL-2	NN	O	il-2	prep_with	4	SENT_181	[p17l1353t2185r1512b2252],
12	,	,	O	,	_	0	SENT_181	[p17l1353t2185r1512b2252],
13	or	CC	O	or	_	0	SENT_181	[p17l1535t2203r1606b2243],
14	anti-PD-1	JJ	O	anti-pd-1	amod	16	SENT_181	[p17l1625t2185r1957b2243],
15	antibody	NN	O	antibody	nn	16	SENT_181	[p17l1985t2186r2138b2243, p17l7t2283r226b2367],
16	)	NN	O	)	conj_or	8	SENT_181	[p17l1985t2186r2138b2243, p17l7t2283r226b2367],
17	,	,	O	,	_	0	SENT_181	[p17l1985t2186r2138b2243, p17l7t2283r226b2367],
18	VEGF	NN	O	vegf	nn	20	SENT_181	[p17l247t2287r459b2346],
19	pathway	NN	O	pathway	nn	20	SENT_181	[p17l480t2283r767b2367],
20	inhibitors	NNS	O	inhibitor	dobj	2	SENT_181	[p17l784t2283r1132b2355],
21	,	,	O	,	_	0	SENT_181	[p17l784t2283r1132b2355],
22	or	CC	O	or	_	0	SENT_181	[p17l1155t2306r1226b2346],
23	other	JJ	O	other	dobj	2	SENT_181	[p17l1246t2283r1426b2346],
24	molecularly	RB	O	molecularly	advmod	25	SENT_181	[p17l1445t2283r1851b2367],
25	targeted	VBN	O	target	partmod	23	SENT_181	[p17l1867t2283r2143b2367],
26	agents	NNS	O	agent	dobj	25	SENT_181	[p17l10t2398r229b2470],
27	(	VBP	O	(	_	0	SENT_181	[p17l258t2387r489b2462],
28	MEK	NN	O	mek	nsubj	42	SENT_181	[p17l258t2387r489b2462],
29	,	,	O	,	_	0	SENT_181	[p17l258t2387r489b2462],
30	PI3K-Akt	NN	O	pi3k-akt	nn	31	SENT_181	[p17l516t2386r859b2449],
31	inhibitors	NNS	O	inhibitor	conj_and	28	SENT_181	[p17l882t2386r1245b2458],
32	,	,	O	,	_	0	SENT_181	[p17l882t2386r1245b2458],
33	and	CC	O	and	_	0	SENT_181	[p17l1272t2386r1402b2449],
34	CDK4	NN	O	cdk4	nn	36	SENT_181	[p17l1426t2390r1647b2449],
35	inhibitor	NN	O	inhibitor	nn	36	SENT_181	[p17l1671t2386r2010b2463],
36	)	NN	O	)	conj_and	28	SENT_181	[p17l1671t2386r2010b2463],
37	are	VBP	O	be	ccomp	27	SENT_181	[p17l2040t2409r2142b2449],
38	currently	RB	DATE	currently	advmod	37	SENT_181	[p17l10t2490r340b2574],
39	under	IN	O	under	_	0	SENT_181	[p17l363t2490r576b2553],
40	way	NN	O	way	prep_under	37	SENT_181	[p17l600t2513r741b2574],
41	and	CC	O	and	_	0	SENT_181	[p17l766t2490r896b2553],
42	represent	VBP	O	represent	ccomp	27	SENT_181	[p17l922t2502r1255b2573],
43	opportunities	NNS	O	opportunity	dobj	42	SENT_181	[p17l1281t2496r1766b2573],
44	to	TO	O	to	_	0	SENT_181	[p17l1793t2502r1861b2553],
45	further	JJ	O	further	prep_to	42	SENT_181	[p17l1889t2490r2144b2553],
46	improve	VB	O	improve	dep	37	SENT_181	[p17l10t2599r309b2676],
47	outcomes	NNS	O	outcome	dobj	46	SENT_181	[p17l340t2605r687b2656],
48	for	IN	O	for	_	0	SENT_181	[p17l718t2593r821b2656],
49	patients	NNS	O	patient	prep_for	46	SENT_181	[p17l850t2599r1137b2676],
50	with	IN	O	with	_	0	SENT_181	[p17l1167t2593r1328b2656],
51	advanced	JJ	O	advanced	amod	54	SENT_181	[p17l1359t2593r1702b2656],
52	BRAFV600	NN	O	brafv600	nn	54	SENT_181	[p17l1732t2597r2143b2656],
53	mutant	JJ	O	mutant	amod	54	SENT_181	[p17l9t2688r256b2739],
54	melanoma	NN	O	melanoma	prep_with	49	SENT_181	[p17l276t2676r654b2739],
55	.	.	O	.	_	0	SENT_181	[p17l276t2676r654b2739],

1	CLINICAL	JJ	O	clinical	amod	2	SENT_182	[p17l20t2814r139b2835],
2	PHARMACOLOGY	NNP	O	PHARMACOLOGY	dep	12	SENT_182	[p17l148t2814r373b2835],
3	&	CC	O	&	_	0	SENT_182	[p17l380t2814r600b2835],
4	THERAPEUT	NNP	O	THERAPEUT	nn	6	SENT_182	[p17l380t2814r600b2835],
5	|	CD	NUMBER	|	num	6	SENT_182	[p17l380t2814r600b2835],
6	CS	NNP	O	CS	conj_and	2	SENT_182	[p17l380t2814r600b2835],
7	|	NNP	O	|	nn	8	SENT_182	[p17l610t2812r612b2842],
8	VOLUME	NNP	O	VOLUME	dep	2	SENT_182	[p17l620t2814r728b2835],
9	95	CD	NUMBER	95	num	10	SENT_182	[p17l736t2814r763b2835],
10	NUMBER	NN	O	number	dep	12	SENT_182	[p17l773t2814r881b2835],
11	1	CD	NUMBER	1	num	12	SENT_182	[p17l891t2815r898b2835],
12	|	CD	NUMBER	|	dep	15	SENT_182	[p17l912t2812r914b2842],
13	JANUARY	NNP	DATE	JANUARY	dep	12	SENT_182	[p17l923t2814r1041b2835],
14	2014	CD	DATE	2014	num	15	SENT_182	[p17l1049t2814r1107b2835],
15	29	CD	DATE	29	_	0	SENT_182	[p17l2109t2814r2139b2835],

1	CONFLICT	NN	O	conflict	nsubj	5	SENT_183	[p17l9t3190r323b3239],
2	OF	IN	O	of	_	0	SENT_183	[p17l337t3190r420b3239],
3	INTEREST	NN	O	interest	nn	4	SENT_183	[p17l439t3190r738b3239],
4	M.B.A.	NNP	O	M.B.A.	prep_of	1	SENT_183	[p17l10t3276r180b3325],
5	is	VBZ	O	be	_	0	SENT_183	[p17l198t3277r235b3325],
6	on	IN	O	on	_	0	SENT_183	[p17l251t3289r320b3325],
7	advisory	JJ	O	advisory	amod	8	SENT_183	[p17l338t3274r578b3339],
8	boards	NNS	O	board	prep_on	5	SENT_183	[p17l594t3274r785b3325],
9	for	IN	O	for	_	0	SENT_183	[p17l800t3273r877b3325],
10	Genentech	NNP	ORGANIZATION	Genentech	prep_for	8	SENT_183	[p17l891t3274r1217b3333],
11	,	,	O	,	_	0	SENT_183	[p17l891t3274r1217b3333],
12	Bristol-Myers	NNP	O	Bristol-Myers	nn	17	SENT_183	[p17l1235t3274r1600b3339],
13	Squibb	NNP	O	Squibb	nn	17	SENT_183	[p17l1616t3274r1829b3338],
14	,	,	O	,	_	0	SENT_183	[p17l1616t3274r1829b3338],
15	G	NNP	O	G	appos	17	SENT_183	[p17l8t3359r490b3417],
16	|	CD	NUMBER	|	num	17	SENT_183	[p17l8t3359r490b3417],
17	axoSmithK	NNP	O	axoSmithK	prep_on	5	SENT_183	[p17l8t3359r490b3417],
18	|	CD	NUMBER	|	num	19	SENT_183	[p17l8t3359r490b3417],
19	ine	NN	O	ine	dep	17	SENT_183	[p17l8t3359r490b3417],
20	,	,	O	,	_	0	SENT_183	[p17l8t3359r490b3417],
21	and	CC	O	and	_	0	SENT_183	[p17l506t3359r610b3410],
22	Prometheus	NNP	O	Prometheus	conj_and	8	SENT_183	[p17l630t3359r984b3410],
23	.	.	O	.	_	0	SENT_183	[p17l630t3359r984b3410],

1	S.J.	NNP	PERSON	S.J.	nsubj	2	SENT_184	[p17l1000t3361r1082b3410],
2	declared	VBD	O	declare	_	0	SENT_184	[p17l1098t3359r1339b3410],
3	no	DT	O	no	det	4	SENT_184	[p17l1359t3374r1429b3410],
4	conflict	NN	O	conflict	dobj	2	SENT_184	[p17l1445t3359r1654b3410],
5	of	IN	O	of	_	0	SENT_184	[p17l1669t3359r1727b3410],
6	interest	NN	O	interest	prep_of	4	SENT_184	[p17l1739t3362r1964b3410],
7	.	.	O	.	_	0	SENT_184	[p17l1739t3362r1964b3410],

1	©	RB	O	©	dep	2	SENT_185	[p17l8t3547r48b3588],
2	2014	CD	DATE	2014	dep	4	SENT_185	[p17l64t3547r194b3591],
3	American	NNP	ORGANIZATION	American	nn	4	SENT_185	[p17l208t3546r462b3591],
4	Society	NNP	ORGANIZATION	Society	_	0	SENT_185	[p17l480t3545r675b3604],
5	for	IN	O	for	_	0	SENT_185	[p17l687t3543r761b3591],
6	Clinical	JJ	O	clinical	amod	7	SENT_185	[p17l775t3543r964b3591],
7	Pharmacology	NN	O	pharmacology	prep_for	4	SENT_185	[p17l984t3543r1371b3604],
8	and	CC	O	and	_	0	SENT_185	[p17l1384t3543r1482b3591],
9	Therapeutics	NNS	O	therapeutics	prep_for	4	SENT_185	[p17l1494t3543r1843b3603],

1	Siegel	NNP	PERSON	Siegel	_	0	SENT_186	[p18l130t66r299b129],
2	,	,	O	,	_	0	SENT_186	[p18l130t66r299b129],
3	R.	NNP	O	R.	conj_and	1	SENT_186	[p18l316t68r370b123],
4	,	,	O	,	_	0	SENT_186	[p18l316t68r370b123],
5	Naishadham	NNP	LOCATION	Naishadham	conj_and	1	SENT_186	[p18l387t66r727b123],
6	,	,	O	,	_	0	SENT_186	[p18l387t66r727b123],
7	D.	NNP	ORGANIZATION	D.	conj_and	1	SENT_186	[p18l744t68r791b115],
8	&	CC	ORGANIZATION	&	_	0	SENT_186	[p18l805t67r842b115],
9	Jemal	NNP	ORGANIZATION	Jemal	conj_and	1	SENT_186	[p18l853t66r1018b123],
10	,	,	O	,	_	0	SENT_186	[p18l853t66r1018b123],
11	A.	NNP	O	A.	nn	13	SENT_186	[p18l1032t68r1080b115],
12	Cancer	NNP	O	Cancer	nn	13	SENT_186	[p18l1095t67r1276b115],
13	statistics	NNS	O	statistics	appos	1	SENT_186	[p18l1289t68r1524b123],
14	,	,	O	,	_	0	SENT_186	[p18l1289t68r1524b123],
15	2013	CD	DATE	2013	appos	13	SENT_186	[p18l1539t69r1678b115],
16	.	.	O	.	_	0	SENT_186	[p18l1539t69r1678b115],

1	CA	NNP	O	CA	_	0	SENT_187	[p18l1693t67r1772b115],
2	.	.	O	.	_	0	SENT_187	[p18l1693t67r1772b115],

1	Cancer	NN	O	cancer	_	0	SENT_188	[p18l1787t67r2003b115],
2	}	NN	O	}	dep	1	SENT_188	[p18l1787t67r2003b115],
3	.	.	O	.	_	0	SENT_188	[p18l1787t67r2003b115],

1	Clin	NNP	O	Clin	_	0	SENT_189	[p18l2019t66r2126b115],
2	.	.	O	.	_	0	SENT_189	[p18l2019t66r2126b115],

1	63	CD	NUMBER	63	_	0	SENT_190	[p18l131t146r211b199],
2	,	,	O	,	_	0	SENT_190	[p18l131t146r211b199],
3	1	CD	NUMBER	1	number	4	SENT_190	[p18l230t147r245b191],
4	1-30	CD	NUMBER	1-30	appos	1	SENT_190	[p18l263t146r384b192],
5	(	CD	NUMBER	(	num	7	SENT_190	[p18l401t144r575b199],
6	2013	CD	DATE	2013	num	7	SENT_190	[p18l401t144r575b199],
7	)	NN	O	)	dep	4	SENT_190	[p18l401t144r575b199],
8	.	.	O	.	_	0	SENT_190	[p18l401t144r575b199],

1	Middleton	NNP	LOCATION	Middleton	nn	3	SENT_191	[p18l131t221r416b278],
2	,	,	O	,	_	0	SENT_191	[p18l131t221r416b278],
3	M.R.	NNP	O	M.R.	_	0	SENT_191	[p18l431t223r538b270],
4	et	FW	O	et	nn	5	SENT_191	[p18l552t228r601b270],
5	al.	FW	O	al.	dep	3	SENT_191	[p18l610t221r667b270],
6	.	.	O	.	_	0	SENT_191	[p18l610t221r667b270],

1	Randomized	VBN	O	randomize	_	0	SENT_192	[p18l684t221r1010b270],
2	phase	NN	O	phase	nn	4	SENT_192	[p18l1029t221r1182b283],
3	III	CD	NUMBER	iii	num	4	SENT_192	[p18l1199t223r1235b270],
4	study	NN	O	study	dobj	1	SENT_192	[p18l1253t221r1397b284],
5	of	IN	O	of	_	0	SENT_192	[p18l1410t220r1465b270],
6	temozolomide	NN	O	temozolomide	prep_of	4	SENT_192	[p18l1473t221r1858b270],
7	versus	CC	O	versus	_	0	SENT_192	[p18l1872t235r2036b270],
8	dacarbazine	NN	O	dacarbazine	conj_versus	4	SENT_192	[p18l131t299r450b348],
9	in	IN	O	in	_	0	SENT_192	[p18l466t301r509b348],
10	the	DT	O	the	det	11	SENT_192	[p18l524t299r610b348],
11	treatment	NN	O	treatment	prep_in	8	SENT_192	[p18l623t306r887b348],
12	of	IN	O	of	_	0	SENT_192	[p18l901t298r955b348],
13	patients	NNS	O	patient	prep_of	11	SENT_192	[p18l966t301r1176b361],
14	with	IN	O	with	_	0	SENT_192	[p18l1190t299r1303b348],
15	advanced	JJ	O	advanced	amod	20	SENT_192	[p18l1319t299r1573b348],
16	metastatic	JJ	O	metastatic	amod	20	SENT_192	[p18l1591t301r1863b348],
17	malignant	JJ	O	malignant	amod	20	SENT_192	[p18l1880t299r2146b362],
18	me	PRP	O	I	dep	17	SENT_192	[p18l133t376r470b425],
19	|	JJ	O	|	amod	20	SENT_192	[p18l133t376r470b425],
20	anoma	NN	O	anoma	prep_with	13	SENT_192	[p18l133t376r470b425],
21	.	.	O	.	_	0	SENT_192	[p18l133t376r470b425],

1	J.	NNP	PERSON	J.	nn	2	SENT_193	[p18l133t376r470b425],
2	Clin	NNP	PERSON	Clin	_	0	SENT_193	[p18l486t376r591b425],
3	.	.	O	.	_	0	SENT_193	[p18l486t376r591b425],

1	Oncol	NN	O	oncol	_	0	SENT_194	[p18l607t376r766b425],
2	.	.	O	.	_	0	SENT_194	[p18l607t376r766b425],

1	18	CD	NUMBER	18	_	0	SENT_195	[p18l784t379r860b432],
2	,	,	O	,	_	0	SENT_195	[p18l784t379r860b432],
3	158-166	CD	NUMBER	158-166	number	4	SENT_195	[p18l880t379r1099b425],
4	(	CD	NUMBER	(	appos	1	SENT_195	[p18l1115t377r1289b432],
5	2000	CD	DATE	2000	num	6	SENT_195	[p18l1115t377r1289b432],
6	)	NN	O	)	dep	4	SENT_195	[p18l1115t377r1289b432],
7	.	.	O	.	_	0	SENT_195	[p18l1115t377r1289b432],

1	Bhatia	NNP	PERSON	Bhatia	_	0	SENT_196	[p18l132t454r306b511],
2	,	,	O	,	_	0	SENT_196	[p18l132t454r306b511],
3	S.	NNP	O	S.	conj_and	1	SENT_196	[p18l320t454r569b517],
4	,	,	O	,	_	0	SENT_196	[p18l320t454r569b517],
5	Tykodi	NNP	LOCATION	Tykodi	conj_and	1	SENT_196	[p18l320t454r569b517],
6	,	,	O	,	_	0	SENT_196	[p18l320t454r569b517],
7	S.S.	NNP	ORGANIZATION	S.S.	conj_and	1	SENT_196	[p18l584t455r669b503],
8	&	CC	ORGANIZATION	&	_	0	SENT_196	[p18l683t454r1026b516],
9	Thompson	NNP	ORGANIZATION	Thompson	conj_and	1	SENT_196	[p18l683t454r1026b516],
10	,	,	O	,	_	0	SENT_196	[p18l683t454r1026b516],
11	J.A.	NNP	O	J.A.	nn	12	SENT_196	[p18l1038t456r1406b503],
12	Treatment	NN	O	treatment	appos	1	SENT_196	[p18l1038t456r1406b503],
13	of	IN	O	of	_	0	SENT_196	[p18l1420t453r1474b503],
14	metastatic	JJ	O	metastatic	amod	15	SENT_196	[p18l1486t456r1758b503],
15	melanoma	NN	O	melanoma	prep_of	12	SENT_196	[p18l1774t454r2066b503],
16	:	:	O	:	_	0	SENT_196	[p18l1774t454r2066b503],
17	an	DT	O	a	det	18	SENT_196	[p18l2081t468r2141b503],
18	overview	NN	O	overview	dep	1	SENT_196	[p18l131t534r381b581],
19	.	.	O	.	_	0	SENT_196	[p18l131t534r381b581],

1	Oncology	NNP	O	Oncology	nn	4	SENT_197	[p18l396t532r641b595],
2	(	NNP	O	(	nn	4	SENT_197	[p18l653t532r887b589],
3	Williston	NNP	LOCATION	Williston	nn	4	SENT_197	[p18l653t532r887b589],
4	Park	NNP	LOCATION	Park	_	0	SENT_197	[p18l901t532r1023b589],
5	,	,	O	,	_	0	SENT_197	[p18l901t532r1023b589],
6	NY	NNP	O	NY	appos	4	SENT_197	[p18l1037t533r1126b589],
7	)	CD	NUMBER	)	number	8	SENT_197	[p18l1037t533r1126b589],
8	23	CD	NUMBER	23	dep	6	SENT_197	[p18l1141t535r1221b589],
9	,	,	O	,	_	0	SENT_197	[p18l1141t535r1221b589],
10	488-496	CD	NUMBER	488-496	number	11	SENT_197	[p18l1234t535r1459b581],
11	(	CD	NUMBER	(	appos	4	SENT_197	[p18l1475t533r1649b589],
12	2009	CD	DATE	2009	num	13	SENT_197	[p18l1475t533r1649b589],
13	)	NN	O	)	dep	11	SENT_197	[p18l1475t533r1649b589],
14	.	.	O	.	_	0	SENT_197	[p18l1475t533r1649b589],

1	Eggermont	NNP	O	Eggermont	_	0	SENT_198	[p18l132t612r438b673],
2	,	,	O	,	_	0	SENT_198	[p18l132t612r438b673],
3	A.M.	NNP	ORGANIZATION	A.M.	conj_and	1	SENT_198	[p18l452t612r565b659],
4	&	CC	ORGANIZATION	&	_	0	SENT_198	[p18l580t611r616b659],
5	Kirkwood	NNP	ORGANIZATION	Kirkwood	conj_and	1	SENT_198	[p18l631t610r892b667],
6	,	,	O	,	_	0	SENT_198	[p18l631t610r892b667],
7	J.M.	NNP	O	J.M.	appos	1	SENT_198	[p18l904t612r1002b659],
8	Re-evaluating	VBG	O	re-evaluate	partmod	7	SENT_198	[p18l1019t610r1379b673],
9	the	DT	O	the	det	10	SENT_198	[p18l1394t610r1480b659],
10	role	NN	O	role	dobj	8	SENT_198	[p18l1497t610r1593b659],
11	of	IN	O	of	_	0	SENT_198	[p18l1607t609r1662b659],
12	dacarbazine	NN	O	dacarbazine	prep_of	10	SENT_198	[p18l1671t610r1991b659],
13	in	IN	O	in	_	0	SENT_198	[p18l2007t612r2049b659],
14	metastatic	JJ	O	metastatic	amod	15	SENT_198	[p18l133t690r405b737],
15	melanoma	NN	O	melanoma	prep_in	12	SENT_198	[p18l422t688r714b737],
16	:	:	O	:	_	0	SENT_198	[p18l422t688r714b737],
17	what	WP	O	what	nsubj	18	SENT_198	[p18l728t688r859b737],
18	have	VBP	O	have	rcmod	7	SENT_198	[p18l875t688r996b737],
19	we	PRP	O	we	nsubj	20	SENT_198	[p18l1010t702r1085b737],
20	learned	VBD	O	learn	ccomp	18	SENT_198	[p18l1102t688r1295b737],
21	in	IN	O	in	_	0	SENT_198	[p18l1313t690r1356b737],
22	30	CD	DURATION	30	num	23	SENT_198	[p18l1373t691r1434b737],
23	years	NNS	NUMBER	year	prep_in	20	SENT_198	[p18l1447t689r1608b751],
24	?	.	O	?	_	0	SENT_198	[p18l1447t689r1608b751],

1	Eur	NNP	O	Eur	_	0	SENT_199	[p18l1622t690r1711b737],
2	.	.	O	.	_	0	SENT_199	[p18l1622t690r1711b737],

1	J.	NNP	O	J.	nn	2	SENT_200	[p18l1722t690r1756b737],
2	Cancer	NNP	O	Cancer	_	0	SENT_200	[p18l1772t689r1949b737],
3	40	CD	NUMBER	40	num	2	SENT_200	[p18l1958t691r2039b745],
4	,	,	O	,	_	0	SENT_200	[p18l1958t691r2039b745],
5	1825-1836	CD	DATE	1825-1836	num	2	SENT_200	[p18l136t768r421b814],
6	(	CD	NUMBER	(	num	8	SENT_200	[p18l437t766r611b821],
7	2004	CD	DATE	2004	num	8	SENT_200	[p18l437t766r611b821],
8	)	NN	O	)	dep	2	SENT_200	[p18l437t766r611b821],
9	.	.	O	.	_	0	SENT_200	[p18l437t766r611b821],

1	Atkins	NNP	PERSON	Atkins	_	0	SENT_201	[p18l129t843r304b900],
2	,	,	O	,	_	0	SENT_201	[p18l129t843r304b900],
3	M.B.	NNP	PERSON	M.B.	nn	4	SENT_201	[p18l319t845r425b892],
4	etal	NNP	O	etal	appos	1	SENT_201	[p18l440t843r554b892],
5	.	.	O	.	_	0	SENT_201	[p18l440t843r554b892],

1	High-dose	JJ	O	high-dose	amod	3	SENT_202	[p18l571t843r842b906],
2	recombinant	JJ	O	recombinant	amod	3	SENT_202	[p18l858t843r1195b892],
3	interleukin	NN	O	interleukin	_	0	SENT_202	[p18l1210t843r1489b892],
4	2	CD	NUMBER	2	num	5	SENT_202	[p18l1506t846r1533b892],
5	therapy	NN	O	therapy	dep	3	SENT_202	[p18l1547t843r1751b906],
6	for	IN	O	for	_	0	SENT_202	[p18l1763t842r1835b892],
7	patients	NNS	O	patient	prep_for	5	SENT_202	[p18l1850t845r2060b905],
8	with	IN	O	with	_	0	SENT_202	[p18l130t921r244b970],
9	metastatic	JJ	O	metastatic	amod	10	SENT_202	[p18l262t923r534b970],
10	melanoma	NN	O	melanoma	prep_with	7	SENT_202	[p18l550t921r843b970],
11	:	:	O	:	_	0	SENT_202	[p18l550t921r843b970],
12	analysis	NN	O	analysis	dep	3	SENT_202	[p18l857t921r1059b984],
13	of	IN	O	of	_	0	SENT_202	[p18l1074t920r1128b970],
14	270	CD	NUMBER	270	num	15	SENT_202	[p18l1138t924r1232b970],
15	patients	NNS	O	patient	prep_of	12	SENT_202	[p18l1249t923r1458b983],
16	treated	VBN	O	treat	partmod	15	SENT_202	[p18l1471t921r1658b970],
17	between	IN	O	between	_	0	SENT_202	[p18l1677t921r1904b970],
18	1985	CD	DATE	1985	prep_between	16	SENT_202	[p18l1925t924r2046b970],
19	and	CC	O	and	_	0	SENT_202	[p18l131t998r227b1047],
20	1993.1	CD	NUMBER	1993.1	prep_between	16	SENT_202	[p18l248t1000r428b1047],
21	.	.	O	.	_	0	SENT_202	[p18l248t1000r428b1047],

1	Clin	NNP	O	Clin	_	0	SENT_203	[p18l444t998r549b1047],
2	.	.	O	.	_	0	SENT_203	[p18l444t998r549b1047],

1	Oncol	NN	O	oncol	_	0	SENT_204	[p18l565t998r724b1047],
2	.	.	O	.	_	0	SENT_204	[p18l565t998r724b1047],

1	17	CD	NUMBER	17	_	0	SENT_205	[p18l742t1002r819b1054],
2	,	,	O	,	_	0	SENT_205	[p18l742t1002r819b1054],
3	2105-21	CD	NUMBER	2105-21	number	4	SENT_205	[p18l833t1001r1047b1047],
4	16	CD	NUMBER	16	appos	1	SENT_205	[p18l1065t1001r1123b1047],
5	(	CD	NUMBER	(	num	7	SENT_205	[p18l1139t999r1313b1054],
6	1999	CD	DATE	1999	num	7	SENT_205	[p18l1139t999r1313b1054],
7	)	NN	O	)	dep	4	SENT_205	[p18l1139t999r1313b1054],
8	.	.	O	.	_	0	SENT_205	[p18l1139t999r1313b1054],

1	Atkins	NNP	PERSON	Atkins	nn	4	SENT_206	[p18l129t1076r304b1133],
2	,	,	O	,	_	0	SENT_206	[p18l129t1076r304b1133],
3	M.B.	NNP	O	M.B.	appos	4	SENT_206	[p18l319t1078r425b1125],
4	etal.	NNP	O	etal.	_	0	SENT_206	[p18l440t1076r568b1133],
5	;	:	O	;	_	0	SENT_206	[p18l440t1076r568b1133],
6	Eastern	NNP	ORGANIZATION	Eastern	nn	9	SENT_206	[p18l584t1078r772b1125],
7	Cooperative	NNP	ORGANIZATION	Cooperative	nn	9	SENT_206	[p18l788t1077r1107b1138],
8	Oncology	NNP	ORGANIZATION	Oncology	nn	9	SENT_206	[p18l1122t1076r1378b1139],
9	Group	NNP	ORGANIZATION	Group	dep	4	SENT_206	[p18l1390t1078r1566b1138],
10	.	.	O	.	_	0	SENT_206	[p18l1390t1078r1566b1138],

1	Phase	NN	O	phase	nn	3	SENT_207	[p18l1583t1076r1733b1125],
2	III	CD	NUMBER	iii	num	3	SENT_207	[p18l1750t1078r1786b1125],
3	trial	NN	O	trial	_	0	SENT_207	[p18l1802t1076r1899b1125],
4	comparing	VBG	O	compare	rcmod	3	SENT_207	[p18l131t1156r415b1217],
5	concurrent	JJ	O	concurrent	amod	6	SENT_207	[p18l432t1161r720b1203],
6	biochemotherapy	NN	O	biochemotherapy	dobj	4	SENT_207	[p18l736t1154r1207b1217],
7	with	IN	O	with	_	0	SENT_207	[p18l1218t1154r1331b1203],
8	cisplatin	NN	O	cisplatin	nn	14	SENT_207	[p18l1348t1154r1578b1216],
9	,	,	O	,	_	0	SENT_207	[p18l1348t1154r1578b1216],
10	vinblastine	NN	O	vinblastine	dep	14	SENT_207	[p18l1591t1154r1892b1211],
11	,	,	O	,	_	0	SENT_207	[p18l1591t1154r1892b1211],
12	dacarbazine	NN	O	dacarbazine	dep	14	SENT_207	[p18l131t1232r463b1289],
13	,	,	O	,	_	0	SENT_207	[p18l131t1232r463b1289],
14	interleukin-2	NN	O	interleukin-2	prep_with	4	SENT_207	[p18l479t1232r825b1289],
15	,	,	O	,	_	0	SENT_207	[p18l479t1232r825b1289],
16	and	CC	O	and	_	0	SENT_207	[p18l839t1232r935b1281],
17	interferon	NN	O	interferon	nn	18	SENT_207	[p18l953t1231r1211b1281],
18	alfa-2b	NN	O	alfa-2b	conj_and	14	SENT_207	[p18l1227t1231r1406b1281],
19	with	IN	O	with	_	0	SENT_207	[p18l1420t1232r1533b1281],
20	cisplatin	NN	O	cisplatin	prep_with	4	SENT_207	[p18l1550t1232r1780b1294],
21	,	,	O	,	_	0	SENT_207	[p18l1550t1232r1780b1294],
22	vinblastine	NN	O	vinblastine	conj_and	20	SENT_207	[p18l1793t1232r2094b1289],
23	,	,	O	,	_	0	SENT_207	[p18l1793t1232r2094b1289],
24	and	CC	O	and	_	0	SENT_207	[p18l131t1310r227b1359],
25	dacarbazine	NN	O	dacarbazine	conj_and	20	SENT_207	[p18l244t1310r563b1359],
26	alone	RB	O	alone	advmod	20	SENT_207	[p18l578t1310r722b1359],
27	in	IN	O	in	_	0	SENT_207	[p18l737t1312r780b1359],
28	patients	NNS	O	patient	prep_in	20	SENT_207	[p18l799t1312r1008b1372],
29	with	IN	O	with	_	0	SENT_207	[p18l1022t1310r1135b1359],
30	metastatic	JJ	O	metastatic	amod	33	SENT_207	[p18l1154t1312r1426b1359],
31	malignant	JJ	O	malignant	amod	33	SENT_207	[p18l1441t1310r1708b1373],
32	melanoma	NN	O	melanoma	nn	33	SENT_207	[p18l1723t1310r2001b1359],
33	(	NN	O	(	prep_with	28	SENT_207	[p18l133t1389r338b1445],
34	E3695	NN	O	e3695	dep	39	SENT_207	[p18l133t1389r338b1445],
35	)	CD	NUMBER	)	num	34	SENT_207	[p18l133t1389r338b1445],
36	:	:	O	:	_	0	SENT_207	[p18l133t1389r338b1445],
37	a	DT	O	a	det	38	SENT_207	[p18l353t1402r378b1437],
38	trial	NN	O	trial	nsubj	39	SENT_207	[p18l393t1388r490b1437],
39	coordinated	VBN	O	coordinate	dep	3	SENT_207	[p18l507t1388r824b1437],
40	by	IN	O	by	_	0	SENT_207	[p18l842t1388r904b1451],
41	the	DT	O	the	det	45	SENT_207	[p18l916t1388r1001b1437],
42	Eastern	NNP	ORGANIZATION	Eastern	nn	45	SENT_207	[p18l1018t1390r1206b1437],
43	Cooperative	NNP	ORGANIZATION	Cooperative	nn	45	SENT_207	[p18l1223t1389r1542b1450],
44	Oncology	NNP	ORGANIZATION	Oncology	nn	45	SENT_207	[p18l1556t1388r1812b1451],
45	Group	NNP	ORGANIZATION	Group	prep_by	39	SENT_207	[p18l1824t1390r2000b1450],
46	.	.	O	.	_	0	SENT_207	[p18l1824t1390r2000b1450],

1	J.	NNP	PERSON	J.	nn	2	SENT_208	[p18l2010t1390r2045b1437],
2	Clin	NNP	PERSON	Clin	_	0	SENT_208	[p18l132t1465r236b1514],
3	.	.	O	.	_	0	SENT_208	[p18l132t1465r236b1514],

1	Oncol	NN	O	oncol	_	0	SENT_209	[p18l253t1465r412b1514],
2	.	.	O	.	_	0	SENT_209	[p18l253t1465r412b1514],

1	26	CD	NUMBER	26	_	0	SENT_210	[p18l427t1468r506b1521],
2	,	,	O	,	_	0	SENT_210	[p18l427t1468r506b1521],
3	5748-5754	CD	DURATION	5748-5754	number	4	SENT_210	[p18l521t1468r811b1514],
4	(	CD	NUMBER	(	appos	1	SENT_210	[p18l826t1466r1000b1521],
5	2008	CD	DATE	2008	num	6	SENT_210	[p18l826t1466r1000b1521],
6	)	NN	O	)	dep	4	SENT_210	[p18l826t1466r1000b1521],
7	.	.	O	.	_	0	SENT_210	[p18l826t1466r1000b1521],

1	Gray-Schopfer	NNP	PERSON	Gray-Schopfer	nsubj	16	SENT_211	[p18l130t1542r865b1607],
2	,	,	O	,	_	0	SENT_211	[p18l130t1542r865b1607],
3	V.	NNP	O	V.	nsubj	16	SENT_211	[p18l130t1542r865b1607],
4	,	,	O	,	_	0	SENT_211	[p18l130t1542r865b1607],
5	Wellbrock	NNP	O	Wellbrock	nsubj	16	SENT_211	[p18l130t1542r865b1607],
6	,	,	O	,	_	0	SENT_211	[p18l130t1542r865b1607],
7	C.	NNP	ORGANIZATION	C.	nsubj	16	SENT_211	[p18l880t1545r926b1593],
8	&	CC	ORGANIZATION	&	_	0	SENT_211	[p18l940t1545r977b1593],
9	Marais	NNP	ORGANIZATION	Marais	nsubj	16	SENT_211	[p18l991t1545r1172b1600],
10	,	,	O	,	_	0	SENT_211	[p18l991t1545r1172b1600],
11	R.	NNP	PERSON	R.	nn	13	SENT_211	[p18l1188t1545r1229b1592],
12	Melanoma	NNP	PERSON	Melanoma	nn	13	SENT_211	[p18l1245t1543r1522b1593],
13	biology	NN	O	biology	conj_and	1	SENT_211	[p18l1540t1543r1737b1606],
14	and	CC	O	and	_	0	SENT_211	[p18l1750t1543r1846b1593],
15	new	JJ	O	new	nsubj	16	SENT_211	[p18l1865t1558r1974b1593],
16	targeted	VBN	O	target	_	0	SENT_211	[p18l130t1621r353b1684],
17	therapy	NN	O	therapy	dobj	16	SENT_211	[p18l368t1621r581b1684],
18	.	.	O	.	_	0	SENT_211	[p18l368t1621r581b1684],

1	Nature	NNP	O	Nature	_	0	SENT_212	[p18l595t1623r769b1670],
2	445	CD	NUMBER	445	num	1	SENT_212	[p18l781t1625r897b1678],
3	,	,	O	,	_	0	SENT_212	[p18l781t1625r897b1678],
4	851	CD	NUMBER	851	num	1	SENT_212	[p18l912t1624r996b1670],
5	-857	CD	NUMBER	-857	number	6	SENT_212	[p18l1009t1624r1135b1670],
6	(	CD	NUMBER	(	dep	1	SENT_212	[p18l1152t1622r1326b1678],
7	2007	CD	DATE	2007	num	8	SENT_212	[p18l1152t1622r1326b1678],
8	)	NN	O	)	dep	6	SENT_212	[p18l1152t1622r1326b1678],
9	.	.	O	.	_	0	SENT_212	[p18l1152t1622r1326b1678],

1	Ball	NNP	O	Ball	_	0	SENT_213	[p18l132t1698r233b1754],
2	,	,	O	,	_	0	SENT_213	[p18l132t1698r233b1754],
3	N.J.	NNP	LOCATION	N.J.	conj_and	1	SENT_213	[p18l250t1698r503b1754],
4	,	,	O	,	_	0	SENT_213	[p18l250t1698r503b1754],
5	Yohn	NNP	PERSON	Yohn	conj_and	1	SENT_213	[p18l250t1698r503b1754],
6	,	,	O	,	_	0	SENT_213	[p18l250t1698r503b1754],
7	J.J.	NNP	PERSON	J.J.	conj_and	1	SENT_213	[p18l516t1700r598b1754],
8	,	,	O	,	_	0	SENT_213	[p18l516t1700r598b1754],
9	Morelli	NNP	PERSON	Morelli	conj_and	1	SENT_213	[p18l614t1698r805b1754],
10	,	,	O	,	_	0	SENT_213	[p18l614t1698r805b1754],
11	J.G.	NNP	LOCATION	J.G.	conj_and	1	SENT_213	[p18l817t1700r919b1754],
12	,	,	O	,	_	0	SENT_213	[p18l817t1700r919b1754],
13	Norris	NNP	PERSON	Norris	conj_and	1	SENT_213	[p18l936t1700r1100b1754],
14	,	,	O	,	_	0	SENT_213	[p18l936t1700r1100b1754],
15	D.A.	NNP	LOCATION	D.A.	conj_and	1	SENT_213	[p18l1117t1700r1229b1754],
16	,	,	O	,	_	0	SENT_213	[p18l1117t1700r1229b1754],
17	Golitz	NNP	LOCATION	Golitz	conj_and	1	SENT_213	[p18l1244t1698r1407b1754],
18	,	,	O	,	_	0	SENT_213	[p18l1244t1698r1407b1754],
19	L.E.	NNP	ORGANIZATION	L.E.	conj_and	1	SENT_213	[p18l1424t1700r1505b1747],
20	&	CC	ORGANIZATION	&	_	0	SENT_213	[p18l1519t1700r1556b1747],
21	Hoefﬂer	NNP	ORGANIZATION	Hoefﬂer	conj_and	1	SENT_213	[p18l1571t1697r1788b1754],
22	,	,	O	,	_	0	SENT_213	[p18l1571t1697r1788b1754],
23	J.P.	NNP	O	J.P.	nn	25	SENT_213	[p18l1800t1700r1872b1747],
24	Ras	NN	O	ra	nn	25	SENT_213	[p18l1888t1700r1973b1747],
25	mutations	NNS	O	mutation	appos	1	SENT_213	[p18l133t1778r398b1826],
26	in	IN	O	in	_	0	SENT_213	[p18l414t1778r457b1825],
27	human	JJ	O	human	amod	28	SENT_213	[p18l476t1776r657b1826],
28	melanoma	NN	O	melanoma	prep_in	25	SENT_213	[p18l676t1776r969b1826],
29	:	:	O	:	_	0	SENT_213	[p18l676t1776r969b1826],
30	a	DT	O	a	det	31	SENT_213	[p18l983t1791r1008b1826],
31	marker	NN	O	marker	dep	1	SENT_213	[p18l1026t1776r1209b1826],
32	of	IN	O	of	_	0	SENT_213	[p18l1222t1775r1277b1826],
33	malignant	JJ	O	malignant	amod	34	SENT_213	[p18l1288t1776r1554b1839],
34	progression	NN	O	progression	prep_of	31	SENT_213	[p18l1570t1778r1936b1839],
35	.	.	O	.	_	0	SENT_213	[p18l1570t1778r1936b1839],

1	J.	NNP	O	J.	nn	2	SENT_214	[p18l1570t1778r1936b1839],
2	Invest	NNP	O	Invest	_	0	SENT_214	[p18l1951t1778r2107b1826],
3	.	.	O	.	_	0	SENT_214	[p18l1951t1778r2107b1826],

1	Dermatol	NNP	PERSON	Dermatol	_	0	SENT_215	[p18l131t1853r383b1902],
2	.	.	O	.	_	0	SENT_215	[p18l131t1853r383b1902],

1	102	CD	NUMBER	102	_	0	SENT_216	[p18l401t1856r513b1909],
2	,	,	O	,	_	0	SENT_216	[p18l401t1856r513b1909],
3	285-290	CD	NUMBER	285-290	number	4	SENT_216	[p18l528t1856r752b1902],
4	(	CD	NUMBER	(	appos	1	SENT_216	[p18l768t1854r942b1909],
5	1994	CD	DATE	1994	num	6	SENT_216	[p18l768t1854r942b1909],
6	)	NN	O	)	dep	4	SENT_216	[p18l768t1854r942b1909],
7	.	.	O	.	_	0	SENT_216	[p18l768t1854r942b1909],

1	Curtin	NNP	PERSON	Curtin	nn	3	SENT_217	[p18l130t1933r304b1988],
2	,	,	O	,	_	0	SENT_217	[p18l130t1933r304b1988],
3	J.A.	NNP	PERSON	J.A.	_	0	SENT_217	[p18l316t1933r402b1981],
4	et	FW	O	et	nn	5	SENT_217	[p18l416t1938r465b1981],
5	al.	FW	O	al.	dep	3	SENT_217	[p18l474t1931r531b1981],
6	.	.	O	.	_	0	SENT_217	[p18l474t1931r531b1981],

1	Distinct	JJ	O	distinct	amod	2	SENT_218	[p18l548t1933r746b1981],
2	sets	NNS	O	set	_	0	SENT_218	[p18l760t1938r859b1981],
3	of	IN	O	of	_	0	SENT_218	[p18l874t1930r928b1981],
4	genetic	JJ	O	genetic	amod	5	SENT_218	[p18l937t1933r1133b1994],
5	alterations	NNS	O	alteration	prep_of	2	SENT_218	[p18l1147t1931r1423b1981],
6	in	IN	O	in	_	0	SENT_218	[p18l1439t1933r1482b1980],
7	melanoma	NN	O	melanoma	prep_in	2	SENT_218	[p18l1501t1931r1793b1981],
8	.	.	O	.	_	0	SENT_218	[p18l1501t1931r1793b1981],

1	N.	NNP	O	N.	nn	2	SENT_219	[p18l1807t1933r1855b1981],
2	Engl	NNP	O	Engl	_	0	SENT_219	[p18l1870t1931r1988b1994],
3	.	.	O	.	_	0	SENT_219	[p18l1870t1931r1988b1994],

1	J.	NNP	O	J.	nn	2	SENT_220	[p18l1999t1933r2033b1981],
2	Med	NNP	O	Med	_	0	SENT_220	[p18l130t2008r252b2057],
3	.	.	O	.	_	0	SENT_220	[p18l130t2008r252b2057],

1	353	CD	NUMBER	353	_	0	SENT_221	[p18l267t2011r382b2064],
2	,	,	O	,	_	0	SENT_221	[p18l267t2011r382b2064],
3	21	CD	NUMBER	21	number	4	SENT_221	[p18l397t2011r448b2056],
4	35-2147	CD	NUMBER	35-2147	appos	1	SENT_221	[p18l463t2011r685b2057],
5	(	CD	NUMBER	(	num	7	SENT_221	[p18l702t2009r876b2064],
6	2005	CD	DATE	2005	num	7	SENT_221	[p18l702t2009r876b2064],
7	)	NN	O	)	dep	4	SENT_221	[p18l702t2009r876b2064],
8	.	.	O	.	_	0	SENT_221	[p18l702t2009r876b2064],

1	Davies	NNP	PERSON	Davies	_	0	SENT_222	[p18l132t2088r314b2143],
2	,	,	O	,	_	0	SENT_222	[p18l132t2088r314b2143],
3	H.	NNP	O	H.	nn	4	SENT_222	[p18l330t2088r378b2136],
4	etal	NN	O	etal	appos	1	SENT_222	[p18l392t2086r507b2136],
5	.	.	O	.	_	0	SENT_222	[p18l392t2086r507b2136],

1	Mutations	NNS	O	mutation	_	0	SENT_223	[p18l524t2088r787b2136],
2	of	IN	O	of	_	0	SENT_223	[p18l802t2085r856b2136],
3	the	DT	O	the	det	5	SENT_223	[p18l865t2086r950b2136],
4	BRAF	NN	O	braf	nn	5	SENT_223	[p18l967t2088r1100b2135],
5	gene	NN	O	gene	prep_of	1	SENT_223	[p18l1115t2101r1246b2149],
6	in	IN	O	in	_	0	SENT_223	[p18l1262t2088r1304b2135],
7	human	JJ	O	human	amod	8	SENT_223	[p18l1323t2086r1505b2136],
8	cancer	NN	O	cancer	prep_in	1	SENT_223	[p18l1521t2101r1702b2136],
9	.	.	O	.	_	0	SENT_223	[p18l1521t2101r1702b2136],

1	Nature	NNP	O	Nature	_	0	SENT_224	[p18l1716t2088r1890b2136],
2	417	CD	NUMBER	417	num	1	SENT_224	[p18l1902t2090r2018b2143],
3	,	,	O	,	_	0	SENT_224	[p18l1902t2090r2018b2143],
4	949-954	CD	NUMBER	949-954	num	1	SENT_224	[p18l132t2166r356b2212],
5	(	CD	NUMBER	(	num	7	SENT_224	[p18l371t2164r546b2219],
6	2002	CD	DATE	2002	num	7	SENT_224	[p18l371t2164r546b2219],
7	)	NN	O	)	dep	1	SENT_224	[p18l371t2164r546b2219],
8	.	.	O	.	_	0	SENT_224	[p18l371t2164r546b2219],

1	Wan	NNP	O	Wan	nn	3	SENT_225	[p18l129t2243r257b2298],
2	,	,	O	,	_	0	SENT_225	[p18l129t2243r257b2298],
3	P.T.	NNP	O	P.T.	_	0	SENT_225	[p18l274t2243r346b2291],
4	et	FW	O	et	nn	5	SENT_225	[p18l360t2248r409b2291],
5	al.	FW	O	al.	dep	3	SENT_225	[p18l418t2241r489b2298],
6	;	:	O	;	_	0	SENT_225	[p18l418t2241r489b2298],
7	Cancer	NN	O	cancer	dep	3	SENT_225	[p18l503t2242r683b2291],
8	Genome	NNP	O	Genome	nn	9	SENT_225	[p18l696t2243r922b2291],
9	Project	NNP	O	Project	dep	7	SENT_225	[p18l939t2243r1131b2304],
10	.	.	O	.	_	0	SENT_225	[p18l939t2243r1131b2304],

1	Mechanism	NN	O	mechanism	_	0	SENT_226	[p18l1146t2241r1446b2291],
2	of	IN	O	of	_	0	SENT_226	[p18l1462t2240r1517b2291],
3	activation	NN	O	activation	prep_of	1	SENT_226	[p18l1527t2243r1783b2291],
4	of	IN	O	of	_	0	SENT_226	[p18l1800t2240r1854b2291],
5	the	DT	O	the	det	8	SENT_226	[p18l1862t2241r1948b2291],
6	RAFERK	NN	O	raferk	nn	8	SENT_226	[p18l1965t2243r2083b2290, p18l134t2321r230b2368],
7	signaling	NN	O	signaling	nn	8	SENT_226	[p18l242t2319r478b2382],
8	pathway	NN	O	pathway	prep_of	1	SENT_226	[p18l496t2319r721b2382],
9	by	IN	O	by	_	0	SENT_226	[p18l736t2319r798b2382],
10	oncogenic	JJ	O	oncogenic	amod	11	SENT_226	[p18l811t2321r1087b2382],
11	mutations	NNS	O	mutation	prep_by	8	SENT_226	[p18l1103t2321r1368b2369],
12	of	IN	O	of	_	0	SENT_226	[p18l1383t2318r1437b2368],
13	B-RAF	NN	O	b-raf	prep_of	1	SENT_226	[p18l1449t2321r1608b2368],
14	.	.	O	.	_	0	SENT_226	[p18l1449t2321r1608b2368],

1	Cell	NN	O	cell	_	0	SENT_227	[p18l1624t2319r1715b2369],
2	1	CD	NUMBER	1	number	3	SENT_227	[p18l1729t2323r1749b2368],
3	16	CD	NUMBER	16	dep	1	SENT_227	[p18l1764t2322r1841b2376],
4	,	,	O	,	_	0	SENT_227	[p18l1764t2322r1841b2376],
5	855-867	CD	NUMBER	855-867	number	6	SENT_227	[p18l1855t2322r2079b2369],
6	(	CD	NUMBER	(	appos	1	SENT_227	[p18l133t2397r307b2452],
7	2004	CD	DATE	2004	num	8	SENT_227	[p18l133t2397r307b2452],
8	)	NN	O	)	dep	6	SENT_227	[p18l133t2397r307b2452],
9	.	.	O	.	_	0	SENT_227	[p18l133t2397r307b2452],

1	Long	NNP	O	Long	nn	3	SENT_228	[p18l132t2476r273b2537],
2	,	,	O	,	_	0	SENT_228	[p18l132t2476r273b2537],
3	G.V.	NNP	O	G.V.	_	0	SENT_228	[p18l287t2476r383b2524],
4	et	FW	O	et	nn	5	SENT_228	[p18l397t2481r446b2524],
5	al.	FW	O	al.	dep	3	SENT_228	[p18l455t2474r512b2524],
6	.	.	O	.	_	0	SENT_228	[p18l455t2474r512b2524],

1	Prognostic	JJ	O	prognostic	amod	4	SENT_229	[p18l529t2476r805b2537],
2	and	CC	O	and	_	0	SENT_229	[p18l820t2474r916b2524],
3	clinicopathologic	JJ	O	clinicopathologic	conj_and	1	SENT_229	[p18l933t2474r1387b2537],
4	associations	NNS	O	association	_	0	SENT_229	[p18l1401t2476r1718b2524],
5	of	IN	O	of	_	0	SENT_229	[p18l1732t2473r1786b2524],
6	oncogenic	JJ	O	oncogenic	amod	7	SENT_229	[p18l1796t2476r2072b2537],
7	BRAF	NN	O	braf	prep_of	4	SENT_229	[p18l134t2553r266b2600],
8	in	IN	O	in	_	0	SENT_229	[p18l283t2553r325b2599],
9	metastatic	JJ	O	metastatic	amod	12	SENT_229	[p18l344t2553r616b2600],
10	me	PRP	O	I	npadvmod	11	SENT_229	[p18l632t2551r969b2600],
11	|	JJ	O	|	amod	12	SENT_229	[p18l632t2551r969b2600],
12	anoma	NN	O	anoma	prep_in	4	SENT_229	[p18l632t2551r969b2600],
13	.	.	O	.	_	0	SENT_229	[p18l632t2551r969b2600],

1	J.	NNP	PERSON	J.	nn	2	SENT_230	[p18l632t2551r969b2600],
2	Clin	NNP	PERSON	Clin	_	0	SENT_230	[p18l985t2551r1090b2600],
3	.	.	O	.	_	0	SENT_230	[p18l985t2551r1090b2600],

1	Oncol	NN	O	oncol	_	0	SENT_231	[p18l1105t2551r1265b2600],
2	.	.	O	.	_	0	SENT_231	[p18l1105t2551r1265b2600],

1	29	CD	NUMBER	29	_	0	SENT_232	[p18l1280t2554r1359b2607],
2	,	,	O	,	_	0	SENT_232	[p18l1280t2554r1359b2607],
3	1239-1246	CD	DATE	1239-1246	num	4	SENT_232	[p18l1378t2554r1663b2600],
4	(	NN	O	(	appos	1	SENT_232	[p18l1679t2552r1779b2607],
5	201	CD	NUMBER	201	number	6	SENT_232	[p18l1679t2552r1779b2607],
6	1	CD	NUMBER	1	num	7	SENT_232	[p18l1798t2552r1853b2607],
7	)	NN	O	)	dep	4	SENT_232	[p18l1798t2552r1853b2607],
8	.	.	O	.	_	0	SENT_232	[p18l1798t2552r1853b2607],

1	Houben	NNP	PERSON	Houben	nn	3	SENT_233	[p18l132t2629r354b2686],
2	,	,	O	,	_	0	SENT_233	[p18l132t2629r354b2686],
3	R.	NNP	O	R.	_	0	SENT_233	[p18l371t2631r412b2679],
4	et	FW	O	et	nn	5	SENT_233	[p18l426t2636r475b2679],
5	al.	FW	O	al.	dep	3	SENT_233	[p18l484t2629r541b2679],
6	.	.	O	.	_	0	SENT_233	[p18l484t2629r541b2679],

1	Constitutive	JJ	O	constitutive	amod	2	SENT_234	[p18l555t2631r873b2679],
2	activation	NN	O	activation	nsubjpass	12	SENT_234	[p18l887t2631r1144b2679],
3	of	IN	O	of	_	0	SENT_234	[p18l1160t2628r1215b2679],
4	the	DT	O	the	det	7	SENT_234	[p18l1223t2629r1309b2679],
5	Ras-Raf	NN	MISC	ras-raf	nn	7	SENT_234	[p18l1326t2628r1519b2679],
6	signaling	NN	O	signaling	nn	7	SENT_234	[p18l1529t2629r1764b2692],
7	pathway	NN	O	pathway	prep_of	2	SENT_234	[p18l1783t2629r2008b2692],
8	in	IN	O	in	_	0	SENT_234	[p18l133t2709r175b2756],
9	metastatic	JJ	O	metastatic	amod	10	SENT_234	[p18l194t2709r466b2757],
10	melanoma	NN	O	melanoma	prep_in	7	SENT_234	[p18l482t2707r760b2757],
11	is	VBZ	O	be	auxpass	12	SENT_234	[p18l778t2709r812b2757],
12	associated	VBN	O	associate	_	0	SENT_234	[p18l826t2707r1098b2757],
13	with	IN	O	with	_	0	SENT_234	[p18l1114t2707r1227b2757],
14	poor	JJ	O	poor	amod	15	SENT_234	[p18l1246t2721r1368b2769],
15	prognosis	NN	O	prognosis	prep_with	12	SENT_234	[p18l1383t2709r1652b2770],
16	.	.	O	.	_	0	SENT_234	[p18l1383t2709r1652b2770],

1	J.	NNP	PERSON	J.	nn	2	SENT_235	[p18l1662t2709r1696b2757],
2	Carcinog	NNP	PERSON	Carcinog	_	0	SENT_235	[p18l1712t2709r1951b2770],
3	.	.	O	.	_	0	SENT_235	[p18l1712t2709r1951b2770],

1	3	CD	NUMBER	3	_	0	SENT_236	[p18l1965t2710r2009b2764],
2	,	,	O	,	_	0	SENT_236	[p18l1965t2710r2009b2764],
3	6	CD	NUMBER	6	number	4	SENT_236	[p18l2024t2710r2053b2757],
4	(	CD	NUMBER	(	appos	1	SENT_236	[p18l133t2785r307b2840],
5	2004	CD	DATE	2004	num	6	SENT_236	[p18l133t2785r307b2840],
6	)	NN	O	)	dep	4	SENT_236	[p18l133t2785r307b2840],
7	.	.	O	.	_	0	SENT_236	[p18l133t2785r307b2840],

1	Moreau	NNP	PERSON	Moreau	_	0	SENT_237	[p18l131t2863r343b2918],
2	,	,	O	,	_	0	SENT_237	[p18l131t2863r343b2918],
3	S.	NNP	O	S.	nn	4	SENT_237	[p18l358t2863r398b2911],
4	etal	NNP	O	etal	appos	1	SENT_237	[p18l412t2861r527b2911],
5	.	.	O	.	_	0	SENT_237	[p18l412t2861r527b2911],

1	Prognostic	JJ	O	prognostic	amod	2	SENT_238	[p18l543t2863r821b2924],
2	value	NN	O	value	nsubj	6	SENT_238	[p18l833t2861r974b2911],
3	of	IN	O	of	_	0	SENT_238	[p18l988t2860r1043b2911],
4	BRAF	NN	O	braf	prep_of	2	SENT_238	[p18l1055t2853r1334b2918],
5	(	CD	NUMBER	(	num	6	SENT_238	[p18l1055t2853r1334b2918],
6	V5	NN	O	v5	_	0	SENT_238	[p18l1055t2853r1334b2918],
7	°	CD	NUMBER	°	number	8	SENT_238	[p18l1055t2853r1334b2918],
8	°	CD	NUMBER	°	num	10	SENT_238	[p18l1055t2853r1334b2918],
9	)	NN	O	)	nn	10	SENT_238	[p18l1055t2853r1334b2918],
10	mutations	NNS	O	mutation	dobj	6	SENT_238	[p18l1353t2863r1618b2911],
11	in	IN	O	in	_	0	SENT_238	[p18l1634t2863r1676b2910],
12	melanoma	NN	O	melanoma	nn	13	SENT_238	[p18l1695t2861r1973b2911],
13	patients	NNS	O	patient	prep_in	10	SENT_238	[p18l133t2941r343b3001],
14	after	IN	O	after	_	0	SENT_238	[p18l357t2938r478b2988],
15	resection	NN	O	resection	prep_after	6	SENT_238	[p18l493t2941r730b2988],
16	of	IN	O	of	_	0	SENT_238	[p18l746t2938r801b2988],
17	metastatic	JJ	O	metastatic	amod	19	SENT_238	[p18l812t2941r1084b2988],
18	lymph	NN	O	lymph	nn	19	SENT_238	[p18l1101t2939r1263b3002],
19	nodes	NNS	O	node	prep_of	15	SENT_238	[p18l1281t2939r1451b2988],
20	.	.	O	.	_	0	SENT_238	[p18l1281t2939r1451b2988],

1	Ann	NNP	PERSON	Ann	_	0	SENT_239	[p18l1461t2941r1577b2988],
2	.	.	O	.	_	0	SENT_239	[p18l1461t2941r1577b2988],

1	Surg	NNP	O	Surg	_	0	SENT_240	[p18l1591t2940r1715b3002],
2	.	.	O	.	_	0	SENT_240	[p18l1591t2940r1715b3002],

1	Oncol	NN	O	oncol	_	0	SENT_241	[p18l1731t2939r1890b2988],
2	.	.	O	.	_	0	SENT_241	[p18l1731t2939r1890b2988],

1	19	CD	NUMBER	19	_	0	SENT_242	[p18l1907t2942r1984b2996],
2	,	,	O	,	_	0	SENT_242	[p18l1907t2942r1984b2996],
3	4314-4321	CD	DURATION	4314-4321	number	4	SENT_242	[p18l130t3019r411b3065],
4	(	CD	NUMBER	(	appos	1	SENT_242	[p18l437t3017r611b3072],
5	2012	CD	DATE	2012	num	6	SENT_242	[p18l437t3017r611b3072],
6	)	NN	O	)	dep	4	SENT_242	[p18l437t3017r611b3072],
7	.	.	O	.	_	0	SENT_242	[p18l437t3017r611b3072],

1	Sumimoto	NNP	PERSON	Sumimoto	_	0	SENT_243	[p18l130t3095r416b3151],
2	,	,	O	,	_	0	SENT_243	[p18l130t3095r416b3151],
3	H.	NNP	O	H.	appos	1	SENT_243	[p18l433t3096r494b3151],
4	,	,	O	,	_	0	SENT_243	[p18l433t3096r494b3151],
5	lmabayashi	NN	O	lmabayashus	appos	3	SENT_243	[p18l511t3094r820b3157],
6	,	,	O	,	_	0	SENT_243	[p18l511t3094r820b3157],
7	F.	NNP	O	F.	appos	3	SENT_243	[p18l836t3096r881b3151],
8	,	,	O	,	_	0	SENT_243	[p18l836t3096r881b3151],
9	|	CD	NUMBER	|	num	10	SENT_243	[p18l898t3096r1098b3151],
10	wata	NN	O	wa	appos	3	SENT_243	[p18l898t3096r1098b3151],
11	,	,	O	,	_	0	SENT_243	[p18l898t3096r1098b3151],
12	T.	NNP	ORGANIZATION	T.	appos	3	SENT_243	[p18l898t3096r1098b3151],
13	&	CC	ORGANIZATION	&	_	0	SENT_243	[p18l1112t3095r1149b3143],
14	Kawakami	NNP	ORGANIZATION	Kawakami	conj_and	12	SENT_243	[p18l1164t3094r1599b3151],
15	,	,	O	,	_	0	SENT_243	[p18l1164t3094r1599b3151],
16	Y.	NNP	O	Y.	nn	18	SENT_243	[p18l1164t3094r1599b3151],
17	The	NNP	O	The	nn	18	SENT_243	[p18l1164t3094r1599b3151],
18	BRAF	NNP	O	BRAF	appos	3	SENT_243	[p18l1615t3096r1929b3143],
19	.	.	O	.	_	0	SENT_243	[p18l1615t3096r1929b3143],

1	—	NN	O	—	_	0	SENT_244	[p18l1615t3096r1929b3143],
2	.	.	O	.	_	0	SENT_244	[p18l1615t3096r1929b3143],

1	MAPK	NN	ORGANIZATION	mapk	nn	3	SENT_245	[p18l1615t3096r1929b3143],
2	signaling	NN	O	signaling	nn	3	SENT_245	[p18l132t3172r367b3235],
3	pathway	NN	O	pathway	nsubj	5	SENT_245	[p18l386t3172r610b3235],
4	is	VBZ	O	be	cop	5	SENT_245	[p18l625t3174r659b3221],
5	essential	JJ	O	essential	_	0	SENT_245	[p18l674t3172r898b3221],
6	for	IN	O	for	_	0	SENT_245	[p18l913t3171r986b3221],
7	cancer-immune	JJ	O	cancer-immune	amod	8	SENT_245	[p18l999t3174r1413b3221],
8	evasion	NN	O	evasion	prep_for	5	SENT_245	[p18l1428t3174r1625b3221],
9	in	IN	O	in	_	0	SENT_245	[p18l1643t3174r1686b3221],
10	human	JJ	O	human	amod	12	SENT_245	[p18l1705t3172r1886b3221],
11	melanoma	NN	O	melanoma	nn	12	SENT_245	[p18l134t3249r411b3298],
12	cells	NNS	O	cell	prep_in	8	SENT_245	[p18l427t3249r550b3298],
13	.	.	O	.	_	0	SENT_245	[p18l427t3249r550b3298],

1	J.	NNP	O	J.	nn	2	SENT_246	[p18l561t3251r595b3298],
2	Exp	NNP	O	Exp	_	0	SENT_246	[p18l610t3251r708b3310],
3	.	.	O	.	_	0	SENT_246	[p18l610t3251r708b3310],

1	Med	NNP	O	Med	_	0	SENT_247	[p18l721t3249r844b3298],
2	.	.	O	.	_	0	SENT_247	[p18l721t3249r844b3298],

1	203	CD	NUMBER	203	_	0	SENT_248	[p18l859t3252r974b3305],
2	,	,	O	,	_	0	SENT_248	[p18l859t3252r974b3305],
3	1651-1656	CD	DATE	1651-1656	number	4	SENT_248	[p18l993t3252r1278b3298],
4	(	CD	NUMBER	(	appos	1	SENT_248	[p18l1294t3250r1468b3305],
5	2006	CD	DATE	2006	num	6	SENT_248	[p18l1294t3250r1468b3305],
6	)	NN	O	)	dep	4	SENT_248	[p18l1294t3250r1468b3305],
7	.	.	O	.	_	0	SENT_248	[p18l1294t3250r1468b3305],

1	Sharma	FW	PERSON	sharma	nsubj	25	SENT_249	[p18l130t3326r341b3382],
2	,	,	O	,	_	0	SENT_249	[p18l130t3326r341b3382],
3	A.	NN	O	a.	appos	1	SENT_249	[p18l355t3326r615b3382],
4	,	,	O	,	_	0	SENT_249	[p18l355t3326r615b3382],
5	Trivedi	NNP	PERSON	Trivedi	appos	1	SENT_249	[p18l355t3326r615b3382],
6	,	,	O	,	_	0	SENT_249	[p18l355t3326r615b3382],
7	N.R.	NNP	PERSON	N.R.	conj_and	5	SENT_249	[p18l632t3328r741b3382],
8	,	,	O	,	_	0	SENT_249	[p18l632t3328r741b3382],
9	Zimmerman	NNP	PERSON	Zimmerman	conj_and	5	SENT_249	[p18l755t3328r1093b3382],
10	,	,	O	,	_	0	SENT_249	[p18l755t3328r1093b3382],
11	M.A.	NNP	LOCATION	M.A.	conj_and	5	SENT_249	[p18l1109t3328r1476b3382],
12	,	,	O	,	_	0	SENT_249	[p18l1109t3328r1476b3382],
13	Tuveson	NNP	LOCATION	Tuveson	conj_and	5	SENT_249	[p18l1109t3328r1476b3382],
14	,	,	O	,	_	0	SENT_249	[p18l1109t3328r1476b3382],
15	D.A.	NNP	LOCATION	D.A.	conj_and	5	SENT_249	[p18l1493t3328r1604b3382],
16	,	,	O	,	_	0	SENT_249	[p18l1493t3328r1604b3382],
17	Smith	NNP	PERSON	Smith	conj_and	5	SENT_249	[p18l1620t3326r1784b3382],
18	,	,	O	,	_	0	SENT_249	[p18l1620t3326r1784b3382],
19	C.D.	NNP	ORGANIZATION	C.D.	conj_and	5	SENT_249	[p18l1799t3327r1898b3375],
20	&	CC	ORGANIZATION	&	_	0	SENT_249	[p18l131t3405r168b3453],
21	Robertson	NNP	ORGANIZATION	Robertson	appos	1	SENT_249	[p18l183t3404r466b3461],
22	,	,	O	,	_	0	SENT_249	[p18l183t3404r466b3461],
23	G.P.	NNP	PERSON	G.P.	nn	24	SENT_249	[p18l481t3406r569b3453],
24	MutantV599EB-Raf	NNP	PERSON	MutantV599EB-Raf	appos	1	SENT_249	[p18l585t3403r1091b3453],
25	regulates	VBZ	O	regulate	_	0	SENT_249	[p18l1102t3404r1342b3467],
26	growth	NN	O	growth	nn	29	SENT_249	[p18l1356t3404r1544b3467],
27	and	CC	O	and	_	0	SENT_249	[p18l1560t3404r1656b3453],
28	vascular	JJ	O	vascular	nn	29	SENT_249	[p18l1672t3404r1886b3453],
29	development	NN	O	development	dobj	25	SENT_249	[p18l131t3482r485b3544],
30	of	IN	O	of	_	0	SENT_249	[p18l499t3481r554b3531],
31	malignant	JJ	O	malignant	amod	33	SENT_249	[p18l565t3482r831b3545],
32	melanoma	NN	O	melanoma	nn	33	SENT_249	[p18l847t3482r1124b3531],
33	tumors	NNS	O	tumor	prep_of	29	SENT_249	[p18l1139t3489r1339b3531],
34	.	.	O	.	_	0	SENT_249	[p18l1139t3489r1339b3531],

1	Cancer	NN	O	cancer	_	0	SENT_250	[p18l1354t3483r1531b3531],
2	Res	NNP	O	Res	dep	1	SENT_250	[p18l1540t3484r1635b3531],
3	.	.	O	.	_	0	SENT_250	[p18l1540t3484r1635b3531],

1	65	CD	NUMBER	65	_	0	SENT_251	[p18l1649t3485r1729b3539],
2	,	,	O	,	_	0	SENT_251	[p18l1649t3485r1729b3539],
3	241	CD	NUMBER	241	number	4	SENT_251	[p18l1744t3485r1828b3531],
4	2-2421	CD	NUMBER	2-2421	appos	1	SENT_251	[p18l1842t3485r2023b3531],
5	(	CD	NUMBER	(	num	7	SENT_251	[p18l133t3560r307b3615],
6	2005	CD	DATE	2005	num	7	SENT_251	[p18l133t3560r307b3615],
7	)	NN	O	)	dep	4	SENT_251	[p18l133t3560r307b3615],
8	.	.	O	.	_	0	SENT_251	[p18l133t3560r307b3615],

1	Eisen	NNP	PERSON	Eisen	_	0	SENT_252	[p18l132t3638r326b3692],
2	,	,	O	,	_	0	SENT_252	[p18l132t3638r326b3692],
3	T.	NNP	O	T.	nn	4	SENT_252	[p18l132t3638r326b3692],
4	etal	NNP	O	etal	appos	1	SENT_252	[p18l340t3636r455b3685],
5	.	.	O	.	_	0	SENT_252	[p18l340t3636r455b3685],

1	Sorafenib	NNP	O	Sorafenib	_	0	SENT_253	[p18l470t3635r720b3685],
2	in	IN	O	in	_	0	SENT_253	[p18l736t3638r778b3684],
3	advanced	JJ	O	advanced	amod	4	SENT_253	[p18l794t3636r1048b3685],
4	melanoma	NN	O	melanoma	prep_in	1	SENT_253	[p18l1066t3636r1358b3685],
5	:	:	O	:	_	0	SENT_253	[p18l1066t3636r1358b3685],
6	a	DT	O	a	det	11	SENT_253	[p18l1373t3650r1398b3685],
7	Phase	NN	O	phase	nn	11	SENT_253	[p18l1417t3636r1567b3685],
8	II	CD	NUMBER	ii	num	11	SENT_253	[p18l1584t3638r1605b3684],
9	randomised	JJ	O	randomised	amod	11	SENT_253	[p18l1625t3636r1935b3685],
10	discontinuation	NN	O	discontinuation	nn	11	SENT_253	[p19l131t18r542b67],
11	trial	NN	O	trial	dep	1	SENT_253	[p19l557t18r655b67],
12	analysis	NN	O	analysis	dep	11	SENT_253	[p19l671t18r886b81],
13	.	.	O	.	_	0	SENT_253	[p19l671t18r886b81],

1	Br	NN	O	br	_	0	SENT_254	[p19l901t20r958b67],
2	.	.	O	.	_	0	SENT_254	[p19l901t20r958b67],

1	J.	NNP	O	J.	nn	2	SENT_255	[p19l969t20r1004b67],
2	Cancer	NNP	O	Cancer	_	0	SENT_255	[p19l1020t19r1197b67],
3	95	CD	NUMBER	95	num	2	SENT_255	[p19l1206t21r1287b75],
4	,	,	O	,	_	0	SENT_255	[p19l1206t21r1287b75],
5	581	CD	NUMBER	581	num	2	SENT_255	[p19l1302t21r1385b67],
6	-586	CD	NUMBER	-586	number	7	SENT_255	[p19l1399t21r1526b67],
7	(	CD	NUMBER	(	dep	2	SENT_255	[p19l1541t19r1716b75],
8	2006	CD	DATE	2006	num	9	SENT_255	[p19l1541t19r1716b75],
9	)	NN	O	)	dep	7	SENT_255	[p19l1541t19r1716b75],
10	.	.	O	.	_	0	SENT_255	[p19l1541t19r1716b75],

1	Hauschild	NNP	O	Hauschild	_	0	SENT_256	[p19l132t96r400b153],
2	,	,	O	,	_	0	SENT_256	[p19l132t96r400b153],
3	A.	NNP	O	A.	nn	4	SENT_256	[p19l414t98r463b145],
4	etal	NNP	O	etal	appos	1	SENT_256	[p19l477t96r592b145],
5	.	.	O	.	_	0	SENT_256	[p19l477t96r592b145],

1	Results	NNS	O	result	nsubj	5	SENT_257	[p19l608t96r790b145],
2	of	IN	O	of	_	0	SENT_257	[p19l804t95r858b145],
3	a	DT	O	a	det	4	SENT_257	[p19l868t110r894b145],
4	phase	NN	O	phase	prep_of	1	SENT_257	[p19l911t96r1065b158],
5	III	CD	NUMBER	iii	_	0	SENT_257	[p19l1082t98r1134b153],
6	,	,	O	,	_	0	SENT_257	[p19l1082t98r1134b153],
7	randomized	VBN	O	randomize	partmod	5	SENT_257	[p19l1150t96r1477b153],
8	,	,	O	,	_	0	SENT_257	[p19l1150t96r1477b153],
9	placebo-controlled	JJ	O	placebo-controlled	amod	10	SENT_257	[p19l1493t96r1992b158],
10	study	NN	O	study	nn	33	SENT_257	[p19l2008t96r2153b159],
11	of	IN	O	of	_	0	SENT_257	[p19l131t173r186b223],
12	sorafenib	NN	O	sorafenib	prep_of	10	SENT_257	[p19l195t173r438b223],
13	in	IN	O	in	_	0	SENT_257	[p19l455t176r497b223],
14	combination	NN	O	combination	prep_in	12	SENT_257	[p19l514t174r847b223],
15	with	IN	O	with	_	0	SENT_257	[p19l862t174r976b223],
16	carboplatin	NN	O	carboplatin	prep_with	14	SENT_257	[p19l992t174r1291b236],
17	and	CC	O	and	_	0	SENT_257	[p19l1307t174r1403b223],
18	paclitaxel	NN	O	paclitaxel	conj_and	16	SENT_257	[p19l1422t174r1666b236],
19	as	IN	O	as	_	0	SENT_257	[p19l1682t188r1734b223],
20	second-line	JJ	O	second-line	amod	21	SENT_257	[p19l1749t174r2053b223],
21	treatment	NN	O	treatment	prep_as	10	SENT_257	[p19l130t259r394b301],
22	in	IN	O	in	_	0	SENT_257	[p19l409t254r452b301],
23	patients	NNS	O	patient	prep_in	21	SENT_257	[p19l470t254r680b314],
24	with	IN	O	with	_	0	SENT_257	[p19l693t252r806b301],
25	unresectable	JJ	O	unresectable	amod	26	SENT_257	[p19l825t252r1163b301],
26	stage	NN	O	stage	prep_with	23	SENT_257	[p19l1178t259r1318b315],
27	III	CD	NUMBER	iii	num	26	SENT_257	[p19l1334t254r1371b301],
28	or	CC	O	or	_	0	SENT_257	[p19l1388t266r1441b301],
29	stage	NN	O	stage	conj_or	26	SENT_257	[p19l1455t259r1595b315],
30	IV	CD	NUMBER	iv	num	29	SENT_257	[p19l1612t254r1658b301],
31	me	PRP	O	I	npadvmod	32	SENT_257	[p19l1673t252r2009b301],
32	|	JJ	O	|	amod	33	SENT_257	[p19l1673t252r2009b301],
33	anoma	NN	O	anoma	dobj	5	SENT_257	[p19l1673t252r2009b301],
34	.	.	O	.	_	0	SENT_257	[p19l1673t252r2009b301],

1	J.	NNP	PERSON	J.	nn	2	SENT_258	[p19l1673t252r2009b301],
2	Clin	NNP	PERSON	Clin	_	0	SENT_258	[p19l2026t252r2130b301],
3	.	.	O	.	_	0	SENT_258	[p19l2026t252r2130b301],

1	Oncol	NN	O	oncol	_	0	SENT_259	[p19l132t329r292b378],
2	.	.	O	.	_	0	SENT_259	[p19l132t329r292b378],

1	27	CD	NUMBER	27	_	0	SENT_260	[p19l306t332r386b385],
2	,	,	O	,	_	0	SENT_260	[p19l306t332r386b385],
3	2823-2830	CD	DATE	2823-2830	number	4	SENT_260	[p19l401t332r690b378],
4	(	CD	NUMBER	(	appos	1	SENT_260	[p19l706t330r880b385],
5	2009	CD	DATE	2009	num	6	SENT_260	[p19l706t330r880b385],
6	)	NN	O	)	dep	4	SENT_260	[p19l706t330r880b385],
7	.	.	O	.	_	0	SENT_260	[p19l706t330r880b385],

1	Flaherty	NNP	PERSON	Flaherty	nn	3	SENT_261	[p19l132t407r353b470],
2	,	,	O	,	_	0	SENT_261	[p19l132t407r353b470],
3	K.T.	NNP	O	K.T.	_	0	SENT_261	[p19l370t409r453b456],
4	et	FW	O	et	nn	5	SENT_261	[p19l467t414r516b456],
5	al.	FW	O	al.	dep	3	SENT_261	[p19l525t407r582b456],
6	.	.	O	.	_	0	SENT_261	[p19l525t407r582b456],

1	Phase	NN	O	phase	nn	2	SENT_262	[p19l599t407r749b456],
2	I/II	NN	O	i/ii	_	0	SENT_262	[p19l766t408r840b464],
3	,	,	O	,	_	0	SENT_262	[p19l766t408r840b464],
4	pharmacokinetic	JJ	O	pharmacokinetic	amod	7	SENT_262	[p19l856t407r1298b469],
5	and	CC	O	and	_	0	SENT_262	[p19l1312t407r1408b456],
6	pharmacodynamic	JJ	O	pharmacodynamic	amod	7	SENT_262	[p19l1427t407r1921b470],
7	trial	NN	O	trial	appos	2	SENT_262	[p19l1933t407r2030b456],
8	of	IN	O	of	_	0	SENT_262	[p19l2048t406r2102b456],
9	BAY43	NN	O	bay43	prep_of	7	SENT_262	[p19l134t486r446b533],
10	—	CD	NUMBER	—	num	11	SENT_262	[p19l134t486r446b533],
11	9006	CD	DATE	9006	npadvmod	12	SENT_262	[p19l134t486r446b533],
12	alone	RB	O	alone	advmod	9	SENT_262	[p19l460t484r604b533],
13	in	IN	O	in	_	0	SENT_262	[p19l620t486r663b532],
14	patients	NNS	O	patient	prep_in	9	SENT_262	[p19l681t486r891b545],
15	with	IN	O	with	_	0	SENT_262	[p19l905t484r1018b533],
16	metastatic	JJ	O	metastatic	amod	17	SENT_262	[p19l1036t486r1308b533],
17	melanoma	NN	O	melanoma	prep_with	14	SENT_262	[p19l1325t484r1617b533],
18	.	.	O	.	_	0	SENT_262	[p19l1325t484r1617b533],

1	Proc	NNP	O	Proc	_	0	SENT_263	[p19l1631t486r1860b533],
2	.	.	O	.	_	0	SENT_263	[p19l1631t486r1860b533],

1	Am	NNP	O	Am	_	0	SENT_264	[p19l1631t486r1860b533],
2	.	.	O	.	_	0	SENT_264	[p19l1631t486r1860b533],

1	Soc	NN	O	soc	_	0	SENT_265	[p19l1874t485r1972b533],
2	.	.	O	.	_	0	SENT_265	[p19l1874t485r1972b533],

1	Clin	NNP	O	Clin	_	0	SENT_266	[p19l1988t484r2093b533],
2	.	.	O	.	_	0	SENT_266	[p19l1988t484r2093b533],

1	Oncol	NN	O	oncol	_	0	SENT_267	[p19l132t561r292b610],
2	.	.	O	.	_	0	SENT_267	[p19l132t561r292b610],

1	23	CD	NUMBER	23	_	0	SENT_268	[p19l306t564r386b617],
2	,	,	O	,	_	0	SENT_268	[p19l306t564r386b617],
3	3037	CD	NUMBER	3037	number	4	SENT_268	[p19l401t564r526b610],
4	(	CD	NUMBER	(	appos	1	SENT_268	[p19l543t562r717b617],
5	2005	CD	DATE	2005	num	6	SENT_268	[p19l543t562r717b617],
6	)	NN	O	)	dep	4	SENT_268	[p19l543t562r717b617],
7	.	.	O	.	_	0	SENT_268	[p19l543t562r717b617],

1	Sharman	NNP	PERSON	Sharman	nn	3	SENT_269	[p19l130t639r377b696],
2	,	,	O	,	_	0	SENT_269	[p19l130t639r377b696],
3	W.H.	NNP	O	W.H.	_	0	SENT_269	[p19l387t641r503b688],
4	et	FW	O	et	nn	5	SENT_269	[p19l517t646r566b689],
5	al.	FW	O	al.	dep	3	SENT_269	[p19l575t639r632b689],
6	.	.	O	.	_	0	SENT_269	[p19l575t639r632b689],

1	Results	NNS	O	result	nsubj	16	SENT_270	[p19l649t639r830b689],
2	from	IN	O	from	_	0	SENT_270	[p19l843t638r966b688],
3	the	DT	O	the	det	7	SENT_270	[p19l981t639r1067b688],
4	ﬁrst	NN	O	ﬁrst	nn	7	SENT_270	[p19l1080t638r1454b689],
5	—	NN	O	—	nn	7	SENT_270	[p19l1080t638r1454b689],
6	in-human	JJ	O	in-human	amod	7	SENT_270	[p19l1080t638r1454b689],
7	phase	NN	O	phase	prep_from	1	SENT_270	[p19l1473t639r1626b701],
8	I	PRP	O	I	dep	9	SENT_270	[p19l1643t641r1649b688],
9	study	NN	O	study	dep	7	SENT_270	[p19l1666t639r1811b703],
10	of	IN	O	of	_	0	SENT_270	[p19l1824t638r1878b688],
11	the	DT	O	the	det	15	SENT_270	[p19l1887t639r1972b689],
12	oral	JJ	O	oral	amod	15	SENT_270	[p19l131t717r226b766],
13	RAF	NN	O	raf	nn	15	SENT_270	[p19l245t719r343b766],
14	inhibitor	NN	O	inhibitor	nn	15	SENT_270	[p19l360t717r583b766],
15	RAF265	NN	O	raf265	prep_of	9	SENT_270	[p19l599t719r793b766],
16	administered	VBN	O	administer	_	0	SENT_270	[p19l809t717r1154b766],
17	daily	RB	SET	daily	advmod	16	SENT_270	[p19l1170t717r1295b780],
18	to	TO	O	to	_	0	SENT_270	[p19l1306t724r1359b766],
19	patients	NNS	O	patient	prep_to	16	SENT_270	[p19l1376t719r1585b779],
20	with	IN	O	with	_	0	SENT_270	[p19l1599t717r1712b766],
21	advanced	JJ	O	advanced	amod	23	SENT_270	[p19l1728t717r1981b766],
22	cutaneous	JJ	O	cutaneous	amod	23	SENT_270	[p19l131t801r405b843],
23	melanoma	NN	O	melanoma	prep_with	19	SENT_270	[p19l422t794r758b843],
24	.	.	O	.	_	0	SENT_270	[p19l422t794r758b843],

1	J.	NNP	PERSON	J.	nn	2	SENT_271	[p19l422t794r758b843],
2	Clin	NNP	PERSON	Clin	_	0	SENT_271	[p19l775t794r879b843],
3	.	.	O	.	_	0	SENT_271	[p19l775t794r879b843],

1	Oncol	NN	O	oncol	_	0	SENT_272	[p19l895t794r1054b843],
2	.	.	O	.	_	0	SENT_272	[p19l895t794r1054b843],

1	29	CD	NUMBER	29	_	0	SENT_273	[p19l1069t797r1149b850],
2	,	,	O	,	_	0	SENT_273	[p19l1069t797r1149b850],
3	8508	CD	DATE	8508	num	4	SENT_273	[p19l1163t797r1290b843],
4	(	NN	O	(	appos	1	SENT_273	[p19l1306t795r1406b850],
5	201	CD	NUMBER	201	number	6	SENT_273	[p19l1306t795r1406b850],
6	1	CD	NUMBER	1	num	7	SENT_273	[p19l1425t795r1480b850],
7	)	NN	O	)	dep	4	SENT_273	[p19l1425t795r1480b850],
8	.	.	O	.	_	0	SENT_273	[p19l1425t795r1480b850],

1	Adjei	NNP	PERSON	Adjei	_	0	SENT_274	[p19l129t872r275b935],
2	,	,	O	,	_	0	SENT_274	[p19l129t872r275b935],
3	A.A.	NNP	O	A.A.	nn	4	SENT_274	[p19l289t874r390b921],
4	etal	NNP	O	etal	appos	1	SENT_274	[p19l404t872r519b921],
5	.	.	O	.	_	0	SENT_274	[p19l404t872r519b921],

1	Phase	NN	O	phase	_	0	SENT_275	[p19l536t872r686b921],
2	I	CD	NUMBER	i	number	3	SENT_275	[p19l703t874r709b921],
3	pharmacokinetic	JJ	O	pharmacokinetic	dep	1	SENT_275	[p19l728t872r1170b934],
4	and	CC	O	and	_	0	SENT_275	[p19l1184t872r1280b921],
5	pharmacodynamic	JJ	O	pharmacodynamic	amod	6	SENT_275	[p19l1299t872r1792b936],
6	study	NN	O	study	dep	1	SENT_275	[p19l1807t872r1952b935],
7	of	IN	O	of	_	0	SENT_275	[p19l1964t871r2019b921],
8	the	DT	O	the	det	14	SENT_275	[p19l2027t872r2113b921],
9	oral	JJ	O	oral	amod	14	SENT_275	[p19l131t950r241b1007],
10	,	,	O	,	_	0	SENT_275	[p19l131t950r241b1007],
11	small-molecule	JJ	O	small-molecule	amod	14	SENT_275	[p19l255t950r655b1000],
12	mitogen-activated	JJ	O	mitogen-activated	amod	14	SENT_275	[p19l671t950r1154b1013],
13	protein	NN	O	protein	nn	14	SENT_275	[p19l1173t952r1359b1012],
14	kinase	NN	O	kinase	prep_of	3	SENT_275	[p19l1378t950r1541b1000],
15	kinase	NN	O	kinase	nn	18	SENT_275	[p19l1557t950r1720b1000],
16	1/2	CD	NUMBER	1/2	num	18	SENT_275	[p19l1739t951r1817b1002],
17	inhibitor	NN	O	inhibitor	nn	18	SENT_275	[p19l1834t950r2057b1000],
18	AZD6244	NN	O	azd6244	dep	1	SENT_275	[p19l131t1029r376b1076],
19	(	CD	NUMBER	(	num	20	SENT_275	[p19l391t1028r773b1083],
20	ARRY	NN	O	arry	dep	18	SENT_275	[p19l391t1028r773b1083],
21	—	CD	NUMBER	—	number	22	SENT_275	[p19l391t1028r773b1083],
22	142886	CD	NUMBER	142886	num	23	SENT_275	[p19l391t1028r773b1083],
23	)	NN	O	)	dep	1	SENT_275	[p19l391t1028r773b1083],
24	in	IN	O	in	_	0	SENT_275	[p19l790t1029r833b1075],
25	patients	NNS	O	patient	prep_in	23	SENT_275	[p19l852t1029r1061b1088],
26	with	IN	O	with	_	0	SENT_275	[p19l1075t1027r1188b1076],
27	advanced	JJ	O	advanced	amod	28	SENT_275	[p19l1204t1027r1457b1076],
28	cancers	NNS	O	cancer	prep_with	25	SENT_275	[p19l1474t1029r1728b1076],
29	.	.	O	.	_	0	SENT_275	[p19l1474t1029r1728b1076],

1	J.	NNP	PERSON	J.	nn	2	SENT_276	[p19l1474t1029r1728b1076],
2	Clin	NNP	PERSON	Clin	_	0	SENT_276	[p19l1743t1027r1848b1076],
3	.	.	O	.	_	0	SENT_276	[p19l1743t1027r1848b1076],

1	Oncol	NN	O	oncol	_	0	SENT_277	[p19l1864t1027r2023b1076],
2	.	.	O	.	_	0	SENT_277	[p19l1864t1027r2023b1076],

1	26	CD	NUMBER	26	_	0	SENT_278	[p19l2038t1030r2118b1083],
2	,	,	O	,	_	0	SENT_278	[p19l2038t1030r2118b1083],
3	2139-2146	CD	DATE	2139-2146	number	4	SENT_278	[p19l132t1107r421b1153],
4	(	CD	NUMBER	(	appos	1	SENT_278	[p19l437t1105r611b1160],
5	2008	CD	DATE	2008	num	6	SENT_278	[p19l437t1105r611b1160],
6	)	NN	O	)	dep	4	SENT_278	[p19l437t1105r611b1160],
7	.	.	O	.	_	0	SENT_278	[p19l437t1105r611b1160],

1	Kirkwood	NNP	PERSON	Kirkwood	_	0	SENT_279	[p19l132t1182r392b1239],
2	,	,	O	,	_	0	SENT_279	[p19l132t1182r392b1239],
3	J.M.	NNP	O	J.M.	nn	4	SENT_279	[p19l405t1184r503b1232],
4	etal	NN	O	etal	appos	1	SENT_279	[p19l517t1182r632b1232],
5	.	.	O	.	_	0	SENT_279	[p19l517t1182r632b1232],

1	Phase	NN	O	phase	nsubj	9	SENT_280	[p19l649t1182r799b1232],
2	II	CD	NUMBER	ii	num	1	SENT_280	[p19l816t1184r853b1239],
3	,	,	O	,	_	0	SENT_280	[p19l816t1184r853b1239],
4	open	JJ	O	open	amod	7	SENT_280	[p19l867t1182r1162b1244],
5	—	CD	NUMBER	—	tmod	4	SENT_280	[p19l867t1182r1162b1244],
6	labe	NN	O	labe	nn	7	SENT_280	[p19l867t1182r1162b1244],
7	|	NN	O	|	appos	1	SENT_280	[p19l867t1182r1162b1244],
8	,	,	O	,	_	0	SENT_280	[p19l867t1182r1162b1244],
9	randomized	VBN	O	randomize	_	0	SENT_280	[p19l1179t1182r1491b1232],
10	trial	NN	O	trial	dobj	9	SENT_280	[p19l1506t1182r1603b1232],
11	of	IN	O	of	_	0	SENT_280	[p19l1620t1181r1675b1232],
12	the	DT	O	the	det	15	SENT_280	[p19l1683t1182r1769b1232],
13	MEK1/2	NN	O	mek1/2	nn	15	SENT_280	[p19l1784t1183r1983b1234],
14	inhibitor	NN	O	inhibitor	nn	15	SENT_280	[p19l133t1260r356b1310],
15	selumetinib	NN	O	selumetinib	prep_of	10	SENT_280	[p19l369t1260r680b1310],
16	as	IN	O	as	_	0	SENT_280	[p19l694t1274r746b1310],
17	monotherapy	NN	O	monotherapy	prep_as	9	SENT_280	[p19l763t1260r1122b1323],
18	versus	CC	O	versus	prep	17	SENT_280	[p19l1134t1274r1299b1310],
19	temozolomide	NN	O	temozolomide	dep	18	SENT_280	[p19l1312t1260r1698b1310],
20	in	IN	O	in	_	0	SENT_280	[p19l1714t1262r1756b1309],
21	patients	NNS	O	patient	prep_in	9	SENT_280	[p19l1775t1262r1984b1322],
22	with	IN	O	with	_	0	SENT_280	[p19l1998t1260r2111b1310],
23	advanced	JJ	O	advanced	amod	24	SENT_280	[p19l131t1337r384b1386],
24	melanoma	NN	O	melanoma	prep_with	21	SENT_280	[p19l403t1337r695b1386],
25	.	.	O	.	_	0	SENT_280	[p19l403t1337r695b1386],

1	Clin	NNP	O	Clin	_	0	SENT_281	[p19l710t1337r815b1386],
2	.	.	O	.	_	0	SENT_281	[p19l710t1337r815b1386],

1	CancerRes	NNS	O	cancerre	_	0	SENT_282	[p19l831t1338r1112b1386],
2	.	.	O	.	_	0	SENT_282	[p19l831t1338r1112b1386],

1	18	CD	NUMBER	18	_	0	SENT_283	[p19l1129t1340r1206b1393],
2	,	,	O	,	_	0	SENT_283	[p19l1129t1340r1206b1393],
3	555-567	CD	NUMBER	555-567	number	4	SENT_283	[p19l1221t1340r1444b1386],
4	(	CD	NUMBER	(	appos	1	SENT_283	[p19l1460t1338r1634b1393],
5	2012	CD	DATE	2012	num	6	SENT_283	[p19l1460t1338r1634b1393],
6	)	NN	O	)	dep	4	SENT_283	[p19l1460t1338r1634b1393],
7	.	.	O	.	_	0	SENT_283	[p19l1460t1338r1634b1393],

1	Bollag	NNP	PERSON	Bollag	_	0	SENT_284	[p19l132t1415r304b1478],
2	,	,	O	,	_	0	SENT_284	[p19l132t1415r304b1478],
3	G.	NNP	O	G.	nn	4	SENT_284	[p19l318t1417r369b1464],
4	etal	NN	O	etal	appos	1	SENT_284	[p19l383t1415r498b1465],
5	.	.	O	.	_	0	SENT_284	[p19l383t1415r498b1465],

1	Clinical	JJ	O	clinical	amod	2	SENT_285	[p19l512t1415r697b1465],
2	efﬁcacy	NN	O	efﬁcacy	nsubj	7	SENT_285	[p19l713t1414r914b1478],
3	of	IN	O	of	_	0	SENT_285	[p19l927t1414r981b1465],
4	a	DT	O	a	det	6	SENT_285	[p19l991t1430r1016b1465],
5	RAF	NN	ORGANIZATION	raf	nn	6	SENT_285	[p19l1035t1417r1132b1464],
6	inhibitor	NN	O	inhibitor	prep_of	2	SENT_285	[p19l1149t1415r1373b1465],
7	needs	VBZ	O	need	_	0	SENT_285	[p19l1388t1415r1542b1465],
8	broad	JJ	O	broad	amod	10	SENT_285	[p19l1558t1415r1708b1465],
9	target	NN	O	target	nn	10	SENT_285	[p19l1724t1422r1882b1478],
10	blockade	NN	O	blockade	dobj	7	SENT_285	[p19l1898t1415r2136b1465],
11	in	IN	O	in	_	0	SENT_285	[p19l133t1494r175b1540],
12	BRAF	NN	O	braf	nn	15	SENT_285	[p19l194t1494r544b1541],
13	—	NN	O	—	nn	15	SENT_285	[p19l194t1494r544b1541],
14	mutant	JJ	O	mutant	amod	15	SENT_285	[p19l194t1494r544b1541],
15	melanoma	NN	O	melanoma	prep_in	10	SENT_285	[p19l559t1492r852b1541],
16	.	.	O	.	_	0	SENT_285	[p19l559t1492r852b1541],

1	Nature	NNP	O	Nature	_	0	SENT_286	[p19l866t1494r1039b1541],
2	467	CD	NUMBER	467	num	1	SENT_286	[p19l1051t1495r1167b1548],
3	,	,	O	,	_	0	SENT_286	[p19l1051t1495r1167b1548],
4	596-599	CD	NUMBER	596-599	num	1	SENT_286	[p19l1182t1495r1406b1541],
5	(	CD	NUMBER	(	num	7	SENT_286	[p19l1422t1493r1596b1548],
6	2010	CD	DATE	2010	num	7	SENT_286	[p19l1422t1493r1596b1548],
7	)	NN	O	)	dep	1	SENT_286	[p19l1422t1493r1596b1548],
8	.	.	O	.	_	0	SENT_286	[p19l1422t1493r1596b1548],

1	Joseph	NNP	PERSON	Joseph	_	0	SENT_287	[p19l128t1774r327b1837],
2	,	,	O	,	_	0	SENT_287	[p19l128t1774r327b1837],
3	E.W.	NNP	O	E.W.	nn	4	SENT_287	[p19l343t1776r445b1824],
4	etal	NN	O	etal	appos	1	SENT_287	[p19l459t1774r680b1824],
5	.	.	O	.	_	0	SENT_287	[p19l459t1774r680b1824],

1	The	DT	O	the	det	4	SENT_288	[p19l459t1774r680b1824],
2	RAF	NN	ORGANIZATION	raf	nn	4	SENT_288	[p19l697t1776r795b1823],
3	inhibitor	NN	O	inhibitor	nn	4	SENT_288	[p19l812t1774r1035b1824],
4	PLX4032	NN	O	plx4032	nsubj	5	SENT_288	[p19l1051t1776r1275b1824],
5	inhibits	VBZ	O	inhibit	_	0	SENT_288	[p19l1291t1774r1483b1824],
6	ERK	NN	ORGANIZATION	erk	nn	7	SENT_288	[p19l1500t1776r1597b1823],
7	signaling	NN	O	signaling	dobj	5	SENT_288	[p19l1609t1774r1845b1837],
8	and	CC	O	and	_	0	SENT_288	[p19l1861t1774r1957b1824],
9	tumor	NN	O	tumor	nn	11	SENT_288	[p19l1972t1781r2136b1824],
10	cell	NN	O	cell	nn	11	SENT_288	[p19l132t1852r215b1902],
11	proliferation	NN	O	proliferation	dobj	5	SENT_288	[p19l234t1851r554b1915],
12	in	IN	O	in	_	0	SENT_288	[p19l572t1854r614b1901],
13	a	DT	O	a	det	15	SENT_288	[p19l631t1867r656b1902],
14	V600E	NN	O	v600e	nn	15	SENT_288	[p19l668t1854r831b1902],
15	BRAF	NN	O	braf	prep_in	7	SENT_288	[p19l848t1852r1231b1902],
16	—	FW	O	—	nn	20	SENT_288	[p19l848t1852r1231b1902],
17	se	FW	O	se	dep	20	SENT_288	[p19l848t1852r1231b1902],
18	|	CD	NUMBER	|	num	20	SENT_288	[p19l848t1852r1231b1902],
19	ective	JJ	O	ective	amod	20	SENT_288	[p19l848t1852r1231b1902],
20	manner	NN	O	manner	advmod	5	SENT_288	[p19l1247t1867r1458b1902],
21	.	.	O	.	_	0	SENT_288	[p19l1247t1867r1458b1902],

1	Proc	NNP	O	Proc	_	0	SENT_289	[p19l1473t1854r1592b1902],
2	.	.	O	.	_	0	SENT_289	[p19l1473t1854r1592b1902],

1	Natl.	NNP	O	Natl.	nn	2	SENT_290	[p19l1606t1852r1720b1902],
2	Acad	NNP	O	Acad	_	0	SENT_290	[p19l1732t1852r1870b1902],
3	.	.	O	.	_	0	SENT_290	[p19l1732t1852r1870b1902],

1	Sci	NNP	O	Sci	_	0	SENT_291	[p19l1884t1854r1964b1902],
2	.	.	O	.	_	0	SENT_291	[p19l1884t1854r1964b1902],

1	U.S.A.	NNP	O	U.S.A.	_	0	SENT_292	[p19l1981t1854r2121b1902],
2	107	CD	NUMBER	107	num	1	SENT_292	[p19l135t1932r247b1986],
3	,	,	O	,	_	0	SENT_292	[p19l135t1932r247b1986],
4	14903-14908	CD	NUMBER	14903-14908	num	1	SENT_292	[p19l266t1932r617b1978],
5	(	CD	NUMBER	(	num	7	SENT_292	[p19l633t1930r807b1986],
6	2010	CD	DATE	2010	num	7	SENT_292	[p19l633t1930r807b1986],
7	)	NN	O	)	dep	1	SENT_292	[p19l633t1930r807b1986],
8	.	.	O	.	_	0	SENT_292	[p19l633t1930r807b1986],

1	Flaherty	NNP	PERSON	Flaherty	nn	3	SENT_293	[p19l133t2007r354b2071],
2	,	,	O	,	_	0	SENT_293	[p19l133t2007r354b2071],
3	K.T.	NNP	O	K.T.	_	0	SENT_293	[p19l370t2009r453b2057],
4	et	FW	O	et	nn	5	SENT_293	[p19l468t2014r517b2057],
5	al.	FW	O	al.	dep	3	SENT_293	[p19l526t2007r582b2057],
6	.	.	O	.	_	0	SENT_293	[p19l526t2007r582b2057],

1	Inhibition	NN	O	inhibition	_	0	SENT_294	[p19l600t2007r849b2057],
2	of	IN	O	of	_	0	SENT_294	[p19l866t2006r920b2057],
3	mutated	VBN	O	mutate	dep	6	SENT_294	[p19l932t2007r1167b2064],
4	,	,	O	,	_	0	SENT_294	[p19l932t2007r1167b2064],
5	activated	VBN	O	activate	amod	6	SENT_294	[p19l1181t2007r1420b2057],
6	BRAF	NN	O	braf	prep_of	1	SENT_294	[p19l1439t2009r1571b2056],
7	in	IN	O	in	_	0	SENT_294	[p19l1588t2009r1631b2056],
8	metastatic	JJ	O	metastatic	amod	9	SENT_294	[p19l1649t2009r1922b2057],
9	melanoma	NN	O	melanoma	prep_in	6	SENT_294	[p19l134t2085r426b2135],
10	.	.	O	.	_	0	SENT_294	[p19l134t2085r426b2135],

1	N.	NNP	O	N.	nn	2	SENT_295	[p19l440t2087r488b2135],
2	Engl	NNP	O	Engl	_	0	SENT_295	[p19l503t2085r621b2148],
3	.	.	O	.	_	0	SENT_295	[p19l503t2085r621b2148],

1	J.	NNP	O	J.	nn	2	SENT_296	[p19l632t2087r667b2135],
2	Med	NNP	O	Med	_	0	SENT_296	[p19l681t2085r803b2135],
3	.	.	O	.	_	0	SENT_296	[p19l681t2085r803b2135],

1	363	CD	NUMBER	363	_	0	SENT_297	[p19l818t2088r933b2142],
2	,	,	O	,	_	0	SENT_297	[p19l818t2088r933b2142],
3	809-81	CD	NUMBER	809-81	number	4	SENT_297	[p19l947t2088r1128b2135],
4	9	CD	NUMBER	9	appos	1	SENT_297	[p19l1142t2088r1171b2135],
5	(	NN	O	(	nn	8	SENT_297	[p19l1187t2086r1288b2142],
6	201	CD	NUMBER	201	num	8	SENT_297	[p19l1187t2086r1288b2142],
7	o	NN	O	o	nn	8	SENT_297	[p19l1302t2086r1361b2142],
8	)	NN	O	)	dep	4	SENT_297	[p19l1302t2086r1361b2142],
9	.	.	O	.	_	0	SENT_297	[p19l1302t2086r1361b2142],

1	Sosman	NNP	PERSON	Sosman	_	0	SENT_298	[p19l131t2164r351b2219],
2	,	,	O	,	_	0	SENT_298	[p19l131t2164r351b2219],
3	J.A.	NNP	PERSON	J.A.	nn	4	SENT_298	[p19l363t2164r449b2211],
4	etal	NNP	O	etal	appos	1	SENT_298	[p19l463t2162r578b2211],
5	.	.	O	.	_	0	SENT_298	[p19l463t2162r578b2211],

1	Survival	NN	O	survival	nsubj	8	SENT_299	[p19l593t2162r797b2211],
2	in	IN	O	in	_	0	SENT_299	[p19l815t2164r857b2211],
3	BRAFV600	NN	O	brafv600	nn	4	SENT_299	[p19l877t2164r1368b2211],
4	—	NN	O	—	prep_in	1	SENT_299	[p19l877t2164r1368b2211],
5	mutant	JJ	O	mutant	amod	7	SENT_299	[p19l877t2164r1368b2211],
6	advanced	JJ	O	advanced	amod	7	SENT_299	[p19l1381t2162r1634b2211],
7	melanoma	NN	O	melanoma	dep	4	SENT_299	[p19l1653t2162r1931b2211],
8	treated	VBN	O	treat	_	0	SENT_299	[p19l1945t2162r2132b2211],
9	with	IN	O	with	_	0	SENT_299	[p19l131t2240r244b2290],
10	vemurafenib	NN	O	vemurafenib	prep_with	8	SENT_299	[p19l259t2239r605b2290],
11	.	.	O	.	_	0	SENT_299	[p19l259t2239r605b2290],

1	N.	NNP	O	N.	nn	4	SENT_300	[p19l620t2242r668b2290],
2	Engl	NNP	O	Engl	nn	4	SENT_300	[p19l683t2240r846b2303],
3	.	.	O	.	_	0	SENT_300	[p19l683t2240r846b2303],
4	]	NN	O	]	_	0	SENT_300	[p19l683t2240r846b2303],

1	.	.	O	.	_	0	SENT_301	[p19l683t2240r846b2303],

1	Med	NNP	O	Med	_	0	SENT_302	[p19l860t2240r982b2290],
2	.	.	O	.	_	0	SENT_302	[p19l860t2240r982b2290],

1	366	CD	NUMBER	366	_	0	SENT_303	[p19l997t2243r1112b2298],
2	,	,	O	,	_	0	SENT_303	[p19l997t2243r1112b2298],
3	707-714	CD	NUMBER	707-714	number	4	SENT_303	[p19l1128t2243r1352b2290],
4	(	CD	NUMBER	(	appos	1	SENT_303	[p19l1367t2241r1541b2297],
5	2012	CD	DATE	2012	num	6	SENT_303	[p19l1367t2241r1541b2297],
6	)	NN	O	)	dep	4	SENT_303	[p19l1367t2241r1541b2297],
7	.	.	O	.	_	0	SENT_303	[p19l1367t2241r1541b2297],

1	Chapman	NNP	PERSON	Chapman	nn	4	SENT_304	[p19l130t2318r398b2380],
2	,	,	O	,	_	0	SENT_304	[p19l130t2318r398b2380],
3	P.B.	NNP	O	P.B.	appos	4	SENT_304	[p19l415t2320r494b2368],
4	etal.	NNP	O	etal.	_	0	SENT_304	[p19l508t2318r636b2375],
5	;	:	O	;	_	0	SENT_304	[p19l508t2318r636b2375],
6	BR	NNP	O	BR	nn	8	SENT_304	[p19l652t2320r832b2368],
7	|	CD	NUMBER	|	num	8	SENT_304	[p19l652t2320r832b2368],
8	M	NN	O	m	dep	4	SENT_304	[p19l652t2320r832b2368],
9	—	NN	O	—	nn	12	SENT_304	[p19l652t2320r832b2368],
10	3	CD	NUMBER	3	num	12	SENT_304	[p19l652t2320r832b2368],
11	Study	NNP	O	Study	nn	12	SENT_304	[p19l849t2318r999b2382],
12	Group	NNP	O	Group	dep	8	SENT_304	[p19l1012t2320r1187b2380],
13	.	.	O	.	_	0	SENT_304	[p19l1012t2320r1187b2380],

1	Improved	VBN	O	improve	_	0	SENT_305	[p19l1204t2318r1454b2381],
2	survival	NN	O	survival	dobj	1	SENT_305	[p19l1470t2318r1668b2368],
3	with	IN	O	with	_	0	SENT_305	[p19l1683t2318r1797b2368],
4	vemurafenib	NN	O	vemurafenib	prep_with	1	SENT_305	[p19l1812t2317r2147b2368],
5	in	IN	O	in	_	0	SENT_305	[p19l133t2398r176b2445],
6	melanoma	NN	O	melanoma	prep_in	4	SENT_305	[p19l194t2396r472b2446],
7	with	IN	O	with	_	0	SENT_305	[p19l487t2396r600b2446],
8	BRAFV600E	NN	O	brafv600e	nn	9	SENT_305	[p19l619t2398r926b2446],
9	mutation	NN	O	mutation	prep_with	1	SENT_305	[p19l942t2398r1195b2446],
10	.	.	O	.	_	0	SENT_305	[p19l942t2398r1195b2446],

1	N.	NNP	O	N.	nn	2	SENT_306	[p19l1209t2398r1257b2446],
2	Engl	NNP	O	Engl	_	0	SENT_306	[p19l1272t2396r1435b2459],
3	.	.	O	.	_	0	SENT_306	[p19l1272t2396r1435b2459],

1	J.	NNP	O	J.	nn	2	SENT_307	[p19l1272t2396r1435b2459],
2	Med	NNP	O	Med	_	0	SENT_307	[p19l1449t2396r1572b2446],
3	.	.	O	.	_	0	SENT_307	[p19l1449t2396r1572b2446],

1	364	CD	NUMBER	364	_	0	SENT_308	[p19l1586t2399r1702b2453],
2	,	,	O	,	_	0	SENT_308	[p19l1586t2399r1702b2453],
3	2507-2516	CD	DATE	2507-2516	num	4	SENT_308	[p19l1716t2399r2005b2446],
4	(	NN	O	(	appos	1	SENT_308	[p19l134t2474r234b2529],
5	201	CD	NUMBER	201	number	6	SENT_308	[p19l134t2474r234b2529],
6	1	CD	NUMBER	1	num	7	SENT_308	[p19l252t2474r308b2530],
7	)	NN	O	)	dep	4	SENT_308	[p19l252t2474r308b2530],
8	.	.	O	.	_	0	SENT_308	[p19l252t2474r308b2530],

1	Chapman	NNP	PERSON	Chapman	_	0	SENT_309	[p19l130t2551r398b2614],
2	,	,	O	,	_	0	SENT_309	[p19l130t2551r398b2614],
3	P.B.	NNP	O	P.B.	nn	4	SENT_309	[p19l415t2553r493b2601],
4	etal	NN	O	etal	appos	1	SENT_309	[p19l508t2551r622b2601],
5	.	.	O	.	_	0	SENT_309	[p19l508t2551r622b2601],

1	Updated	VBN	O	update	_	0	SENT_310	[p19l639t2551r863b2614],
2	overall	JJ	O	overall	amod	3	SENT_310	[p19l880t2551r1051b2601],
3	survival	NN	O	survival	dobj	1	SENT_310	[p19l1068t2551r1265b2601],
4	results	VBZ	O	result	dep	1	SENT_310	[p19l1284t2551r1451b2601],
5	for	IN	O	for	_	0	SENT_310	[p19l1464t2550r1537b2601],
6	BR	NNP	O	BR	nn	8	SENT_310	[p19l1552t2553r1747b2608],
7	|	CD	NUMBER	|	num	8	SENT_310	[p19l1552t2553r1747b2608],
8	M	NN	O	m	prep_for	4	SENT_310	[p19l1552t2553r1747b2608],
9	—	NN	O	—	nsubj	1	SENT_310	[p19l1552t2553r1747b2608],
10	3	CD	NUMBER	3	num	9	SENT_310	[p19l1552t2553r1747b2608],
11	,	,	O	,	_	0	SENT_310	[p19l1552t2553r1747b2608],
12	a	DT	O	a	det	13	SENT_310	[p19l1761t2566r1786b2601],
13	phase	NN	O	phase	appos	9	SENT_310	[p19l1805t2551r1958b2613],
14	III	CD	NUMBER	iii	num	13	SENT_310	[p19l134t2631r171b2678],
15	randomized	VBN	O	randomize	partmod	13	SENT_310	[p19l189t2629r516b2686],
16	,	,	O	,	_	0	SENT_310	[p19l189t2629r516b2686],
17	open	JJ	O	open	acomp	15	SENT_310	[p19l531t2629r826b2691],
18	—	CD	NUMBER	—	number	19	SENT_310	[p19l531t2629r826b2691],
19	|	CD	NUMBER	|	num	21	SENT_310	[p19l531t2629r826b2691],
20	abe	NN	O	abe	nn	21	SENT_310	[p19l531t2629r826b2691],
21	|	NN	O	|	dep	17	SENT_310	[p19l531t2629r826b2691],
22	,	,	O	,	_	0	SENT_310	[p19l531t2629r826b2691],
23	multicentertrial	JJ	O	multicentertrial	acomp	24	SENT_310	[p19l842t2629r1254b2679],
24	comparing	VBG	O	compare	ccomp	15	SENT_310	[p19l1271t2631r1555b2692],
25	BRAF	NN	ORGANIZATION	braf	nn	27	SENT_310	[p19l1574t2631r1706b2678],
26	inhibitor	NN	O	inhibitor	nn	27	SENT_310	[p19l1723t2629r1947b2679],
27	vemurafenib	NN	O	vemurafenib	dobj	24	SENT_310	[p19l131t2706r465b2757],
28	with	IN	O	with	_	0	SENT_310	[p19l479t2707r592b2757],
29	dacarbazine	NN	O	dacarbazine	prep_with	24	SENT_310	[p19l608t2707r928b2757],
30	in	IN	O	in	_	0	SENT_310	[p19l944t2709r986b2756],
31	previously	RB	DATE	previously	advmod	32	SENT_310	[p19l1005t2707r1274b2771],
32	untreated	JJ	O	untreated	amod	33	SENT_310	[p19l1289t2707r1543b2757],
33	patients	NNS	O	patient	prep_in	29	SENT_310	[p19l1562t2709r1771b2769],
34	with	IN	O	with	_	0	SENT_310	[p19l1785t2707r1898b2757],
35	BRAF	NN	O	braf	npadvmod	36	SENT_310	[p19l1917t2709r2049b2756],
36	V600E-mutated	JJ	O	v600e-mutated	amod	39	SENT_310	[p19l130t2784r538b2833],
37	me	PRP	O	I	npadvmod	38	SENT_310	[p19l557t2784r894b2833],
38	|	JJ	O	|	amod	39	SENT_310	[p19l557t2784r894b2833],
39	anoma	NN	O	anoma	prep_with	33	SENT_310	[p19l557t2784r894b2833],
40	.	.	O	.	_	0	SENT_310	[p19l557t2784r894b2833],

1	J.	NNP	PERSON	J.	nn	2	SENT_311	[p19l557t2784r894b2833],
2	Clin	NNP	PERSON	Clin	_	0	SENT_311	[p19l910t2784r1015b2833],
3	.	.	O	.	_	0	SENT_311	[p19l910t2784r1015b2833],

1	Oncol	NN	O	oncol	_	0	SENT_312	[p19l1031t2784r1190b2833],
2	.	.	O	.	_	0	SENT_312	[p19l1031t2784r1190b2833],

1	30	CD	NUMBER	30	num	2	SENT_313	[p19l1205t2787r1271b2833],
2	(	CD	NUMBER	(	_	0	SENT_313	[p19l1287t2785r1461b2840],
3	2012	CD	DATE	2012	num	4	SENT_313	[p19l1287t2785r1461b2840],
4	)	NN	O	)	dep	2	SENT_313	[p19l1287t2785r1461b2840],
5	.	.	O	.	_	0	SENT_313	[p19l1287t2785r1461b2840],

1	Su	FW	O	su	_	0	SENT_314	[p19l131t2864r205b2919],
2	,	,	O	,	_	0	SENT_314	[p19l131t2864r205b2919],
3	F.	NNP	O	F.	nn	4	SENT_314	[p19l222t2864r254b2912],
4	etal	NNP	O	etal	appos	1	SENT_314	[p19l268t2862r383b2912],
5	.	.	O	.	_	0	SENT_314	[p19l268t2862r383b2912],

1	RAS	NN	O	ra	nn	2	SENT_315	[p19l400t2864r498b2912],
2	mutations	NNS	O	mutation	nsubj	13	SENT_315	[p19l515t2864r780b2912],
3	in	IN	O	in	_	0	SENT_315	[p19l796t2864r839b2911],
4	cutaneous	JJ	O	cutaneous	amod	10	SENT_315	[p19l855t2870r1129b2912],
5	squamous	JJ	O	squamous	amod	10	SENT_315	[p19l1144t2862r1523b2924],
6	—	NN	O	—	nn	10	SENT_315	[p19l1144t2862r1523b2924],
7	ce	NN	O	ce	nn	10	SENT_315	[p19l1144t2862r1523b2924],
8	|	CD	NUMBER	|	num	10	SENT_315	[p19l1144t2862r1523b2924],
9	|	NN	O	|	nn	10	SENT_315	[p19l1144t2862r1523b2924],
10	carcinomas	NNS	O	carcinoma	prep_in	2	SENT_315	[p19l1540t2864r1838b2912],
11	in	IN	O	in	_	0	SENT_315	[p19l1855t2864r1897b2911],
12	patients	NNS	O	patient	prep_in	2	SENT_315	[p19l1915t2864r2125b2924],
13	treated	VBN	O	treat	_	0	SENT_315	[p19l131t2940r318b2990],
14	with	IN	O	with	_	0	SENT_315	[p19l333t2940r446b2990],
15	BRAF	NN	O	braf	nn	16	SENT_315	[p19l465t2942r598b2989],
16	inhibitors	NNS	O	inhibitor	prep_with	13	SENT_315	[p19l614t2940r874b2990],
17	.	.	O	.	_	0	SENT_315	[p19l614t2940r874b2990],

1	N.	NNP	O	N.	nn	2	SENT_316	[p19l888t2942r936b2990],
2	Engl	NNP	O	Engl	_	0	SENT_316	[p19l951t2940r1069b3003],
3	.	.	O	.	_	0	SENT_316	[p19l951t2940r1069b3003],

1	J.	NNP	O	J.	nn	2	SENT_317	[p19l1080t2942r1114b2990],
2	Med	NNP	O	Med	_	0	SENT_317	[p19l1128t2940r1251b2990],
3	.	.	O	.	_	0	SENT_317	[p19l1128t2940r1251b2990],

1	366	CD	NUMBER	366	_	0	SENT_318	[p19l1265t2943r1380b2997],
2	,	,	O	,	_	0	SENT_318	[p19l1265t2943r1380b2997],
3	207-21	CD	NUMBER	207-21	number	4	SENT_318	[p19l1395t2943r1576b2990],
4	5	CD	NUMBER	5	appos	1	SENT_318	[p19l1590t2944r1617b2990],
5	(	CD	NUMBER	(	num	7	SENT_318	[p19l1635t2941r1809b2997],
6	2012	CD	DATE	2012	num	7	SENT_318	[p19l1635t2941r1809b2997],
7	)	NN	O	)	dep	4	SENT_318	[p19l1635t2941r1809b2997],
8	.	.	O	.	_	0	SENT_318	[p19l1635t2941r1809b2997],

1	Oberholzer	NNP	O	Oberholzer	_	0	SENT_319	[p19l130t3018r434b3075],
2	,	,	O	,	_	0	SENT_319	[p19l130t3018r434b3075],
3	P.A.	NNP	O	P.A.	nn	4	SENT_319	[p19l451t3020r534b3068],
4	etal	NN	O	etal	appos	1	SENT_319	[p19l549t3018r663b3068],
5	.	.	O	.	_	0	SENT_319	[p19l549t3018r663b3068],

1	RAS	NN	O	ra	nn	2	SENT_320	[p19l680t3020r778b3068],
2	mutations	NNS	O	mutation	nsubjpass	4	SENT_320	[p19l795t3020r1060b3068],
3	are	VBP	O	be	auxpass	4	SENT_320	[p19l1075t3033r1154b3068],
4	associated	VBN	O	associate	_	0	SENT_320	[p19l1168t3018r1441b3068],
5	with	IN	O	with	_	0	SENT_320	[p19l1456t3018r1569b3068],
6	the	DT	O	the	det	7	SENT_320	[p19l1584t3018r1670b3068],
7	development	NN	O	development	prep_with	4	SENT_320	[p19l1684t3018r2039b3080],
8	of	IN	O	of	_	0	SENT_320	[p19l2053t3017r2107b3068],
9	cutaneous	JJ	O	cutaneous	amod	12	SENT_320	[p19l132t3103r405b3146],
10	squamous	JJ	O	squamous	amod	12	SENT_320	[p19l420t3111r692b3158],
11	cell	NN	O	cell	nn	12	SENT_320	[p19l706t3096r790b3146],
12	tumors	NNS	O	tumor	prep_of	7	SENT_320	[p19l805t3104r993b3146],
13	in	IN	O	in	_	0	SENT_320	[p19l1009t3098r1052b3145],
14	patients	NNS	O	patient	prep_in	4	SENT_320	[p19l1070t3098r1280b3158],
15	treated	VBN	O	treat	partmod	14	SENT_320	[p19l1293t3096r1480b3146],
16	with	IN	O	with	_	0	SENT_320	[p19l1495t3096r1609b3146],
17	RAF	NN	ORGANIZATION	raf	nn	18	SENT_320	[p19l1628t3098r1725b3145],
18	inhibitors	NNS	O	inhibitor	prep_with	15	SENT_320	[p19l1742t3096r2046b3146],
19	.	.	O	.	_	0	SENT_320	[p19l1742t3096r2046b3146],

1	J.	NNP	PERSON	J.	nn	2	SENT_321	[p19l1742t3096r2046b3146],
2	Clin	NNP	PERSON	Clin	_	0	SENT_321	[p19l132t3173r237b3222],
3	.	.	O	.	_	0	SENT_321	[p19l132t3173r237b3222],

1	Oncol	NN	O	oncol	_	0	SENT_322	[p19l253t3173r412b3222],
2	.	.	O	.	_	0	SENT_322	[p19l253t3173r412b3222],

1	30	CD	NUMBER	30	_	0	SENT_323	[p19l427t3176r506b3230],
2	,	,	O	,	_	0	SENT_323	[p19l427t3176r506b3230],
3	316-321	CD	NUMBER	316-321	number	4	SENT_323	[p19l522t3176r735b3222],
4	(	CD	NUMBER	(	appos	1	SENT_323	[p19l761t3174r935b3229],
5	2012	CD	DATE	2012	num	6	SENT_323	[p19l761t3174r935b3229],
6	)	NN	O	)	dep	4	SENT_323	[p19l761t3174r935b3229],
7	.	.	O	.	_	0	SENT_323	[p19l761t3174r935b3229],

1	Falchook	NNP	O	Falchook	_	0	SENT_324	[p19l133t3251r377b3309],
2	,	,	O	,	_	0	SENT_324	[p19l133t3251r377b3309],
3	G.S.	NNP	PERSON	G.S.	nn	4	SENT_324	[p19l392t3253r487b3301],
4	etal	NNP	O	etal	appos	1	SENT_324	[p19l501t3251r616b3301],
5	.	.	O	.	_	0	SENT_324	[p19l501t3251r616b3301],

1	Dabrafenib	NNP	O	Dabrafenib	_	0	SENT_325	[p19l633t3251r923b3301],
2	in	IN	O	in	_	0	SENT_325	[p19l939t3254r981b3300],
3	patients	NNS	O	patient	prep_in	1	SENT_325	[p19l1000t3254r1209b3314],
4	with	IN	O	with	_	0	SENT_325	[p19l1223t3251r1336b3301],
5	melanoma	NN	O	melanoma	prep_with	3	SENT_325	[p19l1355t3251r1647b3309],
6	,	,	O	,	_	0	SENT_325	[p19l1355t3251r1647b3309],
7	untreated	JJ	O	untreated	amod	9	SENT_325	[p19l1664t3251r1918b3301],
8	brain	NN	O	brain	nn	9	SENT_325	[p19l1936t3251r2066b3301],
9	metastases	NNS	O	metastase	prep_with	3	SENT_325	[p19l134t3337r436b3387],
10	,	,	O	,	_	0	SENT_325	[p19l134t3337r436b3387],
11	and	CC	O	and	_	0	SENT_325	[p19l450t3329r547b3379],
12	other	JJ	O	other	amod	14	SENT_325	[p19l563t3329r705b3379],
13	solid	JJ	O	solid	amod	14	SENT_325	[p19l718t3329r837b3379],
14	tumours	NNS	O	tumour	conj_and	5	SENT_325	[p19l853t3337r1089b3379],
15	:	:	O	:	_	0	SENT_325	[p19l853t3337r1089b3379],
16	a	DT	O	a	det	20	SENT_325	[p19l1103t3344r1128b3379],
17	phase	NN	O	phase	nn	20	SENT_325	[p19l1146t3329r1300b3392],
18	1	CD	NUMBER	1	num	20	SENT_325	[p19l1319t3333r1333b3378],
19	dose	NN	O	dose	nn	20	SENT_325	[p19l1358t3329r1770b3379],
20	—	NN	O	—	dep	1	SENT_325	[p19l1358t3329r1770b3379],
21	escalation	NN	O	escalation	nn	22	SENT_325	[p19l1358t3329r1770b3379],
22	trial	NN	O	trial	dep	20	SENT_325	[p19l1785t3329r1897b3379],
23	.	.	O	.	_	0	SENT_325	[p19l1785t3329r1897b3379],

1	Lancet	NNP	O	Lancet	_	0	SENT_326	[p19l1911t3332r2081b3379],
2	379,1893-1901	CD	DURATION	379,1893-1901	num	1	SENT_326	[p19l132t3409r541b3463],
3	(	CD	NUMBER	(	num	5	SENT_326	[p19l567t3407r741b3463],
4	2012	CD	DATE	2012	num	5	SENT_326	[p19l567t3407r741b3463],
5	)	NN	O	)	dep	1	SENT_326	[p19l567t3407r741b3463],
6	.	.	O	.	_	0	SENT_326	[p19l567t3407r741b3463],

1	Trefzer	NNP	O	Trefzer	nn	3	SENT_327	[p19l128t3483r314b3540],
2	,	,	O	,	_	0	SENT_327	[p19l128t3483r314b3540],
3	U.	NNP	O	U.	dep	4	SENT_327	[p19l331t3486r377b3532],
4	etal	JJ	O	etal	_	0	SENT_327	[p19l392t3483r506b3532],
5	.	.	O	.	_	0	SENT_327	[p19l392t3483r506b3532],

1	BREAK	VB	O	break	_	0	SENT_328	[p19l524t3485r755b3532],
2	—	CD	NUMBER	—	number	3	SENT_328	[p19l524t3485r755b3532],
3	2	CD	NUMBER	2	dobj	1	SENT_328	[p19l524t3485r755b3532],
4	:	:	O	:	_	0	SENT_328	[p19l524t3485r755b3532],
5	a	DT	O	a	det	8	SENT_328	[p19l769t3498r795b3532],
6	Phase	NN	O	phase	nn	8	SENT_328	[p19l813t3483r963b3532],
7	|	CD	NUMBER	|	num	8	SENT_328	[p19l980t3486r1044b3532],
8	|	NN	O	|	dep	3	SENT_328	[p19l980t3486r1044b3532],
9	A	DT	O	a	det	10	SENT_328	[p19l980t3486r1044b3532],
10	trial	NN	O	trial	dep	8	SENT_328	[p19l1056t3483r1154b3532],
11	of	IN	O	of	_	0	SENT_328	[p19l1170t3483r1225b3532],
12	the	DT	O	the	det	16	SENT_328	[p19l1233t3483r1319b3532],
13	selective	JJ	O	selective	amod	16	SENT_328	[p19l1334t3483r1560b3532],
14	BRAF	NN	O	braf	nn	16	SENT_328	[p19l1577t3485r1709b3532],
15	kinase	NN	O	kinase	nn	16	SENT_328	[p19l1727t3483r1890b3532],
16	inhibitor	NN	O	inhibitor	prep_of	10	SENT_328	[p19l1906t3483r2129b3532],
17	GSK21	NN	O	gsk21	dep	27	SENT_328	[p19l132t3563r290b3611],
18	18436	CD	NUMBER	18436	num	17	SENT_328	[p19l309t3564r464b3611],
19	in	IN	O	in	_	0	SENT_328	[p19l480t3564r522b3610],
20	patients	NNS	O	patient	prep_in	17	SENT_328	[p19l541t3564r750b3624],
21	with	IN	O	with	_	0	SENT_328	[p19l764t3561r877b3611],
22	BRAF	NN	O	braf	prep_with	20	SENT_328	[p19l896t3563r1028b3611],
23	mutation	NN	O	mutation	dep	27	SENT_328	[p19l1046t3564r1514b3624],
24	—	CD	NUMBER	—	num	23	SENT_328	[p19l1046t3564r1514b3624],
25	positive	JJ	O	positive	amod	27	SENT_328	[p19l1046t3564r1514b3624],
26	(	NN	O	(	nn	27	SENT_328	[p19l1530t3562r1784b3619],
27	V600E/K	NN	O	v600e/k	dep	10	SENT_328	[p19l1530t3562r1784b3619],
28	)	CD	NUMBER	)	num	30	SENT_328	[p19l1530t3562r1784b3619],
29	metastatic	JJ	O	metastatic	amod	30	SENT_328	[p19l1803t3564r2075b3611],
30	melanoma	NN	O	melanoma	dep	27	SENT_328	[p19l134t3639r426b3689],
31	.	.	O	.	_	0	SENT_328	[p19l134t3639r426b3689],

1	PigmentCeIl	NN	O	pigmentceil	nn	2	SENT_329	[p19l440t3639r755b3702],
2	Melanoma	NN	O	melanoma	_	0	SENT_329	[p19l763t3639r1040b3689],
3	Res	NNP	O	Res	dep	2	SENT_329	[p19l1052t3641r1147b3689],
4	.	.	O	.	_	0	SENT_329	[p19l1052t3641r1147b3689],

1	24	CD	NUMBER	24	_	0	SENT_330	[p19l1162t3642r1242b3697],
2	,	,	O	,	_	0	SENT_330	[p19l1162t3642r1242b3697],
3	1020	CD	DATE	1020	num	4	SENT_330	[p19l1260t3642r1383b3689],
4	(	NN	O	(	appos	1	SENT_330	[p19l1399t3640r1500b3697],
5	201	CD	NUMBER	201	number	6	SENT_330	[p19l1399t3640r1500b3697],
6	1	CD	NUMBER	1	num	7	SENT_330	[p19l1518t3640r1573b3697],
7	)	NN	O	)	dep	4	SENT_330	[p19l1518t3640r1573b3697],
8	.	.	O	.	_	0	SENT_330	[p19l1518t3640r1573b3697],

1	Hauschild	NNP	O	Hauschild	_	0	SENT_331	[p19l133t3716r401b3773],
2	,	,	O	,	_	0	SENT_331	[p19l133t3716r401b3773],
3	A.	NNP	O	A.	nn	4	SENT_331	[p19l414t3719r463b3765],
4	etal	NNP	O	etal	appos	1	SENT_331	[p19l478t3716r592b3765],
5	.	.	O	.	_	0	SENT_331	[p19l478t3716r592b3765],

1	Dabrafenib	NNP	O	Dabrafenib	_	0	SENT_332	[p19l609t3716r899b3765],
2	in	IN	O	in	_	0	SENT_332	[p19l915t3719r958b3765],
3	BRAF	NNP	O	BRAF	prep_in	1	SENT_332	[p19l977t3716r1355b3765],
4	—	CD	NUMBER	—	num	3	SENT_332	[p19l977t3716r1355b3765],
5	mutated	VBN	O	mutate	partmod	1	SENT_332	[p19l977t3716r1355b3765],
6	metastatic	JJ	O	metastatic	amod	7	SENT_332	[p19l1374t3719r1646b3765],
7	melanoma	NN	O	melanoma	dobj	5	SENT_332	[p19l1662t3716r1955b3765],
8	:	:	O	:	_	0	SENT_332	[p19l1662t3716r1955b3765],
9	a	DT	O	a	det	16	SENT_332	[p19l1969t3730r1994b3765],
10	multicentre	JJ	O	multicentre	amod	16	SENT_332	[p20l134t17r447b75],
11	,	,	O	,	_	0	SENT_332	[p20l134t17r447b75],
12	open	JJ	O	open	amod	16	SENT_332	[p20l461t17r757b80],
13	—	CD	NUMBER	—	number	14	SENT_332	[p20l461t17r757b80],
14	|	CD	NUMBER	|	dep	12	SENT_332	[p20l461t17r757b80],
15	abe	NN	O	abe	nn	16	SENT_332	[p20l461t17r757b80],
16	|	NN	O	|	dep	1	SENT_332	[p20l461t17r757b80],
17	,	,	O	,	_	0	SENT_332	[p20l461t17r757b80],
18	phase	NN	O	phase	npadvmod	20	SENT_332	[p20l773t17r927b80],
19	3	CD	NUMBER	3	num	18	SENT_332	[p20l941t20r968b67],
20	randomised	JJ	O	randomised	amod	22	SENT_332	[p20l986t17r1297b67],
21	controlled	JJ	O	controlled	amod	22	SENT_332	[p20l1313t17r1579b67],
22	trial	NN	O	trial	appos	16	SENT_332	[p20l1595t17r1707b67],
23	.	.	O	.	_	0	SENT_332	[p20l1595t17r1707b67],

1	Lancet380	NN	O	lancet380	_	0	SENT_333	[p20l1721t20r2017b75],
2	,	,	O	,	_	0	SENT_333	[p20l1721t20r2017b75],
3	358-365	CD	NUMBER	358-365	number	4	SENT_333	[p20l132t97r354b143],
4	(	CD	NUMBER	(	appos	1	SENT_333	[p20l372t95r546b151],
5	2012	CD	DATE	2012	num	6	SENT_333	[p20l372t95r546b151],
6	)	NN	O	)	dep	4	SENT_333	[p20l372t95r546b151],
7	.	.	O	.	_	0	SENT_333	[p20l372t95r546b151],

1	Hauschild	NNP	O	Hauschild	_	0	SENT_334	[p20l132t172r401b230],
2	,	,	O	,	_	0	SENT_334	[p20l132t172r401b230],
3	A.	NNP	O	A.	nn	4	SENT_334	[p20l414t175r463b222],
4	etal	NNP	O	etal	appos	1	SENT_334	[p20l478t172r592b222],
5	.	.	O	.	_	0	SENT_334	[p20l478t172r592b222],

1	An	DT	O	a	det	15	SENT_335	[p20l606t175r675b221],
2	update	VBP	O	update	dep	15	SENT_335	[p20l693t172r878b235],
3	on	IN	O	on	_	0	SENT_335	[p20l892t187r957b222],
4	BREAK	NN	O	break	prep_on	2	SENT_335	[p20l976t174r1207b230],
5	—	CD	NUMBER	—	number	6	SENT_335	[p20l976t174r1207b230],
6	3	CD	NUMBER	3	amod	4	SENT_335	[p20l976t174r1207b230],
7	,	,	O	,	_	0	SENT_335	[p20l976t174r1207b230],
8	a	DT	O	a	det	9	SENT_335	[p20l1221t187r1247b222],
9	phase	NN	O	phase	dep	6	SENT_335	[p20l1265t172r1419b235],
10	III	CD	NUMBER	iii	dep	9	SENT_335	[p20l1435t175r1487b230],
11	,	,	O	,	_	0	SENT_335	[p20l1435t175r1487b230],
12	randomized	VBN	O	randomize	partmod	4	SENT_335	[p20l1504t172r1816b222],
13	trial	NN	O	trial	dobj	12	SENT_335	[p20l1831t172r1944b222],
14	:	:	O	:	_	0	SENT_335	[p20l1831t172r1944b222],
15	Dabrafenib	NNP	O	Dabrafenib	_	0	SENT_335	[p20l134t250r424b300],
16	(	CD	NUMBER	(	num	15	SENT_335	[p20l440t251r584b308],
17	DAB	NNP	O	DAB	dep	15	SENT_335	[p20l440t251r584b308],
18	)	CD	NUMBER	)	num	17	SENT_335	[p20l440t251r584b308],
19	versus	CC	O	versus	prep	17	SENT_335	[p20l599t265r764b300],
20	dacarbazine	NN	O	dacarbazine	nn	23	SENT_335	[p20l779t250r1098b300],
21	(	CD	NUMBER	(	num	23	SENT_335	[p20l1114t251r1269b308],
22	DTIC	NN	O	dtic	nn	23	SENT_335	[p20l1114t251r1269b308],
23	)	NN	O	)	dep	19	SENT_335	[p20l1114t251r1269b308],
24	in	IN	O	in	prep	23	SENT_335	[p20l1286t253r1329b299],
25	patients	NNS	O	patient	dep	35	SENT_335	[p20l1348t253r1557b313],
26	with	IN	O	with	_	0	SENT_335	[p20l1571t250r1684b300],
27	BRAFV600E	NN	O	brafv600e	nn	32	SENT_335	[p20l1703t252r2029b300],
28	—	CD	NUMBER	—	num	32	SENT_335	[p20l1703t252r2029b300],
29	positive	JJ	O	positive	amod	32	SENT_335	[p20l133t331r336b391],
30	mutation	NN	O	mutation	nn	32	SENT_335	[p20l353t331r591b378],
31	metastatic	JJ	O	metastatic	amod	32	SENT_335	[p20l609t331r881b378],
32	melanoma	NN	O	melanoma	prep_with	25	SENT_335	[p20l898t328r1175b378],
33	(	CD	NUMBER	(	num	35	SENT_335	[p20l1193t329r1324b386],
34	MM	NN	O	mm	nn	35	SENT_335	[p20l1193t329r1324b386],
35	)	NN	O	)	dep	24	SENT_335	[p20l1193t329r1324b386],
36	[	CD	NUMBER	[	num	37	SENT_335	[p20l1343t328r1574b385],
37	abstr	NN	O	abstr	dep	35	SENT_335	[p20l1343t328r1574b385],
38	.	.	O	.	_	0	SENT_335	[p20l1343t328r1574b385],
39	]	SYM	O	]	dep	17	SENT_335	[p20l1343t328r1574b385],

1	.	.	O	.	_	0	SENT_336	[p20l1343t328r1574b385],

1	J.	NNP	PERSON	J.	nn	2	SENT_337	[p20l1343t328r1574b385],
2	Clin	NNP	PERSON	Clin	_	0	SENT_337	[p20l1590t328r1694b378],
3	.	.	O	.	_	0	SENT_337	[p20l1590t328r1694b378],

1	Oncol	NN	O	oncol	_	0	SENT_338	[p20l1710t328r1870b378],
2	.	.	O	.	_	0	SENT_338	[p20l1710t328r1870b378],

1	31	CD	NUMBER	31	_	0	SENT_339	[p20l1884t331r1964b386],
2	,	,	O	,	_	0	SENT_339	[p20l1884t331r1964b386],
3	9010	CD	NUMBER	9010	number	4	SENT_339	[p20l1979t332r2105b378],
4	(	CD	NUMBER	(	appos	1	SENT_339	[p20l133t406r307b462],
5	2013	CD	DATE	2013	num	6	SENT_339	[p20l133t406r307b462],
6	)	NN	O	)	dep	4	SENT_339	[p20l133t406r307b462],
7	.	.	O	.	_	0	SENT_339	[p20l133t406r307b462],

1	Gi	NN	O	gi	nn	3	SENT_340	[p20l130t483r774b541],
2	|	CD	NUMBER	|	num	3	SENT_340	[p20l130t483r774b541],
3	martin	NN	O	martin	_	0	SENT_340	[p20l130t483r774b541],
4	,	,	O	,	_	0	SENT_340	[p20l130t483r774b541],
5	A.G.	NNP	PERSON	A.G.	nn	6	SENT_340	[p20l130t483r774b541],
6	etal	NNP	O	etal	appos	3	SENT_340	[p20l130t483r774b541],
7	.	.	O	.	_	0	SENT_340	[p20l130t483r774b541],

1	GSK1	NN	O	gsk1	nsubj	10	SENT_341	[p20l130t483r774b541],
2	120212	CD	NUMBER	120212	num	1	SENT_341	[p20l792t486r979b533],
3	(	CD	NUMBER	(	num	4	SENT_341	[p20l996t484r1296b541],
4	JTP	NN	O	jtp	dep	1	SENT_341	[p20l996t484r1296b541],
5	—	CD	NUMBER	—	number	6	SENT_341	[p20l996t484r1296b541],
6	74057	CD	NUMBER	74057	dep	1	SENT_341	[p20l996t484r1296b541],
7	)	NN	O	)	dep	6	SENT_341	[p20l996t484r1296b541],
8	is	VBZ	O	be	cop	10	SENT_341	[p20l1314t486r1348b533],
9	an	DT	O	a	det	10	SENT_341	[p20l1362t498r1423b533],
10	inhibitor	NN	O	inhibitor	_	0	SENT_341	[p20l1441t483r1665b533],
11	of	IN	O	of	_	0	SENT_341	[p20l1678t483r1732b533],
12	MEK	NN	O	mek	nn	13	SENT_341	[p20l1743t486r1858b532],
13	activity	NN	O	activity	prep_of	10	SENT_341	[p20l1869t486r2060b547],
14	and	CC	O	and	_	0	SENT_341	[p20l131t561r228b611],
15	activation	NN	O	activation	prep_of	10	SENT_341	[p20l244t564r501b611],
16	with	IN	O	with	_	0	SENT_341	[p20l516t561r629b611],
17	favorable	JJ	O	favorable	amod	19	SENT_341	[p20l644t561r890b611],
18	pharmacokinetic	JJ	O	pharmacokinetic	amod	19	SENT_341	[p20l906t561r1349b624],
19	properties	NNS	O	property	prep_with	10	SENT_341	[p20l1364t564r1633b624],
20	for	IN	O	for	_	0	SENT_341	[p20l1646t561r1719b611],
21	sustained	JJ	O	sustained	prep_for	19	SENT_341	[p20l1732t561r1981b611],
22	in	FW	O	in	nn	23	SENT_341	[p20l1997t564r2041b610],
23	vivo	FW	O	vivo	advmod	25	SENT_341	[p20l132t642r233b689],
24	pathway	NN	O	pathway	nn	25	SENT_341	[p20l249t639r474b703],
25	inhibition	NN	O	inhibition	rcmod	21	SENT_341	[p20l488t639r753b689],
26	.	.	O	.	_	0	SENT_341	[p20l488t639r753b689],

1	Clin	NNP	O	Clin	_	0	SENT_342	[p20l768t639r873b689],
2	.	.	O	.	_	0	SENT_342	[p20l768t639r873b689],

1	Cancer	NN	O	cancer	_	0	SENT_343	[p20l889t641r1066b689],
2	Res	NNP	O	Res	dep	1	SENT_343	[p20l1075t641r1170b689],
3	.	.	O	.	_	0	SENT_343	[p20l1075t641r1170b689],

1	17	CD	NUMBER	17	_	0	SENT_344	[p20l1187t643r1264b697],
2	,	,	O	,	_	0	SENT_344	[p20l1187t643r1264b697],
3	989-1000	CD	NUMBER	989-1000	num	4	SENT_344	[p20l1279t642r1535b689],
4	(	NN	O	(	appos	1	SENT_344	[p20l1551t640r1652b697],
5	201	CD	NUMBER	201	number	6	SENT_344	[p20l1551t640r1652b697],
6	1	CD	NUMBER	1	num	7	SENT_344	[p20l1670t640r1725b697],
7	)	NN	O	)	dep	4	SENT_344	[p20l1670t640r1725b697],
8	.	.	O	.	_	0	SENT_344	[p20l1670t640r1725b697],

1	Flaherty	NNP	PERSON	Flaherty	nn	4	SENT_345	[p20l132t717r361b781],
2	,	,	O	,	_	0	SENT_345	[p20l132t717r361b781],
3	K.T.	NNP	O	K.T.	appos	4	SENT_345	[p20l380t720r466b767],
4	etal.	NNP	O	etal.	_	0	SENT_345	[p20l482t717r616b775],
5	;	:	O	;	_	0	SENT_345	[p20l482t717r616b775],
6	METRIC	NNP	O	METRIC	nn	8	SENT_345	[p20l633t719r834b767],
7	Study	NNP	O	Study	nn	8	SENT_345	[p20l851t717r1006b781],
8	Group	NNP	O	Group	dep	4	SENT_345	[p20l1020t719r1201b780],
9	.	.	O	.	_	0	SENT_345	[p20l1020t719r1201b780],

1	Improved	VBN	O	improve	csubj	9	SENT_346	[p20l1219t717r1476b780],
2	survival	NN	O	survival	dobj	1	SENT_346	[p20l1494t717r1698b767],
3	with	IN	O	with	_	0	SENT_346	[p20l1716t717r1832b767],
4	MEK	NN	O	mek	nn	5	SENT_346	[p20l1852t720r1969b766],
5	inhibition	NN	O	inhibition	prep_with	1	SENT_346	[p20l133t795r392b845],
6	in	IN	O	in	_	0	SENT_346	[p20l412t798r455b844],
7	BRAF	NN	O	braf	prep_in	1	SENT_346	[p20l476t795r865b845],
8	—	CD	NUMBER	—	num	7	SENT_346	[p20l476t795r865b845],
9	mutated	VBN	O	mutate	_	0	SENT_346	[p20l476t795r865b845],
10	melanoma	NN	O	melanoma	dobj	9	SENT_346	[p20l886t795r1186b845],
11	.	.	O	.	_	0	SENT_346	[p20l886t795r1186b845],

1	N.	NNP	O	N.	nn	2	SENT_347	[p20l1202t798r1251b845],
2	Engl	NNP	O	Engl	_	0	SENT_347	[p20l1267t795r1438b858],
3	.	.	O	.	_	0	SENT_347	[p20l1267t795r1438b858],

1	J.	NNP	O	J.	nn	2	SENT_348	[p20l1267t795r1438b858],
2	Med	NNP	O	Med	_	0	SENT_348	[p20l1454t795r1579b845],
3	.	.	O	.	_	0	SENT_348	[p20l1454t795r1579b845],

1	367	CD	NUMBER	367	_	0	SENT_349	[p20l1595t798r1713b853],
2	,	,	O	,	_	0	SENT_349	[p20l1595t798r1713b853],
3	107-1	CD	NUMBER	107-1	number	4	SENT_349	[p20l1734t799r1882b845],
4	14	CD	NUMBER	14	appos	1	SENT_349	[p20l1902t799r1960b844],
5	(	CD	NUMBER	(	num	7	SENT_349	[p20l133t873r313b929],
6	2012	CD	DATE	2012	num	7	SENT_349	[p20l133t873r313b929],
7	)	NN	O	)	dep	4	SENT_349	[p20l133t873r313b929],
8	.	.	O	.	_	0	SENT_349	[p20l133t873r313b929],

1	Stuart	NNP	PERSON	Stuart	_	0	SENT_350	[p20l131t952r300b1008],
2	,	,	O	,	_	0	SENT_350	[p20l131t952r300b1008],
3	D.D.	NNP	PERSON	D.D.	nn	4	SENT_350	[p20l317t952r417b1000],
4	etal	NNP	O	etal	appos	1	SENT_350	[p20l432t950r546b1000],
5	.	.	O	.	_	0	SENT_350	[p20l432t950r546b1000],

1	Preclinical	JJ	O	preclinical	_	0	SENT_351	[p20l563t950r822b1000],
2	proﬁle	NN	O	proﬁle	dep	1	SENT_351	[p20l840t950r1006b1013],
3	of	IN	O	of	prep	2	SENT_351	[p20l1020t950r1075b1000],
4	LGX81	NN	O	lgx81	dep	3	SENT_351	[p20l1087t952r1241b1000],
5	8	CD	NUMBER	8	num	4	SENT_351	[p20l1255t954r1297b1000],
6	:	:	O	:	_	0	SENT_351	[p20l1255t954r1297b1000],
7	A	DT	O	a	det	12	SENT_351	[p20l1311t953r1347b999],
8	potent	JJ	O	potent	amod	12	SENT_351	[p20l1363t958r1538b1013],
9	and	CC	O	and	_	0	SENT_351	[p20l1551t950r1648b1000],
10	selective	JJ	O	selective	amod	12	SENT_351	[p20l1664t950r1891b1000],
11	RAF	NN	ORGANIZATION	raf	nn	12	SENT_351	[p20l1908t952r2006b999],
12	kinase	NN	O	kinase	dep	4	SENT_351	[p20l134t1027r297b1077],
13	inhibitor	NN	O	inhibitor	nn	15	SENT_351	[p20l312t1027r536b1077],
14	[	NN	O	[	nn	15	SENT_351	[p20l552t1027r737b1083],
15	abstr	NN	O	abstr	dep	12	SENT_351	[p20l552t1027r737b1083],
16	.	.	O	.	_	0	SENT_351	[p20l552t1027r737b1083],
17	]	SYM	O	]	dep	2	SENT_351	[p20l552t1027r737b1083],

1	.	.	O	.	_	0	SENT_352	[p20l552t1027r737b1083],

1	Cancer	NN	O	cancer	_	0	SENT_353	[p20l753t1029r929b1077],
2	Res	NNP	O	Res	dep	1	SENT_353	[p20l938t1029r1033b1077],
3	.	.	O	.	_	0	SENT_353	[p20l938t1029r1033b1077],

1	72	CD	NUMBER	72	_	0	SENT_354	[p20l1048t1031r1127b1084],
2	,	,	O	,	_	0	SENT_354	[p20l1048t1031r1127b1084],
3	3790	CD	NUMBER	3790	num	4	SENT_354	[p20l1142t1031r1269b1077],
4	(	NN	O	(	appos	1	SENT_354	[p20l1285t1028r1385b1084],
5	201	CD	NUMBER	201	number	6	SENT_354	[p20l1285t1028r1385b1084],
6	2	CD	NUMBER	2	num	7	SENT_354	[p20l1400t1028r1459b1084],
7	)	NN	O	)	dep	4	SENT_354	[p20l1400t1028r1459b1084],
8	.	.	O	.	_	0	SENT_354	[p20l1400t1028r1459b1084],

1	Dummer	NNP	PERSON	Dummer	_	0	SENT_355	[p20l132t1107r373b1163],
2	,	,	O	,	_	0	SENT_355	[p20l132t1107r373b1163],
3	R.	NNP	O	R.	nn	4	SENT_355	[p20l390t1107r431b1155],
4	etal	NN	O	etal	appos	1	SENT_355	[p20l445t1105r559b1155],
5	.	.	O	.	_	0	SENT_355	[p20l445t1105r559b1155],

1	Initial	JJ	O	initial	amod	2	SENT_356	[p20l577t1105r715b1155],
2	results	NNS	O	result	_	0	SENT_356	[p20l734t1105r901b1155],
3	from	IN	O	from	_	0	SENT_356	[p20l914t1105r1036b1155],
4	a	DT	O	a	det	5	SENT_356	[p20l1053t1120r1078b1155],
5	phase	NN	O	phase	prep_from	2	SENT_356	[p20l1096t1105r1250b1168],
6	I	PRP	O	I	dep	2	SENT_356	[p20l1267t1108r1289b1163],
7	,	,	O	,	_	0	SENT_356	[p20l1267t1108r1289b1163],
8	open	JJ	O	open	amod	12	SENT_356	[p20l1303t1105r1598b1168],
9	—	CD	NUMBER	—	number	10	SENT_356	[p20l1303t1105r1598b1168],
10	|	CD	NUMBER	|	dep	8	SENT_356	[p20l1303t1105r1598b1168],
11	abe	NN	O	abe	nn	12	SENT_356	[p20l1303t1105r1598b1168],
12	|	NN	O	|	appos	6	SENT_356	[p20l1303t1105r1598b1168],
13	,	,	O	,	_	0	SENT_356	[p20l1303t1105r1598b1168],
14	dose	NN	O	dose	nn	16	SENT_356	[p20l1612t1105r1737b1155],
15	escalation	NN	O	escalation	nn	16	SENT_356	[p20l1751t1105r2013b1155],
16	study	NN	O	study	appos	12	SENT_356	[p20l132t1183r276b1247],
17	of	IN	O	of	_	0	SENT_356	[p20l289t1183r344b1233],
18	the	DT	O	the	det	22	SENT_356	[p20l352t1183r437b1233],
19	oral	JJ	O	oral	amod	22	SENT_356	[p20l452t1183r547b1233],
20	BRAF	NN	O	braf	nn	22	SENT_356	[p20l566t1185r698b1233],
21	inhibitor	NN	O	inhibitor	nn	22	SENT_356	[p20l715t1183r939b1233],
22	LGX818	NN	O	lgx818	prep_of	16	SENT_356	[p20l954t1185r1151b1233],
23	in	IN	O	in	_	0	SENT_356	[p20l1167t1186r1209b1232],
24	patients	NNS	O	patient	prep_in	22	SENT_356	[p20l1228t1186r1438b1246],
25	with	IN	O	with	prep	24	SENT_356	[p20l1451t1183r1565b1233],
26	BRAF	NN	O	braf	nn	27	SENT_356	[p20l1583t1185r1716b1233],
27	V600	NN	O	v600	dep	25	SENT_356	[p20l1727t1186r1858b1233],
28	mutant	JJ	O	mutant	amod	34	SENT_356	[p20l1875t1191r2066b1233],
29	advanced	JJ	O	advanced	amod	34	SENT_356	[p20l131t1260r384b1310],
30	or	CC	O	or	_	0	SENT_356	[p20l401t1275r454b1310],
31	metastatic	JJ	O	metastatic	amod	34	SENT_356	[p20l469t1263r742b1310],
32	melanoma	NN	O	melanoma	nn	34	SENT_356	[p20l758t1260r1035b1310],
33	[	NN	O	[	nn	34	SENT_356	[p20l1054t1260r1284b1316],
34	abstr	NN	O	abstr	dep	27	SENT_356	[p20l1054t1260r1284b1316],
35	.	.	O	.	_	0	SENT_356	[p20l1054t1260r1284b1316],
36	]	SYM	O	]	dep	16	SENT_356	[p20l1054t1260r1284b1316],

1	.	.	O	.	_	0	SENT_357	[p20l1054t1260r1284b1316],

1	J.	NNP	O	J.	nn	2	SENT_358	[p20l1054t1260r1284b1316],
2	C/in	NNP	O	C/in	_	0	SENT_358	[p20l1301t1260r1405b1310],
3	.	.	O	.	_	0	SENT_358	[p20l1301t1260r1405b1310],

1	Onco	NNP	LOCATION	Onco	_	0	SENT_359	[p20l1421t1260r1816b1317],
2	/	:	O	/	punct	1	SENT_359	[p20l1421t1260r1816b1317],
3	.31,9028	CD	NUMBER	.31,9028	num	4	SENT_359	[p20l1421t1260r1816b1317],
4	(	CD	NUMBER	(	dep	1	SENT_359	[p20l1832t1261r2006b1317],
5	2013	CD	DATE	2013	num	6	SENT_359	[p20l1832t1261r2006b1317],
6	)	NN	O	)	dep	4	SENT_359	[p20l1832t1261r2006b1317],
7	.	.	O	.	_	0	SENT_359	[p20l1832t1261r2006b1317],

1	Flanigan	NNP	PERSON	Flanigan	_	0	SENT_360	[p20l132t1338r366b1402],
2	,	,	O	,	_	0	SENT_360	[p20l132t1338r366b1402],
3	J.C.	NNP	O	J.C.	nn	4	SENT_360	[p20l379t1340r462b1388],
4	etal	NNP	O	etal	appos	1	SENT_360	[p20l477t1338r592b1388],
5	.	.	O	.	_	0	SENT_360	[p20l477t1338r592b1388],

1	Melanoma	NN	O	melanoma	nn	3	SENT_361	[p20l607t1338r884b1388],
2	brain	NN	O	brain	nn	3	SENT_361	[p20l902t1338r1032b1388],
3	metastases	NNS	O	metastase	_	0	SENT_361	[p20l1050t1346r1353b1388],
4	:	:	O	:	_	0	SENT_361	[p20l1050t1346r1353b1388],
5	is	VBZ	O	be	dep	3	SENT_361	[p20l1369t1341r1404b1388],
6	it	PRP	O	it	dep	5	SENT_361	[p20l1420t1341r1451b1388],
7	time	NN	O	time	dep	9	SENT_361	[p20l1463t1341r1582b1388],
8	to	TO	O	to	dep	9	SENT_361	[p20l1595t1346r1648b1388],
9	reassess	NN	O	reassess	advmod	5	SENT_361	[p20l1664t1353r1873b1388],
10	the	DT	O	the	det	11	SENT_361	[p20l1887t1338r1973b1388],
11	bias	NN	O	bias	dep	5	SENT_361	[p20l1989t1338r2115b1388],
12	?	.	O	?	_	0	SENT_361	[p20l1989t1338r2115b1388],

1	Curr	NN	O	curr	_	0	SENT_362	[p20l132t1417r245b1465],
2	.	.	O	.	_	0	SENT_362	[p20l132t1417r245b1465],

1	Probl	NNP	O	Probl	_	0	SENT_363	[p20l260t1415r399b1465],
2	.	.	O	.	_	0	SENT_363	[p20l260t1415r399b1465],

1	Cancer	NN	O	cancer	_	0	SENT_364	[p20l415t1417r592b1465],
2	35	CD	NUMBER	35	num	1	SENT_364	[p20l602t1419r682b1472],
3	,	,	O	,	_	0	SENT_364	[p20l602t1419r682b1472],
4	200-210	CD	NUMBER	200-210	num	5	SENT_364	[p20l697t1419r920b1465],
5	(	NN	O	(	appos	1	SENT_364	[p20l936t1416r1037b1472],
6	201	CD	NUMBER	201	number	7	SENT_364	[p20l936t1416r1037b1472],
7	1	CD	NUMBER	1	num	8	SENT_364	[p20l1055t1416r1110b1472],
8	)	NN	O	)	dep	5	SENT_364	[p20l1055t1416r1110b1472],
9	.	.	O	.	_	0	SENT_364	[p20l1055t1416r1110b1472],

1	Agarwala	NNP	PERSON	Agarwala	_	0	SENT_365	[p20l130t1493r389b1557],
2	,	,	O	,	_	0	SENT_365	[p20l130t1493r389b1557],
3	S.S.	NNP	O	S.S.	nn	4	SENT_365	[p20l404t1495r488b1543],
4	etal	NN	O	etal	appos	1	SENT_365	[p20l503t1493r1020b1543],
5	.	.	O	.	_	0	SENT_365	[p20l503t1493r1020b1543],

1	Temozo	NNP	O	Temozo	nn	3	SENT_366	[p20l503t1493r1020b1543],
2	|	NN	O	|	nn	3	SENT_366	[p20l503t1493r1020b1543],
3	omide	NN	O	omide	_	0	SENT_366	[p20l503t1493r1020b1543],
4	for	IN	O	for	_	0	SENT_366	[p20l1033t1493r1105b1543],
5	the	DT	O	the	det	6	SENT_366	[p20l1117t1493r1202b1543],
6	treatment	NN	O	treatment	prep_for	3	SENT_366	[p20l1215t1501r1479b1543],
7	of	IN	O	of	_	0	SENT_366	[p20l1493t1493r1548b1543],
8	brain	NN	O	brain	nn	9	SENT_366	[p20l1559t1493r1689b1543],
9	metastases	NNS	O	metastase	prep_of	6	SENT_366	[p20l1707t1501r1997b1543],
10	associated	VBN	O	associate	partmod	9	SENT_366	[p20l131t1571r404b1621],
11	with	IN	O	with	_	0	SENT_366	[p20l419t1571r532b1621],
12	metastatic	JJ	O	metastatic	amod	13	SENT_366	[p20l551t1574r823b1621],
13	melanoma	NN	O	melanoma	prep_with	10	SENT_366	[p20l839t1571r1131b1621],
14	:	:	O	:	_	0	SENT_366	[p20l839t1571r1131b1621],
15	a	DT	O	a	det	16	SENT_366	[p20l1146t1586r1171b1621],
16	phase	NN	O	phase	dep	3	SENT_366	[p20l1189t1571r1343b1634],
17	II	CD	NUMBER	ii	num	18	SENT_366	[p20l1360t1574r1381b1621],
18	study	NN	O	study	dep	16	SENT_366	[p20l1398t1571r1552b1635],
19	.	.	O	.	_	0	SENT_366	[p20l1398t1571r1552b1635],

1	J.	NNP	PERSON	J.	nn	2	SENT_367	[p20l1562t1574r1596b1621],
2	Clin	NNP	PERSON	Clin	_	0	SENT_367	[p20l1612t1571r1717b1621],
3	.	.	O	.	_	0	SENT_367	[p20l1612t1571r1717b1621],

1	Oncol	NN	O	oncol	_	0	SENT_368	[p20l1733t1571r1893b1621],
2	.	.	O	.	_	0	SENT_368	[p20l1733t1571r1893b1621],

1	22	CD	NUMBER	22	_	0	SENT_369	[p20l1907t1575r1986b1629],
2	,	,	O	,	_	0	SENT_369	[p20l1907t1575r1986b1629],
3	2101-2107	CD	DATE	2101-2107	number	4	SENT_369	[p20l132t1652r420b1698],
4	(	CD	NUMBER	(	appos	1	SENT_369	[p20l437t1649r611b1705],
5	2004	CD	DATE	2004	num	6	SENT_369	[p20l437t1649r611b1705],
6	)	NN	O	)	dep	4	SENT_369	[p20l437t1649r611b1705],
7	.	.	O	.	_	0	SENT_369	[p20l437t1649r611b1705],

1	Long	NNP	O	Long	_	0	SENT_370	[p20l132t1729r273b1790],
2	,	,	O	,	_	0	SENT_370	[p20l132t1729r273b1790],
3	G.V.	NNP	O	G.V.	nn	4	SENT_370	[p20l287t1728r383b1776],
4	etal	NN	O	etal	appos	1	SENT_370	[p20l397t1726r512b1776],
5	.	.	O	.	_	0	SENT_370	[p20l397t1726r512b1776],

1	Dabrafenib	NNP	O	Dabrafenib	nsubj	12	SENT_371	[p20l529t1726r819b1776],
2	in	IN	O	in	_	0	SENT_371	[p20l835t1729r878b1775],
3	patients	NNS	O	patient	prep_in	1	SENT_371	[p20l896t1729r1106b1789],
4	with	IN	O	with	_	0	SENT_371	[p20l1119t1726r1232b1776],
5	Va	NNP	O	Va	prep_with	3	SENT_371	[p20l1245t1726r1509b1776],
6	|	CD	NUMBER	|	num	5	SENT_371	[p20l1245t1726r1509b1776],
7	600G	JJ	O	600g	amod	12	SENT_371	[p20l1245t1726r1509b1776],
8	|	NN	O	|	nn	12	SENT_371	[p20l1245t1726r1509b1776],
9	u	NN	O	u	nn	12	SENT_371	[p20l1245t1726r1509b1776],
10	orVa	NN	O	orva	nn	12	SENT_371	[p20l1526t1726r1846b1790],
11	|	CD	NUMBER	|	num	12	SENT_371	[p20l1526t1726r1846b1790],
12	600Lys	NNS	O	600ly	_	0	SENT_371	[p20l1526t1726r1846b1790],
13	BRAFmutant	JJ	O	brafmutant	amod	14	SENT_371	[p20l1863t1728r2016b1776, p20l133t1812r324b1854],
14	melanoma	NN	O	melanoma	dobj	12	SENT_371	[p20l340t1804r618b1854],
15	metastatic	JJ	O	metastatic	amod	14	SENT_371	[p20l636t1807r908b1854],
16	to	TO	O	to	_	0	SENT_371	[p20l921t1812r974b1854],
17	the	DT	O	the	det	20	SENT_371	[p20l987t1804r1073b1854],
18	brain	NN	O	brain	nn	20	SENT_371	[p20l1089t1804r1219b1854],
19	(	CD	NUMBER	(	num	20	SENT_371	[p20l1237t1805r1558b1862],
20	BREAK	NN	O	break	prep_to	12	SENT_371	[p20l1237t1805r1558b1862],
21	.	.	O	.	_	0	SENT_371	[p20l1237t1805r1558b1862],

1	—	NN	O	—	_	0	SENT_372	[p20l1237t1805r1558b1862],
2	.	.	O	.	_	0	SENT_372	[p20l1237t1805r1558b1862],

1	MB	NN	O	mb	nn	2	SENT_373	[p20l1237t1805r1558b1862],
2	)	NN	O	)	_	0	SENT_373	[p20l1237t1805r1558b1862],
3	:	:	O	:	_	0	SENT_373	[p20l1237t1805r1558b1862],
4	a	DT	O	a	det	9	SENT_373	[p20l1573t1819r1598b1854],
5	multicentre	JJ	O	multicentre	amod	9	SENT_373	[p20l1616t1804r1929b1862],
6	,	,	O	,	_	0	SENT_373	[p20l1616t1804r1929b1862],
7	openlabel	NN	O	openlabel	dep	9	SENT_373	[p20l1944t1819r2099b1867, p20l133t1882r269b1940],
8	,	,	O	,	_	0	SENT_373	[p20l1944t1819r2099b1867, p20l133t1882r269b1940],
9	phase	NN	O	phase	dep	2	SENT_373	[p20l285t1882r438b1945],
10	2	CD	NUMBER	2	num	11	SENT_373	[p20l454t1886r481b1932],
11	trial	NN	O	trial	dep	9	SENT_373	[p20l495t1882r607b1932],
12	.	.	O	.	_	0	SENT_373	[p20l495t1882r607b1932],

1	Lancet	NNP	O	Lancet	nn	2	SENT_374	[p20l621t1885r791b1932],
2	Oncol	NNP	O	Oncol	_	0	SENT_374	[p20l801t1882r961b1932],
3	.	.	O	.	_	0	SENT_374	[p20l801t1882r961b1932],

1	1	CD	NUMBER	1	num	2	SENT_375	[p20l978t1886r998b1932],
2	3	CD	NUMBER	3	_	0	SENT_375	[p20l1011t1886r1055b1940],
3	,	,	O	,	_	0	SENT_375	[p20l1011t1886r1055b1940],
4	1087-1095	CD	DATE	1087-1095	number	5	SENT_375	[p20l1074t1886r1357b1932],
5	(	CD	NUMBER	(	appos	2	SENT_375	[p20l1375t1883r1549b1940],
6	2012	CD	DATE	2012	num	7	SENT_375	[p20l1375t1883r1549b1940],
7	)	NN	O	)	dep	5	SENT_375	[p20l1375t1883r1549b1940],
8	.	.	O	.	_	0	SENT_375	[p20l1375t1883r1549b1940],

1	Dummer	NNP	PERSON	Dummer	_	0	SENT_376	[p20l132t1963r373b2018],
2	,	,	O	,	_	0	SENT_376	[p20l132t1963r373b2018],
3	R.	NNP	O	R.	nn	4	SENT_376	[p20l389t1963r431b2010],
4	etal	NN	O	etal	appos	1	SENT_376	[p20l445t1960r559b2010],
5	.	.	O	.	_	0	SENT_376	[p20l445t1960r559b2010],

1	An	DT	O	a	det	3	SENT_377	[p20l573t1963r642b2009],
2	open	JJ	O	open	amod	3	SENT_377	[p20l659t1960r939b2023],
3	—	CD	NUMBER	—	_	0	SENT_377	[p20l659t1960r939b2023],
4	|	CD	NUMBER	|	num	7	SENT_377	[p20l659t1960r939b2023],
5	abel	NN	O	abel	nn	7	SENT_377	[p20l659t1960r939b2023],
6	pilot	NN	O	pilot	nn	7	SENT_377	[p20l958t1960r1075b2023],
7	study	NN	O	study	npadvmod	10	SENT_377	[p20l1089t1960r1233b2024],
8	of	IN	O	of	_	0	SENT_377	[p20l1246t1960r1301b2010],
9	vemurafenib	NN	O	vemurafenib	prep_of	7	SENT_377	[p20l1309t1960r1644b2010],
10	in	IN	O	in	advmod	12	SENT_377	[p20l1660t1963r1702b2010],
11	previously	RB	DATE	previously	advmod	12	SENT_377	[p20l1721t1960r1991b2024],
12	treated	VBN	O	treat	partmod	3	SENT_377	[p20l130t2038r317b2088],
13	metastatic	JJ	O	metastatic	amod	15	SENT_377	[p20l336t2041r608b2088],
14	melanoma	NN	O	melanoma	nn	15	SENT_377	[p20l624t2038r902b2088],
15	patients	NNS	O	patient	dobj	12	SENT_377	[p20l920t2041r1129b2101],
16	with	IN	O	with	mark	19	SENT_377	[p20l1143t2038r1256b2088],
17	brain	NN	O	brain	nn	18	SENT_377	[p20l1275t2038r1404b2088],
18	metastases	NNS	O	metastase	nsubj	19	SENT_377	[p20l1423t2046r1712b2088],
19	[	VBP	O	[	advcl	12	SENT_377	[p20l1730t2038r1960b2095],
20	abstr	NN	O	abstr	dobj	19	SENT_377	[p20l1730t2038r1960b2095],
21	.	.	O	.	_	0	SENT_377	[p20l1730t2038r1960b2095],
22	]	SYM	O	]	dep	3	SENT_377	[p20l1730t2038r1960b2095],

1	.	.	O	.	_	0	SENT_378	[p20l1730t2038r1960b2095],

1	J.	NNP	PERSON	J.	nn	2	SENT_379	[p20l1730t2038r1960b2095],
2	Clin	NNP	PERSON	Clin	_	0	SENT_379	[p20l1976t2038r2081b2088],
3	.	.	O	.	_	0	SENT_379	[p20l1976t2038r2081b2088],

1	Oncol	NN	O	oncol	_	0	SENT_380	[p20l132t2115r291b2165],
2	.	.	O	.	_	0	SENT_380	[p20l132t2115r291b2165],

1	29	CD	NUMBER	29	_	0	SENT_381	[p20l306t2119r386b2172],
2	,	,	O	,	_	0	SENT_381	[p20l306t2119r386b2172],
3	9548	CD	DATE	9548	num	4	SENT_381	[p20l401t2119r527b2165],
4	(	NN	O	(	appos	1	SENT_381	[p20l543t2116r644b2172],
5	201	CD	NUMBER	201	number	6	SENT_381	[p20l543t2116r644b2172],
6	1	CD	NUMBER	1	num	7	SENT_381	[p20l662t2116r717b2172],
7	)	NN	O	)	dep	4	SENT_381	[p20l662t2116r717b2172],
8	.	.	O	.	_	0	SENT_381	[p20l662t2116r717b2172],

1	Joseph	NNP	PERSON	Joseph	_	0	SENT_382	[p20l128t2193r326b2256],
2	,	,	O	,	_	0	SENT_382	[p20l128t2193r326b2256],
3	R.W.	NNP	O	R.W.	nn	4	SENT_382	[p20l343t2195r448b2243],
4	etal	NN	O	etal	appos	1	SENT_382	[p20l462t2193r576b2243],
5	.	.	O	.	_	0	SENT_382	[p20l462t2193r576b2243],

1	Correlation	NN	O	correlation	_	0	SENT_383	[p20l591t2193r881b2243],
2	of	IN	O	of	_	0	SENT_383	[p20l897t2193r952b2243],
3	NRAS	NNS	O	nra	nn	4	SENT_383	[p20l964t2195r1104b2243],
4	mutations	NNS	O	mutation	prep_of	1	SENT_383	[p20l1121t2196r1386b2243],
5	with	IN	O	with	_	0	SENT_383	[p20l1400t2193r1513b2243],
6	clinical	JJ	O	clinical	amod	7	SENT_383	[p20l1529t2193r1705b2243],
7	response	NN	O	response	prep_with	4	SENT_383	[p20l1724t2208r1959b2256],
8	to	TO	O	to	_	0	SENT_383	[p20l1972t2201r2025b2243],
9	high	JJ	O	high	amod	12	SENT_383	[p20l133t2271r397b2335],
10	—	NN	O	—	nn	12	SENT_383	[p20l133t2271r397b2335],
11	dose	NN	O	dose	nn	12	SENT_383	[p20l133t2271r397b2335],
12	IL-2	NN	O	il-2	prep_to	1	SENT_383	[p20l414t2274r501b2320],
13	in	IN	O	in	_	0	SENT_383	[p20l518t2274r561b2321],
14	patients	NNS	O	patient	prep_in	1	SENT_383	[p20l580t2274r789b2334],
15	with	IN	O	with	_	0	SENT_383	[p20l803t2271r916b2321],
16	advanced	JJ	O	advanced	amod	19	SENT_383	[p20l932t2271r1185b2321],
17	me	PRP	O	I	npadvmod	18	SENT_383	[p20l1204t2271r1541b2321],
18	|	JJ	O	|	amod	19	SENT_383	[p20l1204t2271r1541b2321],
19	anoma	NN	O	anoma	prep_with	14	SENT_383	[p20l1204t2271r1541b2321],
20	.	.	O	.	_	0	SENT_383	[p20l1204t2271r1541b2321],

1	J.	NNP	PERSON	J.	nn	2	SENT_384	[p20l1204t2271r1541b2321],
2	Immunother	NNP	PERSON	Immunother	_	0	SENT_384	[p20l1556t2271r1886b2321],
3	.	.	O	.	_	0	SENT_384	[p20l1556t2271r1886b2321],

1	35	CD	NUMBER	35	_	0	SENT_385	[p20l1901t2275r1981b2329],
2	,	,	O	,	_	0	SENT_385	[p20l1901t2275r1981b2329],
3	66-72	CD	NUMBER	66-72	number	4	SENT_385	[p20l131t2352r289b2398],
4	(	CD	NUMBER	(	appos	1	SENT_385	[p20l306t2349r480b2405],
5	2012	CD	DATE	2012	num	6	SENT_385	[p20l306t2349r480b2405],
6	)	NN	O	)	dep	4	SENT_385	[p20l306t2349r480b2405],
7	.	.	O	.	_	0	SENT_385	[p20l306t2349r480b2405],

1	Hodi	NNP	LOCATION	Hodi	_	0	SENT_386	[p20l132t2426r266b2484],
2	,	,	O	,	_	0	SENT_386	[p20l132t2426r266b2484],
3	F.S.	NNP	LOCATION	F.S.	nn	4	SENT_386	[p20l283t2428r359b2476],
4	etal	NNP	O	etal	appos	1	SENT_386	[p20l373t2426r488b2476],
5	.	.	O	.	_	0	SENT_386	[p20l373t2426r488b2476],

1	Improved	VBN	O	improve	_	0	SENT_387	[p20l505t2426r754b2489],
2	survival	NN	O	survival	dobj	1	SENT_387	[p20l771t2426r969b2476],
3	with	IN	O	with	_	0	SENT_387	[p20l984t2426r1097b2476],
4	ipilimumab	NN	O	ipilimumab	prep_with	1	SENT_387	[p20l1115t2426r1414b2489],
5	in	IN	O	in	_	0	SENT_387	[p20l1430t2429r1473b2476],
6	patients	NNS	O	patient	prep_in	1	SENT_387	[p20l1491t2429r1701b2489],
7	with	IN	O	with	_	0	SENT_387	[p20l1714t2426r1828b2476],
8	metastatic	JJ	O	metastatic	amod	9	SENT_387	[p20l1846t2429r2119b2476],
9	melanoma	NN	O	melanoma	prep_with	6	SENT_387	[p20l133t2504r426b2554],
10	.	.	O	.	_	0	SENT_387	[p20l133t2504r426b2554],

1	N.	NNP	O	N.	nn	2	SENT_388	[p20l440t2507r487b2554],
2	Engl	NNP	O	Engl	_	0	SENT_388	[p20l503t2504r621b2568],
3	.	.	O	.	_	0	SENT_388	[p20l503t2504r621b2568],

1	J.	NNP	O	J.	nn	2	SENT_389	[p20l632t2507r666b2554],
2	Med	NNP	O	Med	_	0	SENT_389	[p20l680t2504r803b2554],
3	.	.	O	.	_	0	SENT_389	[p20l680t2504r803b2554],

1	363	CD	NUMBER	363	_	0	SENT_390	[p20l817t2508r932b2562],
2	,	,	O	,	_	0	SENT_390	[p20l817t2508r932b2562],
3	71	CD	NUMBER	71	number	4	SENT_390	[p20l948t2508r998b2553],
4	1-723	CD	NUMBER	1-723	appos	1	SENT_390	[p20l1016t2508r1169b2554],
5	(	NN	O	(	nn	8	SENT_390	[p20l1187t2505r1287b2562],
6	201	CD	NUMBER	201	num	8	SENT_390	[p20l1187t2505r1287b2562],
7	o	NN	O	o	nn	8	SENT_390	[p20l1301t2505r1361b2562],
8	)	NN	O	)	dep	4	SENT_390	[p20l1301t2505r1361b2562],
9	.	.	O	.	_	0	SENT_390	[p20l1301t2505r1361b2562],

1	Robert	NNP	PERSON	Robert	_	0	SENT_391	[p20l132t2583r320b2640],
2	,	,	O	,	_	0	SENT_391	[p20l132t2583r320b2640],
3	C.	NNP	O	C.	nn	4	SENT_391	[p20l334t2584r380b2632],
4	etal	NNP	O	etal	appos	1	SENT_391	[p20l394t2583r509b2632],
5	.	.	O	.	_	0	SENT_391	[p20l394t2583r509b2632],

1	Ipilimumab	NNP	O	Ipilimumab	_	0	SENT_392	[p20l526t2583r825b2645],
2	plus	CC	O	plus	prep	1	SENT_392	[p20l841t2583r947b2645],
3	dacarbazine	NN	O	dacarbazine	dep	2	SENT_392	[p20l961t2583r1280b2632],
4	for	IN	O	for	_	0	SENT_392	[p20l1293t2582r1366b2632],
5	previously	RB	DATE	previously	advmod	6	SENT_392	[p20l1381t2583r1650b2646],
6	untreated	JJ	O	untreated	amod	8	SENT_392	[p20l1665t2583r1919b2632],
7	metastatic	JJ	O	metastatic	amod	8	SENT_392	[p20l133t2663r405b2710],
8	melanoma	NN	O	melanoma	prep_for	1	SENT_392	[p20l421t2661r714b2710],
9	.	.	O	.	_	0	SENT_392	[p20l421t2661r714b2710],

1	N.	NNP	O	N.	nn	2	SENT_393	[p20l728t2663r776b2710],
2	Engl	NNP	O	Engl	_	0	SENT_393	[p20l790t2661r909b2724],
3	.	.	O	.	_	0	SENT_393	[p20l790t2661r909b2724],

1	J.	NNP	O	J.	nn	2	SENT_394	[p20l920t2663r954b2710],
2	Med	NNP	O	Med	_	0	SENT_394	[p20l968t2661r1091b2710],
3	.	.	O	.	_	0	SENT_394	[p20l968t2661r1091b2710],

1	364	CD	NUMBER	364	_	0	SENT_395	[p20l1105t2664r1220b2718],
2	,	,	O	,	_	0	SENT_395	[p20l1105t2664r1220b2718],
3	251	CD	NUMBER	251	number	4	SENT_395	[p20l1235t2664r1319b2710],
4	7-2526	CD	NUMBER	7-2526	num	5	SENT_395	[p20l1334t2664r1524b2710],
5	(	NN	O	(	appos	1	SENT_395	[p20l1540t2662r1641b2718],
6	201	CD	NUMBER	201	number	7	SENT_395	[p20l1540t2662r1641b2718],
7	1	CD	NUMBER	1	num	8	SENT_395	[p20l1659t2662r1714b2718],
8	)	NN	O	)	dep	5	SENT_395	[p20l1659t2662r1714b2718],
9	.	.	O	.	_	0	SENT_395	[p20l1659t2662r1714b2718],

1	Jackson	NNP	PERSON	Jackson	_	0	SENT_396	[p20l128t2738r347b2794],
2	,	,	O	,	_	0	SENT_396	[p20l128t2738r347b2794],
3	J.	NNP	O	J.	nn	4	SENT_396	[p20l359t2740r393b2787],
4	etal	NNP	O	etal	appos	1	SENT_396	[p20l407t2738r522b2787],
5	.	.	O	.	_	0	SENT_396	[p20l407t2738r522b2787],

1	Assessment	NNP	O	Assessment	_	0	SENT_397	[p20l536t2740r846b2787],
2	of	IN	O	of	_	0	SENT_397	[p20l860t2737r914b2787],
3	association	NN	O	association	prep_of	1	SENT_397	[p20l924t2740r1213b2787],
4	between	IN	O	between	_	0	SENT_397	[p20l1232t2738r1459b2787],
5	BRAF	NN	O	braf	prep_between	3	SENT_397	[p20l1479t2740r1611b2786],
6	mutation	NN	O	mutation	dep	1	SENT_397	[p20l1628t2740r1866b2787],
7	status	NN	O	status	dep	6	SENT_397	[p20l1883t2745r2036b2787],
8	in	IN	O	in	prep	7	SENT_397	[p20l2052t2740r2095b2786],
9	melanoma	NN	O	melanoma	nn	10	SENT_397	[p20l133t2815r411b2864],
10	tumors	NNS	O	tumor	dep	8	SENT_397	[p20l426t2822r613b2864],
11	and	CC	O	and	_	0	SENT_397	[p20l628t2815r724b2864],
12	response	NN	O	response	conj_and	10	SENT_397	[p20l742t2829r977b2876],
13	to	TO	O	to	_	0	SENT_397	[p20l990t2822r1044b2864],
14	ipilimumab	JJ	O	ipilimumab	amod	16	SENT_397	[p20l1060t2815r1358b2876],
15	[	NN	O	[	nn	16	SENT_397	[p20l1376t2815r1561b2870],
16	abstr	NN	O	abstr	prep_to	10	SENT_397	[p20l1376t2815r1561b2870],
17	.	.	O	.	_	0	SENT_397	[p20l1376t2815r1561b2870],
18	]	SYM	O	]	dep	7	SENT_397	[p20l1376t2815r1561b2870],

1	.	.	O	.	_	0	SENT_398	[p20l1376t2815r1561b2870],

1	J.	NNP	PERSON	J.	nn	2	SENT_399	[p20l1572t2817r1606b2864],
2	Clin	NNP	PERSON	Clin	_	0	SENT_399	[p20l1622t2815r1727b2864],
3	.	.	O	.	_	0	SENT_399	[p20l1622t2815r1727b2864],

1	Oncol	NN	O	oncol	_	0	SENT_400	[p20l1742t2815r1902b2864],
2	.	.	O	.	_	0	SENT_400	[p20l1742t2815r1902b2864],

1	29	CD	NUMBER	29	_	0	SENT_401	[p20l1916t2818r1996b2871],
2	,	,	O	,	_	0	SENT_401	[p20l1916t2818r1996b2871],
3	2587	CD	DATE	2587	num	4	SENT_401	[p20l2011t2818r2137b2864],
4	(	NN	O	(	appos	1	SENT_401	[p20l133t2893r233b2948],
5	201	CD	NUMBER	201	number	6	SENT_401	[p20l133t2893r233b2948],
6	1	CD	NUMBER	1	num	7	SENT_401	[p20l252t2893r307b2948],
7	)	NN	O	)	dep	4	SENT_401	[p20l252t2893r307b2948],
8	.	.	O	.	_	0	SENT_401	[p20l252t2893r307b2948],

1	Hamid	NNP	PERSON	Hamid	nn	3	SENT_402	[p20l132t2970r315b3027],
2	,	,	O	,	_	0	SENT_402	[p20l132t2970r315b3027],
3	O.	NNP	O	O.	_	0	SENT_402	[p20l329t2971r380b3019],
4	et	FW	O	et	nn	5	SENT_402	[p20l394t2977r443b3019],
5	al.	FW	O	al.	dep	3	SENT_402	[p20l452t2970r509b3019],
6	.	.	O	.	_	0	SENT_402	[p20l452t2970r509b3019],

1	Safety	NN	O	safety	nn	4	SENT_403	[p20l524t2969r684b3033],
2	and	CC	O	and	_	0	SENT_403	[p20l697t2970r794b3019],
3	tumor	NN	O	tumor	nn	4	SENT_403	[p20l809t2977r973b3019],
4	responses	NNS	O	response	_	0	SENT_403	[p20l988t2984r1248b3032],
5	with	IN	O	with	_	0	SENT_403	[p20l1261t2970r1375b3019],
6	lambrolizumab	NN	O	lambrolizumab	prep_with	4	SENT_403	[p20l1393t2970r1790b3019],
7	(	CD	NUMBER	(	num	9	SENT_403	[p20l1806t2971r2085b3027],
8	anti-PD-1	JJ	O	anti-pd-1	amod	9	SENT_403	[p20l1806t2971r2085b3027],
9	)	NN	O	)	dep	4	SENT_403	[p20l1806t2971r2085b3027],
10	in	IN	O	in	_	0	SENT_403	[p20l2103t2972r2145b3019],
11	melanoma	NN	O	melanoma	prep_in	9	SENT_403	[p20l134t3048r426b3097],
12	.	.	O	.	_	0	SENT_403	[p20l134t3048r426b3097],

1	N.	NNP	O	N.	nn	2	SENT_404	[p20l440t3050r488b3097],
2	Engl	NNP	O	Engl	_	0	SENT_404	[p20l503t3048r667b3111],
3	.	.	O	.	_	0	SENT_404	[p20l503t3048r667b3111],

1	J.	NNP	O	J.	nn	2	SENT_405	[p20l503t3048r667b3111],
2	Med	NNP	O	Med	_	0	SENT_405	[p20l681t3048r803b3097],
3	.	.	O	.	_	0	SENT_405	[p20l681t3048r803b3097],

1	369	CD	NUMBER	369	_	0	SENT_406	[p20l818t3051r933b3105],
2	,	,	O	,	_	0	SENT_406	[p20l818t3051r933b3105],
3	1	CD	NUMBER	1	number	4	SENT_406	[p20l952t3052r966b3097],
4	34-144	CD	NUMBER	34-144	appos	1	SENT_406	[p20l981t3051r1172b3097],
5	(	CD	NUMBER	(	num	7	SENT_406	[p20l1187t3049r1362b3105],
6	2013	CD	DATE	2013	num	7	SENT_406	[p20l1187t3049r1362b3105],
7	)	NN	O	)	dep	4	SENT_406	[p20l1187t3049r1362b3105],
8	.	.	O	.	_	0	SENT_406	[p20l1187t3049r1362b3105],

1	Topalian	NNP	PERSON	Topalian	_	0	SENT_407	[p20l128t3126r364b3188],
2	,	,	O	,	_	0	SENT_407	[p20l128t3126r364b3188],
3	S.L.	NNP	O	S.L.	nn	4	SENT_407	[p20l379t3127r462b3175],
4	etal	NNP	O	etal	appos	1	SENT_407	[p20l477t3126r592b3175],
5	.	.	O	.	_	0	SENT_407	[p20l477t3126r592b3175],

1	Safety	NN	O	safety	_	0	SENT_408	[p20l606t3125r776b3189],
2	,	,	O	,	_	0	SENT_408	[p20l606t3125r776b3189],
3	activity	NN	O	activity	conj_and	1	SENT_408	[p20l790t3128r990b3189],
4	,	,	O	,	_	0	SENT_408	[p20l790t3128r990b3189],
5	and	CC	O	and	_	0	SENT_408	[p20l1004t3126r1100b3175],
6	immune	JJ	O	immune	amod	7	SENT_408	[p20l1118t3128r1337b3175],
7	correlates	NNS	O	correlate	conj_and	1	SENT_408	[p20l1351t3126r1606b3175],
8	of	IN	O	of	_	0	SENT_408	[p20l1621t3125r1675b3175],
9	anti-PD-1	JJ	O	anti-pd-1	amod	10	SENT_408	[p20l1684t3128r1921b3175],
10	antibody	NN	O	antibody	prep_of	7	SENT_408	[p20l132t3204r369b3267],
11	in	IN	O	in	_	0	SENT_408	[p20l383t3206r426b3253],
12	cancer	NN	O	cancer	prep_in	10	SENT_408	[p20l442t3218r623b3253],
13	.	.	O	.	_	0	SENT_408	[p20l442t3218r623b3253],

1	N.	NNP	O	N.	nn	2	SENT_409	[p20l637t3206r685b3253],
2	Engl	NNP	O	Engl	_	0	SENT_409	[p20l700t3204r818b3267],
3	.	.	O	.	_	0	SENT_409	[p20l700t3204r818b3267],

1	J.	NNP	O	J.	nn	2	SENT_410	[p20l829t3206r864b3253],
2	Med	NNP	O	Med	_	0	SENT_410	[p20l877t3204r1000b3253],
3	.	.	O	.	_	0	SENT_410	[p20l877t3204r1000b3253],

1	366	CD	NUMBER	366	_	0	SENT_411	[p20l1014t3207r1130b3261],
2	,	,	O	,	_	0	SENT_411	[p20l1014t3207r1130b3261],
3	2443-2454	CD	DATE	2443-2454	number	4	SENT_411	[p20l1144t3207r1434b3253],
4	(	CD	NUMBER	(	appos	1	SENT_411	[p20l1450t3205r1624b3261],
5	2012	CD	DATE	2012	num	6	SENT_411	[p20l1450t3205r1624b3261],
6	)	NN	O	)	dep	4	SENT_411	[p20l1450t3205r1624b3261],
7	.	.	O	.	_	0	SENT_411	[p20l1450t3205r1624b3261],

1	Hamid	NNP	PERSON	Hamid	nn	3	SENT_412	[p20l133t3282r316b3339],
2	,	,	O	,	_	0	SENT_412	[p20l133t3282r316b3339],
3	O.	NNP	O	O.	_	0	SENT_412	[p20l330t3283r381b3331],
4	et	FW	O	et	nn	5	SENT_412	[p20l395t3289r444b3331],
5	al.	FW	O	al.	dep	3	SENT_412	[p20l453t3282r510b3331],
6	.	.	O	.	_	0	SENT_412	[p20l453t3282r510b3331],

1	Clinical	JJ	O	clinical	_	0	SENT_413	[p20l524t3282r708b3331],
2	activity	NN	O	activity	dobj	12	SENT_413	[p20l726t3284r925b3345],
3	,	,	O	,	_	0	SENT_413	[p20l726t3284r925b3345],
4	safety	NN	O	safety	dobj	12	SENT_413	[p20l939t3281r1103b3345],
5	,	,	O	,	_	0	SENT_413	[p20l939t3281r1103b3345],
6	and	CC	O	and	_	0	SENT_413	[p20l1117t3282r1213b3331],
7	biomarkers	NNS	O	biomarker	dobj	12	SENT_413	[p20l1232t3282r1524b3331],
8	of	IN	O	of	_	0	SENT_413	[p20l1539t3281r1594b3331],
9	MPDL3280A	NN	O	mpdl3280a	prep_of	7	SENT_413	[p20l1605t3284r1940b3339],
10	,	,	O	,	_	0	SENT_413	[p20l1605t3284r1940b3339],
11	an	DT	O	a	advmod	2	SENT_413	[p20l1954t3296r2015b3331],
12	engineered	VBN	O	engineer	dep	1	SENT_413	[p20l132t3360r430b3423],
13	PD-L1	NN	O	pd-l1	nn	14	SENT_413	[p20l450t3362r593b3409],
14	antibody	NN	O	antibody	dep	12	SENT_413	[p20l617t3360r854b3423],
15	in	IN	O	in	rcmod	14	SENT_413	[p20l868t3362r910b3409],
16	patients	NNS	O	patient	pobj	15	SENT_413	[p20l929t3362r1139b3422],
17	with	IN	O	with	prep	16	SENT_413	[p20l1153t3360r1266b3409],
18	locally	RB	O	locally	advmod	19	SENT_413	[p20l1284t3360r1449b3423],
19	advanced	VBN	O	advance	amod	16	SENT_413	[p20l1461t3360r1715b3409],
20	or	CC	O	or	_	0	SENT_413	[p20l1731t3374r1784b3409],
21	metastatic	JJ	O	metastatic	amod	24	SENT_413	[p20l1800t3362r2072b3409],
22	melanoma	NN	O	melanoma	nn	24	SENT_413	[p20l134t3437r411b3486],
23	[	NN	O	[	nn	24	SENT_413	[p20l431t3437r661b3493],
24	abstr	NN	O	abstr	pobj	15	SENT_413	[p20l431t3437r661b3493],
25	.	.	O	.	_	0	SENT_413	[p20l431t3437r661b3493],
26	]	SYM	O	]	dep	1	SENT_413	[p20l431t3437r661b3493],

1	.	.	O	.	_	0	SENT_414	[p20l431t3437r661b3493],

1	J.	NNP	PERSON	J.	nn	2	SENT_415	[p20l431t3437r661b3493],
2	Clin	NNP	PERSON	Clin	_	0	SENT_415	[p20l677t3437r781b3486],
3	.	.	O	.	_	0	SENT_415	[p20l677t3437r781b3486],

1	Oncol	NN	O	oncol	_	0	SENT_416	[p20l797t3437r957b3486],
2	.	.	O	.	_	0	SENT_416	[p20l797t3437r957b3486],

1	31	CD	NUMBER	31	_	0	SENT_417	[p20l971t3440r1051b3493],
2	,	,	O	,	_	0	SENT_417	[p20l971t3440r1051b3493],
3	9010	CD	NUMBER	9010	number	4	SENT_417	[p20l1066t3440r1193b3486],
4	(	CD	NUMBER	(	appos	1	SENT_417	[p20l1209t3438r1382b3493],
5	2013	CD	DATE	2013	num	6	SENT_417	[p20l1209t3438r1382b3493],
6	)	NN	O	)	dep	4	SENT_417	[p20l1209t3438r1382b3493],
7	.	.	O	.	_	0	SENT_417	[p20l1209t3438r1382b3493],

1	Ackerman	NNP	PERSON	Ackerman	_	0	SENT_418	[p20l130t3515r408b3572],
2	,	,	O	,	_	0	SENT_418	[p20l130t3515r408b3572],
3	A.	NNP	O	A.	nn	4	SENT_418	[p20l422t3517r471b3564],
4	etal	NNP	O	etal	appos	1	SENT_418	[p20l485t3515r600b3564],
5	.	.	O	.	_	0	SENT_418	[p20l485t3515r600b3564],

1	Outcomes	NNS	O	outcome	_	0	SENT_419	[p20l614t3516r884b3564],
2	of	IN	O	of	advmod	7	SENT_419	[p20l899t3514r953b3564],
3	patients	NNS	O	patient	pobj	2	SENT_419	[p20l965t3517r1174b3577],
4	with	IN	O	with	_	0	SENT_419	[p20l1188t3515r1301b3564],
5	malignant	JJ	O	malignant	amod	6	SENT_419	[p20l1319t3515r1585b3578],
6	melanoma	NN	O	melanoma	prep_with	2	SENT_419	[p20l1601t3515r1879b3564],
7	treated	VBN	O	treat	partmod	1	SENT_419	[p20l1894t3515r2081b3564],
8	with	IN	O	with	_	0	SENT_419	[p20l131t3593r244b3642],
9	immunotherapy	NN	O	immunotherapy	prep_with	7	SENT_419	[p20l262t3593r690b3656],
10	prior	RB	O	prior	dep	9	SENT_419	[p20l705t3595r828b3655],
11	to	TO	O	to	prep	10	SENT_419	[p20l840t3600r893b3642],
12	or	CC	O	or	_	0	SENT_419	[p20l908t3607r961b3642],
13	after	IN	O	after	conj_or	10	SENT_419	[p20l974t3592r1095b3642],
14	vemurafenib	NN	O	vemurafenib	nn	16	SENT_419	[p20l1107t3592r1441b3642],
15	[	NN	O	[	nn	16	SENT_419	[p20l1458t3593r1689b3649],
16	abstr	NN	O	abstr	pobj	13	SENT_419	[p20l1458t3593r1689b3649],
17	.	.	O	.	_	0	SENT_419	[p20l1458t3593r1689b3649],
18	]	SYM	O	]	dep	1	SENT_419	[p20l1458t3593r1689b3649],

1	.	.	O	.	_	0	SENT_420	[p20l1458t3593r1689b3649],

1	J.	NNP	PERSON	J.	nn	2	SENT_421	[p20l1458t3593r1689b3649],
2	Clin	NNP	PERSON	Clin	_	0	SENT_421	[p20l1705t3593r1809b3642],
3	.	.	O	.	_	0	SENT_421	[p20l1705t3593r1809b3642],

1	Oncol	NN	O	oncol	_	0	SENT_422	[p20l1826t3593r1985b3642],
2	.	.	O	.	_	0	SENT_422	[p20l1826t3593r1985b3642],

1	30	CD	NUMBER	30	_	0	SENT_423	[p20l1999t3596r2079b3650],
2	,	,	O	,	_	0	SENT_423	[p20l1999t3596r2079b3650],
3	8569	CD	NUMBER	8569	number	4	SENT_423	[p20l132t3673r259b3719],
4	(	CD	NUMBER	(	appos	1	SENT_423	[p20l275t3671r449b3726],
5	2012	CD	DATE	2012	num	6	SENT_423	[p20l275t3671r449b3726],
6	)	NN	O	)	dep	4	SENT_423	[p20l275t3671r449b3726],
7	.	.	O	.	_	0	SENT_423	[p20l275t3671r449b3726],

1	VOLUME	NN	O	volume	nn	3	SENT_424	[p21l544t113r769b155],
2	95	CD	NUMBER	95	num	3	SENT_424	[p21l786t114r843b155],
3	NUMBER	NN	O	number	_	0	SENT_424	[p21l864t113r1088b155],
4	1	CD	NUMBER	1	number	5	SENT_424	[p21l1110t115r1123b155],
5	|	CD	NUMBER	|	dep	3	SENT_424	[p21l1152t109r1157b170],
6	JANUARY	NNP	DATE	JANUARY	dep	5	SENT_424	[p21l1176t113r1422b155],
7	2014	CD	DATE	2014	num	6	SENT_424	[p21l1438t114r1559b155],
8	|	CD	NUMBER	|	num	9	SENT_424	[p21l1578t109r1582b170],
9	www.nature.com/cpt	NN	O	www.nature.com/cpt	dep	3	SENT_424	[p21l1601t113r2153b166],

1	Ascierto	NNP	O	Ascierto	_	0	SENT_425	[p21l128t521r354b576],
2	,	,	O	,	_	0	SENT_425	[p21l128t521r354b576],
3	PA.	NNP	LOCATION	PA.	conj_and	1	SENT_425	[p21l371t521r468b576],
4	,	,	O	,	_	0	SENT_425	[p21l371t521r468b576],
5	Simeone	NNP	PERSON	Simeone	conj_and	1	SENT_425	[p21l483t520r725b576],
6	,	,	O	,	_	0	SENT_425	[p21l483t520r725b576],
7	E.	NNP	O	E.	conj_and	1	SENT_425	[p21l743t521r794b576],
8	,	,	O	,	_	0	SENT_425	[p21l743t521r794b576],
9	Giannarelli	NNP	PERSON	Giannarelli	conj_and	1	SENT_425	[p21l808t519r1103b576],
10	,	,	O	,	_	0	SENT_425	[p21l808t519r1103b576],
11	D.	NNP	O	D.	conj_and	1	SENT_425	[p21l1120t521r1181b576],
12	,	,	O	,	_	0	SENT_425	[p21l1120t521r1181b576],
13	Grimaldi	NNP	PERSON	Grimaldi	conj_and	1	SENT_425	[p21l1195t519r1432b576],
14	,	,	O	,	_	0	SENT_425	[p21l1195t519r1432b576],
15	A.M.	NNP	O	A.M.	conj_and	1	SENT_425	[p21l1446t521r1573b576],
16	,	,	O	,	_	0	SENT_425	[p21l1446t521r1573b576],
17	Romano	NNP	PERSON	Romano	conj_and	1	SENT_425	[p21l1590t521r1820b576],
18	,	,	O	,	_	0	SENT_425	[p21l1590t521r1820b576],
19	A.	NNP	ORGANIZATION	A.	conj_and	1	SENT_425	[p21l1834t521r1883b569],
20	&	CC	ORGANIZATION	&	_	0	SENT_425	[p21l1897t520r1934b569],
21	Mozzillo	NNP	ORGANIZATION	Mozzillo	conj_and	1	SENT_425	[p21l131t598r359b655],
22	,	,	O	,	_	0	SENT_425	[p21l131t598r359b655],
23	N.	NNP	O	N.	nn	24	SENT_425	[p21l376t600r425b647],
24	Sequencing	NN	O	sequencing	appos	1	SENT_425	[p21l439t599r751b661],
25	of	IN	O	of	_	0	SENT_425	[p21l768t597r823b647],
26	BRAF	NN	O	braf	nn	27	SENT_425	[p21l834t600r967b647],
27	inhibitors	NNS	O	inhibitor	prep_of	24	SENT_425	[p21l984t598r1233b647],
28	and	CC	O	and	_	0	SENT_425	[p21l1247t598r1344b647],
29	ipilimumab	NN	O	ipilimumab	conj_and	27	SENT_425	[p21l1362t598r1662b660],
30	in	IN	O	in	_	0	SENT_425	[p21l1678t600r1721b647],
31	patients	NNS	O	patient	prep_in	27	SENT_425	[p21l1739t600r1950b660],
32	with	IN	O	with	_	0	SENT_425	[p21l1964t598r2078b647],
33	metastatic	JJ	O	metastatic	amod	34	SENT_425	[p21l132t678r405b725],
34	melanoma	NN	O	melanoma	prep_with	31	SENT_425	[p21l421t676r715b725],
35	:	:	O	:	_	0	SENT_425	[p21l421t676r715b725],
36	a	DT	O	a	det	38	SENT_425	[p21l730t690r755b725],
37	possible	JJ	O	possible	amod	38	SENT_425	[p21l773t676r988b738],
38	algorithm	NN	O	algorithm	dep	1	SENT_425	[p21l1002t676r1259b739],
39	for	IN	O	for	_	0	SENT_425	[p21l1274t675r1347b725],
40	clinical	JJ	O	clinical	amod	41	SENT_425	[p21l1360t676r1537b725],
41	use	NN	O	use	prep_for	38	SENT_425	[p21l1556t690r1655b725],
42	.	.	O	.	_	0	SENT_425	[p21l1556t690r1655b725],

1	J.	NNP	MISC	J.	nn	2	SENT_426	[p21l1665t678r1700b725],
2	Trans	NNP	MISC	Trans	_	0	SENT_426	[p21l1717t676r1874b725],
3	]	NN	O	]	dep	2	SENT_426	[p21l1717t676r1874b725],
4	.	.	O	.	_	0	SENT_426	[p21l1717t676r1874b725],

1	Med	NNP	O	Med	_	0	SENT_427	[p21l1887t676r2011b725],
2	.	.	O	.	_	0	SENT_427	[p21l1887t676r2011b725],

1	10	CD	NUMBER	10	_	0	SENT_428	[p21l2028t679r2105b733],
2	,	,	O	,	_	0	SENT_428	[p21l2028t679r2105b733],
3	107	CD	NUMBER	107	number	4	SENT_428	[p21l134t756r224b802],
4	(	CD	NUMBER	(	appos	1	SENT_428	[p21l241t754r416b809],
5	2012	CD	DATE	2012	num	6	SENT_428	[p21l241t754r416b809],
6	)	NN	O	)	dep	4	SENT_428	[p21l241t754r416b809],
7	.	.	O	.	_	0	SENT_428	[p21l241t754r416b809],

1	Jang	NNP	PERSON	Jang	_	0	SENT_429	[p21l126t833r263b894],
2	,	,	O	,	_	0	SENT_429	[p21l126t833r263b894],
3	S.	NNP	ORGANIZATION	S.	conj_and	1	SENT_429	[p21l277t832r318b880],
4	&	CC	ORGANIZATION	&	_	0	SENT_429	[p21l332t832r369b880],
5	Atkins	NNP	ORGANIZATION	Atkins	conj_and	1	SENT_429	[p21l381t831r557b888],
6	,	,	O	,	_	0	SENT_429	[p21l381t831r557b888],
7	M.B.	NNP	O	M.B.	appos	1	SENT_429	[p21l572t831r854b880],
8	Which	WDT	O	which	det	9	SENT_429	[p21l572t831r854b880],
9	drug	NN	O	drug	rcmod	7	SENT_429	[p21l870t831r1007b894],
10	,	,	O	,	_	0	SENT_429	[p21l870t831r1007b894],
11	and	CC	O	and	advmod	7	SENT_429	[p21l1021t831r1118b880],
12	when	WRB	O	when	advmod	14	SENT_429	[p21l1133t831r1294b888],
13	,	,	O	,	_	0	SENT_429	[p21l1133t831r1294b888],
14	for	IN	O	for	dep	7	SENT_429	[p21l1307t830r1380b880],
15	patients	NNS	O	patient	pobj	14	SENT_429	[p21l1395t833r1605b893],
16	with	IN	O	with	dep	14	SENT_429	[p21l1619t831r1733b880],
17	BRAF-mutant	JJ	O	braf-mutant	amod	18	SENT_429	[p21l1752t833r2103b880],
18	melanoma	NN	O	melanoma	pobj	16	SENT_429	[p21l132t908r438b958],
19	?	.	O	?	_	0	SENT_429	[p21l132t908r438b958],

1	Lancet	NNP	O	Lancet	nn	2	SENT_430	[p21l453t910r624b958],
2	Oncol	NNP	O	Oncol	_	0	SENT_430	[p21l634t908r794b958],
3	.	.	O	.	_	0	SENT_430	[p21l634t908r794b958],

1	14	CD	NUMBER	14	_	0	SENT_431	[p21l812t912r889b965],
2	,	,	O	,	_	0	SENT_431	[p21l812t912r889b965],
3	e60	NN	O	e60	nn	6	SENT_431	[p21l903t911r1128b958],
4	—	CD	NUMBER	—	num	6	SENT_431	[p21l903t911r1128b958],
5	e69	NN	O	e69	nn	6	SENT_431	[p21l903t911r1128b958],
6	(	NN	O	(	appos	1	SENT_431	[p21l1145t909r1245b965],
7	201	CD	NUMBER	201	number	8	SENT_431	[p21l1145t909r1245b965],
8	3	CD	NUMBER	3	num	9	SENT_431	[p21l1260t909r1319b965],
9	)	NN	O	)	dep	6	SENT_431	[p21l1260t909r1319b965],
10	.	.	O	.	_	0	SENT_431	[p21l1260t909r1319b965],

1	Shi	NNP	PERSON	Shi	_	0	SENT_432	[p21l129t987r220b1044],
2	,	,	O	,	_	0	SENT_432	[p21l129t987r220b1044],
3	H.	NNP	O	H.	nn	4	SENT_432	[p21l236t989r285b1036],
4	etal	NN	O	etal	appos	1	SENT_432	[p21l299t987r414b1036],
5	.	.	O	.	_	0	SENT_432	[p21l299t987r414b1036],

1	Melanoma	NN	O	melanoma	nn	4	SENT_433	[p21l431t987r709b1036],
2	whole-exome	JJ	O	whole-exome	amod	4	SENT_433	[p21l724t987r1090b1036],
3	sequencing	NN	O	sequencing	nn	4	SENT_433	[p21l1104t989r1409b1050],
4	identiﬁes	NNS	O	identiﬁes	nsubj	5	SENT_433	[p21l1427t986r1667b1036],
5	(	VBP	O	(	_	0	SENT_433	[p21l1683t988r2042b1044],
6	V600E	NN	O	v600e	nsubj	10	SENT_433	[p21l1683t988r2042b1044],
7	)	CD	NUMBER	)	num	8	SENT_433	[p21l1683t988r2042b1044],
8	B-RAF	NN	O	b-raf	npadvmod	9	SENT_433	[p21l1683t988r2042b1044],
9	ampliﬁcation-mediated	JJ	O	ampliﬁcation-mediated	dep	10	SENT_433	[p21l129t1064r749b1127],
10	acquired	VBN	O	acquire	xcomp	5	SENT_433	[p21l766t1065r993b1127],
11	B-RAF	NN	O	b-raf	nn	13	SENT_433	[p21l1013t1067r1165b1114],
12	inhibitor	NN	O	inhibitor	nn	13	SENT_433	[p21l1182t1065r1407b1115],
13	resistance	NN	O	resistance	dobj	10	SENT_433	[p21l1422t1067r1694b1115],
14	.	.	O	.	_	0	SENT_433	[p21l1422t1067r1694b1115],

1	Nat	NN	PERSON	nat	_	0	SENT_434	[p21l1708t1067r1809b1114],
2	.	.	O	.	_	0	SENT_434	[p21l1708t1067r1809b1114],

1	Commun	NNP	O	Commun	_	0	SENT_435	[p21l1825t1066r2074b1115],
2	.	.	O	.	_	0	SENT_435	[p21l1825t1066r2074b1115],

1	3	CD	NUMBER	3	_	0	SENT_436	[p21l2088t1068r2133b1122],
2	,	,	O	,	_	0	SENT_436	[p21l2088t1068r2133b1122],
3	724	CD	NUMBER	724	number	4	SENT_436	[p21l131t1145r225b1190],
4	(	CD	NUMBER	(	appos	1	SENT_436	[p21l241t1143r416b1198],
5	2012	CD	DATE	2012	num	6	SENT_436	[p21l241t1143r416b1198],
6	)	NN	O	)	dep	4	SENT_436	[p21l241t1143r416b1198],
7	.	.	O	.	_	0	SENT_436	[p21l241t1143r416b1198],

1	Poulikakos	NNP	O	Poulikakos	_	0	SENT_437	[p21l131t1220r422b1277],
2	,	,	O	,	_	0	SENT_437	[p21l131t1220r422b1277],
3	P.	NNP	O	P.	nn	4	SENT_437	[p21l439t1222r499b1269],
4	|	NNP	O	|	appos	1	SENT_437	[p21l439t1222r499b1269],
5	.	.	O	.	_	0	SENT_437	[p21l439t1222r499b1269],

1	etal	NN	O	etal	_	0	SENT_438	[p21l513t1220r628b1269],
2	.	.	O	.	_	0	SENT_438	[p21l513t1220r628b1269],

1	RAF	NN	ORGANIZATION	raf	nn	3	SENT_439	[p21l645t1222r744b1269],
2	inhibitor	NN	O	inhibitor	nn	3	SENT_439	[p21l760t1220r985b1269],
3	resistance	NN	O	resistance	nsubjpass	5	SENT_439	[p21l1000t1222r1259b1269],
4	is	VBZ	O	be	auxpass	5	SENT_439	[p21l1276t1222r1310b1269],
5	mediated	VBN	O	mediate	_	0	SENT_439	[p21l1327t1220r1575b1269],
6	by	IN	O	by	_	0	SENT_439	[p21l1594t1220r1655b1283],
7	dimerization	NN	O	dimerization	agent	5	SENT_439	[p21l1668t1220r1999b1269],
8	of	IN	O	of	prep	7	SENT_439	[p21l2016t1219r2071b1269],
9	aberrantly	RB	O	aberrantly	pcomp	8	SENT_439	[p21l129t1298r401b1361],
10	spliced	VBN	O	splice	partmod	7	SENT_439	[p21l414t1298r596b1360],
11	BRAF	NN	O	braf	nsubj	14	SENT_439	[p21l615t1299r966b1355],
12	(	CD	NUMBER	(	num	14	SENT_439	[p21l615t1299r966b1355],
13	V600E	NN	O	v600e	nn	14	SENT_439	[p21l615t1299r966b1355],
14	)	NN	O	)	xcomp	10	SENT_439	[p21l615t1299r966b1355],
15	.	.	O	.	_	0	SENT_439	[p21l615t1299r966b1355],

1	Nature	NNP	O	Nature	_	0	SENT_440	[p21l980t1300r1155b1347],
2	480	CD	NUMBER	480	num	1	SENT_440	[p21l1167t1301r1283b1355],
3	,	,	O	,	_	0	SENT_440	[p21l1167t1301r1283b1355],
4	387-390	CD	NUMBER	387-390	num	1	SENT_440	[p21l1299t1301r1523b1347],
5	(	NN	O	(	dep	1	SENT_440	[p21l1539t1299r1640b1355],
6	201	CD	NUMBER	201	number	7	SENT_440	[p21l1539t1299r1640b1355],
7	1	CD	NUMBER	1	num	8	SENT_440	[p21l1659t1299r1714b1355],
8	)	NN	O	)	dep	5	SENT_440	[p21l1659t1299r1714b1355],
9	.	.	O	.	_	0	SENT_440	[p21l1659t1299r1714b1355],

1	Gorre	NNP	LOCATION	Gorre	nn	3	SENT_441	[p21l128t1378r287b1433],
2	,	,	O	,	_	0	SENT_441	[p21l128t1378r287b1433],
3	M.E.	NNP	O	M.E.	_	0	SENT_441	[p21l303t1378r406b1425],
4	et	FW	O	et	nn	5	SENT_441	[p21l421t1383r470b1425],
5	al.	FW	O	al.	dep	3	SENT_441	[p21l479t1376r536b1425],
6	.	.	O	.	_	0	SENT_441	[p21l479t1376r536b1425],

1	Clinical	JJ	O	clinical	amod	2	SENT_442	[p21l550t1376r736b1425],
2	resistance	NN	O	resistance	nsubj	7	SENT_442	[p21l755t1378r1014b1425],
3	to	TO	O	to	_	0	SENT_442	[p21l1028t1383r1081b1425],
4	STI-571	NN	O	sti-571	nn	6	SENT_442	[p21l1096t1377r1278b1425],
5	cancer	NN	O	cancer	nn	6	SENT_442	[p21l1303t1390r1476b1425],
6	therapy	NN	O	therapy	prep_to	2	SENT_442	[p21l1488t1376r1693b1439],
7	caused	VBN	O	cause	_	0	SENT_442	[p21l1706t1376r1889b1425],
8	by	IN	O	by	_	0	SENT_442	[p21l1907t1376r1969b1439],
9	BCRABL	NN	O	bcrabl	nn	11	SENT_442	[p21l1984t1377r2104b1425, p21l129t1456r231b1503],
10	gene	NN	O	gene	nn	11	SENT_442	[p21l245t1469r376b1517],
11	mutation	NN	O	mutation	prep_by	7	SENT_442	[p21l393t1456r632b1504],
12	or	CC	O	or	_	0	SENT_442	[p21l649t1469r702b1504],
13	ampliﬁcation	NN	O	ampliﬁcation	prep_by	7	SENT_442	[p21l715t1453r1074b1516],
14	.	.	O	.	_	0	SENT_442	[p21l715t1453r1074b1516],

1	Science	NNP	O	Science	_	0	SENT_443	[p21l1087t1456r1277b1504],
2	293	CD	NUMBER	293	num	1	SENT_443	[p21l1290t1457r1406b1511],
3	,	,	O	,	_	0	SENT_443	[p21l1290t1457r1406b1511],
4	876-880	CD	NUMBER	876-880	num	1	SENT_443	[p21l1420t1457r1645b1504],
5	(	CD	NUMBER	(	num	7	SENT_443	[p21l1662t1455r1836b1511],
6	2001	CD	DATE	2001	num	7	SENT_443	[p21l1662t1455r1836b1511],
7	)	NN	O	)	dep	1	SENT_443	[p21l1662t1455r1836b1511],
8	.	.	O	.	_	0	SENT_443	[p21l1662t1455r1836b1511],

1	Pao	NNP	O	Pao	_	0	SENT_444	[p21l130t1534r234b1589],
2	,	,	O	,	_	0	SENT_444	[p21l130t1534r234b1589],
3	W.	NNP	O	W.	nn	4	SENT_444	[p21l245t1534r307b1582],
4	etal	NNP	O	etal	appos	1	SENT_444	[p21l321t1532r436b1582],
5	.	.	O	.	_	0	SENT_444	[p21l321t1532r436b1582],

1	Acquired	VBN	O	acquire	csubjpass	11	SENT_445	[p21l450t1532r686b1594],
2	resistance	NN	O	resistance	dobj	1	SENT_445	[p21l704t1534r964b1582],
3	of	IN	O	of	_	0	SENT_445	[p21l978t1531r1033b1582],
4	lung	NN	O	lung	nn	5	SENT_445	[p21l1045t1532r1159b1595],
5	adenocarcinomas	NNS	O	adenocarcinoma	prep_of	2	SENT_445	[p21l1175t1532r1644b1582],
6	to	TO	O	to	_	0	SENT_445	[p21l1658t1539r1711b1582],
7	geﬁtinib	NN	O	geﬁtinib	prep_to	1	SENT_445	[p21l1726t1531r1946b1595],
8	or	CC	O	or	_	0	SENT_445	[p21l1960t1547r2014b1582],
9	erlotinib	NN	O	erlotinib	prep_to	1	SENT_445	[p21l130t1609r352b1658],
10	is	VBZ	O	be	auxpass	11	SENT_445	[p21l368t1611r402b1658],
11	associated	VBN	O	associate	_	0	SENT_445	[p21l417t1609r691b1658],
12	with	IN	O	with	_	0	SENT_445	[p21l706t1609r820b1658],
13	a	DT	DURATION	a	det	15	SENT_445	[p21l836t1623r862b1658],
14	second	JJ	DURATION	second	amod	15	SENT_445	[p21l878t1609r1064b1658],
15	mutation	NN	O	mutation	prep_with	11	SENT_445	[p21l1083t1611r1322b1658],
16	in	IN	O	in	_	0	SENT_445	[p21l1340t1611r1383b1657],
17	the	DT	O	the	det	20	SENT_445	[p21l1398t1609r1485b1658],
18	EGFR	NN	ORGANIZATION	egfr	nn	20	SENT_445	[p21l1502t1611r1635b1658],
19	kinase	NN	O	kinase	nn	20	SENT_445	[p21l1650t1609r1814b1658],
20	domain	NN	O	domain	prep_in	15	SENT_445	[p21l1828t1609r2044b1658],
21	.	.	O	.	_	0	SENT_445	[p21l1828t1609r2044b1658],

1	PLoS	NNP	O	PLoS	nn	2	SENT_446	[p21l129t1688r250b1736],
2	Med	NNP	O	Med	_	0	SENT_446	[p21l260t1686r383b1736],
3	.	.	O	.	_	0	SENT_446	[p21l260t1686r383b1736],

1	2	CD	NUMBER	2	_	0	SENT_447	[p21l397t1689r442b1743],
2	,	,	O	,	_	0	SENT_447	[p21l397t1689r442b1743],
3	e73	NN	O	e73	appos	1	SENT_447	[p21l457t1689r548b1736],
4	(	CD	NUMBER	(	num	3	SENT_447	[p21l567t1687r742b1743],
5	2005	CD	DATE	2005	num	6	SENT_447	[p21l567t1687r742b1743],
6	)	NN	O	)	dep	3	SENT_447	[p21l567t1687r742b1743],
7	.	.	O	.	_	0	SENT_447	[p21l567t1687r742b1743],

1	Nazarian	NNP	PERSON	Nazarian	_	0	SENT_448	[p21l130t1767r371b1822],
2	,	,	O	,	_	0	SENT_448	[p21l130t1767r371b1822],
3	R.	NNP	O	R.	nn	4	SENT_448	[p21l388t1767r429b1814],
4	etal	NN	O	etal	appos	1	SENT_448	[p21l443t1765r559b1814],
5	.	.	O	.	_	0	SENT_448	[p21l443t1765r559b1814],

1	Melanomas	NNS	O	melanoma	nsubj	2	SENT_449	[p21l574t1765r879b1814],
2	acquire	VBP	O	acquire	_	0	SENT_449	[p21l894t1767r1088b1827],
3	resistance	NN	O	resistance	dobj	2	SENT_449	[p21l1104t1767r1364b1814],
4	to	TO	O	to	_	0	SENT_449	[p21l1377t1772r1430b1814],
5	B-RAF	NN	O	b-raf	nn	9	SENT_449	[p21l1447t1766r1804b1822],
6	(	CD	NUMBER	(	num	9	SENT_449	[p21l1447t1766r1804b1822],
7	V600E	NN	O	v600e	nn	9	SENT_449	[p21l1447t1766r1804b1822],
8	)	NN	O	)	nn	9	SENT_449	[p21l1447t1766r1804b1822],
9	inhibition	NN	O	inhibition	prep_to	2	SENT_449	[p21l1822t1765r2073b1814],
10	by	IN	O	by	_	0	SENT_449	[p21l2091t1765r2153b1829],
11	RTK	NN	O	rtk	nn	14	SENT_449	[p21l132t1845r230b1892],
12	or	CC	O	or	_	0	SENT_449	[p21l242t1857r295b1893],
13	N-RAS	NN	O	n-ra	nn	14	SENT_449	[p21l311t1844r471b1893],
14	upregulation	NN	O	upregulation	prep_by	2	SENT_449	[p21l488t1843r843b1906],
15	.	.	O	.	_	0	SENT_449	[p21l488t1843r843b1906],

1	Nature	NNP	O	Nature	_	0	SENT_450	[p21l857t1845r1031b1893],
2	468	CD	NUMBER	468	num	1	SENT_450	[p21l1043t1846r1160b1900],
3	,	,	O	,	_	0	SENT_450	[p21l1043t1846r1160b1900],
4	973-977	CD	NUMBER	973-977	num	1	SENT_450	[p21l1175t1846r1399b1893],
5	(	CD	NUMBER	(	num	7	SENT_450	[p21l1416t1844r1591b1900],
6	2010	CD	DATE	2010	num	7	SENT_450	[p21l1416t1844r1591b1900],
7	)	NN	O	)	dep	1	SENT_450	[p21l1416t1844r1591b1900],
8	.	.	O	.	_	0	SENT_450	[p21l1416t1844r1591b1900],

1	Wagle	NNP	PERSON	Wagle	_	0	SENT_451	[p21l127t1921r308b1984],
2	,	,	O	,	_	0	SENT_451	[p21l127t1921r308b1984],
3	N.	NNP	O	N.	nn	4	SENT_451	[p21l326t1923r376b1971],
4	etal	NN	O	etal	appos	1	SENT_451	[p21l392t1921r513b1971],
5	.	.	O	.	_	0	SENT_451	[p21l392t1921r513b1971],

1	Dissecting	VBG	O	dissect	_	0	SENT_452	[p21l531t1923r809b1984],
2	therapeutic	JJ	O	therapeutic	amod	3	SENT_452	[p21l826t1921r1142b1983],
3	resistance	NN	O	resistance	dobj	1	SENT_452	[p21l1160t1923r1428b1971],
4	to	TO	O	to	_	0	SENT_452	[p21l1443t1928r1497b1971],
5	RAF	NN	ORGANIZATION	raf	nn	6	SENT_452	[p21l1516t1923r1616b1970],
6	inhibition	NN	O	inhibition	prep_to	1	SENT_452	[p21l1635t1921r1895b1971],
7	in	IN	O	in	_	0	SENT_452	[p21l1915t1923r1959b1970],
8	melanoma	NN	O	melanoma	prep_in	6	SENT_452	[p21l131t1999r418b2049],
9	by	IN	O	by	_	0	SENT_452	[p21l438t1999r500b2063],
10	tumor	NN	O	tumor	prep_by	1	SENT_452	[p21l514t2006r682b2049],
11	genomic	JJ	O	genomic	amod	14	SENT_452	[p21l698t2001r936b2062],
12	proﬁ	NN	O	proﬁ	nn	14	SENT_452	[p21l954t1998r1242b2062],
13	|	NN	O	|	nn	14	SENT_452	[p21l954t1998r1242b2062],
14	ing	NN	O	ing	dep	10	SENT_452	[p21l954t1998r1242b2062],
15	.	.	O	.	_	0	SENT_452	[p21l954t1998r1242b2062],

1	J.	NNP	PERSON	J.	nn	2	SENT_453	[p21l954t1998r1242b2062],
2	Clin	NNP	PERSON	Clin	_	0	SENT_453	[p21l1260t1999r1369b2049],
3	.	.	O	.	_	0	SENT_453	[p21l1260t1999r1369b2049],

1	Oncol	NN	O	oncol	_	0	SENT_454	[p21l1387t1999r1552b2049],
2	.	.	O	.	_	0	SENT_454	[p21l1387t1999r1552b2049],

1	29	CD	NUMBER	29	_	0	SENT_455	[p21l1569t2002r1651b2056],
2	,	,	O	,	_	0	SENT_455	[p21l1569t2002r1651b2056],
3	3085-3096	CD	DURATION	3085-3096	num	4	SENT_455	[p21l1667t2002r1966b2049],
4	(	NN	O	(	appos	1	SENT_455	[p21l131t2077r235b2132],
5	201	CD	NUMBER	201	number	6	SENT_455	[p21l131t2077r235b2132],
6	1	CD	NUMBER	1	num	7	SENT_455	[p21l254t2077r312b2132],
7	)	NN	O	)	dep	4	SENT_455	[p21l254t2077r312b2132],
8	.	.	O	.	_	0	SENT_455	[p21l254t2077r312b2132],

1	Johannessen	NNP	PERSON	Johannessen	_	0	SENT_456	[p21l126t2154r484b2211],
2	,	,	O	,	_	0	SENT_456	[p21l126t2154r484b2211],
3	C.M.	NNP	PERSON	C.M.	nn	4	SENT_456	[p21l498t2155r609b2204],
4	etal	NNP	O	etal	appos	1	SENT_456	[p21l623t2154r739b2204],
5	.	.	O	.	_	0	SENT_456	[p21l623t2154r739b2204],

1	COT	NN	O	cot	nn	2	SENT_457	[p21l753t2155r862b2204],
2	drives	NNS	O	drive	_	0	SENT_457	[p21l874t2154r1030b2204],
3	resistance	NN	O	resistance	dep	2	SENT_457	[p21l1046t2156r1306b2204],
4	to	TO	O	to	_	0	SENT_457	[p21l1319t2161r1372b2204],
5	RAF	NN	ORGANIZATION	raf	nn	6	SENT_457	[p21l1390t2156r1488b2203],
6	inhibition	NN	O	inhibition	prep_to	3	SENT_457	[p21l1505t2154r1755b2204],
7	through	IN	O	through	_	0	SENT_457	[p21l1771t2154r1985b2217],
8	MAP	NN	O	map	nn	11	SENT_457	[p21l2002t2156r2121b2203],
9	kinase	NN	O	kinase	nn	11	SENT_457	[p21l132t2232r295b2281],
10	pathway	NN	O	pathway	nn	11	SENT_457	[p21l312t2232r538b2295],
11	reactivation	NN	O	reactivation	prep_through	6	SENT_457	[p21l553t2234r876b2281],
12	.	.	O	.	_	0	SENT_457	[p21l553t2234r876b2281],

1	Nature	NNP	O	Nature	_	0	SENT_458	[p21l890t2234r1064b2281],
2	468	CD	NUMBER	468	num	1	SENT_458	[p21l1077t2235r1193b2289],
3	,	,	O	,	_	0	SENT_458	[p21l1077t2235r1193b2289],
4	968-972	CD	NUMBER	968-972	num	1	SENT_458	[p21l1208t2235r1432b2281],
5	(	CD	NUMBER	(	num	7	SENT_458	[p21l1449t2233r1624b2289],
6	2010	CD	DATE	2010	num	7	SENT_458	[p21l1449t2233r1624b2289],
7	)	NN	O	)	dep	1	SENT_458	[p21l1449t2233r1624b2289],
8	.	.	O	.	_	0	SENT_458	[p21l1449t2233r1624b2289],

1	Infante	NNP	PERSON	Infante	_	0	SENT_459	[p21l130t2309r325b2367],
2	,	,	O	,	_	0	SENT_459	[p21l130t2309r325b2367],
3	J.R.	NNP	PERSON	J.R.	nn	4	SENT_459	[p21l338t2312r419b2359],
4	etal	NNP	O	etal	appos	1	SENT_459	[p21l433t2310r549b2360],
5	.	.	O	.	_	0	SENT_459	[p21l433t2310r549b2360],

1	Phase	NN	O	phase	nn	3	SENT_460	[p21l566t2310r717b2359],
2	I/II	NN	O	i/ii	nn	3	SENT_460	[p21l734t2311r792b2362],
3	study	NN	O	study	_	0	SENT_460	[p21l810t2310r955b2373],
4	to	TO	O	to	aux	5	SENT_460	[p21l967t2317r1020b2359],
5	assess	VB	O	assess	infmod	3	SENT_460	[p21l1034t2325r1194b2359],
6	safety	NN	O	safety	dobj	5	SENT_460	[p21l1210t2309r1374b2373],
7	,	,	O	,	_	0	SENT_460	[p21l1210t2309r1374b2373],
8	pharmacokinetics	NNS	O	pharmacokinetic	dobj	5	SENT_460	[p21l1390t2310r1872b2372],
9	,	,	O	,	_	0	SENT_460	[p21l1390t2310r1872b2372],
10	and	CC	O	and	_	0	SENT_460	[p21l1886t2310r1983b2359],
11	efﬁcacy	NN	O	efﬁcacy	nn	12	SENT_460	[p21l129t2387r331b2451],
12	ofthe	NN	O	ofthe	dobj	5	SENT_460	[p21l344t2387r493b2438],
13	oral	JJ	O	oral	amod	14	SENT_460	[p21l508t2388r603b2438],
14	MEK	NN	O	mek	dep	21	SENT_460	[p21l621t2390r736b2437],
15	1/2	CD	NUMBER	1/2	num	16	SENT_460	[p21l753t2389r831b2440],
16	inhibitor	NN	O	inhibitor	dep	14	SENT_460	[p21l848t2388r1073b2438],
17	GSK1	NN	O	gsk1	dep	21	SENT_460	[p21l1086t2390r1212b2438],
18	12021	CD	NUMBER	12021	num	17	SENT_460	[p21l1231t2391r1377b2438],
19	2	CD	NUMBER	2	number	20	SENT_460	[p21l1391t2391r1418b2437],
20	(	CD	NUMBER	(	num	21	SENT_460	[p21l1436t2389r1611b2445],
21	GSK21	NN	O	gsk21	dep	23	SENT_460	[p21l1436t2389r1611b2445],
22	2	CD	NUMBER	2	dep	21	SENT_460	[p21l1625t2389r1670b2445],
23	)	CD	NUMBER	)	dep	3	SENT_460	[p21l1625t2389r1670b2445],
24	dosed	VBN	O	dose	partmod	23	SENT_460	[p21l1686t2388r1845b2438],
25	in	IN	O	in	prt	24	SENT_460	[p21l1864t2390r1906b2437],
26	combination	NN	O	combination	dobj	24	SENT_460	[p21l129t2465r465b2515],
27	with	IN	O	with	_	0	SENT_460	[p21l480t2465r594b2515],
28	the	DT	O	the	det	30	SENT_460	[p21l609t2465r695b2515],
29	oral	JJ	O	oral	amod	30	SENT_460	[p21l710t2465r805b2515],
30	BRAF	NN	O	braf	prep_with	26	SENT_460	[p21l824t2467r958b2515],
31	inhibitor	NN	O	inhibitor	nn	32	SENT_460	[p21l974t2465r1199b2515],
32	GSK21	NN	O	gsk21	dep	35	SENT_460	[p21l1212t2466r1371b2515],
33	18436	CD	NUMBER	18436	dep	32	SENT_460	[p21l1390t2468r1546b2515],
34	(	CD	NUMBER	(	num	35	SENT_460	[p21l1562t2466r1796b2522],
35	GSK436	NN	O	gsk436	dep	26	SENT_460	[p21l1562t2466r1796b2522],
36	)	CD	NUMBER	)	num	38	SENT_460	[p21l1562t2466r1796b2522],
37	[	NN	O	[	nn	38	SENT_460	[p21l1815t2465r2001b2522],
38	abstr	NN	O	abstr	dep	35	SENT_460	[p21l1815t2465r2001b2522],
39	.	.	O	.	_	0	SENT_460	[p21l1815t2465r2001b2522],
40	]	SYM	O	]	dep	26	SENT_460	[p21l1815t2465r2001b2522],

1	.	.	O	.	_	0	SENT_461	[p21l1815t2465r2001b2522],

1	J.	NNP	PERSON	J.	nn	2	SENT_462	[p21l2012t2467r2046b2515],
2	Clin	NNP	PERSON	Clin	_	0	SENT_462	[p21l130t2543r235b2593],
3	.	.	O	.	_	0	SENT_462	[p21l130t2543r235b2593],

1	Oncol	NN	O	oncol	_	0	SENT_463	[p21l252t2543r412b2593],
2	.	.	O	.	_	0	SENT_463	[p21l252t2543r412b2593],

1	29	CD	NUMBER	29	_	0	SENT_464	[p21l427t2546r507b2600],
2	,	,	O	,	_	0	SENT_464	[p21l427t2546r507b2600],
3	201	CD	NUMBER	201	number	4	SENT_464	[p21l522t2546r606b2593],
4	1	CD	NUMBER	1	num	5	SENT_464	[p21l624t2547r638b2592],
5	(	NN	O	(	appos	1	SENT_464	[p21l665t2544r766b2600],
6	201	CD	NUMBER	201	number	7	SENT_464	[p21l665t2544r766b2600],
7	1	CD	NUMBER	1	num	8	SENT_464	[p21l784t2544r840b2600],
8	)	NN	O	)	dep	5	SENT_464	[p21l784t2544r840b2600],
9	.	.	O	.	_	0	SENT_464	[p21l784t2544r840b2600],

1	Flaherty	NNP	PERSON	Flaherty	nn	3	SENT_465	[p21l130t2622r353b2686],
2	,	,	O	,	_	0	SENT_465	[p21l130t2622r353b2686],
3	K.T.	NNP	O	K.T.	dep	4	SENT_465	[p21l369t2624r453b2671],
4	etal	JJ	O	etal	_	0	SENT_465	[p21l467t2622r582b2671],
5	.	.	O	.	_	0	SENT_465	[p21l467t2622r582b2671],

1	Combined	VBN	O	combine	amod	2	SENT_466	[p21l597t2622r871b2671],
2	BRAF	NN	O	braf	_	0	SENT_466	[p21l890t2624r1023b2671],
3	and	CC	O	and	_	0	SENT_466	[p21l1038t2622r1135b2671],
4	MEK	NN	O	mek	nn	5	SENT_466	[p21l1153t2624r1268b2671],
5	inhibition	NN	O	inhibition	conj_and	2	SENT_466	[p21l1282t2622r1532b2671],
6	in	IN	O	in	_	0	SENT_466	[p21l1551t2624r1594b2671],
7	melanoma	NN	O	melanoma	prep_in	2	SENT_466	[p21l1612t2622r1891b2671],
8	with	IN	O	with	_	0	SENT_466	[p21l1907t2622r2020b2671],
9	BRAF	NN	O	braf	nn	11	SENT_466	[p21l132t2702r265b2749],
10	V600	NN	O	v600	nn	11	SENT_466	[p21l276t2702r408b2750],
11	mutations	NNS	O	mutation	prep_with	7	SENT_466	[p21l425t2702r703b2750],
12	.	.	O	.	_	0	SENT_466	[p21l425t2702r703b2750],

1	N.	NNP	O	N.	nn	2	SENT_467	[p21l718t2702r766b2750],
2	Engl	NNP	O	Engl	_	0	SENT_467	[p21l781t2700r899b2763],
3	.	.	O	.	_	0	SENT_467	[p21l781t2700r899b2763],

1	J.	NNP	O	J.	nn	2	SENT_468	[p21l910t2702r945b2750],
2	Med	NNP	O	Med	_	0	SENT_468	[p21l959t2700r1082b2750],
3	.	.	O	.	_	0	SENT_468	[p21l959t2700r1082b2750],

1	367	CD	NUMBER	367	_	0	SENT_469	[p21l1097t2703r1213b2757],
2	,	,	O	,	_	0	SENT_469	[p21l1097t2703r1213b2757],
3	1694-1703	CD	DATE	1694-1703	number	4	SENT_469	[p21l1232t2703r1516b2750],
4	(	CD	NUMBER	(	appos	1	SENT_469	[p21l1534t2701r1709b2757],
5	2012	CD	DATE	2012	num	6	SENT_469	[p21l1534t2701r1709b2757],
6	)	NN	O	)	dep	4	SENT_469	[p21l1534t2701r1709b2757],
7	.	.	O	.	_	0	SENT_469	[p21l1534t2701r1709b2757],

1	Ribas	NNP	PERSON	Ribas	_	0	SENT_470	[p21l130t2778r279b2835],
2	,	,	O	,	_	0	SENT_470	[p21l130t2778r279b2835],
3	A.	NNP	O	A.	nn	4	SENT_470	[p21l293t2780r342b2828],
4	etal	NNP	O	etal	appos	1	SENT_470	[p21l356t2778r471b2828],
5	.	.	O	.	_	0	SENT_470	[p21l356t2778r471b2828],

1	Results	NNS	O	result	dep	7	SENT_471	[p21l488t2778r671b2828],
2	of	IN	O	of	_	0	SENT_471	[p21l685t2777r740b2828],
3	phase	NN	O	phase	prep_of	1	SENT_471	[p21l752t2778r906b2840],
4	1	CD	NUMBER	1	num	5	SENT_471	[p21l925t2782r940b2827],
5	B	NN	O	b	dep	7	SENT_471	[p21l956t2780r984b2827],
6	combined	JJ	O	combined	amod	7	SENT_471	[p21l999t2778r1265b2828],
7	BRAF	NN	ORGANIZATION	braf	dep	19	SENT_471	[p21l1284t2780r1417b2827],
8	and	CC	O	and	_	0	SENT_471	[p21l1432t2778r1528b2828],
9	MEK	NN	O	mek	nn	10	SENT_471	[p21l1547t2780r1662b2827],
10	inhibition	NN	O	inhibition	dep	19	SENT_471	[p21l1675t2778r1926b2828],
11	with	IN	O	with	_	0	SENT_471	[p21l1942t2778r2056b2828],
12	vemurafenib	NN	O	vemurafenib	prep_with	7	SENT_471	[p21l128t2855r465b2906],
13	and	CC	O	and	_	0	SENT_471	[p21l479t2856r576b2906],
14	GDC-0973	NN	O	gdc-0973	conj_and	12	SENT_471	[p21l592t2857r859b2906],
15	in	IN	O	in	_	0	SENT_471	[p21l877t2858r920b2905],
16	patients	NNS	O	patient	prep_in	12	SENT_471	[p21l938t2858r1149b2918],
17	with	IN	O	with	_	0	SENT_471	[p21l1162t2856r1276b2906],
18	BRAFV600	NN	O	brafv600	prep_with	16	SENT_471	[p21l1295t2858r1563b2906],
19	advanced	VBD	O	advance	_	0	SENT_471	[p21l1577t2856r1832b2906],
20	melanoma	NN	O	melanoma	dobj	19	SENT_471	[p21l1850t2856r2129b2906],
21	and	CC	O	and	_	0	SENT_471	[p21l129t2934r226b2984],
22	establishing	VBG	O	establish	conj_and	19	SENT_471	[p21l243t2934r559b2997],
23	a	DT	O	a	det	26	SENT_471	[p21l575t2949r601b2984],
24	phase	NN	O	phase	nn	26	SENT_471	[p21l619t2934r773b2996],
25	III	CD	NUMBER	iii	num	26	SENT_471	[p21l790t2936r827b2983],
26	dose	NN	O	dose	dobj	22	SENT_471	[p21l844t2934r981b2984],
27	.	.	O	.	_	0	SENT_471	[p21l844t2934r981b2984],

1	Paper	NNP	O	Paper	nsubj	2	SENT_472	[p21l998t2936r1146b2996],
2	presented	VBD	O	present	_	0	SENT_472	[p21l1161t2934r1423b2996],
3	at	IN	O	at	_	0	SENT_472	[p21l1440t2941r1488b2984],
4	the	DT	O	the	det	5	SENT_472	[p21l1501t2934r1587b2984],
5	Society	NNP	ORGANIZATION	Society	prep_at	2	SENT_472	[p21l1602t2936r1794b2997],
6	for	IN	ORGANIZATION	for	_	0	SENT_472	[p21l1805t2933r1878b2984],
7	Melanoma	NNP	ORGANIZATION	Melanoma	nn	10	SENT_472	[p21l131t3011r409b3061],
8	Research	NNP	ORGANIZATION	Research	nn	10	SENT_472	[p21l428t3011r658b3061],
9	2012	CD	ORGANIZATION	2012	num	10	SENT_472	[p21l676t3014r802b3061],
10	Congress	NNP	ORGANIZATION	Congress	prep_for	2	SENT_472	[p21l817t3013r1071b3074],
11	,	,	O	,	_	0	SENT_472	[p21l817t3013r1071b3074],
12	Los	NNP	LOCATION	Los	nn	13	SENT_472	[p21l1088t3013r1171b3061],
13	Angeles	NNP	LOCATION	Angeles	appos	10	SENT_472	[p21l1186t3011r1409b3074],
14	,	,	O	,	_	0	SENT_472	[p21l1186t3011r1409b3074],
15	8-11	CD	NUMBER	8-11	num	16	SENT_472	[p21l1423t3014r1528b3061],
16	November	NNP	DATE	November	appos	13	SENT_472	[p21l1555t3011r1832b3061],
17	201	CD	NUMBER	201	num	16	SENT_472	[p21l1845t3014r1930b3061],
18	2	CD	NUMBER	2	dep	16	SENT_472	[p21l1944t3014r1986b3061],
19	.	.	O	.	_	0	SENT_472	[p21l1944t3014r1986b3061],

1	Kefford	NNP	O	Kefford	_	0	SENT_473	[p21l130t3088r331b3146],
2	,	,	O	,	_	0	SENT_473	[p21l130t3088r331b3146],
3	R.	NNP	O	R.	nn	4	SENT_473	[p21l348t3091r389b3139],
4	etal	NN	O	etal	appos	1	SENT_473	[p21l404t3089r519b3139],
5	.	.	O	.	_	0	SENT_473	[p21l404t3089r519b3139],

1	Preliminary	JJ	O	preliminary	amod	2	SENT_474	[p21l536t3089r834b3153],
2	results	NNS	O	result	_	0	SENT_474	[p21l849t3089r1016b3139],
3	from	IN	O	from	_	0	SENT_474	[p21l1030t3088r1153b3139],
4	a	DT	O	a	det	6	SENT_474	[p21l1169t3104r1195b3139],
5	phase	NN	O	phase	nn	6	SENT_474	[p21l1213t3089r1367b3151],
6	lb/II	NN	O	lb/ii	prep_from	8	SENT_474	[p21l1384t3089r1495b3146],
7	,	,	O	,	_	0	SENT_474	[p21l1384t3089r1495b3146],
8	open	JJ	O	open	amod	32	SENT_474	[p21l1510t3089r1807b3152],
9	—	CD	NUMBER	—	number	10	SENT_474	[p21l1510t3089r1807b3152],
10	|	CD	NUMBER	|	num	11	SENT_474	[p21l1510t3089r1807b3152],
11	abel	NN	O	abel	npadvmod	8	SENT_474	[p21l1510t3089r1807b3152],
12	,	,	O	,	_	0	SENT_474	[p21l1510t3089r1807b3152],
13	doseescalation	NN	O	doseescalation	nn	14	SENT_474	[p21l1821t3089r1967b3139, p21l129t3167r392b3217],
14	study	NN	O	study	appos	11	SENT_474	[p21l409t3167r555b3230],
15	of	IN	O	of	_	0	SENT_474	[p21l568t3166r622b3217],
16	the	DT	O	the	det	21	SENT_474	[p21l631t3167r717b3217],
17	oral	JJ	O	oral	amod	21	SENT_474	[p21l731t3167r826b3217],
18	selective	JJ	O	selective	amod	21	SENT_474	[p21l843t3167r1072b3217],
19	BRAF	NN	O	braf	nn	21	SENT_474	[p21l1088t3169r1221b3216],
20	inhibitor	NN	O	inhibitor	nn	21	SENT_474	[p21l1238t3167r1463b3217],
21	LGX818	NN	O	lgx818	prep_of	14	SENT_474	[p21l1478t3169r1676b3217],
22	in	IN	O	in	_	0	SENT_474	[p21l1692t3169r1735b3216],
23	combination	NN	O	combination	prep_in	21	SENT_474	[p21l1752t3167r2087b3217],
24	with	IN	O	with	_	0	SENT_474	[p21l130t3245r243b3295],
25	the	DT	O	the	det	29	SENT_474	[p21l259t3245r345b3295],
26	oral	JJ	O	oral	amod	29	SENT_474	[p21l359t3245r454b3295],
27	MEK1/2	NN	O	mek1/2	nn	29	SENT_474	[p21l473t3247r671b3297],
28	inhibitor	NN	O	inhibitor	nn	29	SENT_474	[p21l688t3245r912b3295],
29	MEK162	NN	O	mek162	prep_with	8	SENT_474	[p21l927t3247r1137b3295],
30	in	IN	O	in	_	0	SENT_474	[p21l1154t3247r1196b3294],
31	BRAFV600	NN	O	brafv600	prep_in	8	SENT_474	[p21l1215t3245r1800b3307],
32	—	NN	O	—	dobj	33	SENT_474	[p21l1215t3245r1800b3307],
33	dependent	JJ	O	dependent	dep	2	SENT_474	[p21l1215t3245r1800b3307],
34	advanced	JJ	O	advanced	amod	36	SENT_474	[p21l1814t3245r2068b3295],
35	solid	JJ	O	solid	amod	36	SENT_474	[p21l131t3322r251b3371],
36	tumors	NNS	O	tumor	nsubj	37	SENT_474	[p21l266t3330r454b3371],
37	[	VBP	O	[	ccomp	33	SENT_474	[p21l472t3322r703b3378],
38	abstr	NN	O	abstr	dobj	37	SENT_474	[p21l472t3322r703b3378],
39	.	.	O	.	_	0	SENT_474	[p21l472t3322r703b3378],
40	]	SYM	O	]	dep	2	SENT_474	[p21l472t3322r703b3378],

1	.	.	O	.	_	0	SENT_475	[p21l472t3322r703b3378],

1	J.	NNP	PERSON	J.	nn	2	SENT_476	[p21l472t3322r703b3378],
2	Clin	NNP	PERSON	Clin	_	0	SENT_476	[p21l719t3322r824b3371],
3	.	.	O	.	_	0	SENT_476	[p21l719t3322r824b3371],

1	OncoI	NN	O	oncous	_	0	SENT_477	[p21l840t3322r1094b3379],
2	.31	CD	NUMBER	.31	num	1	SENT_477	[p21l840t3322r1094b3379],
3	,	,	O	,	_	0	SENT_477	[p21l840t3322r1094b3379],
4	9029	CD	NUMBER	9029	number	5	SENT_477	[p21l1109t3325r1236b3371],
5	(	CD	NUMBER	(	appos	1	SENT_477	[p21l1252t3323r1427b3378],
6	2013	CD	DATE	2013	num	7	SENT_477	[p21l1252t3323r1427b3378],
7	)	NN	O	)	dep	5	SENT_477	[p21l1252t3323r1427b3378],
8	.	.	O	.	_	0	SENT_477	[p21l1252t3323r1427b3378],

1	Ribas	NNP	PERSON	Ribas	nsubj	9	SENT_478	[p21l132t3400r280b3457],
2	,	,	O	,	_	0	SENT_478	[p21l132t3400r280b3457],
3	A.	NNP	ORGANIZATION	A.	nsubj	9	SENT_478	[p21l294t3402r343b3450],
4	&	CC	ORGANIZATION	&	_	0	SENT_478	[p21l357t3402r394b3450],
5	Flaherty	NNP	ORGANIZATION	Flaherty	nsubj	9	SENT_478	[p21l409t3400r631b3464],
6	,	,	O	,	_	0	SENT_478	[p21l409t3400r631b3464],
7	K.T.	NNP	O	K.T.	nn	8	SENT_478	[p21l647t3402r731b3450],
8	BRAF	NNP	O	BRAF	appos	1	SENT_478	[p21l748t3402r881b3449],
9	targeted	VBD	O	target	_	0	SENT_478	[p21l894t3400r1118b3463],
10	therapy	NN	O	therapy	nn	11	SENT_478	[p21l1133t3400r1338b3464],
11	changes	NNS	O	change	nsubj	14	SENT_478	[p21l1351t3400r1570b3463],
12	the	DT	O	the	det	14	SENT_478	[p21l1584t3400r1670b3450],
13	treatment	NN	O	treatment	nn	14	SENT_478	[p21l1683t3408r1947b3450],
14	paradigm	NN	O	paradigm	xcomp	9	SENT_478	[p21l133t3478r383b3541],
15	in	IN	O	in	_	0	SENT_478	[p21l401t3480r444b3527],
16	melanoma	NN	O	melanoma	prep_in	14	SENT_478	[p21l462t3478r756b3528],
17	.	.	O	.	_	0	SENT_478	[p21l462t3478r756b3528],

1	Nat	NN	PERSON	nat	_	0	SENT_479	[p21l770t3480r871b3528],
2	.	.	O	.	_	0	SENT_479	[p21l770t3480r871b3528],

1	Rev.	NNP	O	Rev.	nn	2	SENT_480	[p21l886t3480r982b3528],
2	Clin	NNP	PERSON	Clin	_	0	SENT_480	[p21l998t3478r1103b3528],
3	.	.	O	.	_	0	SENT_480	[p21l998t3478r1103b3528],

1	Oncol	NN	O	oncol	_	0	SENT_481	[p21l1119t3478r1279b3528],
2	.	.	O	.	_	0	SENT_481	[p21l1119t3478r1279b3528],

1	8	CD	NUMBER	8	_	0	SENT_482	[p21l1293t3481r1338b3535],
2	,	,	O	,	_	0	SENT_482	[p21l1293t3481r1338b3535],
3	426-433	CD	NUMBER	426-433	num	4	SENT_482	[p21l1351t3481r1575b3528],
4	(	NN	O	(	appos	1	SENT_482	[p21l1593t3479r1694b3535],
5	201	CD	NUMBER	201	number	6	SENT_482	[p21l1593t3479r1694b3535],
6	1	CD	NUMBER	1	num	7	SENT_482	[p21l1712t3479r1768b3535],
7	)	NN	O	)	dep	4	SENT_482	[p21l1712t3479r1768b3535],
8	.	.	O	.	_	0	SENT_482	[p21l1712t3479r1768b3535],

1	Boni	NNP	PERSON	Boni	_	0	SENT_483	[p21l132t3558r259b3613],
2	,	,	O	,	_	0	SENT_483	[p21l132t3558r259b3613],
3	A.	NNP	O	A.	nn	4	SENT_483	[p21l273t3558r322b3606],
4	etal	NNP	O	etal	appos	1	SENT_483	[p21l336t3556r451b3606],
5	.	.	O	.	_	0	SENT_483	[p21l336t3556r451b3606],

1	Selective	JJ	O	selective	amod	3	SENT_484	[p21l466t3556r700b3606],
2	BRAFV600E	NN	O	brafv600e	nn	3	SENT_484	[p21l716t3558r1015b3606],
3	inhibition	NN	O	inhibition	nsubj	4	SENT_484	[p21l1032t3556r1282b3606],
4	enhances	VBZ	O	enhance	_	0	SENT_484	[p21l1299t3556r1549b3606],
5	T	NN	O	t	nsubj	10	SENT_484	[p21l1559t3556r1694b3606],
6	—	CD	NUMBER	—	num	5	SENT_484	[p21l1559t3556r1694b3606],
7	ce	NN	O	ce	nn	10	SENT_484	[p21l1559t3556r1694b3606],
8	|	CD	NUMBER	|	num	10	SENT_484	[p21l1559t3556r1694b3606],
9	|	NN	O	|	nn	10	SENT_484	[p21l1559t3556r1694b3606],
10	recognition	NN	O	recognition	xcomp	4	SENT_484	[p21l1713t3558r2012b3619],
11	of	IN	O	of	_	0	SENT_484	[p21l2029t3555r2083b3606],
12	melanoma	NN	O	melanoma	prep_of	10	SENT_484	[p21l133t3634r411b3684],
13	without	IN	O	without	_	0	SENT_484	[p21l426t3634r634b3684],
14	affecting	VBG	O	affect	prepc_without	4	SENT_484	[p21l648t3633r878b3697],
15	lymphocyte	NN	O	lymphocyte	nn	16	SENT_484	[p21l896t3634r1208b3698],
16	function	NN	O	function	dobj	14	SENT_484	[p21l1221t3633r1457b3684],
17	.	.	O	.	_	0	SENT_484	[p21l1221t3633r1457b3684],

1	CancerRes	NNS	O	cancerre	_	0	SENT_485	[p21l1472t3636r1754b3684],
2	.	.	O	.	_	0	SENT_485	[p21l1472t3636r1754b3684],

1	70	CD	NUMBER	70	_	0	SENT_486	[p21l1768t3637r1848b3691],
2	,	,	O	,	_	0	SENT_486	[p21l1768t3637r1848b3691],
3	521	CD	NUMBER	521	number	4	SENT_486	[p21l1863t3637r1947b3684],
4	3-521	CD	NUMBER	3-521	num	6	SENT_486	[p21l1962t3637r2110b3684],
5	9	CD	NUMBER	9	number	6	SENT_486	[p21l2124t3637r2153b3684],
6	(	CD	NUMBER	(	appos	1	SENT_486	[p21l132t3712r307b3767],
7	2010	CD	DATE	2010	num	8	SENT_486	[p21l132t3712r307b3767],
8	)	NN	O	)	dep	6	SENT_486	[p21l132t3712r307b3767],
9	.	.	O	.	_	0	SENT_486	[p21l132t3712r307b3767],

1	Comin	NNP	O	Comin	_	0	SENT_487	[p22l129t17r523b74],
2	.	.	O	.	_	0	SENT_487	[p22l129t17r523b74],

1	—	NN	O	—	_	0	SENT_488	[p22l129t17r523b74],
2	.	.	O	.	_	0	SENT_488	[p22l129t17r523b74],

1	Anduix	NNP	O	Anduix	_	0	SENT_489	[p22l129t17r523b74],
2	,	,	O	,	_	0	SENT_489	[p22l129t17r523b74],
3	B.	NNP	O	B.	nn	4	SENT_489	[p22l540t19r580b67],
4	etaI	NNP	O	etaI	appos	1	SENT_489	[p22l594t17r817b67],
5	.	.	O	.	_	0	SENT_489	[p22l594t17r817b67],

1	The	DT	O	the	det	6	SENT_490	[p22l594t17r817b67],
2	oncogenic	JJ	O	oncogenic	amod	6	SENT_490	[p22l831t19r1108b80],
3	BRAF	NN	O	braf	nn	6	SENT_490	[p22l1125t19r1257b66],
4	kinase	NN	O	kinase	nn	6	SENT_490	[p22l1275t17r1438b67],
5	inhibitor	NN	O	inhibitor	nn	6	SENT_490	[p22l1454t17r1678b67],
6	PLX4032/RG7204	NN	O	plx4032/rg7204	nsubj	9	SENT_490	[p22l1694t19r2149b69],
7	does	VBZ	O	do	aux	9	SENT_490	[p22l131t95r255b145],
8	not	RB	O	not	neg	9	SENT_490	[p22l272t103r358b145],
9	affect	VB	O	affect	_	0	SENT_490	[p22l372t94r518b145],
10	the	DT	O	the	det	11	SENT_490	[p22l531t95r617b145],
11	viability	NN	O	viability	dobj	9	SENT_490	[p22l630t95r838b159],
12	or	CC	O	or	_	0	SENT_490	[p22l851t110r904b145],
13	function	NN	O	function	dobj	9	SENT_490	[p22l916t94r1137b145],
14	of	IN	O	of	_	0	SENT_490	[p22l1153t94r1208b145],
15	human	JJ	O	human	amod	16	SENT_490	[p22l1220t95r1402b145],
16	lymphocytes	NNS	O	lymphocyte	prep_of	11	SENT_490	[p22l1421t95r1757b159],
17	across	IN	O	across	_	0	SENT_490	[p22l1772t110r1933b145],
18	a	DT	O	a	det	20	SENT_490	[p22l1948t110r1973b145],
19	wide	JJ	O	wide	amod	20	SENT_490	[p22l1988t95r2115b145],
20	range	NN	O	range	prep_across	9	SENT_490	[p22l133t188r281b236],
21	of	IN	O	of	_	0	SENT_490	[p22l296t172r350b223],
22	concentrations	NNS	O	concentration	prep_of	20	SENT_490	[p22l360t175r766b223],
23	.	.	O	.	_	0	SENT_490	[p22l360t175r766b223],

1	Clin	NNP	O	Clin	_	0	SENT_491	[p22l782t173r887b223],
2	.	.	O	.	_	0	SENT_491	[p22l782t173r887b223],

1	Cancer	NN	O	cancer	_	0	SENT_492	[p22l902t175r1080b223],
2	Res	NNP	O	Res	dep	1	SENT_492	[p22l1088t175r1184b223],
3	.	.	O	.	_	0	SENT_492	[p22l1088t175r1184b223],

1	16	CD	NUMBER	16	_	0	SENT_493	[p22l1201t176r1279b230],
2	,	,	O	,	_	0	SENT_493	[p22l1201t176r1279b230],
3	6040-6048	CD	DURATION	6040-6048	number	4	SENT_493	[p22l1293t176r1583b223],
4	(	CD	NUMBER	(	appos	1	SENT_493	[p22l1599t174r1774b230],
5	2010	CD	DATE	2010	num	6	SENT_493	[p22l1599t174r1774b230],
6	)	NN	O	)	dep	4	SENT_493	[p22l1599t174r1774b230],
7	.	.	O	.	_	0	SENT_493	[p22l1599t174r1774b230],

1	Wargo	NNP	PERSON	Wargo	_	0	SENT_494	[p22l128t253r311b314],
2	,	,	O	,	_	0	SENT_494	[p22l128t253r311b314],
3	J.A.	NNP	PERSON	J.A.	nn	4	SENT_494	[p22l323t253r409b301],
4	etal	NNP	O	etal	appos	1	SENT_494	[p22l424t251r539b301],
5	.	.	O	.	_	0	SENT_494	[p22l424t251r539b301],

1	Treatment	NN	O	treatment	nsubj	8	SENT_495	[p22l548t253r822b301],
2	with	IN	O	with	_	0	SENT_495	[p22l834t251r948b301],
3	a	DT	O	a	det	5	SENT_495	[p22l965t266r990b301],
4	selective	JJ	O	selective	amod	5	SENT_495	[p22l1006t251r1234b301],
5	inhibitor	NN	O	inhibitor	prep_with	1	SENT_495	[p22l1250t251r1474b301],
6	of	IN	O	of	_	0	SENT_495	[p22l1487t250r1541b301],
7	BRAFV600E	NN	O	brafv600e	prep_of	5	SENT_495	[p22l1554t253r1852b301],
8	increases	VBZ	O	increase	_	0	SENT_495	[p22l1869t253r2107b301],
9	melanocyte	NN	O	melanocyte	nn	11	SENT_495	[p22l133t329r441b393],
10	antigen	NN	O	antigen	nn	11	SENT_495	[p22l455t331r655b392],
11	expression	NN	O	expression	dobj	8	SENT_495	[p22l671t331r951b391],
12	and	CC	O	and	_	0	SENT_495	[p22l967t329r1064b379],
13	CD8T	NN	O	cd8t	nn	15	SENT_495	[p22l1080t331r1232b379],
14	cell	NN	O	cell	nn	15	SENT_495	[p22l1244t329r1327b379],
15	inﬁltrate	NN	O	inﬁltrate	conj_and	11	SENT_495	[p22l1346t328r1564b379],
16	in	IN	O	in	_	0	SENT_495	[p22l1579t331r1622b378],
17	tumors	NNS	O	tumor	prep_in	11	SENT_495	[p22l1638t337r1826b379],
18	of	IN	O	of	_	0	SENT_495	[p22l1840t328r1895b379],
19	patients	NNS	O	patient	prep_of	17	SENT_495	[p22l1906t331r2117b391],
20	with	IN	O	with	prep	19	SENT_495	[p22l130t406r243b455],
21	metastatic	JJ	O	metastatic	amod	23	SENT_495	[p22l262t408r535b455],
22	melanoma	NN	O	melanoma	nn	23	SENT_495	[p22l551t406r829b455],
23	[	NN	O	[	dep	20	SENT_495	[p22l848t406r1034b462],
24	abstr	NN	O	abstr	dep	23	SENT_495	[p22l848t406r1034b462],
25	.	.	O	.	_	0	SENT_495	[p22l848t406r1034b462],
26	]	SYM	O	]	dep	11	SENT_495	[p22l848t406r1034b462],

1	.	.	O	.	_	0	SENT_496	[p22l848t406r1034b462],

1	CancerRes	NNS	O	cancerre	_	0	SENT_497	[p22l1050t408r1331b455],
2	.	.	O	.	_	0	SENT_497	[p22l1050t408r1331b455],

1	71	CD	NUMBER	71	_	0	SENT_498	[p22l1346t410r1426b462],
2	,	,	O	,	_	0	SENT_498	[p22l1346t410r1426b462],
3	95	CD	NUMBER	95	num	4	SENT_498	[p22l1440t409r1500b455],
4	(	NN	O	(	appos	1	SENT_498	[p22l1518t407r1619b462],
5	201	CD	NUMBER	201	number	6	SENT_498	[p22l1518t407r1619b462],
6	1	CD	NUMBER	1	num	7	SENT_498	[p22l1637t407r1693b463],
7	)	NN	O	)	dep	4	SENT_498	[p22l1637t407r1693b463],
8	.	.	O	.	_	0	SENT_498	[p22l1637t407r1693b463],

1	Wilmott	NNP	PERSON	Wilmott	nn	3	SENT_499	[p22l128t483r352b540],
2	,	,	O	,	_	0	SENT_499	[p22l128t483r352b540],
3	J.S.	NNP	O	J.S.	_	0	SENT_499	[p22l364t485r443b533],
4	et	FW	O	et	nn	5	SENT_499	[p22l457t491r506b533],
5	al.	FW	O	al.	dep	3	SENT_499	[p22l515t483r572b533],
6	.	.	O	.	_	0	SENT_499	[p22l515t483r572b533],

1	Selective	JJ	O	selective	amod	3	SENT_500	[p22l587t483r821b533],
2	BRAF	NN	O	braf	nn	3	SENT_500	[p22l838t485r970b533],
3	inhibitors	NNS	O	inhibitor	nsubj	4	SENT_500	[p22l987t483r1235b533],
4	induce	VBP	O	induce	_	0	SENT_500	[p22l1251t483r1427b533],
5	marked	JJ	O	marked	amod	11	SENT_500	[p22l1444t483r1639b533],
6	T	NN	O	t	nn	11	SENT_500	[p22l1651t483r1786b533],
7	—	CD	NUMBER	—	num	11	SENT_500	[p22l1651t483r1786b533],
8	ce	NN	O	ce	nn	11	SENT_500	[p22l1651t483r1786b533],
9	|	CD	NUMBER	|	num	11	SENT_500	[p22l1651t483r1786b533],
10	|	NN	O	|	nn	11	SENT_500	[p22l1651t483r1786b533],
11	inﬁltration	NN	O	inﬁltration	dep	4	SENT_500	[p22l1805t482r2074b533],
12	into	IN	O	into	dep	11	SENT_500	[p22l132t563r233b610],
13	human	JJ	O	human	amod	15	SENT_500	[p22l249t561r431b610],
14	metastatic	JJ	O	metastatic	amod	15	SENT_500	[p22l450t563r723b610],
15	melanoma	NN	O	melanoma	pobj	12	SENT_500	[p22l739t561r1032b610],
16	.	.	O	.	_	0	SENT_500	[p22l739t561r1032b610],

1	Clin	NNP	O	Clin	_	0	SENT_501	[p22l1048t561r1152b610],
2	.	.	O	.	_	0	SENT_501	[p22l1048t561r1152b610],

1	CancerRes	NNS	O	cancerre	_	0	SENT_502	[p22l1169t563r1450b610],
2	.	.	O	.	_	0	SENT_502	[p22l1169t563r1450b610],

1	18	CD	NUMBER	18	_	0	SENT_503	[p22l1468t564r1544b618],
2	,	,	O	,	_	0	SENT_503	[p22l1468t564r1544b618],
3	1386-1394	CD	DATE	1386-1394	number	4	SENT_503	[p22l1564t564r1850b610],
4	(	CD	NUMBER	(	appos	1	SENT_503	[p22l1866t562r2040b617],
5	2012	CD	DATE	2012	num	6	SENT_503	[p22l1866t562r2040b617],
6	)	NN	O	)	dep	4	SENT_503	[p22l1866t562r2040b617],
7	.	.	O	.	_	0	SENT_503	[p22l1866t562r2040b617],

1	Ribas	NNP	PERSON	Ribas	nn	15	SENT_504	[p22l132t639r280b696],
2	,	,	O	,	_	0	SENT_504	[p22l132t639r280b696],
3	A.	NNP	O	A.	appos	15	SENT_504	[p22l294t641r356b696],
4	,	,	O	,	_	0	SENT_504	[p22l294t641r356b696],
5	Hodi	NNP	LOCATION	Hodi	appos	15	SENT_504	[p22l373t639r507b697],
6	,	,	O	,	_	0	SENT_504	[p22l373t639r507b697],
7	F.S.	NNP	LOCATION	F.S.	appos	15	SENT_504	[p22l524t641r613b696],
8	,	,	O	,	_	0	SENT_504	[p22l524t641r613b696],
9	Callahan	NNP	PERSON	Callahan	appos	15	SENT_504	[p22l627t639r867b696],
10	,	,	O	,	_	0	SENT_504	[p22l627t639r867b696],
11	M.	NNP	O	M.	appos	15	SENT_504	[p22l882t641r955b696],
12	,	,	O	,	_	0	SENT_504	[p22l882t641r955b696],
13	Konto	NNP	LOCATION	Konto	appos	15	SENT_504	[p22l972t641r1138b696],
14	,	,	O	,	_	0	SENT_504	[p22l972t641r1138b696],
15	C.	NNP	O	C.	_	0	SENT_504	[p22l1152t641r1198b689],
16	&	CC	O	&	nsubj	18	SENT_504	[p22l1213t639r1501b696],
17	Wo	MD	O	will	aux	18	SENT_504	[p22l1213t639r1501b696],
18	|	VB	O	|	rcmod	15	SENT_504	[p22l1213t639r1501b696],
19	chok	NN	O	chok	dobj	18	SENT_504	[p22l1213t639r1501b696],
20	,	,	O	,	_	0	SENT_504	[p22l1213t639r1501b696],
21	J.	NNP	PERSON	J.	nn	22	SENT_504	[p22l1513t641r1547b689],
22	Hepatotoxicity	NNP	PERSON	Hepatotoxicity	appos	19	SENT_504	[p22l1564t641r1950b703],
23	with	IN	O	with	_	0	SENT_504	[p22l1962t639r2076b689],
24	combination	NN	O	combination	prep_with	22	SENT_504	[p22l131t717r465b767],
25	of	IN	O	of	_	0	SENT_504	[p22l482t716r536b767],
26	vemurafenib	NN	O	vemurafenib	prep_of	24	SENT_504	[p22l545t716r880b767],
27	and	CC	O	and	_	0	SENT_504	[p22l895t717r991b767],
28	ipilimumab	NN	O	ipilimumab	prep_of	24	SENT_504	[p22l1010t717r1320b779],
29	.	.	O	.	_	0	SENT_504	[p22l1010t717r1320b779],

1	N.	NNP	O	N.	nn	2	SENT_505	[p22l1335t719r1383b767],
2	Engl	NNP	O	Engl	_	0	SENT_505	[p22l1397t717r1516b780],
3	.	.	O	.	_	0	SENT_505	[p22l1397t717r1516b780],

1	J.	NNP	O	J.	nn	2	SENT_506	[p22l1527t719r1562b767],
2	Med	NNP	O	Med	_	0	SENT_506	[p22l1575t717r1698b767],
3	.	.	O	.	_	0	SENT_506	[p22l1575t717r1698b767],

1	368	CD	NUMBER	368	_	0	SENT_507	[p22l1713t720r1828b774],
2	,	,	O	,	_	0	SENT_507	[p22l1713t720r1828b774],
3	1365-1366	CD	DATE	1365-1366	number	4	SENT_507	[p22l1848t720r2133b767],
4	(	CD	NUMBER	(	appos	1	SENT_507	[p22l132t795r307b850],
5	2013	CD	DATE	2013	num	6	SENT_507	[p22l132t795r307b850],
6	)	NN	O	)	dep	4	SENT_507	[p22l132t795r307b850],
7	.	.	O	.	_	0	SENT_507	[p22l132t795r307b850],

1	Shi	NNP	PERSON	Shi	_	0	SENT_508	[p22l130t872r220b929],
2	,	,	O	,	_	0	SENT_508	[p22l130t872r220b929],
3	H.	NNP	O	H.	conj_and	1	SENT_508	[p22l237t874r299b929],
4	,	,	O	,	_	0	SENT_508	[p22l237t874r299b929],
5	Kong	NNP	PERSON	Kong	conj_and	1	SENT_508	[p22l315t874r462b935],
6	,	,	O	,	_	0	SENT_508	[p22l315t874r462b935],
7	X.	NNP	O	X.	conj_and	1	SENT_508	[p22l476t874r536b929],
8	,	,	O	,	_	0	SENT_508	[p22l476t874r536b929],
9	Ribas	NNP	PERSON	Ribas	conj_and	1	SENT_508	[p22l552t872r701b929],
10	,	,	O	,	_	0	SENT_508	[p22l552t872r701b929],
11	A.	NNP	ORGANIZATION	A.	conj_and	1	SENT_508	[p22l715t874r764b922],
12	&	CC	ORGANIZATION	&	_	0	SENT_508	[p22l778t874r814b922],
13	Lo	NNP	ORGANIZATION	Lo	conj_and	1	SENT_508	[p22l830t874r899b929],
14	,	,	O	,	_	0	SENT_508	[p22l830t874r899b929],
15	R.S.	NNP	O	R.S.	nn	17	SENT_508	[p22l916t874r1002b922],
16	Combinatorial	NNP	O	Combinatorial	nn	17	SENT_508	[p22l1016t872r1389b922],
17	treatments	NNS	O	treatment	appos	1	SENT_508	[p22l1405t880r1694b922],
18	that	WDT	O	that	nsubj	19	SENT_508	[p22l1707t872r1814b922],
19	overcome	VBP	O	overcome	rcmod	17	SENT_508	[p22l1827t887r2089b922],
20	PDGFRi3	NN	O	pdgfri3	nn	21	SENT_508	[p22l133t949r533b999],
21	—	NN	O	—	dobj	19	SENT_508	[p22l133t949r533b999],
22	driven	VBN	O	drive	partmod	21	SENT_508	[p22l133t949r533b999],
23	resistance	NN	O	resistance	dobj	22	SENT_508	[p22l552t952r811b999],
24	of	IN	O	of	_	0	SENT_508	[p22l825t949r880b998],
25	melanoma	NN	O	melanoma	nn	26	SENT_508	[p22l892t949r1170b998],
26	cells	NNS	O	cell	prep_of	23	SENT_508	[p22l1186t949r1297b999],
27	to	TO	O	to	_	0	SENT_508	[p22l1311t957r1364b998],
28	V600EB	NN	O	v600eb	prep_to	22	SENT_508	[p22l1374t951r1697b998],
29	.	.	O	.	_	0	SENT_508	[p22l1374t951r1697b998],

1	—	NN	O	—	_	0	SENT_509	[p22l1374t951r1697b998],
2	.	.	O	.	_	0	SENT_509	[p22l1374t951r1697b998],

1	RAF	NN	ORGANIZATION	raf	_	0	SENT_510	[p22l1374t951r1697b998],
2	inhibition	NN	O	inhibition	dep	1	SENT_510	[p22l1713t949r1979b999],
3	.	.	O	.	_	0	SENT_510	[p22l1713t949r1979b999],

1	CancerRes	NNS	O	cancerre	_	0	SENT_511	[p22l131t1028r413b1075],
2	.	.	O	.	_	0	SENT_511	[p22l131t1028r413b1075],

1	71	CD	NUMBER	71	_	0	SENT_512	[p22l428t1030r486b1075],
2	,	,	O	,	_	0	SENT_512	[p22l497t1065r508b1083],
3	5067-5074	CD	DURATION	5067-5074	num	4	SENT_512	[p22l523t1029r813b1075],
4	(	NN	O	(	appos	1	SENT_512	[p22l828t1027r929b1083],
5	201	CD	NUMBER	201	number	6	SENT_512	[p22l828t1027r929b1083],
6	1	CD	NUMBER	1	num	7	SENT_512	[p22l948t1027r1003b1083],
7	)	NN	O	)	dep	4	SENT_512	[p22l948t1027r1003b1083],
8	.	.	O	.	_	0	SENT_512	[p22l948t1027r1003b1083],

1	Villanueva	NNP	PERSON	Villanueva	_	0	SENT_513	[p22l127t1104r412b1162],
2	,	,	O	,	_	0	SENT_513	[p22l127t1104r412b1162],
3	J.	NNP	O	J.	nn	4	SENT_513	[p22l425t1107r459b1154],
4	etal	NNP	O	etal	appos	1	SENT_513	[p22l473t1104r588b1154],
5	.	.	O	.	_	0	SENT_513	[p22l473t1104r588b1154],

1	Acquired	VBN	O	acquire	_	0	SENT_514	[p22l602t1104r838b1167],
2	resistance	NN	O	resistance	dobj	1	SENT_514	[p22l856t1107r1115b1154],
3	to	TO	O	to	_	0	SENT_514	[p22l1128t1112r1181b1154],
4	BRAF	NN	O	braf	nn	5	SENT_514	[p22l1198t1106r1331b1154],
5	inhibitors	NNS	O	inhibitor	prep_to	1	SENT_514	[p22l1347t1104r1595b1154],
6	mediated	VBN	O	mediate	partmod	5	SENT_514	[p22l1612t1104r1860b1154],
7	by	IN	O	by	_	0	SENT_514	[p22l1878t1104r1940b1168],
8	a	DT	O	a	det	11	SENT_514	[p22l1953t1119r1978b1154],
9	RAF	NN	ORGANIZATION	raf	nn	11	SENT_514	[p22l1997t1106r2095b1153],
10	kinase	NN	O	kinase	nn	11	SENT_514	[p22l133t1182r296b1232],
11	switch	NN	O	switch	agent	6	SENT_514	[p22l311t1182r476b1232],
12	in	IN	O	in	_	0	SENT_514	[p22l495t1185r537b1231],
13	melanoma	NN	O	melanoma	prep_in	11	SENT_514	[p22l556t1182r835b1232],
14	can	MD	O	can	aux	16	SENT_514	[p22l851t1197r939b1232],
15	be	VB	O	be	auxpass	16	SENT_514	[p22l958t1182r1021b1232],
16	overcome	VBN	O	overcome	auxpass	1	SENT_514	[p22l1035t1197r1297b1232],
17	by	IN	O	by	_	0	SENT_514	[p22l1313t1182r1375b1246],
18	cotargeting	VBG	O	cotarget	agent	16	SENT_514	[p22l1388t1185r1692b1245],
19	MEK	NN	O	mek	nn	22	SENT_514	[p22l1710t1185r1825b1231],
20	and	CC	O	and	_	0	SENT_514	[p22l1837t1182r1934b1232],
21	|	NN	O	|	conj_and	19	SENT_514	[p22l1952t1184r2145b1234],
22	GF	NN	O	gf	dobj	18	SENT_514	[p22l1952t1184r2145b1234],
23	—	CD	NUMBER	—	num	24	SENT_514	[p22l1952t1184r2145b1234],
24	1R	NN	O	1r	nsubjpass	1	SENT_514	[p22l1952t1184r2145b1234],
25	/	:	O	/	punct	26	SENT_514	[p22l1952t1184r2145b1234],
26	P	NN	O	p	dep	24	SENT_514	[p22l133t1261r258b1308],
27	|	CD	NUMBER	|	num	28	SENT_514	[p22l133t1261r258b1308],
28	3K	NN	O	3k	dep	26	SENT_514	[p22l133t1261r258b1308],
29	.	.	O	.	_	0	SENT_514	[p22l133t1261r258b1308],

1	Cancer	NN	O	cancer	nn	2	SENT_515	[p22l273t1261r450b1308],
2	Cell	NN	O	cell	_	0	SENT_515	[p22l460t1259r551b1308],
3	18	CD	NUMBER	18	dep	2	SENT_515	[p22l566t1262r642b1316],
4	,	,	O	,	_	0	SENT_515	[p22l566t1262r642b1316],
5	683-695	CD	NUMBER	683-695	number	6	SENT_515	[p22l657t1262r880b1308],
6	(	CD	NUMBER	(	appos	3	SENT_515	[p22l898t1260r1073b1316],
7	2010	CD	DATE	2010	num	8	SENT_515	[p22l898t1260r1073b1316],
8	)	NN	O	)	dep	6	SENT_515	[p22l898t1260r1073b1316],
9	.	.	O	.	_	0	SENT_515	[p22l898t1260r1073b1316],

1	Shi	NNP	PERSON	Shi	nn	3	SENT_516	[p22l130t1336r220b1393],
2	,	,	O	,	_	0	SENT_516	[p22l130t1336r220b1393],
3	H.	NNP	O	H.	_	0	SENT_516	[p22l237t1339r285b1385],
4	et	FW	O	et	nn	5	SENT_516	[p22l300t1344r349b1385],
5	al.	FW	O	al.	dep	3	SENT_516	[p22l358t1336r415b1385],
6	.	.	O	.	_	0	SENT_516	[p22l358t1336r415b1385],

1	Combinatorial	JJ	MISC	combinatorial	amod	2	SENT_517	[p22l429t1336r802b1385],
2	treatments	NNS	O	treatment	nsubj	7	SENT_517	[p22l818t1344r1107b1385],
3	that	WDT	O	that	nsubj	4	SENT_517	[p22l1120t1336r1226b1385],
4	overcome	VBP	O	overcome	rcmod	2	SENT_517	[p22l1240t1350r1502b1385],
5	PDGFR	NN	O	pdgfr	nn	6	SENT_517	[p22l1519t1336r2040b1392],
6	{	NN	O	{	dobj	4	SENT_517	[p22l1519t1336r2040b1392],
7	beta	NN	O	beta	_	0	SENT_517	[p22l1519t1336r2040b1392],
8	}	CD	NUMBER	}	dobj	7	SENT_517	[p22l1519t1336r2040b1392],
9	.	.	O	.	_	0	SENT_517	[p22l1519t1336r2040b1392],

1	—	NN	O	—	_	0	SENT_518	[p22l1519t1336r2040b1392],
2	.	.	O	.	_	0	SENT_518	[p22l1519t1336r2040b1392],

1	driven	VBN	O	drive	_	0	SENT_519	[p22l1519t1336r2040b1392],
2	resistance	NN	O	resistance	dobj	1	SENT_519	[p22l133t1416r392b1462],
3	of	IN	O	of	_	0	SENT_519	[p22l406t1413r461b1462],
4	melanoma	NN	O	melanoma	nn	5	SENT_519	[p22l473t1413r751b1462],
5	cells	NNS	O	cell	prep_of	2	SENT_519	[p22l767t1413r878b1462],
6	to	TO	O	to	_	0	SENT_519	[p22l892t1421r944b1462],
7	V600EB	NN	O	v600eb	prep_to	1	SENT_519	[p22l955t1415r1277b1462],
8	.	.	O	.	_	0	SENT_519	[p22l955t1415r1277b1462],

1	—	NN	O	—	_	0	SENT_520	[p22l955t1415r1277b1462],
2	.	.	O	.	_	0	SENT_520	[p22l955t1415r1277b1462],

1	RAF	NN	ORGANIZATION	raf	_	0	SENT_521	[p22l955t1415r1277b1462],
2	inhibition	NN	O	inhibition	dep	1	SENT_521	[p22l1294t1413r1560b1462],
3	.	.	O	.	_	0	SENT_521	[p22l1294t1413r1560b1462],

1	Cancer	NN	O	cancer	_	0	SENT_522	[p22l1575t1415r1752b1462],
2	Res	NNP	O	Res	dep	1	SENT_522	[p22l1761t1415r1856b1462],
3	.	.	O	.	_	0	SENT_522	[p22l1761t1415r1856b1462],

1	71	CD	NUMBER	71	_	0	SENT_523	[p22l1872t1417r1951b1470],
2	,	,	O	,	_	0	SENT_523	[p22l1872t1417r1951b1470],
3	5067-5074	CD	DURATION	5067-5074	num	4	SENT_523	[p22l131t1493r422b1539],
4	(	NN	O	(	appos	1	SENT_523	[p22l437t1491r538b1547],
5	201	CD	NUMBER	201	number	6	SENT_523	[p22l437t1491r538b1547],
6	1	CD	NUMBER	1	num	7	SENT_523	[p22l556t1491r612b1547],
7	)	NN	O	)	dep	4	SENT_523	[p22l556t1491r612b1547],
8	.	.	O	.	_	0	SENT_523	[p22l556t1491r612b1547],

1	Kamb	NNP	PERSON	Kamb	_	0	SENT_524	[p22l131t1568r293b1626],
2	,	,	O	,	_	0	SENT_524	[p22l131t1568r293b1626],
3	A.	NNP	O	A.	nn	4	SENT_524	[p22l307t1571r356b1618],
4	etal	NNP	O	etal	appos	1	SENT_524	[p22l370t1568r485b1618],
5	.	.	O	.	_	0	SENT_524	[p22l370t1568r485b1618],

1	A	DT	O	a	det	4	SENT_525	[p22l499t1571r536b1617],
2	cell	NN	O	cell	nn	4	SENT_525	[p22l549t1568r633b1618],
3	cycle	NN	O	cycle	nn	4	SENT_525	[p22l650t1568r781b1632],
4	regulator	NN	O	regulator	nsubj	6	SENT_525	[p22l798t1568r1038b1631],
5	potentially	RB	O	potentially	advmod	6	SENT_525	[p22l1053t1568r1335b1632],
6	involved	VBN	O	involve	_	0	SENT_525	[p22l1349t1568r1569b1618],
7	in	IN	O	in	_	0	SENT_525	[p22l1588t1571r1630b1617],
8	genesis	NN	O	genesis	prep_in	6	SENT_525	[p22l1647t1571r1843b1631],
9	of	IN	O	of	_	0	SENT_525	[p22l1858t1568r1912b1618],
10	many	JJ	O	many	amod	12	SENT_525	[p22l1924t1583r2069b1632],
11	tumor	NN	O	tumor	nn	12	SENT_525	[p22l129t1654r294b1696],
12	types	NNS	O	type	prep_of	8	SENT_525	[p22l306t1654r461b1710],
13	.	.	O	.	_	0	SENT_525	[p22l306t1654r461b1710],

1	Science	NNP	O	Science	_	0	SENT_526	[p22l474t1648r663b1696],
2	264	CD	NUMBER	264	num	1	SENT_526	[p22l676t1649r792b1704],
3	,	,	O	,	_	0	SENT_526	[p22l676t1649r792b1704],
4	436-440	CD	NUMBER	436-440	num	1	SENT_526	[p22l804t1649r1031b1696],
5	(	CD	NUMBER	(	num	7	SENT_526	[p22l1047t1647r1221b1704],
6	1994	CD	DATE	1994	num	7	SENT_526	[p22l1047t1647r1221b1704],
7	)	NN	O	)	dep	1	SENT_526	[p22l1047t1647r1221b1704],
8	.	.	O	.	_	0	SENT_526	[p22l1047t1647r1221b1704],

1	Shapiro	NNP	PERSON	Shapiro	_	0	SENT_527	[p22l129t1724r341b1787],
2	,	,	O	,	_	0	SENT_527	[p22l129t1724r341b1787],
3	G.	NNP	O	G.	nn	4	SENT_527	[p22l355t1726r406b1774],
4	etal	NN	O	etal	appos	1	SENT_527	[p22l420t1724r535b1774],
5	.	.	O	.	_	0	SENT_527	[p22l420t1724r535b1774],

1	Aﬁrst	JJ	O	aﬁrst	amod	2	SENT_528	[p22l549t1724r973b1774],
2	—	NN	O	—	_	0	SENT_528	[p22l549t1724r973b1774],
3	in	IN	O	in	_	0	SENT_528	[p22l549t1724r973b1774],
4	—	CD	NUMBER	—	num	6	SENT_528	[p22l549t1724r973b1774],
5	human	JJ	O	human	amod	6	SENT_528	[p22l549t1724r973b1774],
6	phase	NN	O	phase	prep_in	2	SENT_528	[p22l992t1724r1146b1787],
7	I	PRP	O	I	dep	2	SENT_528	[p22l1163t1727r1169b1773],
8	study	NN	O	study	dep	7	SENT_528	[p22l1186t1724r1332b1788],
9	of	IN	O	of	_	0	SENT_528	[p22l1344t1724r1399b1774],
10	the	DT	O	the	det	11	SENT_528	[p22l1407t1724r1493b1774],
11	CDK4/6	NN	O	cdk4/6	prep_of	8	SENT_528	[p22l1508t1726r1706b1776],
12	inhibitor	NN	O	inhibitor	dep	11	SENT_528	[p22l1722t1724r1954b1782],
13	,	,	O	,	_	0	SENT_528	[p22l1722t1724r1954b1782],
14	LY283521	NN	O	ly283521	appos	12	SENT_528	[p22l133t1805r373b1852],
15	9	CD	NUMBER	9	num	14	SENT_528	[p22l387t1805r428b1860],
16	,	,	O	,	_	0	SENT_528	[p22l387t1805r428b1860],
17	for	IN	O	for	_	0	SENT_528	[p22l441t1802r514b1852],
18	patients	NNS	O	patient	prep_for	12	SENT_528	[p22l529t1805r739b1865],
19	with	IN	O	with	_	0	SENT_528	[p22l753t1802r867b1852],
20	advanced	JJ	O	advanced	amod	23	SENT_528	[p22l883t1802r1137b1852],
21	cancer	NN	O	cancer	nn	23	SENT_528	[p22l1154t1817r1327b1852],
22	[	NN	O	[	nn	23	SENT_528	[p22l1343t1802r1574b1859],
23	abstr	NN	O	abstr	prep_with	18	SENT_528	[p22l1343t1802r1574b1859],
24	.	.	O	.	_	0	SENT_528	[p22l1343t1802r1574b1859],
25	]	SYM	O	]	dep	8	SENT_528	[p22l1343t1802r1574b1859],

1	.	.	O	.	_	0	SENT_529	[p22l1343t1802r1574b1859],

1	J.	NNP	PERSON	J.	nn	2	SENT_530	[p22l1343t1802r1574b1859],
2	Clin	NNP	PERSON	Clin	_	0	SENT_530	[p22l1590t1802r1695b1852],
3	.	.	O	.	_	0	SENT_530	[p22l1590t1802r1695b1852],

1	Oncol	NN	O	oncol	_	0	SENT_531	[p22l1711t1802r1870b1852],
2	.	.	O	.	_	0	SENT_531	[p22l1711t1802r1870b1852],

1	31	CD	NUMBER	31	_	0	SENT_532	[p22l1885t1805r1965b1860],
2	,	,	O	,	_	0	SENT_532	[p22l1885t1805r1965b1860],
3	2500	CD	DATE	2500	number	4	SENT_532	[p22l1980t1805r2107b1852],
4	(	CD	DATE	(	appos	1	SENT_532	[p22l132t1880r307b1936],
5	2013	CD	DATE	2013	num	6	SENT_532	[p22l132t1880r307b1936],
6	)	NN	O	)	dep	4	SENT_532	[p22l132t1880r307b1936],
7	.	.	O	.	_	0	SENT_532	[p22l132t1880r307b1936],

1	Garbe	NNP	PERSON	Garbe	_	0	SENT_533	[p22l129t1957r300b2015],
2	,	,	O	,	_	0	SENT_533	[p22l129t1957r300b2015],
3	C.	NNP	O	C.	appos	1	SENT_533	[p22l314t1959r373b2015],
4	,	,	O	,	_	0	SENT_533	[p22l314t1959r373b2015],
5	Eigent	NNP	O	Eigent	nn	7	SENT_533	[p22l390t1957r742b2020],
6	|	CD	NUMBER	|	num	7	SENT_533	[p22l390t1957r742b2020],
7	er	NN	O	er	appos	1	SENT_533	[p22l390t1957r742b2020],
8	,	,	O	,	_	0	SENT_533	[p22l390t1957r742b2020],
9	T.K.	NNP	PERSON	T.K.	appos	1	SENT_533	[p22l390t1957r742b2020],
10	,	,	O	,	_	0	SENT_533	[p22l390t1957r742b2020],
11	Keilholz	NNP	PERSON	Keilholz	conj_and	9	SENT_533	[p22l759t1957r975b2015],
12	,	,	O	,	_	0	SENT_533	[p22l759t1957r975b2015],
13	U.	NNP	O	U.	conj_and	9	SENT_533	[p22l992t1960r1051b2015],
14	,	,	O	,	_	0	SENT_533	[p22l992t1960r1051b2015],
15	Hauschild	NNP	O	Hauschild	conj_and	9	SENT_533	[p22l1068t1957r1337b2015],
16	,	,	O	,	_	0	SENT_533	[p22l1068t1957r1337b2015],
17	A.	NNP	ORGANIZATION	A.	conj_and	9	SENT_533	[p22l1351t1960r1400b2007],
18	&	CC	ORGANIZATION	&	_	0	SENT_533	[p22l1414t1959r1451b2007],
19	Kirkwood	NNP	ORGANIZATION	Kirkwood	conj_and	9	SENT_533	[p22l1466t1957r1727b2015],
20	,	,	O	,	_	0	SENT_533	[p22l1466t1957r1727b2015],
21	J.M.	NNP	O	J.M.	nn	23	SENT_533	[p22l1739t1960r1838b2007],
22	Systematic	NNP	O	Systematic	nn	23	SENT_533	[p22l1853t1959r2136b2021],
23	review	NN	O	review	appos	1	SENT_533	[p22l132t2037r305b2084],
24	of	IN	O	of	_	0	SENT_533	[p22l318t2034r373b2083],
25	medical	JJ	O	medical	amod	26	SENT_533	[p22l384t2034r587b2084],
26	treatment	NN	O	treatment	prep_of	23	SENT_533	[p22l602t2042r867b2084],
27	in	IN	O	in	_	0	SENT_533	[p22l882t2037r925b2083],
28	melanoma	NN	O	melanoma	prep_in	1	SENT_533	[p22l943t2034r1237b2084],
29	:	:	O	:	_	0	SENT_533	[p22l943t2034r1237b2084],
30	current	JJ	DATE	current	amod	31	SENT_533	[p22l1251t2042r1441b2084],
31	status	NN	O	status	dep	1	SENT_533	[p22l1455t2042r1609b2083],
32	and	CC	O	and	_	0	SENT_533	[p22l1624t2034r1720b2083],
33	future	JJ	DATE	future	amod	34	SENT_533	[p22l1735t2034r1895b2084],
34	prospects	NNS	O	prospects	dep	1	SENT_533	[p22l132t2120r400b2175],
35	.	.	O	.	_	0	SENT_533	[p22l132t2120r400b2175],

1	Oncologist	NN	O	oncologist	_	0	SENT_534	[p22l415t2112r691b2175],
2	16	CD	NUMBER	16	num	1	SENT_534	[p22l705t2116r781b2170],
3	,	,	O	,	_	0	SENT_534	[p22l705t2116r781b2170],
4	5-24	CD	NUMBER	5-24	num	5	SENT_534	[p22l797t2115r923b2162],
5	(	NN	O	(	appos	1	SENT_534	[p22l939t2113r1039b2170],
6	201	CD	NUMBER	201	number	7	SENT_534	[p22l939t2113r1039b2170],
7	1	CD	NUMBER	1	num	8	SENT_534	[p22l1058t2113r1114b2170],
8	)	NN	O	)	dep	5	SENT_534	[p22l1058t2113r1114b2170],
9	.	.	O	.	_	0	SENT_534	[p22l1058t2113r1114b2170],

1	CLINICAL	JJ	O	clinical	amod	2	SENT_535	[p22l22t2252r141b2273],
2	PHARMACOLOGY	NNP	O	PHARMACOLOGY	dep	12	SENT_535	[p22l150t2252r375b2273],
3	&	CC	O	&	_	0	SENT_535	[p22l382t2252r602b2273],
4	THERAPEUT	NNP	O	THERAPEUT	nn	6	SENT_535	[p22l382t2252r602b2273],
5	|	CD	NUMBER	|	num	6	SENT_535	[p22l382t2252r602b2273],
6	CS	NNP	O	CS	conj_and	2	SENT_535	[p22l382t2252r602b2273],
7	|	NNP	O	|	nn	8	SENT_535	[p22l612t2250r614b2280],
8	VOLUME	NNP	O	VOLUME	dep	2	SENT_535	[p22l622t2252r730b2273],
9	95	CD	NUMBER	95	num	10	SENT_535	[p22l738t2252r765b2273],
10	NUMBER	NN	O	number	dep	12	SENT_535	[p22l775t2252r883b2273],
11	1	CD	NUMBER	1	num	12	SENT_535	[p22l893t2253r900b2273],
12	|	CD	NUMBER	|	dep	15	SENT_535	[p22l914t2250r916b2280],
13	JANUARY	NNP	DATE	JANUARY	dep	12	SENT_535	[p22l925t2252r1043b2273],
14	2014	CD	DATE	2014	num	15	SENT_535	[p22l1051t2252r1109b2273],
15	31	CD	DATE	31	_	0	SENT_535	[p22l2111t2252r2137b2273],

